It 	 O 	O
is 	 O 	O
concluded 	 O 	O
that 	 O 	O
Cushing 	 DISEASE 	O
's 	 DISEASE 	DISEASE
syndrome 	 DISEASE 	O
may 	 O 	O
present 	 O 	O
in 	 O 	O
a 	 O 	O
very 	 O 	O
incomplete 	 O 	O
form 	 O 	O
and 	 O 	O
should 	 O 	O
be 	 O 	O
considered 	 O 	O
in 	 O 	O
the 	 O 	O
differential 	 O 	O
diagnosis 	 O 	O
, 	 O 	O
even 	 O 	O
if 	 O 	O
only 	 O 	O
one 	 O 	O
feature 	 O 	O
is 	 O 	O
present 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
predominance 	 O 	O
of 	 O 	O
T 	 O 	O
lymphocytes 	 O 	O
as 	 O 	O
found 	 O 	O
in 	 O 	O
cases 	 O 	O
with 	 O 	O
a 	 O 	O
mixed 	 O 	O
cellular 	 O 	O
pattern 	 O 	O
with 	 O 	O
or 	 O 	O
without 	 O 	O
nodular 	 O 	O
sclerosis 	 O 	O
is 	 O 	O
therefore 	 O 	O
not 	 O 	O
a 	 O 	O
favourable 	 O 	O
sign 	 O 	O
in 	 O 	O
general 	 O 	O
but 	 O 	O
may 	 O 	O
indicate 	 O 	O
progressive 	 O 	O
disease 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Renin 	 O 	O
profiling 	 O 	O
identifies 	 O 	DISEASE
those 	 O 	O
in 	 O 	O
whom 	 O 	O
treatment 	 O 	O
should 	 O 	O
begin 	 O 	O
with 	 O 	O
a 	 O 	O
beta 	 O 	O
- 	 O 	O
blocker 	 O 	O
as 	 O 	O
opposed 	 O 	O
to 	 O 	O
a 	 O 	O
diuretic 	 O 	O
while 	 O 	O
not 	 O 	O
infrequently 	 O 	O
also 	 O 	O
providing 	 O 	O
baseline 	 O 	O
information 	 O 	O
about 	 O 	O
severity 	 O 	O
and 	 O 	O
prognosis 	 O 	O
in 	 O 	O
individual 	 O 	O
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
computed 	 O 	O
by 	 O 	O
sex 	 O 	O
, 	 O 	O
age 	 O 	O
, 	 O 	O
and 	 O 	O
marital 	 O 	O
status 	 O 	O
for 	 O 	O
whites 	 O 	O
and 	 O 	O
blacks 	 O 	O
separately 	 O 	O
for 	 O 	O
ages 	 O 	O
35 	 O 	O
- 	 O 	O
64 	 O 	O
years 	 O 	O
with 	 O 	O
the 	 O 	O
use 	 O 	O
of 	 O 	O
population 	 O 	O
- 	 O 	O
based 	 O 	O
incidence 	 O 	O
data 	 O 	O
from 	 O 	O
the 	 O 	O
Third 	 O 	O
National 	 O 	DISEASE
Cancer 	 DISEASE 	DISEASE
Survey 	 O 	O
( 	 O 	O
1969 	 O 	O
- 	 O 	O
71 	 O 	O
) 	 O 	O
and 	 O 	O
with 	 O 	O
demographic 	 O 	O
data 	 O 	O
from 	 O 	O
the 	 O 	O
1970 	 O 	O
U.S. 	 O 	O
Census 	 O 	O
. 	 O 	O
This 	 O 	O
study 	 O 	O
was 	 O 	O
undertaken 	 O 	O
to 	 O 	O
determine 	 O 	O
if 	 O 	O
a 	 O 	O
pharmacologic 	 O 	O
dose 	 O 	O
of 	 O 	O
the 	 O 	O
glucocorticoid 	 O 	O
methylprednisolone 	 O 	O
would 	 O 	O
protect 	 O 	O
the 	 O 	O
heart 	 O 	O
during 	 O 	O
ischemic 	 O 	O
cardiac 	 DISEASE 	O
arrest 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
: 	 O 	O
exclusive 	 O 	O
or 	 O 	O
predominant 	 O 	O
reduction 	 O 	O
in 	 O 	O
maximal 	 O 	O
expiratory 	 O 	O
flows 	 O 	O
, 	 O 	O
as 	 O 	O
in 	 O 	O
COPD 	 DISEASE 	O
but 	 O 	O
with 	 O 	O
the 	 O 	O
difference 	 O 	O
that 	 O 	O
the 	 O 	O
expiratory 	 O 	O
limb 	 O 	O
of 	 O 	O
the 	 O 	O
V 	 O 	O
: 	 O 	O
V 	 O 	O
loop 	 O 	O
showed 	 O 	O
an 	 O 	O
excessive 	 O 	O
reduction 	 O 	O
in 	 O 	O
PEFR 	 O 	O
, 	 O 	O
a 	 O 	O
plateau 	 O 	O
in 	 O 	O
the 	 O 	O
midzone 	 O 	O
of 	 O 	O
the 	 O 	O
VC 	 O 	O
and 	 O 	O
a 	 O 	O
terminal 	 O 	O
portion 	 O 	O
with 	 O 	O
normal 	 O 	O
configuration 	 O 	O
. 	 O 	O
The 	 O 	O
results 	 O 	O
may 	 O 	O
imply 	 O 	O
that 	 O 	O
a 	 O 	O
diurnal 	 O 	O
variation 	 O 	O
in 	 O 	O
Hyp 	 O 	O
excretion 	 O 	O
exists 	 O 	O
in 	 O 	O
primary 	 DISEASE 	O
hyperparathyroidism 	 DISEASE 	DISEASE
and 	 O 	O
that 	 O 	O
food 	 O 	O
intake 	 O 	O
produces 	 O 	O
a 	 O 	O
suppression 	 O 	O
of 	 O 	O
Hyp 	 O 	O
excretion 	 O 	O
, 	 O 	O
possibly 	 O 	O
secondary 	 O 	O
to 	 O 	O
suppression 	 O 	O
of 	 O 	O
parathyroid 	 O 	O
function 	 O 	O
or 	 O 	O
, 	 O 	O
in 	 O 	O
our 	 O 	O
view 	 O 	O
, 	 O 	O
to 	 O 	O
increased 	 O 	O
calcitonin 	 O 	O
excretion 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Hepatitis 	 DISEASE 	O
B 	 O 	O
surface 	 O 	O
antigen 	 O 	O
was 	 O 	O
detected 	 O 	O
in 	 O 	O
40 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
Down 	 O 	O
's 	 O 	O
syndrome 	 O 	O
and 	 O 	O
57 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
matched 	 O 	O
other 	 O 	O
retarded 	 O 	O
patients 	 O 	O
. 	 O 	O
Antibody 	 O 	O
against 	 O 	O
Hepatitis 	 O 	O
B 	 O 	O
surface 	 O 	O
antigen 	 O 	O
was 	 O 	O
detected 	 O 	O
in 	 O 	O
40 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
Down 	 DISEASE 	DISEASE
's 	 DISEASE 	DISEASE
syndrome 	 DISEASE 	DISEASE
and 	 O 	O
57 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
matched 	 O 	O
other 	 O 	O
retarded 	 O 	O
patients 	 O 	O
. 	 O 	O
At 	 O 	O
lipoprotein 	 O 	O
concentrations 	 O 	O
equivalent 	 O 	O
to 	 O 	O
those 	 O 	O
found 	 O 	O
in 	 O 	O
hepatic 	 O 	DISEASE
disease 	 O 	O
sera 	 O 	O
, 	 O 	O
the 	 O 	O
results 	 O 	O
indicate 	 O 	O
that 	 O 	O
: 	 O 	O
( 	 O 	O
1 	 O 	O
) 	 O 	O
LP 	 O 	O
- 	 O 	O
X 	 O 	O
levels 	 O 	O
greater 	 O 	O
than 	 O 	O
2.5 	 O 	O
mg 	 O 	O
/ 	 O 	O
ml 	 O 	O
produced 	 O 	O
total 	 O 	O
inhibition 	 O 	O
of 	 O 	O
enzyme 	 O 	O
activity 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Treatment 	 O 	O
results 	 O 	O
in 	 O 	O
31 	 O 	O
patients 	 O 	O
with 	 O 	O
nephroblastoma 	 DISEASE 	O
are 	 O 	O
reported 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
, 	 O 	O
male 	 O 	O
) 	 O 	O
, 	 O 	O
Wilson 	 O 	O
's 	 O 	O
disease 	 O 	O
( 	 O 	O
14-year 	 O 	O
- 	 O 	O
old 	 O 	O
, 	 O 	O
male 	 O 	O
) 	 O 	O
, 	 O 	O
Morquio 	 O 	O
's 	 O 	O
disease 	 O 	O
( 	 O 	O
12-year 	 O 	O
- 	 O 	O
old 	 O 	O
, 	 O 	O
male 	 O 	O
) 	 O 	O
, 	 O 	O
pseudoulegyric 	 O 	O
type 	 O 	O
of 	 O 	O
hepatocerebral 	 O 	O
degeneration 	 O 	O
( 	 O 	O
19-year 	 O 	O
- 	 O 	O
old 	 O 	O
, 	 O 	O
male 	 O 	O
) 	 O 	O
and 	 O 	O
Schilder 	 DISEASE 	O
's 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
( 	 O 	O
15-year 	 O 	O
- 	 O 	O
old 	 O 	O
, 	 O 	O
male 	 O 	O
) 	 O 	O
. 	 O 	O
The 	 O 	O
administration 	 O 	O
of 	 O 	O
commercial 	 O 	O
factor 	 O 	O
VIII 	 O 	O
concentrate 	 O 	DISEASE
corrected 	 O 	O
all 	 O 	O
parameters 	 O 	O
except 	 O 	O
the 	 O 	O
bleeding 	 O 	O
time 	 O 	O
and 	 O 	O
the 	 O 	O
ristocetin 	 O 	O
aggregation 	 O 	O
factor 	 O 	O
measurement 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
It 	 O 	O
is 	 O 	O
concluded 	 O 	O
that 	 O 	O
high 	 O 	O
plasma 	 O 	O
- 	 O 	O
angiotensin 	 O 	O
- 	 O 	O
II 	 O 	O
concentrations 	 O 	O
do 	 O 	O
not 	 O 	O
explain 	 O 	O
the 	 O 	O
pathogenesis 	 O 	O
of 	 O 	O
acute 	 O 	O
renal 	 DISEASE 	O
failure 	 DISEASE 	DISEASE
in 	 O 	O
patients 	 O 	O
in 	 O 	O
shock 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Days 	 O 	O
of 	 O 	O
administration 	 O 	O
and 	 O 	O
total 	 O 	O
administered 	 O 	O
dose 	 O 	O
before 	 O 	O
onset 	 O 	O
of 	 O 	O
ataxia 	 O 	DISEASE
depended 	 O 	O
on 	 O 	O
the 	 O 	O
daily 	 O 	O
dose 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
question 	 O 	O
whether 	 O 	O
these 	 O 	O
13 	 O 	O
patients 	 O 	O
should 	 O 	O
be 	 O 	O
treated 	 O 	O
with 	 O 	O
vitamin 	 O 	DISEASE
B12 	 O 	O
for 	 O 	O
the 	 O 	O
rest 	 O 	O
of 	 O 	O
their 	 O 	O
lives 	 O 	O
is 	 O 	O
difficult 	 O 	O
to 	 O 	O
answer 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Similarly 	 O 	O
, 	 O 	O
the 	 O 	O
cytotoxicity 	 O 	O
of 	 O 	O
effector 	 O 	O
cells 	 O 	O
directed 	 O 	O
against 	 O 	O
semisyngeneic 	 O 	DISEASE
myeloma 	 DISEASE 	DISEASE
targets 	 O 	O
was 	 O 	O
reduced 	 O 	O
by 	 O 	O
Lyt-1 	 O 	O
, 	 O 	O
-2 	 O 	O
, 	 O 	O
or 	 O 	O
-3 	 O 	O
antiserum 	 O 	O
and 	 O 	O
complement 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Three 	 O 	O
examples 	 O 	O
of 	 O 	O
spontaneous 	 O 	O
malignant 	 O 	DISEASE
lymphoma 	 DISEASE 	DISEASE
were 	 O 	O
observed 	 O 	O
in 	 O 	O
owl 	 O 	O
monkeys 	 O 	O
23 	 O 	O
, 	 O 	O
81 	 O 	O
, 	 O 	O
and 	 O 	O
183 	 O 	O
days 	 O 	O
after 	 O 	O
arrival 	 O 	O
in 	 O 	O
our 	 O 	O
laboratories 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
lymph 	 O 	O
nodes 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
lymphocyte 	 O 	O
predominance 	 O 	O
type 	 O 	O
of 	 O 	O
Hodgkin 	 O 	DISEASE
's 	 O 	O
disease 	 O 	DISEASE
, 	 O 	O
the 	 O 	O
majority 	 O 	O
of 	 O 	O
the 	 O 	O
lymphocytes 	 O 	O
in 	 O 	O
the 	 O 	O
involved 	 O 	O
areas 	 O 	O
were 	 O 	O
normal 	 O 	O
B 	 O 	O
lymphocytes 	 O 	O
of 	 O 	O
polyclonal 	 O 	O
origin 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
These 	 O 	O
studies 	 O 	O
provide 	 O 	O
biochemical 	 O 	O
support 	 O 	O
to 	 O 	O
the 	 O 	O
concept 	 O 	O
that 	 O 	O
the 	 O 	O
sympathetic 	 O 	O
nervous 	 O 	O
system 	 O 	O
may 	 O 	O
play 	 O 	O
a 	 O 	O
critical 	 O 	O
role 	 O 	O
in 	 O 	O
the 	 O 	O
initiation 	 O 	O
of 	 O 	O
the 	 O 	O
hypertensive 	 O 	O
syndrome 	 O 	O
and 	 O 	O
that 	 O 	O
chronic 	 O 	DISEASE
hypertension 	 DISEASE 	DISEASE
could 	 O 	O
result 	 O 	O
from 	 O 	O
the 	 O 	O
fixation 	 O 	O
of 	 O 	O
the 	 O 	O
biochemical 	 O 	O
effects 	 O 	O
of 	 O 	O
increased 	 O 	O
sympathetic 	 O 	O
activity 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
term 	 O 	O
	PUNCT	O
39610	semimalignancy	ADJ	O
39610	 	 O 	O
is 	 O 	O
a 	 O 	O
suitable 	 O 	O
one 	 O 	O
for 	 O 	O
many 	 O 	O
forms 	 O 	O
of 	 O 	O
those 	 O 	O
giant 	 O 	DISEASE
- 	 O 	O
cell 	 O 	DISEASE
tumours 	 O 	O
which 	 O 	O
have 	 O 	O
special 	 O 	O
tendency 	 O 	O
towards 	 O 	O
recurrence 	 O 	O
even 	 O 	O
after 	 O 	O
years 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
many 	 O 	O
cases 	 O 	O
PCP 	 O 	DISEASE
is 	 O 	O
sold 	 O 	O
as 	 O 	O
other 	 O 	O
drugs 	 O 	O
, 	 O 	O
particularly 	 O 	O
THC 	 O 	O
, 	 O 	O
and 	 O 	O
in 	 O 	O
various 	 O 	O
colored 	 O 	O
capsules 	 O 	O
, 	 O 	O
tablets 	 O 	O
, 	 O 	O
liquids 	 O 	O
and 	 O 	O
crystals 	 O 	O
which 	 O 	O
may 	 O 	O
explain 	 O 	O
the 	 O 	O
increased 	 O 	O
usage 	 O 	O
despite 	 O 	O
the 	 O 	O
numerous 	 O 	O
warnings 	 O 	O
against 	 O 	O
its 	 O 	O
use 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
clinical 	 O 	O
and 	 O 	O
laboratory 	 O 	O
features 	 O 	O
of 	 O 	O
nine 	 O 	O
patients 	 O 	O
with 	 O 	O
chronic 	 DISEASE 	O
myelomonocytic 	 DISEASE 	O
leukemia 	 DISEASE 	DISEASE
are 	 O 	O
described 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Inadequate 	 O 	O
mixing 	 O 	O
of 	 O 	O
the 	 O 	O
alkali 	 O 	O
with 	 O 	O
the 	 O 	O
stomach 	 O 	O
contents 	 O 	O
when 	 O 	O
it 	 O 	O
is 	 O 	O
given 	 O 	O
as 	 O 	O
an 	 O 	O
immediate 	 O 	O
pre 	 O 	O
- 	 O 	O
induction 	 O 	O
dose 	 O 	O
leads 	 O 	O
to 	 O 	O
a 	 O 	O
hazard 	 O 	O
of 	 O 	O
acid 	 O 	O
regurgitation 	 O 	DISEASE
when 	 O 	O
anaesthesia 	 O 	O
is 	 O 	O
induced 	 O 	O
in 	 O 	O
these 	 O 	O
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Transbronchial 	 O 	O
lung 	 O 	DISEASE
biopsy 	 O 	O
via 	 O 	O
the 	 O 	O
fiberoptic 	 O 	O
bronchoscope 	 O 	O
was 	 O 	O
utilized 	 O 	O
in 	 O 	O
14 	 O 	O
patients 	 O 	O
during 	 O 	O
the 	 O 	O
latter 	 O 	O
part 	 O 	O
of 	 O 	O
this 	 O 	O
study 	 O 	O
; 	 O 	O
diagnoses 	 O 	O
were 	 O 	O
obtained 	 O 	O
in 	 O 	O
nine 	 O 	O
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Additional 	 O 	O
histologic 	 O 	O
features 	 O 	O
useful 	 O 	O
in 	 O 	O
making 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
malignant 	 O 	O
schwannoma 	 DISEASE 	O
included 	 O 	O
the 	 O 	O
arrangement 	 O 	O
of 	 O 	O
the 	 O 	O
spindled 	 O 	O
tumor 	 O 	O
cells 	 O 	O
in 	 O 	O
a 	 O 	O
whorled 	 O 	O
pattern 	 O 	O
about 	 O 	O
thin 	 O 	O
- 	 O 	O
walled 	 O 	O
, 	 O 	O
gaping 	 O 	O
blood 	 O 	O
vessels 	 O 	O
, 	 O 	O
perivascular 	 O 	O
cellular 	 O 	O
proliferation 	 O 	O
and 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
prominent 	 O 	O
myxoid 	 O 	O
stroma 	 O 	O
containing 	 O 	O
abundant 	 O 	O
hyaluronidase 	 O 	O
- 	 O 	O
sensitive 	 O 	O
acid 	 O 	O
mucopolysaccharides 	 O 	O
. 	 O 	O
in 	 O 	O
116 	 O 	O
patients 	 O 	O
with 	 O 	O
malignant 	 DISEASE 	DISEASE
melanoma 	 DISEASE 	O
and 	 O 	O
in 	 O 	O
40 	 O 	O
patients 	 O 	O
with 	 O 	O
skeletal 	 O 	O
and 	 O 	O
soft 	 O 	O
tissue 	 O 	O
sarcoma 	 O 	O
who 	 O 	O
received 	 O 	O
adjunctive 	 O 	O
immunotherapy 	 O 	O
. 	 O 	O
An 	 O 	O
evaluation 	 O 	O
of 	 O 	O
general 	 O 	O
immunologic 	 O 	O
reactivity 	 O 	O
was 	 O 	O
performed 	 O 	O
in 	 O 	O
116 	 O 	O
patients 	 O 	O
with 	 O 	O
malignant 	 O 	O
melanoma 	 O 	O
and 	 O 	O
in 	 O 	O
40 	 O 	O
patients 	 O 	O
with 	 O 	O
skeletal 	 O 	O
and 	 O 	O
soft 	 O 	O
tissue 	 O 	O
sarcoma 	 DISEASE 	DISEASE
who 	 O 	O
received 	 O 	O
adjunctive 	 O 	O
immunotherapy 	 O 	O
. 	 O 	O
Although 	 O 	O
patients 	 O 	O
who 	 O 	O
were 	 O 	O
hypotensive 	 O 	O
for 	 O 	O
periods 	 O 	O
of 	 O 	O
1 	 O 	O
h 	 O 	O
45 	 O 	O
min 	 O 	O
to 	 O 	O
4 	 O 	O
h 	 O 	O
to 	 O 	O
promote 	 O 	O
haemostasis 	 O 	O
during 	 O 	O
surgery 	 O 	O
had 	 O 	O
similarly 	 O 	O
raised 	 O 	O
plasma 	 O 	O
- 	 O 	O
renin 	 O 	O
activity 	 O 	O
and 	 O 	O
angiotensin 	 O 	O
- 	 O 	O
II 	 O 	O
concentrations 	 O 	O
in 	 O 	O
peripheral 	 O 	O
venous 	 O 	O
blood 	 O 	O
, 	 O 	O
they 	 O 	O
did 	 O 	O
not 	 O 	O
have 	 O 	O
acute 	 O 	O
renal 	 DISEASE 	O
failure 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
function 	 O 	O
and 	 O 	O
several 	 O 	O
of 	 O 	O
the 	 O 	O
structural 	 O 	O
features 	 O 	O
of 	 O 	O
the 	 O 	O
C1 	 O 	O
inactivator 	 O 	O
protein 	 O 	O
isolated 	 O 	O
from 	 O 	O
the 	 O 	O
plasma 	 O 	O
of 	 O 	O
a 	 O 	O
mother 	 O 	O
and 	 O 	O
daughter 	 O 	O
with 	 O 	O
the 	 O 	O
variant 	 O 	O
form 	 O 	O
of 	 O 	O
hereditary 	 DISEASE 	O
angioneurotic 	 DISEASE 	O
edema 	 DISEASE 	DISEASE
have 	 O 	O
been 	 O 	O
examined 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
effect 	 O 	O
of 	 O 	O
intestinal 	 O 	DISEASE
microflora 	 O 	O
on 	 O 	O
liver 	 O 	O
tumorigenesis 	 O 	O
was 	 O 	O
studied 	 O 	O
in 	 O 	O
gnotobiotic 	 O 	O
C3H/ 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Previous 	 O 	O
evidence 	 O 	O
for 	 O 	O
activation 	 O 	O
of 	 O 	O
PC 	 O 	O
from 	 O 	O
vaccinia 	 DISEASE 	DISEASE
virus 	 O 	O
- 	 O 	O
infected 	 O 	O
mice 	 O 	O
( 	 O 	O
10(8 	 O 	O
) 	 O 	O
plaque 	 O 	O
- 	 O 	O
forming 	 O 	O
units 	 O 	O
) 	 O 	O
was 	 O 	O
confirmed 	 O 	O
by 	 O 	O
demonstration 	 O 	O
of 	 O 	O
enhanced 	 O 	O
levels 	 O 	O
of 	 O 	O
CL 	 O 	O
on 	 O 	O
days 	 O 	O
3 	 O 	O
, 	 O 	O
6 	 O 	O
, 	 O 	O
and 	 O 	O
13 	 O 	O
after 	 O 	O
murine 	 O 	O
infection 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Three 	 O 	O
new 	 O 	O
angiographic 	 O 	O
features 	 O 	O
of 	 O 	O
cholangiocarcinoma 	 DISEASE 	O
are 	 O 	O
bile 	 O 	O
duct 	 O 	O
dilatation 	 O 	O
, 	 O 	O
venous 	 O 	O
obstruction 	 O 	O
and 	 O 	O
arterio 	 O 	O
- 	 O 	O
arterial 	 O 	O
collaterals 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Introductory 	 O 	O
data 	 O 	O
on 	 O 	O
nephroblastoma 	 DISEASE 	O
occurence 	 O 	O
in 	 O 	O
children 	 O 	O
is 	 O 	O
followed 	 O 	O
by 	 O 	O
a 	 O 	O
general 	 O 	O
discussion 	 O 	O
on 	 O 	O
the 	 O 	O
methods 	 O 	O
of 	 O 	O
procedure 	 O 	O
used 	 O 	O
in 	 O 	O
treatment 	 O 	O
of 	 O 	O
these 	 O 	O
tumours 	 O 	O
in 	 O 	O
the 	 O 	O
last 	 O 	O
century 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
second 	 O 	O
family 	 O 	O
, 	 O 	O
two 	 O 	O
boys 	 O 	O
were 	 O 	O
affected 	 O 	O
and 	 O 	O
there 	 O 	O
was 	 O 	O
a 	 O 	O
family 	 O 	O
history 	 O 	O
of 	 O 	O
spontaneous 	 O 	O
abortion 	 O 	O
, 	 O 	O
inguinal 	 DISEASE 	O
hernia 	 DISEASE 	O
, 	 O 	O
and 	 O 	O
umbilical 	 O 	O
hernia 	 O 	O
. 	 O 	O
In 	 O 	O
the 	 O 	O
second 	 O 	O
family 	 O 	O
, 	 O 	O
two 	 O 	O
boys 	 O 	O
were 	 O 	O
affected 	 O 	O
and 	 O 	O
there 	 O 	O
was 	 O 	O
a 	 O 	O
family 	 O 	O
history 	 O 	O
of 	 O 	O
spontaneous 	 O 	O
abortion 	 O 	O
, 	 O 	O
inguinal 	 O 	O
hernia 	 O 	O
, 	 O 	O
and 	 O 	O
umbilical 	 DISEASE 	O
hernia 	 DISEASE 	DISEASE
. 	 O 	O
Pleomorphic 	 DISEASE 	O
adenoma 	 DISEASE 	DISEASE
of 	 O 	O
the 	 O 	DISEASE
salivary 	 O 	O
gland 	 O 	O
is 	 O 	O
classified 	 O 	O
into 	 O 	O
two 	 O 	O
types 	 O 	O
based 	 O 	O
on 	 O 	O
the 	 O 	O
morphology 	 O 	O
of 	 O 	O
the 	 O 	O
cells 	 O 	O
and 	 O 	O
biochemical 	 O 	O
analysis 	 O 	O
of 	 O 	O
glycosaminoglycans 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
( 	 O 	O
ii 	 O 	O
) 	 O 	O
immune 	 O 	O
adsorbent 	 O 	O
columns 	 O 	O
prepared 	 O 	O
from 	 O 	O
tumor 	 O 	O
- 	 O 	O
immune 	 O 	O
sera 	 O 	O
recognized 	 O 	O
the 	 O 	O
purified 	 O 	O
blocking 	 O 	O
fractions 	 O 	O
in 	 O 	O
a 	 O 	O
tumor 	 O 	O
- 	 O 	O
specific 	 O 	O
fashion 	 O 	O
, 	 O 	O
indicating 	 O 	O
that 	 O 	O
a 	 O 	O
portion 	 O 	O
of 	 O 	O
the 	 O 	O
humoral 	 O 	O
response 	 O 	O
in 	 O 	O
the 	 O 	O
immune 	 O 	O
mice 	 O 	O
was 	 O 	O
directed 	 O 	O
against 	 O 	O
a 	 O 	O
factor 	 O 	O
that 	 O 	O
was 	 O 	O
individually 	 O 	O
distinct 	 O 	O
for 	 O 	O
each 	 O 	O
tumor 	 O 	DISEASE
. 	 O 	O
Development 	 O 	O
of 	 O 	O
homolateral 	 O 	O
atrophy 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
a 	 O 	O
study 	 O 	O
of 	 O 	O
nonsurgical 	 O 	O
therapy 	 O 	O
of 	 O 	O
Cushing 	 O 	O
's 	 O 	DISEASE
disease 	 O 	DISEASE
, 	 O 	O
62 	 O 	O
patients 	 O 	O
received 	 O 	O
O 	 O 	O
, 	 O 	O
p'-dichlorodiphenyldichloroethane 	 O 	O
( 	 O 	O
O 	 O 	O
, 	 O 	O
p'DDD 	 O 	O
) 	 O 	O
, 	 O 	O
16 	 O 	O
of 	 O 	O
whom 	 O 	O
also 	 O 	O
received 	 O 	O
cobalt 	 O 	O
irradiation 	 O 	O
of 	 O 	O
the 	 O 	O
pituitary 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
a 	 O 	O
prospective 	 O 	O
study 	 O 	O
on 	 O 	O
an 	 O 	O
obstetric 	 O 	O
population 	 O 	O
( 	 O 	O
1,059 	 O 	O
cases 	 O 	O
) 	 O 	O
an 	 O 	O
association 	 O 	O
was 	 O 	O
found 	 O 	O
between 	 O 	O
elevated 	 O 	O
levels 	 O 	O
of 	 O 	O
maternal 	 O 	O
serum 	 O 	O
AFP 	 O 	O
at 	 O 	O
weeks 	 O 	O
16 	 O 	O
to 	 O 	O
22 	 O 	O
and 	 O 	O
the 	 O 	O
occurrence 	 O 	O
of 	 O 	O
premature 	 DISEASE 	O
labor 	 DISEASE 	O
or 	 O 	O
the 	 O 	O
need 	 O 	O
for 	 O 	O
emergency 	 O 	O
cesarean 	 O 	O
section 	 O 	O
in 	 O 	O
the 	 O 	O
third 	 O 	O
trimester 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
dorsal 	 O 	O
facilitatory 	 O 	O
area 	 O 	O
appears 	 O 	O
to 	 O 	O
be 	 O 	O
an 	 O 	O
extension 	 O 	O
of 	 O 	O
the 	 O 	O
lateral 	 O 	O
division 	 O 	O
of 	 O 	O
the 	 O 	O
dorsolongitudinal 	 O 	O
fasciculus 	 O 	O
and 	 O 	O
to 	 O 	O
extend 	 O 	O
medially 	 O 	O
to 	 O 	O
join 	 O 	O
the 	 O 	O
Fields 	 O 	O
of 	 O 	O
Forel 	 O 	O
, 	 O 	O
the 	 O 	O
ventral 	 O 	O
tegmental 	 O 	O
area 	 O 	O
of 	 O 	O
Tsai 	 O 	O
, 	 O 	O
and 	 O 	O
the 	 O 	O
parvocellular 	 O 	O
, 	 O 	O
paraventricular 	 O 	O
, 	 O 	O
and 	 O 	O
periventricular 	 O 	DISEASE
nuclei 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Dystrophic 	 O 	O
and 	 O 	O
degenerative 	 O 	O
changes 	 O 	O
in 	 O 	O
axons 	 O 	O
of 	 O 	O
all 	 O 	O
fiber 	 O 	O
classes 	 O 	O
and 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
clusters 	 O 	O
of 	 O 	O
thinly 	 O 	O
myelinated 	 O 	O
small 	 O 	O
fibers 	 O 	O
suggest 	 O 	O
that 	 O 	O
neuroaxonal 	 O 	O
degeneration 	 O 	O
and 	 O 	O
incomplete 	 O 	O
regeneration 	 O 	O
may 	 O 	O
represent 	 O 	O
the 	 O 	O
major 	 O 	O
pathogenetic 	 O 	O
mechanism 	 O 	O
of 	 O 	O
the 	 O 	DISEASE
neuropathy 	 DISEASE 	DISEASE
in 	 O 	O
these 	 O 	O
hypothyroid 	 O 	O
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
However 	 O 	O
, 	 O 	O
mast 	 DISEASE 	DISEASE
cell 	 DISEASE 	DISEASE
hyperplasia 	 DISEASE 	DISEASE
developed 	 O 	DISEASE
more 	 O 	O
slowly 	 O 	O
than 	 O 	O
RVH 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
present 	 O 	O
study 	 O 	O
is 	 O 	O
the 	 O 	O
fourth 	 O 	O
in 	 O 	O
the 	 O 	O
series 	 O 	O
of 	 O 	O
combined 	 O 	O
therapeutic 	 O 	O
trials 	 O 	O
conducted 	 O 	O
in 	 O 	O
advanced 	 O 	O
oral 	 DISEASE 	O
squamous 	 DISEASE 	DISEASE
cell 	 DISEASE 	DISEASE
carcinoma 	 DISEASE 	DISEASE
since 	 O 	O
1958 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
For 	 O 	O
comparison 	 O 	O
, 	 O 	O
cells 	 O 	O
of 	 O 	O
seven 	 O 	O
patients 	 O 	O
with 	 O 	O
chorioretinitis 	 DISEASE 	O
only 	 O 	O
and 	 O 	O
cells 	 O 	O
of 	 O 	O
six 	 O 	O
patients 	 O 	O
with 	 O 	O
encephalitis 	 O 	O
of 	 O 	O
unknown 	 O 	O
etiology 	 O 	O
were 	 O 	O
also 	 O 	O
tested 	 O 	O
. 	 O 	O
For 	 O 	O
comparison 	 O 	O
, 	 O 	O
cells 	 O 	O
of 	 O 	O
seven 	 O 	O
patients 	 O 	O
with 	 O 	O
chorioretinitis 	 O 	O
only 	 O 	O
and 	 O 	O
cells 	 O 	O
of 	 O 	O
six 	 O 	O
patients 	 O 	O
with 	 O 	O
encephalitis 	 DISEASE 	DISEASE
of 	 O 	O
unknown 	 O 	O
etiology 	 O 	O
were 	 O 	O
also 	 O 	O
tested 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Obesity 	 DISEASE 	O
was 	 O 	O
the 	 O 	O
major 	 O 	O
underlying 	 O 	O
factor 	 O 	O
associated 	 O 	O
with 	 O 	O
the 	 O 	O
lipidemia 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
However 	 O 	O
, 	 O 	O
there 	 O 	O
is 	 O 	O
still 	 O 	O
a 	 O 	O
lack 	 O 	O
of 	 O 	O
basic 	 O 	O
knowledge 	 O 	O
about 	 O 	O
the 	 O 	O
biology 	 O 	O
, 	 O 	O
taxonomy 	 O 	O
, 	 O 	O
and 	 O 	O
epidemiology 	 O 	O
of 	 O 	O
P 	 O 	O
carinii 	 O 	O
; 	 O 	O
of 	 O 	O
specific 	 O 	O
host 	 O 	O
immune 	 O 	O
factors 	 O 	O
involved 	 O 	O
in 	 O 	O
the 	 O 	O
pathogenesis 	 O 	O
of 	 O 	O
the 	 O 	DISEASE
infection 	 O 	O
; 	 O 	O
and 	 O 	O
of 	 O 	O
a 	 O 	O
clinically 	 O 	O
reliable 	 O 	O
serologic 	 O 	O
test 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Cultures 	 O 	O
from 	 O 	O
seronegative 	 O 	O
donors 	 O 	O
prepared 	 O 	O
by 	 O 	O
Ficoll 	 O 	O
- 	 O 	O
Hypaque 	 O 	O
gradients 	 O 	O
produced 	 O 	O
interferon 	 O 	O
but 	 O 	O
did 	 O 	O
not 	 O 	O
transform 	 O 	O
when 	 O 	O
stimulated 	 O 	O
by 	 O 	O
herpes 	 DISEASE 	DISEASE
simplex 	 DISEASE 	O
antigen 	 O 	O
. 	 O 	O
	PUNCT	O
6970	Immune	PROPN	O
6970	 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Twenty 	 O 	O
- 	 O 	O
five 	 O 	O
first 	 O 	O
- 	 O 	O
degree 	 O 	O
relatives 	 O 	O
with 	 O 	O
ankylosing 	 DISEASE 	DISEASE
spondylitis 	 DISEASE 	O
were 	 O 	O
all 	 O 	O
B27 	 O 	O
positive 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
An 	 O 	O
animal 	 O 	O
model 	 O 	O
for 	 O 	O
sepsis 	 O 	DISEASE
- 	 O 	O
associated 	 O 	O
DIC 	 O 	O
was 	 O 	O
developed 	 O 	O
in 	 O 	O
order 	 O 	O
to 	 O 	O
permit 	 O 	O
study 	 O 	O
of 	 O 	O
the 	 O 	O
appearance 	 O 	O
and 	 O 	O
development 	 O 	O
of 	 O 	O
this 	 O 	O
syndrome 	 O 	O
in 	 O 	O
relation 	 O 	O
to 	 O 	O
the 	 O 	O
entire 	 O 	O
disease 	 O 	O
process 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
spondylitis 	 O 	O
. 	 O 	O
The 	 O 	O
only 	 O 	O
instance 	 O 	O
of 	 O 	O
disassociation 	 O 	O
of 	 O 	O
B27 	 O 	O
and 	 O 	O
spondylitis 	 O 	O
in 	 O 	O
a 	 O 	O
family 	 O 	O
was 	 O 	O
where 	 O 	O
the 	 O 	O
proband 	 O 	O
had 	 O 	O
ulcerative 	 DISEASE 	DISEASE
colitis 	 DISEASE 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
spondylitis 	 O 	O
. 	 O 	O
The 	 O 	O
only 	 O 	O
instance 	 O 	O
of 	 O 	O
disassociation 	 O 	O
of 	 O 	O
B27 	 O 	O
and 	 O 	O
spondylitis 	 O 	O
in 	 O 	O
a 	 O 	O
family 	 O 	O
was 	 O 	O
where 	 O 	O
the 	 O 	O
proband 	 O 	O
had 	 O 	O
ulcerative 	 O 	O
colitis 	 O 	DISEASE
as 	 O 	O
well 	 O 	O
as 	 O 	O
spondylitis 	 DISEASE 	DISEASE
. 	 O 	O
with 	 O 	O
occasional 	 O 	O
squamous 	 O 	O
metaplasia 	 O 	O
, 	 O 	O
stromal 	 DISEASE 	DISEASE
sarcoma 	 DISEASE 	DISEASE
, 	 O 	O
myxosarcoma 	 O 	O
and 	 O 	O
chondrosarcoma 	 O 	O
. 	 O 	O
The 	 O 	O
tumor 	 O 	O
was 	 O 	O
a 	 O 	O
mixture 	 O 	O
of 	 O 	O
adenocarcinoma 	 O 	O
with 	 O 	O
occasional 	 O 	O
squamous 	 O 	O
metaplasia 	 O 	O
, 	 O 	O
stromal 	 O 	O
sarcoma 	 O 	O
, 	 O 	O
myxosarcoma 	 DISEASE 	O
and 	 O 	O
chondrosarcoma 	 O 	O
. 	 O 	O
The 	 O 	O
tumor 	 O 	O
was 	 O 	O
a 	 O 	O
mixture 	 O 	O
of 	 O 	O
adenocarcinoma 	 O 	O
with 	 O 	O
occasional 	 O 	O
squamous 	 O 	O
metaplasia 	 O 	O
, 	 O 	O
stromal 	 O 	DISEASE
sarcoma 	 O 	DISEASE
, 	 O 	O
myxosarcoma 	 O 	O
and 	 O 	O
chondrosarcoma 	 DISEASE 	O
. 	 O 	O
) 	 O 	O
. 	 O 	O
Explants 	 O 	O
also 	 O 	O
supported 	 O 	O
the 	 O 	O
replication 	 O 	O
of 	 O 	O
type 	 O 	O
1 	 O 	O
herpes 	 O 	O
simplex 	 O 	O
virus 	 O 	O
and 	 O 	O
a 	 O 	O
	PUNCT	O
30934	non	ADJ	O
30934	-	PUNCT	O
30934	human	NOUN	O
30934	 	 O 	O
herpes 	 DISEASE 	DISEASE
simplex 	 DISEASE 	O
virus 	 O 	O
( 	 O 	O
pseudo 	 O 	O
- 	 O 	O
rabies 	 O 	O
virus 	 O 	O
) 	 O 	O
. 	 O 	O
Explants 	 O 	O
also 	 O 	O
supported 	 O 	O
the 	 O 	O
replication 	 O 	O
of 	 O 	O
type 	 O 	O
1 	 O 	O
herpes 	 O 	O
simplex 	 O 	O
virus 	 O 	O
and 	 O 	O
a 	 O 	O
	PUNCT	O
30934	non	ADJ	O
30934	-	PUNCT	O
30934	human	NOUN	O
30934	 	 O 	O
herpes 	 O 	DISEASE
simplex 	 O 	O
virus 	 O 	O
( 	 O 	O
pseudo 	 O 	O
- 	 O 	O
rabies 	 DISEASE 	DISEASE
virus 	 O 	O
) 	 O 	O
. 	 O 	O
On 	 O 	O
the 	 O 	O
basis 	 O 	O
of 	 O 	O
clinicopathologic 	 O 	O
and 	 O 	O
ultrastructural 	 O 	O
features 	 O 	O
found 	 O 	O
by 	 O 	O
both 	 O 	O
light 	 O 	O
and 	 O 	O
electron 	 O 	O
microscopy 	 O 	O
, 	 O 	O
we 	 O 	O
diagnosed 	 O 	O
sweat 	 DISEASE 	O
gland 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
of 	 O 	O
the 	 O 	O
eyelid 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
synthesis 	 O 	O
of 	 O 	O
the 	 O 	O
complex 	 O 	O
- 	 O 	O
type 	 O 	O
oligosaccharide 	 O 	O
unit 	 O 	O
of 	 O 	O
the 	 O 	O
vesicular 	 O 	DISEASE
stomatitis 	 DISEASE 	DISEASE
virus 	 O 	DISEASE
G 	 O 	O
protein 	 O 	O
is 	 O 	O
initiated 	 O 	O
by 	 O 	O
the 	 O 	O
en 	 O 	O
bloc 	 O 	O
transfer 	 O 	O
of 	 O 	O
a 	 O 	O
high 	 O 	O
molecular 	 O 	O
weight 	 O 	O
oligosaccharide 	 O 	O
from 	 O 	O
a 	 O 	O
lipid 	 O 	O
carrier 	 O 	O
to 	 O 	O
the 	 O 	O
nascent 	 O 	O
polypeptide 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Two 	 O 	O
cases 	 O 	O
of 	 O 	O
progressive 	 DISEASE 	O
supranuclear 	 DISEASE 	DISEASE
palsy 	 DISEASE 	DISEASE
( 	 O 	O
PSP 	 O 	O
) 	 O 	O
are 	 O 	O
reported 	 O 	O
in 	 O 	O
two 	 O 	O
men 	 O 	O
( 	 O 	O
49 	 O 	O
and 	 O 	O
75years 	 O 	O
old 	 O 	O
) 	 O 	O
who 	 O 	O
for 	 O 	O
one 	 O 	O
and 	 O 	O
four 	 O 	O
years 	 O 	O
respectively 	 O 	O
had 	 O 	O
sudden 	 O 	O
falling 	 O 	O
while 	 O 	O
walking 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
lysed 	 O 	O
autochthonous 	 O 	O
tumor 	 O 	DISEASE
cell 	 O 	O
vaccine 	 O 	O
( 	 O 	O
vaccinia 	 DISEASE 	O
oncolysate 	 O 	O
) 	 O 	O
is 	 O 	O
introduced 	 O 	O
as 	 O 	O
a 	 O 	O
new 	 O 	O
specific 	 O 	O
, 	 O 	O
active 	 O 	O
immunotherapeutic 	 O 	O
agent 	 O 	O
against 	 O 	O
human 	 O 	O
cancer 	 O 	O
. 	 O 	O
A 	 O 	O
vaccinia 	 O 	O
virus 	 O 	O
- 	 O 	O
lysed 	 O 	O
autochthonous 	 O 	O
tumor 	 O 	O
cell 	 O 	O
vaccine 	 O 	O
( 	 O 	O
vaccinia 	 O 	O
oncolysate 	 O 	O
) 	 O 	O
is 	 O 	O
introduced 	 O 	O
as 	 O 	O
a 	 O 	O
new 	 O 	O
specific 	 O 	O
, 	 O 	O
active 	 O 	O
immunotherapeutic 	 O 	O
agent 	 O 	O
against 	 O 	O
human 	 O 	O
cancer 	 DISEASE 	DISEASE
. 	 O 	O
Absorption 	 O 	O
tests 	 O 	O
indicate 	 O 	O
that 	 O 	O
G(RADA1 	 O 	O
) 	 O 	O
is 	 O 	O
present 	 O 	O
in 	 O 	O
the 	 O 	O
normal 	 O 	O
lymphatic 	 O 	O
tissue 	 O 	O
and 	 O 	O
leukemias 	 O 	O
of 	 O 	O
mouse 	 O 	O
strains 	 O 	O
with 	 O 	O
high 	 O 	DISEASE
spontaneous 	 O 	O
leukemia 	 DISEASE 	DISEASE
- 	 O 	O
incidence 	 O 	O
, 	 O 	O
e.g. 	 O 	O
, 	 O 	O
AKR 	 O 	O
, 	 O 	O
C58 	 O 	O
, 	 O 	O
and 	 O 	O
C3H 	 O 	O
/ 	 O 	O
Figge 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
immunity 	 O 	O
of 	 O 	O
these 	 O 	O
animals 	 O 	O
against 	 O 	O
foot 	 O 	O
- 	 O 	O
and 	 O 	O
- 	 O 	O
mouth 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
was 	 O 	O
controlled 	 O 	O
after 	 O 	O
the 	 O 	O
first 	 O 	O
vaccination 	 O 	O
and 	 O 	O
booster 	 O 	O
by 	 O 	O
serology 	 O 	O
( 	 O 	O
neutralizing 	 O 	O
antibody 	 O 	O
count 	 O 	O
and 	 O 	O
immunology 	 O 	O
virulence 	 O 	O
testing 	 O 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
It 	 O 	O
may 	 O 	O
be 	 O 	O
speculated 	 O 	O
that 	 O 	O
the 	 O 	O
endogenous 	 O 	O
EBV 	 O 	O
genome 	 O 	O
of 	 O 	O
6410 	 O 	O
cells 	 O 	O
was 	 O 	O
activated 	 O 	O
and 	 O 	O
gave 	 O 	O
rise 	 O 	O
to 	 O 	O
a 	 O 	O
different 	 O 	O
strain 	 O 	O
of 	 O 	O
EBV 	 O 	O
or 	 O 	O
to 	 O 	O
a 	 O 	O
mixed 	 O 	O
progeny 	 O 	O
- 	 O 	O
parent 	 O 	O
population 	 O 	O
as 	 O 	O
a 	 O 	O
result 	 O 	O
of 	 O 	O
dual 	 O 	O
infection 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Two 	 O 	O
forms 	 O 	O
of 	 O 	O
rabbit 	 O 	O
pulmonary 	 O 	DISEASE
cytochrome 	 O 	O
P-450 	 O 	O
have 	 O 	O
been 	 O 	O
characterized 	 O 	O
spectrally 	 O 	O
and 	 O 	O
their 	 O 	O
activities 	 O 	O
in 	 O 	O
reconstituted 	 O 	O
monooxygenase 	 O 	O
systems 	 O 	O
investigated 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
case 	 O 	O
is 	 O 	O
reported 	 O 	O
of 	 O 	O
a 	 O 	O
22-year 	 O 	O
- 	 O 	O
old 	 O 	O
man 	 O 	O
with 	 O 	O
Gardner 	 O 	DISEASE
's 	 O 	DISEASE
syndrome 	 O 	DISEASE
who 	 O 	O
died 	 O 	O
as 	 O 	O
a 	 O 	O
consequence 	 O 	O
of 	 O 	O
unremitting 	 O 	O
spread 	 O 	O
of 	 O 	O
an 	 O 	O
intraabdominal 	 O 	O
desmoid 	 O 	O
four 	 O 	O
and 	 O 	O
a 	 O 	O
half 	 O 	O
years 	 O 	O
after 	 O 	O
colectomy 	 O 	O
for 	 O 	O
polyposis 	 O 	O
, 	 O 	O
and 	 O 	O
two 	 O 	O
and 	 O 	O
a 	 O 	O
half 	 O 	O
years 	 O 	O
after 	 O 	O
clinical 	 O 	O
presentation 	 O 	O
of 	 O 	O
the 	 O 	O
desmoid 	 O 	O
tumour 	 O 	O
. 	 O 	O
the 	 O 	O
coronary 	 DISEASE 	O
heart 	 DISEASE 	DISEASE
disease 	 DISEASE 	DISEASE
in 	 O 	O
the 	 O 	O
post 	 O 	O
- 	 O 	O
infarction 	 O 	DISEASE
phase 	 O 	O
, 	 O 	O
a 	 O 	O
basic 	 O 	O
therapy 	 O 	O
with 	 O 	O
a 	 O 	O
glycoside 	 O 	O
and 	 O 	O
anticoagulants 	 O 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
an 	 O 	O
individually 	 O 	O
to 	 O 	O
be 	 O 	O
varied 	 O 	O
additive 	 O 	O
therapy 	 O 	O
with 	 O 	O
nitro 	 O 	O
- 	 O 	O
preparations 	 O 	O
, 	 O 	O
beta 	 O 	O
- 	 O 	O
sympathicolytics 	 O 	O
, 	 O 	O
saluretics 	 O 	O
, 	 O 	O
anti 	 O 	O
- 	 O 	O
hypertensive 	 O 	O
agents 	 O 	O
and 	 O 	O
antiarrhythmic 	 O 	O
agents 	 O 	O
are 	 O 	O
necessary 	 O 	O
. 	 O 	O
Quantitative 	 O 	O
determination 	 O 	O
of 	 O 	O
fibrous 	 O 	DISEASE
amphibole 	 O 	O
phases 	 O 	O
, 	 O 	O
present 	 O 	O
in 	 O 	O
a 	 O 	O
range 	 O 	O
of 	 O 	O
water 	 O 	O
samples 	 O 	O
, 	 O 	O
was 	 O 	O
undertaken 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Serum 	 O 	O
ferritin 	 O 	O
concentrations 	 O 	O
were 	 O 	O
found 	 O 	O
to 	 O 	O
be 	 O 	O
raised 	 O 	O
, 	 O 	O
often 	 O 	O
considerably 	 O 	O
, 	 O 	O
in 	 O 	O
58 	 O 	O
of 	 O 	O
76 	 O 	O
black 	 O 	O
patients 	 O 	O
with 	 O 	O
primary 	 DISEASE 	O
liver 	 DISEASE 	DISEASE
cancer 	 DISEASE 	DISEASE
( 	 O 	O
PLC 	 O 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
10 	 O 	O
per 	 O 	O
cent 	 O 	O
of 	 O 	O
the 	 O 	O
cases 	 O 	O
with 	 O 	O
gastroenteritis 	 DISEASE 	DISEASE
infection 	 O 	DISEASE
was 	 O 	O
caused 	 O 	O
by 	 O 	O
adenovirus 	 O 	O
or 	 O 	O
Salmonella 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Only 	 O 	O
6 	 O 	O
% 	 O 	O
of 	 O 	O
those 	 O 	O
who 	 O 	O
stopped 	 O 	O
gold 	 O 	O
injections 	 O 	O
during 	 O 	O
the 	 O 	O
first 	 O 	O
18 	 O 	O
months 	 O 	O
subsequently 	 O 	O
developed 	 O 	O
	PUNCT	O
18229	spontaneous	ADJ	O
18229	 	 O 	O
remissions 	 O 	O
, 	 O 	O
although 	 O 	O
initially 	 O 	O
both 	 O 	O
groups 	 O 	O
had 	 O 	O
comparable 	 O 	O
moderately 	 O 	O
severe 	 O 	O
rheumatoid 	 DISEASE 	O
arthritis 	 DISEASE 	DISEASE
of 	 O 	O
6 	 O 	O
to 	 O 	O
8 	 O 	O
years 	 O 	O
' 	 O 	O
duration 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
One 	 O 	O
case 	 O 	O
was 	 O 	O
diagnosed 	 O 	O
as 	 O 	O
lichen 	 DISEASE 	O
planus 	 DISEASE 	O
and 	 O 	O
one 	 O 	O
as 	 O 	O
cornu 	 O 	O
cutaneum 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Exploratory 	 O 	O
surgery 	 O 	O
revealed 	 O 	O
bilateral 	 O 	DISEASE
polycystic 	 DISEASE 	DISEASE
ovaries 	 DISEASE 	DISEASE
and 	 O 	O
a 	 O 	O
pure 	 O 	O
thecoma 	 O 	O
in 	 O 	O
the 	 O 	O
right 	 O 	O
ovary 	 O 	O
which 	 O 	O
was 	 O 	O
not 	 O 	O
visible 	 O 	O
on 	 O 	O
surface 	 O 	O
examination 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Diagnostic 	 O 	O
and 	 O 	O
therapeutic 	 O 	O
consequences 	 O 	O
are 	 O 	O
discussed 	 O 	O
, 	 O 	O
with 	 O 	O
special 	 O 	O
emphasis 	 O 	O
on 	 O 	O
the 	 O 	O
diagnostic 	 O 	O
problem 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
endogenous 	 DISEASE 	O
depression 	 DISEASE 	O
who 	 O 	O
complain 	 O 	O
mainly 	 O 	O
of 	 O 	O
gastroenterologic 	 O 	O
symptoms 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Methylmalonyl 	 O 	O
- 	 O 	O
CoA 	 O 	O
carbonylmutase 	 O 	O
( 	 O 	O
mutase 	 O 	O
) 	 O 	O
activity 	 O 	O
was 	 O 	O
measured 	 O 	O
in 	 O 	O
fibroblast 	 O 	O
extracts 	 O 	O
from 	 O 	O
15 	 O 	O
patients 	 O 	O
with 	 O 	O
methylmalonic 	 DISEASE 	O
acidemia 	 DISEASE 	DISEASE
and 	 O 	O
in 	 O 	O
extracts 	 O 	O
of 	 O 	O
postmortem 	 O 	O
tissues 	 O 	O
from 	 O 	O
6 	 O 	O
of 	 O 	O
these 	 O 	O
children 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Approximately 	 O 	O
80 	 O 	O
% 	 O 	O
of 	 O 	O
cells 	 O 	O
will 	 O 	O
usually 	 O 	O
phagocytize 	 O 	O
and 	 O 	O
concentrate 	 O 	O
India 	 O 	O
ink 	 O 	O
granules 	 O 	O
, 	 O 	O
if 	 O 	O
heparinized 	 O 	DISEASE
blood 	 O 	O
mixed 	 O 	DISEASE
with 	 O 	O
India 	 O 	O
ink 	 O 	O
is 	 O 	O
incubated 	 O 	O
for 	 O 	O
two 	 O 	O
hours 	 O 	O
at 	 O 	O
37 	 O 	O
degrees 	 O 	O
C. 	 O 	O
A 	 O 	O
decrease 	 O 	O
of 	 O 	O
the 	 O 	O
India 	 O 	O
ink 	 O 	O
phagocytosis 	 O 	O
was 	 O 	O
detected 	 O 	O
in 	 O 	O
6 	 O 	O
patients 	 O 	O
and 	 O 	O
in 	 O 	O
10 	 O 	O
dogs 	 O 	O
during 	 O 	O
the 	 O 	O
shock 	 O 	O
. 	 O 	O
A 	 O 	O
human 	 O 	O
lung 	 O 	DISEASE
tumor 	 O 	O
- 	 O 	O
associated 	 O 	O
fetal 	 O 	O
antigen 	 O 	O
( 	 O 	O
LTFA 	 O 	O
) 	 O 	O
has 	 O 	O
been 	 O 	O
partially 	 O 	O
isolated 	 O 	O
and 	 O 	O
characterized 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
p 	 O 	O
less 	 O 	O
than 	 O 	O
0.001 	 O 	O
) 	 O 	O
of 	 O 	O
all 	 O 	O
sera 	 O 	O
from 	 O 	O
patients 	 O 	O
with 	 O 	O
squamous 	 O 	O
cell 	 O 	O
carcinoma 	 O 	O
reacted 	 O 	O
with 	 O 	O
antigens 	 O 	O
from 	 O 	O
herpes 	 O 	O
simplex 	 O 	O
virus 	 O 	O
type 	 O 	O
1-transformed 	 O 	O
cells 	 O 	O
, 	 O 	O
while 	 O 	O
84 	 O 	O
% 	 O 	O
( 	 O 	O
p 	 O 	O
less 	 O 	O
than 	 O 	O
0.001 	 O 	O
) 	 O 	O
of 	 O 	O
the 	 O 	O
same 	 O 	O
sera 	 O 	O
reacted 	 O 	O
with 	 O 	O
antigen 	 O 	O
preparations 	 O 	O
from 	 O 	O
herpes 	 DISEASE 	O
simplex 	 DISEASE 	DISEASE
virus 	 O 	O
type 	 O 	O
2-transformed 	 O 	O
cells 	 O 	O
. 	 O 	O
In 	 O 	O
the 	 O 	O
involved 	 O 	O
psoriatic 	 O 	DISEASE
skin 	 O 	O
the 	 O 	O
total 	 O 	O
NAD 	 O 	O
content 	 O 	O
was 	 O 	O
increased 	 O 	O
to 	 O 	O
1.5 	 O 	O
mmoles 	 O 	O
/ 	 O 	O
kg 	 O 	O
, 	 O 	O
this 	 O 	O
increase 	 O 	O
being 	 O 	O
mainly 	 O 	O
due 	 O 	O
to 	 O 	O
a 	 O 	O
rise 	 O 	O
in 	 O 	O
NAD+ 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Virus 	 O 	O
was 	 O 	O
recovered 	 O 	O
from 	 O 	O
its 	 O 	O
principal 	 O 	O
organs 	 O 	O
, 	 O 	O
intestinal 	 O 	DISEASE
canal 	 O 	DISEASE
, 	 O 	O
and 	 O 	O
lymph 	 O 	O
nodes 	 O 	O
of 	 O 	O
various 	 O 	O
regions 	 O 	O
of 	 O 	O
the 	 O 	O
body 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
histologic 	 O 	O
appearance 	 O 	O
of 	 O 	O
the 	 O 	O
tumor 	 O 	DISEASE
changed 	 O 	O
after 	 O 	O
chemotherapy 	 O 	O
, 	 O 	O
varying 	 O 	O
from 	 O 	O
diffuse 	 O 	O
necrosis 	 O 	O
within 	 O 	O
48 	 O 	O
hours 	 O 	O
of 	 O 	O
initial 	 O 	O
therapy 	 O 	O
to 	 O 	O
extreme 	 O 	O
pleomorphism 	 O 	O
of 	 O 	O
tumor 	 O 	O
cells 	 O 	O
after 	 O 	O
9 	 O 	O
months 	 O 	O
of 	 O 	O
therapy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Viral 	 O 	O
studies 	 O 	O
strongly 	 O 	O
supported 	 O 	O
a 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
Herpes 	 DISEASE 	O
Zoster 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
At 	 O 	O
the 	 O 	O
completion 	 O 	O
of 	 O 	O
the 	 O 	O
assay 	 O 	O
, 	 O 	O
the 	 O 	O
leukocytes 	 O 	O
from 	 O 	O
Patient 	 O 	O
1 	 O 	O
were 	 O 	O
equally 	 O 	O
nonadherent 	 O 	O
to 	 O 	O
both 	 O 	O
cancer 	 DISEASE 	DISEASE
extracts 	 O 	O
with 	 O 	O
a 	 O 	O
nonadherence 	 O 	DISEASE
index 	 O 	O
value 	 O 	O
of 	 O 	O
8 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
clinical 	 O 	O
and 	 O 	O
biochemical 	 O 	O
features 	 O 	O
found 	 O 	O
in 	 O 	O
this 	 O 	O
boy 	 O 	O
were 	 O 	O
compared 	 O 	O
with 	 O 	O
the 	 O 	O
known 	 O 	O
types 	 O 	O
of 	 O 	O
mucopolysaccharidosis 	 DISEASE 	O
and 	 O 	O
it 	 O 	O
has 	 O 	O
been 	 O 	O
concluded 	 O 	O
that 	 O 	O
this 	 O 	O
case 	 O 	O
is 	 O 	O
a 	 O 	O
new 	 O 	O
type 	 O 	O
of 	 O 	O
mucopolysacchariduria 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
No 	 O 	O
HindIII 	 O 	O
- 	 O 	O
G 	 O 	O
- 	 O 	O
specific 	 O 	O
sequences 	 O 	O
were 	 O 	O
detected 	 O 	O
in 	 O 	O
RNAs 	 O 	O
from 	 O 	O
21 	 O 	O
squamous 	 O 	O
cell 	 O 	O
Cas 	 O 	O
, 	 O 	O
3 	 O 	O
oat 	 O 	DISEASE
cell 	 O 	O
Cas 	 O 	O
, 	 O 	O
2 	 O 	O
stomach 	 O 	O
Cas 	 O 	O
, 	 O 	O
or 	 O 	O
18 	 O 	O
colon 	 O 	O
Cas 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Because 	 O 	O
of 	 O 	O
inadequate 	 O 	O
possibilities 	 O 	O
of 	 O 	O
mechanically 	 O 	O
reducing 	 O 	O
the 	 O 	O
plaque 	 O 	O
, 	 O 	O
changes 	 O 	O
of 	 O 	O
the 	 O 	O
gingiva 	 O 	O
in 	 O 	O
the 	 O 	O
form 	 O 	O
of 	 O 	O
granulomatous 	 O 	DISEASE
gingivitis 	 DISEASE 	DISEASE
accompanied 	 O 	O
by 	 O 	O
osteolysis 	 O 	O
were 	 O 	O
observed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
the 	 O 	O
precallosal 	 O 	O
cingulate 	 O 	O
gyrus 	 O 	O
, 	 O 	O
gyrus 	 O 	O
rectus 	 O 	O
, 	 O 	O
medial 	 O 	O
amygdata 	 O 	O
, 	 O 	O
central 	 O 	O
amygdaloid 	 O 	O
nucleus 	 O 	O
/ 	 O 	O
substantia 	 O 	O
innominata 	 O 	O
, 	 O 	O
nucleus 	 O 	O
striae 	 O 	O
terminalis 	 O 	O
, 	 O 	O
dorsal 	 O 	O
hypothalamus 	 O 	O
, 	 O 	O
midline 	 O 	O
thalamus 	 O 	O
, 	 O 	O
periventricular 	 O 	DISEASE
grey 	 O 	O
, 	 O 	O
dorsolateral 	 O 	O
and 	 O 	O
ventrolateral 	 O 	O
midbrain 	 O 	O
tegmentum 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
relative 	 O 	O
frequency 	 O 	O
of 	 O 	O
lymphocytes 	 O 	O
with 	 O 	O
surface 	 O 	O
immunoglobulins 	 O 	O
( 	 O 	O
sIgM 	 O 	O
, 	 O 	O
sIgG 	 O 	O
, 	 O 	O
sIgA 	 O 	O
) 	 O 	O
was 	 O 	O
studied 	 O 	O
in 	 O 	O
breast 	 O 	O
- 	 O 	DISEASE
cancer 	 DISEASE 	DISEASE
patients 	 O 	O
' 	 O 	O
axillary 	 O 	O
lymph 	 O 	O
nodes 	 O 	O
by 	 O 	O
the 	 O 	O
immunofluorescence 	 O 	O
technique 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
principle 	 O 	O
and 	 O 	O
the 	 O 	O
underlying 	 O 	O
results 	 O 	O
supporting 	 O 	O
the 	 O 	O
concept 	 O 	O
wil 	 O 	O
be 	 O 	O
presented 	 O 	O
and 	 O 	O
the 	 O 	O
practical 	 O 	O
implications 	 O 	DISEASE
will 	 O 	O
be 	 O 	O
discussed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Alcohol 	 O 	O
and 	 O 	O
opiate 	 O 	DISEASE
abuse 	 O 	DISEASE
among 	 O 	O
Indian 	 O 	O
and 	 O 	O
non 	 O 	O
- 	 O 	O
Indian 	 O 	O
are 	 O 	O
presented 	 O 	O
in 	 O 	O
case 	 O 	O
histories 	 O 	O
proving 	 O 	O
to 	 O 	O
be 	 O 	O
asymptomatic 	 O 	O
under 	 O 	O
Indian 	 O 	O
guidance 	 O 	O
and 	 O 	O
through 	 O 	O
participation 	 O 	O
in 	 O 	O
the 	 O 	O
peyote 	 O 	O
ritual 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
features 	 O 	O
of 	 O 	O
this 	 O 	O
tumor 	 O 	O
were 	 O 	O
similar 	 O 	O
to 	 O 	O
those 	 O 	O
reported 	 O 	O
for 	 O 	O
prostatic 	 O 	O
carcinoma 	 DISEASE 	DISEASE
rather 	 O 	O
than 	 O 	O
endometrial 	 O 	O
carcinoma 	 O 	O
supporting 	 O 	O
a 	 O 	O
prostatic 	 O 	O
orgin 	 O 	O
for 	 O 	O
this 	 O 	O
tumor 	 O 	O
. 	 O 	O
The 	 O 	O
ultrastructural 	 O 	O
features 	 O 	O
of 	 O 	O
this 	 O 	O
tumor 	 O 	O
were 	 O 	O
similar 	 O 	O
to 	 O 	O
those 	 O 	O
reported 	 O 	O
for 	 O 	O
prostatic 	 O 	O
carcinoma 	 O 	O
rather 	 O 	O
than 	 O 	O
endometrial 	 DISEASE 	O
carcinoma 	 DISEASE 	O
supporting 	 O 	O
a 	 O 	O
prostatic 	 O 	O
orgin 	 O 	O
for 	 O 	O
this 	 O 	O
tumor 	 O 	DISEASE
. 	 O 	O
, 	 O 	O
and 	 O 	O
pneumonia 	 O 	O
in 	 O 	O
dogs 	 O 	O
. 	 O 	O
The 	 O 	O
L 	 O 	O
- 	 O 	O
S 	 O 	O
combination 	 O 	O
was 	 O 	O
effective 	 O 	O
for 	 O 	O
the 	 O 	O
treatment 	 O 	O
of 	 O 	O
tonsillitis 	 O 	O
, 	 O 	O
conjunctivitis 	 O 	O
, 	 O 	O
laryngitis 	 DISEASE 	O
, 	 O 	O
and 	 O 	O
pneumonia 	 O 	O
in 	 O 	O
dogs 	 O 	O
. 	 O 	O
The 	 O 	O
L 	 O 	O
- 	 O 	O
S 	 O 	O
combination 	 O 	O
was 	 O 	O
effective 	 O 	O
for 	 O 	O
the 	 O 	O
treatment 	 O 	O
of 	 O 	O
tonsillitis 	 O 	O
, 	 O 	O
conjunctivitis 	 O 	O
, 	 O 	O
laryngitis 	 O 	O
, 	 O 	O
and 	 O 	O
pneumonia 	 DISEASE 	DISEASE
in 	 O 	O
dogs 	 O 	O
. 	 O 	O
The 	 O 	O
appearances 	 O 	O
of 	 O 	O
moderate 	 O 	O
and 	 O 	O
severe 	 O 	O
testicular 	 O 	O
tubular 	 O 	O
atrophy 	 O 	DISEASE
differed 	 O 	O
slightly 	 O 	O
from 	 O 	O
one 	 O 	O
another 	 O 	O
with 	 O 	O
regard 	 O 	O
to 	 O 	O
the 	 O 	O
amount 	 O 	O
of 	 O 	O
elastin 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
, 	 O 	O
but 	 O 	O
not 	 O 	O
in 	 O 	O
B10 	 O 	O
( 	 O 	O
bbbbbb 	 O 	O
) 	 O 	O
, 	 O 	O
mice 	 O 	O
. 	 O 	O
In 	 O 	O
both 	 O 	O
influenza 	 O 	O
and 	 O 	O
vaccinia 	 DISEASE 	O
development 	 O 	O
of 	 O 	O
effector 	 O 	O
T 	 O 	O
cells 	 O 	O
operating 	 O 	O
at 	 O 	O
H-2Db 	 O 	O
is 	 O 	O
greatly 	 O 	O
depressed 	 O 	O
in 	 O 	O
B10.A(2R 	 O 	O
) 	 O 	O
( 	 O 	O
kkkddb 	 O 	O
) 	 O 	O
and 	 O 	O
B10.A(4R 	 O 	O
) 	 O 	O
( 	 O 	O
kkbbbb 	 O 	O
) 	 O 	O
, 	 O 	O
but 	 O 	O
not 	 O 	O
in 	 O 	O
B10 	 O 	O
( 	 O 	O
bbbbbb 	 O 	O
) 	 O 	O
, 	 O 	O
mice 	 O 	O
. 	 O 	O
) 	 O 	O
producing 	 O 	O
type 	 O 	O
- 	 O 	O
A 	 O 	O
and 	 O 	O
type 	 O 	O
- 	 O 	O
B 	 O 	O
virus 	 O 	O
particles 	 O 	O
. 	 O 	O
Sera 	 O 	O
of 	 O 	O
Japanese 	 O 	O
women 	 O 	O
with 	 O 	O
breast 	 O 	O
cancer 	 O 	DISEASE
and 	 O 	O
without 	 O 	O
disorders 	 O 	O
of 	 O 	O
the 	 O 	O
mammary 	 O 	O
gland 	 O 	O
gave 	 O 	O
positive 	 O 	O
immunofluorescence 	 O 	O
reaction 	 O 	O
with 	 O 	O
mouse 	 O 	O
mammary 	 DISEASE 	DISEASE
tumor 	 DISEASE 	O
cells 	 O 	O
( 	 O 	O
MMT 	 O 	O
cells 	 O 	O
) 	 O 	O
producing 	 O 	O
type 	 O 	O
- 	 O 	O
A 	 O 	O
and 	 O 	O
type 	 O 	O
- 	 O 	O
B 	 O 	O
virus 	 O 	O
particles 	 O 	O
. 	 O 	O
An 	 O 	O
awareness 	 O 	O
of 	 O 	O
the 	 O 	O
rapidity 	 O 	O
with 	 O 	O
which 	 O 	O
these 	 O 	O
changes 	 O 	O
occur 	 O 	O
, 	 O 	O
and 	 O 	O
their 	 O 	O
extent 	 O 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
their 	 O 	O
potential 	 O 	O
hazards 	 O 	O
, 	 O 	O
should 	 O 	O
cause 	 O 	O
consideration 	 O 	O
of 	 O 	O
more 	 O 	O
aggressive 	 O 	O
attempts 	 O 	O
to 	 O 	O
maintain 	 O 	O
normocarbia 	 O 	O
and 	 O 	O
to 	 O 	O
use 	 O 	O
supplemental 	 O 	O
potassium 	 O 	O
during 	 O 	O
anaesthesia 	 O 	O
, 	 O 	O
particularly 	 O 	O
in 	 O 	O
patients 	 O 	O
with 	 O 	O
cardiac 	 O 	O
disease 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Chromosome 	 O 	O
imbalance 	 O 	O
( 	 O 	O
aneusomy 	 O 	O
) 	 O 	O
is 	 O 	O
the 	 O 	O
leading 	 O 	O
known 	 O 	O
cause 	 O 	O
of 	 O 	O
both 	 O 	O
spontaneous 	 O 	O
abortion 	 O 	O
and 	 O 	O
mental 	 DISEASE 	O
retardation 	 DISEASE 	O
in 	 O 	O
human 	 O 	O
beings 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Twenty 	 O 	O
patients 	 O 	O
had 	 O 	O
isolated 	 O 	O
atrial 	 O 	DISEASE
septal 	 O 	O
defects 	 O 	O
( 	 O 	O
ASD 	 O 	O
) 	 O 	O
, 	 O 	O
6 	 O 	O
patients 	 O 	O
has 	 O 	O
associated 	 O 	O
partial 	 O 	O
pulmonary 	 O 	O
venous 	 O 	O
returns 	 O 	O
( 	 O 	O
PPVR 	 O 	O
) 	 O 	O
and 	 O 	O
2 	 O 	O
patients 	 O 	O
had 	 O 	O
isolated 	 O 	O
PPVR 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
An 	 O 	O
attempt 	 O 	O
is 	 O 	O
made 	 O 	O
to 	 O 	O
show 	 O 	O
how 	 O 	O
many 	 O 	O
different 	 O 	O
factors 	 O 	O
must 	 O 	O
cooperate 	 O 	O
to 	 O 	O
produce 	 O 	O
atopic 	 O 	DISEASE
disease 	 O 	O
, 	 O 	O
and 	 O 	O
how 	 O 	O
these 	 O 	O
factors 	 O 	O
are 	 O 	O
mutually 	 O 	O
influenced 	 O 	O
by 	 O 	O
their 	 O 	O
actions 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
metabolic 	 O 	O
disorders 	 O 	O
. 	 O 	O
These 	 O 	O
symptoms 	 O 	O
include 	 O 	O
fluctuating 	 O 	O
tachycardia 	 O 	O
and 	 O 	O
hypertension 	 O 	O
, 	 O 	O
electrocardiographic 	 O 	O
changes 	 O 	O
, 	 O 	O
sweating 	 O 	O
, 	 O 	O
constipation 	 DISEASE 	O
with 	 O 	O
development 	 O 	O
of 	 O 	O
paralytic 	 O 	O
ileus 	 O 	O
and 	 O 	O
metabolic 	 O 	O
disorders 	 O 	O
. 	 O 	O
These 	 O 	O
symptoms 	 O 	O
include 	 O 	O
fluctuating 	 O 	O
tachycardia 	 O 	O
and 	 O 	O
hypertension 	 O 	O
, 	 O 	O
electrocardiographic 	 O 	O
changes 	 O 	O
, 	 O 	O
sweating 	 O 	O
, 	 O 	O
constipation 	 O 	O
with 	 O 	O
development 	 O 	O
of 	 O 	O
paralytic 	 DISEASE 	O
ileus 	 DISEASE 	O
and 	 O 	O
metabolic 	 O 	O
disorders 	 O 	O
. 	 O 	O
The 	 O 	O
basal 	 O 	O
and 	 O 	O
apical 	 O 	DISEASE
cell 	 O 	O
surfaces 	 O 	O
are 	 O 	O
extensively 	 O 	O
folded 	 O 	O
, 	 O 	O
and 	 O 	O
mitochondria 	 O 	O
are 	 O 	O
found 	 O 	O
in 	 O 	O
bands 	 O 	O
above 	 O 	O
the 	 O 	O
basal 	 O 	O
infoldings 	 O 	O
and 	 O 	O
below 	 O 	O
the 	 O 	O
microvilli 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
It 	 O 	O
is 	 O 	O
suggested 	 O 	O
that 	 O 	O
this 	 O 	O
fungal 	 O 	O
toxin 	 O 	O
may 	 O 	O
cause 	 O 	O
sterility 	 O 	O
syndrome 	 O 	DISEASE
in 	 O 	O
the 	 O 	O
offspring 	 O 	O
, 	 O 	O
similar 	 O 	O
to 	 O 	O
that 	 O 	O
produced 	 O 	O
by 	 O 	O
androgen 	 O 	O
or 	 O 	O
estrogen 	 O 	O
administration 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
possibility 	 O 	O
of 	 O 	O
a 	 O 	O
coincidental 	 O 	O
HB 	 O 	O
virus 	 DISEASE 	DISEASE
infection 	 DISEASE 	O
existed 	 O 	O
in 	 O 	O
the 	 O 	O
alcoholic 	 O 	O
case 	 O 	O
and 	 O 	O
in 	 O 	O
one 	 O 	O
case 	 O 	O
of 	 O 	O
macronodular 	 O 	O
cirrhosis 	 O 	O
. 	 O 	O
The 	 O 	O
possibility 	 O 	O
of 	 O 	O
a 	 O 	O
coincidental 	 O 	O
HB 	 O 	O
virus 	 O 	O
infection 	 O 	O
existed 	 O 	O
in 	 O 	O
the 	 O 	O
alcoholic 	 O 	O
case 	 O 	O
and 	 O 	O
in 	 O 	O
one 	 O 	O
case 	 O 	O
of 	 O 	O
macronodular 	 O 	DISEASE
cirrhosis 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Six 	 O 	O
of 	 O 	O
the 	 O 	O
7 	 O 	O
patients 	 O 	O
who 	 O 	O
were 	 O 	O
thought 	 O 	O
to 	 O 	O
have 	 O 	O
ovarian 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
localized 	 O 	O
to 	 O 	O
the 	 O 	O
pelvis 	 O 	O
( 	 O 	O
stages 	 O 	O
I 	 O 	O
and 	 O 	O
II 	 O 	O
) 	 O 	O
were 	 O 	O
found 	 O 	O
to 	 O 	O
have 	 O 	O
advanced 	 O 	O
disease 	 O 	O
( 	 O 	O
stage 	 O 	O
III 	 O 	O
) 	 O 	O
at 	 O 	O
peritoneoscopy 	 O 	O
and 	 O 	O
thus 	 O 	O
required 	 O 	O
a 	 O 	O
change 	 O 	O
in 	 O 	O
therapy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
transplantable 	 O 	O
murine 	 O 	O
rhabdomyosarcoma 	 DISEASE 	O
- 	 O 	O
induced 	 O 	O
morphological 	 O 	O
differentiation 	 O 	O
and 	 O 	O
a 	 O 	O
marked 	 O 	O
reduction 	 O 	O
in 	 O 	O
the 	 O 	O
tumorigenicity 	 O 	O
of 	 O 	O
the 	 O 	O
sarcoma 	 O 	O
cells 	 O 	O
. 	 O 	O
N 	 O 	O
, 	 O 	O
N 	 O 	O
- 	 O 	O
Dimethylformamide 	 O 	O
treatment 	 O 	O
of 	 O 	O
cell 	 O 	O
cultures 	 O 	O
established 	 O 	O
from 	 O 	O
a 	 O 	O
transplantable 	 O 	O
murine 	 O 	O
rhabdomyosarcoma 	 O 	O
- 	 O 	O
induced 	 O 	O
morphological 	 O 	O
differentiation 	 O 	O
and 	 O 	O
a 	 O 	O
marked 	 O 	O
reduction 	 O 	O
in 	 O 	O
the 	 O 	O
tumorigenicity 	 O 	O
of 	 O 	O
the 	 O 	O
sarcoma 	 DISEASE 	DISEASE
cells 	 O 	O
. 	 O 	O
There 	 O 	O
is 	 O 	O
considerable 	 O 	O
evidence 	 O 	O
that 	 O 	O
prostaglandins 	 O 	O
are 	 O 	O
potent 	 O 	O
stimulants 	 O 	O
of 	 O 	O
uterine 	 O 	O
activity 	 O 	O
and 	 O 	O
may 	 O 	O
play 	 O 	O
a 	 O 	O
role 	 O 	O
in 	 O 	O
the 	 O 	O
onset 	 O 	O
of 	 O 	O
labor 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
45 	 O 	O
patients 	 O 	O
with 	 O 	O
negative 	 O 	O
scintigrams 	 O 	O
, 	 O 	O
ECG 	 O 	O
or 	 O 	O
serum 	 O 	O
enzyme 	 O 	O
changes 	 O 	O
consistent 	 O 	O
with 	 O 	O
acute 	 O 	O
infarction 	 O 	DISEASE
failed 	 O 	O
to 	 O 	O
develop 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
the 	 O 	O
frequency 	 O 	O
of 	 O 	O
individual 	 O 	O
HL 	 O 	O
- 	 O 	O
A 	 O 	O
antigens 	 O 	O
in 	 O 	O
the 	 O 	O
patients 	 O 	O
with 	 O 	O
aphthous 	 DISEASE 	O
ulceration 	 DISEASE 	O
and 	 O 	O
those 	 O 	O
of 	 O 	O
subjects 	 O 	O
without 	 O 	O
aphthous 	 O 	O
ulceration 	 O 	O
. 	 O 	O
There 	 O 	O
were 	 O 	O
no 	 O 	O
significant 	 O 	O
differences 	 O 	O
between 	 O 	O
the 	 O 	O
frequency 	 O 	O
of 	 O 	O
individual 	 O 	O
HL 	 O 	O
- 	 O 	O
A 	 O 	O
antigens 	 O 	O
in 	 O 	O
the 	 O 	O
patients 	 O 	O
with 	 O 	O
aphthous 	 O 	O
ulceration 	 O 	O
and 	 O 	O
those 	 O 	O
of 	 O 	O
subjects 	 O 	O
without 	 O 	O
aphthous 	 DISEASE 	O
ulceration 	 DISEASE 	O
. 	 O 	O
Two 	 O 	O
years 	 O 	O
before 	 O 	O
death 	 O 	O
, 	 O 	O
while 	 O 	O
on 	 O 	O
hemodialysis 	 O 	O
, 	 O 	O
he 	 O 	O
developed 	 O 	O
severe 	 O 	O
progressive 	 O 	DISEASE
peripheral 	 DISEASE 	DISEASE
neuropathy 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
This 	 O 	O
new 	 O 	O
case 	 O 	O
questions 	 O 	O
the 	 O 	O
hypothesis 	 O 	O
suggested 	 O 	O
of 	 O 	O
possible 	 O 	O
toxicity 	 O 	O
of 	 O 	O
hard 	 O 	O
drugs 	 O 	O
( 	 O 	O
especially 	 O 	O
the 	 O 	O
amphetamines 	 O 	O
) 	 O 	O
as 	 O 	O
being 	 O 	O
an 	 O 	O
etiological 	 O 	O
factor 	 O 	O
for 	 O 	O
periarteritis 	 O 	DISEASE
nodosa 	 O 	O
observed 	 O 	O
in 	 O 	O
addicts 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Recent 	 O 	O
attempts 	 O 	O
to 	 O 	O
express 	 O 	O
the 	 O 	O
effects 	 O 	O
of 	 O 	O
muscular 	 O 	DISEASE
sprain 	 O 	O
or 	 O 	O
strain 	 O 	O
as 	 O 	O
a 	 O 	O
biochemical 	 O 	O
disturbance 	 O 	O
expressed 	 O 	O
in 	 O 	O
an 	 O 	O
unusual 	 O 	O
pattern 	 O 	O
of 	 O 	O
lactate 	 O 	O
dehydrogenase 	 O 	O
isoenzymes 	 O 	O
appear 	 O 	O
not 	 O 	O
only 	 O 	O
to 	 O 	O
be 	 O 	O
technically 	 O 	O
flawed 	 O 	O
but 	 O 	O
inconsistent 	 O 	O
with 	 O 	O
results 	 O 	O
of 	 O 	O
conventional 	 O 	O
enzyme 	 O 	O
studies 	 O 	O
on 	 O 	O
other 	 O 	O
muscle 	 O 	O
and 	 O 	O
interstitial 	 O 	O
inflammations 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Angiography 	 O 	O
showed 	 O 	O
that 	 O 	O
this 	 O 	O
change 	 O 	O
was 	 O 	O
due 	 O 	O
to 	 O 	O
pancreatic 	 DISEASE 	O
tumor 	 DISEASE 	O
with 	 O 	O
intrahepatic 	 O 	O
metastasis 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
left 	 O 	O
atrium 	 O 	O
, 	 O 	O
lowering 	 O 	O
the 	 O 	O
temperature 	 O 	O
from 	 O 	O
31 	 O 	O
C 	 O 	O
to 	 O 	O
17 	 O 	O
- 	 O 	O
19 	 O 	O
C 	 O 	O
did 	 O 	O
not 	 O 	O
significantly 	 O 	O
change 	 O 	O
the 	 O 	O
inotropic 	 O 	O
potency 	 O 	O
of 	 O 	O
isoprenaline 	 O 	O
, 	 O 	O
norepinephrine 	 O 	O
and 	 O 	O
phenylephrine 	 O 	O
, 	 O 	O
did 	 O 	O
not 	 O 	O
diminish 	 O 	O
the 	 O 	O
potency 	 O 	O
of 	 O 	O
propranolol 	 O 	O
, 	 O 	O
and 	 O 	O
did 	 O 	O
not 	 O 	O
increase 	 O 	O
the 	 O 	O
potency 	 O 	O
of 	 O 	O
the 	 O 	O
alpha 	 O 	O
- 	 O 	O
adrenoceptor 	 O 	O
blocking 	 O 	O
drug 	 O 	DISEASE
phentolamine.-- 	 O 	O
Immunity 	 O 	O
to 	 O 	O
influenza 	 DISEASE 	DISEASE
virus 	 O 	O
may 	 O 	O
be 	 O 	O
considered 	 O 	O
from 	 O 	O
the 	 O 	O
standpoints 	 O 	O
of 	 O 	O
viral 	 O 	DISEASE
and 	 O 	O
hostfactors 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Clinical 	 O 	O
reaction 	 O 	O
consisting 	 O 	O
of 	 O 	O
mild 	 O 	O
fever 	 O 	DISEASE
and 	 O 	O
rash 	 DISEASE 	DISEASE
appeared 	 O 	O
in 	 O 	O
only 	 O 	O
two 	 O 	O
children 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
effects 	 O 	O
of 	 O 	O
repeated 	 O 	O
low 	 O 	O
- 	 O 	O
dose 	 O 	O
- 	 O 	O
rate 	 O 	O
, 	 O 	O
high 	 O 	O
- 	 O 	O
dose 	 O 	O
- 	 O 	O
rate 	 O 	O
X 	 O 	O
- 	 O 	O
radiation 	 O 	O
of 	 O 	O
the 	 O 	O
head 	 O 	DISEASE
and 	 O 	O
neck 	 O 	DISEASE
on 	 O 	O
lingual 	 O 	O
tumor 	 O 	O
induction 	 O 	O
by 	 O 	O
7,12-dimethylbenz[a]anthracene 	 O 	O
( 	 O 	O
DMBA 	 O 	O
) 	 O 	O
in 	 O 	O
Syrian 	 O 	O
golden 	 O 	O
hamsters 	 O 	O
were 	 O 	O
studied 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
No 	 O 	O
swine 	 DISEASE 	O
influenza 	 DISEASE 	DISEASE
virus 	 O 	O
was 	 O 	O
isolated 	 O 	O
after 	 O 	O
challenge 	 O 	O
from 	 O 	O
placentas 	 O 	O
or 	 O 	O
pigs 	 O 	O
born 	 O 	O
dead 	 O 	O
or 	 O 	O
that 	 O 	O
died 	 O 	O
after 	 O 	O
farrowing 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
the 	 O 	O
proteinases 	 O 	O
and 	 O 	O
the 	 O 	O
increase 	 O 	O
of 	 O 	O
the 	 O 	O
level 	 O 	O
of 	 O 	O
intact 	 O 	O
immunoglobulins 	 O 	O
combined 	 O 	O
with 	 O 	O
the 	 O 	O
reconstruction 	 O 	O
of 	 O 	O
physiological 	 O 	O
conditions 	 O 	O
in 	 O 	O
the 	 O 	O
chronically 	 O 	O
inflamed 	 O 	O
middle 	 O 	O
ear 	 O 	O
by 	 O 	O
a 	 O 	O
tympanoplasty 	 O 	O
lead 	 O 	O
to 	 O 	O
a 	 O 	O
stabilsation 	 O 	O
of 	 O 	O
the 	 O 	O
immunological 	 O 	O
and 	 O 	O
inhibitory 	 O 	O
system 	 O 	O
and 	 O 	O
create 	 O 	O
the 	 O 	O
prerequisites 	 O 	O
for 	 O 	O
a 	 O 	O
healing 	 O 	O
process 	 O 	O
in 	 O 	O
chronic 	 O 	DISEASE
otitis 	 DISEASE 	DISEASE
media 	 DISEASE 	DISEASE
. 	 O 	O
assess 	 O 	O
its 	 O 	O
long 	 O 	O
term 	 O 	O
effects 	 O 	O
on 	 O 	O
the 	 O 	O
secretion 	 O 	O
of 	 O 	O
these 	 O 	O
hormones 	 O 	O
and 	 O 	O
on 	 O 	O
renal 	 DISEASE 	O
osteodystrophy 	 DISEASE 	DISEASE
; 	 O 	O
( 	 O 	O
ii 	 O 	O
) 	 O 	O
the 	 O 	O
contrast 	 O 	O
between 	 O 	O
the 	 O 	O
significant 	 O 	O
effect 	 O 	O
of 	 O 	O
propranolol 	 O 	O
and 	 O 	O
the 	 O 	O
lack 	 O 	O
of 	 O 	O
effect 	 O 	O
with 	 O 	O
metoprolol 	 O 	O
supports 	 O 	O
the 	 O 	O
concept 	 O 	O
that 	 O 	O
PTH 	 O 	O
and 	 O 	O
CT 	 O 	O
secretion 	 O 	O
are 	 O 	O
moderated 	 O 	O
through 	 O 	O
specific 	 O 	O
beta 	 O 	O
2 	 O 	O
receptors 	 O 	O
. 	 O 	O
Sensitization 	 O 	O
to 	 O 	O
EF 	 O 	O
was 	 O 	O
found 	 O 	O
in 	 O 	O
71 	 O 	O
per 	 O 	O
cent 	 O 	O
of 	 O 	O
women 	 O 	O
with 	 O 	O
carcinoma 	 DISEASE 	DISEASE
in 	 O 	O
situ 	 O 	DISEASE
and 	 O 	O
42 	 O 	O
per 	 O 	O
cent 	 O 	O
of 	 O 	O
women 	 O 	O
with 	 O 	O
dysplasia 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
She 	 O 	O
suffered 	 O 	O
from 	 O 	O
Hashimoto 	 DISEASE 	DISEASE
's 	 DISEASE 	O
thyroiditis 	 DISEASE 	DISEASE
with 	 O 	O
secondary 	 O 	DISEASE
cold 	 O 	O
agglutination 	 O 	O
disease 	 O 	O
and 	 O 	O
from 	 O 	O
polyradicular 	 O 	O
neuritis 	 O 	O
. 	 O 	O
She 	 O 	O
suffered 	 O 	O
from 	 O 	O
Hashimoto 	 O 	O
's 	 O 	O
thyroiditis 	 O 	O
with 	 O 	O
secondary 	 O 	DISEASE
cold 	 DISEASE 	O
agglutination 	 O 	O
disease 	 O 	O
and 	 O 	O
from 	 O 	O
polyradicular 	 O 	O
neuritis 	 O 	O
. 	 O 	O
She 	 O 	O
suffered 	 O 	O
from 	 O 	O
Hashimoto 	 O 	O
's 	 O 	O
thyroiditis 	 O 	O
with 	 O 	O
secondary 	 O 	O
cold 	 O 	O
agglutination 	 O 	O
disease 	 O 	O
and 	 O 	O
from 	 O 	O
polyradicular 	 O 	DISEASE
neuritis 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
present 	 O 	O
6 	 O 	O
cases 	 O 	O
of 	 O 	O
mllerian 	 O 	O
papillary 	 O 	O
adeno 	 O 	O
- 	 O 	O
fibromata 	 O 	O
( 	 O 	O
or 	 O 	O
mixed 	 O 	O
mesodermal 	 O 	O
mllerian 	 O 	O
benign 	 O 	O
tumours 	 O 	O
) 	 O 	O
of 	 O 	O
which 	 O 	O
4 	 O 	O
are 	 O 	O
anatomo 	 O 	O
- 	 O 	O
clinical 	 O 	O
presentations 	 O 	O
and 	 O 	O
2 	 O 	O
are 	 O 	O
histological 	 O 	O
presentations 	 O 	O
, 	 O 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
3 	 O 	O
cases 	 O 	O
of 	 O 	O
mllerian 	 O 	O
adenosarcoma 	 DISEASE 	O
( 	 O 	O
mixed 	 O 	O
mllerian 	 O 	O
mesodermal 	 O 	O
tumour 	 O 	DISEASE
with 	 O 	O
stroma 	 O 	O
only 	 O 	O
sarcomatous 	 O 	O
) 	 O 	O
. 	 O 	O
Since 	 O 	O
retinitis 	 DISEASE 	O
is 	 O 	O
a 	 O 	O
reliable 	 O 	O
sign 	 O 	O
of 	 O 	O
disseminated 	 O 	O
disease 	 O 	DISEASE
and 	 O 	O
ophthalmoscopic 	 O 	O
examination 	 O 	O
a 	 O 	O
rapid 	 O 	O
method 	 O 	O
of 	 O 	O
establishing 	 O 	O
its 	 O 	O
presence 	 O 	O
, 	 O 	O
recognition 	 O 	O
of 	 O 	O
this 	 O 	O
manifestation 	 O 	O
should 	 O 	O
allow 	 O 	O
earlier 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
serious 	 O 	O
CMV 	 O 	O
infection 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Cultures 	 O 	O
of 	 O 	O
human 	 O 	O
embryonic 	 O 	O
lung 	 O 	O
( 	 O 	O
HEL 	 O 	O
) 	 O 	O
cells 	 O 	O
in 	 O 	O
different 	 O 	O
physiological 	 O 	O
states 	 O 	O
were 	 O 	O
studied 	 O 	O
for 	 O 	O
their 	 O 	O
susceptibility 	 O 	O
to 	 O 	O
infection 	 O 	O
with 	 O 	O
human 	 O 	O
cytomegalovirus 	 O 	O
( 	 O 	O
CMV 	 O 	O
) 	 O 	O
with 	 O 	O
respect 	 O 	O
to 	 O 	O
production 	 O 	O
of 	 O 	O
infectious 	 O 	O
virus 	 O 	O
, 	 O 	O
synthesis 	 O 	O
of 	 O 	O
viral 	 O 	DISEASE
antigens 	 O 	O
, 	 O 	O
and 	 O 	O
virus 	 O 	O
- 	 O 	O
induced 	 O 	O
stimulation 	 O 	O
of 	 O 	O
cellular 	 O 	O
DNA 	 O 	O
synthesis 	 O 	O
. 	 O 	O
bleached 	 O 	O
virus 	 O 	O
of 	 O 	O
acute 	 O 	O
gastroenteritis 	 DISEASE 	DISEASE
of 	 O 	O
children 	 O 	O
( 	 O 	O
viral 	 O 	O
gastroenteritis 	 O 	O
A 	 O 	O
) 	 O 	O
is 	 O 	O
circulating 	 O 	O
, 	 O 	O
causing 	 O 	O
outbreaks 	 O 	O
of 	 O 	O
the 	 O 	O
disease 	 O 	O
. 	 O 	O
The 	 O 	O
results 	 O 	O
permit 	 O 	O
a 	 O 	O
conclusion 	 O 	O
that 	 O 	O
in 	 O 	O
this 	 O 	O
country 	 O 	O
a 	 O 	O
virus 	 O 	O
of 	 O 	O
acute 	 O 	O
gastroenteritis 	 O 	O
of 	 O 	O
children 	 O 	O
( 	 O 	O
viral 	 O 	DISEASE
gastroenteritis 	 DISEASE 	DISEASE
A 	 O 	O
) 	 O 	O
is 	 O 	O
circulating 	 O 	O
, 	 O 	O
causing 	 O 	O
outbreaks 	 O 	O
of 	 O 	O
the 	 O 	O
disease 	 O 	O
. 	 O 	O
A 	 O 	O
torpid 	 O 	O
meningoencephalitis 	 DISEASE 	O
may 	 O 	O
also 	 O 	O
occur 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
These 	 O 	O
habits 	 O 	O
can 	 O 	O
lead 	 O 	O
to 	 O 	O
clinical 	 O 	O
leukoplakia 	 O 	O
, 	 O 	O
gingival 	 DISEASE 	O
recession 	 DISEASE 	O
, 	 O 	O
tooth 	 O 	O
abrasion 	 O 	O
, 	 O 	O
and 	 O 	O
periodontal 	 O 	O
bone 	 O 	O
destruction 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Retinitis 	 DISEASE 	O
caused 	 O 	O
by 	 O 	O
cytomegalovirus 	 O 	O
( 	 O 	O
CMV 	 O 	O
) 	 O 	O
infection 	 O 	DISEASE
is 	 O 	O
unusual 	 O 	O
in 	 O 	O
adults 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
No 	 O 	O
positive 	 O 	O
correlation 	 O 	O
between 	 O 	O
H.T.C.T. 	 O 	O
and 	 O 	O
AT 	 O 	DISEASE
III 	 O 	O
could 	 O 	O
be 	 O 	O
observed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Ten 	 O 	O
other 	 O 	O
patients 	 O 	O
had 	 O 	O
hyperoxaluria 	 O 	DISEASE
, 	 O 	O
but 	 O 	O
the 	 O 	O
faecal 	 O 	O
fat 	 O 	O
determinations 	 O 	O
were 	 O 	O
regarded 	 O 	O
as 	 O 	O
unreliable 	 O 	O
in 	 O 	O
almost 	 O 	O
all 	 O 	O
and 	 O 	O
malabsorption 	 O 	O
could 	 O 	O
not 	 O 	O
be 	 O 	O
confirmed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Patients 	 O 	O
treated 	 O 	O
at 	 O 	O
the 	 O 	O
Barnes 	 O 	O
Hospital 	 O 	O
in 	 O 	O
St. 	 O 	O
Louis 	 O 	O
between 	 O 	O
1912 	 O 	O
and 	 O 	O
1933 	 O 	O
were 	 O 	O
contrasted 	 O 	O
with 	 O 	O
similarly 	 O 	O
treated 	 O 	O
patients 	 O 	O
at 	 O 	O
the 	 O 	O
Barnes 	 O 	O
Hospital 	 O 	O
and 	 O 	O
the 	 O 	O
Ellis 	 O 	O
Fischel 	 O 	O
Cancer 	 DISEASE 	O
Hospital 	 O 	O
from 	 O 	O
1940 	 O 	O
to 	 O 	O
1955 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
seven 	 O 	O
- 	 O 	O
year 	 O 	O
- 	 O 	O
old 	 O 	O
boy 	 O 	O
had 	 O 	O
cardiac 	 O 	O
symptoms 	 O 	O
for 	 O 	O
five 	 O 	O
months 	 O 	O
before 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
Wilms 	 O 	DISEASE
tumor 	 O 	DISEASE
was 	 O 	O
made 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
	PUNCT	O
23719	active	ADJ	O
23719	 	 O 	O
rosette 	 O 	O
test 	 O 	O
was 	 O 	O
adapted 	 O 	O
as 	 O 	O
an 	 O 	O
in 	 O 	O
vitro 	 O 	O
assay 	 O 	O
and 	 O 	O
correlated 	 O 	O
with 	 O 	O
human 	 O 	O
delayed 	 O 	O
cutaneous 	 O 	DISEASE
hypersensitivity 	 DISEASE 	DISEASE
( 	 O 	O
DCH 	 O 	O
) 	 O 	O
to 	 O 	O
two 	 O 	O
microbial 	 O 	O
antigens 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
main 	 O 	O
vectors 	 O 	O
of 	 O 	O
bancroftian 	 DISEASE 	O
filariasis 	 DISEASE 	DISEASE
in 	 O 	O
Kwale 	 O 	O
, 	 O 	O
Tanzania 	 O 	O
, 	 O 	O
were 	 O 	O
Anopheles 	 O 	O
gambiae 	 O 	O
complex 	 O 	O
and 	 O 	O
Culex 	 O 	O
p. 	 O 	O
quinquefasciatus 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Except 	 O 	O
in 	 O 	O
four 	 O 	O
patients 	 O 	O
with 	 O 	O
previously 	 O 	O
known 	 O 	O
cardiac 	 O 	O
murmurs 	 O 	O
, 	 O 	O
infection 	 O 	DISEASE
occurred 	 O 	O
on 	 O 	O
normal 	 O 	O
valves 	 O 	O
in 	 O 	O
these 	 O 	O
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
child 	 O 	O
with 	 O 	O
primary 	 O 	O
liver 	 O 	DISEASE
cell 	 O 	O
carcinoma 	 DISEASE 	DISEASE
was 	 O 	O
treated 	 O 	O
for 	 O 	O
2 	 O 	O
1/2 	 O 	O
years 	 O 	O
with 	 O 	O
cyclophosphamide 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
left 	 O 	O
ventricular 	 O 	O
posterior 	 O 	O
wall 	 O 	O
( 	 O 	O
LVPW 	 O 	O
) 	 O 	O
thicknesses 	 O 	O
and 	 O 	O
their 	 O 	O
ratios 	 O 	O
were 	 O 	O
studied 	 O 	O
at 	 O 	O
the 	 O 	O
left 	 O 	O
ventricular 	 O 	O
outflow 	 O 	O
tract 	 O 	O
and 	 O 	O
left 	 O 	O
ventricular 	 O 	O
cavity 	 O 	O
in 	 O 	O
66 	 O 	O
patients 	 O 	O
with 	 O 	O
echocardiographically 	 O 	O
diagnosed 	 O 	O
left 	 O 	O
ventricular 	 O 	O
concentric 	 O 	O
hypertrophy 	 O 	O
, 	 O 	O
20 	 O 	O
with 	 O 	O
idiopathic 	 O 	O
hypertrophic 	 O 	O
subaortic 	 O 	O
stenosis 	 O 	DISEASE
( 	 O 	O
IHSS 	 O 	O
) 	 O 	O
, 	 O 	O
and 	 O 	O
34 	 O 	O
normal 	 O 	O
subjects 	 O 	O
. 	 O 	O
The 	 O 	O
degradation 	 O 	O
has 	 O 	O
not 	 O 	O
produced 	 O 	O
any 	 O 	O
uveitis 	 DISEASE 	O
, 	 O 	O
keratopathy 	 O 	O
, 	 O 	O
or 	 O 	O
instability 	 O 	O
of 	 O 	O
the 	 O 	O
implants 	 O 	O
in 	 O 	O
any 	 O 	O
of 	 O 	O
these 	 O 	O
patients 	 O 	O
. 	 O 	O
The 	 O 	O
degradation 	 O 	O
has 	 O 	O
not 	 O 	O
produced 	 O 	O
any 	 O 	O
uveitis 	 O 	O
, 	 O 	O
keratopathy 	 DISEASE 	O
, 	 O 	O
or 	 O 	O
instability 	 O 	O
of 	 O 	O
the 	 O 	O
implants 	 O 	O
in 	 O 	O
any 	 O 	O
of 	 O 	O
these 	 O 	O
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
ventricular 	 O 	O
insufficiency 	 O 	DISEASE
no 	 O 	O
uniform 	 O 	O
behaviour 	 O 	O
was 	 O 	O
apparent 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
validity 	 O 	O
of 	 O 	O
interspecific 	 O 	O
generalization 	 O 	O
can 	 O 	DISEASE
never 	 O 	O
exceed 	 O 	DISEASE
the 	 O 	O
reliability 	 O 	O
of 	 O 	O
intraspecific 	 O 	O
analysis 	 O 	O
; 	 O 	O
and 	 O 	O
the 	 O 	O
latter 	 O 	O
is 	 O 	O
an 	 O 	O
indispensable 	 O 	O
antecedent 	 O 	O
of 	 O 	O
the 	 O 	O
former 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Rectosigmoid- 	 O 	O
or 	 O 	O
colonoscopy 	 O 	O
biopsies 	 O 	O
were 	 O 	O
performed 	 O 	O
at 	 O 	O
different 	 O 	O
levels 	 O 	O
of 	 O 	O
the 	 O 	O
large 	 O 	O
intestine 	 O 	O
of 	 O 	O
16 	 O 	O
adult 	 O 	O
subjects 	 O 	O
free 	 O 	O
from 	 O 	O
major 	 O 	O
intestinal 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
the 	 O 	O
remaining 	 O 	O
19 	 O 	O
patients 	 O 	O
we 	 O 	O
found 	 O 	O
a 	 O 	O
mild 	 O 	O
vitamin 	 DISEASE 	DISEASE
B12 	 DISEASE 	DISEASE
deficiency 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
those 	 O 	O
for 	 O 	O
seven 	 O 	O
subjects 	 O 	O
with 	 O 	O
normal 	 O 	O
left 	 O 	O
ventricular 	 O 	O
function 	 O 	O
and 	 O 	O
with 	 O 	O
those 	 O 	O
for 	 O 	O
five 	 O 	O
patients 	 O 	O
with 	 O 	O
idiopathic 	 O 	O
congestive 	 O 	O
cardiomyopathy 	 O 	DISEASE
. 	 O 	O
Results 	 O 	O
for 	 O 	O
eight 	 O 	O
patients 	 O 	O
with 	 O 	O
aortic 	 O 	O
stenosis 	 O 	O
were 	 O 	O
compared 	 O 	O
with 	 O 	O
those 	 O 	O
for 	 O 	O
seven 	 O 	O
subjects 	 O 	O
with 	 O 	O
normal 	 O 	O
left 	 O 	O
ventricular 	 O 	O
function 	 O 	O
and 	 O 	O
with 	 O 	O
those 	 O 	O
for 	 O 	O
five 	 O 	O
patients 	 O 	O
with 	 O 	O
idiopathic 	 O 	O
congestive 	 DISEASE 	DISEASE
cardiomyopathy 	 DISEASE 	DISEASE
. 	 O 	O
of 	 O 	O
genital 	 O 	O
mycoplasmas 	 O 	DISEASE
and 	 O 	O
infection 	 O 	O
with 	 O 	O
cytomegalovirus 	 O 	O
( 	 O 	O
CMV 	 O 	O
) 	 O 	O
was 	 O 	O
studied 	 O 	O
yielding 	 O 	O
the 	 O 	O
following 	 O 	O
information 	 O 	O
: 	 O 	O
1 	 O 	O
) 	 O 	O
Genital 	 O 	O
mycoplasma 	 O 	O
colonization 	 O 	O
among 	 O 	O
the 	 O 	O
groups 	 O 	O
studied 	 O 	O
differed 	 O 	O
insignificantly 	 O 	O
; 	 O 	O
2 	 O 	O
) 	 O 	O
  	 O 	O
An 	 O 	O
insignificant 	 O 	O
increase 	 O 	O
in 	 O 	O
colonization 	 O 	O
of 	 O 	O
genital 	 O 	O
mycoplasmas 	 O 	O
or 	 O 	O
infection 	 O 	O
with 	 O 	O
CMV 	 O 	O
was 	 O 	O
noted 	 O 	O
in 	 O 	O
IUD 	 O 	O
users 	 O 	O
; 	 O 	O
The 	 O 	O
problem 	 O 	O
of 	 O 	O
the 	 O 	O
patient 	 O 	O
who 	 O 	O
has 	 O 	O
had 	 O 	O
one 	 O 	O
operation 	 O 	O
for 	 O 	O
coarctation 	 O 	DISEASE
of 	 O 	O
the 	 O 	O
aorta 	 O 	O
and 	 O 	O
who 	 O 	O
then 	 O 	O
requires 	 O 	O
another 	 O 	O
because 	 O 	O
of 	 O 	O
a 	 O 	O
late 	 O 	O
complication 	 O 	O
at 	 O 	O
or 	 O 	O
near 	 O 	O
the 	 O 	O
coarctation 	 O 	O
site 	 O 	O
is 	 O 	O
a 	 O 	O
demanding 	 O 	O
one 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
discutable 	 O 	O
	PUNCT	O
54391	;	PUNCT	O
54391	when	ADV	O
54391	an	DET	O
54391	important	ADJ	O
54391	secretion	NOUN	O
54391	of	ADP	O
54391	B	NOUN	O
54391	substance	NOUN	O
54391	can	VERB	O
54391	be	VERB	O
54391	evidenced	VERB	O
54391	in	ADP	O
54391	saliva	NOUN	O
54391	,	PUNCT	O
54391	and	CCONJ	O
54391	the	DET	O
54391	phenotype	NOUN	O
54391	is	VERB	O
54391	proved	VERB	O
54391	to	PART	O
54391	be	VERB	O
54391	inherited	VERB	O
54391	as	ADP	O
54391	a	DET	O
54391	dominant	ADJ	O
54391	character	NOUN	O
54391	,	PUNCT	O
54391	the	DET	O
54391	appellation	NOUN	O
54391	Bm	PROPN	O
54391	can	VERB	O
54391	be	VERB	O
54391	proposed	VERB	O
54391	.	PUNCT	O
54392	On	ADP	O
54392	the	DET	O
54392	contrary	NOUN	O
54392	,	PUNCT	O
54392	when	ADV	O
54392	genetics	NOUN	O
54392	suggest	VERB	O
54392	the	DET	O
54392	presence	NOUN	O
54392	of	ADP	O
54392	a	DET	O
54392	modifying	VERB	O
54392	gene	NOUN	O
54392	,	PUNCT	O
54392	the	DET	O
54392	Bel	PROPN	O
54392	mod	NOUN	O
54392	or	CCONJ	O
54392	By	ADP	O
54392	appellation	NOUN	O
54392	can	VERB	O
54392	be	VERB	O
54392	used	VERB	O
54392	,	PUNCT	O
54392	according	VERB	O
54392	as	ADP	O
54392	the	DET	O
54392	type	NOUN	O
54392	of	ADP	O
54392	modification	NOUN	O
54392	is	VERB	O
54392	dominant	ADJ	O
54392	or	CCONJ	O
54392	recessive	ADJ	O
54392	.	PUNCT	O
54393	Only	ADV	O
54393	one	NUM	O
54393	sample	NOUN	O
54393	appeared	VERB	O
54393	to	PART	O
54393	be	VERB	O
54393	unclassable	ADJ	O
54393	,	PUNCT	O
54393	for	ADP	O
54393	which	ADJ	O
54393	the	DET	O
54393	fixation	NOUN	O
54393	-	PUNCT	O
54393	elution	NOUN	O
54393	test	NOUN	O
54393	is	VERB	O
54393	positive	ADJ	O
54393	,	PUNCT	O
54393	but	CCONJ	O
54393	only	ADV	O
54393	5	NUM	O
54393	to	PART	O
54393	10	NUM	O
54393	%	NOUN	O
54393	of	ADP	O
54393	the	DET	O
54393	red	ADJ	O
54393	cells	NOUN	O
54393	are	VERB	O
54393	agglutinated	VERB	O
54393	,	PUNCT	O
54393	giving	VERB	O
54393	a	DET	O
54393	dual	ADJ	O
54393	population	NOUN	O
54393	pattern	NOUN	O
54393	;	PUNCT	O
54393	the	DET	O
54393	galactosyl	ADJ	O
54393	-	PUNCT	O
54393	transferase	NOUN	O
54393	activity	NOUN	O
54393	seems	VERB	O
54393	to	PART	O
54393	be	VERB	O
54393	normal	ADJ	O
54393	,	PUNCT	O
54393	as	ADV	O
54393	well	ADV	O
54393	as	ADP	O
54393	the	DET	O
54393	--	PUNCT	O
54393	delta	NOUN	O
54393	H	NOUN	O
54393	(	PUNCT	O
54393	20.000	NUM	O
54393	cal	NOUN	O
54393	/	SYM	O
54393	mol	NOUN	O
54393	.	PUNCT	O
54393	)	PUNCT	O
54393	.	PUNCT	O
54394	The	DET	O
54394	B	PROPN	O
54394	weak	ADJ	O
54394	appellation	NOUN	O
54394	appears	VERB	O
54394	to	PART	O
54394	be	VERB	O
54394	the	DET	O
54394	most	ADV	O
54394	appropriate	ADJ	O
54394	for	ADP	O
54394	this	DET	O
54394	given	VERB	O
54394	sample	NOUN	O
54394	.	PUNCT	O
54395	This	DET	O
54395	case	NOUN	O
54395	expected	VERB	O
54395	,	PUNCT	O
54395	the	DET	O
54395	proposed	VERB	O
54395	practical	ADJ	O
54395	classification	NOUN	O
54395	appears	VERB	O
54395	to	PART	O
54395	fit	VERB	O
54395	well	ADV	O
54395	the	DET	O
54395	studied	VERB	O
54395	phenotypes	NOUN	O
54395	.	PUNCT	O
54396	As	ADP	O
54396	the	DET	O
54396	various	ADJ	O
54396	studies	NOUN	O
54396	on	ADP	O
54396	weak	ADJ	O
54396	B	PROPN	O
54396	phenotypes	NOUN	O
54396	,	PUNCT	O
54396	reported	VERB	O
54396	in	ADP	O
54396	the	DET	O
54396	literature	NOUN	O
54396	have	VERB	O
54396	not	ADV	O
54396	been	VERB	O
54396	compared	VERB	O
54396	within	ADP	O
54396	a	DET	O
54396	same	ADJ	O
54396	laboratory	NOUN	O
54396	,	PUNCT	O
54396	using	VERB	O
54396	the	DET	O
54396	same	ADJ	O
54396	technics	NOUN	O
54396	,	PUNCT	O
54396	it	PRON	O
54396	appears	VERB	O
54396	illusive	ADV	O
54396	to	PART	O
54396	apply	VERB	O
54396	the	DET	O
54396	proposed	VERB	O
54396	classification	NOUN	O
54396	to	ADP	O
54396	the	DET	O
54396	different	ADJ	O
54396	reported	VERB	O
54396	samples	NOUN	O
54396	.	PUNCT	O
54397	Several	ADJ	O
54397	already	ADV	O
54397	published	VERB	O
54397	samples	NOUN	O
54397	form	VERB	O
54397	a	DET	O
54397	part	NOUN	O
54397	of	ADP	O
54397	the	DET	O
54397	present	ADJ	O
54397	study	NOUN	O
54397	,	PUNCT	O
54397	but	CCONJ	O
54397	their	ADJ	O
54397	appellation	NOUN	O
54397	do	VERB	O
54397	not	ADV	O
54397	correspond	VERB	O
54397	to	ADP	O
54397	the	DET	O
54397	previous	ADJ	O
54397	one	NOUN	O
54397	;	PUNCT	O
54397	stricklingly	ADV	O
54397	,	PUNCT	O
54397	only	ADV	O
54397	few	ADJ	O
54397	B3	PROPN	O
54397	(	PUNCT	O
54397	new	ADJ	O
54397	appellation	NOUN	O
54397	)	PUNCT	O
54397	have	VERB	O
54397	been	VERB	O
54397	described	VERB	O
54397	in	ADP	O
54397	the	DET	O
54397	literature	NOUN	O
54397	,	PUNCT	O
54397	which	ADJ	O
54397	let	VERB	O
54397	one	PRON	O
54397	think	VERB	O
54397	that	ADP	O
54397	they	PRON	O
54397	might	VERB	O
54397	be	VERB	O
54397	undetected	ADJ	O
54397	using	VERB	O
54397	classical	ADJ	O
54397	grouping	NOUN	O
54397	tests	NOUN	O
54397	,	PUNCT	O
54397	and	CCONJ	O
54397	thus	ADV	O
54397	considered	VERB	O
54397	as	ADP	O
54397	normal	ADJ	O
54397	B.	PROPN	O
54398	Of	ADV	O
54398	course	ADV	O
54398	,	PUNCT	O
54398	there	ADV	O
54398	is	VERB	O
54398	not	ADV	O
54398	an	DET	O
54398	absolute	ADJ	O
54398	correspondance	NOUN	O
54398	between	ADP	O
54398	the	DET	O
54398	criteria	NOUN	O
54398	defining	VERB	O
54398	A3	PROPN	O
54398	,	PUNCT	O
54398	Ax	PROPN	O
54398	,	PUNCT	O
54398	Ael	PROPN	O
54398	phenotypes	NOUN	O
54398	and	CCONJ	O
54398	those	DET	O
54398	proposed	VERB	O
54398	here	ADV	O
54398	for	ADP	O
54398	B3	PROPN	O
54398	,	PUNCT	O
54398	Bx	PROPN	O
54398	,	PUNCT	O
54398	Bel	PROPN	O
54398	...	PUNCT	O
54399	Platelet	VERB	O
54399	adhesiviness	NOUN	O
54399	and	CCONJ	O
54399	thrombelastographic	VERB	O
54399	investigations	NOUN	O
54399	in	ADP	O
54399	plasma	NOUN	O
54399	by	ADP	O
54399	102	NUM	O
54399	women	NOUN	O
54399	treated	VERB	O
54399	with	ADP	O
54399	Ovosiston	PROPN	O
54399	,	PUNCT	O
54399	an	DET	O
54399	anticonceptive	ADJ	O
54399	agent	NOUN	O
54399	were	VERB	O
54399	observed	VERB	O
54399	.	PUNCT	O
54400	A	DET	O
54400	significant	ADJ	O
54400	increase	NOUN	O
54400	of	ADP	O
54400	adhesiveness	NOUN	O
54400	and	CCONJ	O
54400	thrombelastographic	VERB	O
54400	variations	NOUN	O
54400	was	VERB	O
54400	found	VERB	O
54400	.	PUNCT	O
54401	In	ADP	O
54401	conclusion	NOUN	O
54401	showed	VERB	O
54401	abnormalities	NOUN	O
54401	of	ADP	O
54401	platelet	NOUN	O
54401	functions	NOUN	O
54401	and	CCONJ	O
54401	thrombelastographic	VERB	O
54401	values	NOUN	O
54401	point	NOUN	O
54401	to	ADP	O
54401	influences	NOUN	O
54401	by	ADP	O
54401	oral	ADJ	O
54401	contraceptive	ADJ	O
54401	agent	NOUN	O
54401	Ovosiston	PROPN	O
54401	.	PUNCT	O
54402	In	ADP	O
54402	combination	NOUN	O
54402	with	ADP	O
54402	other	ADJ	O
54402	favouring	VERB	O
54402	factors	NOUN	O
54402	the	DET	O
54402	risk	NOUN	O
54402	of	ADP	O
54402	thromboembolism	NOUN	O
54402	must	VERB	O
54402	be	VERB	O
54402	enhanced	VERB	O
54402	.	PUNCT	O
54403	An	DET	O
54403	investigation	NOUN	O
54403	was	VERB	O
54403	undertaken	VERB	O
54403	to	PART	O
54403	demonstrate	VERB	O
54403	the	DET	O
54403	neural	ADJ	O
54403	elements	NOUN	O
54403	of	ADP	O
54403	the	DET	O
54403	lung	NOUN	O
54403	of	ADP	O
54403	Francolinus	PROPN	O
54403	pondicerianus	NOUN	O
54403	,	PUNCT	O
54403	from	ADP	O
54403	the	DET	O
54403	point	NOUN	O
54403	of	ADP	O
54403	view	NOUN	O
54403	of	ADP	O
54403	neurohistology	NOUN	O
54403	and	CCONJ	O
54403	histochemistry	NOUN	O
54403	.	PUNCT	O
54404	The	DET	O
54404	staining	NOUN	O
54404	of	ADP	O
54404	the	DET	O
54404	neural	ADJ	O
54404	elements	NOUN	O
54404	was	VERB	O
54404	done	VERB	O
54404	by	ADP	O
54404	the	DET	O
54404	cholinesterase	NOUN	O
54404	technique	NOUN	O
54404	with	ADP	O
54404	a	DET	O
54404	maintained	VERB	O
54404	pH	NOUN	O
54404	of	ADP	O
54404	5.2	NUM	O
54404	,	PUNCT	O
54404	temperature	NOUN	O
54404	40	NUM	O
54404	degrees	NOUN	O
54404	C	NOUN	O
54404	and	CCONJ	O
54404	incubation	NOUN	O
54404	period	NOUN	O
54404	of	ADP	O
54404	19	NUM	O
54404	h.	NOUN	O
54404	Distribution	NOUN	O
54404	of	ADP	O
54404	nerves	NOUN	O
54404	in	ADP	O
54404	association	NOUN	O
54404	with	ADP	O
54404	bronchial	ADJ	O
54404	cartilage	NOUN	O
54404	,	PUNCT	O
54404	pulmonary	ADJ	O
54404	vessels	NOUN	O
54404	and	CCONJ	O
54404	bronchi	NOUN	O
54404	has	VERB	O
54404	been	VERB	O
54404	described	VERB	O
54404	and	CCONJ	O
54404	discussed	VERB	O
54404	.	PUNCT	O
54405	The	DET	O
54405	distribution	NOUN	O
54405	of	ADP	O
54405	the	DET	O
54405	ganglia	NOUN	O
54405	in	ADP	O
54405	association	NOUN	O
54405	with	ADP	O
54405	blood	NOUN	O
54405	vessels	NOUN	O
54405	,	PUNCT	O
54405	bronchi	NOUN	O
54405	,	PUNCT	O
54405	cartilage	NOUN	O
54405	,	PUNCT	O
54405	various	ADJ	O
54405	plexuses	NOUN	O
54405	and	CCONJ	O
54405	the	DET	O
54405	neural	ADJ	O
54405	terminal	NOUN	O
54405	terminal	NOUN	O
54405	network	NOUN	O
54405	has	VERB	O
54405	also	ADV	O
54405	been	VERB	O
54405	described	VERB	O
54405	.	PUNCT	O
54406	The	DET	O
54406	innervation	NOUN	O
54406	of	ADP	O
54406	the	DET	O
54406	bronchi	NOUN	O
54406	and	CCONJ	O
54406	their	ADJ	O
54406	branches	NOUN	O
54406	,	PUNCT	O
54406	and	CCONJ	O
54406	formation	NOUN	O
54406	of	ADP	O
54406	the	DET	O
54406	neural	ADJ	O
54406	terminal	NOUN	O
54406	network	NOUN	O
54406	has	VERB	O
54406	been	VERB	O
54406	studied	VERB	O
54406	,	PUNCT	O
54406	as	ADV	O
54406	well	ADV	O
54406	as	ADP	O
54406	the	DET	O
54406	distribution	NOUN	O
54406	of	ADP	O
54406	cholinesterase	NOUN	O
54406	in	ADP	O
54406	bronchi	NOUN	O
54406	,	PUNCT	O
54406	blood	NOUN	O
54406	vessels	NOUN	O
54406	,	PUNCT	O
54406	muscles	NOUN	O
54406	,	PUNCT	O
54406	ganglia	NOUN	O
54406	,	PUNCT	O
54406	and	CCONJ	O
54406	nerve	NOUN	O
54406	fibres	NOUN	O
54406	.	PUNCT	O
54407	HCT	PROPN	O
54407	,	PUNCT	O
54407	TSH	PROPN	O
54407	,	PUNCT	O
54407	T3	PROPN	O
54407	,	PUNCT	O
54407	T4	PROPN	O
54407	,	PUNCT	O
54407	PBI	PROPN	O
54407	,	PUNCT	O
54407	T3-RSU	PROPN	O
54407	,	PUNCT	O
54408	TBG	PROPN	O
54408	binding	ADJ	O
54408	capacity	NOUN	O
54408	,	PUNCT	O
54408	BMR	PROPN	O
54408	and	CCONJ	O
54408	thyroid	NOUN	O
54408	uptake	NOUN	O
54408	of	ADP	O
54408	radioiodine	NOUN	O
54408	were	VERB	O
54408	measured	VERB	O
54408	simultaneously	ADV	O
54408	on	ADP	O
54408	the	DET	O
54408	volunteers	NOUN	O
54408	with	ADP	O
54408	hydatidiform	NOUN	DISEASE
54408	mole	NOUN	DISEASE
54408	and	CCONJ	O
54408	normal	ADJ	O
54408	pregnancy	NOUN	O
54408	.	PUNCT	O
54409	TRH	PROPN	O
54409	stimulation	NOUN	O
54409	tests	NOUN	O
54409	were	VERB	O
54409	performed	VERB	O
54409	on	ADP	O
54409	the	DET	O
54409	two	NUM	O
54409	groups	NOUN	O
54409	.	PUNCT	O
54410	The	DET	O
54410	serum	NOUN	O
54410	HCT	PROPN	O
54410	levels	NOUN	O
54410	were	VERB	O
54410	higher	ADJ	O
54410	in	ADP	O
54410	association	NOUN	O
54410	with	ADP	O
54410	molar	ADJ	DISEASE
54410	pregnancy	NOUN	DISEASE
54410	than	ADP	O
54410	in	ADP	O
54410	normal	ADJ	O
54410	pregnancy	NOUN	O
54410	.	PUNCT	O
54411	TSH	NOUN	O
54411	levels	NOUN	O
54411	were	VERB	O
54411	within	ADP	O
54411	the	DET	O
54411	nonpregnant	ADJ	O
54411	range	NOUN	O
54411	in	ADP	O
54411	the	DET	O
54411	two	NUM	O
54411	groups	NOUN	O
54411	.	PUNCT	O
54412	T3	PROPN	O
54412	,	PUNCT	O
54412	T4	PROPN	O
54412	,	PUNCT	O
54412	PBI	PROPN	O
54412	,	PUNCT	O
54412	ETR	PROPN	O
54412	,	PUNCT	O
54412	BMR	PROPN	O
54412	and	CCONJ	O
54412	thyroid	NOUN	O
54412	uptake	NOUN	O
54412	of	ADP	O
54412	radioiodine	NOUN	O
54412	suggested	VERB	O
54412	thyroid	NOUN	O
54412	hyperfunction	NOUN	O
54412	in	ADP	O
54412	molar	ADJ	DISEASE
54412	pregnancy	NOUN	DISEASE
54412	with	ADP	O
54412	a	DET	O
54412	greater	ADJ	O
54412	degree	NOUN	O
54412	than	ADP	O
54412	that	DET	O
54412	in	ADP	O
54412	normal	ADJ	O
54412	pregnancy	NOUN	O
54412	.	PUNCT	O
54413	TBG	PROPN	O
54413	binding	VERB	O
54413	capacity	NOUN	O
54413	and	CCONJ	O
54413	T3-RSU	PROPN	O
54413	were	VERB	O
54413	similar	ADJ	O
54413	in	ADP	O
54413	two	NUM	O
54413	groups	NOUN	O
54413	.	PUNCT	O
54414	The	DET	O
54414	peak	NOUN	O
54414	TSH	NOUN	O
54414	levels	NOUN	O
54414	of	ADP	O
54414	TRH	PROPN	O
54414	stimulation	NOUN	O
54414	tests	NOUN	O
54414	ranged	VERB	O
54414	widely	ADV	O
54414	in	ADP	O
54414	patients	NOUN	O
54414	with	ADP	O
54414	molar	ADJ	O
54414	pregnancies	NOUN	O
54414	but	CCONJ	O
54414	were	VERB	O
54414	within	ADP	O
54414	the	DET	O
54414	nonpregnant	ADJ	O
54414	range	NOUN	O
54414	in	ADP	O
54414	the	DET	O
54414	subjects	NOUN	O
54414	with	ADP	O
54414	normal	ADJ	O
54414	pregnancies	NOUN	O
54414	.	PUNCT	O
54415	These	DET	O
54415	findings	NOUN	O
54415	suggest	VERB	O
54415	thyroid	NOUN	O
54415	hyperfunction	NOUN	O
54415	in	ADP	O
54415	the	DET	O
54415	molar	ADJ	DISEASE
54415	pregnancy	NOUN	DISEASE
54415	is	VERB	O
54415	due	ADJ	O
54415	to	ADP	O
54415	a	DET	O
54415	larger	ADJ	O
54415	amount	NOUN	O
54415	of	ADP	O
54415	HCT	PROPN	O
54415	than	ADP	O
54415	in	ADP	O
54415	normal	ADJ	O
54415	pregnancy	NOUN	O
54415	.	PUNCT	O
54416	The	DET	O
54416	root	NOUN	O
54416	and	CCONJ	O
54416	stem	NOUN	O
54416	decoctions	NOUN	O
54416	of	ADP	O
54416	Sinomenium	PROPN	O
54416	acutum	NOUN	O
54416	Rehd	PROPN	O
54416	.	PUNCT	O
54417	et	PROPN	O
54417	Wils	PROPN	O
54417	.	PUNCT	O
54418	(	PUNCT	O
54418	formerly	ADV	O
54418	Sinomenium	PROPN	O
54418	diversifolius	NOUN	O
54418	Diels	PROPN	O
54418	,	PUNCT	O
54418	one	NUM	O
54418	type	NOUN	O
54418	of	ADP	O
54418	Fang	PROPN	O
54418	-	PUNCT	O
54418	chi	PROPN	O
54418	(	PUNCT	O
54418	Chinese	PROPN	O
54418	)	PUNCT	O
54418	)	PUNCT	O
54418	have	VERB	O
54418	been	VERB	O
54418	used	VERB	O
54418	as	ADP	O
54418	a	DET	O
54418	folk	NOUN	O
54418	remedy	NOUN	O
54418	for	ADP	O
54418	neuralgia	NOUN	O
54418	and	CCONJ	O
54418	rheumatoid	NOUN	DISEASE
54418	arthritis	NOUN	DISEASE
54418	in	ADP	O
54418	many	ADJ	O
54418	areas	NOUN	O
54418	of	ADP	O
54418	the	DET	O
54418	Far	PROPN	O
54418	East	PROPN	O
54418	.	PUNCT	O
54419	In	ADP	O
54419	Japan	PROPN	O
54419	and	CCONJ	O
54419	China	PROPN	O
54419	various	ADJ	O
54419	viny	NOUN	O
54419	plants	NOUN	O
54419	have	VERB	O
54419	been	VERB	O
54419	identified	VERB	O
54419	as	ADP	O
54419	Fang	PROPN	O
54419	-	PUNCT	O
54419	chi	PROPN	O
54419	(	PUNCT	O
54419	Boi	PROPN	O
54419	in	ADP	O
54419	Japanese	PROPN	O
54419	)	PUNCT	O
54419	since	ADP	O
54419	antiquity	NOUN	O
54419	.	PUNCT	O
54420	This	DET	O
54420	uncertain	ADJ	O
54420	nomenclature	NOUN	O
54420	has	VERB	O
54420	made	VERB	O
54420	it	PRON	O
54420	difficult	ADJ	O
54420	to	PART	O
54420	evaluate	VERB	O
54420	the	DET	O
54420	efficacy	NOUN	O
54420	of	ADP	O
54420	the	DET	O
54420	Fang	PROPN	O
54420	-	PUNCT	O
54420	chi	PROPN	O
54420	described	VERB	O
54420	in	ADP	O
54420	the	DET	O
54420	classic	ADJ	O
54420	literature	NOUN	O
54420	.	PUNCT	O
54421	Among	ADP	O
54421	traditional	ADJ	O
54421	Fang	PROPN	O
54421	-	PUNCT	O
54421	chi	PROPN	O
54421	plants	NOUN	O
54421	only	ADV	O
54421	Sinomeniumacutum	PROPN	O
54421	has	VERB	O
54421	been	VERB	O
54421	demonstrated	VERB	O
54421	to	PART	O
54421	contain	VERB	O
54421	the	DET	O
54421	alkaloid	ADJ	O
54421	sinomenine	NOUN	O
54421	,	PUNCT	O
54421	which	ADJ	O
54421	is	VERB	O
54421	now	ADV	O
54421	known	VERB	O
54421	to	PART	O
54421	be	VERB	O
54421	effective	ADJ	O
54421	in	ADP	O
54421	neuralgia	NOUN	O
54421	and	CCONJ	O
54421	rheumatic	ADJ	O
54421	diseases	NOUN	O
54421	.	PUNCT	O
54422	Sinomenine	PROPN	O
54422	is	VERB	O
54422	a	DET	O
54422	unique	ADJ	O
54422	plant	NOUN	O
54422	alkaloid	NOUN	O
54422	,	PUNCT	O
54422	as	ADP	O
54422	it	PRON	O
54422	potently	ADV	O
54422	releases	VERB	O
54422	histamine	NOUN	O
54422	in	ADP	O
54422	association	NOUN	O
54422	 	SPACE	O
54422	with	ADP	O
54422	degranulation	NOUN	O
54422	of	ADP	O
54422	tissue	NOUN	O
54422	mast	NOUN	O
54422	cells	NOUN	O
54422	in	ADP	O
54422	mammalian	ADJ	O
54422	tissues	NOUN	O
54422	.	PUNCT	O
54423	This	DET	O
54423	action	NOUN	O
54423	occurs	VERB	O
54423	preferentially	ADV	O
54423	in	ADP	O
54423	the	DET	O
54423	skin	NOUN	O
54423	and	CCONJ	O
54423	joint	ADJ	O
54423	capsules	NOUN	O
54423	.	PUNCT	O
54424	The	DET	O
54424	released	VERB	O
54424	histamine	NOUN	O
54424	is	VERB	O
54424	responsible	ADJ	O
54424	for	ADP	O
54424	the	DET	O
54424	dominant	ADJ	O
54424	pharmacological	ADJ	O
54424	actions	NOUN	O
54424	of	ADP	O
54424	sinomenine	NOUN	O
54424	,	PUNCT	O
54424	such	ADJ	O
54424	as	ADP	O
54424	vasodilatation	NOUN	O
54424	,	PUNCT	O
54424	increased	VERB	O
54424	vascular	ADJ	O
54424	permeability	NOUN	O
54424	,	PUNCT	O
54424	acceleration	NOUN	O
54424	of	ADP	O
54424	the	DET	O
54424	thoracic	ADJ	O
54424	and	CCONJ	O
54424	peripheral	ADJ	O
54424	lymph	NOUN	O
54424	flow	NOUN	O
54424	,	PUNCT	O
54424	contraction	NOUN	O
54424	of	ADP	O
54424	plain	ADJ	O
54424	muscles	NOUN	O
54424	,	PUNCT	O
54424	increased	VERB	O
54424	peristalsis	NOUN	O
54424	of	ADP	O
54424	the	DET	O
54424	intestines	NOUN	O
54424	,	PUNCT	O
54424	and	CCONJ	O
54424	stimulation	NOUN	O
54424	of	ADP	O
54424	gastric	ADJ	O
54424	acid	NOUN	O
54424	secretion	NOUN	O
54424	.	PUNCT	O
54425	At	ADP	O
54425	toxic	ADJ	O
54425	doses	NOUN	O
54425	of	ADP	O
54425	sinomenine	NOUN	O
54425	,	PUNCT	O
54425	convulsive	ADJ	O
54425	central	ADJ	O
54425	excitation	NOUN	O
54425	was	VERB	O
54425	observed	VERB	O
54425	in	ADP	O
54425	most	ADJ	O
54425	laboratory	NOUN	O
54425	animals	NOUN	O
54425	.	PUNCT	O
54426	Clinical	ADJ	O
54426	side	NOUN	O
54426	effects	NOUN	O
54426	encountered	VERB	O
54426	with	ADP	O
54426	high	ADJ	O
54426	doses	NOUN	O
54426	of	ADP	O
54426	injected	VERB	O
54426	sinomenine	NOUN	O
54426	or	CCONJ	O
54426	of	ADP	O
54426	decocted	VERB	O
54426	Sinomenium	PROPN	O
54426	acutum	NOUN	O
54426	were	VERB	O
54426	:	PUNCT	O
54426	injection	NOUN	O
54426	site	NOUN	O
54426	flare	NOUN	O
54426	,	PUNCT	O
54426	pruritus	NOUN	O
54426	in	ADP	O
54426	the	DET	O
54426	head	NOUN	O
54426	and	CCONJ	O
54426	upper	ADJ	O
54426	part	NOUN	O
54426	of	ADP	O
54426	the	DET	O
54426	body	NOUN	O
54426	,	PUNCT	O
54426	edema	VERB	O
54426	around	ADP	O
54426	the	DET	O
54426	lips	NOUN	O
54426	and	CCONJ	O
54426	eyelids	NOUN	O
54426	,	PUNCT	O
54426	and	CCONJ	O
54426	temporary	ADJ	O
54426	cephalalgia	NOUN	O
54426	.	PUNCT	O
54427	Most	ADJ	O
54427	of	ADP	O
54427	these	DET	O
54427	side	NOUN	O
54427	effects	NOUN	O
54427	were	VERB	O
54427	reduced	VERB	O
54427	by	ADP	O
54427	classical	ADJ	O
54427	antihistamines	NOUN	O
54427	(	PUNCT	O
54427	H1-receptor	NOUN	O
54427	antagonists	NOUN	O
54427	)	PUNCT	O
54427	.	PUNCT	O
54428	Daily	ADJ	O
54428	subcutaneous	ADJ	O
54428	injections	NOUN	O
54428	of	ADP	O
54428	sinomenine	NOUN	O
54428	for	ADP	O
54428	more	ADJ	O
54428	than	ADP	O
54428	one	NUM	O
54428	week	NOUN	O
54428	produced	VERB	O
54428	an	DET	O
54428	analgesic	ADJ	O
54428	effect	NOUN	O
54428	in	ADP	O
54428	mice	NOUN	O
54428	.	PUNCT	O
54429	Granulation	PROPN	O
54429	tissue	NOUN	O
54429	growth	NOUN	O
54429	and	CCONJ	O
54429	adjuvant	ADJ	O
54429	arthritis	NOUN	DISEASE
54429	induced	VERB	O
54429	in	ADP	O
54429	rats	NOUN	O
54429	were	VERB	O
54429	both	DET	O
54429	inhibited	VERB	O
54429	by	ADP	O
54429	daily	ADJ	O
54429	injections	NOUN	O
54429	of	ADP	O
54429	a	DET	O
54429	small	ADJ	O
54429	dose	NOUN	O
54429	of	ADP	O
54429	sinomenine	NOUN	O
54429	hydrochloride	NOUN	O
54429	or	CCONJ	O
54429	histamine	NOUN	O
54429	dihydrochloride	NOUN	O
54429	.	PUNCT	O
54430	These	DET	O
54430	inhibitory	ADJ	O
54430	effects	NOUN	O
54430	were	VERB	O
54430	mediated	VERB	O
54430	through	ADP	O
54430	histamine	NOUN	O
54430	H2-receptors	NOUN	O
54430	probably	ADV	O
54430	on	ADP	O
54430	fibroblasts	NOUN	O
54430	(	PUNCT	O
54430	for	ADP	O
54430	granulation	NOUN	O
54430	tissue	NOUN	O
54430	growth	NOUN	O
54430	)	PUNCT	O
54430	and	CCONJ	O
54430	on	ADP	O
54430	T	PROPN	O
54430	-	PUNCT	O
54430	cells	NOUN	O
54430	(	PUNCT	O
54430	for	ADP	O
54430	adjuvant	ADJ	O
54430	arthritis	NOUN	DISEASE
54430	)	PUNCT	O
54430	,	PUNCT	O
54430	since	ADP	O
54430	these	DET	O
54430	effects	NOUN	O
54430	were	VERB	O
54430	clearly	ADV	O
54430	inhibited	VERB	O
54430	by	ADP	O
54430	the	DET	O
54430	H2-antagonist	ADJ	O
54430	burimamide	NOUN	O
54430	but	CCONJ	O
54430	not	ADV	O
54430	by	ADP	O
54430	the	DET	O
54430	H1-antagonist	ADJ	O
54430	mepyramine	NOUN	O
54430	.	PUNCT	O
54431	The	DET	O
54431	anti	ADV	O
54431	-	PUNCT	O
54431	rheumatic	ADJ	O
54431	effect	NOUN	O
54431	on	ADP	O
54431	Sinomenium	PROPN	O
54431	acutum	NOUN	O
54431	are	VERB	O
54431	probably	ADV	O
54431	genuine	ADJ	O
54431	and	CCONJ	O
54431	can	VERB	O
54431	probably	ADV	O
54431	be	VERB	O
54431	attributed	VERB	O
54431	to	ADP	O
54431	the	DET	O
54431	histamine	NOUN	O
54431	-	PUNCT	O
54431	releasing	VERB	O
54431	properties	NOUN	O
54431	of	ADP	O
54431	sinomenine	NOUN	O
54431	.	PUNCT	O
54432	The	DET	O
54432	sinus	NOUN	O
54432	function	NOUN	O
54432	of	ADP	O
54432	60	NUM	O
54432	patients	NOUN	O
54432	was	VERB	O
54432	studied	VERB	O
54432	by	ADP	O
54432	atrial	ADJ	O
54432	stimulation	NOUN	O
54432	at	ADP	O
54432	a	DET	O
54432	fixed	VERB	O
54432	rate	NOUN	O
54432	,	PUNCT	O
54432	and	CCONJ	O
54432	also	ADV	O
54432	at	ADP	O
54432	a	DET	O
54432	rate	NOUN	O
54432	linked	VERB	O
54432	with	ADP	O
54432	the	DET	O
54432	preceding	VERB	O
54432	sinus	NOUN	O
54432	cycle	NOUN	O
54432	.	PUNCT	O
54433	These	DET	O
54433	patients	NOUN	O
54433	were	VERB	O
54433	divided	VERB	O
54433	into	ADP	O
54433	3	NUM	O
54433	groups	NOUN	O
54433	according	VERB	O
54433	to	ADP	O
54433	the	DET	O
54433	surface	NOUN	O
54433	-	PUNCT	O
54433	recorded	VERB	O
54433	ECG	PROPN	O
54433	;	PUNCT	O
54433	10	NUM	O
54433	had	VERB	O
54433	clear	ADJ	O
54433	evidence	NOUN	O
54433	of	ADP	O
54433	sinus	NOUN	O
54433	dysfunction	NOUN	O
54433	,	PUNCT	O
54433	23	NUM	O
54433	had	VERB	O
54433	an	DET	O
54433	isolated	ADJ	O
54433	sinus	NOUN	O
54433	bradycardia	NOUN	O
54433	,	PUNCT	O
54433	and	CCONJ	O
54433	27	NUM	O
54433	were	VERB	O
54433	considered	VERB	O
54433	as	ADP	O
54433	controls	NOUN	O
54434	a	DET	O
54434	their	ADJ	O
54434	sinus	NOUN	O
54434	rate	NOUN	O
54434	was	VERB	O
54434	above	ADP	O
54434	60/min	NOUN	O
54434	.	PUNCT	O
54435	,	PUNCT	O
54435	with	ADP	O
54435	a	DET	O
54435	normal	ADJ	O
54435	PR	NOUN	O
54435	interval	NOUN	O
54435	.	PUNCT	O
54436	Calculation	PROPN	O
54436	of	ADP	O
54436	the	DET	O
54436	limits	NOUN	O
54436	of	ADP	O
54436	tolerance	NOUN	O
54436	showed	VERB	O
54436	that	ADP	O
54436	at	ADP	O
54436	the	DET	O
54436	5	NUM	O
54436	%	NOUN	O
54436	level	NOUN	O
54436	,	PUNCT	O
54436	95	NUM	O
54436	%	NOUN	O
54436	of	ADP	O
54436	the	DET	O
54436	values	NOUN	O
54436	for	ADP	O
54436	all	ADJ	O
54436	the	DET	O
54436	controls	NOUN	O
54436	fell	VERB	O
54436	between	ADP	O
54436	96.8	NUM	O
54436	and	CCONJ	O
54436	568.7	NUM	O
54436	ms	NOUN	O
54436	for	ADP	O
54436	the	DET	O
54436	corrected	VERB	O
54436	post	NOUN	O
54436	-	PUNCT	O
54436	stimulatory	NOUN	O
54436	pause	NOUN	O
54436	,	PUNCT	O
54436	and	CCONJ	O
54436	between	ADP	O
54436	114.5	NUM	O
54436	and	CCONJ	O
54436	434.3	NUM	O
54436	ms	NOUN	O
54436	for	ADP	O
54436	the	DET	O
54436	corrected	VERB	O
54436	maximum	ADJ	O
54436	return	NOUN	O
54436	cycle	NOUN	O
54436	.	PUNCT	O
54437	A	DET	O
54437	study	NOUN	O
54437	of	ADP	O
54437	the	DET	O
54437	distribution	NOUN	O
54437	zones	NOUN	O
54437	of	ADP	O
54437	the	DET	O
54437	graph	NOUN	O
54437	CT	PROPN	O
54437	/	SYM	O
54437	CR	PROPN	O
54437	-	PUNCT	O
54437	AA	PROPN	O
54437	/	SYM	O
54437	AA	PROPN	O
54437	proved	VERB	O
54437	that	ADP	O
54437	an	DET	O
54437	absent	ADJ	O
54437	zone	NOUN	O
54437	II	PROPN	O
54437	is	VERB	O
54437	a	DET	O
54437	pathological	ADJ	O
54437	finding	NOUN	O
54437	.	PUNCT	O
54438	In	ADP	O
54438	the	DET	O
54438	group	NOUN	O
54438	of	ADP	O
54438	sinus	NOUN	O
54438	bradycardias	NOUN	O
54438	the	DET	O
54438	limits	NOUN	O
54438	of	ADP	O
54438	what	NOUN	O
54438	constitutes	VERB	O
54438	pathology	NOUN	O
54438	are	VERB	O
54438	less	ADV	O
54438	clear	ADJ	O
54438	,	PUNCT	O
54438	and	CCONJ	O
54438	the	DET	O
54438	situation	NOUN	O
54438	is	VERB	O
54438	not	ADV	O
54438	improved	VERB	O
54438	by	ADP	O
54438	noting	VERB	O
54438	whether	ADP	O
54438	atrial	ADJ	O
54438	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
a 	 O 	O
comparative 	 O 	O
study 	 O 	O
of 	 O 	O
doxycycline 	 O 	O
and 	 O 	O
cephalothin 	 O 	O
, 	 O 	O
patients 	 O 	O
suffering 	 O 	O
intraabdominal 	 O 	O
contamination 	 O 	O
by 	 O 	O
gastrointestinal 	 O 	O
contents 	 O 	O
from 	 O 	O
perforation 	 O 	DISEASE
were 	 O 	O
divided 	 O 	O
in 	 O 	O
half 	 O 	O
; 	 O 	O
half 	 O 	O
were 	 O 	O
treated 	 O 	O
with 	 O 	O
the 	 O 	O
tetracycline 	 O 	O
analog 	 O 	O
and 	 O 	O
74 	 O 	O
% 	 O 	O
responded 	 O 	O
; 	 O 	O
the 	 O 	O
other 	 O 	O
half 	 O 	O
were 	 O 	O
treated 	 O 	O
with 	 O 	O
the 	 O 	O
cephalothin 	 O 	O
and 	 O 	O
response 	 O 	O
was 	 O 	O
57 	 O 	O
% 	 O 	O
. 	 O 	O
bleached 	 O 	O
The 	 O 	O
Raji(A44 	 O 	O
) 	 O 	O
line 	 O 	O
( 	 O 	O
cells 	 O 	O
in 	 O 	O
suspension 	 O 	O
) 	 O 	O
can 	 O 	O
be 	 O 	O
routinely 	 O 	O
used 	 O 	O
for 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
HSV 	 O 	O
infection 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
mixed 	 O 	O
edema 	 O 	DISEASE
or 	 O 	O
of 	 O 	O
unknown 	 O 	O
pathogenesis 	 O 	O
	PUNCT	O
49501	.	PUNCT	O
49502	In	ADP	O
49502	contrast	NOUN	O
49502	with	ADP	O
49502	this	DET	O
49502	lack	NOUN	O
49502	of	ADP	O
49502	information	NOUN	O
49502	in	ADP	O
49502	man	NOUN	O
49502	,	PUNCT	O
49502	animal	NOUN	O
49502	experimental	ADJ	O
49502	works	NOUN	O
49502	are	VERB	O
49502	surprising	ADJ	O
49502	by	ADP	O
49502	their	ADJ	O
49502	coherence	NOUN	O
49502	and	CCONJ	O
49502	the	DET	O
49502	experimental	ADJ	O
49502	facility	NOUN	O
49502	of	ADP	O
49502	producing	VERB	O
49502	neurogenic	NOUN	O
49502	edema	NOUN	O
49502	(	PUNCT	O
49502	cranial	NOUN	O
49502	hypertension	NOUN	DISEASE
49502	by	ADP	O
49502	a	DET	O
49502	small	ADJ	O
49502	inflatable	ADJ	O
49502	balloon	NOUN	O
49502	and	CCONJ	O
49502	cisternal	ADJ	O
49502	infection	NOUN	O
49502	of	ADP	O
49502	fibrin	NOUN	O
49502	)	PUNCT	O
49502	.	PUNCT	O
49503	If	ADP	O
49503	one	NUM	O
49503	excludes	VERB	O
49503	the	DET	O
49503	now	ADV	O
49503	ancient	ADJ	O
49503	vagal	ADJ	O
49503	theories	NOUN	O
49503	(	PUNCT	O
49503	CAMERON	PROPN	O
49503	1949	NUM	O
49503	;	PUNCT	O
49503	CAMPBELL	PROPN	O
49503	,	PUNCT	O
49503	1949	NUM	O
49503	)	PUNCT	O
49503	which	ADJ	O
49503	were	VERB	O
49503	never	ADV	O
49503	confirmed	VERB	O
49503	,	PUNCT	O
49503	all	DET	O
49503	of	ADP	O
49503	the	DET	O
49503	most	ADV	O
49503	recent	ADJ	O
49503	experimental	ADJ	O
49503	works	NOUN	O
49503	(	PUNCT	O
49503	SARNOFF	NOUN	O
49503	,	PUNCT	O
49503	1952	NUM	O
49503	;	PUNCT	O
49503	DUCKER	NOUN	O
49503	,	PUNCT	O
49503	1968	NUM	O
49503	;	PUNCT	O
49503	LUISADA	PROPN	O
49503	,	PUNCT	O
49503	1967	NUM	O
49503	;	PUNCT	O
49503	MORITZ	PROPN	O
49503	,	PUNCT	O
49503	1974	NUM	O
49503	)	PUNCT	O
49503	confirm	VERB	O
49503	the	DET	O
49503	adrenergic	ADJ	O
49503	disorder	NOUN	O
49503	of	ADP	O
49503	central	ADJ	O
49503	origin	NOUN	O
49503	during	ADP	O
49503	neurogenic	NOUN	O
49503	A.P.E.	PROPN	O
49503	which	ADJ	O
49503	from	ADP	O
49503	the	DET	O
49503	hemodynamic	ADJ	O
49503	standpoint	NOUN	O
49503	is	VERB	O
49503	like	ADP	O
49503	an	DET	O
49503	authentic	ADJ	O
49503	hemodynamic	NOUN	O
49503	A.P.E.	NOUN	O
49503	with	ADP	O
49503	raised	VERB	O
49503	left	VERB	O
49503	atrial	ADJ	O
49503	pressure	NOUN	O
49503	,	PUNCT	O
49503	pulmonary	ADJ	O
49503	venous	ADJ	O
49503	pressure	NOUN	O
49503	and	CCONJ	O
49503	pulmonary	ADJ	O
49503	capillary	ADJ	O
49503	pressure	NOUN	O
49503	.	PUNCT	O
49504	Their	ADJ	O
49504	frequency	NOUN	O
49504	is	VERB	O
49504	estimated	VERB	O
49504	with	ADP	O
49504	difficulty	NOUN	O
49504	,	PUNCT	O
49504	although	ADP	O
49504	on	ADP	O
49504	autopsy	ADJ	O
49504	pulmonary	ADJ	DISEASE
49504	edema	NOUN	DISEASE
49504	is	VERB	O
49504	found	VERB	O
49504	almost	ADV	O
49504	routinely	ADV	O
49504	.	PUNCT	O
49505	It	PRON	O
49505	is	VERB	O
49505	a	DET	O
49505	major	ADJ	O
49505	complication	NOUN	O
49505	of	ADP	O
49505	overdoses	NOUN	O
49505	(	PUNCT	O
49505	48	NUM	O
49505	p.	NOUN	O
49505	100	NUM	O
49505	of	ADP	O
49505	severe	ADJ	O
49505	intoxications	NOUN	O
49505	)	PUNCT	O
49505	.	PUNCT	O
49506	Their	ADJ	O
49506	formation	NOUN	O
49506	can	VERB	O
49506	be	VERB	O
49506	suspected	VERB	O
49506	,	PUNCT	O
49506	when	ADV	O
49506	after	ADP	O
49506	the	DET	O
49506	first	ADJ	O
49506	phase	NOUN	O
49506	of	ADP	O
49506	respiratory	ADJ	O
49506	depressions	NOUN	O
49506	,	PUNCT	O
49506	with	ADP	O
49506	coma	NOUN	O
49506	,	PUNCT	O
49506	myosis	NOUN	O
49506	,	PUNCT	O
49506	and	CCONJ	O
49506	a	DET	O
49506	variable	ADJ	O
49506	latent	ADJ	O
49506	period	NOUN	O
49506	,	PUNCT	O
49506	a	DET	O
49506	second	ADJ	O
49506	attack	NOUN	O
49506	of	ADP	O
49506	respiratory	ADJ	O
49506	insufficiency	NOUN	O
49506	occurs	VERB	O
49506	with	ADP	O
49506	tachypnea	NOUN	O
49506	,	PUNCT	O
49506	and	CCONJ	O
49506	cyanosis	NOUN	O
49506	.	PUNCT	O
49507	The	DET	O
49507	chest	NOUN	O
49507	X	NOUN	O
49507	-	PUNCT	O
49507	ray	NOUN	O
49507	shows	VERB	O
49507	diffuse	NOUN	O
49507	alveolar	NOUN	O
49507	infiltration	NOUN	O
49507	,	PUNCT	O
49507	sparing	VERB	O
49507	the	DET	O
49507	apices	NOUN	O
49507	.	PUNCT	O
49508	The	DET	O
49508	heart	NOUN	O
49508	being	VERB	O
49508	generally	ADV	O
49508	of	ADP	O
49508	normal	ADJ	O
49508	size	NOUN	O
49508	.	PUNCT	O
49509	Rapid	ADJ	O
49509	disappearance	NOUN	O
49509	of	ADP	O
49509	this	DET	O
49509	infiltrate	NOUN	O
49509	(	PUNCT	O
49509	24	NUM	O
49509	to	PART	O
49509	48	NUM	O
49509	hours	NOUN	O
49509	)	PUNCT	O
49509	enables	VERB	O
49509	the	DET	O
49509	elimination	NOUN	O
49509	of	ADP	O
49509	two	NUM	O
49509	diagnoses	NOUN	O
49509	:	PUNCT	O
49509	pneumonia	VERB	DISEASE
49509	due	ADP	O
49509	to	ADP	O
49509	inhalation	NOUN	O
49509	of	ADP	O
49509	gastric	ADJ	O
49509	fluid	NOUN	O
49509	,	PUNCT	O
49509	an	DET	O
49509	infectious	ADJ	O
49509	pneumonia	NOUN	O
49509	.	PUNCT	O
49509	Rapid	ADJ	O
49509	disappearance	NOUN	O
49509	of	ADP	O
49509	this	DET	O
49509	infiltrate	NOUN	O
49509	(	PUNCT	O
49509	24	NUM	O
49509	to	PART	O
49509	48	NUM	O
49509	hours	NOUN	O
49509	)	PUNCT	O
49509	enables	VERB	O
49509	the	DET	O
49509	elimination	NOUN	O
49509	of	ADP	O
49509	two	NUM	O
49509	diagnoses	NOUN	O
49509	:	PUNCT	O
49509	pneumonia	VERB	O
49509	due	ADP	O
49509	to	ADP	O
49509	inhalation	NOUN	O
49509	of	ADP	O
49509	gastric	ADJ	O
49509	fluid	NOUN	O
49509	,	PUNCT	O
49509	an	DET	O
49509	infectious	ADJ	O
49509	pneumonia	NOUN	DISEASE
49509	.	PUNCT	O
49510	Their	ADJ	O
49510	pathogenesis	NOUN	O
49510	remains	VERB	O
49510	very	ADV	O
49510	debatable	ADJ	O
49510	:	PUNCT	O
49510	-	PUNCT	O
49510	in	ADP	O
49510	the	DET	O
49510	majority	NOUN	O
49510	of	ADP	O
49510	cases	NOUN	O
49510	abrupt	ADJ	O
49510	L.V.F.	PROPN	O
49510	can	VERB	O
49510	be	VERB	O
49510	eliminated	VERB	O
49510	:	PUNCT	O
49510	-on	PUNCT	O
49510	the	DET	O
49510	other	ADJ	O
49510	hand	NOUN	O
49510	it	PRON	O
49510	could	VERB	O
49510	be	VERB	O
49510	an	DET	O
49510	allergic	ADJ	O
49510	accident	NOUN	O
49510	of	ADP	O
49510	the	DET	O
49510	anaphylactic	ADJ	O
49510	type	NOUN	O
49510	,	PUNCT	O
49510	or	CCONJ	O
49510	local	ADJ	O
49510	liberation	NOUN	O
49510	of	ADP	O
49510	histamine	NOUN	O
49510	,	PUNCT	O
49510	or	CCONJ	O
49510	a	DET	O
49510	local	ADJ	O
49510	toxic	ADJ	O
49510	action	NOUN	O
49510	on	ADP	O
49510	the	DET	O
49510	pulmonary	ADJ	O
49510	capillaries	NOUN	O
49510	;	PUNCT	O
49510	-	PUNCT	O
49510	hypoxia	NOUN	O
49510	,	PUNCT	O
49510	secondary	ADJ	O
49510	to	ADP	O
49510	respiratory	ADJ	O
49510	depression	NOUN	O
49510	,	PUNCT	O
49510	could	VERB	O
49510	lead	VERB	O
49510	to	ADP	O
49510	pulmonary	ADJ	DISEASE
49510	edema	NOUN	DISEASE
49510	,	PUNCT	O
49510	by	ADP	O
49510	the	DET	O
49510	same	ADJ	O
49510	mechanism	NOUN	O
49510	as	ADP	O
49510	at	ADP	O
49510	altitude	NOUN	O
49510	;	PUNCT	O
49510	-	PUNCT	O
49510	finally	ADV	O
49510	,	PUNCT	O
49510	owing	VERB	O
49510	to	ADP	O
49510	the	DET	O
49510	central	ADJ	O
49510	neurological	ADJ	O
49510	disorders	NOUN	O
49510	a	DET	O
49510	neurogenic	NOUN	O
49510	theory	NOUN	O
49510	can	VERB	O
49510	be	VERB	O
49510	put	VERB	O
49510	forward	ADV	O
49510	.	PUNCT	O
49511	Their	ADJ	O
49511	treatment	NOUN	O
49511	is	VERB	O
49511	essentially	ADV	O
49511	a	DET	O
49511	combination	NOUN	O
49511	of	ADP	O
49511	Nalorphine	PROPN	O
49511	with	ADP	O
49511	oxygen	NOUN	O
49511	therapy	NOUN	O
49511	(	PUNCT	O
49511	by	ADP	O
49511	mask	NOUN	O
49511	,	PUNCT	O
49511	or	CCONJ	O
49511	if	ADP	O
49511	necessary	ADJ	O
49511	by	ADP	O
49511	assisted	VERB	O
49511	,	PUNCT	O
49511	controlled	VERB	O
49511	ventilation	NOUN	O
49511	)	PUNCT	O
49511	with	ADP	O
49511	prevention	NOUN	O
49511	of	ADP	O
49511	inhalation	NOUN	O
49511	of	ADP	O
49511	gastric	ADJ	O
49511	fluid	NOUN	O
49511	(	PUNCT	O
49511	gastric	ADJ	O
49511	emptying	NOUN	O
49511	)	PUNCT	O
49511	or	CCONJ	O
49511	curative	ADJ	O
49511	treatment	NOUN	O
49511	of	ADP	O
49511	possible	ADJ	O
49511	aspiration	NOUN	O
49511	by	ADP	O
49511	antibiotics	NOUN	O
49511	,	PUNCT	O
49511	and	CCONJ	O
49511	cortico	NOUN	O
49511	-	PUNCT	O
49511	steroids	NOUN	O
49511	.	PUNCT	O
49512	Diuretics	NOUN	O
49512	can	VERB	O
49512	be	VERB	O
49512	useful	ADJ	O
49512	,	PUNCT	O
49512	as	ADV	O
49512	well	ADV	O
49512	as	ADP	O
49512	cardiotonics	NOUN	O
49512	.	PUNCT	O
49513	Functional	ADJ	O
49513	digestive	ADJ	O
49513	complaints	NOUN	O
49513	are	VERB	O
49513	frequent	ADJ	O
49513	in	ADP	O
49513	psychiatri	NOUN	O
49513	patients	NOUN	O
49513	:	PUNCT	O
49513	simple	ADJ	O
49513	constipation	NOUN	DISEASE
49513	,	PUNCT	O
49513	which	ADJ	O
49513	can	VERB	O
49513	not	ADV	O
49513	be	VERB	O
49513	explained	VERB	O
49513	solely	ADV	O
49513	by	ADP	O
49513	the	DET	O
49513	loss	NOUN	O
49513	of	ADP	O
49513	the	DET	O
49513	sensation	NOUN	O
49513	of	ADP	O
49513	rectal	ADJ	O
49513	fullness	NOUN	O
49513	;	PUNCT	O
49513	occlusions	NOUN	O
49513	,	PUNCT	O
49513	occasionally	ADV	O
49513	hemorragies	NOUN	O
49513	;	PUNCT	O
49513	the	DET	O
49513	late	ADJ	O
49513	complication	NOUN	O
49513	of	ADP	O
49513	dolichomegacolon	NOUN	O
49513	(	PUNCT	O
49513	Bourgeois	PROPN	O
49513	,	PUNCT	O
49513	1973	NUM	O
49513	)	PUNCT	O
49513	.	PUNCT	O
49514	In	ADP	O
49514	160	NUM	O
49514	subjects	NOUN	O
49514	,	PUNCT	O
49514	an	DET	O
49514	attempt	NOUN	O
49514	to	PART	O
49514	understand	VERB	O
49514	the	DET	O
49514	physio	NOUN	O
49514	-	PUNCT	O
49514	pathology	NOUN	O
49514	were	VERB	O
49514	made	VERB	O
49514	by	ADP	O
49514	recording	VERB	O
49514	diurnal	ADJ	O
49514	digestive	ADJ	O
49514	motor	NOUN	O
49514	activity	NOUN	O
49514	using	VERB	O
49514	skin	NOUN	O
49514	electrodes	NOUN	O
49514	placed	VERB	O
49514	on	ADP	O
49514	the	DET	O
49514	abdomen	NOUN	O
49514	and	CCONJ	O
49514	extremities	NOUN	O
49514	(	PUNCT	O
49514	electrogastroenterography	NOUN	O
49514	or	CCONJ	O
49514	E.G.E.G.	PROPN	O
49514	)	PUNCT	O
49514	.	PUNCT	O
49515	A	DET	O
49515	hypoactive	ADJ	O
49515	E.G.E.G.	PROPN	O
49515	was	VERB	O
49515	observed	VERB	O
49515	in	ADP	O
49515	2/3	NUM	O
49515	of	ADP	O
49515	18	NUM	O
49515	psychotic	ADJ	O
49515	depressive	ADJ	O
49515	patients	NOUN	O
49515	,	PUNCT	O
49515	in	ADP	O
49515	3/4	NUM	O
49515	of	ADP	O
49515	36	NUM	O
49515	schizophrenies	NOUN	O
49515	.	PUNCT	O
49516	The	DET	O
49516	nocive	ADJ	O
49516	effect	NOUN	O
49516	of	ADP	O
49516	giving	VERB	O
49516	sedative	ADJ	O
49516	phenothiazine	NOUN	O
49516	and	CCONJ	O
49516	antiparkinsonian	ADJ	O
49516	drugs	NOUN	O
49516	(	PUNCT	O
49516	trihexyphenidyl	NOUN	O
49516	or	CCONJ	O
49516	ethybenzatropine	VERB	O
49516	)	PUNCT	O
49516	during	ADP	O
49516	long	ADJ	O
49516	periods	NOUN	O
49516	is	VERB	O
49516	clear	ADJ	O
49516	.	PUNCT	O
49517	Whereas	ADP	O
49517	non	ADJ	O
49517	sedative	ADJ	O
49517	phenothiazine	NOUN	O
49517	and	CCONJ	O
49517	clotiapine	NOUN	O
49517	gicen	NOUN	O
49517	in	ADP	O
49517	small	ADJ	O
49517	doses	NOUN	O
49517	,	PUNCT	O
49517	do	VERB	O
49517	not	ADV	O
49517	have	VERB	O
49517	an	DET	O
49517	undesirable	ADJ	O
49517	effect	NOUN	O
49517	.	PUNCT	O
49518	Sulpiride	PROPN	O
49518	has	VERB	O
49518	been	VERB	O
49518	used	VERB	O
49518	in	ADP	O
49518	gastroduodenal	ADJ	O
49518	dyskinesia	NOUN	DISEASE
49518	.	PUNCT	O
49519	The	DET	O
49519	dyskinesia	NOUN	DISEASE
49519	noted	VERB	O
49519	by	ADP	O
49519	the	DET	O
49519	E.G.E.G.	PROPN	O
49519	,	PUNCT	O
49519	sometimes	ADV	O
49519	found	VERB	O
49519	in	ADP	O
49519	the	DET	O
49519	large	ADJ	O
49519	intestin	NOUN	O
49519	,	PUNCT	O
49519	were	VERB	O
49519	found	VERB	O
49519	in	ADP	O
49519	55	NUM	O
49519	%	NOUN	O
49519	of	ADP	O
49519	30	NUM	O
49519	patients	NOUN	O
49519	with	ADP	O
49519	caracter	NOUN	O
49519	disorders	NOUN	O
49519	;	PUNCT	O
49519	they	PRON	O
49519	coincide	VERB	O
49519	with	ADP	O
49519	the	DET	O
49519	high	ADJ	O
49519	frequency	NOUN	O
49519	of	ADP	O
49519	electro	ADJ	O
49519	-	PUNCT	O
49519	encephalogram	NOUN	O
49519	dysrythmies	NOUN	O
49519	.	PUNCT	O
49520	Finally	ADV	O
49520	,	PUNCT	O
49520	in	ADP	O
49520	hysterical	ADJ	O
49520	patients	NOUN	O
49520	,	PUNCT	O
49520	one	NUM	O
49520	usually	ADV	O
49520	observes	VERB	O
49520	normal	ADJ	O
49520	E.G.E.G.	PROPN	O
49520	,	PUNCT	O
49520	tracings	NOUN	O
49520	which	ADJ	O
49520	confirms	VERB	O
49520	the	DET	O
49520	clinical	ADJ	O
49520	observation	NOUN	O
49520	that	ADP	O
49520	hysterical	ADJ	O
49520	and	CCONJ	O
49520	psychosomatic	ADJ	O
49520	symptoms	NOUN	O
49520	,	PUNCT	O
49520	may	VERB	O
49520	succeed	VERB	O
49520	each	DET	O
49520	other	ADJ	O
49520	,	PUNCT	O
49520	but	CCONJ	O
49520	do	VERB	O
49520	not	ADV	O
49520	appear	VERB	O
49520	at	ADP	O
49520	the	DET	O
49520	same	ADJ	O
49520	time	NOUN	O
49520	.	PUNCT	O
49521	In	ADP	O
49521	the	DET	O
49521	same	ADJ	O
49521	categories	NOUN	O
49521	of	ADP	O
49521	patients	NOUN	O
49521	,	PUNCT	O
49521	no	ADV	O
49521	longer	ADV	O
49521	treated	VERB	O
49521	in	ADP	O
49521	a	DET	O
49521	classical	ADJ	O
49521	psychiatric	ADJ	O
49521	environment	NOUN	O
49521	but	CCONJ	O
49521	in	ADP	O
49521	a	DET	O
49521	group	NOUN	O
49521	with	ADP	O
49521	institutional	ADJ	O
49521	objectives	NOUN	O
49521	,	PUNCT	O
49521	the	DET	O
49521	same	ADJ	O
49521	clinic	NOUN	O
49521	results	NOUN	O
49521	were	VERB	O
49521	obtained	VERB	O
49521	with	ADP	O
49521	fewer	ADJ	O
49521	digestive	ADJ	O
49521	disturbances	NOUN	O
49521	.	PUNCT	O
49522	This	DET	O
49522	tends	VERB	O
49522	to	PART	O
49522	show	VERB	O
49522	the	DET	O
49522	inutility	NOUN	O
49522	and	CCONJ	O
49522	nocivity	NOUN	O
49522	of	ADP	O
49522	excessive	ADJ	O
49522	doses	NOUN	O
49522	of	ADP	O
49522	psychotropic	ADJ	O
49522	drugs	NOUN	O
49522	given	VERB	O
49522	alone	ADV	O
49522	or	CCONJ	O
49522	in	ADP	O
49522	complexe	NOUN	O
49522	association	NOUN	O
49522	.	PUNCT	O
49523	The	DET	O
49523	isolation	NOUN	O
49523	and	CCONJ	O
49523	the	DET	O
49523	characterization	NOUN	O
49523	of	ADP	O
49523	one	NUM	O
49523	of	ADP	O
49523	the	DET	O
49523	enzymes	NOUN	O
49523	of	ADP	O
49523	Micropolyspora	PROPN	O
49523	faeni	NOUN	O
49523	that	ADJ	O
49523	hydrolyzes	VERB	O
49523	the	DET	O
49523	substrate	NOUN	O
49523	N	NOUN	O
49523	-	PUNCT	O
49523	benzoyl	NOUN	O
49523	-	PUNCT	O
49523	DL	PROPN	O
49523	-	PUNCT	O
49523	phenylalanine	NOUN	O
49523	-	PUNCT	O
49523	beta	NOUN	O
49523	-	PUNCT	O
49523	naphthyl	NOUN	O
49523	ester	NOUN	O
49523	and	CCONJ	O
49523	that	DET	O
49523	seems	VERB	O
49523	to	PART	O
49523	be	VERB	O
49523	of	ADP	O
49523	medical	ADJ	O
49523	importance	NOUN	O
49523	are	VERB	O
49523	described	VERB	O
49523	.	PUNCT	O
49524	This	DET	O
49524	enzyme	NOUN	O
49524	(	PUNCT	O
49524	enzyme	NOUN	O
49524	1	NUM	O
49524	)	PUNCT	O
49524	was	VERB	O
49524	isolated	VERB	O
49524	with	ADP	O
49524	an	DET	O
49524	86-fold	NUM	O
49524	purification	NOUN	O
49524	by	ADP	O
49524	using	VERB	O
49524	the	DET	O
49524	following	VERB	O
49524	seven	NUM	O
49524	steps	NOUN	O
49524	:	PUNCT	O
49524	ammonium	NOUN	O
49524	sulfate	NOUN	O
49524	precipitation	NOUN	O
49524	,	PUNCT	O
49524	gel	NOUN	O
49524	filtration	NOUN	O
49524	through	ADP	O
49524	Sephadex	PROPN	O
49524	G-150	PROPN	O
49524	,	PUNCT	O
49524	heat	NOUN	O
49524	treatment	NOUN	O
49524	,	PUNCT	O
49524	chromatography	VERB	O
49524	on	ADP	O
49524	diethylaminoethyl	NOUN	O
49524	-	PUNCT	O
49524	cellulose	ADJ	O
49524	,	PUNCT	O
49524	rechromatography	NOUN	O
49524	on	ADP	O
49524	diethylaminoethyl	NOUN	O
49524	-	PUNCT	O
49524	Sephadex	PROPN	O
49524	,	PUNCT	O
49524	gel	NOUN	O
49524	filtration	NOUN	O
49524	through	ADP	O
49524	Sephadex	PROPN	O
49524	G-200	PROPN	O
49524	,	PUNCT	O
49524	and	CCONJ	O
49524	affinity	NOUN	O
49524	chromatography	NOUN	O
49524	.	PUNCT	O
49525	Enzyme	PROPN	O
49525	1	NUM	O
49525	has	VERB	O
49525	a	DET	O
49525	molecular	ADJ	O
49525	weight	NOUN	O
49525	of	ADP	O
49525	approximately	ADV	O
49525	500,000	NUM	O
49525	and	CCONJ	O
49525	maximum	ADJ	O
49525	activity	NOUN	O
49525	at	ADP	O
49525	pH	PROPN	O
49525	7.8	NUM	O
49525	to	PART	O
49525	8.0	NUM	O
49525	and	CCONJ	O
49525	at	ADP	O
49525	20	NUM	O
49525	degrees	NOUN	O
49525	C.	NOUN	O
49526	The	DET	O
49526	enzyme	NOUN	O
49526	is	VERB	O
49526	stable	ADJ	O
49526	between	ADP	O
49526	pH	PROPN	O
49526	7.5	NUM	O
49526	and	CCONJ	O
49526	10.5	NUM	O
49526	and	CCONJ	O
49526	at	ADP	O
49526	temperatures	NOUN	O
49527	up	ADP	O
49527	to	PART	O
49527	60	NUM	O
49527	degrees	NOUN	O
49527	C.	NOUN	O
49528	Its	ADJ	O
49528	activity	NOUN	O
49528	is	VERB	O
49528	not	ADV	O
49528	inhibited	VERB	O
49528	by	ADP	O
49528	ethylenediaminetetraacetic	ADJ	O
49528	acid	NOUN	O
49528	.	PUNCT	O
49529	It	PRON	O
49529	is	VERB	O
49529	,	PUNCT	O
49529	however	ADV	O
49529	,	PUNCT	O
49529	sensitive	ADJ	O
49529	to	ADP	O
49529	diisopropyl	ADJ	O
49529	phosphofluoride	NOUN	O
49529	and	CCONJ	O
49529	phenylmethyl	NOUN	O
49529	sulfonyl	NOUN	O
49529	fluoride	NOUN	O
49529	.	PUNCT	O
49530	These	DET	O
49530	properties	NOUN	O
49530	and	CCONJ	O
49530	the	DET	O
49530	ability	NOUN	O
49530	to	PART	O
49530	hydrolyze	VERB	O
49530	the	DET	O
49530	esters	NOUN	O
49530	of	ADP	O
49530	phenylalanine	NOUN	O
49530	,	PUNCT	O
49530	tyrosine	NOUN	O
49530	,	PUNCT	O
49530	and	CCONJ	O
49530	tryptophan	NOUN	O
49530	without	ADP	O
49530	endopeptidasic	ADJ	O
49530	activity	NOUN	O
49530	and	CCONJ	O
49530	no	DET	O
49530	marked	ADJ	O
49530	proteolytic	ADJ	O
49530	activity	NOUN	O
49530	suggest	VERB	O
49530	that	ADP	O
49530	the	DET	O
49530	enzyme	NOUN	O
49530	is	VERB	O
49530	an	DET	O
49530	esterase	NOUN	O
49530	.	PUNCT	O
49531	Lithium	NOUN	O
49531	carbonate	NOUN	O
49531	is	VERB	O
49531	commonly	ADV	O
49531	used	VERB	O
49531	in	ADP	O
49531	psychiatry	NOUN	O
49531	,	PUNCT	O
49531	particularly	ADV	O
49531	in	ADP	O
49531	the	DET	O
49531	management	NOUN	O
49531	of	ADP	O
49531	the	DET	O
49531	manic	ADJ	O
49531	-	PUNCT	O
49531	depressive	ADJ	O
49531	syndrome	NOUN	O
49531	.	PUNCT	O
49532	It	PRON	O
49532	is	VERB	O
49532	also	ADV	O
49532	being	VERB	O
49532	increasingly	ADV	O
49532	tried	VERB	O
49532	in	ADP	O
49532	a	DET	O
49532	variety	NOUN	O
49532	of	ADP	O
49532	physical	ADJ	O
49532	disorders	NOUN	O
49532	.	PUNCT	O
49533	This	DET	O
49533	essentially	ADV	O
49533	practical	ADJ	O
49533	article	NOUN	O
49533	summarizes	VERB	O
49533	important	ADJ	O
49533	non	ADJ	O
49533	-	PUNCT	O
49533	psychiatric	ADJ	O
49533	aspects	NOUN	O
49533	of	ADP	O
49533	the	DET	O
49533	use	NOUN	O
49533	of	ADP	O
49533	the	DET	O
49533	drug	NOUN	O
49533	,	PUNCT	O
49533	including	VERB	O
49533	its	ADJ	O
49533	less	ADV	O
49533	common	ADJ	O
49533	actions	NOUN	O
49533	.	PUNCT	O
49534	Contra	PROPN	O
49534	-	PUNCT	O
49534	indications	NOUN	O
49534	to	ADP	O
49534	the	DET	O
49534	use	NOUN	O
49534	of	ADP	O
49534	lithium	NOUN	O
49534	are	VERB	O
49534	discussed	VERB	O
49534	,	PUNCT	O
49534	and	CCONJ	O
49534	the	DET	O
49534	management	NOUN	O
49534	of	ADP	O
49534	lithium	NOUN	O
49534	intoxication	NOUN	O
49534	is	VERB	O
49534	outlined	VERB	O
49534	.	PUNCT	O
49535	Psychomotor	NOUN	O
49535	skills	NOUN	O
49535	and	CCONJ	O
49535	visual	ADJ	O
49535	functions	NOUN	O
49535	related	VERB	O
49535	to	ADP	O
49535	driving	VERB	O
49535	were	VERB	O
49535	measured	VERB	O
49535	double	ADJ	O
49535	-	PUNCT	O
49535	blind	ADJ	O
49535	cross	NOUN	O
49535	-	PUNCT	O
49535	over	NOUN	O
49535	in	ADP	O
49535	ten	NUM	O
49535	healthy	ADJ	O
49535	volunteers	NOUN	O
49535	before	ADV	O
49535	,	PUNCT	O
49535	and	CCONJ	O
49535	1,3,5	NUM	O
49535	and	CCONJ	O
49535	7	NUM	O
49535	h	NOUN	O
49535	after	ADP	O
49535	a	DET	O
49535	single	ADJ	O
49535	oral	ADJ	O
49535	administration	NOUN	O
49535	of	ADP	O
49535	diazepam	NOUN	O
49535	(	PUNCT	O
49535	10	NUM	O
49535	mg	NOUN	O
49535	)	PUNCT	O
49535	,	PUNCT	O
49535	medazepam	NOUN	O
49535	(	PUNCT	O
49535	15	NUM	O
49535	mg	NOUN	O
49535	)	PUNCT	O
49535	or	CCONJ	O
49535	lorazepam	NOUN	O
49535	(	PUNCT	O
49535	2.5	NUM	O
49535	mg	NOUN	O
49535	)	PUNCT	O
49535	.	PUNCT	O
49536	The	DET	O
49536	late	ADJ	O
49536	effects	NOUN	O
49536	of	ADP	O
49536	lorazepam	NOUN	O
49536	were	VERB	O
49536	tested	VERB	O
49536	in	ADP	O
49536	seven	NUM	O
49536	other	ADJ	O
49536	subjects	NOUN	O
49536	12	NUM	O
49536	and	CCONJ	O
49536	24	NUM	O
49536	h	NOUN	O
49536	after	ADP	O
49536	the	DET	O
49536	administration	NOUN	O
49536	.	PUNCT	O
49537	Lorazepam	PROPN	O
49537	impaired	VERB	O
49537	almost	ADV	O
49537	all	ADJ	O
49537	the	DET	O
49537	measured	VERB	O
49537	skills	NOUN	O
49537	more	ADJ	O
49537	(	PUNCT	O
49537	P	NOUN	O
49537	less	ADJ	O
49537	than	ADP	O
49537	0.05	NUM	O
49537	to	ADP	O
49537	0.001	NUM	O
49537	)	PUNCT	O
49537	than	ADP	O
49537	diazepam	NOUN	O
49537	,	PUNCT	O
49537	medizepam	NOUN	O
49537	or	CCONJ	O
49537	the	DET	O
49537	placebo	NOUN	O
49537	.	PUNCT	O
49538	The	DET	O
49538	lorazepam	NOUN	O
49538	impairment	NOUN	O
49538	of	ADP	O
49538	reactive	ADJ	O
49538	skills	NOUN	O
49538	and	CCONJ	O
49538	flicker	NOUN	O
49538	fusion	NOUN	O
49538	discrimination	NOUN	O
49538	remained	VERB	O
49538	statistically	ADV	O
49538	significant	ADJ	O
49538	(	PUNCT	O
49538	P	NOUN	O
49538	less	ADJ	O
49538	than	ADP	O
49538	0.05	NUM	O
49538	)	PUNCT	O
49538	for	ADP	O
49538	as	ADV	O
49538	long	ADJ	O
49538	as	ADP	O
49538	12	NUM	O
49538	h.	NOUN	O
49539	Medazepam	PROPN	O
49539	impaired	VERB	O
49539	only	ADV	O
49539	reactive	ADJ	O
49539	skills	NOUN	O
49539	and	CCONJ	O
49539	flicker	NOUN	O
49539	fusion	NOUN	O
49539	,	PUNCT	O
49539	the	DET	O
49539	latter	ADJ	O
49539	remaining	VERB	O
49539	impaired	ADJ	O
49539	(	PUNCT	O
49539	P	NOUN	O
49539	less	ADJ	O
49539	than	ADP	O
49539	0.05	NUM	O
49539	)	PUNCT	O
49539	for	ADP	O
49539	as	ADV	O
49539	long	ADV	O
49539	a	DET	O
49539	5	NUM	O
49539	h	NOUN	O
49539	after	ADP	O
49539	the	DET	O
49539	administration	NOUN	O
49539	.	PUNCT	O
49540	The	DET	O
49540	magnitude	NOUN	O
49540	 	SPACE	O
49540	and	CCONJ	O
49540	duration	NOUN	O
49540	of	ADP	O
49540	the	DET	O
49540	effects	NOUN	O
49540	of	ADP	O
49540	diazepam	NOUN	O
49540	were	VERB	O
49540	intermediate	ADJ	O
49540	between	ADP	O
49540	those	DET	O
49540	of	ADP	O
49540	lorazepam	NOUN	O
49540	and	CCONJ	O
49540	medazepam	NOUN	O
49540	.	PUNCT	O
49541	Diazepam	PROPN	O
49541	impaired	VERB	O
49541	perceptual	ADJ	O
49541	speed	NOUN	O
49541	and	CCONJ	O
49541	reactive	NOUN	O
49541	and	CCONJ	O
49541	co	NOUN	O
49541	-	PUNCT	O
49541	ordinative	ADJ	O
49541	skills	NOUN	O
49541	as	ADV	O
49541	well	ADV	O
49541	as	ADP	O
49541	flicker	ADJ	O
49541	fusion	NOUN	O
49541	discrimination	NOUN	O
49541	and	CCONJ	O
49541	visual	ADJ	O
49541	parameters	NOUN	O
49541	related	VERB	O
49541	to	ADP	O
49541	driving	VERB	O
49541	.	PUNCT	O
49542	Slight	ADJ	O
49542	impairments	NOUN	O
49542	in	ADP	O
49542	performance	NOUN	O
49542	were	VERB	O
49542	measurable	ADJ	O
49542	for	ADP	O
49542	up	ADP	O
49542	to	PART	O
49542	5	NUM	O
49542	h	NOUN	O
49542	after	ADP	O
49542	administration	NOUN	O
49542	but	CCONJ	O
49542	at	ADP	O
49542	7	NUM	O
49542	h	NOUN	O
49542	the	DET	O
49542	results	NOUN	O
49542	resembled	VERB	O
49542	those	DET	O
49542	measured	VERB	O
49542	after	ADP	O
49542	the	DET	O
49542	placebo	NOUN	O
49542	.	PUNCT	O
49543	The	DET	O
49543	lack	NOUN	O
49543	of	ADP	O
49543	alterations	NOUN	O
49543	in	ADP	O
49543	adaptation	NOUN	O
49543	to	ADP	O
49543	darkness	NOUN	O
49543	,	PUNCT	O
49543	sensitivity	NOUN	O
49543	to	ADP	O
49543	brightness	NOUN	O
49543	or	CCONJ	O
49543	visual	ADJ	O
49543	discrimination	NOUN	O
49543	ability	NOUN	O
49543	in	ADP	O
49543	bright	ADJ	O
49543	counterlight	NOUN	O
49543	at	ADP	O
49543	a	DET	O
49543	time	NOUN	O
49543	when	ADV	O
49543	flicker	ADJ	O
49543	fusion	NOUN	O
49543	discrimination	NOUN	O
49543	was	VERB	O
49543	severely	ADV	O
49543	depressed	VERB	O
49543	suggests	VERB	O
49543	that	ADP	O
49543	an	DET	O
49543	impaired	ADJ	O
49543	ability	NOUN	O
49543	to	PART	O
49543	discriminate	VERB	O
49543	flickering	NOUN	O
49543	light	NOUN	O
49543	is	VERB	O
49543	of	ADP	O
49543	no	DET	O
49543	or	CCONJ	O
49543	little	ADJ	O
49543	clinical	ADJ	O
49543	significance	NOUN	O
49543	to	ADP	O
49543	driving	VERB	O
49543	ability	NOUN	O
49543	.	PUNCT	O
49544	It	PRON	O
49544	is	VERB	O
49544	concluded	VERB	O
49544	that	ADP	O
49544	patients	NOUN	O
49544	receiving	VERB	O
49544	a	DET	O
49544	2.5	NUM	O
49544	mg	NOUN	O
49544	dose	NOUN	O
49544	of	ADP	O
49544	lorazepam	NOUN	O
49544	should	VERB	O
49544	not	ADV	O
49544	drive	VERB	O
49544	or	CCONJ	O
49544	operate	VERB	O
49544	machinery	NOUN	O
49544	for	ADP	O
49544	24	NUM	O
49544	h	NOUN	O
49544	after	ADP	O
49544	the	DET	O
49544	administration	NOUN	O
49544	.	PUNCT	O
49545	After	ADP	O
49545	diazepam	NOUN	O
49545	(	PUNCT	O
49545	10	NUM	O
49545	mg	NOUN	O
49545	)	PUNCT	O
49545	or	CCONJ	O
49545	medazepam	NOUN	O
49545	(	PUNCT	O
49545	15	NUM	O
49545	mg	NOUN	O
49545	)	PUNCT	O
49545	patients	NOUN	O
49545	should	VERB	O
49545	refrain	VERB	O
49545	from	ADP	O
49545	driving	VERB	O
49545	or	CCONJ	O
49545	participating	VERB	O
49545	inskilled	ADJ	O
49545	performances	NOUN	O
49545	for	ADP	O
49545	only	ADV	O
49545	5	NUM	O
49545	to	PART	O
49545	7	NUM	O
49545	hours	NOUN	O
49545	.	PUNCT	O
49546	Bovine	ADJ	O
49546	brain	NOUN	O
49546	purine	NOUN	O
49546	-	PUNCT	O
49546	nucleoside	NOUN	O
49546	phosphorylase	NOUN	O
49546	(	PUNCT	O
49546	purine	NOUN	O
49546	-	PUNCT	O
49546	nucleoside	NOUN	O
49546	:	PUNCT	O
49546	orthophosphate	NOUN	O
49546	ribosyltransferase	NOUN	O
49546	,	PUNCT	O
49546	EC	PROPN	O
49546	2.4.2.1	NUM	O
49546	)	PUNCT	O
49546	was	VERB	O
49546	purified	VERB	O
49546	to	ADP	O
49546	homogeneity	NOUN	O
49546	at	ADP	O
49546	a	DET	O
49546	specific	ADJ	O
49546	activity	NOUN	O
49546	of	ADP	O
49546	78	NUM	O
49546	mumol	NOUN	O
49546	min-1	NOUN	O
49546	mg	NOUN	O
49546	of	ADP	O
49546	protein-1	NOUN	O
49546	.	PUNCT	O
49547	A	DET	O
49547	molecular	ADJ	O
49547	weight	NOUN	O
49547	of	ADP	O
49547	78	NUM	O
49547	000	NUM	O
49547	-	SYM	O
49547	80	NUM	O
49547	000	NUM	O
49547	was	VERB	O
49547	calculated	VERB	O
49547	for	ADP	O
49547	the	DET	O
49547	native	ADJ	O
49547	enzyme	NOUN	O
49547	by	ADP	O
49547	fel	ADJ	O
49547	filtration	NOUN	O
49547	on	ADP	O
49547	Sephadex	PROPN	O
49547	.	PUNCT	O
49548	Gel	PROPN	O
49548	electrophoresis	NOUN	O
49548	in	ADP	O
49548	the	DET	O
49548	presence	NOUN	O
49548	of	ADP	O
49548	sodium	NOUN	O
49548	dodecyl	NOUN	O
49548	sulfate	NOUN	O
49548	indicated	VERB	O
49548	subunits	NOUN	O
49548	of	ADP	O
49548	molecular	ADJ	O
49548	weight	NOUN	O
49548	of	ADP	O
49548	38	NUM	O
49548	000	NUM	O
49548	.	PUNCT	O
49549	Chemical	ADJ	O
49549	and	CCONJ	O
49549	kinetic	ADJ	O
49549	studies	NOUN	O
49549	strongly	ADV	O
49549	implicated	VERB	O
49549	histidine	NOUN	O
49549	and	CCONJ	O
49549	cysteine	NOUN	O
49549	as	ADP	O
49549	catalytic	ADJ	O
49549	groups	NOUN	O
49549	at	ADP	O
49549	the	DET	O
49549	active	ADJ	O
49549	site	NOUN	O
49549	of	ADP	O
49549	the	DET	O
49549	enzyme	NOUN	O
49549	.	PUNCT	O
49550	The	DET	O
49550	pKa	NOUN	O
49550	's	PART	O
49550	determined	VERB	O
49550	for	ADP	O
49550	ionizable	ADJ	O
49550	groups	NOUN	O
49550	at	ADP	O
49550	the	DET	O
49550	active	ADJ	O
49550	site	NOUN	O
49550	of	ADP	O
49550	the	DET	O
49550	free	ADJ	O
49550	enzyme	NOUN	O
49550	were	VERB	O
49550	5.8	NUM	O
49550	and	CCONJ	O
49550	8.2	NUM	O
49550	.	PUNCT	O
49551	Enzyme	PROPN	O
49551	completely	ADV	O
49551	inactivated	VERB	O
49551	by	ADP	O
49551	p	NOUN	O
49551	-	PUNCT	O
49551	chloromercuribenzoate	NOUN	O
49551	was	VERB	O
49551	partially	ADV	O
49551	reactivated	VERB	O
49551	enzyme	NOUN	O
49551	.	PUNCT	O
49552	A	DET	O
49552	strong	ADJ	O
49552	susceptibility	NOUN	O
49552	to	ADP	O
49552	photooxidation	NOUN	O
49552	in	ADP	O
49552	presence	NOUN	O
49552	of	ADP	O
49552	methylene	NOUN	O
49552	blue	ADJ	O
49552	was	VERB	O
49552	observed	VERB	O
49552	.	PUNCT	O
49553	Photoinactivation	NOUN	O
49553	was	VERB	O
49553	pH	VERB	O
49553	dependent	ADJ	O
49553	,	PUNCT	O
49553	implicating	VERB	O
49553	histidine	NOUN	O
49553	as	ADP	O
49553	the	DET	O
49553	susceptible	ADJ	O
49553	group	NOUN	O
49553	at	ADP	O
49553	the	DET	O
49553	active	ADJ	O
49553	site	NOUN	O
49553	.	PUNCT	O
49554	A	DET	O
49554	rapid	ADJ	O
49554	loss	NOUN	O
49554	of	ADP	O
49554	catalytic	ADJ	O
49554	activity	NOUN	O
49554	upon	ADP	O
49554	incubation	NOUN	O
49554	at	ADP	O
49554	55	NUM	O
49554	degrees	NOUN	O
49554	C	PROPN	O
49554	suggested	VERB	O
49554	heat	NOUN	O
49554	lability	NOUN	O
49554	.	PUNCT	O
49555	An	DET	O
49555	activation	NOUN	O
49555	energy	NOUN	O
49555	of	ADP	O
49555	9.6	NUM	O
49555	kcal	ADJ	O
49555	/	SYM	O
49555	mol	NOUN	O
49555	was	VERB	O
49555	calculated	VERB	O
49555	.	PUNCT	O
49556	The	DET	O
49556	nature	NOUN	O
49556	of	ADP	O
49556	the	DET	O
49556	catalytic	ADJ	O
49556	mechanism	NOUN	O
49556	of	ADP	O
49556	the	DET	O
49556	enzyme	NOUN	O
49556	was	VERB	O
49556	investigated	VERB	O
49556	,	PUNCT	O
49556	and	CCONJ	O
49556	initial	ADJ	O
49556	velocity	NOUN	O
49556	studies	NOUN	O
49556	showed	VERB	O
49556	linear	ADJ	O
49556	converging	VERB	O
49556	patterns	NOUN	O
49556	of	ADP	O
49556	double	ADJ	O
49556	-	PUNCT	O
49556	reciprocal	ADJ	O
49556	plots	NOUN	O
49556	of	ADP	O
49556	the	DET	O
49556	data	NOUN	O
49556	,	PUNCT	O
49556	consistent	ADJ	O
49556	with	ADP	O
49556	a	DET	O
49556	sequential	ADJ	O
49556	catalytic	ADJ	O
49556	mechanism	NOUN	O
49556	.	PUNCT	O
49557	The	DET	O
49557	product	NOUN	O
49557	inhibition	NOUN	O
49557	pattern	NOUN	O
49557	was	VERB	O
49557	at	ADP	O
49557	variance	NOUN	O
49557	with	ADP	O
49557	both	DET	O
49557	the	DET	O
49557	ordered	VERB	O
49557	Bi	PROPN	O
49557	-	PUNCT	O
49557	Bi	PROPN	O
49557	and	CCONJ	O
49557	random	ADJ	O
49557	mechanisms	NOUN	O
49557	.	PUNCT	O
49558	The	DET	O
49558	observed	ADJ	O
49558	competition	NOUN	O
49558	between	ADP	O
49558	purine	NOUN	O
49558	and	CCONJ	O
49558	nucleoside	NOUN	O
49558	,	PUNCT	O
49558	and	CCONJ	O
49558	between	ADP	O
49558	inorganic	ADJ	O
49558	orthophosphate	NOUN	O
49558	and	CCONJ	O
49558	ribose	VERB	O
49558	1-phosphate	NOUN	O
49558	for	ADP	O
49558	this	DET	O
49558	ordered	VERB	O
49558	mechanism	NOUN	O
49558	,	PUNCT	O
49558	suggest	VERB	O
49558	a	DET	O
49558	Theorell	PROPN	O
49558	-	PUNCT	O
49558	Chance	PROPN	O
49558	mechanism	NOUN	O
49558	.	PUNCT	O
49559	Michaelis	NOUN	O
49559	constants	NOUN	O
49559	determined	VERB	O
49559	for	ADP	O
49559	substrates	NOUN	O
49559	of	ADP	O
49559	the	DET	O
49559	enzyme	NOUN	O
49559	were	VERB	O
49559	4.35	NUM	O
49559	X	NOUN	O
49559	10(-5	NUM	O
49559	)	PUNCT	O
49560	M	NOUN	O
49560	for	ADP	O
49560	guanosine	NOUN	O
49560	,	PUNCT	O
49560	3.00	NUM	O
49560	X	NOUN	O
49560	10(-5	NUM	O
49560	)	PUNCT	O
49561	M	NOUN	O
49561	for	ADP	O
49561	guanine	NOUN	O
49561	,	PUNCT	O
49561	and	CCONJ	O
49561	2.15	NUM	O
49561	X	NOUN	O
49561	10(-2	NUM	O
49561	)	PUNCT	O
49561	M	NOUN	O
49561	for	ADP	O
49561	inorganic	ADJ	O
49561	orthophosphate	NOUN	O
49561	.	PUNCT	O
49562	The	DET	O
49562	method	NOUN	O
49562	of	ADP	O
49562	alkaline	NOUN	O
49562	elution	NOUN	O
49562	provides	VERB	O
49562	a	DET	O
49562	sensitive	ADJ	O
49562	measure	NOUN	O
49562	of	ADP	O
49562	DNA	NOUN	O
49562	single	ADJ	O
49562	-	PUNCT	O
49562	strand	NOUN	O
49562	length	NOUN	O
49562	distribution	NOUN	O
49562	in	ADP	O
49562	mamalian	ADJ	O
49562	cells	NOUN	O
49562	and	CCONJ	O
49562	is	VERB	O
49562	applicable	ADJ	O
49562	to	ADP	O
49562	a	DET	O
49562	variety	NOUN	O
49562	of	ADP	O
49562	problems	NOUN	O
49562	concerning	VERB	O
49562	DNA	NOUN	O
49562	damage	NOUN	O
49562	,	PUNCT	O
49562	repair	NOUN	O
49562	,	PUNCT	O
49562	and	CCONJ	O
49562	replication	NOUN	O
49562	.	PUNCT	O
49563	The	DET	O
49563	physical	ADJ	O
49563	basis	NOUN	O
49563	of	ADP	O
49563	the	DET	O
49563	elution	NOUN	O
49563	process	NOUN	O
49563	was	VERB	O
49563	studied	VERB	O
49563	.	PUNCT	O
49564	The	DET	O
49564	kinetics	NOUN	O
49564	of	ADP	O
49564	elution	NOUN	O
49564	above	ADP	O
49564	the	DET	O
49564	alkaline	NOUN	O
49564	transition	NOUN	O
49564	pH	PROPN	O
49564	were	VERB	O
49564	found	VERB	O
49564	to	PART	O
49564	occur	VERB	O
49564	in	ADP	O
49564	two	NUM	O
49564	phases	NOUN	O
49564	:	PUNCT	O
49564	an	DET	O
49564	initial	ADJ	O
49564	phase	NOUN	O
49564	in	ADP	O
49564	which	ADJ	O
49564	single	ADJ	O
49564	-	PUNCT	O
49564	strand	NOUN	O
49564	length	NOUN	O
49564	is	VERB	O
49564	rate	NOUN	O
49564	limiting	NOUN	O
49564	,	PUNCT	O
49564	followed	VERB	O
49564	by	ADP	O
49564	a	DET	O
49564	phase	NOUN	O
49564	in	ADP	O
49564	which	ADJ	O
49564	elution	NOUN	O
49564	is	VERB	O
49564	accelerated	VERB	O
49564	due	ADP	O
49564	to	ADP	O
49564	the	DET	O
49564	accumulation	NOUN	O
49564	of	ADP	O
49564	alkali	ADV	O
49564	-	PUNCT	O
49564	induced	VERB	O
49564	strand	NOUN	O
49564	breaks	NOUN	O
49564	.	PUNCT	O
49565	The	DET	O
49565	range	NOUN	O
49565	of	ADP	O
49565	DNA	PROPN	O
49565	single	ADJ	O
49565	-	PUNCT	O
49565	strand	NOUN	O
49565	lengths	NOUN	O
49565	that	ADJ	O
49565	can	VERB	O
49565	be	VERB	O
49565	discriminated	VERB	O
49565	by	ADP	O
49565	elution	NOUN	O
49565	above	ADP	O
49565	the	DET	O
49565	alkaline	NOUN	O
49565	transition	NOUN	O
49565	pH	PROPN	O
49565	was	VERB	O
49565	estimated	VERB	O
49565	by	ADP	O
49565	calibration	NOUN	O
49565	relative	ADJ	O
49565	to	ADP	O
49565	the	DET	O
49565	effects	NOUN	O
49565	of	ADP	O
49565	x	SYM	O
49565	ray	NOUN	O
49565	,	PUNCT	O
49565	and	CCONJ	O
49565	was	VERB	O
49565	found	VERB	O
49565	to	PART	O
49565	be	VERB	O
49565	5	NUM	O
49565	X	NOUN	O
49565	10(8)-10(10	NUM	O
49565	)	PUNCT	O
49565	daltons	NOUN	O
49565	.	PUNCT	O
49566	Shorter	PROPN	O
49566	DNA	PROPN	O
49566	strands	VERB	O
49566	elute	VERB	O
49566	within	ADP	O
49566	the	DET	O
49566	pH	PROPN	O
49566	transition	NOUN	O
49566	zone	NOUN	O
49566	,	PUNCT	O
49566	which	ADJ	O
49566	extended	VERB	O
49566	from	ADP	O
49566	pH	PROPN	O
49566	11.3	NUM	O
49566	to	ADP	O
49566	11.7	NUM	O
49566	when	ADV	O
49566	tetrapropylammonium	NOUN	O
49566	hydroxide	NOUN	O
49566	was	VERB	O
49566	used	VERB	O
49566	as	ADP	O
49566	base	NOUN	O
49566	.	PUNCT	O
49567	This	DET	O
49567	elution	NOUN	O
49567	was	VERB	O
49567	relatively	ADV	O
49567	rapid	ADJ	O
49567	,	PUNCT	O
49567	but	CCONJ	O
49567	was	VERB	O
49567	sharply	ADV	O
49567	limited	VERB	O
49567	by	ADP	O
49567	pH	PROPN	O
49567	,	PUNCT	O
49567	according	VERB	O
49567	to	ADP	O
49567	the	DET	O
49567	length	NOUN	O
49567	of	ADP	O
49567	the	DET	O
49567	strands	NOUN	O
49567	:	PUNCT	O
49567	the	DET	O
49567	length	NOUN	O
49567	of	ADP	O
49567	the	DET	O
49567	strands	NOUN	O
49567	eluted	VERB	O
49567	increased	VERB	O
49567	with	ADP	O
49567	increasing	VERB	O
49567	pH.	PROPN	O
49567	Alkaline	PROPN	O
49567	elution	NOUN	O
49567	was	VERB	O
49567	inhibited	VERB	O
49567	by	ADP	O
49567	treatment	NOUN	O
49567	of	ADP	O
49567	cells	NOUN	O
49567	with	ADP	O
49567	low	ADJ	O
49567	concentrations	NOUN	O
49567	of	ADP	O
49567	nitrogen	NOUN	O
49567	mustard	NOUN	O
49567	,	PUNCT	O
49567	a	DET	O
49567	bifunctional	ADJ	O
49567	alkylating	NOUN	O
49567	known	VERB	O
49567	to	ADP	O
49567	cross	VERB	O
49567	-	PUNCT	O
49567	link	NOUN	O
49567	DNA	NOUN	O
49567	.	PUNCT	O
49568	On	ADP	O
49568	investigation	NOUN	O
49568	of	ADP	O
49568	the	DET	O
49568	possibility	NOUN	O
49568	that	ADP	O
49568	DNA	NOUN	O
49568	subclasses	NOUN	O
49568	may	VERB	O
49568	differ	VERB	O
49568	in	ADP	O
49568	their	ADJ	O
49568	elution	NOUN	O
49568	behavior	NOUN	O
49568	,	PUNCT	O
49568	satellite	NOUN	O
49568	L	NOUN	O
49568	strands	NOUN	O
49568	were	VERB	O
49568	found	VERB	O
49568	to	PART	O
49568	elute	VERB	O
49568	more	ADV	O
49568	slowly	ADV	O
49568	from	ADP	O
49568	cells	NOUN	O
49568	exposed	VERB	O
49568	to	ADP	O
49568	a	DET	O
49568	low	ADJ	O
49568	dose	NOUN	O
49568	of	ADP	O
49568	x	SYM	O
49568	ray	NOUN	O
49568	than	ADP	O
49568	did	VERB	O
49568	the	DET	O
49568	bulk	ADJ	O
49568	DNA	NOUN	O
49568	.	PUNCT	O
49569	Active	ADJ	O
49569	enzyme	NOUN	O
49569	ultracentrifugation	NOUN	O
49569	studies	NOUN	O
49569	of	ADP	O
49569	the	DET	O
49569	pyridine	ADJ	O
49569	nucleotide	NOUN	O
49569	transhydrogenase	NOUN	O
49569	from	ADP	O
49569	Pseudomonas	PROPN	O
49569	aeruginosa	NOUN	O
49569	(	PUNCT	O
49569	EC	PROPN	O
49569	1.6.1.1	NUM	O
49569	.	PUNCT	O
49569	)	PUNCT	O
49569	show	VERB	O
49569	that	ADP	O
49569	the	DET	O
49569	enzymatic	ADJ	O
49569	reaction	NOUN	O
49569	is	VERB	O
49569	catalyzed	VERB	O
49569	by	ADP	O
49569	a	DET	O
49569	molecular	ADJ	O
49569	species	NOUN	O
49569	characterized	VERB	O
49569	by	ADP	O
49569	an	DET	O
49569	S20,W	ADJ	O
49569	value	NOUN	O
49569	of	ADP	O
49569	about	ADV	O
49569	34	NUM	O
49569	S	NOUN	O
49569	,	PUNCT	O
49569	whatever	ADJ	O
49569	the	DET	O
49569	reduced	VERB	O
49569	substrate	NOUN	O
49569	may	VERB	O
49569	be	VERB	O
49569	(	PUNCT	O
49569	tri-	NOUN	O
49569	or	CCONJ	O
49569	diphosphopyridine	VERB	O
49569	nucleotide	NOUN	O
49569	)	PUNCT	O
49569	.	PUNCT	O
49570	The	DET	O
49570	filamentous	ADJ	O
49570	aggregated	VERB	O
49570	form	NOUN	O
49570	of	ADP	O
49570	the	DET	O
49570	enzyme	NOUN	O
49570	(	PUNCT	O
49570	S20,W	PROPN	O
49570	=	SYM	O
49570	121	NUM	O
49570	S	NOUN	O
49570	and	CCONJ	O
49570	higher	ADJ	O
49570	)	PUNCT	O
49570	,	PUNCT	O
49570	identified	VERB	O
49570	by	ADP	O
49570	previous	ADJ	O
49570	investigations	NOUN	O
49570	(	PUNCT	O
49570	Cohen	PROPN	O
49570	,	PUNCT	O
49570	P.	PROPN	O
49570	T.	PROPN	O
49570	,	PUNCT	O
49570	and	CCONJ	O
49570	Kaplan	PROPN	O
49570	,	PUNCT	O
49570	N.	PROPN	O
49570	O.	PROPN	O
49570	(	PUNCT	O
49570	1970	NUM	O
49570	)	PUNCT	O
49570	,	PUNCT	O
49570	J.	PROPN	O
49570	Biol	PROPN	O
49570	.	PUNCT	O
49571	Chem	PRON	O
49571	.	PUNCT	O
49572	245	NUM	O
49572	,	PUNCT	O
49572	2825	NUM	O
49572	-	SYM	O
49572	2836	NUM	O
49572	;	PUNCT	O
49572	Louie	PROPN	O
49572	,	PUNCT	O
49572	D.	PROPN	O
49572	D.	PROPN	O
49572	,	PUNCT	O
49572	Kaplan	PROPN	O
49572	,	PUNCT	O
49572	N.	PROPN	O
49572	O.	PROPN	O
49572	,	PUNCT	O
49572	and	CCONJ	O
49572	Mc	PROPN	O
49572	Lean	PROPN	O
49572	,	PUNCT	O
49572	J.	PROPN	O
49572	D.	PROPN	O
49572	(	PUNCT	O
49572	1972	NUM	O
49572	)	PUNCT	O
49572	,	PUNCT	O
49572	J.	PROPN	O
49572	Mol	PROPN	O
49572	.	PUNCT	O
49573	Biol	PROPN	O
49573	.	PUNCT	O
49574	70	NUM	O
49574	,	PUNCT	O
49574	651	NUM	O
49574	-	SYM	O
49574	664	NUM	O
49574	)	PUNCT	O
49574	,	PUNCT	O
49574	appears	VERB	O
49574	,	PUNCT	O
49574	therefore	ADV	O
49574	,	PUNCT	O
49574	to	PART	O
49574	be	VERB	O
49574	an	DET	O
49574	inactive	ADJ	O
49574	species	NOUN	O
49574	.	PUNCT	O
49575	The	DET	O
49575	physiological	ADJ	O
49575	implications	NOUN	O
49575	of	ADP	O
49575	the	DET	O
49575	enzyme	NOUN	O
49575	are	VERB	O
49575	discussed	VERB	O
49575	.	PUNCT	O
49576	Several	ADJ	O
49576	lines	NOUN	O
49576	of	ADP	O
49576	evidence	NOUN	O
49576	lead	VERB	O
49576	to	ADP	O
49576	the	DET	O
49576	conclusion	NOUN	O
49576	that	ADP	O
49576	the	DET	O
49576	transhydrogenase	NOUN	O
49576	might	VERB	O
49576	act	VERB	O
49576	as	ADP	O
49576	an	DET	O
49576	essential	ADJ	O
49576	link	NOUN	O
49576	between	ADP	O
49576	carbohydrate	NOUN	O
49576	catabolism	NOUN	O
49576	and	CCONJ	O
49576	the	DET	O
49576	respiratory	ADJ	O
49576	chain	NOUN	O
49576	.	PUNCT	O
49577	The	DET	O
49577	size	NOUN	O
49577	and	CCONJ	O
49577	structure	NOUN	O
49577	of	ADP	O
49577	the	DET	O
49577	covalently	ADV	O
49577	closed	ADJ	O
49577	circular	ADJ	O
49577	chloroplast	NOUN	O
49577	DNAs	NOUN	O
49577	(	PUNCT	O
49577	ctDNA	NOUN	O
49577	)	PUNCT	O
49577	from	ADP	O
49577	pea	NOUN	O
49577	,	PUNCT	O
49577	lettuce	NOUN	O
49577	,	PUNCT	O
49577	and	CCONJ	O
49577	spinach	VERB	O
49577	plants	NOUN	O
49577	,	PUNCT	O
49577	have	VERB	O
49577	been	VERB	O
49577	studied	VERB	O
49577	by	ADP	O
49577	analytical	ADJ	O
49577	ultracentrifugation	NOUN	O
49577	.	PUNCT	O
49578	The	DET	O
49578	values	NOUN	O
49578	of	ADP	O
49578	so20,w	NOUN	O
49578	,	PUNCT	O
49578	Na+	ADP	O
49578	of	ADP	O
49578	the	DET	O
49578	native	ADJ	O
49578	and	CCONJ	O
49578	denatured	VERB	O
49578	forms	NOUN	O
49578	of	ADP	O
49578	the	DET	O
49578	open	ADJ	O
49578	and	CCONJ	O
49578	closed	ADJ	O
49578	circular	ADJ	O
49578	DNAs	NOUN	O
49578	from	ADP	O
49578	these	DET	O
49578	plants	NOUN	O
49578	have	VERB	O
49578	been	VERB	O
49578	determined	VERB	O
49578	.	PUNCT	O
49579	The	DET	O
49579	absolute	ADJ	O
49579	molecular	ADJ	O
49579	weight	NOUN	O
49579	of	ADP	O
49579	purified	ADJ	O
49579	closed	ADJ	O
49579	circular	ADJ	O
49579	pea	NOUN	O
49579	ctDNA	NOUN	O
49579	monomers	NOUN	O
49579	has	VERB	O
49579	been	VERB	O
49579	determined	VERB	O
49579	by	ADP	O
49579	buoyant	ADJ	O
49579	equilibrium	NOUN	O
49579	sedimentation	NOUN	O
49579	to	PART	O
49579	be	VERB	O
49579	89.1	NUM	O
49579	(	PUNCT	O
49579	S.D.	NOUN	O
49579	+	X	O
49579	/-	PUNCT	O
49580	0.7)-10(6	PUNCT	O
49580	)	PUNCT	O
49580	.	PUNCT	O
49581	The	DET	O
49581	value	NOUN	O
49581	of	ADP	O
49581	the	DET	O
49581	so20,w	NOUN	O
49581	,	PUNCT	O
49581	Na+	ADP	O
49581	of	ADP	O
49581	open	ADJ	O
49581	circular	ADJ	O
49581	pea	NOUN	O
49581	ctDNA	NOUN	O
49581	and	CCONJ	O
49581	its	ADJ	O
49581	molecular	ADJ	O
49581	weight	NOUN	O
49581	,	PUNCT	O
49581	in	ADP	O
49581	conjunction	NOUN	O
49581	with	ADP	O
49581	corresponding	VERB	O
49581	values	NOUN	O
49581	for	ADP	O
49581	other	ADJ	O
49581	sizes	NOUN	O
49581	of	ADP	O
49581	circular	ADJ	O
49581	DNA	NOUN	O
49581	,	PUNCT	O
49581	has	VERB	O
49581	been	VERB	O
49581	used	VERB	O
49581	to	PART	O
49581	derive	VERB	O
49581	an	DET	O
49581	empirical	ADJ	O
49581	relationship	NOUN	O
49581	between	ADP	O
49581	so20,w	NOUN	O
49581	,	PUNCT	O
49581	Na+	ADJ	O
49581	and	CCONJ	O
49581	molecular	ADJ	O
49581	weight	NOUN	O
49581	for	ADP	O
49581	open	ADJ	O
49581	circular	ADJ	O
49581	DNAs	NOUN	O
49581	.	PUNCT	O
49582	Using	VERB	O
49582	this	DET	O
49582	relationship	NOUN	O
49582	,	PUNCT	O
49582	the	DET	O
49582	molecular	ADJ	O
49582	weights	NOUN	O
49582	of	ADP	O
49582	lettuce	NOUN	O
49582	and	CCONJ	O
49582	spinach	NOUN	O
49582	ctDNAs	PROPN	O
49582	have	VERB	O
49582	been	VERB	O
49582	determined	VERB	O
49582	to	PART	O
49582	be	VERB	O
49582	98.2	NUM	O
49582	(	PUNCT	O
49582	S.D.	PROPN	O
49582	+	X	O
49582	/-	PUNCT	O
49583	1.5)-10(6	PUNCT	O
49583	)	PUNCT	O
49583	and	CCONJ	O
49583	97.2	NUM	O
49583	(	PUNCT	O
49583	S.D.	PROPN	O
49583	+	X	O
49583	/-	PUNCT	O
49584	1.5)-10(6	PUNCT	O
49584	)	PUNCT	O
49584	,	PUNCT	O
49584	respectively	ADV	O
49584	.	PUNCT	O
49585	At	ADP	O
49585	pH	PROPN	O
49585	values	NOUN	O
49585	12.7	NUM	O
49585	and	CCONJ	O
49585	13	NUM	O
49585	,	PUNCT	O
49585	closed	ADJ	O
49585	circular	ADJ	O
49585	lettuce	NOUN	O
49585	and	CCONJ	O
49585	pea	NOUN	O
49585	ctDNAs	PROPN	O
49585	have	VERB	O
49585	been	VERB	O
49585	found	VERB	O
49585	to	PART	O
49585	exist	VERB	O
49585	as	ADP	O
49585	mixtures	NOUN	O
49585	of	ADP	O
49585	reversibly	ADV	O
49585	and	CCONJ	O
49585	irreversibly	ADV	O
49585	denatured	VERB	O
49585	closed	ADJ	O
49585	circular	ADJ	O
49585	DNAs	NOUN	O
49585	.	PUNCT	O
49586	Passive	ADJ	O
49586	redistributions	NOUN	O
49586	of	ADP	O
49586	Mg2	NOUN	O
49586	+	NOUN	O
49586	and	CCONJ	O
49586	K+	VERB	O
49586	ions	NOUN	O
49586	across	ADP	O
49586	the	DET	O
49586	thylakoid	ADJ	O
49586	membranes	NOUN	O
49586	,	PUNCT	O
49586	occurring	VERB	O
49586	in	ADP	O
49586	association	NOUN	O
49586	with	ADP	O
49586	the	DET	O
49586	light	ADV	O
49586	-	PUNCT	O
49586	driven	VERB	O
49586	electrogenic	ADJ	O
49586	influx	NOUN	O
49586	of	ADP	O
49586	hydrogen	NOUN	O
49586	ions	NOUN	O
49586	have	VERB	O
49586	been	VERB	O
49586	examined	VERB	O
49586	in	ADP	O
49586	suspensions	NOUN	O
49586	of	ADP	O
49586	broken	VERB	O
49586	spinach	NOUN	O
49586	chloroplasts	NOUN	O
49586	under	ADP	O
49586	a	DET	O
49586	variety	NOUN	O
49586	of	ADP	O
49586	conditions	NOUN	O
49586	.	PUNCT	O
49587	(	PUNCT	O
49587	i	PUNCT	O
49587	)	PUNCT	O
49588	In	ADP	O
49588	accord	NOUN	O
49588	with	ADP	O
49588	results	NOUN	O
49588	of	ADP	O
49588	Hind	PROPN	O
49588	el	PROPN	O
49588	al	PROPN	O
49588	.	PUNCT	O
49589	(	PUNCT	O
49589	Proc	INTJ	O
49589	.	PUNCT	O
49590	Natl	PROPN	O
49590	.	PUNCT	O
49591	Acad	ADJ	O
49591	.	PUNCT	O
49592	Sci	PROPN	O
49592	.	PUNCT	O
49592	U.S.	PROPN	O
49592	(	PUNCT	O
49592	1974	NUM	O
49592	)	PUNCT	O
49592	71	NUM	O
49592	,	PUNCT	O
49592	1484	NUM	O
49592	)	PUNCT	O
49593	,	PUNCT	O
49593	it	PRON	O
49593	was	VERB	O
49593	found	VERB	O
49593	that	ADP	O
49593	at	ADP	O
49593	a	DET	O
49593	low	ADJ	O
49593	K	PROPN	O
49593	/	SYM	O
49593	Mg	PROPN	O
49593	concentration	NOUN	O
49593	ratio	NOUN	O
49593	in	ADP	O
49593	the	DET	O
49593	medium	NOUN	O
49593	,	PUNCT	O
49593	the	DET	O
49593	K	PROPN	O
49593	-	PUNCT	O
49593	efflux	PROPN	O
49593	is	VERB	O
49593	negligibly	ADV	O
49593	small	ADJ	O
49593	,	PUNCT	O
49593	whereas	ADP	O
49593	a	DET	O
49593	substantial	ADJ	O
49593	Mg	PROPN	O
49593	-	PUNCT	O
49593	efflux	PROPN	O
49593	is	VERB	O
49593	observed	VERB	O
49593	.	PUNCT	O
49594	The	DET	O
49594	converse	NOUN	O
49594	is	VERB	O
49594	true	ADJ	O
49594	when	ADV	O
49594	the	DET	O
49594	K	PROPN	O
49594	/	SYM	O
49594	Mg	PROPN	O
49594	concentration	NOUN	O
49594	ratio	NOUN	O
49594	in	ADP	O
49594	the	DET	O
49594	medium	NOUN	O
49594	is	VERB	O
49594	high	ADJ	O
49594	.	PUNCT	O
49595	(	PUNCT	O
49595	ii	PUNCT	O
49595	)	PUNCT	O
49596	In	ADP	O
49596	the	DET	O
49596	presence	NOUN	O
49596	of	ADP	O
49596	A23187	PROPN	O
49596	,	PUNCT	O
49596	which	ADJ	O
49596	was	VERB	O
49596	found	VERB	O
49596	to	PART	O
49596	cause	VERB	O
49596	approximately	ADV	O
49596	a	DET	O
49596	60	NUM	O
49596	%	NOUN	O
49596	inhibition	NOUN	O
49596	of	ADP	O
49596	the	DET	O
49596	light	ADV	O
49596	-	PUNCT	O
49596	induced	VERB	O
49596	pH	NOUN	O
49596	-	PUNCT	O
49596	gradient	NOUN	O
49596	,	PUNCT	O
49596	a	DET	O
49596	significant	ADJ	O
49596	influx	NOUN	O
49596	of	ADP	O
49596	Mg2	NOUN	O
49596	+	CCONJ	O
49596	was	VERB	O
49596	observed	VERB	O
49596	in	ADP	O
49596	the	DET	O
49596	light	NOUN	O
49596	at	ADP	O
49596	a	DET	O
49596	high	ADJ	O
49596	K	PROPN	O
49596	/	SYM	O
49596	Mg	PROPN	O
49596	concentration	NOUN	O
49596	ratio	NOUN	O
49596	.	PUNCT	O
49597	Conversely	ADV	O
49597	the	DET	O
49597	Mg	PROPN	O
49597	-	PUNCT	O
49597	influx	PROPN	O
49597	was	VERB	O
49597	small	ADJ	O
49597	in	ADP	O
49597	the	DET	O
49597	presence	NOUN	O
49597	of	ADP	O
49597	A23187	PROPN	O
49597	when	ADV	O
49597	the	DET	O
49597	K	PROPN	O
49597	/	SYM	O
49597	Mg	PROPN	O
49597	concentration	NOUN	O
49597	ratio	NOUN	O
49597	in	ADP	O
49597	the	DET	O
49597	medium	NOUN	O
49597	was	VERB	O
49597	low	ADJ	O
49597	.	PUNCT	O
49598	Under	ADP	O
49598	these	DET	O
49598	conditions	NOUN	O
49598	,	PUNCT	O
49598	the	DET	O
49598	Mg	PROPN	O
49598	-	PUNCT	O
49598	influx	PROPN	O
49598	was	VERB	O
49598	considerably	ADV	O
49598	increased	VERB	O
49598	upon	ADP	O
49598	the	DET	O
49598	addition	NOUN	O
49598	of	ADP	O
49598	valinomycin	NOUN	O
49598	.	PUNCT	O
49599	A23187	PROPN	O
49599	was	VERB	O
49599	found	VERB	O
49599	not	ADV	O
49599	to	PART	O
49599	affect	VERB	O
49599	the	DET	O
49599	K	NOUN	O
49599	-	PUNCT	O
49599	efflux	PROPN	O
49599	in	ADP	O
49599	the	DET	O
49599	light	NOUN	O
49599	.	PUNCT	O
49600	(	PUNCT	O
49600	iii	NOUN	O
49600	)	PUNCT	O
49601	The	DET	O
49601	light	ADV	O
49601	-	PUNCT	O
49601	induced	VERB	O
49601	K	NOUN	O
49601	-	PUNCT	O
49601	influx	NOUN	O
49601	observed	VERB	O
49601	in	ADP	O
49601	the	DET	O
49601	presence	NOUN	O
49601	of	ADP	O
49601	nigericin	NOUN	O
49601	also	ADV	O
49601	was	VERB	O
49601	found	VERB	O
49601	to	PART	O
49601	be	VERB	O
49601	dependent	ADJ	O
49601	on	ADP	O
49601	the	DET	O
49601	concentration	NOUN	O
49601	ratio	NOUN	O
49601	of	ADP	O
49601	the	DET	O
49601	monovalent	NOUN	O
49601	and	CCONJ	O
49601	divalent	ADJ	O
49601	cation	NOUN	O
49601	.	PUNCT	O
49602	Its	ADJ	O
49602	magnitude	NOUN	O
49602	increased	VERB	O
49602	upon	ADP	O
49602	an	DET	O
49602	increase	NOUN	O
49602	in	ADP	O
49602	the	DET	O
49602	K	PROPN	O
49602	/	SYM	O
49602	Mg	PROPN	O
49602	ratio	NOUN	O
49602	.	PUNCT	O
49603	The	DET	O
49603	results	NOUN	O
49603	are	VERB	O
49603	interpreted	VERB	O
49603	in	ADP	O
49603	terms	NOUN	O
49603	of	ADP	O
49603	a	DET	O
49603	simplified	ADJ	O
49603	model	NOUN	O
49603	in	ADP	O
49603	which	ADJ	O
49603	the	DET	O
49603	total	ADJ	O
49603	passive	ADJ	O
49603	efflux	NOUN	O
49603	of	ADP	O
49603	cations	NOUN	O
49603	,	PUNCT	O
49603	driven	VERB	O
49603	by	ADP	O
49603	the	DET	O
49603	potential	ADJ	O
49603	set	VERB	O
49603	by	ADP	O
49603	the	DET	O
49603	electrogenic	ADJ	O
49603	proton	NOUN	O
49603	pump	NOUN	O
49603	,	PUNCT	O
49603	is	VERB	O
49603	considered	VERB	O
49603	to	PART	O
49603	be	VERB	O
49603	a	DET	O
49603	constant	ADJ	O
49603	fraction	NOUN	O
49603	of	ADP	O
49603	the	DET	O
49603	proton	NOUN	O
49603	influx	NOUN	O
49603	.	PUNCT	O
49604	According	VERB	O
49604	to	ADP	O
49604	this	DET	O
49604	,	PUNCT	O
49604	an	DET	O
49604	increase	NOUN	O
49604	in	ADP	O
49604	the	DET	O
49604	flux	NOUN	O
49604	of	ADP	O
49604	an	DET	O
49604	ion	NOUN	O
49604	species	NOUN	O
49604	,	PUNCT	O
49604	induced	VERB	O
49604	either	CCONJ	O
49604	by	ADP	O
49604	raising	VERB	O
49604	its	ADJ	O
49604	concentration	NOUN	O
49604	,	PUNCT	O
49604	or	CCONJ	O
49604	by	ADP	O
49604	increasing	VERB	O
49604	its	ADJ	O
49604	permeability	NOUN	O
49604	through	ADP	O
49604	the	DET	O
49604	membrane	NOUN	O
49604	,	PUNCT	O
49604	will	VERB	O
49604	cause	VERB	O
49604	a	DET	O
49604	decrease	NOUN	O
49604	in	ADP	O
49604	the	DET	O
49604	flux	NOUN	O
49604	of	ADP	O
49604	the	DET	O
49604	other	ADJ	O
49604	cations	NOUN	O
49604	.	PUNCT	O
49605	The	DET	O
49605	relevance	NOUN	O
49605	of	ADP	O
49605	the	DET	O
49605	results	NOUN	O
49605	is	VERB	O
49605	discussed	VERB	O
49605	with	ADP	O
49605	respect	NOUN	O
49605	to	ADP	O
49605	conclusions	NOUN	O
49605	about	ADP	O
49605	the	DET	O
49605	involvement	NOUN	O
49605	and	CCONJ	O
49605	relative	ADJ	O
49605	magnitudes	NOUN	O
49605	of	ADP	O
49605	the	DET	O
49605	passive	ADJ	O
49605	K	PROPN	O
49605	and	CCONJ	O
49605	Mg	PROPN	O
49605	effluxes	NOUN	O
49605	across	ADP	O
49605	the	DET	O
49605	thylakoid	ADJ	O
49605	membrane	NOUN	O
49605	during	ADP	O
49605	energization	NOUN	O
49605	of	ADP	O
49605	intact	ADJ	O
49605	chloroplasts	NOUN	O
49605	and	CCONJ	O
49605	chloroplasts	NOUN	O
49605	in	ADP	O
49605	situ	NOUN	O
49605	.	PUNCT	O
49606	2	NUM	O
49606	distinct	ADJ	O
49606	17-ketosteroid	NUM	O
49606	reductases	NOUN	O
49606	,	PUNCT	O
49606	1	NUM	O
49606	in	ADP	O
49606	interstitial	ADJ	O
49606	tissue	NOUN	O
49606	and	CCONJ	O
49606	the	DET	O
49606	other	ADJ	O
49606	in	ADP	O
49606	the	DET	O
49606	seminiferous	ADJ	O
49606	tubules	NOUN	O
49606	,	PUNCT	O
49606	were	VERB	O
49606	identified	VERB	O
49606	in	ADP	O
49606	rat	NOUN	O
49606	testes	NOUN	O
49606	and	CCONJ	O
49606	characterized	VERB	O
49606	.	PUNCT	O
49607	The	DET	O
49607	pH	VERB	O
49607	optima	NOUN	O
49607	was	VERB	O
49607	5.6	NUM	O
49607	for	ADP	O
49607	the	DET	O
49607	interstitial	ADJ	O
49607	tissue	NOUN	O
49607	enzyme	NOUN	O
49607	and	CCONJ	O
49607	6.5	NUM	O
49607	for	ADP	O
49607	the	DET	O
49607	seminiferous	ADJ	O
49607	tubule	NOUN	O
49607	enzyme	NOUN	O
49607	.	PUNCT	O
49608	At	ADP	O
49608	optimum	ADJ	O
49608	pH	PROPN	O
49608	,	PUNCT	O
49608	K	PROPN	O
49608	m	VERB	O
49608	values	NOUN	O
49608	for	ADP	O
49608	the	DET	O
49608	interstitial	ADJ	O
49608	tissue	NOUN	O
49608	enzyme	NOUN	O
49608	was	VERB	O
49608	17	NUM	O
49608	mcM	NUM	O
49608	while	ADP	O
49608	that	DET	O
49608	for	ADP	O
49608	the	DET	O
49608	seminiferous	ADJ	O
49608	tubule	NOUN	O
49608	enzyme	NOUN	O
49608	was	VERB	O
49608	.25	PRON	O
49608	mcM.	ADJ	O
49608	 	SPACE	O
49608	Testosterone	PROPN	O
49608	,	PUNCT	O
49608	several	ADJ	O
49608	5alpha	NUM	O
49608	-	PUNCT	O
49608	reduced	VERB	O
49608	testosterone	NOUN	O
49608	metabolites	NOUN	O
49608	,	PUNCT	O
49608	and	CCONJ	O
49608	estrogens	VERB	O
49608	inhibited	VERB	O
49608	interstitial	ADJ	O
49608	tissue	NOUN	O
49608	enzyme	NOUN	O
49608	activity	NOUN	O
49608	,	PUNCT	O
49608	with	ADP	O
49608	5alpha	NUM	O
49608	-	PUNCT	O
49608	androstane-3alpha	NOUN	O
49608	,	PUNCT	O
49608	17beta	NUM	O
49608	-	PUNCT	O
49608	diol	NOUN	O
49608	being	VERB	O
49608	the	DET	O
49608	most	ADV	O
49608	potent	ADJ	O
49608	inhibitor	NOUN	O
49608	,	PUNCT	O
49608	followed	VERB	O
49608	by	ADP	O
49608	17beta	NUM	O
49608	-	PUNCT	O
49608	estradiol	NOUN	O
49608	and	CCONJ	O
49608	 	SPACE	O
49608	dihydrotestosterone	NOUN	O
49608	,	PUNCT	O
49608	testosterone	NOUN	O
49608	,	PUNCT	O
49608	estrone	NOUN	O
49608	,	PUNCT	O
49608	and	CCONJ	O
49608	estriol	ADJ	O
49608	.	PUNCT	O
49609	5alpha	NUM	O
49609	-	PUNCT	O
49609	androstane-3alpha	NOUN	O
49609	,	PUNCT	O
49609	17beta	NUM	O
49609	-	PUNCT	O
49609	diol	NOUN	O
49609	and	CCONJ	O
49609	17beta	NUM	O
49609	-	PUNCT	O
49609	estradiol	NOUN	O
49609	were	VERB	O
49609	found	VERB	O
49609	to	PART	O
49609	act	VERB	O
49609	by	ADP	O
49609	competitive	ADJ	O
49609	inhibition	NOUN	O
49609	.	PUNCT	O
49610	Of	ADP	O
49610	the	DET	O
49610	above	ADJ	O
49610	steroids	NOUN	O
49610	,	PUNCT	O
49610	only	ADV	O
49610	dihydrotestosterone	NOUN	O
49610	was	VERB	O
49610	able	ADJ	O
49610	to	PART	O
49610	inhibit	VERB	O
49610	enzyme	NOUN	O
49610	activity	NOUN	O
49610	in	ADP	O
49610	the	DET	O
49610	seminiferous	ADJ	O
49610	tubules	NOUN	O
49610	,	PUNCT	O
49610	and	CCONJ	O
49610	then	ADV	O
49610	at	ADP	O
49610	only	ADV	O
49610	very	ADV	O
49610	high	ADJ	O
49610	concentrations	NOUN	O
49610	of	ADP	O
49610	the	DET	O
49610	androgen	NOUN	O
49610	.	PUNCT	O
49611	17-ketosteroid	NUM	O
49611	reductase	NOUN	O
49611	activity	NOUN	O
49611	in	ADP	O
49611	seminiferous	ADJ	O
49611	tubules	NOUN	O
49611	was	VERB	O
49611	stimulated	VERB	O
49611	by	ADP	O
49611	testosterone	NOUN	O
49611	and	CCONJ	O
49611	low	ADJ	O
49611	concentrations	NOUN	O
49611	of	ADP	O
49611	5alpha	NUM	O
49611	-	PUNCT	O
49611	androstane-3alpha	NOUN	O
49611	,	PUNCT	O
49611	17beta	NUM	O
49611	-	PUNCT	O
49611	diol	NOUN	O
49611	.	PUNCT	O
49612	The	DET	O
49612	results	NOUN	O
49612	suggest	VERB	O
49612	an	DET	O
49612	extrapituitary	ADJ	O
49612	mechanism	NOUN	O
49612	for	ADP	O
49612	the	DET	O
49612	local	ADJ	O
49612	regulation	NOUN	O
49612	of	ADP	O
49612	testosterone	NOUN	O
49612	synthesis	NOUN	O
49612	in	ADP	O
49612	interstitial	ADJ	O
49612	tissue	NOUN	O
49612	and	CCONJ	O
49612	the	DET	O
49612	seminiferous	ADJ	O
49612	tubules	NOUN	O
49612	.	PUNCT	O
49613	The	DET	O
49613	photochemical	ADJ	O
49613	reaction	NOUN	O
49613	cycle	NOUN	O
49613	of	ADP	O
49613	bacteriorhodopsin	NOUN	O
49613	was	VERB	O
49613	investigated	VERB	O
49613	by	ADP	O
49613	means	NOUN	O
49613	of	ADP	O
49613	flash	NOUN	O
49613	photometric	ADJ	O
49613	methods	NOUN	O
49613	.	PUNCT	O
49614	Three	NUM	O
49614	different	ADJ	O
49614	intermediates	NOUN	O
49614	with	ADP	O
49614	absorption	NOUN	O
49614	maxima	NOUN	O
49614	at	ADP	O
49614	about	ADV	O
49614	630	NUM	O
49614	nm	NUM	O
49614	,	PUNCT	O
49614	411	NUM	O
49614	nm	NUM	O
49614	,	PUNCT	O
49614	and	CCONJ	O
49614	646	NUM	O
49614	nm	NUM	O
49614	could	VERB	O
49614	be	VERB	O
49614	detected	VERB	O
49614	.	PUNCT	O
49615	Kinetic	PROPN	O
49615	data	NOUN	O
49615	of	ADP	O
49615	the	DET	O
49615	occurrence	NOUN	O
49615	of	ADP	O
49615	these	DET	O
49615	intermediates	NOUN	O
49615	were	VERB	O
49615	obtained	VERB	O
49615	from	ADP	O
49615	isolated	ADJ	O
49615	purple	ADJ	O
49615	membrane	NOUN	O
49615	in	ADP	O
49615	different	ADJ	O
49615	mediums	NOUN	O
49615	and	CCONJ	O
49615	from	ADP	O
49615	intact	ADJ	O
49615	halobacteria	NOUN	O
49615	.	PUNCT	O
49616	An	DET	O
49616	activation	NOUN	O
49616	energy	NOUN	O
49616	of	ADP	O
49616	14.1	NUM	O
49616	+	SYM	O
49616	/-	PUNCT	O
49617	0.4	NUM	O
49617	kcal	ADJ	O
49617	-	PUNCT	O
49617	mol-1	PROPN	O
49617	and	CCONJ	O
49617	of	ADP	O
49617	about	ADV	O
49617	19	NUM	O
49617	kcal	ADJ	O
49617	-	PUNCT	O
49617	mol-1	NOUN	O
49617	for	ADP	O
49617	formation	NOUN	O
49617	of	ADP	O
49617	bacteriorhodopsin	NOUN	O
49617	411	NUM	O
49617	and	CCONJ	O
49617	of	ADP	O
49617	bacteriorhodopsin	NOUN	O
49617	565	NUM	O
49617	,	PUNCT	O
49617	resp	NOUN	O
49617	.	PUNCT	O
49617	,	PUNCT	O
49617	was	VERB	O
49617	calculated	VERB	O
49617	.	PUNCT	O
49618	pH	VERB	O
49618	-	PUNCT	O
49618	changes	NOUN	O
49618	in	ADP	O
49618	the	DET	O
49618	medium	NOUN	O
49618	caused	VERB	O
49618	by	ADP	O
49618	the	DET	O
49618	reaction	NOUN	O
49618	cycle	NOUN	O
49618	of	ADP	O
49618	bacteriorhodopsin	NOUN	O
49618	were	VERB	O
49618	detected	VERB	O
49618	by	ADP	O
49618	use	NOUN	O
49618	of	ADP	O
49618	the	DET	O
49618	pH	VERB	O
49618	-	PUNCT	O
49618	indicator	NOUN	O
49618	bromocresol	NOUN	O
49618	green	ADJ	O
49618	.	PUNCT	O
49619	Uptake	NOUN	O
49619	of	ADP	O
49619	5-hydroxytryptamine	NOUN	O
49619	(	PUNCT	O
49619	5-HT	NUM	O
49619	)	PUNCT	O
49619	by	ADP	O
49619	adult	NOUN	O
49619	and	CCONJ	O
49619	fetal	ADJ	O
49619	rabbit	NOUN	O
49619	's	PART	O
49619	ileum	NOUN	O
49619	was	VERB	O
49619	studied	VERB	O
49619	.	PUNCT	O
49620	The	DET	O
49620	adult	NOUN	O
49620	myenteric	ADJ	O
49620	plexus	NOUN	O
49620	accumulated	VERB	O
49620	tritium	NOUN	O
49620	when	ADV	O
49620	incubated	VERB	O
49620	with	ADP	O
49620	tritiated	ADJ	O
49620	5-HT	NUM	O
49620	.	PUNCT	O
49621	However	ADV	O
49621	,	PUNCT	O
49621	in	ADP	O
49621	addition	NOUN	O
49621	to	ADP	O
49621	labeled	VERB	O
49621	5-HT	NUM	O
49621	,	PUNCT	O
49621	tritiated	ADJ	O
49621	5-hydroxyindole	ADJ	O
49621	acetic	ADJ	O
49621	acid	NOUN	O
49621	and	CCONJ	O
49621	,	PUNCT	O
49621	when	ADV	O
49621	monoamine	NOUN	O
49621	oxidase	ADJ	O
49621	(	PUNCT	O
49621	MAO	PROPN	O
49621	)	PUNCT	O
49621	was	VERB	O
49621	inhibited	VERB	O
49621	,	PUNCT	O
49621	5-HT	NUM	O
49621	-	PUNCT	O
49621	o	NOUN	O
49621	-	PUNCT	O
49621	glucuronide	NOUN	O
49621	were	VERB	O
49621	found	VERB	O
49621	in	ADP	O
49621	the	DET	O
49621	tissue	NOUN	O
49621	.	PUNCT	O
49622	Two	NUM	O
49622	uptake	NOUN	O
49622	processes	NOUN	O
49622	differing	VERB	O
49622	in	ADP	O
49622	affinity	NOUN	O
49622	could	VERB	O
49622	be	VERB	O
49622	defined	VERB	O
49622	.	PUNCT	O
49623	Only	ADV	O
49623	the	DET	O
49623	high	ADJ	O
49623	affinity	NOUN	O
49623	process	NOUN	O
49623	was	VERB	O
49623	saturable	ADJ	O
49623	.	PUNCT	O
49624	Fetal	ADJ	O
49624	ileum	NOUN	O
49624	took	VERB	O
49624	up	PART	O
49624	tritiated	ADJ	O
49624	5-HT	NUM	O
49624	but	CCONJ	O
49624	glucuronidation	NOUN	O
49624	did	VERB	O
49624	not	ADV	O
49624	occur	VERB	O
49624	when	ADV	O
49624	MAO	PROPN	O
49624	was	VERB	O
49624	inhibited	VERB	O
49624	.	PUNCT	O
49625	The	DET	O
49625	uptake	NOUN	O
49625	of	ADP	O
49625	tritiated	ADJ	O
49625	5-HT	NUM	O
49625	by	ADP	O
49625	the	DET	O
49625	fetal	ADJ	O
49625	ileum	NOUN	O
49625	was	VERB	O
49625	due	ADJ	O
49625	to	ADP	O
49625	a	DET	O
49625	single	ADJ	O
49625	,	PUNCT	O
49625	saturable	ADJ	O
49625	,	PUNCT	O
49625	temperature	NOUN	O
49625	sensitive	ADJ	O
49625	(	PUNCT	O
49625	Q10	NOUN	O
49625	at	ADP	O
49625	27	NUM	O
49625	-	SYM	O
49625	37	NUM	O
49625	degress	NOUN	O
49625	C	NOUN	O
49625	=	SYM	O
49625	2.4	NUM	O
49625	)	PUNCT	O
49625	process	NOUN	O
49625	inhibited	VERB	O
49625	by	ADP	O
49625	ouabain	NOUN	O
49625	.	PUNCT	O
49626	It	PRON	O
49626	was	VERB	O
49626	identical	ADJ	O
49626	to	ADP	O
49626	the	DET	O
49626	high	ADJ	O
49626	affinity	NOUN	O
49626	uptake	NOUN	O
49626	found	VERB	O
49626	in	ADP	O
49626	adult	NOUN	O
49626	tissue	NOUN	O
49626	.	PUNCT	O
49627	This	DET	O
49627	specific	ADJ	O
49627	high	ADJ	O
49627	affinity	NOUN	O
49627	uptake	NOUN	O
49627	could	VERB	O
49627	be	VERB	O
49627	found	VERB	O
49627	as	ADV	O
49627	early	ADV	O
49627	as	ADP	O
49627	the	DET	O
49627	16th	ADJ	O
49627	day	NOUN	O
49627	of	ADP	O
49627	gestation	NOUN	O
49627	,	PUNCT	O
49627	5	NUM	O
49627	-	SYM	O
49627	8	NUM	O
49627	days	NOUN	O
49627	before	ADP	O
49627	uptake	NOUN	O
49627	of	ADP	O
49627	norepinephrine	NOUN	O
49627	(	PUNCT	O
49627	NE	PROPN	O
49627	)	PUNCT	O
49627	begins	VERB	O
49627	.	PUNCT	O
49628	Light	NOUN	O
49628	and	CCONJ	O
49628	electron	NOUN	O
49628	microscope	NOUN	O
49628	radioautography	NOUN	O
49628	revealed	VERB	O
49628	that	ADP	O
49628	the	DET	O
49628	uptake	NOUN	O
49628	of	ADP	O
49628	5-HT	NUM	O
49628	was	VERB	O
49628	primarily	ADV	O
49628	into	ADP	O
49628	axons	NOUN	O
49628	and	CCONJ	O
49628	a	DET	O
49628	characteristic	ADJ	O
49628	structure	NOUN	O
49628	called	VERB	O
49628	the	DET	O
49628	expanded	VERB	O
49628	process	NOUN	O
49628	,	PUNCT	O
49628	both	CCONJ	O
49628	in	ADP	O
49628	the	DET	O
49628	myenteric	ADJ	O
49628	plexus	NOUN	O
49628	.	PUNCT	O
49629	Both	DET	O
49629	contained	VERB	O
49629	dense	ADJ	O
49629	-	PUNCT	O
49629	cored	VERB	O
49629	vesicles	NOUN	O
49629	.	PUNCT	O
49630	Axons	NOUN	O
49630	were	VERB	O
49630	not	ADV	O
49630	labeled	VERB	O
49630	by	ADP	O
49630	tritiated	ADJ	O
49630	NE	PROPN	O
49630	until	ADP	O
49630	after	ADP	O
49630	24	NUM	O
49630	days	NOUN	O
49630	and	CCONJ	O
49630	the	DET	O
49630	expanded	VERB	O
49630	process	NOUN	O
49630	was	VERB	O
49630	never	ADV	O
49630	labeled	VERB	O
49630	by	ADP	O
49630	tritiated	ADJ	O
49630	NE	PROPN	O
49630	.	PUNCT	O
49631	This	DET	O
49631	study	NOUN	O
49631	shows	VERB	O
49631	that	ADP	O
49631	uptake	NOUN	O
49631	of	ADP	O
49631	5-HT	NUM	O
49631	is	VERB	O
49631	a	DET	O
49631	property	NOUN	O
49631	of	ADP	O
49631	distinct	ADJ	O
49631	system	NOUN	O
49631	of	ADP	O
49631	axons	NOUN	O
49631	in	ADP	O
49631	the	DET	O
49631	mammalian	ADJ	O
49631	myenteric	ADJ	O
49631	plexus	NOUN	O
49631	which	ADJ	O
49631	develops	VERB	O
49631	prior	ADV	O
49631	to	ADP	O
49631	adrenergic	VERB	O
49631	axons	NOUN	O
49631	during	ADP	O
49631	ontogeny	ADJ	O
49631	.	PUNCT	O
49632	The	DET	O
49632	results	NOUN	O
49632	of	ADP	O
49632	morphological	ADJ	O
49632	,	PUNCT	O
49632	base	NOUN	O
49632	ratio	NOUN	O
49632	,	PUNCT	O
49632	nutritional	ADJ	O
49632	,	PUNCT	O
49632	temperature	NOUN	O
49632	,	PUNCT	O
49632	and	CCONJ	O
49632	pH	VERB	O
49632	studies	NOUN	O
49632	on	ADP	O
49632	a	DET	O
49632	strain	NOUN	O
49632	of	ADP	O
49632	Methanospirillum	PROPN	O
49632	hungatii	NOUN	O
49632	,	PUNCT	O
49632	isolated	VERB	O
49632	from	ADP	O
49632	an	DET	O
49632	anaerobic	ADJ	O
49632	pear	NOUN	O
49632	waste	NOUN	O
49632	digester	NOUN	O
49632	,	PUNCT	O
49632	are	VERB	O
49632	described	VERB	O
49632	.	PUNCT	O
49633	The	DET	O
49633	isolate	ADJ	O
49633	,	PUNCT	O
49633	designated	VERB	O
49633	as	ADP	O
49633	strain	NOUN	O
49633	GP	PROPN	O
49633	1	NUM	O
49633	,	PUNCT	O
49633	was	VERB	O
49633	compared	VERB	O
49633	with	ADP	O
49633	some	DET	O
49633	of	ADP	O
49633	the	DET	O
49633	characteristics	NOUN	O
49633	of	ADP	O
49633	type	NOUN	O
49633	-	PUNCT	O
49633	strain	NOUN	O
49633	M.	PROPN	O
49633	hungatii	NOUN	O
49633	JF	PROPN	O
49633	1	NUM	O
49633	.	PUNCT	O
49634	Strain	NOUN	O
49634	GP	PROPN	O
49634	1	NUM	O
49634	is	VERB	O
49634	Gram	PROPN	O
49634	-	PUNCT	O
49634	negative	PROPN	O
49634	,	PUNCT	O
49634	weakly	ADV	O
49634	motile	ADJ	O
49634	,	PUNCT	O
49634	and	CCONJ	O
49634	a	DET	O
49634	strict	ADJ	O
49634	anaerobe	NOUN	O
49634	with	ADP	O
49634	a	DET	O
49634	guanine	NOUN	O
49634	plus	CCONJ	O
49634	cytosine	NOUN	O
49634	(	PUNCT	O
49634	G	NOUN	O
49634	+	SYM	O
49634	C	PROPN	O
49634	)	PUNCT	O
49634	content	NOUN	O
49634	of	ADP	O
49634	46.5	NUM	O
49634	mol%	NOUN	O
49634	.	PUNCT	O
49635	The	DET	O
49635	preferred	ADJ	O
49635	substrates	NOUN	O
49635	for	ADP	O
49635	methane	NOUN	O
49635	production	NOUN	O
49635	are	VERB	O
49635	hydrogen	NOUN	O
49635	,	PUNCT	O
49635	carbon	NOUN	O
49635	dioxide	NOUN	O
49635	,	PUNCT	O
49635	and	CCONJ	O
49635	formate	ADJ	O
49635	.	PUNCT	O
49636	Acetate	NOUN	O
49636	is	VERB	O
49636	used	VERB	O
49636	under	ADP	O
49636	certain	ADJ	O
49636	conditions	NOUN	O
49636	but	CCONJ	O
49636	its	ADJ	O
49636	specific	ADJ	O
49636	contribution	NOUN	O
49636	to	ADP	O
49636	cell	NOUN	O
49636	carbon	NOUN	O
49636	and	CCONJ	O
49636	(	PUNCT	O
49636	or	CCONJ	O
49636	)	PUNCT	O
49636	methane	NOUN	O
49636	formation	NOUN	O
49636	was	VERB	O
49636	not	ADV	O
49636	established	VERB	O
49636	.	PUNCT	O
49637	The	DET	O
49637	optimum	ADJ	O
49637	temperature	NOUN	O
49637	for	ADP	O
49637	both	DET	O
49637	growth	NOUN	O
49637	and	CCONJ	O
49637	methane	NOUN	O
49637	production	NOUN	O
49637	is	VERB	O
49637	35	NUM	O
49637	degrees	NOUN	O
49637	C	NOUN	O
49637	,	PUNCT	O
49637	but	CCONJ	O
49637	growth	NOUN	O
49637	and	CCONJ	O
49637	methane	NOUN	O
49637	production	NOUN	O
49637	occur	VERB	O
49637	over	ADP	O
49637	the	DET	O
49637	range	NOUN	O
49637	25	NUM	O
49637	-	SYM	O
49637	45	NUM	O
49637	degrees	NOUN	O
49637	C.	PROPN	O
49637	Methane	PROPN	O
49637	production	NOUN	O
49637	is	VERB	O
49637	optimal	ADJ	O
49637	at	ADP	O
49637	pH	NOUN	O
49637	7.0	NUM	O
49637	.	PUNCT	O
49638	The	DET	O
49638	objective	NOUN	O
49638	of	ADP	O
49638	this	DET	O
49638	investigation	NOUN	O
49638	was	VERB	O
49638	to	PART	O
49638	throw	VERB	O
49638	light	NOUN	O
49638	on	ADP	O
49638	the	DET	O
49638	biological	ADJ	O
49638	behavior	NOUN	O
49638	 	SPACE	O
49638	and	CCONJ	O
49638	metabolic	ADJ	O
49638	regulation	NOUN	O
49638	of	ADP	O
49638	hepatic	ADJ	O
49638	enzymes	NOUN	O
49638	of	ADP	O
49638	the	DET	O
49638	nonoxidative	ADJ	O
49638	branch	NOUN	O
49638	of	ADP	O
49638	the	DET	O
49638	pentose	NOUN	O
49638	phosphate	ADJ	O
49638	pathway	NOUN	O
49638	.	PUNCT	O
49639	The	DET	O
49639	activities	NOUN	O
49639	of	ADP	O
49639	transaldolase	NOUN	O
49639	(	PUNCT	O
49639	EC	PROPN	O
49639	2.2.1.2	NUM	O
49639	)	PUNCT	O
49639	and	CCONJ	O
49639	trasketolase	NOUN	O
49639	(	PUNCT	O
49639	EC	PROPN	O
49639	2.2.1.1	NUM	O
49639	)	PUNCT	O
49639	Were	VERB	O
49639	compared	VERB	O
49639	in	ADP	O
49639	biological	ADJ	O
49639	conditions	NOUN	O
49639	that	ADJ	O
49639	involve	VERB	O
49639	modulation	NOUN	O
49639	of	ADP	O
49639	gene	NOUN	O
49639	expression	NOUN	O
49639	such	ADJ	O
49639	as	ADP	O
49639	in	ADP	O
49639	starvation	NOUN	O
49639	,	PUNCT	O
49639	in	ADP	O
49639	differentiation	NOUN	O
49639	,	PUNCT	O
49639	after	ADP	O
49639	partial	ADJ	O
49639	hepatectomy	NOUN	O
49639	,	PUNCT	O
49639	and	CCONJ	O
49639	in	ADP	O
49639	a	DET	O
49639	spectrum	NOUN	O
49639	of	ADP	O
49639	hepatomas	NOUN	O
49639	of	ADP	O
49639	different	ADJ	O
49639	growth	NOUN	O
49639	rates	NOUN	O
49639	.	PUNCT	O
49640	The	DET	O
49640	enzyme	NOUN	O
49640	activities	NOUN	O
49640	were	VERB	O
49640	determined	VERB	O
49640	under	ADP	O
49640	optimal	ADJ	O
49640	kinetic	ADJ	O
49640	conditions	NOUN	O
49640	by	ADP	O
49640	spectrophotometric	ADJ	O
49640	methods	NOUN	O
49640	in	ADP	O
49640	the	DET	O
49640	100,000	NUM	O
49640	X	NOUN	O
49640	g	DET	O
49640	supernatant	NOUN	O
49640	fluids	NOUN	O
49640	prepared	VERB	O
49640	from	ADP	O
49640	tissue	NOUN	O
49640	homogenates	NOUN	O
49640	.	PUNCT	O
49641	The	DET	O
49641	kinetic	ADJ	O
49641	properties	NOUN	O
49641	of	ADP	O
49641	transaldolase	NOUN	O
49641	and	CCONJ	O
49641	transketolase	NOUN	O
49641	were	VERB	O
49641	similar	ADJ	O
49641	in	ADP	O
49641	normal	ADJ	O
49641	liver	NOUN	O
49641	and	CCONJ	O
49641	in	ADP	O
49641	rapidly	ADV	O
49641	growing	VERB	O
49641	hepatoma	NOUN	DISEASE
49641	3924A.	NUM	O
49642	For	ADP	O
49642	transaldolase	NOUN	O
49642	,	PUNCT	O
49642	apparent	ADJ	O
49642	Km	PROPN	O
49642	values	NOUN	O
49642	of	ADP	O
49642	0.13	NUM	O
49642	mM	PROPN	O
49642	(	PUNCT	O
49642	normal	ADJ	O
49642	liver	NOUN	O
49642	)	PUNCT	O
49642	and	CCONJ	O
49642	0.17	NUM	O
49642	mM	PROPN	O
49642	(	PUNCT	O
49642	hepatoma	NOUN	DISEASE
49642	)	PUNCT	O
49642	were	VERB	O
49642	observed	VERB	O
49642	for	ADP	O
49642	erythrose	NOUN	O
49642	4-phosphate	NOUN	O
49642	and	CCONJ	O
49642	of	ADP	O
49642	0.30	NUM	O
49642	to	ADP	O
49642	0.35	NUM	O
49642	mM	PROPN	O
49642	for	ADP	O
49642	fructose	NOUN	O
49642	6-phosphate	NOUN	O
49642	.	PUNCT	O
49643	The	DET	O
49643	pH	VERB	O
49643	optima	NOUN	O
49643	in	ADP	O
49643	liver	NOUN	O
49643	and	CCONJ	O
49643	hepatoma	NOUN	DISEASE
49643	were	VERB	O
49643	at	ADP	O
49643	approximately	ADV	O
49643	6.9	NUM	O
49643	to	ADP	O
49643	7.2	NUM	O
49643	.	PUNCT	O
49644	For	ADP	O
49644	the	DET	O
49644	transketolase	ADJ	O
49644	substrates	NOUN	O
49644	,	PUNCT	O
49644	ribose	VERB	O
49644	5-phosphate	NOUN	O
49644	and	CCONJ	O
49644	xylulose	ADJ	O
49644	5-phosphate	NOUN	O
49644	,	PUNCT	O
49644	the	DET	O
49644	apparent	ADJ	O
49644	Km	PROPN	O
49644	values	NOUN	O
49644	were	VERB	O
49644	0.3	NUM	O
49644	and	CCONJ	O
49644	0.5	NUM	O
49644	mM	NOUN	O
49644	,	PUNCT	O
49644	respectively	ADV	O
49644	,	PUNCT	O
49644	in	ADP	O
49644	both	DET	O
49644	liver	NOUN	O
49644	and	CCONJ	O
49644	hepatoma	NOUN	DISEASE
49644	.	PUNCT	O
49645	A	DET	O
49645	broad	ADJ	O
49645	pH	NOUN	O
49645	optimum	ADJ	O
49645	around	ADV	O
49645	7.6	NUM	O
49645	was	VERB	O
49645	observed	VERB	O
49645	in	ADP	O
49645	both	DET	O
49645	tissues	NOUN	O
49645	.	PUNCT	O
49646	In	ADP	O
49646	organ	NOUN	O
49646	distribution	NOUN	O
49646	studies	NOUN	O
49646	,	PUNCT	O
49646	enzyme	NOUN	O
49646	activities	NOUN	O
49646	were	VERB	O
49646	measured	VERB	O
49646	in	ADP	O
49646	liver	NOUN	O
49646	,	PUNCT	O
49646	intestinal	ADJ	O
49646	mucosa	NOUN	O
49646	,	PUNCT	O
49646	thymus	NOUN	O
49646	,	PUNCT	O
49646	kidney	NOUN	O
49646	,	PUNCT	O
49646	spleen	NOUN	O
49646	,	PUNCT	O
49646	brain	NOUN	O
49646	,	PUNCT	O
49646	adipose	ADJ	O
49646	tissue	NOUN	O
49646	,	PUNCT	O
49646	lung	NOUN	O
49646	,	PUNCT	O
49646	heart	NOUN	O
49646	,	PUNCT	O
49646	and	CCONJ	O
49646	skeletal	ADJ	O
49646	muscle	NOUN	O
49646	.	PUNCT	O
49647	Taking	VERB	O
49647	the	DET	O
49647	specific	ADJ	O
49647	activity	NOUN	O
49647	of	ADP	O
49647	liver	NOUN	O
49647	as	ADP	O
49647	100	NUM	O
49647	%	NOUN	O
49647	,	PUNCT	O
49647	transaldolase	NOUN	O
49647	activity	NOUN	O
49647	was	VERB	O
49647	the	DET	O
49647	highest	ADJ	O
49647	in	ADP	O
49647	intestinal	ADJ	O
49647	mucosa	NOUN	O
49647	(	PUNCT	O
49647	316	NUM	O
49647	%	NOUN	O
49647	)	PUNCT	O
49647	and	CCONJ	O
49647	in	ADP	O
49647	thymus	NOUN	O
49647	(	PUNCT	O
49647	219	NUM	O
49647	%	NOUN	O
49647	)	PUNCT	O
49647	;	PUNCT	O
49647	it	PRON	O
49647	was	VERB	O
49647	the	DET	O
49647	lowest	ADJ	O
49647	in	ADP	O
49647	heart	NOUN	O
49647	(	PUNCT	O
49647	53	NUM	O
49647	%	NOUN	O
49647	)	PUNCT	O
49647	and	CCONJ	O
49647	in	ADP	O
49647	skeletal	ADJ	O
49647	muscle	NOUN	O
49647	(	PUNCT	O
49647	21	NUM	O
49647	%	NOUN	O
49647	)	PUNCT	O
49647	.	PUNCT	O
49648	Transketolase	ADJ	O
49648	activity	NOUN	O
49648	was	VERB	O
49648	highest	ADJ	O
49648	in	ADP	O
49648	kidney	NOUN	O
49648	(	PUNCT	O
49648	155	NUM	O
49648	%	NOUN	O
49648	)	PUNCT	O
49648	and	CCONJ	O
49648	lowest	ADJ	O
49648	in	ADP	O
49648	heart	NOUN	O
49648	(	PUNCT	O
49648	26	NUM	O
49648	%	NOUN	O
49648	)	PUNCT	O
49648	and	CCONJ	O
49648	skeletal	ADJ	O
49648	muscle	NOUN	O
49648	(	PUNCT	O
49648	23	NUM	O
49648	%	NOUN	O
49648	)	PUNCT	O
49648	.	PUNCT	O
49649	Starvation	NOUN	O
49649	decreased	VERB	O
49649	transaldolase	NOUN	O
49649	and	CCONJ	O
49649	transketolase	NOUN	O
49649	activities	NOUN	O
49649	in	ADP	O
49649	6	NUM	O
49649	days	NOUN	O
49649	to	ADP	O
49649	69	NUM	O
49649	and	CCONJ	O
49649	74	NUM	O
49649	%	NOUN	O
49649	,	PUNCT	O
49649	respectively	ADV	O
49649	,	PUNCT	O
49649	of	ADP	O
49649	those	DET	O
49649	of	ADP	O
49649	the	DET	O
49649	liver	NOUN	O
49649	of	ADP	O
49649	the	DET	O
49649	normal	ADJ	O
49649	,	PUNCT	O
49649	fed	ADJ	O
49649	rat	NOUN	O
49649	.	PUNCT	O
49650	This	DET	O
49650	was	VERB	O
49650	in	ADP	O
49650	the	DET	O
49650	same	ADJ	O
49650	range	NOUN	O
49650	as	ADP	O
49650	the	DET	O
49650	decrease	NOUN	O
49650	in	ADP	O
49650	the	DET	O
49650	protein	NOUN	O
49650	concentration	NOUN	O
49650	(	PUNCT	O
49650	66%y	NUM	O
49650	.	PUNCT	O
49651	In	ADP	O
49651	the	DET	O
49651	liver	NOUN	O
49651	tumors	NOUN	O
49651	,	PUNCT	O
49651	transaldolase	NOUN	O
49651	activity	NOUN	O
49651	was	VERB	O
49651	increased	VERB	O
49651	1.5-	NUM	O
49651	to	ADP	O
49651	3.4-fold	NUM	O
49651	over	ADP	O
49651	the	DET	O
49651	activities	NOUN	O
49651	observed	VERB	O
49651	in	ADP	O
49651	normal	ADJ	O
49651	control	NOUN	O
49651	rat	NOUN	O
49651	liver	NOUN	O
49651	.	PUNCT	O
49652	Transketolase	ADJ	O
49652	activity	NOUN	O
49652	showed	VERB	O
49652	no	DET	O
49652	relationship	NOUN	O
49652	to	PART	O
49652	tumor	VERB	O
49652	proliferation	NOUN	O
49652	rate	NOUN	O
49652	.	PUNCT	O
49653	In	ADP	O
49653	the	DET	O
49653	regenerating	NOUN	O
49653	liver	NOUN	O
49653	at	ADP	O
49653	24	NUM	O
49653	hr	NOUN	O
49653	after	ADP	O
49653	partial	ADJ	O
49653	hepatectomy	NOUN	O
49653	,	PUNCT	O
49653	the	DET	O
49653	activity	NOUN	O
49653	of	ADP	O
49653	both	DET	O
49653	pentose	NOUN	O
49653	phosphate	ADJ	O
49653	pathway	NOUN	O
49653	enzymes	NOUN	O
49653	was	VERB	O
49653	in	ADP	O
49653	the	DET	O
49653	same	ADJ	O
49653	range	NOUN	O
49653	as	ADP	O
49653	that	DET	O
49653	of	ADP	O
49653	the	DET	O
49653	sham	ADJ	O
49653	-	PUNCT	O
49653	operated	VERB	O
49653	controls	NOUN	O
49653	.	PUNCT	O
49654	In	ADP	O
49654	differentiation	NOUN	O
49654	at	ADP	O
49654	the	DET	O
49654	postnatal	ADJ	O
49654	age	NOUN	O
49654	of	ADP	O
49654	5	NUM	O
49654	,	PUNCT	O
49654	12	NUM	O
49654	,	PUNCT	O
49654	23	NUM	O
49654	,	PUNCT	O
49654	and	CCONJ	O
49654	32	NUM	O
49654	days	NOUN	O
49654	,	PUNCT	O
49654	hepatic	ADJ	O
49654	transaldolase	NOUN	O
49654	activities	NOUN	O
49654	were	VERB	O
49654	33	NUM	O
49654	,	PUNCT	O
49654	44	NUM	O
49654	,	PUNCT	O
49654	55	NUM	O
49654	,	PUNCT	O
49654	and	CCONJ	O
49654	72	NUM	O
49654	%	NOUN	O
49654	,	PUNCT	O
49654	respectively	ADV	O
49654	,	PUNCT	O
49654	of	ADP	O
49654	the	DET	O
49654	activities	NOUN	O
49654	observed	VERB	O
49654	in	ADP	O
49654	the	DET	O
49654	60-day	NUM	O
49654	-	PUNCT	O
49654	old	ADJ	O
49654	,	PUNCT	O
49654	adult	NOUN	O
49654	male	NOUN	O
49654	rat	NOUN	O
49654	.	PUNCT	O
49655	During	ADP	O
49655	the	DET	O
49655	same	ADJ	O
49655	period	NOUN	O
49655	,	PUNCT	O
49655	transketolase	ADJ	O
49655	activ	ADJ	O
49655	-	PUNCT	O
49655	ties	NOUN	O
49655	were	VERB	O
49655	18	NUM	O
49655	,	PUNCT	O
49655	21	NUM	O
49655	,	PUNCT	O
49655	26	NUM	O
49655	,	PUNCT	O
49655	and	CCONJ	O
49655	55	NUM	O
49655	%	NOUN	O
49655	of	ADP	O
49655	the	DET	O
49655	activities	NOUN	O
49655	observed	VERB	O
49655	in	ADP	O
49655	liver	NOUN	O
49655	of	ADP	O
49655	adult	NOUN	O
49655	rat	NOUN	O
49655	.	PUNCT	O
49656	The	DET	O
49656	demonstration	NOUN	O
49656	of	ADP	O
49656	increased	VERB	O
49656	transaldolase	NOUN	O
49656	activity	NOUN	O
49656	in	ADP	O
49656	hepatomas	NOUN	O
49656	,	PUNCT	O
49656	irrespective	ADV	O
49656	of	ADP	O
49656	the	DET	O
49656	degree	NOUN	O
49656	of	ADP	O
49656	tumor	NOUN	O
49656	malignancy	NOUN	O
49656	,	PUNCT	O
49656	differentiation	NOUN	O
49656	,	PUNCT	O
49656	or	CCONJ	O
49656	growth	NOUN	O
49656	rate	NOUN	O
49656	,	PUNCT	O
49656	suggests	VERB	O
49656	that	ADP	O
49656	the	DET	O
49656	reprogramming	NOUN	O
49656	of	ADP	O
49656	gene	NOUN	O
49656	expression	NOUN	O
49656	in	ADP	O
49656	malignant	ADJ	O
49656	transformation	NOUN	O
49656	is	VERB	O
49656	linked	VERB	O
49656	with	ADP	O
49656	an	DET	O
49656	increase	NOUN	O
49656	in	ADP	O
49656	the	DET	O
49656	expression	NOUN	O
49656	of	ADP	O
49656	this	DET	O
49656	pentose	NOUN	O
49656	phosphate	ADJ	O
49656	pathway	NOUN	O
49656	enzyme	NOUN	O
49656	...	PUNCT	O
49657	We	PRON	O
49657	used	VERB	O
49657	the	DET	O
49657	method	NOUN	O
49657	described	VERB	O
49657	here	ADV	O
49657	to	PART	O
49657	detect	VERB	O
49657	and	CCONJ	O
49657	identify	VERB	O
49657	seven	NUM	O
49657	benzodiazepine	NOUN	O
49657	derivatives	NOUN	O
49657	--	PUNCT	O
49657	diazepam	NOUN	O
49657	,	PUNCT	O
49657	chlorodiazepoxide	NOUN	O
49657	,	PUNCT	O
49657	nitrazepam	NOUN	O
49657	,	PUNCT	O
49657	cloxazolam	NOUN	O
49657	,	PUNCT	O
49657	oxazolam	NOUN	O
49657	,	PUNCT	O
49657	oxazepam	NOUN	O
49657	,	PUNCT	O
49657	and	CCONJ	O
49657	medazepam	NOUN	O
49657	--	PUNCT	O
49657	and	CCONJ	O
49657	their	ADJ	O
49657	metabolites	NOUN	O
49657	in	ADP	O
49657	the	DET	O
49657	urine	NOUN	O
49657	of	ADP	O
49657	rabbits	NOUN	O
49657	given	VERB	O
49657	the	DET	O
49657	seven	NUM	O
49657	drugs	NOUN	O
49657	orally	ADV	O
49657	.	PUNCT	O
49658	We	PRON	O
49658	column	NOUN	O
49658	-	PUNCT	O
49658	chromatographed	VERB	O
49658	25-ml	NUM	O
49658	samples	NOUN	O
49658	of	ADP	O
49658	urine	NOUN	O
49658	on	ADP	O
49658	Amberlite	PROPN	O
49658	XAD-2	PROPN	O
49658	.	PUNCT	O
49659	The	DET	O
49659	drugs	NOUN	O
49659	and	CCONJ	O
49659	their	ADJ	O
49659	metabolites	NOUN	O
49659	in	ADP	O
49659	the	DET	O
49659	urine	NOUN	O
49659	were	VERB	O
49659	adsorbed	VERB	O
49659	by	ADP	O
49659	the	DET	O
49659	resin	NOUN	O
49659	,	PUNCT	O
49659	irrespective	ADV	O
49659	of	ADP	O
49659	urinary	ADJ	O
49659	pH	PROPN	O
49659	,	PUNCT	O
49659	and	CCONJ	O
49659	upon	ADP	O
49659	successive	ADJ	O
49659	elution	NOUN	O
49659	with	ADP	O
49659	methanol	NOUN	O
49659	and	CCONJ	O
49659	ethyl	VERB	O
49659	acetate	NOUN	O
49659	/	SYM	O
49659	methanol	NOUN	O
49659	/	SYM	O
49659	acetic	NOUN	O
49659	acid	NOUN	O
49659	(	PUNCT	O
49659	90/10/0.1	NUM	O
49659	by	ADP	O
49659	vol	NUM	O
49659	)	PUNCT	O
49659	they	PRON	O
49659	could	VERB	O
49659	be	VERB	O
49659	separated	VERB	O
49659	and	CCONJ	O
49659	extracted	VERB	O
49659	from	ADP	O
49659	the	DET	O
49659	normal	ADJ	O
49659	components	NOUN	O
49659	of	ADP	O
49659	urine	NOUN	O
49659	with	ADP	O
49659	satisfactory	ADJ	O
49659	analytical	ADJ	O
49659	recovery	NOUN	O
49659	.	PUNCT	O
49660	The	DET	O
49660	conjugated	VERB	O
49660	metabolites	NOUN	O
49660	were	VERB	O
49660	then	ADV	O
49660	enzymatically	ADV	O
49660	hydrolyzed	VERB	O
49660	and	CCONJ	O
49660	the	DET	O
49660	hydrolysate	NOUN	O
49660	was	VERB	O
49660	extracted	VERB	O
49660	into	ADP	O
49660	ethyl	NOUN	O
49660	acetate	NOUN	O
49660	and	CCONJ	O
49660	the	DET	O
49660	extract	NOUN	O
49660	thin	ADJ	O
49660	-	PUNCT	O
49660	layer	NOUN	O
49660	chromatographed	VERB	O
49660	to	PART	O
49660	detect	VERB	O
49660	and	CCONJ	O
49660	identify	VERB	O
49660	each	DET	O
49660	drug	NOUN	O
49660	and	CCONJ	O
49660	each	DET	O
49660	of	ADP	O
49660	its	ADJ	O
49660	metabolites	NOUN	O
49660	.	PUNCT	O
49661	In	ADP	O
49661	an	DET	O
49661	experiment	NOUN	O
49661	in	ADP	O
49661	which	ADJ	O
49661	the	DET	O
49661	urine	NOUN	O
49661	of	ADP	O
49661	human	ADJ	O
49661	subjects	NOUN	O
49661	given	VERB	O
49661	5	NUM	O
49661	mg	NOUN	O
49661	of	ADP	O
49661	nitrazepam	NOUN	O
49661	orally	ADV	O
49661	was	VERB	O
49661	analyzed	VERB	O
49661	by	ADP	O
49661	this	DET	O
49661	method	NOUN	O
49661	,	PUNCT	O
49661	the	DET	O
49661	metabolites	NOUN	O
49661	of	ADP	O
49661	nitrazepam	NOUN	O
49661	in	ADP	O
49661	the	DET	O
49661	24-h	NUM	O
49661	urine	NOUN	O
49661	could	VERB	O
49661	be	VERB	O
49661	identified	VERB	O
49661	satisfactorily	ADV	O
49661	.	PUNCT	O
49662	1	PUNCT	O
49662	.	PUNCT	O
49663	An	DET	O
49663	in	ADP	O
49663	vivo	NOUN	O
49663	stathmokinetic	ADJ	O
49663	technique	NOUN	O
49663	was	VERB	O
49663	used	VERB	O
49663	to	PART	O
49663	determine	VERB	O
49663	the	DET	O
49663	immediate	ADJ	O
49663	effect	NOUN	O
49663	of	ADP	O
49663	various	ADJ	O
49663	adrenoceptor	NOUN	O
49663	agonists	NOUN	O
49663	and	CCONJ	O
49663	antagonists	NOUN	O
49663	on	ADP	O
49663	the	DET	O
49663	mitotic	ADJ	O
49663	rate	NOUN	O
49663	in	ADP	O
49663	the	DET	O
49663	stratified	ADJ	O
49663	squamous	ADJ	O
49663	epithelium	NOUN	O
49663	of	ADP	O
49663	the	DET	O
49663	rat	ADJ	O
49663	buccal	ADJ	O
49663	mucosa	NOUN	O
49663	.	PUNCT	O
49664	2	PUNCT	O
49664	.	PUNCT	O
49665	The	DET	O
49665	mitotic	ADJ	O
49665	rate	NOUN	O
49665	increased	VERB	O
49665	significantly	ADV	O
49665	in	ADP	O
49665	rats	NOUN	O
49665	treated	VERB	O
49665	with	ADP	O
49665	propranolol	NOUN	O
49665	and	CCONJ	O
49665	with	ADP	O
49665	practolol	NOUN	O
49665	,	PUNCT	O
49665	whereas	ADP	O
49665	the	DET	O
49665	mitotic	ADJ	O
49665	rate	NOUN	O
49665	decreased	VERB	O
49665	significantly	ADV	O
49665	in	ADP	O
49665	rats	NOUN	O
49665	treated	VERB	O
49665	with	ADP	O
49665	metaraminol	NOUN	O
49665	.	PUNCT	O
49666	In	ADP	O
49666	animals	NOUN	O
49666	treated	VERB	O
49666	with	ADP	O
49666	isoprenaline	NOUN	O
49666	and	CCONJ	O
49666	phentolamine	VERB	O
49666	the	DET	O
49666	mitotic	ADJ	O
49666	rate	NOUN	O
49666	did	VERB	O
49666	not	ADV	O
49666	differ	VERB	O
49666	significantly	ADV	O
49666	from	ADP	O
49666	the	DET	O
49666	control	NOUN	O
49666	value	NOUN	O
49666	.	PUNCT	O
49667	3	PUNCT	O
49667	.	PUNCT	O
49668	The	DET	O
49668	nature	NOUN	O
49668	of	ADP	O
49668	the	DET	O
49668	involvement	NOUN	O
49668	of	ADP	O
49668	adrenergic	ADJ	O
49668	mechanisms	NOUN	O
49668	with	ADP	O
49668	cell	NOUN	O
49668	proliferation	NOUN	O
49668	is	VERB	O
49668	still	ADV	O
49668	uncertain	ADJ	O
49668	but	CCONJ	O
49668	both	DET	O
49668	alpha-	ADJ	O
49668	and	CCONJ	O
49668	beta	ADJ	O
49668	-	PUNCT	O
49668	adrenergic	ADJ	O
49668	mechanisms	NOUN	O
49668	appear	VERB	O
49668	to	PART	O
49668	be	VERB	O
49668	associated	VERB	O
49668	with	ADP	O
49668	the	DET	O
49668	control	NOUN	O
49668	of	ADP	O
49668	cell	NOUN	O
49668	proliferation	NOUN	O
49668	.	PUNCT	O
49669	Megaloblastic	ADJ	O
49669	anaemia	NOUN	DISEASE
49669	is	VERB	O
49669	due	ADJ	O
49669	to	ADP	O
49669	a	DET	O
49669	derangement	NOUN	O
49669	of	ADP	O
49669	DNA	NOUN	O
49669	synthesis	NOUN	O
49669	caused	VERB	O
49669	by	ADP	O
49669	insufficient	ADJ	O
49669	supply	NOUN	O
49669	of	ADP	O
49669	one	NUM	O
49669	or	CCONJ	O
49669	other	ADJ	O
49669	of	ADP	O
49669	the	DET	O
49669	four	NUM	O
49669	deoxyribonucleoside	NOUN	O
49669	triphosphate	NOUN	O
49669	(	PUNCT	O
49669	dNTP	NOUN	O
49669	)	PUNCT	O
49669	precursors	NOUN	O
49669	of	ADP	O
49669	DNA	NOUN	O
49669	synthesis	NOUN	O
49669	or	CCONJ	O
49669	by	ADP	O
49669	direct	ADJ	O
49669	inhibition	NOUN	O
49669	of	ADP	O
49669	one	NUM	O
49669	or	CCONJ	O
49669	other	ADJ	O
49669	DNA	NOUN	O
49669	polymerase	NOUN	O
49669	.	PUNCT	O
49670	Reduced	VERB	O
49670	supply	NOUN	O
49670	of	ADP	O
49670	the	DET	O
49670	pyrimidine	NOUN	O
49670	deoxythymidine	NOUN	O
49670	triphosphate	NOUN	O
49670	(	PUNCT	O
49670	dTTP	PROPN	O
49670	)	PUNCT	O
49670	may	VERB	O
49670	be	VERB	O
49670	caused	VERB	O
49670	by	ADP	O
49670	folate	NOUN	O
49670	or	CCONJ	O
49670	vitamin	NOUN	O
49670	B12	NOUN	O
49670	deficiencies	NOUN	O
49670	or	CCONJ	O
49670	by	ADP	O
49670	the	DET	O
49670	action	NOUN	O
49670	of	ADP	O
49670	dihydrofolate	ADJ	O
49670	reductase	NOUN	O
49670	inhibitors	NOUN	O
49670	(	PUNCT	O
49670	e.g.	ADV	O
49670	methotrexate	NOUN	O
49670	,	PUNCT	O
49670	pyrimethamine	NOUN	O
49670	or	CCONJ	O
49670	trimethoprim	ADJ	O
49670	)	PUNCT	O
49670	,	PUNCT	O
49670	all	DET	O
49670	of	ADP	O
49670	which	ADJ	O
49670	cause	ADP	O
49670	reduced	VERB	O
49670	supply	NOUN	O
49670	of	ADP	O
49670	the	DET	O
49670	coenzyme	NOUN	O
49670	5	NUM	O
49670	,	PUNCT	O
49670	10	NUM	O
49670	methylene	NOUN	O
49670	tetrahydrofolate	NOUN	O
49670	(	PUNCT	O
49670	pentaglutamate	VERB	O
49670	)	PUNCT	O
49670	needed	VERB	O
49670	for	ADP	O
49670	thymidylate	ADJ	O
49670	synthetase	NOUN	O
49670	.	PUNCT	O
49671	Reduced	ADJ	O
49671	dTTP	PROPN	O
49671	supply	NOUN	O
49671	may	VERB	O
49671	also	ADV	O
49671	be	VERB	O
49671	caused	VERB	O
49671	by	ADP	O
49671	direct	ADJ	O
49671	inhibition	NOUN	O
49671	of	ADP	O
49671	thymidylate	ADJ	O
49671	synthetase	NOUN	O
49671	by	ADP	O
49671	5-fluorouracil	NOUN	O
49671	.	PUNCT	O
49672	Reduced	VERB	O
49672	supply	NOUN	O
49672	of	ADP	O
49672	both	DET	O
49672	purines	NOUN	O
49672	,	PUNCT	O
49672	deoxyadenosine	ADP	O
49672	triphosphate	NOUN	O
49672	(	PUNCT	O
49672	dATP	NOUN	O
49672	)	PUNCT	O
49672	and	CCONJ	O
49672	deoxyguanosine	VERB	O
49672	triphosphate	NOUN	O
49672	(	PUNCT	O
49672	dGTP	NOUN	O
49672	)	PUNCT	O
49672	,	PUNCT	O
49672	may	VERB	O
49672	be	VERB	O
49672	caused	VERB	O
49672	by	ADP	O
49672	hydroxyurea	NOUN	O
49672	,	PUNCT	O
49672	6-mercaptopurine	NOUN	O
49673	(	PUNCT	O
49673	and	CCONJ	O
49673	probably	ADV	O
49673	by	ADP	O
49673	another	DET	O
49673	purine	NOUN	O
49673	antagonist	NOUN	O
49673	azaserine	NOUN	O
49673	)	PUNCT	O
49673	,	PUNCT	O
49673	whilst	ADP	O
49673	reduced	VERB	O
49673	supply	NOUN	O
49673	of	ADP	O
49673	both	DET	O
49673	pyrimidine	ADJ	O
49673	DNA	NOUN	O
49673	precursors	NOUN	O
49673	,	PUNCT	O
49673	dTTP	PROPN	O
49673	and	CCONJ	O
49673	dCTP	NOUN	O
49673	(	PUNCT	O
49673	deoxycytidine	VERB	O
49673	triphosphate	NOUN	O
49673	)	PUNCT	O
49673	may	VERB	O
49673	be	VERB	O
49673	due	ADJ	O
49673	to	ADP	O
49673	inherited	VERB	O
49673	orotic	ADJ	DISEASE
49673	aciduria	NOUN	DISEASE
49673	or	CCONJ	O
49673	to	PART	O
49673	treatment	VERB	O
49673	with	ADP	O
49673	azauridine	NOUN	O
49673	.	PUNCT	O
49674	Cytosine	PROPN	O
49674	arabinoside	VERB	O
49674	directly	ADV	O
49674	inhibits	VERB	O
49674	DNA	NOUN	O
49674	polymerase	NOUN	O
49674	.	PUNCT	O
49675	DNA	NOUN	O
49675	replication	NOUN	O
49675	is	VERB	O
49675	a	DET	O
49675	discontinuous	ADJ	O
49675	process	NOUN	O
49675	and	CCONJ	O
49675	a	DET	O
49675	number	NOUN	O
49675	of	ADP	O
49675	enzymes	NOUN	O
49675	are	VERB	O
49675	concerned	VERB	O
49675	with	ADP	O
49675	different	ADJ	O
49675	aspects	NOUN	O
49675	of	ADP	O
49675	the	DET	O
49675	process	NOUN	O
49675	.	PUNCT	O
49676	The	DET	O
49676	parental	ADJ	O
49676	strands	NOUN	O
49676	partly	ADV	O
49676	unwind	ADJ	O
49676	and	CCONJ	O
49676	a	DET	O
49676	large	ADJ	O
49676	number	NOUN	O
49676	of	ADP	O
49676	initiation	NOUN	O
49676	points	NOUN	O
49676	or	CCONJ	O
49676	origins	NOUN	O
49676	are	VERB	O
49676	activated	VERB	O
49676	on	ADP	O
49676	both	DET	O
49676	strands	NOUN	O
49676	.	PUNCT	O
49677	A	DET	O
49677	primer	NOUN	O
49677	RNA	PROPN	O
49677	is	VERB	O
49677	first	ADV	O
49677	synthesised	VERB	O
49677	using	VERB	O
49677	the	DET	O
49677	parental	ADJ	O
49677	strand	NOUN	O
49677	of	ADP	O
49677	DNA	NOUN	O
49677	as	ADP	O
49677	template	NOUN	O
49677	.	PUNCT	O
49678	Fragments	NOUN	O
49678	of	ADP	O
49678	new	ADJ	O
49678	DNA	NOUN	O
49678	are	VERB	O
49678	then	ADV	O
49678	synthesised	VERB	O
49678	on	ADP	O
49678	the	DET	O
49678	parental	ADJ	O
49678	DNA	NOUN	O
49678	template	NOUN	O
49678	,	PUNCT	O
49678	starting	VERB	O
49678	at	ADP	O
49678	the	DET	O
49678	RNA	PROPN	O
49678	primer	NOUN	O
49678	,	PUNCT	O
49678	under	ADP	O
49678	the	DET	O
49678	action	NOUN	O
49678	of	ADP	O
49678	one	NUM	O
49678	or	CCONJ	O
49678	other	ADJ	O
49678	DNA	NOUN	O
49678	polymerase	NOUN	O
49678	(	PUNCT	O
49678	probably	ADV	O
49678	gamma	NOUN	O
49678	)	PUNCT	O
49678	.	PUNCT	O
49679	The	DET	O
49679	RNA	PROPN	O
49679	primer	NOUN	O
49679	is	VERB	O
49679	then	ADV	O
49679	removed	VERB	O
49679	and	CCONJ	O
49679	the	DET	O
49679	gap	NOUN	O
49679	left	VERB	O
49679	is	VERB	O
49679	filled	VERB	O
49679	by	ADP	O
49679	further	ADJ	O
49679	DNA	NOUN	O
49679	synthesis	NOUN	O
49679	under	ADP	O
49679	the	DET	O
49679	action	NOUN	O
49679	of	ADP	O
49679	a	DET	O
49679	different	ADJ	O
49679	DNA	NOUN	O
49679	polymerase	NOUN	O
49679	(	PUNCT	O
49679	probably	ADV	O
49679	alpha	NOUN	O
49679	)	PUNCT	O
49679	.	PUNCT	O
49680	The	DET	O
49680	fragments	NOUN	O
49680	of	ADP	O
49680	new	ADJ	O
49680	DNA	NOUN	O
49680	are	VERB	O
49680	joined	VERB	O
49680	to	PART	O
49680	give	VERB	O
49680	newly	ADV	O
49680	synthesised	VERB	O
49680	stretches	NOUN	O
49680	of	ADP	O
49680	DNA	NOUN	O
49680	(	PUNCT	O
49680	replicons	NOUN	O
49680	)	PUNCT	O
49680	which	ADJ	O
49680	are	VERB	O
49680	then	ADV	O
49680	liigated	VERB	O
49680	together	ADV	O
49680	to	PART	O
49680	form	VERB	O
49680	bulk	ADJ	O
49680	DNA	NOUN	O
49680	of	ADP	O
49680	enormous	ADJ	O
49680	molecular	ADJ	O
49680	weight	NOUN	O
49680	.	PUNCT	O
49681	It	PRON	O
49681	is	VERB	O
49681	suggested	VERB	O
49681	here	ADV	O
49681	that	ADP	O
49681	reduced	VERB	O
49681	supply	NOUN	O
49681	of	ADP	O
49681	one	NUM	O
49681	or	CCONJ	O
49681	other	ADJ	O
49681	of	ADP	O
49681	the	DET	O
49681	four	NUM	O
49681	deoxyribonucleoside	NOUN	O
49681	triphosphate	NOUN	O
49681	(	PUNCT	O
49681	dNTP	NOUN	O
49681	)	PUNCT	O
49681	during	ADP	O
49681	the	DET	O
49681	'S	NOUN	O
49681	'	PUNCT	O
49681	phase	NOUN	O
49681	of	ADP	O
49681	the	DET	O
49681	cell	NOUN	O
49681	cycle	NOUN	O
49681	(	PUNCT	O
49681	due	ADJ	O
49681	to	ADP	O
49681	vitamin	NOUN	O
49681	B12	NOUN	O
49681	or	CCONJ	O
49681	folate	VERB	DISEASE
49681	deficiency	NOUN	DISEASE
49681	,	PUNCT	O
49681	drug	NOUN	O
49681	treatment	NOUN	O
49681	or	CCONJ	O
49681	other	ADJ	O
49681	congenital	ADJ	O
49681	or	CCONJ	O
49681	acquired	VERB	O
49681	abnormality	NOUN	O
49681	in	ADP	O
49681	synthesis	NOUN	O
49681	of	ADP	O
49681	the	DET	O
49681	dNTP	NOUN	O
49681	)	PUNCT	O
49681	impairs	VERB	O
49681	the	DET	O
49681	cell	NOUN	O
49681	's	PART	O
49681	ability	NOUN	O
49681	to	PART	O
49681	elongate	VERB	O
49681	newly	ADV	O
49681	initiated	VERB	O
49681	DNA	NOUN	O
49681	fragments	NOUN	O
49681	by	ADP	O
49681	preventing	VERB	O
49681	gap	NOUN	O
49681	-	PUNCT	O
49681	filling	NOUN	O
49681	,	PUNCT	O
49681	the	DET	O
49681	polymerase	NOUN	O
49681	needed	VERB	O
49681	for	ADP	O
49681	gap	NOUN	O
49681	-	PUNCT	O
49681	filling	VERB	O
49681	requiring	VERB	O
49681	substantially	ADV	O
49681	greater	ADJ	O
49681	concentrations	NOUN	O
49681	of	ADP	O
49681	the	DET	O
49681	deoxyribonucleoside	NOUN	O
49681	triphosphates	NOUN	O
49681	than	ADP	O
49681	the	DET	O
49681	polymerase	NOUN	O
49681	involved	VERB	O
49681	in	ADP	O
49681	chain	NOUN	O
49681	initiation	NOUN	O
49681	.	PUNCT	O
49682	Cytosine	PROPN	O
49682	arabinoside	VERB	O
49682	,	PUNCT	O
49682	which	ADJ	O
49682	also	ADV	O
49682	may	VERB	O
49682	cause	VERB	O
49682	megaloblastosis	NOUN	O
49682	,	PUNCT	O
49682	may	VERB	O
49682	affect	VERB	O
49682	principally	ADV	O
49682	the	DET	O
49682	synthesis	NOUN	O
49682	of	ADP	O
49682	new	ADJ	O
49682	DNA	NOUN	O
49682	fragments	NOUN	O
49682	.	PUNCT	O
49683	Since	ADP	O
49683	active	ADJ	O
49683	protein	NOUN	O
49683	synthesis	NOUN	O
49683	is	VERB	O
49683	needed	VERB	O
49683	for	ADP	O
49683	the	DET	O
49683	cell	NOUN	O
49683	to	PART	O
49683	enter	VERB	O
49683	the	DET	O
49683	S	PROPN	O
49683	phase	NOUN	O
49683	and	CCONJ	O
49683	RNA	PROPN	O
49683	synthesis	NOUN	O
49683	is	VERB	O
49683	needed	VERB	O
49683	to	PART	O
49683	prime	ADJ	O
49683	new	ADJ	O
49683	DNA	NOUN	O
49683	synthesis	NOUN	O
49683	,	PUNCT	O
49683	megaloblastic	ADJ	O
49683	anaemia	NOUN	DISEASE
49683	may	VERB	O
49683	be	VERB	O
49683	expected	VERB	O
49683	to	PART	O
49683	occur	VERB	O
49683	only	ADV	O
49683	when	ADV	O
49683	DNA	NOUN	O
49683	synthesis	NOUN	O
49683	is	VERB	O
49683	inhibited	VERB	O
49683	but	CCONJ	O
49683	protein	NOUN	O
49683	and	CCONJ	O
49683	RNA	PROPN	O
49683	synthesis	NOUN	O
49683	are	VERB	O
49683	relatively	ADV	O
49683	unimpaired	ADJ	O
49683	...	PUNCT	O
49684	The	DET	O
49684	effect	NOUN	O
49684	of	ADP	O
49684	oxprenolol	NOUN	O
49684	administered	VERB	O
49684	intravenously	ADV	O
49684	(	PUNCT	O
49684	10	NUM	O
49684	and	CCONJ	O
49684	20	NUM	O
49684	mg	NOUN	O
49684	)	PUNCT	O
49684	and	CCONJ	O
49684	orally	ADV	O
49684	(	PUNCT	O
49684	20	NUM	O
49684	,	PUNCT	O
49684	40	NUM	O
49684	,	PUNCT	O
49684	80	NUM	O
49684	,	PUNCT	O
49684	and	CCONJ	O
49684	160	NUM	O
49684	mg	NOUN	O
49684	)	PUNCT	O
49684	on	ADP	O
49684	plasma	NOUN	O
49684	concentrations	NOUN	O
49684	of	ADP	O
49684	the	DET	O
49684	drug	NOUN	O
49684	,	PUNCT	O
49684	resting	VERB	O
49684	heart	NOUN	O
49684	rate	NOUN	O
49684	,	PUNCT	O
49684	exercise	NOUN	O
49684	-	PUNCT	O
49684	induced	VERB	O
49684	tachycardia	NOUN	O
49684	,	PUNCT	O
49684	and	CCONJ	O
49684	arterial	ADJ	O
49684	blood	NOUN	O
49684	pressure	NOUN	O
49684	was	VERB	O
49684	assessed	VERB	O
49684	as	ADP	O
49684	a	DET	O
49684	function	NOUN	O
49684	of	ADP	O
49684	time	NOUN	O
49684	in	ADP	O
49684	6	NUM	O
49684	healthy	ADJ	O
49684	subjects	NOUN	O
49684	.	PUNCT	O
49685	The	DET	O
49685	pharmacokinetics	NOUN	O
49685	of	ADP	O
49685	oxprenolol	NOUN	O
49685	following	VERB	O
49685	intravenous	ADJ	O
49685	administration	NOUN	O
49685	are	VERB	O
49685	best	ADV	O
49685	described	VERB	O
49685	as	ADP	O
49685	2-compartnent	ADJ	O
49685	open	ADJ	O
49685	model	NOUN	O
49685	with	ADP	O
49685	dose	NOUN	O
49685	-	PUNCT	O
49685	dependent	ADJ	O
49685	parameters	NOUN	O
49685	.	PUNCT	O
49686	The	DET	O
49686	mean	ADJ	O
49686	(	PUNCT	O
49686	+	SYM	O
49686	/-SD	PROPN	O
49686	)	PUNCT	O
49686	plasma	NOUN	O
49686	half	ADJ	O
49686	-	PUNCT	O
49686	life	NOUN	O
49686	for	ADP	O
49686	oral	ADJ	O
49686	doses	NOUN	O
49686	is	VERB	O
49686	1.94	NUM	O
49686	+	SYM	O
49686	/-	PUNCT	O
49687	0.37	NUM	O
49687	and	CCONJ	O
49687	for	ADP	O
49687	intravenous	ADJ	O
49687	doses	NOUN	O
49687	is	VERB	O
49687	2.31	NUM	O
49687	+	SYM	O
49687	/-	PUNCT	O
49688	0.64	NUM	O
49688	hr	ADP	O
49688	.	PUNCT	O
49689	After	ADP	O
49689	oral	ADJ	O
49689	administration	NOUN	O
49689	,	PUNCT	O
49689	peak	ADJ	O
49689	plasma	NOUN	O
49689	concentrations	NOUN	O
49689	are	VERB	O
49689	reached	VERB	O
49689	within	ADP	O
49689	30	NUM	O
49689	to	PART	O
49689	90	NUM	O
49689	min	NOUN	O
49689	,	PUNCT	O
49689	and	CCONJ	O
49689	the	DET	O
49689	area	NOUN	O
49689	under	ADP	O
49689	the	DET	O
49689	plasma	NOUN	O
49689	concentration	NOUN	O
49689	-	PUNCT	O
49689	time	NOUN	O
49689	curve	NOUN	O
49689	varies	VERB	O
49689	linearly	ADV	O
49689	with	ADP	O
49689	the	DET	O
49689	dose	NOUN	O
49689	.	PUNCT	O
49690	Comparison	PROPN	O
49690	of	ADP	O
49690	oral	ADJ	O
49690	and	CCONJ	O
49690	intravenous	ADJ	O
49690	data	NOUN	O
49690	reveals	VERB	O
49690	the	DET	O
49690	variation	NOUN	O
49690	in	ADP	O
49690	bioavailabilty	NOUN	O
49690	of	ADP	O
49690	orally	ADV	O
49690	administered	VERB	O
49690	oxprenolol	NOUN	O
49690	to	PART	O
49690	range	VERB	O
49690	from	ADP	O
49690	19	NUM	O
49690	%	NOUN	O
49690	to	ADP	O
49690	74	NUM	O
49690	%	NOUN	O
49690	.	PUNCT	O
49691	Unlike	ADP	O
49691	propranolol	NOUN	O
49691	,	PUNCT	O
49691	oxprenolol	NOUN	O
49691	does	VERB	O
49691	not	ADV	O
49691	show	VERB	O
49691	a	DET	O
49691	saturable	ADJ	O
49691	 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
patients 	 O 	O
with 	 O 	O
this 	 O 	O
diagnosis 	 O 	O
. 	 O 	O
The 	 O 	O
group 	 O 	O
of 	 O 	O
conditions 	 O 	O
variously 	 O 	O
termed 	 O 	O
biliary 	 O 	O
dyskinesia 	 O 	O
, 	 O 	O
acalculous 	 DISEASE 	O
cholecystitis 	 DISEASE 	DISEASE
, 	 O 	O
biliary 	 O 	O
pain 	 O 	O
without 	 O 	O
stones 	 O 	O
, 	 O 	O
or 	 O 	O
functional 	 O 	O
disorders 	 O 	O
of 	 O 	O
the 	 O 	O
biliary 	 O 	O
tract 	 O 	O
, 	 O 	O
is 	 O 	O
poorly 	 O 	O
defined 	 O 	O
clinically 	 O 	O
, 	 O 	O
and 	 O 	O
no 	 O 	O
consistent 	 O 	O
pathological 	 O 	O
abnormalities 	 O 	O
have 	 O 	O
been 	 O 	O
previously 	 O 	O
described 	 O 	O
in 	 O 	O
patients 	 O 	O
with 	 O 	O
this 	 O 	O
diagnosis 	 O 	O
. 	 O 	O
) 	 O 	O
mixed 	 DISEASE 	O
tumor 	 DISEASE 	O
previously 	 O 	O
described 	 O 	O
to 	 O 	O
occur 	 O 	O
in 	 O 	O
the 	 O 	O
uterus 	 O 	O
and 	 O 	O
designated 	 O 	O
mllerian 	 O 	O
adenosarcoma 	 O 	O
are 	 O 	O
reported 	 O 	O
. 	 O 	O
Five 	 O 	O
extrauterine 	 O 	O
examples 	 O 	O
( 	 O 	O
three 	 O 	O
pelvic 	 O 	O
and 	 O 	O
two 	 O 	O
ovarian 	 O 	O
) 	 O 	O
of 	 O 	O
a 	 O 	O
distinctive 	 O 	O
mesodermal 	 O 	O
( 	 O 	O
mllerian 	 O 	O
) 	 O 	O
mixed 	 O 	DISEASE
tumor 	 O 	O
previously 	 O 	O
described 	 O 	O
to 	 O 	O
occur 	 O 	O
in 	 O 	O
the 	 O 	O
uterus 	 O 	O
and 	 O 	O
designated 	 O 	O
mllerian 	 O 	O
adenosarcoma 	 DISEASE 	O
are 	 O 	O
reported 	 O 	O
. 	 O 	O
accumulate 	 O 	O
in 	 O 	O
abnormal 	 O 	O
histiocytes 	 O 	O
. 	 O 	O
The 	 O 	O
foam 	 O 	O
cells 	 O 	O
in 	 O 	O
Tangier 	 O 	O
disease 	 O 	O
differ 	 O 	O
morphologically 	 O 	O
from 	 O 	O
those 	 O 	O
in 	 O 	O
numerous 	 O 	O
lysosomal 	 O 	O
enzyme 	 O 	O
deficiency 	 O 	O
states 	 O 	O
, 	 O 	O
particularly 	 O 	O
Wolman 	 DISEASE 	O
's 	 DISEASE 	O
disease 	 DISEASE 	O
and 	 O 	O
cholesteryl 	 O 	O
ester 	 O 	O
stroage 	 O 	O
disease 	 O 	O
, 	 O 	O
and 	 O 	O
in 	 O 	O
proliferative 	 O 	O
diseases 	 O 	O
of 	 O 	O
the 	 O 	O
reticuloendothelial 	 O 	O
system 	 O 	O
in 	 O 	O
which 	 O 	O
cholesteryl 	 O 	O
esters 	 O 	O
also 	 O 	O
accumulate 	 O 	O
in 	 O 	O
abnormal 	 O 	O
histiocytes 	 O 	O
. 	 O 	O
for 	 O 	O
cytotoxic 	 O 	O
T 	 O 	O
- 	 O 	O
cell 	 O 	O
recognition 	 O 	O
of 	 O 	O
virus 	 O 	O
- 	 O 	O
infected 	 O 	O
cells 	 O 	O
. 	 O 	O
These 	 O 	O
results 	 O 	O
are 	 O 	O
discussed 	 O 	O
in 	 O 	O
the 	 O 	O
light 	 O 	O
of 	 O 	O
available 	 O 	O
information 	 O 	O
on 	 O 	O
influenza 	 O 	O
virus 	 O 	O
structure 	 O 	O
and 	 O 	O
the 	 O 	O
biology 	 O 	O
of 	 O 	O
influenza 	 DISEASE 	DISEASE
infection 	 O 	DISEASE
and 	 O 	O
in 	 O 	O
terms 	 O 	O
of 	 O 	O
current 	 O 	O
models 	 O 	O
for 	 O 	O
cytotoxic 	 O 	O
T 	 O 	O
- 	 O 	O
cell 	 O 	O
recognition 	 O 	O
of 	 O 	O
virus 	 O 	O
- 	 O 	O
infected 	 O 	O
cells 	 O 	O
. 	 O 	O
If 	 O 	O
, 	 O 	O
as 	 O 	O
is 	 O 	O
hoped 	 O 	O
, 	 O 	O
patients 	 O 	O
are 	 O 	O
diagnosed 	 O 	O
younger 	 O 	O
and 	 O 	O
more 	 O 	O
patients 	 O 	O
with 	 O 	O
partial 	 O 	DISEASE
deficiency 	 O 	DISEASE
are 	 O 	O
recognized 	 O 	O
, 	 O 	O
demand 	 O 	O
may 	 O 	O
soon 	 O 	O
outstrip 	 O 	O
supply 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Three 	 O 	O
French 	 O 	O
registers 	 O 	O
give 	 O 	O
similar 	 O 	O
results 	 O 	O
about 	 O 	O
the 	 O 	O
incidence 	 O 	O
of 	 O 	O
acute 	 DISEASE 	O
myocardial 	 DISEASE 	DISEASE
infarction 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
glands 	 O 	O
were 	 O 	O
lined 	 O 	O
by 	 O 	O
a 	 O 	O
variety 	 O 	O
of 	 O 	O
mllerian 	 O 	O
epithelial 	 O 	O
cell 	 O 	O
types 	 O 	O
, 	 O 	O
and 	 O 	O
the 	 O 	O
stromal 	 O 	O
element 	 O 	O
resembled 	 O 	O
endometrial 	 DISEASE 	O
stromal 	 DISEASE 	DISEASE
sarcoma 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
preliminary 	 O 	O
analysis 	 O 	O
of 	 O 	O
an 	 O 	O
RNA 	 O 	O
- 	 O 	O
directed 	 O 	O
DNA 	 O 	O
polymerase 	 O 	O
was 	 O 	O
made 	 O 	O
and 	 O 	O
a 	 O 	O
C 	 O 	O
- 	 O 	O
type 	 O 	O
virus 	 O 	O
- 	 O 	O
like 	 O 	O
particle 	 O 	O
was 	 O 	O
identified 	 O 	O
in 	 O 	O
platelets 	 O 	O
from 	 O 	O
2 	 O 	O
patients 	 O 	O
with 	 O 	O
the 	 O 	O
myeloproliferative 	 O 	O
disorder 	 O 	O
thrombocythemia 	 O 	O
( 	 O 	O
primary 	 O 	O
, 	 O 	O
essential 	 O 	DISEASE
, 	 O 	O
hemorrhagic 	 O 	O
, 	 O 	O
or 	 O 	O
idiopathic 	 O 	O
thrombocythemia 	 O 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
favorably 	 O 	O
influenced 	 O 	O
the 	 O 	O
prognosis 	 O 	O
were 	 O 	O
: 	 O 	O
small 	 O 	O
size 	 O 	O
( 	 O 	O
74 	 O 	O
% 	 O 	O
, 	 O 	O
5-year 	 O 	O
survival 	 O 	O
) 	 O 	O
, 	 O 	O
	PUNCT	O
35346	exposed	VERB	O
35346	 	 O 	O
primary 	 O 	O
site 	 O 	O
( 	 O 	O
53 	 O 	O
% 	 O 	O
, 	 O 	O
5-year 	 O 	O
survival 	 O 	O
) 	 O 	O
, 	 O 	O
and 	 O 	O
histologic 	 O 	O
type 	 O 	O
( 	 O 	O
biphasic 	 O 	O
form 	 O 	O
: 	 O 	O
55 	 O 	O
% 	 O 	O
, 	 O 	O
5-year 	 O 	O
survival 	 O 	O
and 	 O 	O
epithelioid 	 DISEASE 	O
sarcoma 	 DISEASE 	DISEASE
: 	 O 	O
58 	 O 	O
% 	 O 	O
, 	 O 	O
5-year 	 O 	O
survival 	 O 	O
) 	 O 	O
. 	 O 	O
Concerning 	 O 	O
these 	 O 	O
aspects 	 O 	O
, 	 O 	O
must 	 O 	O
be 	 O 	O
enlarged 	 O 	O
the 	 O 	O
indication 	 O 	O
of 	 O 	O
removal 	 O 	O
the 	 O 	O
bladder 	 DISEASE 	DISEASE
neck 	 DISEASE 	DISEASE
obstruction 	 DISEASE 	O
per 	 O 	O
transurethral 	 O 	O
resection 	 O 	O
, 	 O 	O
more 	 O 	O
and 	 O 	O
more 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Whether 	 O 	O
this 	 O 	O
reduced 	 O 	O
retention 	 O 	O
of 	 O 	O
chromium 	 O 	O
is 	 O 	O
causally 	 O 	O
related 	 O 	O
to 	 O 	O
diabetes 	 O 	O
in 	 O 	O
hemochromatosis 	 DISEASE 	O
and 	 O 	O
whether 	 O 	O
abnormal 	 O 	O
chromium 	 O 	O
metabolism 	 O 	O
is 	 O 	O
involved 	 O 	O
in 	 O 	O
endogenous 	 O 	O
diabetes 	 O 	O
, 	 O 	O
thus 	 O 	O
, 	 O 	O
becomes 	 O 	O
an 	 O 	O
important 	 O 	O
question 	 O 	O
for 	 O 	O
future 	 O 	O
study 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Of 	 O 	O
children 	 O 	O
under 	 O 	O
six 	 O 	O
months 	 O 	O
of 	 O 	O
age 	 O 	O
with 	 O 	O
congenital 	 O 	O
diseases 	 O 	O
such 	 O 	O
as 	 O 	O
dysplasia 	 O 	O
, 	 O 	O
cerebral 	 O 	O
defects 	 O 	O
, 	 O 	O
and 	 O 	O
hyperbilirubinemia 	 DISEASE 	O
and 	 O 	O
hepatosplenomegaly 	 O 	O
, 	 O 	O
4.2 	 O 	O
% 	 O 	O
( 	 O 	O
17/402 	 O 	O
) 	 O 	O
had 	 O 	O
BK 	 O 	O
virus 	 O 	O
- 	 O 	O
specific 	 O 	O
IgM 	 O 	O
antibodies 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
standing 	 O 	O
Graves 	 DISEASE 	DISEASE
' 	 DISEASE 	O
disease 	 DISEASE 	O
, 	 O 	O
and 	 O 	O
it 	 O 	O
is 	 O 	O
suggested 	 O 	O
that 	 O 	O
this 	 O 	O
results 	 O 	O
from 	 O 	O
concomitant 	 O 	O
chronic 	 O 	O
thyroiditis 	 O 	O
. 	 O 	O
It 	 O 	O
is 	 O 	O
concluded 	 O 	O
that 	 O 	O
progressive 	 O 	O
failure 	 O 	O
of 	 O 	O
thyroid 	 O 	O
function 	 O 	O
is 	 O 	O
a 	 O 	O
common 	 O 	O
occurence 	 O 	O
in 	 O 	O
long 	 O 	O
- 	 O 	O
standing 	 O 	O
Graves 	 O 	O
' 	 O 	O
disease 	 O 	O
, 	 O 	O
and 	 O 	O
it 	 O 	O
is 	 O 	O
suggested 	 O 	O
that 	 O 	O
this 	 O 	O
results 	 O 	O
from 	 O 	O
concomitant 	 O 	O
chronic 	 O 	O
thyroiditis 	 DISEASE 	DISEASE
. 	 O 	O
The 	 O 	O
interactions 	 O 	O
which 	 O 	O
occur 	 O 	O
between 	 O 	O
antigenic 	 O 	O
tumor 	 O 	O
cells 	 O 	O
and 	 O 	O
normal 	 O 	O
or 	 O 	O
immune 	 O 	O
lymphoid 	 O 	O
cells 	 O 	O
in 	 O 	O
a 	 O 	O
3-day 	 O 	O
in 	 O 	O
vitro 	 O 	O
culture 	 O 	O
, 	 O 	O
have 	 O 	O
been 	 O 	O
studied 	 O 	O
with 	 O 	O
a 	 O 	O
murine 	 O 	O
sarcoma 	 DISEASE 	DISEASE
virus 	 O 	O
( 	 O 	O
MSV)-induced 	 O 	DISEASE
tumor 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
comparative 	 O 	O
group 	 O 	O
of 	 O 	O
69 	 O 	O
cases 	 O 	O
with 	 O 	O
pulmonary 	 O 	O
metastases 	 O 	O
showed 	 O 	O
that 	 O 	O
neoplasms 	 O 	O
considered 	 O 	O
of 	 O 	O
embryonal 	 O 	DISEASE
type 	 O 	O
are 	 O 	O
practically 	 O 	O
always 	 O 	O
multiple 	 O 	O
and 	 O 	O
appear 	 O 	O
during 	 O 	O
the 	 O 	O
final 	 O 	O
stage 	 O 	O
of 	 O 	O
the 	 O 	O
disease 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
We 	 O 	O
agree 	 O 	O
with 	 O 	O
the 	 O 	O
view 	 O 	O
generally 	 O 	O
held 	 O 	O
that 	 O 	O
acanthosis 	 O 	O
, 	 O 	O
pseudoepitheliomatous 	 O 	O
hyperplasia 	 O 	DISEASE
, 	 O 	O
basal 	 O 	DISEASE
cell 	 O 	O
buddings 	 O 	O
, 	 O 	O
and 	 O 	O
hair 	 O 	O
follicle 	 O 	O
- 	 O 	O
like 	 O 	O
proliferations 	 O 	O
of 	 O 	O
basal 	 O 	O
cells 	 O 	O
represent 	 O 	O
reactive 	 O 	O
changes 	 O 	O
of 	 O 	O
a 	 O 	O
spectrum 	 O 	O
of 	 O 	O
epidermal 	 O 	O
alterations 	 O 	O
overlying 	 O 	O
dermatofibromas 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Our 	 O 	O
test 	 O 	O
subjects 	 O 	O
were 	 O 	O
only 	 O 	O
investigated 	 O 	O
for 	 O 	O
tuberculos 	 O 	DISEASE
infection 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Nematocysts 	 O 	O
of 	 O 	O
Actinia 	 O 	O
equina 	 O 	DISEASE
are 	 O 	O
stained 	 O 	O
black 	 O 	O
by 	 O 	O
incubation 	 O 	O
in 	 O 	O
2 	 O 	O
% 	 O 	O
CoCl2 	 O 	O
followed 	 O 	O
by 	 O 	O
an 	 O 	O
aqueous 	 O 	O
wash 	 O 	O
and 	 O 	O
H2S 	 O 	O
treatment 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
syndrome 	 O 	O
) 	 O 	O
, 	 O 	O
en 	 O 	O
plaque 	 O 	O
and 	 O 	O
en 	 O 	O
grappe 	 O 	O
endings 	 O 	O
were 	 O 	O
atrophic 	 O 	O
, 	 O 	O
though 	 O 	O
only 	 O 	O
the 	 O 	O
diffuse 	 O 	O
endings 	 O 	O
were 	 O 	O
spared 	 O 	O
. 	 O 	O
In 	 O 	O
myasthenia 	 O 	O
gravis 	 O 	O
and 	 O 	O
myasthenic 	 O 	O
syndrome 	 O 	O
( 	 O 	O
Eaton 	 DISEASE 	O
- 	 DISEASE 	O
Lambert 	 DISEASE 	O
syndrome 	 DISEASE 	O
) 	 O 	O
, 	 O 	O
en 	 O 	O
plaque 	 O 	O
and 	 O 	O
en 	 O 	O
grappe 	 O 	O
endings 	 O 	O
were 	 O 	O
atrophic 	 O 	O
, 	 O 	O
though 	 O 	O
only 	 O 	O
the 	 O 	O
diffuse 	 O 	O
endings 	 O 	O
were 	 O 	O
spared 	 O 	O
. 	 O 	O
The 	 O 	O
incidence 	 O 	O
of 	 O 	O
trophoblastic 	 O 	O
tumour 	 O 	O
requiring 	 O 	O
chemotherapy 	 O 	O
after 	 O 	O
hydatidiform 	 DISEASE 	DISEASE
mole 	 DISEASE 	O
was 	 O 	O
greatest 	 O 	O
in 	 O 	O
the 	 O 	O
30 	 O 	O
to 	 O 	O
34 	 O 	O
years 	 O 	O
age 	 O 	O
group 	 O 	O
and 	 O 	O
it 	 O 	O
was 	 O 	O
also 	 O 	O
high 	 O 	O
in 	 O 	O
the 	 O 	O
20 	 O 	O
to 	 O 	O
24 	 O 	O
years 	 O 	O
age 	 O 	O
group 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Furthermore 	 O 	O
, 	 O 	O
they 	 O 	O
had 	 O 	O
multiple 	 O 	DISEASE
enlarged 	 O 	O
parathyroid 	 O 	O
glands 	 O 	O
and 	 O 	O
recurrence 	 O 	O
of 	 O 	O
the 	 O 	O
disease 	 O 	O
significantly 	 O 	O
more 	 O 	O
often 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
drug 	 O 	O
abuse 	 O 	O
) 	 O 	O
disorder 	 O 	O
. 	 O 	O
SSS 	 O 	O
scores 	 O 	O
were 	 O 	O
not 	 O 	O
related 	 O 	O
to 	 O 	O
general 	 O 	O
psychopathology 	 O 	O
, 	 O 	O
unipolar 	 O 	O
depression 	 O 	O
, 	 O 	O
schizophrenia 	 O 	O
, 	 O 	O
or 	 O 	O
neurosis 	 O 	O
, 	 O 	O
but 	 O 	O
were 	 O 	O
found 	 O 	O
to 	 O 	O
be 	 O 	O
elevated 	 O 	O
in 	 O 	O
persons 	 O 	O
reporting 	 O 	O
a 	 O 	O
history 	 O 	O
of 	 O 	O
manic 	 O 	O
- 	 O 	O
depressive 	 O 	O
or 	 O 	O
sociopathic 	 O 	O
spectrum 	 O 	O
( 	 O 	O
including 	 O 	O
alcoholism 	 DISEASE 	O
and 	 O 	O
drug 	 O 	DISEASE
abuse 	 O 	DISEASE
) 	 O 	O
disorder 	 O 	O
. 	 O 	O
evidence 	 O 	O
of 	 O 	O
an 	 O 	O
inverse 	 O 	O
relationship 	 O 	O
between 	 O 	O
plasma 	 O 	O
high 	 O 	O
- 	 O 	O
density 	 O 	O
lipoprotein 	 O 	O
cholesterol 	 O 	O
level 	 O 	O
and 	 O 	O
frequency 	 O 	O
of 	 O 	O
coronary 	 DISEASE 	O
heart 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
, 	 O 	O
we 	 O 	O
determined 	 O 	O
concentrations 	 O 	O
of 	 O 	O
fasting 	 O 	O
plasma 	 O 	O
cholesterol 	 O 	O
, 	 O 	O
triglyceride 	 O 	O
, 	 O 	O
and 	 O 	O
lipoproteins 	 O 	O
in 	 O 	O
41 	 O 	O
very 	 O 	O
active 	 O 	O
men 	 O 	O
( 	 O 	O
running 	 O 	O
greater 	 O 	O
than 	 O 	O
15 	 O 	O
miles 	 O 	O
/ 	 O 	O
wk 	 O 	O
for 	 O 	O
the 	 O 	O
previous 	 O 	O
year 	 O 	O
) 	 O 	O
new 	 O 	O
bivalent 	 O 	DISEASE
influenza 	 DISEASE 	DISEASE
subunit 	 O 	O
vaccine 	 O 	O
, 	 O 	O
Sandovac 	 O 	O
, 	 O 	O
it 	 O 	O
was 	 O 	O
given 	 O 	O
in 	 O 	O
two 	 O 	O
different 	 O 	O
concentrations 	 O 	O
( 	 O 	O
1000 	 O 	O
and 	 O 	O
2000 	 O 	O
IU 	 O 	O
) 	 O 	O
to 	 O 	O
156 	 O 	O
subjects 	 O 	O
from 	 O 	O
two 	 O 	O
epidemiologically 	 O 	O
destinct 	 O 	O
areas 	 O 	O
( 	 O 	O
119 	 O 	O
students 	 O 	O
from 	 O 	O
Essen 	 O 	O
, 	 O 	O
average 	 O 	O
age 	 O 	O
22 	 O 	O
years 	 O 	O
, 	 O 	O
37 	 O 	O
residents 	 O 	O
from 	 O 	O
Kassel 	 O 	O
average 	 O 	O
age 	 O 	O
56 	 O 	O
years 	 O 	O
) 	 O 	O
. 	 O 	O
Aplastic 	 DISEASE 	O
anemia 	 DISEASE 	DISEASE
and 	 O 	O
two 	 O 	O
types 	 O 	O
of 	 O 	O
preleukemia 	 O 	O
could 	 O 	O
be 	 O 	O
distinguished 	 O 	O
by 	 O 	O
a 	 O 	O
different 	 O 	O
growth 	 O 	O
pattern 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
There 	 O 	O
is 	 O 	O
an 	 O 	O
unexpectedly 	 O 	O
small 	 O 	O
dependence 	 O 	DISEASE
on 	 O 	O
cell 	 O 	O
concentration 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
These 	 O 	O
findings 	 O 	O
suggest 	 O 	O
that 	 O 	O
demyelination 	 O 	O
of 	 O 	O
TMEV 	 O 	DISEASE
infection 	 O 	O
is 	 O 	O
immune 	 O 	O
mediated 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
disinfecting 	 O 	O
effect 	 O 	O
on 	 O 	O
microbes 	 O 	DISEASE
growing 	 O 	O
in 	 O 	O
End 	 O 	O
's 	 O 	O
agar 	 O 	O
and 	 O 	O
in 	 O 	O
blood 	 O 	O
agar 	 O 	O
with 	 O 	O
crystal 	 O 	O
violet 	 O 	O
was 	 O 	O
manifested 	 O 	O
only 	 O 	O
after 	 O 	O
adding 	 O 	O
dried 	 O 	O
liquid 	 O 	O
manure 	 O 	O
of 	 O 	O
pigs 	 O 	O
with 	 O 	O
paraformaldehyde 	 O 	O
foam 	 O 	O
at 	 O 	O
a 	 O 	O
volume 	 O 	O
ratio 	 O 	O
of 	 O 	O
50 	 O 	O
% 	 O 	O
to 	 O 	O
50 	 O 	O
% 	 O 	O
after 	 O 	O
exposure 	 O 	O
times 	 O 	O
of 	 O 	O
1 	 O 	O
, 	 O 	O
3 	 O 	O
and 	 O 	O
6.0 	 O 	O
weeks 	 O 	O
. 	 O 	O
Giant 	 DISEASE 	O
cell 	 DISEASE 	DISEASE
tumor 	 DISEASE 	O
of 	 O 	O
the 	 O 	O
tendon 	 O 	O
sheath 	 O 	O
is 	 O 	O
the 	 O 	O
second 	 O 	O
most 	 O 	O
common 	 O 	O
tumor 	 O 	O
of 	 O 	O
the 	 O 	O
fingers 	 O 	O
and 	 O 	O
hands 	 O 	O
but 	 O 	O
is 	 O 	O
only 	 O 	O
rarely 	 O 	O
mentioned 	 O 	O
in 	 O 	O
the 	 O 	O
dermatologic 	 O 	O
literature 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
neural 	 O 	O
	PUNCT	O
50070	component	NOUN	O
50070	.	PUNCT	O
50071	Preparation	NOUN	O
50071	and	CCONJ	O
50071	incubation	NOUN	O
50071	of	ADP	O
50071	renal	ADJ	O
50071	cortical	ADJ	O
50071	slices	NOUN	O
50071	from	ADP	O
50071	adult	NOUN	O
50071	,	PUNCT	O
50071	female	ADJ	O
50071	,	PUNCT	O
50071	New	PROPN	O
50071	Zealand	PROPN	O
50071	white	ADJ	O
50071	rabbit	NOUN	O
50071	depleted	VERB	O
50071	tissue	NOUN	O
50071	citrate	ADJ	O
50071	concentration	NOUN	O
50071	.	PUNCT	O
50072	Acetate	PROPN	O
50072	(	PUNCT	O
50072	10.0	NUM	O
50072	mM	PROPN	O
50072	)	PUNCT	O
50072	in	ADP	O
50072	the	DET	O
50072	incubation	NOUN	O
50072	significantly	ADV	O
50072	increased	VERB	O
50072	slice	NOUN	O
50072	citrate	ADJ	O
50072	concentration	NOUN	O
50072	and	CCONJ	O
50072	p	NOUN	O
50072	-	PUNCT	O
50072	aminohippurate	NOUN	O
50072	(	PUNCT	O
50072	PAH	NOUN	O
50072	)	PUNCT	O
50072	accumulation	NOUN	O
50072	.	PUNCT	O
50073	Physiological	ADJ	O
50073	concentrations	NOUN	O
50073	of	ADP	O
50073	citrate	NOUN	O
50073	increased	VERB	O
50073	PAH	NOUN	O
50073	accumulation	NOUN	O
50073	and	CCONJ	O
50073	final	ADJ	O
50073	medium	ADJ	O
50073	pH.	NOUN	O
50073	increasing	VERB	O
50073	concentrations	NOUN	O
50073	of	ADP	O
50073	citrate	NOUN	O
50073	produced	VERB	O
50073	a	DET	O
50073	biphasic	ADJ	O
50073	effect	NOUN	O
50073	on	ADP	O
50073	PAH	PROPN	O
50073	accumulation	NOUN	O
50073	.	PUNCT	O
50074	These	DET	O
50074	data	NOUN	O
50074	suggested	VERB	O
50074	that	ADP	O
50074	citrate	NOUN	O
50074	may	VERB	O
50074	act	VERB	O
50074	as	ADP	O
50074	an	DET	O
50074	intracellular	ADJ	O
50074	modulator	NOUN	O
50074	of	ADP	O
50074	organic	ADJ	O
50074	anion	NOUN	O
50074	transport	NOUN	O
50074	.	PUNCT	O
50075	This	DET	O
50075	hypothesis	NOUN	O
50075	was	VERB	O
50075	tested	VERB	O
50075	with	ADP	O
50075	other	ADJ	O
50075	stimulators	NOUN	O
50075	of	ADP	O
50075	PAH	PROPN	O
50075	accumulation	NOUN	O
50075	.	PUNCT	O
50076	Physiological	ADJ	O
50076	concentrations	NOUN	O
50076	of	ADP	O
50076	alpha	NOUN	O
50076	-	PUNCT	O
50076	ketoglutarate	VERB	O
50076	or	CCONJ	O
50076	succinate	VERB	O
50076	increased	VERB	O
50076	slice	NOUN	O
50076	accumulation	NOUN	O
50076	of	ADP	O
50076	PAH	PROPN	O
50076	.	PUNCT	O
50077	Higher	ADJ	O
50077	concentrations	NOUN	O
50077	of	ADP	O
50077	either	DET	O
50077	substrate	NOUN	O
50077	significantly	ADV	O
50077	inhibited	VERB	O
50077	PAH	PROPN	O
50077	accumulation	NOUN	O
50077	.	PUNCT	O
50078	Final	ADJ	O
50078	medium	NOUN	O
50078	pH	PROPN	O
50078	increased	VERB	O
50078	with	ADP	O
50078	increased	VERB	O
50078	medium	ADJ	O
50078	concentration	NOUN	O
50078	of	ADP	O
50078	both	DET	O
50078	substrates	NOUN	O
50078	.	PUNCT	O
50079	alpha	NOUN	O
50079	-	PUNCT	O
50079	Ketoglutarate	PROPN	O
50079	(	PUNCT	O
50079	0.5	NUM	O
50079	mM	PROPN	O
50079	)	PUNCT	O
50079	increased	VERB	O
50079	PAH	PROPN	O
50079	accumulation	NOUN	O
50079	but	CCONJ	O
50079	had	VERB	O
50079	no	DET	O
50079	effect	NOUN	O
50079	on	ADP	O
50079	slice	NOUN	O
50079	citrate	ADJ	O
50079	concentration	NOUN	O
50079	.	PUNCT	O
50080	Glucose	PROPN	O
50080	did	VERB	O
50080	not	ADV	O
50080	alter	VERB	O
50080	either	CCONJ	O
50080	PAH	PROPN	O
50080	accumulation	NOUN	O
50080	or	CCONJ	O
50080	slice	NOUN	O
50080	citrate	ADJ	O
50080	concentration	NOUN	O
50080	.	PUNCT	O
50081	Slices	NOUN	O
50081	incubated	VERB	O
50081	without	ADP	O
50081	substrate	NOUN	O
50081	were	VERB	O
50081	depleted	VERB	O
50081	of	ADP	O
50081	citrate	NOUN	O
50081	but	CCONJ	O
50081	not	ADV	O
50081	of	ADP	O
50081	alpha	NOUN	O
50081	-	PUNCT	O
50081	ketoglutarate	VERB	O
50081	.	PUNCT	O
50082	Acetate	NOUN	O
50082	(	PUNCT	O
50082	1.0	NUM	O
50082	mM	PROPN	O
50082	)	PUNCT	O
50082	significantly	ADV	O
50082	increased	VERB	O
50082	slice	NOUN	O
50082	concentration	NOUN	O
50082	of	ADP	O
50082	both	CCONJ	O
50082	alpha	NOUN	O
50082	-	PUNCT	O
50082	ketoglutarate	VERB	O
50082	and	CCONJ	O
50082	citrate	ADJ	O
50082	.	PUNCT	O
50083	These	DET	O
50083	data	NOUN	O
50083	suggested	VERB	O
50083	that	ADP	O
50083	organic	ADJ	O
50083	anion	NOUN	O
50083	transport	NOUN	O
50083	could	VERB	O
50083	be	VERB	O
50083	modulated	VERB	O
50083	by	ADP	O
50083	several	ADJ	O
50083	metabolic	NOUN	O
50083	intermediates	NOUN	O
50083	acting	VERB	O
50083	through	ADP	O
50083	similar	ADJ	O
50083	but	CCONJ	O
50083	separate	ADJ	O
50083	mechanisms	NOUN	O
50083	.	PUNCT	O
50084	Potassium	NOUN	O
50084	sorbate	NOUN	O
50084	,	PUNCT	O
50084	sodium	NOUN	O
50084	benzoate	NOUN	O
50084	,	PUNCT	O
50084	sulfur	NOUN	O
50084	dioxide	NOUN	O
50084	,	PUNCT	O
50084	and	CCONJ	O
50084	diethylpyrocarbonate	VERB	O
50084	(	PUNCT	O
50084	DEPC	PROPN	O
50084	)	PUNCT	O
50084	were	VERB	O
50084	tested	VERB	O
50084	for	ADP	O
50084	their	ADJ	O
50084	effectiveness	NOUN	O
50084	in	ADP	O
50084	preventing	VERB	O
50084	the	DET	O
50084	outgrowth	NOUN	O
50084	of	ADP	O
50084	Byssochlamys	PROPN	O
50084	nivea	NOUN	O
50084	Westling	VERB	O
50084	ascospores	NOUN	O
50084	.	PUNCT	O
50085	Sulfur	NOUN	O
50085	dioxide	NOUN	O
50085	was	VERB	O
50085	the	DET	O
50085	most	ADV	O
50085	inhibitory	ADJ	O
50085	of	ADP	O
50085	the	DET	O
50085	test	NOUN	O
50085	antimycotics	NOUN	O
50085	,	PUNCT	O
50085	complete	ADJ	O
50085	inhibition	NOUN	O
50085	of	ADP	O
50085	colony	NOUN	O
50085	formation	NOUN	O
50085	occuring	NOUN	O
50085	in	PART	O
50085	acidified	VERB	O
50085	(	PUNCT	O
50085	pH	VERB	O
50085	3.5	NUM	O
50085	)	PUNCT	O
50085	potato	NOUN	O
50085	dextrose	NOUN	O
50085	agar	NOUN	O
50085	containing	VERB	O
50085	50	NUM	O
50085	ppm	NOUN	O
50085	of	ADP	O
50085	the	DET	O
50085	preservative	NOUN	O
50085	.	PUNCT	O
50086	Complete	ADJ	O
50086	inhibition	NOUN	O
50086	of	ADP	O
50086	B.	PROPN	O
50086	nivea	NOUN	O
50086	ascospore	NOUN	O
50086	outgrowth	NOUN	O
50086	in	ADP	O
50086	grape	NOUN	O
50086	juice	NOUN	O
50086	stored	VERB	O
50086	for	ADP	O
50086	60	NUM	O
50086	days	NOUN	O
50086	was	VERB	O
50086	noted	VERB	O
50086	in	ADP	O
50086	the	DET	O
50086	presence	NOUN	O
50086	of	ADP	O
50086	300	NUM	O
50086	ppm	NUM	O
50086	sulfur	NOUN	O
50086	dioxide	NOUN	O
50086	,	PUNCT	O
50086	400	NUM	O
50086	ppm	NOUN	O
50086	potassium	NOUN	O
50086	sorbate	NOUN	O
50086	,	PUNCT	O
50086	and	CCONJ	O
50086	600	NUM	O
50086	ppm	NOUN	O
50086	DEPC	PROPN	O
50086	.	PUNCT	O
50087	Growth	PROPN	O
50087	was	VERB	O
50087	observed	VERB	O
50087	in	ADP	O
50087	grape	NOUN	O
50087	juice	NOUN	O
50087	containing	VERB	O
50087	1000	NUM	O
50087	ppm	NOUN	O
50087	sodium	NOUN	O
50087	benzoate	NOUN	O
50087	.	PUNCT	O
50088	The	DET	O
50088	presence	NOUN	O
50088	of	ADP	O
50088	up	ADP	O
50088	to	PART	O
50088	100	NUM	O
50088	ppm	NOUN	O
50088	potassium	NOUN	O
50088	sorbate	NOUN	O
50088	in	ADP	O
50088	grape	NOUN	O
50088	juice	NOUN	O
50088	during	ADP	O
50088	heat	NOUN	O
50088	activation	NOUN	O
50088	appears	VERB	O
50088	to	PART	O
50088	have	VERB	O
50088	a	DET	O
50088	stimulatory	ADJ	O
50088	effect	NOUN	O
50088	on	ADP	O
50088	breaking	VERB	O
50088	dormancy	NOUN	O
50088	,	PUNCT	O
50088	while	ADP	O
50088	the	DET	O
50088	other	ADJ	O
50088	test	NOUN	O
50088	preservatives	NOUN	O
50088	at	ADP	O
50088	this	DET	O
50088	concentration	NOUN	O
50088	decrease	VERB	O
50088	the	DET	O
50088	heat	NOUN	O
50088	resistance	NOUN	O
50088	of	ADP	O
50088	B.	PROPN	O
50088	nivea	NOUN	O
50088	ascospores	NOUN	O
50088	.	PUNCT	O
50089	The	DET	O
50089	time	NOUN	O
50089	elapsed	VERB	O
50089	between	ADP	O
50089	heat	NOUN	O
50089	shock	NOUN	O
50089	and	CCONJ	O
50089	exposure	NOUN	O
50089	to	ADP	O
50089	DEPC	PROPN	O
50089	or	CCONJ	O
50089	sodium	NOUN	O
50089	benzoate	NOUN	O
50089	is	VERB	O
50089	critical	ADJ	O
50089	with	ADP	O
50089	respect	NOUN	O
50089	to	ADP	O
50089	the	DET	O
50089	sensitivity	NOUN	O
50089	of	ADP	O
50089	ascospores	NOUN	O
50089	to	ADP	O
50089	these	DET	O
50089	preservatives	NOUN	O
50089	.	PUNCT	O
50090	Male	ADJ	O
50090	and	CCONJ	O
50090	female	ADJ	O
50090	virgin	NOUN	O
50090	rats	NOUN	O
50090	and	CCONJ	O
50090	breeder	NOUN	O
50090	rats	NOUN	O
50090	with	ADP	O
50090	naturally	ADV	O
50090	-	PUNCT	O
50090	occurring	VERB	O
50090	diabetes	NOUN	O
50090	,	PUNCT	O
50090	hypertension	NOUN	DISEASE
50090	and	CCONJ	O
50090	arteriosclerosis	NOUN	O
50090	,	PUNCT	O
50090	were	VERB	O
50090	made	VERB	O
50090	severely	ADV	O
50090	diabetic	ADJ	O
50090	with	ADP	O
50090	a	DET	O
50090	single	ADJ	O
50090	,	PUNCT	O
50090	subcutaneous	ADJ	O
50090	injection	NOUN	O
50090	of	ADP	O
50090	alloxan	NOUN	O
50090	(	PUNCT	O
50090	10	NUM	O
50090	mg/100	NOUN	O
50090	g	NOUN	O
50090	b.w	PROPN	O
50090	.	PUNCT	O
50090	)	PUNCT	O
50090	,	PUNCT	O
50090	after	ADP	O
50090	an	DET	O
50090	18	NUM	O
50090	h	NOUN	O
50090	fast	ADV	O
50090	.	PUNCT	O
50090	Male	ADJ	O
50090	and	CCONJ	O
50090	female	ADJ	O
50090	virgin	NOUN	O
50090	rats	NOUN	O
50090	and	CCONJ	O
50090	breeder	NOUN	O
50090	rats	NOUN	O
50090	with	ADP	O
50090	naturally	ADV	O
50090	-	PUNCT	O
50090	occurring	VERB	O
50090	diabetes	NOUN	O
50090	,	PUNCT	O
50090	hypertension	NOUN	O
50090	and	CCONJ	O
50090	arteriosclerosis	NOUN	DISEASE
50090	,	PUNCT	O
50090	were	VERB	O
50090	made	VERB	O
50090	severely	ADV	O
50090	diabetic	ADJ	O
50090	with	ADP	O
50090	a	DET	O
50090	single	ADJ	O
50090	,	PUNCT	O
50090	subcutaneous	ADJ	O
50090	injection	NOUN	O
50090	of	ADP	O
50090	alloxan	NOUN	O
50090	(	PUNCT	O
50090	10	NUM	O
50090	mg/100	NOUN	O
50090	g	NOUN	O
50090	b.w	PROPN	O
50090	.	PUNCT	O
50090	)	PUNCT	O
50090	,	PUNCT	O
50090	after	ADP	O
50090	an	DET	O
50090	18	NUM	O
50090	h	NOUN	O
50090	fast	ADV	O
50090	.	PUNCT	O
50091	During	ADP	O
50091	five	NUM	O
50091	months	NOUN	O
50091	of	ADP	O
50091	unrelenting	ADJ	O
50091	diabetes	NOUN	O
50091	,	PUNCT	O
50091	some	DET	O
50091	animals	NOUN	O
50091	became	VERB	O
50091	obese	ADJ	O
50091	while	ADP	O
50091	others	NOUN	O
50091	became	VERB	O
50091	emaciated	VERB	O
50091	.	PUNCT	O
50092	Only	ADV	O
50092	the	DET	O
50092	emaciated	VERB	O
50092	animals	NOUN	O
50092	survived	VERB	O
50092	but	CCONJ	O
50092	they	PRON	O
50092	were	VERB	O
50092	blind	ADJ	O
50092	,	PUNCT	O
50092	their	ADJ	O
50092	adrenal	ADJ	O
50092	glands	NOUN	O
50092	were	VERB	O
50092	hemorrhagic	ADJ	O
50092	,	PUNCT	O
50092	hypertrophied	ADJ	O
50092	and	CCONJ	O
50092	thrombosed	ADJ	O
50092	,	PUNCT	O
50092	thymi	NOUN	O
50092	involuted	VERB	O
50092	,	PUNCT	O
50092	kidneys	NOUN	O
50092	swollen	ADJ	O
50092	,	PUNCT	O
50092	hearts	NOUN	O
50092	reduced	VERB	O
50092	in	ADP	O
50092	size	NOUN	O
50092	while	ADP	O
50092	testes	NOUN	O
50092	and	CCONJ	O
50092	ovaries	NOUN	O
50092	were	VERB	O
50092	atrophic	ADJ	O
50092	.	PUNCT	O
50093	Serum	PROPN	O
50093	CPK	PROPN	O
50093	,	PUNCT	O
50093	SGOT	PROPN	O
50093	and	CCONJ	O
50093	SGPT	PROPN	O
50093	were	VERB	O
50093	elevated	ADJ	O
50093	concomitant	ADJ	O
50093	with	ADP	O
50093	extensive	ADJ	O
50093	cardiovascular	ADJ	O
50093	damage	NOUN	O
50093	,	PUNCT	O
50093	hepatic	ADJ	O
50093	steatosis	NOUN	O
50093	and	CCONJ	O
50093	generalized	VERB	O
50093	catabolism	NOUN	O
50093	.	PUNCT	O
50094	Circulating	VERB	O
50094	triglycerides	NOUN	O
50094	and	CCONJ	O
50094	free	ADJ	O
50094	fatty	ADJ	O
50094	acids	NOUN	O
50094	were	VERB	O
50094	markedly	ADV	O
50094	elevated	ADJ	O
50094	with	ADP	O
50094	total	ADJ	O
50094	cholesterol	NOUN	O
50094	only	ADV	O
50094	slightly	ADV	O
50094	increased	VERB	O
50094	.	PUNCT	O
50095	BUN	NOUN	O
50095	and	CCONJ	O
50095	serum	VERB	O
50095	calcium	NOUN	O
50095	levels	NOUN	O
50095	were	VERB	O
50095	also	ADV	O
50095	greatly	ADV	O
50095	elevated	ADJ	O
50095	.	PUNCT	O
50096	Sub	NOUN	O
50096	-	PUNCT	O
50096	normal	ADJ	O
50096	Cmpd	PROPN	DISEASE
50096	.	PUNCT	O
50096	B	NOUN	O
50096	levels	NOUN	O
50096	indicated	VERB	O
50096	impaired	ADJ	O
50096	adrenal	ADJ	O
50096	steroidogenesis	NOUN	O
50096	.	PUNCT	O
50097	Virgin	PROPN	O
50097	rats	NOUN	O
50097	developed	VERB	O
50097	arteriosclerosis	NOUN	DISEASE
50097	and	CCONJ	O
50097	male	ADJ	O
50097	and	CCONJ	O
50097	female	ADJ	O
50097	breeder	NOUN	O
50097	rats	NOUN	O
50097	showed	VERB	O
50097	exacerbation	NOUN	O
50097	of	ADP	O
50097	their	ADJ	O
50097	pre	ADJ	O
50097	-	PUNCT	O
50097	existing	VERB	O
50097	aortic	ADJ	O
50097	sclerosis	NOUN	O
50097	as	ADV	O
50097	well	ADV	O
50097	as	ADP	O
50097	P.A.N.	PROPN	O
50097	lesions	VERB	O
50097	in	ADP	O
50097	their	ADJ	O
50097	small	ADJ	O
50097	-	PUNCT	O
50097	sized	ADJ	O
50097	arteries	NOUN	O
50097	.	PUNCT	O
50098	It	PRON	O
50098	is	VERB	O
50098	believed	VERB	O
50098	that	ADP	O
50098	severe	ADJ	O
50098	diabetes	NOUN	O
50098	causes	NOUN	O
50098	exacerbation	NOUN	O
50098	of	ADP	O
50098	the	DET	O
50098	endogenous	ADJ	O
50098	hormonal	ADJ	O
50098	milieu	NOUN	O
50098	resulting	VERB	O
50098	from	ADP	O
50098	abnormal	ADJ	O
50098	hypothalamic	ADJ	O
50098	-	PUNCT	O
50098	pituitary	ADJ	O
50098	-	PUNCT	O
50098	adrenal	ADJ	O
50098	function	NOUN	O
50098	induced	VERB	O
50098	by	ADP	O
50098	repeated	VERB	O
50098	breeding	NOUN	O
50098	,	PUNCT	O
50098	which	ADJ	O
50098	conditions	VERB	O
50098	the	DET	O
50098	connective	ADJ	O
50098	tissue	NOUN	O
50098	components	NOUN	O
50098	of	ADP	O
50098	the	DET	O
50098	arterial	ADJ	O
50098	wall	NOUN	O
50098	of	ADP	O
50098	rats	NOUN	O
50098	toward	ADP	O
50098	accelerated	VERB	O
50098	degenerative	ADJ	O
50098	changes	NOUN	O
50098	.	PUNCT	O
50099	Alterations	NOUN	O
50099	of	ADP	O
50099	red	ADJ	O
50099	cell	NOUN	O
50099	pH	PROPN	O
50099	(	PUNCT	O
50099	pHc	CCONJ	O
50099	)	PUNCT	O
50099	and	CCONJ	O
50099	distribution	NOUN	O
50099	ratios	NOUN	O
50099	of	ADP	O
50099	H+	PROPN	O
50099	(	PUNCT	O
50099	gammaH+	PROPN	O
50099	)	PUNCT	O
50099	and	CCONJ	O
50099	Cl	PROPN	O
50099	(	PUNCT	O
50099	gammaCl-	PROPN	O
50099	)	PUNCT	O
50099	between	ADP	O
50099	plasma	NOUN	O
50099	and	CCONJ	O
50099	red	ADJ	O
50099	blood	NOUN	O
50099	cells	NOUN	O
50099	with	ADP	O
50099	oxygenation	NOUN	O
50099	of	ADP	O
50099	blood	NOUN	O
50099	were	VERB	O
50099	studied	VERB	O
50099	in	ADP	O
50099	human	ADJ	O
50099	blood	NOUN	O
50099	(	PUNCT	O
50099	audult	NOUN	O
50099	and	CCONJ	O
50099	fetal	ADJ	O
50099	)	PUNCT	O
50099	and	CCONJ	O
50099	ruminant	NOUN	O
50099	blood	NOUN	O
50099	(	PUNCT	O
50099	bovine	NOUN	O
50099	,	PUNCT	O
50099	goat	NOUN	O
50099	and	CCONJ	O
50099	sheep	NOUN	O
50099	)	PUNCT	O
50099	.	PUNCT	O
50100	The	DET	O
50100	experiments	NOUN	O
50100	were	VERB	O
50100	carried	VERB	O
50100	out	PART	O
50100	at	ADP	O
50100	a	DET	O
50100	plasma	NOUN	O
50100	pH	PROPN	O
50100	of	ADP	O
50100	7.0	NUM	O
50100	to	ADP	O
50100	7.7	NUM	O
50100	and	CCONJ	O
50100	at	ADP	O
50100	37	NUM	O
50100	degrees	NOUN	O
50100	C.	PROPN	O
50101	In	ADP	O
50101	human	ADJ	O
50101	blood	NOUN	O
50101	pHc	ADJ	O
50101	of	ADP	O
50101	fully	ADV	O
50101	oxygenated	ADJ	O
50101	blood	NOUN	O
50101	was	VERB	O
50101	0.035	NUM	O
50101	pH	VERB	O
50101	lower	ADJ	O
50101	than	ADP	O
50101	that	DET	O
50101	of	ADP	O
50101	fully	ADV	O
50101	deoxygenated	VERB	O
50101	blood	NOUN	O
50101	in	ADP	O
50101	all	DET	O
50101	ranges	NOUN	O
50101	of	ADP	O
50101	plasma	NOUN	O
50101	pH	NOUN	O
50101	studied	VERB	O
50101	.	PUNCT	O
50102	In	ADP	O
50102	ruminant	NOUN	O
50102	blood	NOUN	O
50102	,	PUNCT	O
50102	however	ADV	O
50102	,	PUNCT	O
50102	the	DET	O
50102	differences	NOUN	O
50102	in	ADP	O
50102	pHc	ADJ	O
50102	between	ADP	O
50102	oxygenated	ADJ	O
50102	and	CCONJ	O
50102	deoxygenated	ADJ	O
50102	blood	NOUN	O
50102	were	VERB	O
50102	0.011	NUM	O
50102	in	ADP	O
50102	ox	NOUN	O
50102	,	PUNCT	O
50102	and	CCONJ	O
50102	0.003	NUM	O
50102	in	ADP	O
50102	goat	NOUN	O
50102	and	CCONJ	O
50102	sheep	NOUN	O
50102	,	PUNCT	O
50102	all	DET	O
50102	of	ADP	O
50102	them	PRON	O
50102	not	ADV	O
50102	being	VERB	O
50102	significant	ADJ	O
50102	.	PUNCT	O
50103	The	DET	O
50103	decreases	NOUN	O
50103	in	ADP	O
50103	gammaH+	ADJ	O
50103	accompanying	VERB	O
50103	oxygenation	NOUN	O
50103	were	VERB	O
50103	in	ADP	O
50103	fairly	ADV	O
50103	good	ADJ	O
50103	agreement	NOUN	O
50103	with	ADP	O
50103	those	DET	O
50103	in	ADP	O
50103	gammaCl-	NOUN	O
50103	in	ADP	O
50103	human	ADJ	O
50103	blood	NOUN	O
50103	and	CCONJ	O
50103	amounted	VERB	O
50103	to	ADP	O
50103	about	ADV	O
50103	0.05	NUM	O
50103	.	PUNCT	O
50104	In	ADP	O
50104	ruminant	NOUN	O
50104	blood	NOUN	O
50104	,	PUNCT	O
50104	in	ADP	O
50104	spite	NOUN	O
50104	of	ADP	O
50104	virtually	ADV	O
50104	zero	NUM	O
50104	changes	NOUN	O
50104	in	ADP	O
50104	gammaH+	ADJ	O
50104	with	ADP	O
50104	oxygenation	NOUN	O
50104	,	PUNCT	O
50104	the	DET	O
50104	decreases	NOUN	O
50104	in	ADP	O
50104	gammaCl-	PROPN	O
50104	were	VERB	O
50104	slightly	ADV	O
50104	greater	ADJ	O
50104	than	ADP	O
50104	those	DET	O
50104	in	ADP	O
50104	human	ADJ	O
50104	blood	NOUN	O
50104	.	PUNCT	O
50105	There	ADV	O
50105	might	VERB	O
50105	be	VERB	O
50105	a	DET	O
50105	species	NOUN	O
50105	difference	NOUN	O
50105	in	ADP	O
50105	the	DET	O
50105	mechanisms	NOUN	O
50105	of	ADP	O
50105	distribution	NOUN	O
50105	of	ADP	O
50105	Cl-	PROPN	O
50105	and	CCONJ	O
50105	H+	PROPN	O
50105	across	ADP	O
50105	the	DET	O
50105	red	ADJ	O
50105	cell	NOUN	O
50105	membrane	NOUN	O
50105	.	PUNCT	O
50106	Forty	NUM	O
50106	naive	ADJ	O
50106	male	NOUN	O
50106	albino	ADJ	O
50106	rats	NOUN	O
50106	were	VERB	O
50106	trained	VERB	O
50106	to	PART	O
50106	press	VERB	O
50106	a	DET	O
50106	bar	NOUN	O
50106	on	ADP	O
50106	a	DET	O
50106	fixed	VERB	O
50106	-	PUNCT	O
50106	ratio	NOUN	O
50106	(	PUNCT	O
50106	FR	PROPN	O
50106	32	NUM	O
50106	)	PUNCT	O
50106	schedule	NOUN	O
50106	of	ADP	O
50106	water	NOUN	O
50106	reinforcement	NOUN	O
50106	.	PUNCT	O
50107	They	PRON	O
50107	were	VERB	O
50107	then	ADV	O
50107	divided	VERB	O
50107	into	ADP	O
50107	two	NUM	O
50107	groups	NOUN	O
50107	,	PUNCT	O
50107	one	NUM	O
50107	of	ADP	O
50107	which	ADJ	O
50107	(	PUNCT	O
50107	N	NOUN	O
50107	=	SYM	O
50107	20	NUM	O
50107	)	PUNCT	O
50107	received	VERB	O
50107	5	NUM	O
50107	min	NOUN	O
50107	of	ADP	O
50107	extra	ADJ	O
50107	water	NOUN	O
50107	12	NUM	O
50107	hr	ADP	O
50107	before	ADP	O
50107	each	DET	O
50107	experimental	ADJ	O
50107	session	NOUN	O
50107	;	PUNCT	O
50107	the	DET	O
50107	other	ADJ	O
50107	group	NOUN	O
50107	(	PUNCT	O
50107	N	PROPN	O
50107	=	SYM	O
50107	20	NUM	O
50107	)	PUNCT	O
50107	received	VERB	O
50107	no	DET	O
50107	extra	ADJ	O
50107	water	NOUN	O
50107	.	PUNCT	O
50108	Half	NOUN	O
50108	of	ADP	O
50108	the	DET	O
50108	animals	NOUN	O
50108	in	ADP	O
50108	each	DET	O
50108	group	NOUN	O
50108	was	VERB	O
50108	given	VERB	O
50108	three	NUM	O
50108	daily	ADJ	O
50108	doses	NOUN	O
50108	(	PUNCT	O
50108	100	NUM	O
50108	mg	NOUN	O
50108	/	SYM	O
50108	kg	PROPN	O
50108	)	PUNCT	O
50108	of	ADP	O
50108	the	DET	O
50108	trytophan	ADJ	O
50108	hydroxylase	NOUN	O
50108	inhibitor	NOUN	O
50108	p	NOUN	O
50108	-	PUNCT	O
50108	chlorophenylalanine	NOUN	O
50108	methyl	NOUN	O
50108	ester	NOUN	O
50108	(	PUNCT	O
50108	PCPA	PROPN	O
50108	)	PUNCT	O
50108	while	ADP	O
50108	the	DET	O
50108	remaining	VERB	O
50108	animals	NOUN	O
50108	were	VERB	O
50108	given	VERB	O
50108	control	NOUN	O
50108	injections	NOUN	O
50108	of	ADP	O
50108	the	DET	O
50108	PCPA	PROPN	O
50108	vehicle	NOUN	O
50108	.	PUNCT	O
50109	Ten	NUM	O
50109	days	NOUN	O
50109	following	VERB	O
50109	the	DET	O
50109	last	ADJ	O
50109	administration	NOUN	O
50109	of	ADP	O
50109	PCPA	PROPN	O
50109	(	PUNCT	O
50109	or	CCONJ	O
50109	vehicle	NOUN	O
50109	)	PUNCT	O
50109	all	DET	O
50109	animals	NOUN	O
50109	were	VERB	O
50109	given	VERB	O
50109	a	DET	O
50109	low	ADJ	O
50109	dose	NOUN	O
50109	of	ADP	O
50109	LSD	NOUN	O
50109	(	PUNCT	O
50109	20	NUM	O
50109	mug	INTJ	O
50109	/	SYM	O
50109	kg	NOUN	O
50109	)	PUNCT	O
50109	.	PUNCT	O
50110	Bar	NOUN	O
50110	-	PUNCT	O
50110	pressing	VERB	O
50110	behavior	NOUN	O
50110	was	VERB	O
50110	significantly	ADV	O
50110	disrupted	VERB	O
50110	only	ADV	O
50110	in	ADP	O
50110	those	DET	O
50110	animals	NOUN	O
50110	receiving	VERB	O
50110	both	DET	O
50110	PCPA	PROPN	O
50110	and	CCONJ	O
50110	extra	ADJ	O
50110	water	NOUN	O
50110	.	PUNCT	O
50111	Central	ADJ	O
50111	(	PUNCT	O
50111	whold	VERB	O
50111	brain	NOUN	O
50111	)	PUNCT	O
50111	concentrations	NOUN	O
50111	of	ADP	O
50111	serotonin	NOUN	O
50111	(	PUNCT	O
50111	5-HT	NUM	O
50111	)	PUNCT	O
50111	were	VERB	O
50111	significantly	ADV	O
50111	lower	ADJ	O
50111	in	ADP	O
50111	all	DET	O
50111	animals	NOUN	O
50111	which	ADJ	O
50111	had	VERB	O
50111	been	VERB	O
50111	treated	VERB	O
50111	with	ADP	O
50111	PCPA	PROPN	O
50111	.	PUNCT	O
50112	These	DET	O
50112	results	NOUN	O
50112	,	PUNCT	O
50112	along	ADP	O
50112	with	ADP	O
50112	those	DET	O
50112	previously	ADV	O
50112	reported	VERB	O
50112	,	PUNCT	O
50112	suggest	VERB	O
50112	that	ADP	O
50112	amount	NOUN	O
50112	of	ADP	O
50112	deprivation	NOUN	O
50112	can	VERB	O
50112	be	VERB	O
50112	an	DET	O
50112	important	ADJ	O
50112	determinant	NOUN	O
50112	of	ADP	O
50112	both	CCONJ	O
50112	the	DET	O
50112	ability	NOUN	O
50112	of	ADP	O
50112	drugs	NOUN	O
50112	to	PART	O
50112	alter	VERB	O
50112	behavior	NOUN	O
50112	and	CCONJ	O
50112	the	DET	O
50112	dependence	NOUN	O
50112	of	ADP	O
50112	such	ADJ	O
50112	alterations	NOUN	O
50112	upon	ADP	O
50112	underlying	ADJ	O
50112	neuronal	ADJ	O
50112	activity	NOUN	O
50112	.	PUNCT	O
50113	Injection	NOUN	O
50113	of	ADP	O
50113	CBA	PROPN	O
50113	mice	NOUN	O
50113	with	ADP	O
50113	H-2-compatible	ADJ	O
50113	lymphoid	ADJ	O
50113	cells	NOUN	O
50113	from	ADP	O
50113	C3H	PROPN	O
50113	hybrids	VERB	O
50113	induces	VERB	O
50113	a	DET	O
50113	specific	ADJ	O
50113	reduction	NOUN	O
50113	of	ADP	O
50113	the	DET	O
50113	mixed	ADJ	O
50113	lymphocyte	NOUN	O
50113	culture	NOUN	O
50113	(	PUNCT	O
50113	MLC	PROPN	O
50113	)	PUNCT	O
50113	response	NOUN	O
50113	of	ADP	O
50113	their	ADJ	O
50113	lymphoytes	NOUN	O
50113	.	PUNCT	O
50114	This	DET	O
50114	is	VERB	O
50114	not	ADV	O
50114	the	DET	O
50114	case	NOUN	O
50114	after	ADP	O
50114	injection	NOUN	O
50114	of	ADP	O
50114	H-2-disparate	PROPN	O
50114	C3H	PROPN	O
50114	-	PUNCT	O
50114	hybrid	NOUN	O
50114	cells	NOUN	O
50114	,	PUNCT	O
50114	presumably	ADV	O
50114	because	ADP	O
50114	they	PRON	O
50114	are	VERB	O
50114	rapidly	ADV	O
50114	eliminated	VERB	O
50114	due	ADJ	O
50114	to	ADP	O
50114	the	DET	O
50114	immune	ADJ	O
50114	response	NOUN	O
50114	of	ADP	O
50114	the	DET	O
50114	host	NOUN	O
50114	.	PUNCT	O
50115	This	DET	O
50115	investigation	NOUN	O
50115	shows	VERB	O
50115	that	ADP	O
50115	CBA	PROPN	O
50115	mice	NOUN	O
50115	injected	VERB	O
50115	with	ADP	O
50115	CBA	PROPN	O
50115	X	NOUN	O
50115	C57Bl	ADJ	O
50115	cells	NOUN	O
50115	(	PUNCT	O
50115	H-2-disparate	PROPN	O
50115	)	PUNCT	O
50115	at	ADP	O
50115	an	DET	O
50115	age	NOUN	O
50115	of	ADP	O
50115	0	NUM	O
50115	-	SYM	O
50115	3	NUM	O
50115	days	NOUN	O
50115	,	PUNCT	O
50115	but	CCONJ	O
50115	not	ADV	O
50115	older	ADJ	O
50115	,	PUNCT	O
50115	develop	VERB	O
50115	a	DET	O
50115	specifically	ADV	O
50115	reduced	VERB	O
50115	MLC	PROPN	O
50115	response	NOUN	O
50115	after	ADP	O
50115	infusion	NOUN	O
50115	of	ADP	O
50115	C3H	PROPN	O
50115	X	PROPN	O
50115	C57Bl	ADJ	O
50115	cells	NOUN	O
50115	as	ADP	O
50115	adults	NOUN	O
50115	,	PUNCT	O
50115	indicating	VERB	O
50115	that	ADP	O
50115	they	PRON	O
50115	were	VERB	O
50115	tolerant	ADJ	O
50115	to	ADP	O
50115	the	DET	O
50115	C57Bl	NOUN	O
50115	-	PUNCT	O
50115	determined	VERB	O
50115	antigens	NOUN	O
50115	.	PUNCT	O
50116	However	ADV	O
50116	,	PUNCT	O
50116	lymphocytes	VERB	O
50116	from	ADP	O
50116	such	ADJ	O
50116	mice	NOUN	O
50116	showed	VERB	O
50116	a	DET	O
50116	normal	ADJ	O
50116	reactivity	NOUN	O
50116	against	ADP	O
50116	C57Bl	NOUN	O
50116	as	ADP	O
50116	assessed	VERB	O
50116	by	ADP	O
50116	MLC	PROPN	O
50116	,	PUNCT	O
50116	graft	NOUN	O
50116	-	PUNCT	O
50116	versus	ADP	O
50116	-	PUNCT	O
50116	host	NOUN	O
50116	tests	NOUN	O
50116	,	PUNCT	O
50116	and	CCONJ	O
50116	capacity	NOUN	O
50116	to	PART	O
50116	produce	VERB	O
50116	specific	ADJ	O
50116	antibodies	NOUN	O
50116	.	PUNCT	O
50117	90	NUM	O
50117	chronic	ADJ	O
50117	alcoholics	NOUN	O
50117	(	PUNCT	O
50117	55	NUM	O
50117	men	NOUN	O
50117	and	CCONJ	O
50117	35	NUM	O
50117	women	NOUN	O
50117	,	PUNCT	O
50117	aged	VERB	O
50117	between	ADP	O
50117	20	NUM	O
50117	and	CCONJ	O
50117	60	NUM	O
50117	years	NOUN	O
50117	)	PUNCT	O
50117	were	VERB	O
50117	investigated	VERB	O
50117	to	PART	O
50117	determine	VERB	O
50117	how	ADV	O
50117	alcohol	NOUN	O
50117	withdrawal	NOUN	O
50117	effects	NOUN	O
50117	the	DET	O
50117	pattern	NOUN	O
50117	of	ADP	O
50117	enzymes	NOUN	O
50117	in	ADP	O
50117	plasma	NOUN	O
50117	and	CCONJ	O
50117	if	ADP	O
50117	changes	NOUN	O
50117	in	ADP	O
50117	this	DET	O
50117	enzyme	NOUN	O
50117	pattern	NOUN	O
50117	could	VERB	O
50117	be	VERB	O
50117	used	VERB	O
50117	as	ADP	O
50117	criteria	NOUN	O
50117	for	ADP	O
50117	evaluation	NOUN	O
50117	of	ADP	O
50117	the	DET	O
50117	recovery	NOUN	O
50117	process	NOUN	O
50117	.	PUNCT	O
50118	Among	ADP	O
50118	the	DET	O
50118	different	ADJ	O
50118	enzymes	NOUN	O
50118	tested	VERB	O
50118	,	PUNCT	O
50118	gamma	NOUN	O
50118	-	PUNCT	O
50118	glutamyl	ADJ	O
50118	-	PUNCT	O
50118	transpeptidase	NOUN	O
50118	(	PUNCT	O
50118	GGTP	PROPN	O
50118	)	PUNCT	O
50118	and	CCONJ	O
50118	the	DET	O
50118	transamines	NOUN	O
50118	seemed	VERB	O
50118	the	DET	O
50118	most	ADV	O
50118	suitable	ADJ	O
50118	parameters	NOUN	O
50118	.	PUNCT	O
50119	At	ADP	O
50119	the	DET	O
50119	beginning	NOUN	O
50119	of	ADP	O
50119	the	DET	O
50119	alcohol	NOUN	O
50119	withdrawal	NOUN	O
50119	course	NOUN	O
50119	,	PUNCT	O
50119	79	NUM	O
50119	out	ADP	O
50119	of	ADP	O
50119	90	NUM	O
50119	patients	NOUN	O
50119	(	PUNCT	O
50119	80	NUM	O
50119	%	NOUN	O
50119	)	PUNCT	O
50119	showed	VERB	O
50119	elevated	ADJ	O
50119	values	NOUN	O
50119	of	ADP	O
50119	one	NUM	O
50119	of	ADP	O
50119	these	DET	O
50119	enzymes	NOUN	O
50119	in	ADP	O
50119	plasma	NOUN	O
50119	.	PUNCT	O
50120	GOT	PROPN	O
50120	was	VERB	O
50120	elevated	VERB	O
50120	in	ADP	O
50120	31	NUM	O
50120	(	PUNCT	O
50120	34	NUM	O
50120	%	NOUN	O
50120	)	PUNCT	O
50120	,	PUNCT	O
50120	GPT	PROPN	O
50120	in	ADP	O
50120	24	NUM	O
50120	(	PUNCT	O
50120	23	NUM	O
50120	%	NOUN	O
50120	)	PUNCT	O
50120	and	CCONJ	O
50120	GGTP	NOUN	O
50120	in	ADP	O
50120	79	NUM	O
50120	(	PUNCT	O
50120	88	NUM	O
50120	%	NOUN	O
50120	)	PUNCT	O
50120	of	ADP	O
50120	the	DET	O
50120	cases	NOUN	O
50120	.	PUNCT	O
50121	In	ADP	O
50121	49	NUM	O
50121	patients	NOUN	O
50121	(	PUNCT	O
50121	54	NUM	O
50121	%	NOUN	O
50121	)	PUNCT	O
50122	GGTP	PROPN	O
50122	was	VERB	O
50122	the	DET	O
50122	only	ADJ	O
50122	enzyme	NOUN	O
50122	found	VERB	O
50122	to	PART	O
50122	be	VERB	O
50122	elevated	ADJ	O
50122	.	PUNCT	O
50123	The	DET	O
50123	values	NOUN	O
50123	of	ADP	O
50123	GGTP	NOUN	O
50123	were	VERB	O
50123	on	ADP	O
50123	the	DET	O
50123	average	NOUN	O
50123	higher	ADJ	O
50123	than	ADP	O
50123	those	DET	O
50123	of	ADP	O
50123	GOT	PROPN	O
50123	and	CCONJ	O
50123	GPT	PROPN	O
50123	.	PUNCT	O
50124	GGTP	NOUN	O
50124	has	VERB	O
50124	thereforeto	NOUN	O
50124	be	VERB	O
50124	regarded	VERB	O
50124	as	ADP	O
50124	the	DET	O
50124	most	ADV	O
50124	sensitive	ADJ	O
50124	enzyme	NOUN	O
50124	since	ADP	O
50124	it	PRON	O
50124	was	VERB	O
50124	elevated	ADJ	O
50124	in	ADP	O
50124	most	ADJ	O
50124	of	ADP	O
50124	the	DET	O
50124	patients	NOUN	O
50124	.	PUNCT	O
50125	GGTP	NOUN	O
50125	reacted	VERB	O
50125	with	ADP	O
50125	6.8	NUM	O
50125	times	NOUN	O
50125	more	ADJ	O
50125	sensitivity	NOUN	O
50125	than	ADP	O
50125	GOT	PROPN	O
50125	and	CCONJ	O
50125	6.3	NUM	O
50125	times	NOUN	O
50125	that	ADP	O
50125	of	ADP	O
50125	GPT	PROPN	O
50125	.	PUNCT	O
50126	After	ADP	O
50126	withdrawal	NOUN	O
50126	of	ADP	O
50126	alcohol	NOUN	O
50126	the	DET	O
50126	three	NUM	O
50126	enzymes	NOUN	O
50126	showed	VERB	O
50126	a	DET	O
50126	decline	NOUN	O
50126	in	ADP	O
50126	all	DET	O
50126	79	NUM	O
50126	patients	NOUN	O
50126	.	PUNCT	O
50127	The	DET	O
50127	transaminases	NOUN	O
50127	normalized	VERB	O
50127	faster	ADV	O
50127	than	ADP	O
50127	GGTP	PROPN	O
50127	.	PUNCT	O
50128	GTP	PROPN	O
50128	fell	VERB	O
50128	into	ADP	O
50128	the	DET	O
50128	upper	ADJ	O
50128	normal	ADJ	O
50128	limit	NOUN	O
50128	after	ADP	O
50128	only	ADV	O
50128	30	NUM	O
50128	days	NOUN	O
50128	.	PUNCT	O
50129	Among	ADP	O
50129	the	DET	O
50129	90	NUM	O
50129	alcoholics	NOUN	O
50129	examined	VERB	O
50129	,	PUNCT	O
50129	14	NUM	O
50129	relapsed	VERB	O
50129	during	ADP	O
50129	the	DET	O
50129	alcohol	NOUN	O
50129	withdrawal	NOUN	O
50129	course	NOUN	O
50129	.	PUNCT	O
50130	After	ADP	O
50130	the	DET	O
50130	new	ADJ	O
50130	excess	NOUN	O
50130	of	ADP	O
50130	alcohol	NOUN	O
50130	intake	NOUN	O
50130	,	PUNCT	O
50130	the	DET	O
50130	GGTP	NOUN	O
50130	in	ADP	O
50130	plasma	NOUN	O
50130	rose	VERB	O
50130	immediately	ADV	O
50130	.	PUNCT	O
50131	Alcohol	NOUN	DISEASE
50131	abuse	NOUN	DISEASE
50131	was	VERB	O
50131	suspected	VERB	O
50131	in	ADP	O
50131	50	NUM	O
50131	%	NOUN	O
50131	of	ADP	O
50131	the	DET	O
50131	patients	NOUN	O
50131	due	ADP	O
50131	to	ADP	O
50131	the	DET	O
50131	increase	NOUN	O
50131	in	ADP	O
50131	this	DET	O
50131	enzyme	NOUN	O
50131	and	CCONJ	O
50131	was	VERB	O
50131	subsequently	ADV	O
50131	confirmed	VERB	O
50131	by	ADP	O
50131	the	DET	O
50131	patients	NOUN	O
50131	.	PUNCT	O
50132	Acute	ADJ	O
50132	alcohol	NOUN	O
50132	loading	NOUN	O
50132	in	ADP	O
50132	normal	ADJ	O
50132	volunteers	NOUN	O
50132	did	VERB	O
50132	not	ADV	O
50132	lead	VERB	O
50132	to	ADP	O
50132	an	DET	O
50132	increase	NOUN	O
50132	in	ADP	O
50132	GGTP	PROPN	O
50132	activity	NOUN	O
50132	.	PUNCT	O
50133	A	DET	O
50133	comparison	NOUN	O
50133	of	ADP	O
50133	the	DET	O
50133	histology	NOUN	O
50133	of	ADP	O
50133	liver	NOUN	O
50133	biopsy	NOUN	O
50133	material	NOUN	O
50133	showed	VERB	O
50133	that	ADP	O
50133	neither	CCONJ	O
50133	the	DET	O
50133	transaminases	NOUN	O
50133	nor	CCONJ	O
50133	the	DET	O
50133	alkaline	NOUN	O
50133	phosphatase	NOUN	O
50133	and	CCONJ	O
50133	GGTP	PROPN	O
50133	served	VERB	O
50133	to	PART	O
50133	differentiate	VERB	O
50133	the	DET	O
50133	various	ADJ	O
50133	forms	NOUN	O
50133	of	ADP	O
50133	alcoholic	ADJ	O
50133	liver	NOUN	O
50133	damage	NOUN	O
50133	.	PUNCT	O
50134	However	ADV	O
50134	,	PUNCT	O
50134	GGTP	PROPN	O
50134	represents	VERB	O
50134	the	DET	O
50134	most	ADV	O
50134	sensitive	ADJ	O
50134	enzymatic	ADJ	O
50134	parameter	NOUN	O
50134	for	ADP	O
50134	the	DET	O
50134	detection	NOUN	O
50134	of	ADP	O
50134	alcoholic	ADJ	O
50134	liver	NOUN	DISEASE
50134	disease	NOUN	DISEASE
50134	.	PUNCT	O
50135	This	DET	O
50135	enzyme	NOUN	O
50135	is	VERB	O
50135	useful	ADJ	O
50135	in	ADP	O
50135	evaluating	VERB	O
50135	the	DET	O
50135	success	NOUN	O
50135	of	ADP	O
50135	a	DET	O
50135	course	NOUN	O
50135	of	ADP	O
50135	alcohol	NOUN	O
50135	deprivation	NOUN	O
50135	.	PUNCT	O
50136	The	DET	O
50136	decreasing	VERB	O
50136	values	NOUN	O
50136	during	ADP	O
50136	such	ADJ	O
50136	treatment	NOUN	O
50136	,	PUNCT	O
50136	as	ADV	O
50136	well	ADV	O
50136	as	ADP	O
50136	the	DET	O
50136	prompt	ADJ	O
50136	increase	NOUN	O
50136	after	ADP	O
50136	a	DET	O
50136	relapse	NOUN	O
50136	,	PUNCT	O
50136	points	VERB	O
50136	to	ADP	O
50136	the	DET	O
50136	high	ADJ	O
50136	sensitivity	NOUN	O
50136	of	ADP	O
50136	this	DET	O
50136	enzyme	NOUN	O
50136	.	PUNCT	O
50137	A	DET	O
50137	further	ADJ	O
50137	argument	NOUN	O
50137	is	VERB	O
50137	that	ADP	O
50137	in	ADP	O
50137	54	NUM	O
50137	%	NOUN	O
50137	of	ADP	O
50137	the	DET	O
50137	patients	NOUN	O
50137	elevation	NOUN	O
50137	of	ADP	O
50137	GGTP	PROPN	O
50137	only	ADV	O
50137	was	VERB	O
50137	present	ADJ	O
50137	.	PUNCT	O
50138	Since	ADP	O
50138	no	DET	O
50138	liver	NOUN	O
50138	damage	NOUN	O
50138	could	VERB	O
50138	be	VERB	O
50138	demonstrated	VERB	O
50138	in	ADP	O
50138	these	DET	O
50138	patients	NOUN	O
50138	with	ADP	O
50138	the	DET	O
50138	aid	NOUN	O
50138	of	ADP	O
50138	the	DET	O
50138	other	ADJ	O
50138	liver	NOUN	O
50138	enzymes	NOUN	O
50138	,	PUNCT	O
50138	the	DET	O
50138	elevation	NOUN	O
50138	of	ADP	O
50138	GGTP	NOUN	O
50138	may	VERB	O
50138	be	VERB	O
50138	related	VERB	O
50138	to	ADP	O
50138	the	DET	O
50138	alcohol	NOUN	O
50138	intake	NOUN	O
50138	through	ADP	O
50138	an	DET	O
50138	enzyme	NOUN	O
50138	induction	NOUN	O
50138	mechanism	NOUN	O
50138	such	ADJ	O
50138	as	ADP	O
50138	has	VERB	O
50138	been	VERB	O
50138	demonstrated	VERB	O
50138	for	ADP	O
50138	this	DET	O
50138	enzyme	NOUN	O
50138	with	ADP	O
50138	certain	ADJ	O
50138	drugs	NOUN	O
50138	.	PUNCT	O
50139	Enhancement	NOUN	O
50139	of	ADP	O
50139	LBN	PROPN	O
50139	F1	PROPN	O
50139	renal	ADJ	O
50139	allograft	NOUN	O
50139	survival	NOUN	O
50139	in	ADP	O
50139	Lewis	PROPN	O
50139	(	PUNCT	O
50139	L	PROPN	O
50139	)	PUNCT	O
50139	rats	NOUN	O
50139	is	VERB	O
50139	achieved	VERB	O
50139	by	ADP	O
50139	injecting	VERB	O
50139	the	DET	O
50139	recipient	NOUN	O
50139	i.v	X	O
50139	.	PUNCT	O
50140	with	ADP	O
50140	donor	NOUN	O
50140	antigen	NOUN	O
50140	(	PUNCT	O
50140	LBN	PROPN	O
50140	F1	PROPN	O
50140	spleen	NOUN	O
50140	cells	NOUN	O
50140	)	PUNCT	O
50141	1	NUM	O
50141	day	NOUN	O
50141	before	ADP	O
50141	transplantation	NOUN	O
50141	and	CCONJ	O
50141	antidonor	NOUN	O
50141	antibody	NOUN	O
50141	(	PUNCT	O
50141	L	PROPN	O
50141	anti	ADV	O
50141	-	PUNCT	O
50141	BN	PROPN	O
50141	alloantiserum	NOUN	O
50141	)	PUNCT	O
50141	at	ADP	O
50141	the	DET	O
50141	time	NOUN	O
50141	of	ADP	O
50141	transplantation	NOUN	O
50141	.	PUNCT	O
50142	Treatment	NOUN	O
50142	with	ADP	O
50142	this	DET	O
50142	combination	NOUN	O
50142	of	ADP	O
50142	antigen	NOUN	O
50142	and	CCONJ	O
50142	antibody	NOUN	O
50142	also	ADV	O
50142	induces	VERB	O
50142	the	DET	O
50142	recipient	NOUN	O
50142	to	PART	O
50142	make	VERB	O
50142	L	PROPN	O
50142	anti-(L	NOUN	O
50142	anti	ADV	O
50142	-	PUNCT	O
50142	BN	PROPN	O
50142	)	PUNCT	O
50142	anti	ADV	O
50142	-	PUNCT	O
50142	idiotypic	ADJ	O
50142	antibody	NOUN	O
50142	that	ADJ	O
50142	reaches	VERB	O
50142	peak	NOUN	O
50142	titers	NOUN	O
50142	within	ADP	O
50142	10	NUM	O
50142	days	NOUN	O
50142	.	PUNCT	O
50143	The	DET	O
50143	degree	NOUN	O
50143	of	ADP	O
50143	graft	NOUN	O
50143	enhancement	NOUN	O
50143	achieved	VERB	O
50143	was	VERB	O
50143	increased	VERB	O
50143	greatly	ADV	O
50143	by	ADP	O
50143	delaying	VERB	O
50143	transplantation	NOUN	O
50143	until	ADP	O
50143	the	DET	O
50143	peak	NOUN	O
50143	of	ADP	O
50143	the	DET	O
50143	anti	ADV	O
50143	-	PUNCT	O
50143	idiotypic	ADJ	O
50143	antibody	NOUN	O
50143	response	NOUN	O
50143	10	NUM	O
50143	days	NOUN	O
50143	after	ADP	O
50143	treatment	NOUN	O
50143	with	ADP	O
50143	antigen	NOUN	O
50143	and	CCONJ	O
50143	antibody	NOUN	O
50143	.	PUNCT	O
50144	Two	NUM	O
50144	in	ADP	O
50144	vitro	X	O
50144	assays	NOUN	O
50144	for	ADP	O
50144	cellular	ADJ	O
50144	immunity	NOUN	O
50144	(	PUNCT	O
50144	51Cr	NUM	O
50144	release	NOUN	O
50144	and	CCONJ	O
50144	microcytotoxicity	NOUN	O
50144	)	PUNCT	O
50144	failed	VERB	O
50144	to	PART	O
50144	demonstrate	VERB	O
50144	antidonor	NOUN	O
50144	activity	NOUN	O
50144	in	ADP	O
50144	spleen	ADJ	O
50144	cells	NOUN	O
50144	from	ADP	O
50144	recipients	NOUN	O
50144	for	ADP	O
50144	which	ADJ	O
50144	transplantation	NOUN	O
50144	had	VERB	O
50144	been	VERB	O
50144	delayed	VERB	O
50144	10	NUM	O
50144	days	NOUN	O
50144	.	PUNCT	O
50145	The	DET	O
50145	close	ADJ	O
50145	correlation	NOUN	O
50145	of	ADP	O
50145	enhancement	NOUN	O
50145	,	PUNCT	O
50145	absence	NOUN	O
50145	of	ADP	O
50145	cellular	ADJ	O
50145	immunity	NOUN	O
50145	in	ADP	O
50145	vitro	X	O
50145	,	PUNCT	O
50145	and	CCONJ	O
50145	the	DET	O
50145	kinetics	NOUN	O
50145	of	ADP	O
50145	the	DET	O
50145	anti	ADV	O
50145	-	PUNCT	O
50145	idiotypic	ADJ	O
50145	antibody	NOUN	O
50145	response	NOUN	O
50145	suggest	VERB	O
50145	that	ADP	O
50145	anti	ADV	O
50145	-	PUNCT	O
50145	idiotypic	ADJ	O
50145	antibody	NOUN	O
50145	may	VERB	O
50145	prevent	VERB	O
50145	either	CCONJ	O
50145	sensitization	NOUN	O
50145	and	CCONJ	O
50145	generation	NOUN	O
50145	of	ADP	O
50145	effector	NOUN	O
50145	T	PROPN	O
50145	lymphocytes	VERB	O
50145	or	CCONJ	O
50145	the	DET	O
50145	destructive	ADJ	O
50145	potential	NOUN	O
50145	of	ADP	O
50145	sensitized	ADJ	O
50145	cells	NOUN	O
50145	.	PUNCT	O
50146	(	PUNCT	O
50146	1)Spleen	NUM	O
50146	cells	NOUN	O
50146	from	ADP	O
50146	newborn	ADJ	O
50146	syngeneic	NOUN	O
50146	and	CCONJ	O
50146	allogeneic	ADJ	O
50146	mice	NOUN	O
50146	that	ADJ	O
50146	lack	VERB	O
50146	fully	ADV	O
50146	differentiated	VERB	O
50146	T	PROPN	O
50146	lymphocytes	NOUN	O
50146	can	VERB	O
50146	be	VERB	O
50146	used	VERB	O
50146	as	ADP	O
50146	a	DET	O
50146	hematopoietic	ADJ	O
50146	source	NOUN	O
50146	to	PART	O
50146	reconstitute	VERB	O
50146	both	CCONJ	O
50146	hematopoietic	ADJ	O
50146	and	CCONJ	O
50146	lymphoid	ADJ	O
50146	systems	NOUN	O
50146	of	ADP	O
50146	lethally	ADV	O
50146	irradiated	ADJ	O
50146	mice	NOUN	O
50146	without	ADP	O
50146	producing	VERB	O
50146	a	DET	O
50146	GVHR	PROPN	O
50146	.	PUNCT	O
50147	(	PUNCT	O
50147	2	PUNCT	O
50147	)	PUNCT	O
50147	Fetal	PROPN	O
50147	liver	NOUN	O
50147	cells	NOUN	O
50147	from	ADP	O
50147	syngeneic	NOUN	O
50147	and	CCONJ	O
50147	allogeneic	ADJ	O
50147	mice	NOUN	O
50147	that	ADJ	O
50147	lack	VERB	O
50147	postthymic	ADJ	O
50147	T	PROPN	O
50147	lymphocytes	NOUN	O
50147	can	VERB	O
50147	also	ADV	O
50147	be	VERB	O
50147	used	VERB	O
50147	for	ADP	O
50147	hematopoietic	ADJ	O
50147	and	CCONJ	O
50147	immunologic	ADJ	O
50147	reconstitution	NOUN	O
50147	of	ADP	O
50147	lethally	ADV	O
50147	irradiated	ADJ	O
50147	mice	NOUN	O
50147	without	ADP	O
50147	producing	VERB	O
50147	GVHR	PROPN	O
50147	.	PUNCT	O
50148	(	PUNCT	O
50148	3	PUNCT	O
50148	)	PUNCT	O
50148	Immunologic	ADJ	O
50148	deficiency	NOUN	O
50148	is	VERB	O
50148	observed	VERB	O
50148	in	ADP	O
50148	some	DET	O
50148	experiments	NOUN	O
50148	in	ADP	O
50148	mice	NOUN	O
50148	given	VERB	O
50148	supralethal	ADJ	O
50148	irradiation	NOUN	O
50148	(	PUNCT	O
50148	1000	NUM	O
50148	R	NOUN	O
50148	)	PUNCT	O
50148	and	CCONJ	O
50148	fetal	ADJ	O
50148	liver	NOUN	O
50148	as	ADP	O
50148	reconstituting	VERB	O
50148	hematopoietic	ADJ	O
50148	tissue	NOUN	O
50148	.	PUNCT	O
50149	(	PUNCT	O
50149	4	PUNCT	O
50149	)	PUNCT	O
50150	The	DET	O
50150	findings	NOUN	O
50150	suggest	VERB	O
50150	that	ADP	O
50150	Tcells	PROPN	O
50150	,	PUNCT	O
50150	at	ADP	O
50150	an	DET	O
50150	early	ADJ	O
50150	stage	NOUN	O
50150	of	ADP	O
50150	differentiation	NOUN	O
50150	,	PUNCT	O
50150	are	VERB	O
50150	more	ADV	O
50150	susceptible	ADJ	O
50150	to	ADP	O
50150	tolerance	NOUN	O
50150	induction	NOUN	O
50150	than	ADP	O
50150	are	VERB	O
50150	T	PROPN	O
50150	lymphocytes	VERB	O
50150	at	ADP	O
50150	later	ADJ	O
50150	stages	NOUN	O
50150	of	ADP	O
50150	differentiation	NOUN	O
50150	and	CCONJ	O
50150	do	VERB	O
50150	not	ADV	O
50150	,	PUNCT	O
50150	in	ADP	O
50150	general	ADJ	O
50150	,	PUNCT	O
50150	produce	VERB	O
50150	GVHR	PROPN	O
50150	.	PUNCT	O
50151	(	PUNCT	O
50151	5	PUNCT	O
50151	)	PUNCT	O
50151	It	PRON	O
50151	is	VERB	O
50151	postulated	VERB	O
50151	that	ADP	O
50151	hematopoietic	ADJ	O
50151	cells	NOUN	O
50151	,	PUNCT	O
50151	free	ADJ	O
50151	of	ADP	O
50151	postthymic	ADJ	O
50151	lymphoid	ADJ	O
50151	cells	NOUN	O
50151	,	PUNCT	O
50151	can	VERB	O
50151	be	VERB	O
50151	used	VERB	O
50151	for	ADP	O
50151	hematopoietic	ADJ	O
50151	or	CCONJ	O
50151	immunologic	ADJ	O
50151	reconstituting	NOUN	O
50151	and	CCONJ	O
50151	cellular	ADJ	O
50151	engineering	NOUN	O
50151	without	ADP	O
50151	producing	VERB	O
50151	GVHD	NOUN	O
50151	.	PUNCT	O
50152	When	ADV	O
50152	phosphate	VERB	O
50152	and	CCONJ	O
50152	tyroxine	NOUN	O
50152	(	PUNCT	O
50152	activators	NOUN	O
50152	of	ADP	O
50152	brain	NOUN	O
50152	glutaminase	NOUN	O
50152	)	PUNCT	O
50152	are	VERB	O
50152	used	VERB	O
50152	in	ADP	O
50152	small	ADJ	O
50152	amounts	NOUN	O
50152	,	PUNCT	O
50152	a	DET	O
50152	potentiation	NOUN	O
50152	of	ADP	O
50152	their	ADJ	O
50152	stimulatory	ADJ	O
50152	effect	NOUN	O
50152	is	VERB	O
50152	observed	VERB	O
50152	.	PUNCT	O
50153	Higher	ADJ	O
50153	concentrations	NOUN	O
50153	exhibit	VERB	O
50153	an	DET	O
50153	opposite	ADJ	O
50153	effect	NOUN	O
50153	.	PUNCT	O
50154	Glutamic	ADJ	O
50154	acid	NOUN	O
50154	has	VERB	O
50154	a	DET	O
50154	strong	ADJ	O
50154	inhibitory	ADJ	O
50154	effect	NOUN	O
50154	on	ADP	O
50154	all	ADJ	O
50154	the	DET	O
50154	activators	NOUN	O
50154	of	ADP	O
50154	glutaminase	NOUN	O
50154	given	VERB	O
50154	separately	ADV	O
50154	.	PUNCT	O
50155	The	DET	O
50155	inhibitory	ADJ	O
50155	effect	NOUN	O
50155	of	ADP	O
50155	glutamate	ADJ	O
50155	increases	NOUN	O
50155	on	ADP	O
50155	lowering	VERB	O
50155	the	DET	O
50155	pH.	PROPN	O
50155	On	ADP	O
50155	the	DET	O
50155	other	ADJ	O
50155	hand	NOUN	O
50155	the	DET	O
50155	potentiation	NOUN	O
50155	observed	VERB	O
50155	on	ADP	O
50155	adding	VERB	O
50155	two	NUM	O
50155	stimulators	NOUN	O
50155	is	VERB	O
50155	increased	VERB	O
50155	greatly	ADV	O
50155	in	ADP	O
50155	the	DET	O
50155	presence	NOUN	O
50155	of	ADP	O
50155	glutamate	NOUN	O
50155	.	PUNCT	O
50156	On	ADP	O
50156	the	DET	O
50156	addition	NOUN	O
50156	of	ADP	O
50156	tyroxine	NOUN	O
50156	to	ADP	O
50156	other	ADJ	O
50156	stimulators	NOUN	O
50156	a	DET	O
50156	greater	ADJ	O
50156	potentiation	NOUN	O
50156	and	CCONJ	O
50156	rise	NOUN	O
50156	of	ADP	O
50156	glutaminase	NOUN	O
50156	activity	NOUN	O
50156	are	VERB	O
50156	observed	VERB	O
50156	.	PUNCT	O
50157	The	DET	O
50157	potentiation	NOUN	O
50157	,	PUNCT	O
50157	which	ADJ	O
50157	occurs	VERB	O
50157	on	ADP	O
50157	the	DET	O
50157	joint	ADJ	O
50157	addition	NOUN	O
50157	of	ADP	O
50157	phosphate	NOUN	O
50157	and	CCONJ	O
50157	tyroxine	NOUN	O
50157	,	PUNCT	O
50157	is	VERB	O
50157	raised	VERB	O
50157	with	ADP	O
50157	the	DET	O
50157	increase	NOUN	O
50157	of	ADP	O
50157	the	DET	O
50157	amount	NOUN	O
50157	of	ADP	O
50157	glutamic	ADJ	O
50157	acid	NOUN	O
50157	,	PUNCT	O
50157	while	ADP	O
50157	on	ADP	O
50157	the	DET	O
50157	contrary	NOUN	O
50157	on	ADP	O
50157	joining	VERB	O
50157	phosphate	NOUN	O
50157	with	ADP	O
50157	other	ADJ	O
50157	stimulators	NOUN	O
50157	potentiation	NOUN	O
50157	is	VERB	O
50157	reduced	VERB	O
50157	.	PUNCT	O
50158	Potentiation	NOUN	O
50158	is	VERB	O
50158	variable	ADJ	O
50158	and	CCONJ	O
50158	depends	VERB	O
50158	on	ADP	O
50158	the	DET	O
50158	pH.	PROPN	O
50158	Preincubation	PROPN	O
50158	of	ADP	O
50158	brain	NOUN	O
50158	mitochondrial	ADJ	O
50158	fraction	NOUN	O
50158	with	ADP	O
50158	guanidine	ADJ	O
50158	chloride	NOUN	O
50158	inhibits	NOUN	O
50158	markedly	ADV	O
50158	the	DET	O
50158	stimulatory	ADJ	O
50158	effect	NOUN	O
50158	of	ADP	O
50158	all	ADJ	O
50158	the	DET	O
50158	stimulators	NOUN	O
50158	used	VERB	O
50158	,	PUNCT	O
50158	but	CCONJ	O
50158	their	ADJ	O
50158	joint	ADJ	O
50158	addition	NOUN	O
50158	almost	ADV	O
50158	abolishes	VERB	O
50158	the	DET	O
50158	potentiating	VERB	O
50158	effect	NOUN	O
50158	.	PUNCT	O
50159	In	ADP	O
50159	the	DET	O
50159	presence	NOUN	O
50159	of	ADP	O
50159	glutamic	ADJ	O
50159	acid	NOUN	O
50159	,	PUNCT	O
50159	due	ADP	O
50159	to	ADP	O
50159	the	DET	O
50159	increase	NOUN	O
50159	of	ADP	O
50159	the	DET	O
50159	cooperative	ADJ	O
50159	effect	NOUN	O
50159	between	ADP	O
50159	the	DET	O
50159	two	NUM	O
50159	stimulators	NOUN	O
50159	,	PUNCT	O
50159	glutaminase	NOUN	O
50159	activity	NOUN	O
50159	is	VERB	O
50159	greatly	ADV	O
50159	increased	VERB	O
50159	and	CCONJ	O
50159	sometimes	ADV	O
50159	its	ADJ	O
50159	inhibitory	ADJ	O
50159	effect	NOUN	O
50159	is	VERB	O
50159	not	ADV	O
50159	even	ADV	O
50159	observed	VERB	O
50159	.	PUNCT	O
50160	The	DET	O
50160	data	NOUN	O
50160	obtained	VERB	O
50160	indicate	VERB	O
50160	that	ADP	O
50160	in	ADP	O
50160	brain	NOUN	O
50160	glutamic	ADJ	O
50160	acid	NOUN	O
50160	in	ADP	O
50160	the	DET	O
50160	presence	NOUN	O
50160	of	ADP	O
50160	phosphate+thyroxine	NOUN	O
50160	can	VERB	O
50160	not	ADV	O
50160	be	VERB	O
50160	considered	VERB	O
50160	as	ADP	O
50160	an	DET	O
50160	inhibitor	NOUN	O
50160	of	ADP	O
50160	glutaminase	NOUN	O
50160	and	CCONJ	O
50160	that	ADP	O
50160	the	DET	O
50160	important	ADJ	O
50160	factor	NOUN	O
50160	here	ADV	O
50160	is	VERB	O
50160	not	ADV	O
50160	so	ADV	O
50160	much	ADJ	O
50160	the	DET	O
50160	absolute	ADJ	O
50160	levels	NOUN	O
50160	of	ADP	O
50160	the	DET	O
50160	activators	NOUN	O
50160	as	ADP	O
50160	their	ADJ	O
50160	favorable	ADJ	O
50160	combinations	NOUN	O
50160	.	PUNCT	O
50161	Experimental	ADJ	O
50161	studies	NOUN	O
50161	on	ADP	O
50161	the	DET	O
50161	reaction	NOUN	O
50161	of	ADP	O
50161	micro	ADJ	O
50161	-	PUNCT	O
50161	organisms	NOUN	O
50161	on	ADP	O
50161	fine	ADJ	O
50161	-	PUNCT	O
50161	dust	NOUN	O
50161	filters	NOUN	O
50161	(	PUNCT	O
50161	type	NOUN	O
50161	C	PROPN	O
50161	)	PUNCT	O
50161	and	CCONJ	O
50161	high	ADJ	O
50161	-	PUNCT	O
50161	efficiency	NOUN	O
50161	particulate	NOUN	O
50161	air	NOUN	O
50161	filters	NOUN	O
50161	(	PUNCT	O
50161	type	NOUN	O
50161	R	NOUN	O
50161	and	CCONJ	O
50161	S	NOUN	O
50161	)	PUNCT	O
50161	have	VERB	O
50161	shown	VERB	O
50161	no	DET	O
50161	evidence	NOUN	O
50161	of	ADP	O
50161	a	DET	O
50161	growth	NOUN	O
50161	of	ADP	O
50161	microorganisms	NOUN	O
50161	.	PUNCT	O
50162	Therefore	ADV	O
50162	efforts	NOUN	O
50162	were	VERB	O
50162	aimed	VERB	O
50162	at	ADP	O
50162	detecting	VERB	O
50162	antimicrobial	ADJ	O
50162	factors	NOUN	O
50162	which	ADJ	O
50162	were	VERB	O
50162	supposed	VERB	O
50162	to	PART	O
50162	exist	VERB	O
50162	in	ADP	O
50162	the	DET	O
50162	precipitated	ADJ	O
50162	acidic	ADJ	O
50162	continental	ADJ	O
50162	aerosol	NOUN	O
50162	.	PUNCT	O
50163	With	ADP	O
50163	this	DET	O
50163	in	ADP	O
50163	mind	NOUN	O
50163	,	PUNCT	O
50163	air	NOUN	O
50163	filters	NOUN	O
50163	from	ADP	O
50163	different	ADJ	O
50163	locations	NOUN	O
50163	and	CCONJ	O
50163	with	ADP	O
50163	service	NOUN	O
50163	times	NOUN	O
50163	were	VERB	O
50163	extracted	VERB	O
50163	in	ADP	O
50163	water	NOUN	O
50163	and	CCONJ	O
50163	the	DET	O
50163	extract	NOUN	O
50163	was	VERB	O
50163	tested	VERB	O
50163	for	ADP	O
50163	its	ADJ	O
50163	antimicrobial	ADJ	O
50163	effects	NOUN	O
50163	.	PUNCT	O
50164	Die	VERB	O
50164	-	PUNCT	O
50164	off	PART	O
50164	rates	NOUN	O
50164	are	VERB	O
50164	used	VERB	O
50164	to	PART	O
50164	demonstrate	VERB	O
50164	the	DET	O
50164	influence	NOUN	O
50164	of	ADP	O
50164	such	ADJ	O
50164	extracts	NOUN	O
50164	with	ADP	O
50164	varying	VERB	O
50164	concentrations	NOUN	O
50164	of	ADP	O
50164	substances	NOUN	O
50164	and	CCONJ	O
50164	pH	VERB	O
50164	values	NOUN	O
50164	on	ADP	O
50164	bacteria	NOUN	O
50164	.	PUNCT	O
50165	A	DET	O
50165	study	NOUN	O
50165	of	ADP	O
50165	the	DET	O
50165	incidence	NOUN	O
50165	of	ADP	O
50165	R.	PROPN	O
50165	fever	NOUN	O
50165	in	ADP	O
50165	an	DET	O
50165	area	NOUN	O
50165	in	ADP	O
50165	southeast	ADJ	O
50165	Teheran	PROPN	O
50165	during	ADP	O
50165	the	DET	O
50165	period	NOUN	O
50165	1972	NUM	O
50165	-	SYM	O
50165	1974	NUM	O
50165	revealed	VERB	O
50165	92	NUM	O
50165	cases	NOUN	O
50165	.	PUNCT	O
50166	The	DET	O
50166	crude	ADJ	O
50166	annual	ADJ	O
50166	incidence	NOUN	O
50166	of	ADP	O
50166	R.	PROPN	O
50166	fever	NOUN	O
50166	ranged	VERB	O
50166	from	ADP	O
50166	a	DET	O
50166	high	NOUN	O
50166	of	ADP	O
50166	58	NUM	O
50166	cases	NOUN	O
50166	to	ADP	O
50166	a	DET	O
50166	low	NOUN	O
50166	of	ADP	O
50166	51	NUM	O
50166	cases	NOUN	O
50166	per	ADP	O
50166	100,000	NUM	O
50166	population	NOUN	O
50166	.	PUNCT	O
50167	The	DET	O
50167	age	NOUN	O
50167	and	CCONJ	O
50167	sex	NOUN	O
50167	specific	ADJ	O
50167	rates	NOUN	O
50167	revealed	VERB	O
50167	the	DET	O
50167	incidence	NOUN	O
50167	to	PART	O
50167	be	VERB	O
50167	strikingly	ADV	O
50167	higher	ADJ	O
50167	in	ADP	O
50167	the	DET	O
50167	5	NUM	O
50167	-	SYM	O
50167	19	NUM	O
50167	year	NOUN	O
50167	age	NOUN	O
50167	group	NOUN	O
50167	,	PUNCT	O
50167	reaching	VERB	O
50167	roughly	ADV	O
50167	80/100,000	NUM	O
50167	.	PUNCT	O
50168	There	ADV	O
50168	was	VERB	O
50168	an	DET	O
50168	approximately	ADV	O
50168	similar	ADJ	O
50168	number	NOUN	O
50168	of	ADP	O
50168	males	NOUN	O
50168	and	CCONJ	O
50168	females	NOUN	O
50168	with	ADP	O
50168	R.	PROPN	O
50168	fever	NOUN	O
50168	.	PUNCT	O
50169	Among	ADP	O
50169	the	DET	O
50169	R.	PROPN	O
50169	fever	NOUN	O
50169	patients	NOUN	O
50169	,	PUNCT	O
50169	there	ADV	O
50169	were	VERB	O
50169	6	NUM	O
50169	cases	NOUN	O
50169	of	ADP	O
50169	chorea	NOUN	DISEASE
50169	,	PUNCT	O
50169	5	NUM	O
50169	girls	NOUN	O
50169	and	CCONJ	O
50169	1	NUM	O
50169	boy	NOUN	O
50169	.	PUNCT	O
50170	From	ADP	O
50170	92	NUM	O
50170	R.	PROPN	O
50170	fever	NOUN	O
50170	cases	NOUN	O
50170	,	PUNCT	O
50170	49	NUM	O
50170	(	PUNCT	O
50170	53	NUM	O
50170	%	NOUN	O
50170	)	PUNCT	O
50170	developed	VERB	O
50170	carditis	NOUN	O
50170	.	PUNCT	O
50171	Among	ADP	O
50171	these	DET	O
50171	patients	NOUN	O
50171	,	PUNCT	O
50171	35	NUM	O
50171	(	PUNCT	O
50171	71	NUM	O
50171	%	NOUN	O
50171	)	PUNCT	O
50171	were	VERB	O
50171	female	ADJ	O
50171	in	ADP	O
50171	contrast	NOUN	O
50171	to	ADP	O
50171	14	NUM	O
50171	(	PUNCT	O
50171	29	NUM	O
50171	%	NOUN	O
50171	)	PUNCT	O
50171	male	ADJ	O
50171	cases	NOUN	O
50171	.	PUNCT	O
50172	Overall	ADV	O
50172	there	ADV	O
50172	were	VERB	O
50172	59	NUM	O
50172	cases	NOUN	O
50172	(	PUNCT	O
50172	62	NUM	O
50172	%	NOUN	O
50172	)	PUNCT	O
50172	which	ADJ	O
50172	were	VERB	O
50172	initial	ADJ	O
50172	attacks	NOUN	O
50172	and	CCONJ	O
50172	33	NUM	O
50172	cases	NOUN	O
50172	(	PUNCT	O
50172	38	NUM	O
50172	%	NOUN	O
50172	)	PUNCT	O
50172	which	ADJ	O
50172	were	VERB	O
50172	recurrences	NOUN	O
50172	.	PUNCT	O
50173	During	ADP	O
50173	the	DET	O
50173	trial	NOUN	O
50173	there	ADV	O
50173	were	VERB	O
50173	also	ADV	O
50173	7	NUM	O
50173	recurrences	NOUN	O
50173	of	ADP	O
50173	R	NOUN	O
50173	fever	NOUN	O
50173	and	CCONJ	O
50173	4	NUM	O
50173	deaths	NOUN	O
50173	.	PUNCT	O
50174	The	DET	O
50174	seasonal	ADJ	O
50174	pattern	NOUN	O
50174	showed	VERB	O
50174	that	ADP	O
50174	the	DET	O
50174	majority	NOUN	O
50174	of	ADP	O
50174	cases	NOUN	O
50174	occurred	VERB	O
50174	during	ADP	O
50174	the	DET	O
50174	winter	NOUN	O
50174	and	CCONJ	O
50174	spring	NOUN	O
50174	months	NOUN	O
50174	.	PUNCT	O
50175	From	ADP	O
50175	the	DET	O
50175	R.	PROPN	O
50175	fever	NOUN	O
50175	/	SYM	O
50175	R.H.D.	NOUN	O
50175	patients	NOUN	O
50175	,	PUNCT	O
50175	63	NUM	O
50175	(	PUNCT	O
50175	70	NUM	O
50175	%	NOUN	O
50175	)	PUNCT	O
50175	and	CCONJ	O
50175	from	ADP	O
50175	cases	NOUN	O
50175	with	ADP	O
50175	carditis	NOUN	O
50175	alone	ADV	O
50175	,	PUNCT	O
50175	24	NUM	O
50175	(	PUNCT	O
50175	40	NUM	O
50175	%	NOUN	O
50175	)	PUNCT	O
50175	were	VERB	O
50175	hospitalized	VERB	O
50175	.	PUNCT	O
50176	Vaccine	NOUN	O
50176	strains	VERB	O
50176	of	ADP	O
50176	influenza	NOUN	DISEASE
50176	A	DET	O
50176	virus	NOUN	O
50176	inhibited	VERB	O
50176	the	DET	O
50176	growth	NOUN	O
50176	of	ADP	O
50176	ascitic	ADJ	O
50176	tumour	NOUN	O
50176	cells	NOUN	O
50176	and	CCONJ	O
50176	outbred	VERB	O
50176	rats	NOUN	O
50176	or	CCONJ	O
50176	inbred	ADJ	O
50176	mice	NOUN	O
50176	.	PUNCT	O
50177	The	DET	O
50177	infected	ADJ	O
50177	tumour	NOUN	O
50177	bearers	NOUN	O
50177	had	VERB	O
50177	an	DET	O
50177	enhanced	VERB	O
50177	immune	ADJ	O
50177	response	NOUN	O
50177	to	ADP	O
50177	viral	ADJ	O
50177	and	CCONJ	O
50177	specific	ADJ	O
50177	tumour	NOUN	O
50177	antigens	NOUN	O
50177	.	PUNCT	O
50178	These	DET	O
50178	phenomena	NOUN	O
50178	are	VERB	O
50178	apparently	ADV	O
50178	due	ADJ	O
50178	to	ADP	O
50178	the	DET	O
50178	formation	NOUN	O
50178	of	ADP	O
50178	complexes	NOUN	O
50178	of	ADP	O
50178	both	DET	O
50178	antigens	NOUN	O
50178	on	ADP	O
50178	cell	NOUN	O
50178	membranes	NOUN	O
50178	and	CCONJ	O
50178	increased	VERB	O
50178	immunogenicity	NOUN	O
50178	of	ADP	O
50178	such	ADJ	O
50178	complexes	NOUN	O
50178	.	PUNCT	O
50179	Bile	ADJ	O
50179	acid	NOUN	O
50179	conjugates	NOUN	O
50179	are	VERB	O
50179	adsorbed	VERB	O
50179	to	PART	O
50179	cereal	VERB	O
50179	fiber	NOUN	O
50179	.	PUNCT	O
50180	Bile	ADJ	O
50180	acid	NOUN	O
50180	conjugates	VERB	O
50180	incorporated	VERB	O
50180	into	ADP	O
50180	micelles	NOUN	O
50180	with	ADP	O
50180	cholesterol	NOUN	O
50180	are	VERB	O
50180	reversibly	ADV	O
50180	adsorbed	NOUN	O
50180	as	ADP	O
50180	micelles	NOUN	O
50180	on	ADP	O
50180	to	ADP	O
50180	the	DET	O
50180	fiber	NOUN	O
50180	.	PUNCT	O
50181	Incorporating	VERB	O
50181	bile	ADJ	O
50181	acid	NOUN	O
50181	conjugates	VERB	O
50181	into	ADP	O
50181	micelles	NOUN	O
50181	with	ADP	O
50181	monoglycerides	NOUN	O
50181	somewhat	ADV	O
50181	depresses	VERB	O
50181	adsorption	NOUN	O
50181	of	ADP	O
50181	bile	ADJ	O
50181	acid	NOUN	O
50181	conjugate	NOUN	O
50181	.	PUNCT	O
50182	If	ADP	O
50182	fatty	ADJ	O
50182	acids	NOUN	O
50182	,	PUNCT	O
50182	monoglycerides	NOUN	O
50182	,	PUNCT	O
50182	and	CCONJ	O
50182	bile	ADJ	O
50182	acid	NOUN	O
50182	conjugate	NOUN	O
50182	mixed	ADJ	O
50182	micelles	NOUN	O
50182	are	VERB	O
50182	exposed	VERB	O
50182	to	PART	O
50182	cereal	NOUN	O
50182	fiber	NOUN	O
50182	,	PUNCT	O
50182	then	ADV	O
50182	adsorption	NOUN	O
50182	of	ADP	O
50182	bile	ADJ	O
50182	acids	NOUN	O
50182	to	ADP	O
50182	the	DET	O
50182	fiber	NOUN	O
50182	is	VERB	O
50182	diminished	VERB	O
50182	.	PUNCT	O
50183	The	DET	O
50183	extent	NOUN	O
50183	to	PART	O
50183	which	ADJ	O
50183	the	DET	O
50183	adsorption	NOUN	O
50183	is	VERB	O
50183	diminished	VERB	O
50183	is	VERB	O
50183	affected	VERB	O
50183	by	ADP	O
50183	the	DET	O
50183	fatty	ADJ	O
50183	acid	ADJ	O
50183	concentration	NOUN	O
50183	,	PUNCT	O
50183	chain	NOUN	O
50183	length	NOUN	O
50183	,	PUNCT	O
50183	and	CCONJ	O
50183	unsaturation	NOUN	O
50183	.	PUNCT	O
50184	This	DET	O
50184	suggests	VERB	O
50184	that	ADP	O
50184	bile	ADJ	O
50184	acid	NOUN	O
50184	conjugates	NOUN	O
50184	are	VERB	O
50184	minimally	ADV	O
50184	adsorbed	VERB	O
50184	to	ADP	O
50184	fiber	NOUN	O
50184	in	ADP	O
50184	the	DET	O
50184	jejunum	NOUN	O
50184	but	CCONJ	O
50184	deconjugation	NOUN	O
50184	and	CCONJ	O
50184	dehydroxylation	NOUN	O
50184	as	ADP	O
50184	in	ADP	O
50184	the	DET	O
50184	cecum	NOUN	O
50184	favors	NOUN	O
50184	adsorption	NOUN	O
50184	.	PUNCT	O
50185	The	DET	O
50185	capacity	NOUN	O
50185	of	ADP	O
50185	guinea	NOUN	O
50185	pig	NOUN	O
50185	antibodies	NOUN	O
50185	to	PART	O
50185	mediate	VERB	O
50185	the	DET	O
50185	antigen	NOUN	O
50185	-	PUNCT	O
50185	induced	VERB	O
50185	release	NOUN	O
50185	of	ADP	O
50185	slow	ADV	O
50185	-	PUNCT	O
50185	reacting	VERB	O
50185	substance	NOUN	O
50185	(	PUNCT	O
50185	SRS	PROPN	O
50185	)	PUNCT	O
50185	in	ADP	O
50185	the	DET	O
50185	rat	ADJ	O
50185	peritoneal	ADJ	O
50185	cavity	NOUN	O
50185	is	VERB	O
50185	restricted	VERB	O
50185	to	ADP	O
50185	IgG2	ADV	O
50185	and	CCONJ	O
50185	,	PUNCT	O
50185	to	ADP	O
50185	a	DET	O
50185	lesser	ADJ	O
50185	extent	NOUN	O
50185	,	PUNCT	O
50185	to	ADP	O
50185	IgG1	PROPN	O
50185	populations	NOUN	O
50185	of	ADP	O
50185	immunoglobulin	NOUN	O
50185	.	PUNCT	O
50186	IgM	X	O
50186	and	CCONJ	O
50186	homocytotropic	ADJ	O
50186	antibody	NOUN	O
50186	of	ADP	O
50186	the	DET	O
50186	reaginic	ADJ	O
50186	type	NOUN	O
50186	lacked	VERB	O
50186	this	DET	O
50186	activity	NOUN	O
50186	.	PUNCT	O
50187	The	DET	O
50187	process	NOUN	O
50187	was	VERB	O
50187	partially	ADV	O
50187	blocked	VERB	O
50187	by	ADP	O
50187	previous	ADJ	O
50187	decomplementation	NOUN	O
50187	of	ADP	O
50187	the	DET	O
50187	rats	NOUN	O
50187	,	PUNCT	O
50187	was	VERB	O
50187	not	ADV	O
50187	affected	VERB	O
50187	by	ADP	O
50187	previous	ADJ	O
50187	reduction	NOUN	O
50187	of	ADP	O
50187	the	DET	O
50187	circulating	VERB	O
50187	leukocytes	NOUN	O
50187	,	PUNCT	O
50187	and	CCONJ	O
50187	was	VERB	O
50187	partially	ADV	O
50187	suppressed	VERB	O
50187	by	ADP	O
50187	previous	ADJ	O
50187	depletion	NOUN	O
50187	of	ADP	O
50187	circulating	VERB	O
50187	platelets	NOUN	O
50187	with	ADP	O
50187	an	DET	O
50187	antiserum	NOUN	O
50187	to	ADP	O
50187	rat	NOUN	O
50187	platelets	NOUN	O
50187	.	PUNCT	O
50188	Enzymic	ADJ	O
50188	activities	NOUN	O
50188	and	CCONJ	O
50188	cofactor	NOUN	O
50188	levels	NOUN	O
50188	in	ADP	O
50188	the	DET	O
50188	epidermis	NOUN	O
50188	are	VERB	O
50188	reviewed	VERB	O
50188	with	ADP	O
50188	special	ADJ	O
50188	regard	NOUN	O
50188	to	ADP	O
50188	psoriasis	NOUN	DISEASE
50188	and	CCONJ	O
50188	the	DET	O
50188	papulosquamous	ADJ	O
50188	disorders	NOUN	O
50188	lichen	VERB	O
50188	simplex	NOUN	O
50188	and	CCONJ	O
50188	lichen	NOUN	O
50188	planus	NOUN	O
50188	.	PUNCT	O
50188	Enzymic	ADJ	O
50188	activities	NOUN	O
50188	and	CCONJ	O
50188	cofactor	NOUN	O
50188	levels	NOUN	O
50188	in	ADP	O
50188	the	DET	O
50188	epidermis	NOUN	O
50188	are	VERB	O
50188	reviewed	VERB	O
50188	with	ADP	O
50188	special	ADJ	O
50188	regard	NOUN	O
50188	to	ADP	O
50188	psoriasis	NOUN	O
50188	and	CCONJ	O
50188	the	DET	O
50188	papulosquamous	ADJ	O
50188	disorders	NOUN	O
50188	lichen	VERB	O
50188	simplex	NOUN	O
50188	and	CCONJ	O
50188	lichen	NOUN	DISEASE
50188	planus	NOUN	DISEASE
50188	.	PUNCT	O
50189	The	DET	O
50189	metabolism	NOUN	O
50189	of	ADP	O
50189	nicotinamide	ADJ	O
50189	adenine	ADJ	O
50189	dinucleotide	NOUN	O
50189	phosphate	NOUN	O
50189	and	CCONJ	O
50189	its	ADJ	O
50189	dependent	ADJ	O
50189	pathways	NOUN	O
50189	seems	VERB	O
50189	to	PART	O
50189	deviate	VERB	O
50189	in	ADP	O
50189	psoriasis	NOUN	DISEASE
50189	from	ADP	O
50189	that	DET	O
50189	in	ADP	O
50189	the	DET	O
50189	contrasted	VERB	O
50189	dermatoses	NOUN	O
50189	,	PUNCT	O
50189	in	ADP	O
50189	normal	ADJ	O
50189	skin	NOUN	O
50189	in	ADP	O
50189	health	NOUN	O
50189	and	CCONJ	O
50189	in	ADP	O
50189	skin	NOUN	O
50189	during	ADP	O
50189	the	DET	O
50189	process	NOUN	O
50189	of	ADP	O
50189	wound	NOUN	O
50189	healing	NOUN	O
50189	.	PUNCT	O
50190	The	DET	O
50190	mitochondrial	ADJ	O
50190	function	NOUN	O
50190	also	ADV	O
50190	differs	VERB	O
50190	between	ADP	O
50190	psoriatic	NOUN	O
50190	and	CCONJ	O
50190	normal	ADJ	O
50190	skin	NOUN	O
50190	.	PUNCT	O
50191	In	ADP	O
50191	some	DET	O
50191	conditions	NOUN	O
50191	in	ADP	O
50191	psoriasis	NOUN	DISEASE
50191	this	DET	O
50191	function	NOUN	O
50191	can	VERB	O
50191	not	ADV	O
50191	be	VERB	O
50191	seen	VERB	O
50191	to	PART	O
50191	deviate	VERB	O
50191	from	ADP	O
50191	normality	NOUN	O
50191	,	PUNCT	O
50191	however	ADV	O
50191	.	PUNCT	O
50192	The	DET	O
50192	regulation	NOUN	O
50192	and	CCONJ	O
50192	control	NOUN	O
50192	of	ADP	O
50192	mitochondrial	ADJ	O
50192	function	NOUN	O
50192	in	ADP	O
50192	psoriasis	NOUN	DISEASE
50192	might	VERB	O
50192	be	VERB	O
50192	another	DET	O
50192	area	NOUN	O
50192	in	ADP	O
50192	which	ADJ	O
50192	future	ADJ	O
50192	investigations	NOUN	O
50192	may	VERB	O
50192	yield	VERB	O
50192	significant	ADJ	O
50192	information	NOUN	O
50192	on	ADP	O
50192	the	DET	O
50192	pathophysiology	NOUN	O
50192	in	ADP	O
50192	this	DET	O
50192	skin	NOUN	O
50192	disease	NOUN	O
50192	.	PUNCT	O
50192	The	DET	O
50192	regulation	NOUN	O
50192	and	CCONJ	O
50192	control	NOUN	O
50192	of	ADP	O
50192	mitochondrial	ADJ	O
50192	function	NOUN	O
50192	in	ADP	O
50192	psoriasis	NOUN	O
50192	might	VERB	O
50192	be	VERB	O
50192	another	DET	O
50192	area	NOUN	O
50192	in	ADP	O
50192	which	ADJ	O
50192	future	ADJ	O
50192	investigations	NOUN	O
50192	may	VERB	O
50192	yield	VERB	O
50192	significant	ADJ	O
50192	information	NOUN	O
50192	on	ADP	O
50192	the	DET	O
50192	pathophysiology	NOUN	O
50192	in	ADP	O
50192	this	DET	O
50192	skin	NOUN	DISEASE
50192	disease	NOUN	DISEASE
50192	.	PUNCT	O
50193	A	DET	O
50193	highly	ADV	O
50193	sensitive	ADJ	O
50193	technique	NOUN	O
50193	for	ADP	O
50193	isoferritin	NOUN	O
50193	detection	NOUN	O
50193	using	VERB	O
50193	125I	PROPN	O
50193	-	PUNCT	O
50193	labeled	VERB	O
50193	monospecific	NOUN	O
50193	anti	ADV	O
50193	-	PUNCT	O
50193	human	ADJ	O
50193	liver	NOUN	O
50193	ferritin	NOUN	O
50193	antibody	NOUN	O
50193	for	ADP	O
50193	the	DET	O
50193	identification	NOUN	O
50193	of	ADP	O
50193	isoferritins	NOUN	O
50193	after	ADP	O
50193	the	DET	O
50193	analysis	NOUN	O
50193	of	ADP	O
50193	small	ADJ	O
50193	quantities	NOUN	O
50193	of	ADP	O
50193	ferritin	NOUN	O
50193	by	ADP	O
50193	isoelectric	ADJ	O
50193	focusing	VERB	O
50193	in	ADP	O
50193	polyacryl	NOUN	O
50193	-	PUNCT	O
50193	amide	NOUN	O
50193	gels	NOUN	O
50193	was	VERB	O
50193	applied	VERB	O
50193	to	ADP	O
50193	the	DET	O
50193	study	NOUN	O
50193	of	ADP	O
50193	renal	ADJ	O
50193	,	PUNCT	O
50193	pancreatic	ADJ	O
50193	,	PUNCT	O
50193	and	CCONJ	O
50193	colonic	ADJ	O
50193	carcinomas	NOUN	O
50193	.	PUNCT	O
50194	In	ADP	O
50194	all	DET	O
50194	tumors	NOUN	O
50194	studied	VERB	O
50194	,	PUNCT	O
50194	the	DET	O
50194	isoferritin	NOUN	O
50194	composition	NOUN	O
50194	differed	VERB	O
50194	from	ADP	O
50194	that	DET	O
50194	of	ADP	O
50194	the	DET	O
50194	corresponding	VERB	O
50194	normal	ADJ	O
50194	tissue	NOUN	O
50194	;	PUNCT	O
50194	major	ADJ	O
50194	isoferritins	NOUN	O
50194	with	ADP	O
50194	pl	DET	O
50194	more	ADV	O
50194	basic	ADJ	O
50194	than	ADP	O
50194	those	DET	O
50194	of	ADP	O
50194	the	DET	O
50194	normal	ADJ	O
50194	tissues	NOUN	O
50194	were	VERB	O
50194	consistently	ADV	O
50194	detected	VERB	O
50194	.	PUNCT	O
50195	Composition	NOUN	O
50195	of	ADP	O
50195	purified	ADJ	O
50195	ferritin	NOUN	O
50195	from	ADP	O
50195	metastases	NOUN	O
50195	closely	ADV	O
50195	resembled	VERB	O
50195	the	DET	O
50195	isoferritin	NOUN	O
50195	composition	NOUN	O
50195	of	ADP	O
50195	the	DET	O
50195	primary	ADJ	O
50195	tumors	NOUN	O
50195	.	PUNCT	O
50196	Examination	NOUN	O
50196	of	ADP	O
50196	the	DET	O
50196	serum	NOUN	O
50196	isoferritin	NOUN	O
50196	profiles	NOUN	O
50196	of	ADP	O
50196	four	NUM	O
50196	patients	NOUN	O
50196	with	ADP	O
50196	cancers	NOUN	O
50196	did	VERB	O
50196	not	ADV	O
50196	reveal	VERB	O
50196	the	DET	O
50196	presence	NOUN	O
50196	of	ADP	O
50196	any	DET	O
50196	tumor	NOUN	O
50196	-	PUNCT	O
50196	specific	ADJ	O
50196	changes	NOUN	O
50196	in	ADP	O
50196	isoferritins	NOUN	O
50196	.	PUNCT	O
50197	It	PRON	O
50197	is	VERB	O
50197	suggested	VERB	O
50197	that	ADP	O
50197	the	DET	O
50197	abnormality	NOUN	O
50197	in	ADP	O
50197	tissue	NOUN	O
50197	ferritins	NOUN	O
50197	in	ADP	O
50197	the	DET	O
50197	three	NUM	O
50197	human	ADJ	O
50197	cancers	NOUN	O
50197	studied	VERB	O
50197	is	VERB	O
50197	the	DET	O
50197	synthesis	NOUN	O
50197	of	ADP	O
50197	major	ADJ	O
50197	isoferritins	NOUN	O
50197	in	ADP	O
50197	the	DET	O
50197	more	ADJ	O
50197	basic	ADJ	O
50197	range	NOUN	O
50197	,	PUNCT	O
50197	rather	ADV	O
50197	than	ADP	O
50197	the	DET	O
50197	appearance	NOUN	O
50197	of	ADP	O
50197	tumor	NOUN	O
50197	-	PUNCT	O
50197	specific	ADJ	O
50197	isoferritins	NOUN	O
50197	in	ADP	O
50197	the	DET	O
50197	more	ADJ	O
50197	acidic	ADJ	O
50197	range	NOUN	O
50197	.	PUNCT	O
50198	The	DET	O
50198	primary	ADJ	O
50198	metabolic	NOUN	O
50198	defect	NOUN	O
50198	in	ADP	O
50198	5-oxoprolinuria	NOUN	O
50198	is	VERB	O
50198	a	DET	O
50198	generalized	VERB	O
50198	deficiency	NOUN	O
50198	of	ADP	O
50198	glutathione	NOUN	O
50198	synthetase	NOUN	O
50198	.	PUNCT	O
50199	The	DET	O
50199	activity	NOUN	O
50199	of	ADP	O
50199	this	DET	O
50199	enzyme	NOUN	O
50199	was	VERB	O
50199	determined	VERB	O
50199	in	ADP	O
50199	cell	NOUN	O
50199	-	PUNCT	O
50199	free	ADJ	O
50199	extracts	NOUN	O
50199	of	ADP	O
50199	erythrocytes	NOUN	O
50199	from	ADP	O
50199	patients	NOUN	O
50199	with	ADP	O
50199	5-oxoprolinuria	NUM	O
50199	,	PUNCT	O
50199	their	ADJ	O
50199	parents	NOUN	O
50199	and	CCONJ	O
50199	a	DET	O
50199	sibling	NOUN	O
50199	as	ADV	O
50199	well	ADV	O
50199	as	ADP	O
50199	from	ADP	O
50199	normal	ADJ	O
50199	control	NOUN	O
50199	individuals	NOUN	O
50199	.	PUNCT	O
50200	The	DET	O
50200	following	VERB	O
50200	activities	NOUN	O
50200	(	PUNCT	O
50200	pkat	VERB	O
50200	/	SYM	O
50200	mg	NOUN	O
50200	of	ADP	O
50200	hemoglobin	NOUN	O
50200	)	PUNCT	O
50200	for	ADP	O
50200	glutathione	NOUN	O
50200	synthetase	NOUN	O
50200	were	VERB	O
50200	obtained	VERB	O
50200	:	PUNCT	O
50200	homozygotes	NOUN	O
50200	mean	VERB	O
50200	0.10	NUM	O
50200	(	PUNCT	O
50200	range	NOUN	O
50200	0.07	NUM	O
50200	-	PUNCT	O
50200	0.12	NUM	O
50200	)	PUNCT	O
50200	,	PUNCT	O
50201	heterozygotes	NOUN	O
50201	mean	VERB	O
50201	3.1	NUM	O
50201	(	PUNCT	O
50201	range	VERB	O
50201	2.8	NUM	O
50201	-	SYM	O
50201	3.7	NUM	O
50201	)	PUNCT	O
50201	and	CCONJ	O
50201	control	NOUN	O
50201	individuals	NOUN	O
50201	mean	VERB	O
50201	6.1	NUM	O
50201	(	PUNCT	O
50201	range	NOUN	O
50201	5.4	NUM	O
50201	-	PUNCT	O
50201	6.7	NUM	O
50201	)	PUNCT	O
50201	.	PUNCT	O
50202	These	DET	O
50202	results	NOUN	O
50202	indicate	VERB	O
50202	that	ADP	O
50202	5-oxoprolinuria	NUM	O
50202	,	PUNCT	O
50202	i.e.	X	O
50202	the	DET	O
50202	defective	ADJ	O
50202	gluthione	NOUN	O
50202	synthetase	NOUN	O
50202	gene(s	NOUN	O
50202	)	PUNCT	O
50202	,	PUNCT	O
50202	is	VERB	O
50202	transmitted	VERB	O
50202	by	ADP	O
50202	autosomal	NOUN	O
50202	recessive	ADJ	O
50202	inheritance	NOUN	O
50202	.	PUNCT	O
50203	Studies	NOUN	O
50203	of	ADP	O
50203	the	DET	O
50203	kinetics	NOUN	O
50203	of	ADP	O
50203	the	DET	O
50203	low	ADJ	O
50203	remaining	ADJ	O
50203	activity	NOUN	O
50203	of	ADP	O
50203	erythrocyte	NOUN	O
50203	glutathione	NOUN	O
50203	synthetase	NOUN	O
50203	in	ADP	O
50203	patients	NOUN	O
50203	with	ADP	O
50203	5-oxoprolinuria	NUM	O
50203	failed	VERB	O
50203	to	PART	O
50203	reveal	VERB	O
50203	defective	ADJ	O
50203	affinity	NOUN	O
50203	for	ADP	O
50203	glycine	NOUN	O
50203	,	PUNCT	O
50203	gamma	NOUN	O
50203	-	PUNCT	O
50203	glutamyl	ADJ	O
50203	-	PUNCT	O
50203	alpha	NOUN	O
50203	-	PUNCT	O
50203	aminobutyrate	ADJ	O
50203	,	PUNCT	O
50203	ATP	PROPN	O
50203	and	CCONJ	O
50203	Mg2	NOUN	O
50203	+	SYM	O
50203	ions	NOUN	O
50203	.	PUNCT	O
50204	Furthermore	ADV	O
50204	,	PUNCT	O
50204	the	DET	O
50204	pH	PROPN	O
50204	optimum	ADJ	O
50204	,	PUNCT	O
50204	time	NOUN	O
50204	curves	NOUN	O
50204	and	CCONJ	O
50204	temperature	NOUN	O
50204	dependence	NOUN	O
50204	for	ADP	O
50204	the	DET	O
50204	mutant	ADJ	O
50204	enzyme	NOUN	O
50204	activity	NOUN	O
50204	did	VERB	O
50204	not	ADV	O
50204	significantly	ADV	O
50204	differ	VERB	O
50204	from	ADP	O
50204	the	DET	O
50204	corresponding	VERB	O
50204	parameters	NOUN	O
50204	observed	VERB	O
50204	with	ADP	O
50204	normal	ADJ	O
50204	enzyme	NOUN	O
50204	.	PUNCT	O
50205	The	DET	O
50205	renal	ADJ	O
50205	clearance	NOUN	O
50205	of	ADP	O
50205	1-aminocyclohexanecarboxylic	ADJ	O
50205	acid	NOUN	O
50205	(	PUNCT	O
50205	ACHC	PROPN	O
50205	)	PUNCT	O
50205	,	PUNCT	O
50205	a	DET	O
50205	metabolite	NOUN	O
50205	of	ADP	O
50205	the	DET	O
50205	semisynthetic	ADJ	O
50205	penicillin	NOUN	O
50205	,	PUNCT	O
50205	cyclacillin	INTJ	O
50205	,	PUNCT	O
50205	is	VERB	O
50205	about	ADV	O
50205	10	NUM	O
50205	times	NOUN	O
50205	faster	ADV	O
50205	in	ADP	O
50205	female	NOUN	O
50205	than	ADP	O
50205	in	ADP	O
50205	male	ADJ	O
50205	rats	NOUN	O
50205	.	PUNCT	O
50206	The	DET	O
50206	slower	ADJ	O
50206	clearance	NOUN	O
50206	in	ADP	O
50206	males	NOUN	O
50206	is	VERB	O
50206	attributed	VERB	O
50206	to	ADP	O
50206	a	DET	O
50206	higher	ADJ	O
50206	net	ADJ	O
50206	rate	NOUN	O
50206	of	ADP	O
50206	reabsorption	NOUN	O
50206	of	ADP	O
50206	the	DET	O
50206	compound	NOUN	O
50206	from	ADP	O
50206	the	DET	O
50206	tubule	NOUN	O
50206	of	ADP	O
50206	the	DET	O
50206	kidney	NOUN	O
50206	.	PUNCT	O
50207	Because	ADP	O
50207	ACHC	PROPN	O
50207	is	VERB	O
50207	not	ADV	O
50207	metabolized	VERB	O
50207	,	PUNCT	O
50207	it	PRON	O
50207	is	VERB	O
50207	apparently	ADV	O
50207	continuously	ADV	O
50207	recirculated	VERB	O
50207	through	ADP	O
50207	the	DET	O
50207	kidney	NOUN	O
50207	of	ADP	O
50207	the	DET	O
50207	male	NOUN	O
50207	,	PUNCT	O
50207	resulting	VERB	O
50207	in	ADP	O
50207	the	DET	O
50207	longer	ADJ	O
50207	half	ADJ	O
50207	-	PUNCT	O
50207	life	NOUN	O
50207	.	PUNCT	O
50208	The	DET	O
50208	sex	NOUN	O
50208	-	PUNCT	O
50208	related	VERB	O
50208	disposition	NOUN	O
50208	of	ADP	O
50208	the	DET	O
50208	metabolite	NOUN	O
50208	can	VERB	O
50208	be	VERB	O
50208	modified	VERB	O
50208	by	ADP	O
50208	gonadectomy	NOUN	O
50208	and/or	CCONJ	O
50208	treatment	NOUN	O
50208	with	ADP	O
50208	sex	NOUN	O
50208	hormones	NOUN	O
50208	.	PUNCT	O
50209	Castrated	VERB	O
50209	males	NOUN	O
50209	show	VERB	O
50209	increased	VERB	O
50209	urinary	ADJ	O
50209	excretion	NOUN	O
50209	and	CCONJ	O
50209	decreased	VERB	O
50209	plasma	NOUN	O
50209	half	ADJ	O
50209	-	PUNCT	O
50209	life	NOUN	O
50209	of	ADP	O
50210	ACHC	ADJ	O
50210	relative	ADJ	O
50210	to	ADP	O
50210	intact	ADJ	O
50210	males	NOUN	O
50210	.	PUNCT	O
50211	In	ADP	O
50211	ovariectomized	ADJ	O
50211	females	NOUN	O
50211	,	PUNCT	O
50211	less	ADV	O
50211	ACHC	PROPN	O
50211	is	VERB	O
50211	excreted	VERB	O
50211	and	CCONJ	O
50211	the	DET	O
50211	half	ADJ	O
50211	-	PUNCT	O
50211	life	NOUN	O
50211	is	VERB	O
50211	longer	ADJ	O
50211	than	ADP	O
50211	in	ADP	O
50211	intact	ADJ	O
50211	females	NOUN	O
50211	.	PUNCT	O
50212	Thus	ADV	O
50212	,	PUNCT	O
50212	in	ADP	O
50212	both	DET	O
50212	sexes	NOUN	O
50212	,	PUNCT	O
50212	gonadectomy	NOUN	O
50212	shifts	VERB	O
50212	the	DET	O
50212	excretion	NOUN	O
50212	and	CCONJ	O
50212	the	DET	O
50212	residence	NOUN	O
50212	time	NOUN	O
50212	in	ADP	O
50212	plasma	NOUN	O
50212	toward	ADP	O
50212	the	DET	O
50212	values	NOUN	O
50212	of	ADP	O
50212	these	DET	O
50212	parameters	NOUN	O
50212	for	ADP	O
50212	the	DET	O
50212	opposite	ADJ	O
50212	sex	NOUN	O
50212	.	PUNCT	O
50213	Treatment	NOUN	O
50213	of	ADP	O
50213	castrated	ADJ	O
50213	males	NOUN	O
50213	with	ADP	O
50213	estradiol	NOUN	O
50213	markedly	ADV	O
50213	enhances	VERB	O
50213	the	DET	O
50213	effect	NOUN	O
50213	of	ADP	O
50213	castration	NOUN	O
50213	,	PUNCT	O
50213	but	CCONJ	O
50213	treatment	NOUN	O
50213	of	ADP	O
50213	ovariectomized	ADJ	O
50213	females	NOUN	O
50213	with	ADP	O
50213	testosterone	ADJ	O
50213	propionate	NOUN	O
50213	has	VERB	O
50213	little	ADJ	O
50213	or	CCONJ	O
50213	no	DET	O
50213	additional	ADJ	O
50213	effect	NOUN	O
50213	over	ADP	O
50213	ovariectomy	NOUN	O
50213	.	PUNCT	O
50214	Treatment	NOUN	O
50214	of	ADP	O
50214	intact	ADJ	O
50214	males	NOUN	O
50214	with	ADP	O
50214	estradiol	NOUN	O
50214	modifies	NOUN	O
50214	both	DET	O
50214	excretion	NOUN	O
50214	and	CCONJ	O
50214	residence	NOUN	O
50214	time	NOUN	O
50214	in	ADP	O
50214	plasma	NOUN	O
50214	to	ADP	O
50214	a	DET	O
50214	great	ADJ	O
50214	extent	NOUN	O
50214	,	PUNCT	O
50214	but	CCONJ	O
50214	treatment	NOUN	O
50214	of	ADP	O
50214	intact	ADJ	O
50214	females	NOUN	O
50214	with	ADP	O
50214	testosterone	NOUN	O
50214	has	VERB	O
50214	a	DET	O
50214	lesser	ADJ	O
50214	effect	NOUN	O
50214	on	ADP	O
50214	the	DET	O
50214	disposition	NOUN	O
50214	of	ADP	O
50214	ACHC	PROPN	O
50214	.	PUNCT	O
50215	These	DET	O
50215	results	NOUN	O
50215	indicate	VERB	O
50215	that	ADP	O
50215	excretion	NOUN	O
50215	and	CCONJ	O
50215	residence	NOUN	O
50215	time	NOUN	O
50215	of	ADP	O
50215	ACHC	PROPN	O
50215	in	ADP	O
50215	both	DET	O
50215	male	ADJ	O
50215	and	CCONJ	O
50215	female	ADJ	O
50215	rats	NOUN	O
50215	are	VERB	O
50215	influenced	VERB	O
50215	by	ADP	O
50215	sex	NOUN	O
50215	hormones	NOUN	O
50215	.	PUNCT	O
50216	The	DET	O
50216	described	VERB	O
50216	effect	NOUN	O
50216	is	VERB	O
50216	an	DET	O
50216	example	NOUN	O
50216	of	ADP	O
50216	the	DET	O
50216	action	NOUN	O
50216	of	ADP	O
50216	sex	NOUN	O
50216	hormones	NOUN	O
50216	on	ADP	O
50216	the	DET	O
50216	transport	NOUN	O
50216	of	ADP	O
50216	foreign	ADJ	O
50216	compounds	NOUN	O
50216	in	ADP	O
50216	this	DET	O
50216	species	NOUN	O
50216	.	PUNCT	O
50217	Its	ADJ	O
50217	mechanism	NOUN	O
50217	is	VERB	O
50217	quite	ADV	O
50217	different	ADJ	O
50217	from	ADP	O
50217	the	DET	O
50217	well	ADV	O
50217	known	VERB	O
50217	influence	NOUN	O
50217	of	ADP	O
50217	sex	NOUN	O
50217	hormones	NOUN	O
50217	on	ADP	O
50217	the	DET	O
50217	microsomal	ADJ	O
50217	metabolism	NOUN	O
50217	of	ADP	O
50217	foreign	ADJ	O
50217	compounds	NOUN	O
50217	in	ADP	O
50217	rats	NOUN	O
50217	.	PUNCT	O
50218	The	DET	O
50218	distribution	NOUN	O
50218	of	ADP	O
50218	L	PROPN	O
50218	-	PUNCT	O
50218	phenylalanine	NOUN	O
50218	mustard	NOUN	O
50218	(	PUNCT	O
50218	L	PROPN	O
50218	-	PUNCT	O
50218	PAM	PROPN	O
50218	)	PUNCT	O
50218	was	VERB	O
50218	studied	VERB	O
50218	in	ADP	O
50218	dogs	NOUN	O
50218	and	CCONJ	O
50218	mice	NOUN	O
50218	by	ADP	O
50218	high	ADJ	O
50218	-	PUNCT	O
50218	pressure	NOUN	O
50218	liquid	ADJ	O
50218	chromatography	NOUN	O
50218	.	PUNCT	O
50219	Separation	NOUN	O
50219	of	ADP	O
50219	L	PROPN	O
50219	-	PUNCT	O
50219	PAM	PROPN	O
50219	from	ADP	O
50219	its	ADJ	O
50219	products	NOUN	O
50219	of	ADP	O
50219	hydrolysis	NOUN	O
50219	was	VERB	O
50219	accomplished	VERB	O
50219	with	ADP	O
50219	a	DET	O
50219	mu	NOUN	O
50219	-	PUNCT	O
50219	Bondapak	PROPN	O
50219	C18	PROPN	O
50219	column	NOUN	O
50219	,	PUNCT	O
50219	a	DET	O
50219	solvent	NOUN	O
50219	system	NOUN	O
50219	composed	VERB	O
50219	of	ADP	O
50219	2-methoxyethanol/0.1	NUM	O
50219	%	NOUN	O
50219	acetic	ADJ	O
50219	acid	NOUN	O
50219	,	PUNCT	O
50219	and	CCONJ	O
50219	solvent	NOUN	O
50219	programming	NOUN	O
50219	with	ADP	O
50219	a	DET	O
50219	step	NOUN	O
50219	gradient	NOUN	O
50219	.	PUNCT	O
50220	Complete	ADJ	O
50220	separation	NOUN	O
50220	was	VERB	O
50220	effected	VERB	O
50220	in	ADP	O
50220	less	ADJ	O
50220	than	ADP	O
50220	15	NUM	O
50220	min	NOUN	O
50220	.	PUNCT	O
50221	The	DET	O
50221	half	ADJ	O
50221	-	PUNCT	O
50221	life	NOUN	O
50221	for	ADP	O
50221	disappearance	NOUN	O
50221	of	ADP	O
50221	L	PROPN	O
50221	-	PUNCT	O
50221	PAM	PROPN	O
50221	from	ADP	O
50221	mouse	NOUN	O
50221	blood	NOUN	O
50221	was	VERB	O
50221	41	NUM	O
50221	min	NOUN	O
50221	,	PUNCT	O
50221	whereas	ADP	O
50221	that	ADP	O
50221	from	ADP	O
50221	dog	NOUN	O
50221	blood	NOUN	O
50221	was	VERB	O
50221	29	NUM	O
50221	min	NOUN	O
50221	.	PUNCT	O
50222	The	DET	O
50222	monohydroxy	ADJ	O
50222	derivative	NOUN	O
50222	of	ADP	O
50222	L	NOUN	O
50222	-	PUNCT	O
50222	PAM	PROPN	O
50222	,	PUNCT	O
50222	L	PROPN	O
50222	-	PUNCT	O
50222	MOH	PROPN	O
50222	,	PUNCT	O
50222	disappeared	VERB	O
50222	from	ADP	O
50222	dog	NOUN	O
50222	serum	NOUN	O
50222	with	ADP	O
50222	a	DET	O
50222	half	ADJ	O
50222	-	PUNCT	O
50222	life	NOUN	O
50222	of	ADP	O
50222	32	NUM	O
50222	min	NOUN	O
50222	.	PUNCT	O
50223	L	NOUN	O
50223	-	PUNCT	O
50223	MOH	PROPN	O
50223	was	VERB	O
50223	not	ADV	O
50223	detectable	ADJ	O
50223	in	ADP	O
50223	mouse	NOUN	O
50223	tissue	NOUN	O
50223	other	ADJ	O
50223	than	ADP	O
50223	blood	NOUN	O
50223	at	ADP	O
50223	times	NOUN	O
50223	greater	ADJ	O
50223	than	ADP	O
50223	15	NUM	O
50223	min	NOUN	O
50223	after	ADP	O
50223	injection	NOUN	O
50223	.	PUNCT	O
50224	In	ADP	O
50224	the	DET	O
50224	dog	NOUN	O
50224	at	ADP	O
50224	4	NUM	O
50224	hr	NOUN	O
50224	after	ADP	O
50224	injection	NOUN	O
50224	,	PUNCT	O
50224	the	DET	O
50224	tissue	NOUN	O
50224	/	SYM	O
50224	serum	NOUN	O
50224	concentration	NOUN	O
50224	ratios	NOUN	O
50224	were	VERB	O
50224	greater	ADJ	O
50224	than	ADP	O
50224	1	NUM	O
50224	for	ADP	O
50224	liver	NOUN	O
50224	,	PUNCT	O
50224	spleen	NOUN	O
50224	,	PUNCT	O
50224	intestine	NOUN	O
50224	,	PUNCT	O
50224	skeletal	ADJ	O
50224	muscle	NOUN	O
50224	,	PUNCT	O
50224	urinary	ADJ	O
50224	bladder	NOUN	O
50224	and	CCONJ	O
50224	gallbladder	NOUN	O
50224	.	PUNCT	O
50225	The	DET	O
50225	concentration	NOUN	O
50225	of	ADP	O
50225	L	PROPN	O
50225	-	PUNCT	O
50225	PAM	PROPN	O
50225	in	ADP	O
50225	the	DET	O
50225	bile	NOUN	O
50225	was	VERB	O
50225	approximately	ADV	O
50225	500	NUM	O
50225	times	NOUN	O
50225	higher	ADJ	O
50225	than	ADP	O
50225	that	DET	O
50225	in	ADP	O
50225	serum	NOUN	O
50225	.	PUNCT	O
50226	It	PRON	O
50226	has	VERB	O
50226	been	VERB	O
50226	suggested	VERB	O
50226	that	ADP	O
50226	the	DET	O
50226	pH	NOUN	O
50226	of	ADP	O
50226	the	DET	O
50226	vagina	NOUN	O
50226	at	ADP	O
50226	the	DET	O
50226	time	NOUN	O
50226	of	ADP	O
50226	fertilization	NOUN	O
50226	may	VERB	O
50226	have	VERB	O
50226	a	DET	O
50226	differential	ADJ	O
50226	effect	NOUN	O
50226	on	ADP	O
50226	X-	PROPN	O
50226	or	CCONJ	O
50226	Y	PROPN	O
50226	-	PUNCT	O
50226	bearing	NOUN	O
50226	sperm	NOUN	O
50226	and	CCONJ	O
50226	thereby	ADV	O
50226	affect	VERB	O
50226	the	DET	O
50226	sex	NOUN	O
50226	of	ADP	O
50226	the	DET	O
50226	offspring	NOUN	O
50226	.	PUNCT	O
50227	To	PART	O
50227	test	VERB	O
50227	this	DET	O
50227	postulate	NOUN	O
50227	,	PUNCT	O
50227	rabbit	NOUN	O
50227	semen	NOUN	O
50227	was	VERB	O
50227	collected	VERB	O
50227	,	PUNCT	O
50227	diluted	VERB	O
50227	1:10	NUM	O
50227	with	ADP	O
50227	a	DET	O
50227	buffer	NOUN	O
50227	of	ADP	O
50227	pH	VERB	O
50227	5.4	NUM	O
50227	,	PUNCT	O
50227	6.9	NUM	O
50227	,	PUNCT	O
50227	or	CCONJ	O
50227	9.6	NUM	O
50227	,	PUNCT	O
50227	and	CCONJ	O
50227	after	ADP	O
50227	20	NUM	O
50227	minutes	NOUN	O
50227	0.5	NUM	O
50227	ml	NOUN	O
50227	of	ADP	O
50227	semen	NOUN	O
50227	-	PUNCT	O
50227	buffer	NOUN	O
50227	mixture	NOUN	O
50227	was	VERB	O
50227	used	VERB	O
50227	for	ADP	O
50227	insemination	NOUN	O
50227	in	ADP	O
50227	an	DET	O
50227	ovulation	NOUN	O
50227	-	PUNCT	O
50227	induced	VERB	O
50227	female	NOUN	O
50227	.	PUNCT	O
50228	Newborn	ADJ	O
50228	pups	NOUN	O
50228	were	VERB	O
50228	examined	VERB	O
50228	both	DET	O
50228	externally	ADV	O
50228	and	CCONJ	O
50228	internally	ADV	O
50228	for	ADP	O
50228	gender	NOUN	O
50228	.	PUNCT	O
50229	The	DET	O
50229	females	NOUN	O
50229	inseminated	VERB	O
50229	with	ADP	O
50229	acidic	ADJ	O
50229	semen	NOUN	O
50229	had	VERB	O
50229	6	NUM	O
50229	litters	NOUN	O
50229	,	PUNCT	O
50229	50	NUM	O
50229	offspring	NOUN	O
50229	,	PUNCT	O
50229	with	ADP	O
50229	48	NUM	O
50229	%	NOUN	O
50229	males	NOUN	O
50229	;	PUNCT	O
50229	those	DET	O
50229	with	ADP	O
50229	neutral	ADJ	O
50229	semen	NOUN	O
50229	had	VERB	O
50229	8	NUM	O
50229	litters	NOUN	O
50229	,	PUNCT	O
50229	48	NUM	O
50229	offspring	NOUN	O
50229	,	PUNCT	O
50229	with	ADP	O
50229	63	NUM	O
50229	%	NOUN	O
50229	males	NOUN	O
50229	;	PUNCT	O
50229	and	CCONJ	O
50229	those	DET	O
50229	with	ADP	O
50229	alkaline	NOUN	O
50229	semen	NOUN	O
50229	had	VERB	O
50229	7	NUM	O
50229	litters	NOUN	O
50229	,	PUNCT	O
50229	49	NUM	O
50229	offspring	NOUN	O
50229	,	PUNCT	O
50229	with	ADP	O
50229	49	NUM	O
50229	%	NOUN	O
50229	males	NOUN	O
50229	.	PUNCT	O
50230	There	ADV	O
50230	was	VERB	O
50230	no	DET	O
50230	significant	ADJ	O
50230	difference	NOUN	O
50230	in	ADP	O
50230	these	DET	O
50230	sex	NOUN	O
50230	ratios	NOUN	O
50230	from	ADP	O
50230	the	DET	O
50230	expected	VERB	O
50230	50	NUM	O
50230	%	NOUN	O
50230	males	NOUN	O
50230	.	PUNCT	O
50231	Motility	NOUN	O
50231	of	ADP	O
50231	rabbit	NOUN	O
50231	sperm	NOUN	O
50231	at	ADP	O
50231	23	NUM	O
50231	degrees	NOUN	O
50231	C	NOUN	O
50231	in	ADP	O
50231	buffers	NOUN	O
50231	of	ADP	O
50231	pH	PROPN	O
50231	4.6	NUM	O
50231	,	PUNCT	O
50231	5.4	NUM	O
50231	,	PUNCT	O
50231	6.9	NUM	O
50231	,	PUNCT	O
50231	9.6	NUM	O
50231	,	PUNCT	O
50231	and	CCONJ	O
50231	9.8	NUM	O
50231	was	VERB	O
50231	reduced	VERB	O
50231	in	ADP	O
50231	vitro	X	O
50231	as	ADP	O
50231	the	DET	O
50231	pH	NOUN	O
50231	deviated	VERB	O
50231	from	ADP	O
50231	neutrality	NOUN	O
50231	.	PUNCT	O
50232	Acid	NOUN	O
50232	conditions	NOUN	O
50232	were	VERB	O
50232	more	ADV	O
50232	detrimental	ADJ	O
50232	than	ADP	O
50232	alkaline	NOUN	O
50232	conditions	NOUN	O
50232	.	PUNCT	O
50233	Sperm	PROPN	O
50233	lost	VERB	O
50233	their	ADJ	O
50233	motility	NOUN	O
50233	more	ADV	O
50233	quickly	ADV	O
50233	in	ADP	O
50233	buffers	NOUN	O
50233	of	ADP	O
50233	37	NUM	O
50233	degrees	NOUN	O
50233	C	NOUN	O
50233	than	ADP	O
50233	in	ADP	O
50233	buffers	NOUN	O
50233	of	ADP	O
50233	23	NUM	O
50233	degrees	NOUN	O
50233	C.	PROPN	O
50234	It	PRON	O
50234	was	VERB	O
50234	not	ADV	O
50234	possible	ADJ	O
50234	with	ADP	O
50234	scanning	VERB	O
50234	electron	NOUN	O
50234	microscopy	NOUN	O
50234	to	PART	O
50234	distinguish	VERB	O
50234	morphologically	ADV	O
50234	between	ADP	O
50234	X-	PROPN	O
50234	and	CCONJ	O
50234	Y	PROPN	O
50234	-	PUNCT	O
50234	bearing	NOUN	O
50234	sperm	NOUN	O
50234	.	PUNCT	O
50235	It	PRON	O
50235	seems	VERB	O
50235	unlikely	ADJ	O
50235	that	ADP	O
50235	a	DET	O
50235	direct	ADJ	O
50235	effect	NOUN	O
50235	of	ADP	O
50235	pH	PROPN	O
50235	on	ADP	O
50235	sperm	NOUN	O
50235	can	VERB	O
50235	be	VERB	O
50235	a	DET	O
50235	single	ADJ	O
50235	influence	NOUN	O
50235	on	ADP	O
50235	the	DET	O
50235	sex	NOUN	O
50235	of	ADP	O
50235	offspring	NOUN	O
50235	.	PUNCT	O
50236	Cultured	ADJ	O
50236	cells	NOUN	O
50236	from	ADP	O
50236	Morris	PROPN	O
50236	hepatoma	NOUN	DISEASE
50236	7316A	PROPN	O
50236	contained	VERB	O
50236	isozymes	NOUN	O
50236	I	PRON	O
50236	and	CCONJ	O
50236	II	PROPN	O
50236	,	PUNCT	O
50236	but	CCONJ	O
50236	not	ADV	O
50236	isozyme	VERB	O
50236	III	NUM	O
50236	,	PUNCT	O
50236	of	ADP	O
50236	branched	ADJ	O
50236	-	PUNCT	O
50236	chain	NOUN	O
50236	amino	NOUN	O
50236	acid	NOUN	O
50236	transaminase	NOUN	O
50236	.	PUNCT	O
50237	They	PRON	O
50237	also	ADV	O
50237	contained	VERB	O
50237	tyrosine	ADJ	O
50237	transaminase	NOUN	O
50237	.	PUNCT	O
50238	Isozyme	PROPN	O
50238	II	PROPN	O
50238	and	CCONJ	O
50238	tyrosine	NOUN	O
50238	transaminase	NOUN	O
50238	were	VERB	O
50238	induced	VERB	O
50238	by	ADP	O
50238	addition	NOUN	O
50238	of	ADP	O
50238	cortisol	NOUN	O
50238	.	PUNCT	O
50239	These	DET	O
50239	findings	NOUN	O
50239	agree	VERB	O
50239	well	ADV	O
50239	with	ADP	O
50239	in	ADP	O
50239	vivo	NOUN	O
50239	findings	NOUN	O
50239	.	PUNCT	O
50240	However	ADV	O
50240	,	PUNCT	O
50240	prolonged	VERB	O
50240	culutre	NOUN	O
50240	of	ADP	O
50240	the	DET	O
50240	cells	NOUN	O
50240	for	ADP	O
50240	over	ADP	O
50240	500	NUM	O
50240	days	NOUN	O
50240	caused	VERB	O
50240	deviation	NOUN	O
50240	of	ADP	O
50240	the	DET	O
50240	chromosomal	ADJ	O
50240	bumber	NOUN	O
50240	and	CCONJ	O
50240	activity	NOUN	O
50240	of	ADP	O
50240	both	DET	O
50240	enzymes	NOUN	O
50240	,	PUNCT	O
50240	and	CCONJ	O
50240	they	PRON	O
50240	were	VERB	O
50240	no	ADV	O
50240	longer	ADV	O
50240	affected	VERB	O
50240	by	ADP	O
50240	cortisol	NOUN	O
50240	.	PUNCT	O
50241	A	DET	O
50241	tumor	NOUN	O
50241	formed	VERB	O
50241	by	ADP	O
50241	back	NOUN	O
50241	-	PUNCT	O
50241	transplantation	NOUN	O
50241	of	ADP	O
50241	the	DET	O
50241	cells	NOUN	O
50241	showed	VERB	O
50241	the	DET	O
50241	typical	ADJ	O
50241	isozyme	NOUN	O
50241	pattern	NOUN	O
50241	of	ADP	O
50241	rapidly	ADV	O
50241	growing	VERB	O
50241	hepatomas	NOUN	O
50241	,	PUNCT	O
50241	such	ADJ	O
50241	as	ADP	O
50241	Yoshida	PROPN	O
50241	ascites	VERB	O
50241	hepatomas	NOUN	O
50241	,	PUNCT	O
50241	i.e.	X	O
50241	,	PUNCT	O
50241	isozymes	NOUN	O
50241	I	PRON	O
50241	and	CCONJ	O
50241	III	NUM	O
50241	.	PUNCT	O
50242	These	DET	O
50242	results	NOUN	O
50242	were	VERB	O
50242	discussed	VERB	O
50242	in	ADP	O
50242	relation	NOUN	O
50242	to	PART	O
50242	change	NOUN	O
50242	of	ADP	O
50242	gene	NOUN	O
50242	expression	NOUN	O
50242	during	ADP	O
50242	culture	NOUN	O
50242	.	PUNCT	O
50243	In	ADP	O
50243	order	NOUN	O
50243	to	PART	O
50243	investigate	VERB	O
50243	the	DET	O
50243	source	NOUN	O
50243	of	ADP	O
50243	free	ADJ	O
50243	amino	NOUN	O
50243	acids	NOUN	O
50243	found	VERB	O
50243	in	ADP	O
50243	the	DET	O
50243	gut	NOUN	O
50243	lumen	NOUN	O
50243	during	ADP	O
50243	absorption	NOUN	O
50243	of	ADP	O
50243	dipeptides	NOUN	O
50243	,	PUNCT	O
50243	as	ADV	O
50243	well	ADV	O
50243	as	ADP	O
50243	evaluating	VERB	O
50243	the	DET	O
50243	role	NOUN	O
50243	of	ADP	O
50243	brush	NOUN	O
50243	border	NOUN	O
50243	peptidases	NOUN	O
50243	in	ADP	O
50243	the	DET	O
50243	mucosal	NOUN	O
50243	hydrolysis	NOUN	O
50243	of	ADP	O
50243	dipeptides	NOUN	O
50243	during	ADP	O
50243	absorption	NOUN	O
50243	,	PUNCT	O
50243	rates	NOUN	O
50243	of	ADP	O
50243	dipeptide	ADJ	O
50243	disappearance	NOUN	O
50243	and	CCONJ	O
50243	appearance	NOUN	O
50243	of	ADP	O
50243	hydrolytic	ADJ	O
50243	products	NOUN	O
50243	were	VERB	O
50243	measured	VERB	O
50243	during	ADP	O
50243	perfusion	NOUN	O
50243	of	ADP	O
50243	rat	ADJ	O
50243	jejunum	NOUN	O
50243	and	CCONJ	O
50243	ileum	NOUN	O
50243	in	ADP	O
50243	vivo	NOUN	O
50243	with	ADP	O
50243	buffered	ADJ	O
50243	and	CCONJ	O
50243	unbuffered	ADJ	O
50243	10	NUM	O
50243	mM	PROPN	O
50243	solutions	NOUN	O
50243	of	ADP	O
50243	glycl	NOUN	O
50243	-	PUNCT	O
50243	L	NOUN	O
50243	-	PUNCT	O
50243	phenylalanine	PROPN	O
50243	(	PUNCT	O
50243	Gly	PROPN	O
50243	-	PUNCT	O
50243	Phe	PROPN	O
50243	)	PUNCT	O
50243	and	CCONJ	O
50243	L	NOUN	O
50243	-	PUNCT	O
50243	phenylalanyl	NOUN	O
50243	-	PUNCT	O
50243	glycine	NOUN	O
50243	(	PUNCT	O
50243	Phe	PROPN	O
50243	-	PUNCT	O
50243	Gly	PROPN	O
50243	)	PUNCT	O
50243	.	PUNCT	O
50244	Mucosal	PROPN	O
50244	brush	NOUN	O
50244	border	NOUN	O
50244	peptidase	NOUN	O
50244	activity	NOUN	O
50244	was	VERB	O
50244	then	ADV	O
50244	measured	VERB	O
50244	in	ADP	O
50244	the	DET	O
50244	perfused	VERB	O
50244	segments	NOUN	O
50244	in	ADP	O
50244	vitro	X	O
50244	at	ADP	O
50244	luminal	ADJ	O
50244	pH	PROPN	O
50244	and	CCONJ	O
50244	at	ADP	O
50244	two	NUM	O
50244	substrate	NOUN	O
50244	concentrations	NOUN	O
50244	.	PUNCT	O
50245	In	ADP	O
50245	addition	NOUN	O
50245	cytosol	NOUN	O
50245	peptidase	NOUN	O
50245	activity	NOUN	O
50245	in	ADP	O
50245	the	DET	O
50245	perfused	VERB	O
50245	segments	NOUN	O
50245	was	VERB	O
50245	measured	VERB	O
50245	at	ADP	O
50245	pH	PROPN	O
50245	7	NUM	O
50245	-	SYM	O
50245	4	NUM	O
50245	and	CCONJ	O
50245	at	ADP	O
50245	10	NUM	O
50245	mM	PROPN	O
50245	substrate	NOUN	O
50245	concentrations	NOUN	O
50245	.	PUNCT	O
50246	In	ADP	O
50246	the	DET	O
50246	jejunum	NOUN	O
50246	,	PUNCT	O
50246	there	ADV	O
50246	was	VERB	O
50246	a	DET	O
50246	relationship	NOUN	O
50246	between	ADP	O
50246	rates	NOUN	O
50246	of	ADP	O
50246	free	ADJ	O
50246	phenylalanine	NOUN	O
50246	appearance	NOUN	O
50246	in	ADP	O
50246	vivo	NOUN	O
50246	(	PUNCT	O
50246	Phe	PROPN	O
50246	-	PUNCT	O
50246	Gly	PROPN	O
50246	greater	ADJ	O
50246	than	ADP	O
50246	Gly	PROPN	O
50246	-	PUNCT	O
50246	Phe	PROPN	O
50246	)	PUNCT	O
50246	and	CCONJ	O
50246	rates	NOUN	O
50246	of	ADP	O
50246	brush	NOUN	O
50246	border	NOUN	O
50246	(	PUNCT	O
50246	Phe	PROPN	O
50246	-	PUNCT	O
50246	Gly	PROPN	O
50246	greater	ADJ	O
50246	than	ADP	O
50246	Gly	PROPN	O
50246	-	PUNCT	O
50246	Phe	PROPN	O
50246	)	PUNCT	O
50246	rather	ADV	O
50246	than	ADP	O
50246	cytosol	NOUN	O
50246	(	PUNCT	O
50247	Gly	PROPN	O
50247	-	PUNCT	O
50247	Phe	PROPN	O
50247	greater	ADJ	O
50247	than	ADP	O
50247	Phe	PROPN	O
50247	-	PUNCT	O
50247	Gly	PROPN	O
50247	)	PUNCT	O
50247	peptidase	NOUN	O
50247	activities	NOUN	O
50247	.	PUNCT	O
50248	No	DET	O
50248	constant	ADJ	O
50248	relationship	NOUN	O
50248	between	ADP	O
50248	free	ADJ	O
50248	phenylalanine	NOUN	O
50248	appearance	NOUN	O
50248	and	CCONJ	O
50248	hydrolysis	NOUN	O
50248	of	ADP	O
50248	the	DET	O
50248	dipeptides	NOUN	O
50248	by	ADP	O
50248	either	DET	O
50248	brush	NOUN	O
50248	border	NOUN	O
50248	or	CCONJ	O
50248	cytosol	NOUN	O
50248	peptidases	NOUN	O
50248	was	VERB	O
50248	observed	VERB	O
50248	in	ADP	O
50248	the	DET	O
50248	ileal	ADJ	O
50248	studies	NOUN	O
50248	.	PUNCT	O
50249	These	DET	O
50249	findings	NOUN	O
50249	suggest	VERB	O
50249	that	ADP	O
50249	,	PUNCT	O
50249	in	ADP	O
50249	the	DET	O
50249	jejunum	NOUN	O
50249	,	PUNCT	O
50249	hydrolytic	ADJ	O
50249	products	NOUN	O
50249	originate	VERB	O
50249	from	ADP	O
50249	the	DET	O
50249	surface	NOUN	O
50249	of	ADP	O
50249	the	DET	O
50249	cell	NOUN	O
50249	whereas	ADP	O
50249	,	PUNCT	O
50249	in	ADP	O
50249	the	DET	O
50249	ileum	NOUN	O
50249	,	PUNCT	O
50249	hydrolytic	ADJ	O
50249	products	NOUN	O
50249	originate	VERB	O
50249	from	ADP	O
50249	both	CCONJ	O
50249	the	DET	O
50249	intracellular	ADJ	O
50249	compartment	NOUN	O
50249	as	ADV	O
50249	well	ADV	O
50249	as	ADP	O
50249	from	ADP	O
50249	the	DET	O
50249	surface	NOUN	O
50249	of	ADP	O
50249	the	DET	O
50249	mucosal	NOUN	O
50249	cell	NOUN	O
50249	.	PUNCT	O
50250	In	ADP	O
50250	the	DET	O
50250	jejunum	NOUN	O
50250	,	PUNCT	O
50250	in	ADP	O
50250	vitro	X	O
50250	rates	NOUN	O
50250	of	ADP	O
50250	brush	NOUN	O
50250	border	NOUN	O
50250	hydrolysis	NOUN	O
50250	of	ADP	O
50250	Gly	PROPN	O
50250	-	PUNCT	O
50250	Phe	PROPN	O
50250	were	VERB	O
50250	always	ADV	O
50250	less	ADJ	O
50250	than	ADP	O
50250	in	ADP	O
50250	vivo	NOUN	O
50250	disappearance	NOUN	O
50250	rates	NOUN	O
50250	,	PUNCT	O
50250	whereas	ADP	O
50250	rates	NOUN	O
50250	of	ADP	O
50250	Phe	PROPN	O
50250	-	PUNCT	O
50250	Gly	PROPN	O
50250	brush	NOUN	O
50250	border	NOUN	O
50250	hydrolysis	NOUN	O
50250	always	ADV	O
50250	exceeded	VERB	O
50250	luminal	ADJ	O
50250	disappearance	NOUN	O
50250	rates	NOUN	O
50250	.	PUNCT	O
50251	These	DET	O
50251	data	NOUN	O
50251	imply	VERB	O
50251	that	ADP	O
50251	Gly	PROPN	O
50251	-	PUNCT	O
50251	Phe	PROPN	O
50251	is	VERB	O
50251	predominantly	ADV	O
50251	transported	VERB	O
50251	intact	ADJ	O
50251	and	CCONJ	O
50251	hydrolysed	VERB	O
50251	by	ADP	O
50251	cytosol	NOUN	O
50251	peptidases	NOUN	O
50251	,	PUNCT	O
50252	In	ADP	O
50252	contrast	NOUN	O
50252	,	PUNCT	O
50252	brush	NOUN	O
50252	border	NOUN	O
50252	peptidases	NOUN	O
50252	play	VERB	O
50252	an	DET	O
50252	importnat	NOUN	O
50252	role	NOUN	O
50252	in	ADP	O
50252	the	DET	O
50252	mucosal	NOUN	O
50252	hydrolysis	NOUN	O
50252	of	ADP	O
50252	Phe	PROPN	O
50252	-	PUNCT	O
50252	Gly	PROPN	O
50252	.	PUNCT	O
50253	The	DET	O
50253	nitrosation	NOUN	O
50253	of	ADP	O
50253	several	ADJ	O
50253	drugs	NOUN	O
50253	under	ADP	O
50253	simulated	VERB	O
50253	stomach	NOUN	O
50253	conditions	NOUN	O
50253	was	VERB	O
50253	only	ADV	O
50253	weakly	ADV	O
50253	inhibited	VERB	O
50253	by	ADP	O
50253	the	DET	O
50253	beverages	NOUN	O
50253	studied	VERB	O
50253	.	PUNCT	O
50254	With	ADP	O
50254	easily	ADV	O
50254	and	CCONJ	O
50254	rapidly	ADV	O
50254	nitrosatable	ADJ	O
50254	drugs	NOUN	O
50254	,	PUNCT	O
50254	such	ADJ	O
50254	as	ADP	O
50254	aminophenazone	NOUN	O
50254	or	CCONJ	O
50254	piperazine	NOUN	O
50254	,	PUNCT	O
50254	administered	VERB	O
50254	orally	ADV	O
50254	,	PUNCT	O
50254	the	DET	O
50254	use	NOUN	O
50254	of	ADP	O
50254	an	DET	O
50254	inhibitor	NOUN	O
50254	of	ADP	O
50254	nitrosation	NOUN	O
50254	is	VERB	O
50254	to	PART	O
50254	be	VERB	O
50254	recommended	VERB	O
50254	.	PUNCT	O
50255	Of	ADP	O
50255	all	ADJ	O
50255	the	DET	O
50255	substances	NOUN	O
50255	investigated	VERB	O
50255	,	PUNCT	O
50255	ascorbic	NOUN	O
50255	acid	NOUN	O
50255	should	VERB	O
50255	be	VERB	O
50255	regarded	VERB	O
50255	as	ADP	O
50255	the	DET	O
50255	best	ADJ	O
50255	inhibitor	NOUN	O
50255	because	ADP	O
50255	of	ADP	O
50255	its	ADJ	O
50255	pronounced	ADJ	O
50255	activity	NOUN	O
50255	at	ADP	O
50255	the	DET	O
50255	pH	PROPN	O
50255	values	NOUN	O
50255	occurring	VERB	O
50255	in	ADP	O
50255	the	DET	O
50255	stomach	NOUN	O
50255	and	CCONJ	O
50255	its	ADJ	O
50255	lack	NOUN	O
50255	of	ADP	O
50255	toxic	ADJ	O
50255	effects	NOUN	O
50255	.	PUNCT	O
50256	We	PRON	O
50256	would	VERB	O
50256	like	VERB	O
50256	to	PART	O
50256	propose	VERB	O
50256	that	ADP	O
50256	the	DET	O
50256	drugs	NOUN	O
50256	under	ADP	O
50256	consideration	NOUN	O
50256	should	VERB	O
50256	be	VERB	O
50256	made	VERB	O
50256	up	PART	O
50256	to	PART	O
50256	contain	VERB	O
50256	a	DET	O
50256	sufficient	ADJ	O
50256	amount	NOUN	O
50256	of	ADP	O
50256	ascorbic	NOUN	O
50256	acid	NOUN	O
50256	.	PUNCT	O
50257	The	DET	O
50257	1st	ADJ	O
50257	2	NUM	O
50257	cases	NOUN	O
50257	of	ADP	O
50257	vascularized	ADJ	O
50257	Fallopian	ADJ	O
50257	tube	NOUN	O
50257	transplants	NOUN	O
50257	were	VERB	O
50257	performed	VERB	O
50257	at	ADP	O
50257	Groote	PROPN	O
50257	Schuur	PROPN	O
50257	Hospital	PROPN	O
50257	in	ADP	O
50257	Cape	PROPN	O
50257	Town	PROPN	O
50257	,	PUNCT	O
50257	South	PROPN	O
50257	Africa	PROPN	O
50257	.	PUNCT	O
50258	In	ADP	O
50258	both	DET	O
50258	cases	NOUN	O
50258	,	PUNCT	O
50258	it	PRON	O
50258	was	VERB	O
50258	determined	VERB	O
50258	that	ADP	O
50258	the	DET	O
50258	tubal	ADJ	O
50258	defect	NOUN	O
50258	was	VERB	O
50258	the	DET	O
50258	only	ADJ	O
50258	barrier	NOUN	O
50258	to	ADP	O
50258	conception	NOUN	O
50258	.	PUNCT	O
50259	The	DET	O
50259	donors	NOUN	O
50259	,	PUNCT	O
50259	both	DET	O
50259	36	NUM	O
50259	 	SPACE	O
50259	years	NOUN	O
50259	of	ADP	O
50259	age	NOUN	O
50259	,	PUNCT	O
50259	had	VERB	O
50259	been	VERB	O
50259	scheduled	VERB	O
50259	for	ADP	O
50259	hysterectomy	NOUN	O
50259	and	CCONJ	O
50259	had	VERB	O
50259	consented	VERB	O
50259	to	PART	O
50259	donation	NOUN	O
50259	of	ADP	O
50259	their	ADJ	O
50259	oviducts	NOUN	O
50259	.	PUNCT	O
50260	The	DET	O
50260	1st	ADJ	O
50260	patient	NOUN	O
50260	was	VERB	O
50260	discharged	VERB	O
50260	on	ADP	O
50260	the	DET	O
50260	16th	ADJ	O
50260	postoperative	ADJ	O
50260	day	NOUN	O
50260	with	ADP	O
50260	no	DET	O
50260	symptoms	NOUN	O
50260	or	CCONJ	O
50260	signs	NOUN	O
50260	of	ADP	O
50260	rejection	NOUN	O
50260	of	ADP	O
50260	the	DET	O
50260	graft	NOUN	O
50260	.	PUNCT	O
50261	However	ADV	O
50261	,	PUNCT	O
50261	a	DET	O
50261	 	SPACE	O
50261	hysterosalpingogram	NOUN	O
50261	performed	VERB	O
50261	3	NUM	O
50261	months	NOUN	O
50261	later	ADV	O
50261	showed	VERB	O
50261	cornual	ADJ	O
50261	patency	NOUN	O
50261	associated	VERB	O
50261	with	ADP	O
50261	narrowing	NOUN	O
50261	and	CCONJ	O
50261	shrinkage	NOUN	O
50261	of	ADP	O
50261	the	DET	O
50261	graft	NOUN	O
50261	specimen	NOUN	O
50261	;	PUNCT	O
50261	 	SPACE	O
50261	the	DET	O
50261	rejected	VERB	O
50261	tube	NOUN	O
50261	was	VERB	O
50261	excised	VERB	O
50261	.	PUNCT	O
50262	In	ADP	O
50262	the	DET	O
50262	2nd	ADJ	O
50262	case	NOUN	O
50262	the	DET	O
50262	patient	NOUN	O
50262	developed	VERB	O
50262	a	DET	O
50262	fever	NOUN	O
50262	and	CCONJ	O
50262	tenderness	NOUN	O
50262	localized	VERB	O
50262	to	ADP	O
50262	the	DET	O
50262	right	ADJ	O
50262	subcostal	ADJ	O
50262	area	NOUN	O
50262	.	PUNCT	O
50263	A	DET	O
50263	subcostal	ADJ	O
50263	exploration	NOUN	O
50263	was	VERB	O
50263	performed	VERB	O
50263	,	PUNCT	O
50263	and	CCONJ	O
50263	a	DET	O
50263	section	NOUN	O
50263	of	ADP	O
50263	the	DET	O
50263	large	ADJ	O
50263	bowel	NOUN	O
50263	and	CCONJ	O
50263	edematous	ADJ	O
50263	omentum	NOUN	O
50263	were	VERB	O
50263	adherent	NOUN	O
50263	 	SPACE	O
50263	over	ADP	O
50263	the	DET	O
50263	pelvis	NOUN	O
50263	with	ADP	O
50263	bloodstained	ADJ	O
50263	fluid	NOUN	O
50263	in	ADP	O
50263	the	DET	O
50263	abdomen	NOUN	O
50263	.	PUNCT	O
50264	The	DET	O
50264	graft	NOUN	O
50264	cornu	NOUN	O
50264	was	VERB	O
50264	excised	VERB	O
50264	,	PUNCT	O
50264	and	CCONJ	O
50264	it	PRON	O
50264	was	VERB	O
50264	necessary	ADJ	O
50264	to	PART	O
50264	remove	VERB	O
50264	the	DET	O
50264	patient	NOUN	O
50264	's	PART	O
50264	right	ADJ	O
50264	ovary	ADJ	O
50264	.	PUNCT	O
50265	The	DET	O
50265	occurrence	NOUN	O
50265	of	ADP	O
50265	rejection	NOUN	O
50265	indicated	VERB	O
50265	that	ADP	O
50265	the	DET	O
50265	transplanted	VERB	O
50265	tubes	NOUN	O
50265	had	VERB	O
50265	been	VERB	O
50265	revascularized	VERB	O
50265	.	PUNCT	O
50266	Rejection	NOUN	O
50266	in	ADP	O
50266	both	DET	O
50266	patients	NOUN	O
50266	was	VERB	O
50266	associated	VERB	O
50266	with	ADP	O
50266	anatomical	ADJ	O
50266	isolation	NOUN	O
50266	of	ADP	O
50266	the	DET	O
50266	graft	NOUN	O
50266	by	ADP	O
50266	the	DET	O
50266	omentum	NOUN	O
50266	.	PUNCT	O
50267	Further	ADJ	O
50267	progress	NOUN	O
50267	in	ADP	O
50267	immunosuppressive	ADJ	O
50267	therapy	NOUN	O
50267	will	VERB	O
50267	be	VERB	O
50267	necessary	ADJ	O
50267	for	ADP	O
50267	Fallopian	ADJ	O
50267	tube	NOUN	O
50267	transplants	NOUN	O
50267	.	PUNCT	O
50268	Alterations	NOUN	O
50268	in	ADP	O
50268	coronary	ADJ	O
50268	blood	NOUN	O
50268	flow	NOUN	O
50268	associated	VERB	O
50268	with	ADP	O
50268	adaptation	NOUN	O
50268	to	ADP	O
50268	high	ADJ	O
50268	altitude	NOUN	O
50268	were	VERB	O
50268	examined	VERB	O
50268	.	PUNCT	O
50269	Three	NUM	O
50269	normal	ADJ	O
50269	men	NOUN	O
50269	native	VERB	O
50269	to	ADP	O
50269	low	ADJ	O
50269	altitude	NOUN	O
50269	were	VERB	O
50269	studied	VERB	O
50269	,	PUNCT	O
50269	first	ADV	O
50269	at	ADP	O
50269	sea	NOUN	O
50269	level	NOUN	O
50269	,	PUNCT	O
50269	and	CCONJ	O
50269	again	ADV	O
50269	after	ADP	O
50269	10	NUM	O
50269	days	NOUN	O
50269	'	PART	O
50269	sojourn	NOUN	O
50269	at	ADP	O
50269	3,100	NUM	O
50269	m	NOUN	O
50269	altitude	NOUN	O
50269	.	PUNCT	O
50270	During	ADP	O
50270	rest	NOUN	O
50270	at	ADP	O
50270	high	ADJ	O
50270	altitude	NOUN	O
50270	,	PUNCT	O
50270	a	DET	O
50270	32	NUM	O
50270	%	NOUN	O
50270	decrease	NOUN	O
50270	in	ADP	O
50270	coronary	ADJ	O
50270	blood	NOUN	O
50270	flow	NOUN	O
50270	was	VERB	O
50270	largely	ADV	O
50270	offset	VERB	O
50270	by	ADP	O
50270	a	DET	O
50270	28	NUM	O
50270	%	NOUN	O
50270	increase	NOUN	O
50270	in	ADP	O
50270	coronary	ADJ	O
50270	arterial	ADJ	O
50270	O2	NOUN	O
50270	extraction	NOUN	O
50270	to	PART	O
50270	maintain	VERB	O
50270	myocardial	ADJ	O
50270	O2	NOUN	O
50270	delivery	NOUN	O
50270	.	PUNCT	O
50271	The	DET	O
50271	increase	NOUN	O
50271	in	ADP	O
50271	O2	NOUN	O
50271	extraction	NOUN	O
50271	resulted	VERB	O
50271	mainly	ADV	O
50271	from	ADP	O
50271	a	DET	O
50271	decrease	NOUN	O
50271	in	ADP	O
50271	coronary	ADJ	O
50271	sinus	NOUN	O
50271	blood	NOUN	O
50271	O2	NOUN	O
50271	content	NOUN	O
50271	and	CCONJ	O
50271	saturation	NOUN	O
50271	.	PUNCT	O
50272	However	ADV	O
50272	,	PUNCT	O
50272	coronary	ADJ	O
50272	sinus	NOUN	O
50272	O2	NOUN	O
50272	tension	NOUN	O
50272	remained	VERB	O
50272	constant	ADJ	O
50272	,	PUNCT	O
50272	implying	VERB	O
50272	a	DET	O
50272	decrease	NOUN	O
50272	in	ADP	O
50272	the	DET	O
50272	affinity	NOUN	O
50272	of	ADP	O
50272	hemoglobin	NOUN	O
50272	for	ADP	O
50272	O2	NOUN	O
50272	.	PUNCT	O
50273	These	DET	O
50273	observations	NOUN	O
50273	are	VERB	O
50273	consistent	ADJ	O
50273	with	ADP	O
50273	the	DET	O
50273	hypothesis	NOUN	O
50273	that	ADP	O
50273	coronary	ADJ	O
50273	blood	NOUN	O
50273	flow	NOUN	O
50273	is	VERB	O
50273	regulated	VERB	O
50273	to	PART	O
50273	maintain	VERB	O
50273	constant	ADJ	O
50273	myocardial	ADJ	O
50273	tissue	NOUN	O
50273	O2	NOUN	O
50273	tension	NOUN	O
50273	(	PUNCT	O
50273	as	ADP	O
50273	reflected	VERB	O
50273	here	ADV	O
50273	by	ADP	O
50273	coronary	ADJ	O
50273	sinus	NOUN	O
50273	blood	NOUN	O
50273	O2	NOUN	O
50273	tension	NOUN	O
50273	)	PUNCT	O
50273	.	PUNCT	O
50274	The	DET	O
50274	absence	NOUN	O
50274	of	ADP	O
50274	a	DET	O
50274	decrease	NOUN	O
50274	in	ADP	O
50274	coronary	ADJ	O
50274	sinus	NOUN	O
50274	O2	NOUN	O
50274	tension	NOUN	O
50274	or	CCONJ	O
50274	a	DET	O
50274	decrease	NOUN	O
50274	in	ADP	O
50274	myocardial	ADJ	O
50274	lactate	NOUN	O
50274	extraction	NOUN	O
50274	imply	VERB	O
50274	that	ADP	O
50274	myocardial	ADJ	O
50274	hypoxia	NOUN	O
50274	did	VERB	O
50274	not	ADV	O
50274	develop	VERB	O
50274	.	PUNCT	O
50275	Therefore	ADV	O
50275	,	PUNCT	O
50275	myocardial	ADJ	O
50275	hypoxia	NOUN	O
50275	is	VERB	O
50275	not	ADV	O
50275	the	DET	O
50275	basis	NOUN	O
50275	for	ADP	O
50275	the	DET	O
50275	decrease	NOUN	O
50275	in	ADP	O
50275	cardiac	ADJ	O
50275	stroke	NOUN	DISEASE
50275	volume	NOUN	O
50275	at	ADP	O
50275	high	ADJ	O
50275	altitude	NOUN	O
50275	reported	VERB	O
50275	previously	ADV	O
50275	and	CCONJ	O
50275	also	ADV	O
50275	observed	VERB	O
50275	in	ADP	O
50275	the	DET	O
50275	present	ADJ	O
50275	study	NOUN	O
50275	.	PUNCT	O
50276	In	ADP	O
50276	order	NOUN	O
50276	to	PART	O
50276	elucidate	VERB	O
50276	the	DET	O
50276	possible	ADJ	O
50276	roles	NOUN	O
50276	of	ADP	O
50276	histidine	NOUN	O
50276	and	CCONJ	O
50276	tyrosine	NOUN	O
50276	residues	NOUN	O
50276	of	ADP	O
50276	catalase	NOUN	O
50276	[	PUNCT	O
50276	EC	PROPN	O
50276	1.11.1.6	NUM	O
50276	]	PUNCT	O
50276	in	ADP	O
50276	maintaining	VERB	O
50276	the	DET	O
50276	quaternary	ADJ	O
50276	structure	NOUN	O
50276	and	CCONJ	O
50276	catalatic	ADJ	O
50276	activity	NOUN	O
50276	,	PUNCT	O
50276	diethylpyrocarbonate	VERB	O
50276	modification	NOUN	O
50276	experiments	NOUN	O
50276	were	VERB	O
50276	carried	VERB	O
50276	out	PART	O
50276	.	PUNCT	O
50277	A	DET	O
50277	method	NOUN	O
50277	for	ADP	O
50277	the	DET	O
50277	estimation	NOUN	O
50277	of	ADP	O
50277	N	PROPN	O
50277	-	PUNCT	O
50277	ethoxyformyl	PROPN	O
50277	(	PUNCT	O
50277	EF)-His	ADV	O
50277	at	ADP	O
50277	pH	PROPN	O
50277	5	NUM	O
50277	-	PUNCT	O
50277	-7	NOUN	O
50277	and	CCONJ	O
50277	of	ADP	O
50277	O	NOUN	O
50277	-	PUNCT	O
50277	ethoxyformyl	NOUN	O
50278	(	PUNCT	O
50278	EF)-Tyr	NOUN	O
50278	in	ADP	O
50278	alkaline	NOUN	O
50278	solution	NOUN	O
50278	by	ADP	O
50278	measuring	VERB	O
50278	A	DET	O
50278	242	NUM	O
50278	nm	NUM	O
50278	(	PUNCT	O
50278	ximM	PROPN	O
50278	=	SYM	O
50278	3.2	NUM	O
50278	)	PUNCT	O
50278	and	CCONJ	O
50279	A278	PROPN	O
50279	nm	NUM	O
50279	(	PUNCT	O
50279	ximM	PROPN	O
50279	=	SYM	O
50279	1.16	NUM	O
50279	)	PUNCT	O
50279	,	PUNCT	O
50279	respectively	ADV	O
50279	,	PUNCT	O
50279	was	VERB	O
50279	developed	VERB	O
50279	.	PUNCT	O
50280	The	DET	O
50280	formation	NOUN	O
50280	of	ADP	O
50280	EF-	PUNCT	O
50281	His	ADJ	O
50281	and	CCONJ	O
50281	EF	PROPN	O
50282	-Tyr	PUNCT	O
50282	was	VERB	O
50282	an	DET	O
50282	electrophilic	ADJ	O
50282	reaction	NOUN	O
50282	and	CCONJ	O
50282	was	VERB	O
50282	dependent	ADJ	O
50282	on	ADP	O
50282	pH	PROPN	O
50282	,	PUNCT	O
50282	exhibiting	VERB	O
50282	pK	PROPN	O
50282	values	NOUN	O
50282	of	ADP	O
50282	6.8	NUM	O
50282	and	CCONJ	O
50282	9.9	NUM	O
50282	,	PUNCT	O
50282	respectively	ADV	O
50282	.	PUNCT	O
50283	The	DET	O
50283	maximal	ADJ	O
50283	yield	NOUN	O
50283	of	ADP	O
50283	EF-	PUNCT	O
50284	His	ADJ	O
50284	at	ADP	O
50284	pH	PROPN	O
50284	6.0	NUM	O
50284	was	VERB	O
50284	49	NUM	O
50284	%	NOUN	O
50284	of	ADP	O
50284	the	DET	O
50284	total	ADJ	O
50284	histidine	NOUN	O
50284	content	NOUN	O
50284	,	PUNCT	O
50284	but	CCONJ	O
50284	no	DET	O
50284	inactivation	NOUN	O
50284	nor	CCONJ	O
50284	unfolding	VERB	O
50284	of	ADP	O
50284	the	DET	O
50284	enzyme	NOUN	O
50284	was	VERB	O
50284	observed	VERB	O
50284	.	PUNCT	O
50285	The	DET	O
50285	formation	NOUN	O
50285	of	ADP	O
50285	12	NUM	O
50285	EF-	NOUN	O
50286	Tyr	PROPN	O
50286	residues	NOUN	O
50286	per	ADP	O
50286	mole	NOUN	O
50286	of	ADP	O
50286	catalase	NOUN	O
50286	at	ADP	O
50286	pH	PROPN	O
50286	8.1	NUM	O
50286	did	VERB	O
50286	not	ADV	O
50286	cause	VERB	O
50286	any	DET	O
50286	inactivation	NOUN	O
50286	,	PUNCT	O
50286	but	CCONJ	O
50286	the	DET	O
50286	formation	NOUN	O
50286	of	ADP	O
50286	8	NUM	O
50286	more	ADJ	O
50286	EF	PROPN	O
50286	-	PUNCT	O
50286	Tyr	PROPN	O
50286	residues	NOUN	O
50286	at	ADP	O
50286	pH	PROPN	O
50286	8.9	NUM	O
50286	resulted	VERB	O
50286	in	ADP	O
50286	both	DET	O
50286	inactivation	NOUN	O
50286	and	CCONJ	O
50286	unfolding	NOUN	O
50286	.	PUNCT	O
50287	Nearly	ADV	O
50287	complete	ADJ	O
50287	inactivation	NOUN	O
50287	and	CCONJ	O
50287	partial	ADJ	O
50287	splitting	NOUN	O
50287	of	ADP	O
50287	catalase	NOUN	O
50287	were	VERB	O
50287	observed	VERB	O
50287	when	ADV	O
50287	43	NUM	O
50287	-	SYM	O
50287	46	NUM	O
50287	EF-	PUNCT	O
50288	Tyr	PROPN	O
50288	residues	NOUN	O
50288	per	ADP	O
50288	mole	NOUN	O
50288	were	VERB	O
50288	produced	VERB	O
50288	at	ADP	O
50288	pH	PROPN	O
50288	10.0	NUM	O
50288	.	PUNCT	O
50289	More	ADJ	O
50289	EF-	PUNCT	O
50290	His	ADJ	O
50290	residues	NOUN	O
50290	were	VERB	O
50290	formed	VERB	O
50290	by	ADP	O
50290	the	DET	O
50290	reaction	NOUN	O
50290	of	ADP	O
50290	diethyl	NUM	O
50290	pyrocarbonate	NOUN	O
50290	with	ADP	O
50290	cyanoethylated	VERB	O
50290	(	PUNCT	O
50290	CE)-catalase	NOUN	O
50290	monomer	NOUN	O
50290	(	PUNCT	O
50290	subunit	NOUN	O
50290	)	PUNCT	O
50290	than	ADP	O
50290	with	ADP	O
50290	CE	PROPN	O
50290	-	PUNCT	O
50290	catalase	NOUN	O
50290	tetramer	NOUN	O
50290	.	PUNCT	O
50291	The	DET	O
50291	CE	PROPN	O
50291	-	PUNCT	O
50291	catalase	NOUN	O
50291	tetramer	NOUN	O
50291	and	CCONJ	O
50291	monomer	NOUN	O
50291	were	VERB	O
50291	extensively	ADV	O
50291	O	NOUN	O
50291	-	PUNCT	O
50291	ethoxyformylated	ADJ	O
50291	,	PUNCT	O
50291	reaching	VERB	O
50291	100	NUM	O
50291	%	NOUN	O
50291	EF	PROPN	O
50291	-	PUNCT	O
50291	Tyr	PROPN	O
50291	formation	NOUN	O
50291	.	PUNCT	O
50292	These	DET	O
50292	results	NOUN	O
50292	indicate	VERB	O
50292	that	ADP	O
50292	a	DET	O
50292	half	NOUN	O
50292	of	ADP	O
50292	the	DET	O
50292	histidine	NOUN	O
50292	residues	NOUN	O
50292	may	VERB	O
50292	lie	VERB	O
50292	outside	ADP	O
50292	the	DET	O
50292	protein	NOUN	O
50292	core	NOUN	O
50292	and	CCONJ	O
50292	that	ADP	O
50292	three	NUM	O
50292	-	PUNCT	O
50292	quarters	NOUN	O
50292	of	ADP	O
50292	the	DET	O
50292	tyrosine	NOUN	O
50292	residues	NOUN	O
50292	are	VERB	O
50292	probably	ADV	O
50292	in	ADP	O
50292	the	DET	O
50292	protein	NOUN	O
50292	core	NOUN	O
50292	of	ADP	O
50292	the	DET	O
50292	enzyme	NOUN	O
50292	.	PUNCT	O
50293	The	DET	O
50293	production	NOUN	O
50293	of	ADP	O
50293	2	NUM	O
50293	-	PUNCT	O
50293	-3	NOUN	O
50293	EF-	PUNCT	O
50294	Tyr	PROPN	O
50294	residues	NOUN	O
50294	per	ADP	O
50294	mole	NOUN	O
50294	of	ADP	O
50294	the	DET	O
50294	monomer	NOUN	O
50294	by	ADP	O
50294	ethoxyformylation	NOUN	O
50294	at	ADP	O
50294	pH	NOUN	O
50294	7.0	NUM	O
50294	was	VERB	O
50294	accompanied	VERB	O
50294	by	ADP	O
50294	a	DET	O
50294	decrease	NOUN	O
50294	in	ADP	O
50294	the	DET	O
50294	magnitude	NOUN	O
50294	of	ADP	O
50294	the	DET	O
50294	Soret	PROPN	O
50294	peak	NOUN	O
50294	.	PUNCT	O
50295	A	DET	O
50295	possible	ADJ	O
50295	interaction	NOUN	O
50295	of	ADP	O
50295	those	DET	O
50295	tyrosine	NOUN	O
50295	residues	NOUN	O
50295	with	ADP	O
50295	porphyrin	NOUN	O
50295	of	ADP	O
50295	the	DET	O
50295	heme	ADJ	O
50295	group	NOUN	O
50295	is	VERB	O
50295	discussed	VERB	O
50295	.	PUNCT	O
50296	Phospholipase	VERB	O
50296	A	DET	O
50296	[	PUNCT	O
50296	EC	PROPN	O
50296	3.1.1.4	NUM	O
50296	]	PUNCT	O
50296	inhibitor	NOUN	O
50296	was	VERB	O
50296	purified	VERB	O
50296	from	ADP	O
50296	Habu	PROPN	O
50296	(	PUNCT	O
50296	Trimeresurus	PROPN	O
50296	flavivurudls	PROPN	O
50296	)	PUNCT	O
50296	serum	VERB	O
50296	by	ADP	O
50296	gel	NOUN	O
50296	filtration	NOUN	O
50296	on	ADP	O
50296	Sephadex	PROPN	O
50296	G-200	PROPN	O
50296	,	PUNCT	O
50296	chromatography	NOUN	O
50296	on	ADP	O
50296	DE-23	PROPN	O
50296	cellulose	NOUN	O
50296	and	CCONJ	O
50296	affinity	NOUN	O
50296	chromatography	NOUN	O
50296	on	ADP	O
50296	a	DET	O
50296	Sepharose	PROPN	O
50296	4B	NOUN	O
50296	-	PUNCT	O
50296	phospholipase	NOUN	O
50296	A	DET	O
50296	column	NOUN	O
50296	.	PUNCT	O
50297	By	ADP	O
50297	these	DET	O
50297	procedures	NOUN	O
50297	,	PUNCT	O
50297	a	DET	O
50297	31-fold	NUM	O
50297	increase	NOUN	O
50297	in	ADP	O
50297	specific	ADJ	O
50297	activity	NOUN	O
50297	was	VERB	O
50297	attained	VERB	O
50297	with	ADP	O
50297	a	DET	O
50297	yield	NOUN	O
50297	of	ADP	O
50297	15	NUM	O
50297	%	NOUN	O
50297	.	PUNCT	O
50298	The	DET	O
50298	purified	ADJ	O
50298	material	NOUN	O
50298	was	VERB	O
50298	homogeneous	ADJ	O
50298	as	ADP	O
50298	judged	VERB	O
50298	by	ADP	O
50298	cellulose	ADJ	O
50298	acetate	NOUN	O
50298	and	CCONJ	O
50298	polyacrylamide	NOUN	O
50298	gel	NOUN	O
50298	electrophoresis	NOUN	O
50298	.	PUNCT	O
50299	It	PRON	O
50299	had	VERB	O
50299	an	DET	O
50299	apparent	ADJ	O
50299	molecular	ADJ	O
50299	weight	NOUN	O
50299	of	ADP	O
50299	100,000	NUM	O
50299	as	ADP	O
50299	measured	VERB	O
50299	by	ADP	O
50299	gel	NOUN	O
50299	filtration	NOUN	O
50299	on	ADP	O
50299	Sephadex	PROPN	O
50299	G-200	PROPN	O
50299	.	PUNCT	O
50300	The	DET	O
50300	purified	ADJ	O
50300	inhibitor	NOUN	O
50300	was	VERB	O
50300	stable	ADJ	O
50300	for	ADP	O
50300	20	NUM	O
50300	min	NOUN	O
50300	at	ADP	O
50300	80	NUM	O
50300	degrees	NOUN	O
50300	and	CCONJ	O
50300	was	VERB	O
50300	unstable	ADJ	O
50300	below	ADP	O
50300	pH	PROPN	O
50300	6	NUM	O
50300	.	PUNCT	O
50301	It	PRON	O
50301	migrated	VERB	O
50301	before	ADP	O
50301	albumin	NOUN	O
50301	in	ADP	O
50301	cellulose	ADJ	O
50301	acetate	NOUN	O
50301	electrophoresis	NOUN	O
50301	and	CCONJ	O
50301	did	VERB	O
50301	not	ADV	O
50301	form	VERB	O
50301	any	DET	O
50301	precipitin	ADJ	O
50301	line	NOUN	O
50301	with	ADP	O
50301	the	DET	O
50301	crude	ADJ	O
50301	venom	NOUN	O
50301	or	CCONJ	O
50301	with	ADP	O
50301	purified	ADJ	O
50301	phospholipase	NOUN	O
50301	A	DET	O
50301	in	ADP	O
50301	immunodiffusin	ADJ	O
50301	tests	NOUN	O
50301	.	PUNCT	O
50302	An	DET	O
50302	8-fold	ADJ	O
50302	excess	NOUN	O
50302	of	ADP	O
50302	the	DET	O
50302	purified	ADJ	O
50302	inhibitor	NOUN	O
50302	by	ADP	O
50302	weight	NOUN	O
50302	was	VERB	O
50302	required	VERB	O
50302	to	PART	O
50302	inhibit	VERB	O
50302	completely	ADV	O
50302	both	CCONJ	O
50302	the	DET	O
50302	egg	NOUN	O
50302	yolk	NOUN	O
50302	clearing	VERB	O
50302	action	NOUN	O
50302	and	CCONJ	O
50302	the	DET	O
50302	hemolytic	ADJ	O
50302	action	NOUN	O
50302	of	ADP	O
50302	phospholipase	NOUN	O
50302	A.	NOUN	O
50303	A	DET	O
50303	transglutaminase	NOUN	O
50303	from	ADP	O
50303	human	ADJ	O
50303	hair	NOUN	O
50303	follicle	NOUN	O
50303	-	PUNCT	O
50303	free	ADJ	O
50303	epidermis	NOUN	O
50303	was	VERB	O
50303	purified	VERB	O
50303	to	ADP	O
50303	homogeneity	NOUN	O
50303	using	VERB	O
50303	gel	NOUN	O
50303	filtration	NOUN	O
50303	and	CCONJ	O
50303	ion	NOUN	O
50303	exchange	NOUN	O
50303	chromatography	NOUN	O
50303	.	PUNCT	O
50304	The	DET	O
50304	enzyme	NOUN	O
50304	had	VERB	O
50304	an	DET	O
50304	apparent	ADJ	O
50304	Mr	PROPN	O
50304	=	SYM	O
50304	51,000	NUM	O
50304	+	X	O
50304	/-	PUNCT	O
50305	2,000	NUM	O
50305	by	ADP	O
50305	sodium	NOUN	O
50305	dodecyl	NOUN	O
50305	sulfate	NOUN	O
50305	electrophoresis	NOUN	O
50305	,	PUNCT	O
50305	100,000	NUM	O
50305	+	X	O
50305	/-	PUNCT	O
50306	5,000	NUM	O
50306	by	ADP	O
50306	discontinuous	ADJ	O
50306	gel	NOUN	O
50306	electrophoresis	NOUN	O
50306	,	PUNCT	O
50306	and	CCONJ	O
50306	50,000	NUM	O
50306	+	NOUN	O
50306	/-	PUNCT	O
50306	2,000	NUM	O
50306	by	ADP	O
50306	gel	NOUN	O
50306	filtration	NOUN	O
50306	in	ADP	O
50306	Bio	PROPN	O
50306	-	PUNCT	O
50306	Gel	PROPN	O
50306	A-0.5	NUM	O
50306	m	VERB	O
50306	agarose	VERB	O
50306	.	PUNCT	O
50307	The	DET	O
50307	enzyme	NOUN	O
50307	cross	NOUN	O
50307	-	PUNCT	O
50307	linked	VERB	O
50307	Factor	PROPN	O
50307	XIII	PROPN	O
50307	-	PUNCT	O
50307	free	ADJ	O
50307	fibrinogen	NOUN	O
50307	forming	VERB	O
50307	gamma	NOUN	O
50307	dimers	NOUN	O
50307	and	CCONJ	O
50307	alpha	NOUN	O
50307	polymers	NOUN	O
50307	.	PUNCT	O
50308	Either	CCONJ	O
50308	calcium	NOUN	O
50308	or	CCONJ	O
50308	strontium	NOUN	O
50308	was	VERB	O
50308	necessary	ADJ	O
50308	for	ADP	O
50308	enzyme	NOUN	O
50308	activity	NOUN	O
50308	.	PUNCT	O
50309	In	ADP	O
50309	the	DET	O
50309	presence	NOUN	O
50309	of	ADP	O
50309	calcium	NOUN	O
50309	,	PUNCT	O
50309	enzyme	NOUN	O
50309	activity	NOUN	O
50309	was	VERB	O
50309	increased	VERB	O
50309	by	ADP	O
50309	heating	VERB	O
50309	at	ADP	O
50309	56	NUM	O
50309	degrees	NOUN	O
50309	or	CCONJ	O
50309	by	ADP	O
50309	treating	VERB	O
50309	with	ADP	O
50309	dimethylsulfoxide	NOUN	O
50309	.	PUNCT	O
50310	Activation	NOUN	O
50310	required	VERB	O
50310	calcium	NOUN	O
50310	and	CCONJ	O
50310	occurred	VERB	O
50310	in	ADP	O
50310	the	DET	O
50310	presence	NOUN	O
50310	of	ADP	O
50310	serine	ADJ	O
50310	protease	NOUN	O
50310	inhibitors	NOUN	O
50310	.	PUNCT	O
50311	The	DET	O
50311	activated	VERB	O
50311	and	CCONJ	O
50311	native	ADJ	O
50311	enzyme	NOUN	O
50311	had	VERB	O
50311	apparently	ADV	O
50311	identical	ADJ	O
50311	mobilities	NOUN	O
50311	in	ADP	O
50311	acrylamide	NOUN	O
50311	disc	NOUN	O
50311	electrophoresis	NOUN	O
50311	and	CCONJ	O
50311	sodium	NOUN	O
50311	dodecyl	NOUN	O
50311	sulfate	VERB	O
50311	electrophoresis	NOUN	O
50311	.	PUNCT	O
50312	The	DET	O
50312	Km	PROPN	O
50312	values	NOUN	O
50312	for	ADP	O
50312	two	NUM	O
50312	substrates	NOUN	O
50312	in	ADP	O
50312	the	DET	O
50312	reaction	NOUN	O
50312	,	PUNCT	O
50312	casein	NOUN	O
50312	and	CCONJ	O
50312	putrescine	VERB	O
50312	,	PUNCT	O
50312	were	VERB	O
50312	very	ADV	O
50312	similar	ADJ	O
50312	for	ADP	O
50312	the	DET	O
50312	native	NOUN	O
50312	and	CCONJ	O
50312	the	DET	O
50312	activated	VERB	O
50312	enzyme	NOUN	O
50312	.	PUNCT	O
50313	The	DET	O
50313	activated	VERB	O
50313	enzyme	NOUN	O
50313	had	VERB	O
50313	a	DET	O
50313	larger	ADJ	O
50313	elution	NOUN	O
50313	volume	NOUN	O
50313	on	ADP	O
50313	Bio	PROPN	O
50313	-	PUNCT	O
50313	Gel	PROPN	O
50313	A-0.5	NUM	O
50313	m	NOUN	O
50313	in	ADP	O
50313	the	DET	O
50313	presence	NOUN	O
50313	of	ADP	O
50313	calcium	NOUN	O
50313	than	ADP	O
50313	did	VERB	O
50313	the	DET	O
50313	native	ADJ	O
50313	enzyme	NOUN	O
50313	.	PUNCT	O
50314	The	DET	O
50314	detailed	ADJ	O
50314	mechanism	NOUN	O
50314	of	ADP	O
50314	activation	NOUN	O
50314	remains	VERB	O
50314	to	PART	O
50314	be	VERB	O
50314	determined	VERB	O
50314	.	PUNCT	O
50315	Under	ADP	O
50315	conditions	NOUN	O
50315	used	VERB	O
50315	previously	ADV	O
50315	for	ADP	O
50315	demonstrating	VERB	O
50315	glycolytic	ADJ	O
50315	oscillations	NOUN	O
50315	in	ADP	O
50315	muscle	NOUN	O
50315	extracts	NOUN	O
50315	(	PUNCT	O
50315	pH	VERB	O
50315	6.65	NUM	O
50315	,	PUNCT	O
50315	0.1	NUM	O
50315	to	PART	O
50315	0.5	NUM	O
50315	mM	PROPN	O
50315	ATP	PROPN	O
50315	)	PUNCT	O
50315	,	PUNCT	O
50315	phosphofructokinase	NOUN	O
50315	from	ADP	O
50315	rat	ADJ	O
50315	skeletal	ADJ	O
50315	muscle	NOUN	O
50315	is	VERB	O
50315	strongly	ADV	O
50315	activated	VERB	O
50315	by	ADP	O
50315	micromolar	ADJ	O
50315	concentrations	NOUN	O
50315	of	ADP	O
50315	fructose	ADJ	O
50315	diphosphate	NOUN	O
50315	.	PUNCT	O
50316	The	DET	O
50316	activation	NOUN	O
50316	is	VERB	O
50316	dependent	ADJ	O
50316	on	ADP	O
50316	the	DET	O
50316	presence	NOUN	O
50316	of	ADP	O
50316	AMP	PROPN	O
50316	.	PUNCT	O
50317	Activation	NOUN	O
50317	by	ADP	O
50317	fructose	ADJ	O
50317	diphosphate	NOUN	O
50317	and	CCONJ	O
50317	AMP	PROPN	O
50317	,	PUNCT	O
50317	and	CCONJ	O
50317	inhibition	NOUN	O
50317	by	ADP	O
50317	ATP	PROPN	O
50317	,	PUNCT	O
50317	is	VERB	O
50317	primarily	ADV	O
50317	due	ADJ	O
50317	to	ADP	O
50317	large	ADJ	O
50317	changes	NOUN	O
50317	in	ADP	O
50317	the	DET	O
50317	apparent	ADJ	O
50317	affinity	NOUN	O
50317	of	ADP	O
50317	the	DET	O
50317	enzyme	NOUN	O
50317	for	ADP	O
50317	the	DET	O
50317	substrate	NOUN	O
50317	fructose	ADJ	O
50317	6-phosphate	ADJ	O
50317	.	PUNCT	O
50318	These	DET	O
50318	control	NOUN	O
50318	properties	NOUN	O
50318	can	VERB	O
50318	account	VERB	O
50318	for	ADP	O
50318	the	DET	O
50318	generation	NOUN	O
50318	of	ADP	O
50318	glycolytic	ADJ	O
50318	oscillations	NOUN	O
50318	.	PUNCT	O
50319	The	DET	O
50319	enzyme	NOUN	O
50319	was	VERB	O
50319	also	ADV	O
50319	studied	VERB	O
50319	under	ADP	O
50319	conditions	NOUN	O
50319	approximating	VERB	O
50319	the	DET	O
50319	metabolite	ADJ	O
50319	contents	NOUN	O
50319	of	ADP	O
50319	skeletal	ADJ	O
50319	muscle	NOUN	O
50319	in	ADP	O
50319	vivo	NOUN	O
50319	(	PUNCT	O
50319	pH	NOUN	O
50319	7.0	NUM	O
50319	,	PUNCT	O
50319	10mM	NUM	O
50319	ATP	PROPN	O
50319	,	PUNCT	O
50319	0.1	NUM	O
50319	mM	PROPN	O
50319	fructose	NOUN	O
50319	6-phosphate	NOUN	O
50319	)	PUNCT	O
50319	.	PUNCT	O
50320	Under	ADP	O
50320	these	DET	O
50320	more	ADJ	O
50320	inhibitory	ADJ	O
50320	conditions	NOUN	O
50320	,	PUNCT	O
50320	phosphofructokinase	NOUN	O
50320	is	VERB	O
50320	strongly	ADV	O
50320	activated	VERB	O
50320	by	ADP	O
50320	low	ADJ	O
50320	concentrations	NOUN	O
50320	of	ADP	O
50320	fructose	ADJ	O
50320	diphosphate	NOUN	O
50320	,	PUNCT	O
50320	with	ADP	O
50320	half	ADJ	O
50320	-	PUNCT	O
50320	maximal	ADJ	O
50320	activation	NOUN	O
50320	at	ADP	O
50320	about	ADP	O
50320	10	NUM	O
50320	muM.	NOUN	O
50320	Citrate	PROPN	O
50320	is	VERB	O
50320	a	DET	O
50320	potent	ADJ	O
50320	inhibitor	NOUN	O
50320	at	ADP	O
50320	physiological	ADJ	O
50320	concentrations	NOUN	O
50320	,	PUNCT	O
50320	whereas	ADP	O
50320	AMP	PROPN	O
50320	is	VERB	O
50320	a	DET	O
50320	strong	ADJ	O
50320	activator	NOUN	O
50320	.	PUNCT	O
50321	Both	DET	O
50321	AMP	PROPN	O
50321	and	CCONJ	O
50321	citrate	NOUN	O
50321	affect	VERB	O
50321	the	DET	O
50321	maximum	ADJ	O
50321	velocity	NOUN	O
50321	and	CCONJ	O
50321	have	VERB	O
50321	little	ADJ	O
50321	effect	NOUN	O
50321	on	ADP	O
50321	affinity	NOUN	O
50321	of	ADP	O
50321	the	DET	O
50321	enzyme	NOUN	O
50321	for	ADP	O
50321	fructose	ADJ	O
50321	diphosphate	NOUN	O
50321	.	PUNCT	O
50322	We	PRON	O
50322	describe	VERB	O
50322	the	DET	O
50322	reactions	NOUN	O
50322	of	ADP	O
50322	three	NUM	O
50322	lipophilic	ADJ	O
50322	,	PUNCT	O
50322	photoactivated	VERB	O
50322	cross	NOUN	O
50322	-	PUNCT	O
50322	linking	VERB	O
50322	reagents	NOUN	O
50322	,	PUNCT	O
50322	1,5-diazidonapthalene	NUM	O
50322	,	PUNCT	O
50322	4,4'-diazidobiphenyl	NUM	O
50322	,	PUNCT	O
50322	and	CCONJ	O
50322	the	DET	O
50322	reversible	ADJ	O
50322	4,4'-dithiobisphenylazide	NUM	O
50322	,	PUNCT	O
50322	with	ADP	O
50322	erythrocyte	ADJ	O
50322	membranes	NOUN	O
50322	.	PUNCT	O
50323	Cross	NOUN	O
50323	-	PUNCT	O
50323	linking	NOUN	O
50323	occurs	VERB	O
50323	only	ADV	O
50323	upon	ADP	O
50323	photoactivation	NOUN	O
50323	.	PUNCT	O
50324	At	ADP	O
50324	pH	PROPN	O
50324	7	NUM	O
50324	to	PART	O
50324	8	NUM	O
50324	,	PUNCT	O
50324	only	ADV	O
50324	spectrin	NOUN	O
50324	components	NOUN	O
50324	are	VERB	O
50324	cross	NOUN	O
50324	-	PUNCT	O
50324	linked	VERB	O
50324	by	ADP	O
50324	these	DET	O
50324	reagents	NOUN	O
50324	.	PUNCT	O
50325	At	ADP	O
50325	pH	VERB	O
50325	5.0	NUM	O
50325	to	ADP	O
50325	5.5	NUM	O
50325	several	ADJ	O
50325	additional	ADJ	O
50325	membrane	ADJ	O
50325	proteins	NOUN	O
50325	including	VERB	O
50325	the	DET	O
50325	major	ADJ	O
50325	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
in 	 O 	O
shock 	 O 	O
had 	 O 	O
raised 	 O 	O
angiotensin 	 O 	O
- 	 O 	O
II 	 O 	O
concentrations 	 O 	O
in 	 O 	O
peripheral 	 O 	O
blood 	 O 	O
and 	 O 	O
acute 	 O 	O
renal 	 DISEASE 	DISEASE
failure 	 DISEASE 	O
manifested 	 O 	O
by 	 O 	O
oliguria 	 O 	O
, 	 O 	O
increasing 	 O 	O
serum 	 O 	O
- 	 O 	O
creatinine 	 O 	O
, 	 O 	O
a 	 O 	O
urine 	 O 	O
osmolality 	 O 	O
of 	 O 	O
less 	 O 	O
than 	 O 	O
400 	 O 	O
mos 	 O 	O
- 	 O 	O
mol 	 O 	O
/ 	 O 	O
kg 	 O 	O
and 	 O 	O
a 	 O 	O
urine 	 O 	O
/ 	 O 	O
plasma 	 O 	O
osmolality 	 O 	O
ratio 	 O 	O
of 	 O 	O
less 	 O 	O
than 	 O 	O
1 	 O 	O
- 	 O 	O
5 	 O 	O
. 	 O 	O
Patients 	 O 	O
with 	 O 	O
tumour 	 O 	O
secondary 	 O 	O
to 	 O 	O
Paget 	 DISEASE 	O
's 	 DISEASE 	DISEASE
disease 	 DISEASE 	DISEASE
and 	 O 	O
to 	 O 	O
irradiation 	 O 	O
did 	 O 	O
poorly 	 O 	O
, 	 O 	O
those 	 O 	O
with 	 O 	O
parosteal 	 O 	O
and 	 O 	O
periosteal 	 O 	O
osteosarcoma 	 O 	O
did 	 O 	O
better 	 O 	O
. 	 O 	O
Patients 	 O 	O
with 	 O 	O
tumour 	 O 	O
secondary 	 O 	O
to 	 O 	O
Paget 	 O 	O
's 	 O 	O
disease 	 O 	O
and 	 O 	O
to 	 O 	O
irradiation 	 O 	O
did 	 O 	O
poorly 	 O 	O
, 	 O 	O
those 	 O 	O
with 	 O 	O
parosteal 	 O 	O
and 	 O 	O
periosteal 	 DISEASE 	DISEASE
osteosarcoma 	 DISEASE 	DISEASE
did 	 O 	O
better 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
None 	 O 	O
of 	 O 	O
the 	 O 	O
infected 	 O 	O
infants 	 O 	O
showed 	 O 	O
obvious 	 O 	O
signs 	 O 	O
of 	 O 	O
congenital 	 O 	O
CMV 	 O 	O
infection 	 O 	DISEASE
at 	 O 	O
birth 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Early 	 O 	O
, 	 O 	O
nonvesicular 	 O 	O
lesions 	 O 	O
showed 	 O 	O
basal 	 O 	DISEASE
cell 	 O 	DISEASE
degeneration 	 O 	DISEASE
and 	 O 	O
dermal 	 O 	O
inflammatory 	 O 	O
cells 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
/ 	 O 	O
ob 	 O 	O
mouse 	 O 	O
, 	 O 	O
which 	 O 	O
is 	 O 	O
a 	 O 	O
genetic 	 O 	O
mutant 	 O 	O
characterized 	 O 	O
by 	 O 	O
obesity 	 O 	DISEASE
, 	 O 	O
hyperinsulinism 	 DISEASE 	DISEASE
and 	 O 	O
resistance 	 O 	O
to 	 O 	O
the 	 O 	O
hypoglycemic 	 O 	O
action 	 O 	O
of 	 O 	O
insulin 	 O 	O
, 	 O 	O
contains 	 O 	O
hepatic 	 O 	O
glutathione 	 O 	O
- 	 O 	O
insulin 	 O 	O
transhydrogenase 	 O 	O
activity 	 O 	O
( 	 O 	O
per 	 O 	O
mg 	 O 	O
microsomal 	 O 	O
protein 	 O 	O
) 	 O 	O
markedly 	 O 	O
higher 	 O 	O
( 	 O 	O
40 	 O 	O
- 	 O 	O
-60 	 O 	O
% 	 O 	O
) 	 O 	O
than 	 O 	O
its 	 O 	O
lean 	 O 	O
litter 	 O 	O
mates 	 O 	O
. 	 O 	O
Lymphoid 	 O 	O
tissue 	 O 	O
of 	 O 	O
51 	 O 	O
patients 	 O 	O
with 	 O 	O
Hodgkin 	 O 	DISEASE
's 	 O 	DISEASE
disease 	 O 	DISEASE
was 	 O 	O
studied 	 O 	O
with 	 O 	O
immunohistological 	 O 	O
, 	 O 	O
enzyme 	 O 	O
histochemical 	 O 	O
and 	 O 	O
rosetting 	 O 	O
techniques 	 O 	O
for 	 O 	O
the 	 O 	O
detection 	 O 	O
of 	 O 	O
B 	 O 	O
and 	 O 	O
T 	 O 	O
cells 	 O 	O
in 	 O 	O
frozen 	 O 	O
sections 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
fibrosis 	 O 	O
mortalities 	 O 	O
were 	 O 	O
examined 	 O 	O
in 	 O 	O
relation 	 O 	O
to 	 O 	O
cumulative 	 O 	O
dust 	 O 	O
exposure 	 O 	O
and 	 O 	O
to 	 O 	O
other 	 O 	O
factors 	 O 	O
after 	 O 	O
taking 	 O 	O
into 	 O 	O
account 	 O 	O
cumulative 	 O 	O
dust 	 O 	O
exposure 	 O 	O
. 	 O 	O
Respiratory 	 O 	O
cancer 	 O 	O
and 	 O 	O
pneumoconiosis 	 O 	O
- 	 O 	O
pulmonary 	 DISEASE 	O
fibrosis 	 DISEASE 	DISEASE
mortalities 	 O 	O
were 	 O 	O
examined 	 O 	O
in 	 O 	O
relation 	 O 	O
to 	 O 	O
cumulative 	 O 	O
dust 	 O 	O
exposure 	 O 	O
and 	 O 	O
to 	 O 	O
other 	 O 	O
factors 	 O 	O
after 	 O 	O
taking 	 O 	O
into 	 O 	O
account 	 O 	O
cumulative 	 O 	O
dust 	 O 	O
exposure 	 O 	O
. 	 O 	O
, 	 O 	O
15 	 O 	O
subjects 	 O 	O
with 	 O 	O
the 	 O 	O
heterozygous 	 O 	O
form 	 O 	O
of 	 O 	O
familial 	 DISEASE 	DISEASE
hypercholesterolemia 	 DISEASE 	O
, 	 O 	O
and 	 O 	O
6 	 O 	O
subjects 	 O 	O
with 	 O 	O
hyperlipidemic 	 O 	O
disorders 	 O 	O
other 	 O 	O
than 	 O 	O
familial 	 O 	O
hypercholesterolemia 	 O 	O
. 	 O 	O
This 	 O 	O
group 	 O 	O
includes 	 O 	O
32 	 O 	O
healthy 	 O 	O
subjects 	 O 	O
, 	 O 	O
15 	 O 	O
subjects 	 O 	O
with 	 O 	O
the 	 O 	O
heterozygous 	 O 	O
form 	 O 	O
of 	 O 	O
familial 	 O 	O
hypercholesterolemia 	 O 	O
, 	 O 	O
and 	 O 	O
6 	 O 	O
subjects 	 O 	O
with 	 O 	O
hyperlipidemic 	 O 	O
disorders 	 O 	O
other 	 O 	O
than 	 O 	O
familial 	 DISEASE 	DISEASE
hypercholesterolemia 	 DISEASE 	DISEASE
. 	 O 	O
A 	 O 	O
57-year 	 O 	O
- 	 O 	O
old 	 O 	O
man 	 O 	O
with 	 O 	O
left 	 O 	O
T8 	 O 	O
- 	 O 	O
9 	 O 	O
cutaneous 	 O 	O
Herpes 	 DISEASE 	O
Zoster 	 DISEASE 	O
lesions 	 O 	O
and 	 O 	O
subsequent 	 O 	O
development 	 O 	O
of 	 O 	O
flaccid 	 O 	O
paralysis 	 O 	O
of 	 O 	O
both 	 O 	O
lower 	 O 	O
limbs 	 O 	O
is 	 O 	O
reported 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Problems 	 O 	O
of 	 O 	O
diagnostic 	 O 	O
value 	 O 	O
of 	 O 	O
the 	 O 	O
test 	 O 	O
with 	 O 	O
rifathyroin 	 O 	O
, 	 O 	O
and 	 O 	O
of 	 O 	O
the 	 O 	O
efficacy 	 O 	O
of 	 O 	O
various 	 O 	O
therapeutic 	 O 	O
methods 	 O 	O
applied 	 O 	O
in 	 O 	O
lactorrhea 	 O 	O
- 	 O 	O
amenorrhea 	 DISEASE 	O
are 	 O 	O
discussed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Mononeuropathy 	 DISEASE 	O
and 	 O 	O
autonomic 	 O 	O
neuropathy 	 O 	O
were 	 O 	O
much 	 O 	O
less 	 O 	O
frequent 	 O 	O
. 	 O 	O
Mononeuropathy 	 O 	O
and 	 O 	O
autonomic 	 DISEASE 	O
neuropathy 	 DISEASE 	DISEASE
were 	 O 	O
much 	 O 	O
less 	 O 	O
frequent 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
presumption 	 O 	O
that 	 O 	O
the 	 O 	O
malignant 	 O 	O
cell 	 O 	DISEASE
constitutes 	 O 	O
the 	 O 	O
disease 	 O 	O
is 	 O 	O
now 	 O 	O
challenged 	 O 	O
by 	 O 	O
a 	 O 	O
variety 	 O 	O
of 	 O 	O
clinical 	 O 	O
observations 	 O 	O
and 	 O 	O
experimental 	 O 	O
studies 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
fibrinolytic 	 O 	O
activity 	 O 	O
of 	 O 	O
blood 	 O 	O
draining 	 O 	O
from 	 O 	O
the 	 O 	O
stomachs 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
gastroduodenal 	 O 	O
disease 	 O 	DISEASE
has 	 O 	O
been 	 O 	O
compared 	 O 	O
with 	 O 	O
the 	 O 	O
fibrinolytic 	 O 	O
activity 	 O 	O
of 	 O 	O
blood 	 O 	O
in 	 O 	O
the 	 O 	O
systemic 	 O 	O
venous 	 O 	O
circulation 	 O 	O
and 	 O 	O
with 	 O 	O
the 	 O 	O
blood 	 O 	O
draining 	 O 	O
from 	 O 	O
normal 	 O 	O
stomachs 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
It 	 O 	O
was 	 O 	O
a 	 O 	O
32-year 	 O 	O
old 	 O 	O
woman 	 O 	O
suffering 	 O 	O
from 	 O 	O
moderate 	 O 	O
epigastric 	 O 	O
pains 	 O 	O
, 	 O 	O
pyrosis 	 O 	O
, 	 O 	O
chronic 	 O 	DISEASE
constipation 	 DISEASE 	DISEASE
, 	 O 	O
markedly 	 O 	O
nervous 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Admixture 	 O 	O
of 	 O 	O
Cytrel 	 O 	O
to 	 O 	O
cigarettes 	 O 	O
reduced 	 O 	O
tar 	 O 	O
deposition 	 O 	O
in 	 O 	O
the 	 O 	O
respiratory 	 O 	O
tract 	 O 	O
, 	 O 	O
which 	 O 	O
paralleled 	 O 	O
the 	 O 	O
decrease 	 O 	O
in 	 O 	O
the 	 O 	O
incidence 	 O 	O
of 	 O 	O
laryngeal 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Tuberculosis 	 DISEASE 	O
was 	 O 	O
the 	 O 	O
cause 	 O 	O
in 	 O 	O
three 	 O 	O
cases 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Direct 	 O 	O
cytotoxicity 	 O 	O
was 	 O 	O
obtained 	 O 	O
with 	 O 	O
the 	 O 	O
lymphocytes 	 O 	O
from 	 O 	O
these 	 O 	O
lymphoid 	 O 	O
tissues 	 O 	O
, 	 O 	O
and 	 O 	O
cells 	 O 	O
obtained 	 O 	O
from 	 O 	O
these 	 O 	O
lymphoid 	 O 	O
tissues 	 O 	O
could 	 O 	O
produce 	 O 	O
secondary 	 O 	O
cytotoxic 	 O 	O
responses 	 O 	O
by 	 O 	O
the 	 O 	O
mixed 	 O 	O
lymphocyte 	 O 	O
tumor 	 O 	DISEASE
cell 	 O 	O
culture 	 O 	O
reactions 	 O 	O
40 	 O 	O
- 	 O 	O
-60 	 O 	O
days 	 O 	O
after 	 O 	O
adoptive 	 O 	O
transfer 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
prednacinolone 	 O 	O
acetonide 	 O 	O
, 	 O 	O
administered 	 O 	O
around 	 O 	O
the 	 O 	O
period 	 O 	O
of 	 O 	O
challenge 	 O 	O
reduced 	 O 	O
the 	 O 	O
exudate 	 O 	O
of 	 O 	O
pleurisy 	 O 	O
due 	 O 	O
to 	 O 	O
Bordetella 	 O 	O
pertussis 	 DISEASE 	DISEASE
hypersensitivity 	 O 	O
in 	 O 	O
the 	 O 	O
rat 	 O 	O
. 	 O 	O
Phenylbutazone 	 O 	O
, 	 O 	O
cyclophosphamide 	 O 	O
and 	 O 	O
prednacinolone 	 O 	O
acetonide 	 O 	O
, 	 O 	O
administered 	 O 	O
around 	 O 	O
the 	 O 	O
period 	 O 	O
of 	 O 	O
challenge 	 O 	O
reduced 	 O 	O
the 	 O 	O
exudate 	 O 	O
of 	 O 	O
pleurisy 	 O 	O
due 	 O 	O
to 	 O 	O
Bordetella 	 O 	O
pertussis 	 O 	DISEASE
hypersensitivity 	 DISEASE 	DISEASE
in 	 O 	O
the 	 O 	O
rat 	 O 	O
. 	 O 	O
The 	 O 	O
dehydroepiandrosterone 	 O 	O
sulfate 	 O 	O
( 	 O 	O
DHEA 	 O 	O
- 	 O 	O
S 	 O 	O
) 	 O 	O
loading 	 O 	O
test 	 O 	O
is 	 O 	O
increasingly 	 O 	O
used 	 O 	O
to 	 O 	O
detect 	 O 	O
fetal 	 O 	O
disorders 	 O 	O
in 	 O 	O
high 	 O 	O
risk 	 O 	O
pregnancies 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
18 	 O 	O
to 	 O 	O
22 	 O 	O
per 	 O 	O
cent 	 O 	O
during 	 O 	O
the 	 O 	O
blastic 	 O 	O
phase 	 O 	O
contained 	 O 	O
fetal 	 O 	O
hemoglobin 	 O 	O
. 	 O 	O
In 	 O 	O
a 	 O 	O
patient 	 O 	O
with 	 O 	O
chronic 	 O 	O
myelogenous 	 O 	O
leukemia 	 O 	DISEASE
and 	 O 	O
sickle 	 O 	O
/ 	 O 	O
beta 	 DISEASE 	O
thalassemia 	 DISEASE 	O
, 	 O 	O
17 	 O 	O
per 	 O 	O
cent 	 O 	O
of 	 O 	O
the 	 O 	O
red 	 O 	O
cells 	 O 	O
during 	 O 	O
remission 	 O 	O
and 	 O 	O
18 	 O 	O
to 	 O 	O
22 	 O 	O
per 	 O 	O
cent 	 O 	O
during 	 O 	O
the 	 O 	O
blastic 	 O 	O
phase 	 O 	O
contained 	 O 	O
fetal 	 O 	O
hemoglobin 	 O 	O
. 	 O 	O
Bilateral 	 O 	O
dissection 	 O 	O
of 	 O 	O
inguinal 	 O 	O
lymph 	 O 	O
- 	 O 	O
nodes 	 O 	O
was 	 O 	O
performed 	 O 	O
only 	 O 	O
if 	 O 	O
inguinal 	 O 	DISEASE
metastases 	 O 	O
were 	 O 	O
suspected 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
significant 	 O 	O
implication 	 O 	O
of 	 O 	O
our 	 O 	O
findings 	 O 	O
is 	 O 	O
that 	 O 	O
the 	 O 	O
development 	 O 	O
of 	 O 	O
astrocytes 	 O 	O
in 	 O 	O
the 	 O 	O
human 	 O 	O
fetal 	 O 	O
brain 	 O 	DISEASE
occurs 	 O 	O
much 	 O 	O
earlier 	 O 	O
than 	 O 	O
formerly 	 O 	O
believed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
initial 	 O 	O
biopsy 	 O 	O
specimens 	 O 	O
were 	 O 	O
reviewed 	 O 	O
and 	 O 	O
small 	 O 	O
but 	 O 	O
definite 	 O 	O
quantities 	 O 	O
of 	 O 	O
follicular 	 DISEASE 	O
mucinosis 	 DISEASE 	DISEASE
were 	 O 	O
noted 	 O 	O
after 	 O 	O
appropriate 	 O 	O
staining 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
exophytely 	 O 	O
growing 	 O 	DISEASE
adenocarcinomas 	 O 	O
of 	 O 	O
the 	 O 	O
stomach 	 O 	O
and 	 O 	O
in 	 O 	O
the 	 O 	O
mucosa 	 O 	O
of 	 O 	O
the 	 O 	O
carcinoma 	 O 	O
affected 	 O 	O
stomach 	 O 	O
at 	 O 	O
a 	 O 	O
distance 	 O 	O
of 	 O 	O
10 	 O 	O
- 	 O 	O
-12 	 O 	O
cm 	 O 	O
from 	 O 	O
the 	 O 	O
site 	 O 	O
of 	 O 	O
affection 	 O 	O
; 	 O 	O
no 	 O 	O
such 	 O 	O
antigen 	 O 	O
was 	 O 	O
revealed 	 O 	O
in 	 O 	O
the 	 O 	O
endophytely 	 O 	O
growing 	 O 	O
carcinoma 	 O 	O
of 	 O 	O
the 	 O 	O
stomach 	 O 	O
and 	 O 	O
in 	 O 	O
mucosa 	 O 	O
areas 	 O 	O
surrounding 	 O 	O
gastric 	 DISEASE 	DISEASE
ulcer 	 DISEASE 	DISEASE
. 	 O 	O
The 	 O 	O
antibody 	 O 	O
against 	 O 	O
the 	 O 	O
microsomal 	 O 	O
fraction 	 O 	O
, 	 O 	O
though 	 O 	O
reacting 	 O 	O
in 	 O 	O
the 	 O 	O
same 	 O 	O
way 	 O 	O
as 	 O 	O
the 	 O 	O
antibody 	 O 	O
to 	 O 	O
parietal 	 O 	O
cell 	 O 	O
canaliculi 	 O 	O
found 	 O 	O
in 	 O 	O
the 	 O 	O
serum 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
pernicious 	 O 	DISEASE
anaemia 	 DISEASE 	DISEASE
, 	 O 	O
showed 	 O 	O
greater 	 O 	O
species 	 O 	O
specificity 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
data 	 O 	O
from 	 O 	O
the 	 O 	O
Wayne 	 O 	O
County 	 O 	O
study 	 O 	O
indicate 	 O 	O
that 	 O 	O
administration 	 O 	O
of 	 O 	O
fluoride 	 O 	O
tablets 	 O 	O
in 	 O 	O
school 	 O 	O
should 	 O 	O
be 	 O 	O
recommended 	 O 	O
in 	 O 	O
nonfluoridated 	 O 	O
areas 	 O 	O
as 	 O 	O
an 	 O 	O
effective 	 O 	O
public 	 O 	O
health 	 O 	O
measure 	 O 	O
for 	 O 	O
the 	 O 	O
prevention 	 O 	O
of 	 O 	O
dental 	 DISEASE 	O
caries 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Thus 	 O 	O
, 	 O 	O
we 	 O 	O
did 	 O 	O
not 	 O 	O
confirm 	 O 	O
a 	 O 	O
recent 	 O 	O
report 	 O 	O
of 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
Ad2 	 O 	O
RNA 	 O 	O
in 	 O 	O
RNAs 	 O 	O
from 	 O 	O
human 	 O 	O
placentas 	 O 	O
; 	 O 	O
the 	 O 	O
possibility 	 O 	O
that 	 O 	O
a 	 O 	O
small 	 O 	O
population 	 O 	O
of 	 O 	O
cells 	 O 	O
in 	 O 	O
placenta 	 O 	O
expresses 	 O 	O
group 	 O 	DISEASE
C 	 O 	O
	PUNCT	O
23371	related	VERB	O
23371	 	 O 	O
sequences 	 O 	O
is 	 O 	O
not 	 O 	O
ruled 	 O 	O
out 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
small 	 O 	DISEASE
thymoma 	 DISEASE 	DISEASE
was 	 O 	O
found 	 O 	O
at 	 O 	O
autopsy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
contrast 	 O 	O
, 	 O 	O
hypocalcemia 	 O 	O
combined 	 O 	O
with 	 O 	O
hypocapnic 	 O 	O
alkalosis 	 O 	DISEASE
always 	 O 	O
produced 	 O 	O
tetany 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Approximately 	 O 	O
1 	 O 	O
mole 	 O 	DISEASE
of 	 O 	O
phosphate 	 O 	O
per 	 O 	O
mole 	 O 	O
of 	 O 	O
troponin 	 O 	O
- 	 O 	O
I 	 O 	O
was 	 O 	O
incorporated 	 O 	O
from 	 O 	O
radioactive 	 O 	O
ATP 	 O 	O
, 	 O 	O
but 	 O 	O
the 	 O 	O
extent 	 O 	O
of 	 O 	O
troponin 	 O 	O
- 	 O 	O
I 	 O 	O
phosphorylation 	 O 	O
could 	 O 	O
be 	 O 	O
varied 	 O 	O
experimentally 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
encephalopathy 	 DISEASE 	O
with 	 O 	O
high 	 O 	O
levels 	 O 	O
of 	 O 	O
aluminium 	 O 	O
in 	 O 	O
the 	 O 	O
brain 	 O 	O
and 	 O 	O
in 	 O 	O
the 	 O 	O
dialysis 	 O 	O
water 	 O 	O
emphasises 	 O 	O
the 	 O 	O
potential 	 O 	O
neurotoxicity 	 O 	O
of 	 O 	O
aluminium 	 O 	O
in 	 O 	O
man 	 O 	O
. 	 O 	O
The 	 O 	O
association 	 O 	O
of 	 O 	O
dialysis 	 O 	O
encephalopathy 	 O 	O
with 	 O 	O
high 	 O 	O
levels 	 O 	O
of 	 O 	O
aluminium 	 O 	O
in 	 O 	O
the 	 O 	O
brain 	 O 	O
and 	 O 	O
in 	 O 	O
the 	 O 	O
dialysis 	 O 	O
water 	 O 	O
emphasises 	 O 	O
the 	 O 	O
potential 	 O 	O
neurotoxicity 	 DISEASE 	DISEASE
of 	 O 	O
aluminium 	 O 	O
in 	 O 	O
man 	 O 	O
. 	 O 	O
This 	 O 	O
organism 	 O 	O
was 	 O 	O
responsible 	 O 	O
for 	 O 	O
both 	 O 	O
colonisation 	 O 	O
and 	 O 	O
invasive 	 O 	DISEASE
infection 	 O 	O
in 	 O 	O
these 	 O 	O
patients 	 O 	O
whose 	 O 	O
burn 	 O 	O
surfaces 	 O 	O
were 	 O 	O
receiving 	 O 	O
topical 	 O 	O
treatment 	 O 	O
with 	 O 	O
0.5 	 O 	O
% 	 O 	O
silver 	 O 	O
nitrate 	 O 	O
( 	 O 	O
AgNO3 	 O 	O
) 	 O 	O
solution 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Preoperative 	 O 	O
differentiation 	 O 	O
of 	 O 	O
acute 	 O 	O
and 	 O 	O
chronic 	 O 	DISEASE
appendicitis 	 DISEASE 	DISEASE
from 	 O 	O
other 	 O 	O
affections 	 O 	O
, 	 O 	O
particularly 	 O 	O
in 	 O 	O
younger 	 O 	O
female 	 O 	O
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Unless 	 O 	O
the 	 O 	O
patient 	 O 	O
is 	 O 	O
allergic 	 O 	O
, 	 O 	O
the 	 O 	O
drug 	 O 	O
of 	 O 	O
choice 	 O 	O
in 	 O 	O
gonococcal 	 DISEASE 	O
salpingitis 	 DISEASE 	DISEASE
is 	 O 	O
penicillin 	 O 	O
or 	 O 	O
a 	 O 	O
derivative 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Neuroradiological 	 O 	O
and 	 O 	O
neurological 	 O 	O
examinations 	 O 	O
failed 	 O 	O
to 	 O 	O
demonstrate 	 O 	O
any 	 O 	O
evidence 	 O 	O
of 	 O 	O
organic 	 O 	O
brain 	 DISEASE 	O
disease 	 DISEASE 	O
in 	 O 	O
this 	 O 	O
epilepsy 	 O 	DISEASE
. 	 O 	O
Neuroradiological 	 O 	O
and 	 O 	O
neurological 	 O 	O
examinations 	 O 	O
failed 	 O 	O
to 	 O 	O
demonstrate 	 O 	O
any 	 O 	O
evidence 	 O 	O
of 	 O 	O
organic 	 O 	O
brain 	 O 	O
disease 	 O 	O
in 	 O 	O
this 	 O 	O
epilepsy 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Marasmus 	 DISEASE 	O
and 	 O 	O
kwashiorkor 	 O 	O
comprised 	 O 	O
5.4 	 O 	O
% 	 O 	O
of 	 O 	O
deaths 	 O 	O
. 	 O 	O
Marasmus 	 O 	O
and 	 O 	O
kwashiorkor 	 DISEASE 	O
comprised 	 O 	O
5.4 	 O 	O
% 	 O 	O
of 	 O 	O
deaths 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
acid 	 O 	O
- 	 O 	O
base 	 O 	O
state 	 O 	O
of 	 O 	O
arterial 	 O 	O
blood 	 O 	O
and 	 O 	O
cerebrospinal 	 O 	O
fluid 	 O 	O
, 	 O 	O
and 	 O 	O
the 	 O 	O
ventilatory 	 O 	O
response 	 O 	O
to 	 O 	O
CO2 	 O 	O
, 	 O 	O
were 	 O 	O
measured 	 O 	O
in 	 O 	O
twelve 	 O 	O
patients 	 O 	O
with 	 O 	O
liver 	 DISEASE 	O
disease 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
present 	 O 	O
studies 	 O 	O
show 	 O 	O
that 	 O 	O
the 	 O 	O
values 	 O 	O
of 	 O 	O
Km 	 O 	O
and 	 O 	O
Vmax 	 O 	O
and 	 O 	O
the 	 O 	O
sensitivity 	 O 	O
of 	 O 	O
phosphodiesterase 	 O 	O
activity 	 O 	O
to 	 O 	O
divalent 	 O 	O
ions 	 O 	O
change 	 O 	O
in 	 O 	O
cyclic 	 O 	O
AMP 	 O 	O
- 	 O 	O
induced 	 O 	O
differentiated 	 O 	O
neuroblastoma 	 DISEASE 	O
cells 	 O 	O
, 	 O 	O
and 	 O 	O
therefore 	 O 	O
we 	 O 	O
propose 	 O 	O
that 	 O 	O
the 	 O 	O
reverse 	 O 	O
may 	 O 	O
be 	 O 	O
true 	 O 	O
during 	 O 	O
malignant 	 O 	O
transformation 	 O 	O
of 	 O 	O
nerve 	 O 	O
cells 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
3 	 O 	O
) 	 O 	O
the 	 O 	O
carotid 	 O 	O
arteriogram 	 O 	O
and 	 O 	O
catheterisation 	 O 	O
show 	 O 	O
the 	 O 	O
characteristic 	 O 	O
abnormalities 	 O 	O
of 	 O 	O
the 	 O 	O
carotid 	 O 	O
arteriogram 	 O 	O
found 	 O 	O
in 	 O 	O
aortic 	 DISEASE 	O
valve 	 DISEASE 	O
disease 	 DISEASE 	O
and 	 O 	O
the 	 O 	O
existence 	 O 	O
of 	 O 	O
a 	 O 	O
trans 	 O 	O
- 	 O 	O
aortic 	 O 	O
or 	 O 	O
intra 	 O 	O
- 	 O 	O
ventricular 	 O 	O
pressure 	 O 	O
gradient 	 O 	O
, 	 O 	O
when 	 O 	O
there 	 O 	O
is 	 O 	O
an 	 O 	O
obstruction 	 O 	O
to 	 O 	O
left 	 O 	O
ventricular 	 O 	O
jection 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
toxaemia 	 O 	O
	PUNCT	O
45655	,	PUNCT	O
45655	severe	ADJ	O
45655	skin	NOUN	O
45655	reactions	NOUN	O
45655	and	CCONJ	O
45655	eosinophilia	NOUN	DISEASE
45655	,	PUNCT	O
45655	three	NUM	O
45655	to	PART	O
45655	six	NUM	O
45655	weeks	NOUN	O
45655	after	ADP	O
45655	commencing	VERB	O
45655	allopurinol	NOUN	O
45655	therapy	NOUN	O
45655	.	PUNCT	O
45656	The	DET	O
45656	presenting	VERB	O
45656	feature	NOUN	O
45656	in	ADP	O
45656	these	DET	O
45656	patients	NOUN	O
45656	was	VERB	O
45656	an	DET	O
45656	extensive	ADJ	O
45656	erythema	NOUN	O
45656	,	PUNCT	O
45656	progressing	VERB	O
45656	to	ADP	O
45656	an	DET	O
45656	exfoliative	ADJ	O
45656	dermatitis	NOUN	DISEASE
45656	,	PUNCT	O
45656	sometimes	ADV	O
45656	with	ADP	O
45656	oral	ADJ	O
45656	mucous	ADJ	O
45656	membrane	ADJ	O
45656	involvement	NOUN	O
45656	.	PUNCT	O
45657	One	NUM	O
45657	patient	NOUN	O
45657	developed	VERB	O
45657	toxic	ADJ	O
45657	epidermal	ADJ	O
45657	necrolysis	NOUN	O
45657	.	PUNCT	O
45658	The	DET	O
45658	clinical	ADJ	O
45658	course	NOUN	O
45658	in	ADP	O
45658	two	NUM	O
45658	patients	NOUN	O
45658	was	VERB	O
45658	complicated	VERB	O
45658	by	ADP	O
45658	acute	ADJ	O
45658	renal	ADJ	DISEASE
45658	failure	NOUN	DISEASE
45658	which	ADJ	O
45658	necessitated	VERB	O
45658	dialysis	NOUN	O
45658	.	PUNCT	O
45659	The	DET	O
45659	clinical	ADJ	O
45659	and	CCONJ	O
45659	laboratory	NOUN	O
45659	features	NOUN	O
45659	support	VERB	O
45659	an	DET	O
45659	acute	ADJ	O
45659	hypersensitivity	NOUN	DISEASE
45659	mechanism	NOUN	O
45659	in	ADP	O
45659	these	DET	O
45659	allopurinol	NOUN	O
45659	associated	VERB	O
45659	reactions	NOUN	O
45659	,	PUNCT	O
45659	in	ADP	O
45659	agreement	NOUN	O
45659	with	ADP	O
45659	previous	ADJ	O
45659	studies	NOUN	O
45659	.	PUNCT	O
45660	Patients	NOUN	O
45660	with	ADP	O
45660	chronic	ADJ	O
45660	renal	ADJ	DISEASE
45660	failure	NOUN	DISEASE
45660	appear	VERB	O
45660	particularly	ADV	O
45660	prone	ADJ	O
45660	to	ADP	O
45660	severe	ADJ	O
45660	,	PUNCT	O
45660	potentially	ADV	O
45660	fatal	ADJ	O
45660	reactions	NOUN	O
45660	.	PUNCT	O
45661	If	ADP	O
45661	these	DET	O
45661	patients	NOUN	O
45661	need	VERB	O
45661	allopurinol	NOUN	O
45661	,	PUNCT	O
45661	a	DET	O
45661	lower	ADJ	O
45661	dose	NOUN	O
45661	than	ADP	O
45661	would	VERB	O
45661	be	VERB	O
45661	normally	ADV	O
45661	required	VERB	O
45661	should	VERB	O
45661	be	VERB	O
45661	given	VERB	O
45661	.	PUNCT	O
45662	The	DET	O
45662	cases	NOUN	O
45662	of	ADP	O
45662	seven	NUM	O
45662	patients	NOUN	O
45662	with	ADP	O
45662	different	ADJ	O
45662	lesions	NOUN	O
45662	of	ADP	O
45662	the	DET	O
45662	base	NOUN	O
45662	of	ADP	O
45662	the	DET	O
45662	skull	NOUN	O
45662	and	CCONJ	O
45662	the	DET	O
45662	orbits	NOUN	O
45662	are	VERB	O
45662	demonstrated	VERB	O
45662	,	PUNCT	O
45662	where	ADV	O
45662	CT	PROPN	O
45662	was	VERB	O
45662	performed	VERB	O
45662	in	ADP	O
45662	horizontal	ADJ	O
45662	and	CCONJ	O
45662	coronal	ADJ	O
45662	sections	NOUN	O
45662	.	PUNCT	O
45663	The	DET	O
45663	results	NOUN	O
45663	make	VERB	O
45663	obvious	ADJ	O
45663	that	ADP	O
45663	only	ADV	O
45663	the	DET	O
45663	combination	NOUN	O
45663	of	ADP	O
45663	both	DET	O
45663	planes	NOUN	O
45663	can	VERB	O
45663	provide	VERB	O
45663	optimal	ADJ	O
45663	information	NOUN	O
45663	in	ADP	O
45663	these	DET	O
45663	cases	NOUN	O
45663	.	PUNCT	O
45664	The	DET	O
45664	existence	NOUN	O
45664	of	ADP	O
45664	a	DET	O
45664	basal	NOUN	O
45664	or	CCONJ	O
45664	orbital	ADJ	O
45664	lesion	NOUN	O
45664	,	PUNCT	O
45664	its	ADJ	O
45664	size	NOUN	O
45664	and	CCONJ	O
45664	location	NOUN	O
45664	,	PUNCT	O
45664	and	CCONJ	O
45664	whether	ADP	O
45664	or	CCONJ	O
45664	not	ADV	O
45664	it	PRON	O
45664	penetrates	VERB	O
45664	through	ADP	O
45664	the	DET	O
45664	base	NOUN	O
45664	of	ADP	O
45664	the	DET	O
45664	skull	NOUN	O
45664	,	PUNCT	O
45664	can	VERB	O
45664	easily	ADV	O
45664	be	VERB	O
45664	detected	VERB	O
45664	.	PUNCT	O
45665	This	DET	O
45665	is	VERB	O
45665	of	ADP	O
45665	great	ADJ	O
45665	help	NOUN	O
45665	in	ADP	O
45665	determining	VERB	O
45665	the	DET	O
45665	therapy	NOUN	O
45665	of	ADP	O
45665	choice	NOUN	O
45665	,	PUNCT	O
45665	i.e.	X	O
45665	operability	NOUN	O
45665	or	CCONJ	O
45665	radiation	NOUN	O
45665	therapy	NOUN	O
45665	treatment	NOUN	O
45665	planning	NOUN	O
45665	.	PUNCT	O
45666	Molds	NOUN	O
45666	are	VERB	O
45666	vegetable	ADJ	O
45666	microorganisms	NOUN	O
45666	,	PUNCT	O
45666	which	ADJ	O
45666	differ	VERB	O
45666	from	ADP	O
45666	dermatophytes	NOUN	O
45666	sensitive	ADJ	O
45666	to	ADP	O
45666	griseofulvin	NOUN	O
45666	,	PUNCT	O
45666	and	CCONJ	O
45666	from	ADP	O
45666	yeasts	NOUN	O
45666	,	PUNCT	O
45666	which	ADJ	O
45666	do	VERB	O
45666	not	ADV	O
45666	form	VERB	O
45666	aerial	ADJ	O
45666	mycelium	NOUN	O
45666	.	PUNCT	O
45667	Most	ADJ	O
45667	of	ADP	O
45667	the	DET	O
45667	molds	NOUN	O
45667	,	PUNCT	O
45667	phytopathogenic	ADJ	O
45667	or	CCONJ	O
45667	which	ADJ	O
45667	live	VERB	O
45667	from	ADP	O
45667	dead	ADJ	O
45667	organic	ADJ	O
45667	substances	NOUN	O
45667	,	PUNCT	O
45667	are	VERB	O
45667	apathogenic	ADJ	O
45667	to	ADP	O
45667	humans	NOUN	O
45667	.	PUNCT	O
45668	Only	ADV	O
45668	a	DET	O
45668	couple	NOUN	O
45668	of	ADP	O
45668	dozen	NOUN	O
45668	species	NOUN	O
45668	can	VERB	O
45668	parasitize	VERB	O
45668	on	ADP	O
45668	the	DET	O
45668	skin	NOUN	O
45668	,	PUNCT	O
45668	usually	ADV	O
45668	together	ADV	O
45668	with	ADP	O
45668	dermatophytes	NOUN	O
45668	or	CCONJ	O
45668	yeasts	NOUN	O
45668	.	PUNCT	O
45669	Onychomycoses	NOUN	O
45669	with	ADP	O
45669	molds	NOUN	O
45669	appear	VERB	O
45669	mostly	ADV	O
45669	in	ADP	O
45669	elderly	ADJ	O
45669	people	NOUN	O
45669	,	PUNCT	O
45669	and	CCONJ	O
45669	fungus	ADJ	O
45669	affections	NOUN	O
45669	of	ADP	O
45669	external	ADJ	O
45669	auditory	ADJ	O
45669	passage	NOUN	O
45669	in	ADP	O
45669	seborrheic	NOUN	O
45669	eczema	NOUN	DISEASE
45669	of	ADP	O
45669	the	DET	O
45669	ear	NOUN	O
45669	.	PUNCT	O
45670	The	DET	O
45670	hair	NOUN	O
45670	can	VERB	O
45670	be	VERB	O
45670	infected	VERB	O
45670	by	ADP	O
45670	Piedraia	PROPN	O
45670	hortae	VERB	O
45670	,	PUNCT	O
45670	resulting	VERB	O
45670	in	ADP	O
45670	hard	ADJ	O
45670	black	ADJ	O
45670	nodules	NOUN	O
45670	.	PUNCT	O
45671	After	ADP	O
45671	the	DET	O
45671	identification	NOUN	O
45671	of	ADP	O
45671	molds	NOUN	O
45671	on	ADP	O
45671	the	DET	O
45671	skin	NOUN	O
45671	,	PUNCT	O
45671	criticism	NOUN	O
45671	is	VERB	O
45671	necessary	ADJ	O
45671	,	PUNCT	O
45671	since	ADP	O
45671	in	ADP	O
45671	more	ADJ	O
45671	than	ADP	O
45671	95	NUM	O
45671	%	NOUN	O
45671	of	ADP	O
45671	the	DET	O
45671	cases	NOUN	O
45671	they	PRON	O
45671	are	VERB	O
45671	accidental	ADJ	O
45671	germs	NOUN	O
45671	.	PUNCT	O
45672	Several	ADJ	O
45672	cultures	NOUN	O
45672	and	CCONJ	O
45672	microscopic	ADJ	O
45672	tests	NOUN	O
45672	are	VERB	O
45672	necessary	ADJ	O
45672	to	PART	O
45672	assure	VERB	O
45672	the	DET	O
45672	diagnosis	NOUN	O
45672	.	PUNCT	O
45673	Broad	ADJ	O
45673	-	PUNCT	O
45673	spectrum	NOUN	O
45673	antimycotics	NOUN	O
45673	is	VERB	O
45673	the	DET	O
45673	predominant	ADJ	O
45673	choice	NOUN	O
45673	for	ADP	O
45673	treatment	NOUN	O
45673	,	PUNCT	O
45673	but	CCONJ	O
45673	also	ADV	O
45673	amphotericin	PROPN	O
45673	B	PROPN	O
45673	,	PUNCT	O
45673	nystatin	ADJ	O
45673	and	CCONJ	O
45673	pimaricin	NOUN	O
45673	.	PUNCT	O
45674	The	DET	O
45674	capacity	NOUN	O
45674	to	PART	O
45674	synthetize	VERB	O
45674	isopropylmalate	ADJ	O
45674	isomerase	NOUN	O
45674	(	PUNCT	O
45674	EC	PROPN	O
45674	4.2.1.33	NUM	O
45674	)	PUNCT	O
45674	by	ADP	O
45674	Neurospora	PROPN	O
45674	crassa	NOUN	O
45674	increased	VERB	O
45674	during	ADP	O
45674	induction	NOUN	O
45674	in	ADP	O
45674	the	DET	O
45674	presence	NOUN	O
45674	of	ADP	O
45674	cycloheximide	NOUN	O
45674	but	CCONJ	O
45674	was	VERB	O
45674	inhibited	VERB	O
45674	by	ADP	O
45674	proflavine	NOUN	O
45674	and	CCONJ	O
45674	other	ADJ	O
45674	inhibitors	NOUN	O
45674	of	ADP	O
45674	RNA	PROPN	O
45674	synthesis	NOUN	O
45674	.	PUNCT	O
45675	Turnover	NOUN	O
45675	of	ADP	O
45675	the	DET	O
45675	enzyme	NOUN	O
45675	once	ADV	O
45675	formed	VERB	O
45675	appeared	VERB	O
45675	negligible	ADJ	O
45675	,	PUNCT	O
45675	but	CCONJ	O
45675	the	DET	O
45675	message	NOUN	O
45675	(	PUNCT	O
45675	measured	VERB	O
45675	as	ADP	O
45675	enzyme	NOUN	O
45675	-	PUNCT	O
45675	forming	VERB	O
45675	capacity	NOUN	O
45675	)	PUNCT	O
45675	had	VERB	O
45675	a	DET	O
45675	half	ADJ	O
45675	-	PUNCT	O
45675	life	NOUN	O
45675	of	ADP	O
45675	4	NUM	O
45675	to	PART	O
45675	8	NUM	O
45675	min	NOUN	O
45675	.	PUNCT	O
45676	A	DET	O
45676	comparison	NOUN	O
45676	of	ADP	O
45676	the	DET	O
45676	kinetics	NOUN	O
45676	of	ADP	O
45676	induction	NOUN	O
45676	in	ADP	O
45676	the	DET	O
45676	wild	ADJ	O
45676	type	NOUN	O
45676	and	CCONJ	O
45676	a	DET	O
45676	newly	ADV	O
45676	isolated	VERB	O
45676	alpha	NOUN	O
45676	-	PUNCT	O
45676	isopropylmalate	NOUN	O
45676	-	PUNCT	O
45676	permeable	ADJ	O
45676	strain	NOUN	O
45676	suggested	VERB	O
45676	strongly	ADV	O
45676	that	ADP	O
45676	feedback	NOUN	O
45676	control	NOUN	O
45676	by	ADP	O
45676	leucine	NOUN	O
45676	of	ADP	O
45676	alpha	NOUN	O
45676	-	PUNCT	O
45676	isopropylmalate	NOUN	O
45676	production	NOUN	O
45676	can	VERB	O
45676	adequately	ADV	O
45676	serve	VERB	O
45676	as	ADP	O
45676	the	DET	O
45676	primary	ADJ	O
45676	physiological	ADJ	O
45676	regulator	NOUN	O
45676	of	ADP	O
45676	endogenous	ADJ	O
45676	inducer	NOUN	O
45676	concentration	NOUN	O
45676	.	PUNCT	O
45677	Genetic	ADJ	O
45677	data	NOUN	O
45677	are	VERB	O
45677	presented	VERB	O
45677	which	ADJ	O
45677	implicate	VERB	O
45677	the	DET	O
45677	involvement	NOUN	O
45677	of	ADP	O
45677	two	NUM	O
45677	unlinked	ADJ	O
45677	genes	NOUN	O
45677	,	PUNCT	O
45677	ipm-1	NOUN	O
45677	and	CCONJ	O
45677	ipm-2	ADV	O
45677	,	PUNCT	O
45677	in	ADP	O
45677	determining	VERB	O
45677	permeation	NOUN	O
45677	of	ADP	O
45677	alpha	NOUN	O
45677	-	PUNCT	O
45677	isopropylmalate	NOUN	O
45677	.	PUNCT	O
45678	The	DET	O
45678	cardiovascular	ADJ	O
45678	and	CCONJ	O
45678	lung	NOUN	O
45678	lesions	NOUN	O
45678	in	ADP	O
45678	23	NUM	O
45678	centenarians	NOUN	O
45678	(	PUNCT	O
45678	7	NUM	O
45678	males	NOUN	O
45678	and	CCONJ	O
45678	16	NUM	O
45678	females	NOUN	O
45678	)	PUNCT	O
45678	were	VERB	O
45678	examined	VERB	O
45678	pathologically	ADV	O
45678	.	PUNCT	O
45679	The	DET	O
45679	heart	NOUN	O
45679	showed	VERB	O
45679	varied	ADJ	O
45679	degrees	NOUN	O
45679	of	ADP	O
45679	hypertrophy	NOUN	O
45679	,	PUNCT	O
45679	and	CCONJ	O
45679	myocardial	ADJ	O
45679	fibrosis	NOUN	O
45679	was	VERB	O
45679	present	ADJ	O
45679	in	ADP	O
45679	15	NUM	O
45679	of	ADP	O
45679	the	DET	O
45679	23	NUM	O
45679	patients	NOUN	O
45679	.	PUNCT	O
45680	Coronary	ADJ	DISEASE
45680	arteriosclerosis	NOUN	DISEASE
45680	was	VERB	O
45680	noted	VERB	O
45680	coincidentally	ADV	O
45680	.	PUNCT	O
45681	In	ADP	O
45681	addition	NOUN	O
45681	to	ADP	O
45681	these	DET	O
45681	findings	NOUN	O
45681	,	PUNCT	O
45681	amyloid	NOUN	O
45681	deposition	NOUN	O
45681	was	VERB	O
45681	seen	VERB	O
45681	in	ADP	O
45681	the	DET	O
45681	hearts	NOUN	O
45681	of	ADP	O
45681	8	NUM	O
45681	patients	NOUN	O
45681	.	PUNCT	O
45682	Generalized	VERB	DISEASE
45682	atherosclerosis	NOUN	DISEASE
45682	of	ADP	O
45682	the	DET	O
45682	arterial	ADJ	O
45682	tree	NOUN	O
45682	was	VERB	O
45682	severe	ADJ	O
45682	to	PART	O
45682	moderate	VERB	O
45682	in	ADP	O
45682	all	DET	O
45682	cases	NOUN	O
45682	.	PUNCT	O
45683	Bronchopneumonia	PROPN	DISEASE
45683	was	VERB	O
45683	present	ADJ	O
45683	in	ADP	O
45683	15	NUM	O
45683	of	ADP	O
45683	the	DET	O
45683	23	NUM	O
45683	patients	NOUN	O
45683	,	PUNCT	O
45683	and	CCONJ	O
45683	fresh	ADJ	O
45683	or	CCONJ	O
45683	old	ADJ	O
45683	thromboembolism	NOUN	O
45683	in	ADP	O
45683	8	NUM	O
45683	.	PUNCT	O
45684	There	ADV	O
45684	was	VERB	O
45684	a	DET	O
45684	tendency	NOUN	O
45684	toward	ADP	O
45684	emphysema	NOUN	O
45684	and	CCONJ	O
45684	chronic	ADJ	DISEASE
45684	bronchitis	NOUN	DISEASE
45684	in	ADP	O
45684	the	DET	O
45684	structure	NOUN	O
45684	of	ADP	O
45684	the	DET	O
45684	lung	NOUN	O
45684	.	PUNCT	O
45685	The	DET	O
45685	frequent	ADJ	O
45685	occurrence	NOUN	O
45685	of	ADP	O
45685	myocardial	ADJ	O
45685	fibrosis	NOUN	O
45685	and	CCONJ	O
45685	bronchopneumonia	NOUN	DISEASE
45685	was	VERB	O
45685	characteristic	ADJ	O
45685	in	ADP	O
45685	the	DET	O
45685	series	NOUN	O
45685	.	PUNCT	O
45686	It	PRON	O
45686	was	VERB	O
45686	significant	ADJ	O
45686	that	ADP	O
45686	cardiac	ADJ	O
45686	amyloid	NOUN	O
45686	deposition	NOUN	O
45686	was	VERB	O
45686	noted	VERB	O
45686	in	ADP	O
45686	these	DET	O
45686	cases	NOUN	O
45686	.	PUNCT	O
45687	Research	NOUN	O
45687	in	ADP	O
45687	human	ADJ	O
45687	subjects	NOUN	O
45687	should	VERB	O
45687	be	VERB	O
45687	conducted	VERB	O
45687	only	ADV	O
45687	if	ADP	O
45687	the	DET	O
45687	rights	NOUN	O
45687	and	CCONJ	O
45687	welfare	NOUN	O
45687	of	ADP	O
45687	the	DET	O
45687	participants	NOUN	O
45687	are	VERB	O
45687	protected	VERB	O
45687	.	PUNCT	O
45688	Prospective	ADJ	O
45688	study	NOUN	O
45688	subjects	NOUN	O
45688	must	VERB	O
45688	be	VERB	O
45688	given	VERB	O
45688	adequate	ADJ	O
45688	information	NOUN	O
45688	about	ADP	O
45688	all	DET	O
45688	aspects	NOUN	O
45688	of	ADP	O
45688	a	DET	O
45688	study	NOUN	O
45688	so	ADP	O
45688	that	ADP	O
45688	they	PRON	O
45688	can	VERB	O
45688	make	VERB	O
45688	a	DET	O
45688	rationally	ADV	O
45688	exercised	VERB	O
45688	decision	NOUN	O
45688	about	ADP	O
45688	participation	NOUN	O
45688	;	PUNCT	O
45688	coercive	ADJ	O
45688	techniques	NOUN	O
45688	to	PART	O
45688	solicit	VERB	O
45688	participants	NOUN	O
45688	should	VERB	O
45688	not	ADV	O
45688	be	VERB	O
45688	used	VERB	O
45688	.	PUNCT	O
45689	Research	NOUN	O
45689	in	ADP	O
45689	humans	NOUN	O
45689	may	VERB	O
45689	be	VERB	O
45689	classified	VERB	O
45689	in	ADP	O
45689	one	NUM	O
45689	of	ADP	O
45689	three	NUM	O
45689	categories	NOUN	O
45689	:	PUNCT	O
45689	A.	PROPN	O
45689	Research	PROPN	O
45689	on	ADP	O
45689	treatment	NOUN	O
45689	of	ADP	O
45689	existing	VERB	O
45689	conditions	NOUN	O
45689	;	PUNCT	O
45689	B.	PROPN	O
45689	Research	PROPN	O
45689	on	ADP	O
45689	preventive	ADJ	O
45689	measures	NOUN	O
45689	;	PUNCT	O
45689	and	CCONJ	O
45689	C.	PROPN	O
45689	Research	PROPN	O
45689	other	ADJ	O
45689	than	ADP	O
45689	for	ADP	O
45689	treatment	NOUN	O
45689	or	CCONJ	O
45689	prevention	NOUN	O
45689	.	PUNCT	O
45690	Different	ADJ	O
45690	concerns	NOUN	O
45690	and	CCONJ	O
45690	aspects	NOUN	O
45690	of	ADP	O
45690	informed	ADJ	O
45690	consent	NOUN	O
45690	assume	VERB	O
45690	particular	ADJ	O
45690	importance	NOUN	O
45690	in	ADP	O
45690	each	DET	O
45690	category	NOUN	O
45690	.	PUNCT	O
45691	In	ADP	O
45691	research	NOUN	O
45691	on	ADP	O
45691	the	DET	O
45691	treatment	NOUN	O
45691	of	ADP	O
45691	existing	VERB	O
45691	conditions	NOUN	O
45691	,	PUNCT	O
45691	untreated	ADJ	O
45691	or	CCONJ	O
45691	placebo	NOUN	O
45691	-	PUNCT	O
45691	treated	VERB	O
45691	control	NOUN	O
45691	groups	NOUN	O
45691	are	VERB	O
45691	rarely	ADV	O
45691	justified	VERB	O
45691	if	ADP	O
45691	the	DET	O
45691	condition	NOUN	O
45691	is	VERB	O
45691	irreversible	ADJ	O
45691	.	PUNCT	O
45692	In	ADP	O
45692	research	NOUN	O
45692	on	ADP	O
45692	preventive	ADJ	O
45692	methods	NOUN	O
45692	prospective	ADJ	O
45692	subjects	NOUN	O
45692	should	VERB	O
45692	be	VERB	O
45692	informed	VERB	O
45692	of	ADP	O
45692	the	DET	O
45692	likelihood	NOUN	O
45692	of	ADP	O
45692	receiving	VERB	O
45692	an	DET	O
45692	ineffective	ADJ	O
45692	treatment	NOUN	O
45692	,	PUNCT	O
45692	if	ADP	O
45692	one	NUM	O
45692	or	CCONJ	O
45692	more	ADJ	O
45692	placebo	NOUN	O
45692	groups	NOUN	O
45692	are	VERB	O
45692	included	VERB	O
45692	.	PUNCT	O
45693	A	DET	O
45693	randomized	ADJ	O
45693	clinical	ADJ	O
45693	trial	NOUN	O
45693	is	VERB	O
45693	usually	ADV	O
45693	the	DET	O
45693	best	ADJ	O
45693	design	NOUN	O
45693	for	ADP	O
45693	studies	NOUN	O
45693	of	ADP	O
45693	preventive	ADJ	O
45693	methods	NOUN	O
45693	.	PUNCT	O
45694	Nonrandomized	ADJ	O
45694	designs	NOUN	O
45694	,	PUNCT	O
45694	that	ADJ	O
45694	are	VERB	O
45694	feasible	ADJ	O
45694	and	CCONJ	O
45694	statistically	ADV	O
45694	valid	ADJ	O
45694	,	PUNCT	O
45694	may	VERB	O
45694	be	VERB	O
45694	employed	VERB	O
45694	in	ADP	O
45694	order	NOUN	O
45694	to	PART	O
45694	avoid	VERB	O
45694	depriving	VERB	O
45694	some	DET	O
45694	subjects	NOUN	O
45694	from	ADP	O
45694	receiving	VERB	O
45694	effective	ADJ	O
45694	preventive	ADJ	O
45694	methods	NOUN	O
45694	.	PUNCT	O
45695	In	ADP	O
45695	social	ADJ	O
45695	or	CCONJ	O
45695	behavioral	ADJ	O
45695	research	NOUN	O
45695	,	PUNCT	O
45695	confidentiality	NOUN	O
45695	of	ADP	O
45695	collected	ADJ	O
45695	information	NOUN	O
45695	and	CCONJ	O
45695	privacy	NOUN	O
45695	of	ADP	O
45695	the	DET	O
45695	subject	NOUN	O
45695	are	VERB	O
45695	essential	ADJ	O
45695	considerations	NOUN	O
45695	.	PUNCT	O
45696	Survival	NOUN	O
45696	in	ADP	O
45696	relation	NOUN	O
45696	to	ADP	O
45696	radiological	ADJ	O
45696	and	CCONJ	O
45696	electrocardiographical	ADJ	O
45696	changes	NOUN	O
45696	was	VERB	O
45696	examined	VERB	O
45696	in	ADP	O
45696	a	DET	O
45696	retrospective	ADJ	O
45696	study	NOUN	O
45696	of	ADP	O
45696	228	NUM	O
45696	hospital	NOUN	O
45696	patients	NOUN	O
45696	aged	VERB	O
45696	40	NUM	O
45696	-	SYM	O
45696	69	NUM	O
45696	years	NOUN	O
45696	with	ADP	O
45696	a	DET	O
45696	FEV1	PROPN	O
45696	of	ADP	O
45696	1.5	NUM	O
45696	1	NUM	O
45696	or	CCONJ	O
45696	less	ADJ	O
45696	,	PUNCT	O
45696	and	CCONJ	O
45696	a	DET	O
45696	FEV1	PROPN	O
45696	of	ADP	O
45696	70	NUM	O
45696	%	NOUN	O
45696	or	CCONJ	O
45696	less	ADJ	O
45696	of	ADP	O
45696	the	DET	O
45696	vital	ADJ	O
45696	capacity	NOUN	O
45696	due	ADP	O
45696	to	ADP	O
45696	chronic	ADJ	DISEASE
45696	obstructive	ADJ	DISEASE
45696	lung	NOUN	DISEASE
45696	disease	NOUN	DISEASE
45696	.	PUNCT	O
45697	The	DET	O
45697	only	ADJ	O
45697	radiological	ADJ	O
45697	changes	NOUN	O
45697	which	ADJ	O
45697	influenced	VERB	O
45697	survival	NOUN	O
45697	after	ADP	O
45697	4	NUM	O
45697	years	NOUN	O
45697	were	VERB	O
45697	enlarged	VERB	O
45697	heart	NOUN	O
45697	and	CCONJ	O
45697	pronounced	VERB	O
45697	dilatation	NOUN	O
45697	of	ADP	O
45697	the	DET	O
45697	pulmonary	ADJ	O
45697	artery	NOUN	O
45697	.	PUNCT	O
45698	Thirty	NUM	O
45698	-	PUNCT	O
45698	eight	NUM	O
45698	percent	NOUN	O
45698	of	ADP	O
45698	the	DET	O
45698	patients	NOUN	O
45698	with	ADP	O
45698	normal	ADJ	O
45698	ECG	PROPN	O
45698	but	CCONJ	O
45698	with	ADP	O
45698	pronounced	VERB	O
45698	dilatation	NOUN	O
45698	of	ADP	O
45698	the	DET	O
45698	pulmonary	ADJ	O
45698	artery	NOUN	O
45698	were	VERB	O
45698	alive	ADJ	O
45698	after	ADP	O
45698	4	NUM	O
45698	years	NOUN	O
45698	.	PUNCT	O
45699	In	ADP	O
45699	patients	NOUN	O
45699	with	ADP	O
45699	normal	ADJ	O
45699	ECG	PROPN	O
45699	and	CCONJ	O
45699	normal	ADJ	O
45699	or	CCONJ	O
45699	moderate	ADJ	O
45699	dilatation	NOUN	O
45699	of	ADP	O
45699	the	DET	O
45699	pulmonary	ADJ	O
45699	artery	NOUN	O
45699	about	ADP	O
45699	80	NUM	O
45699	%	NOUN	O
45699	had	VERB	O
45699	survived	VERB	O
45699	after	ADP	O
45699	4	NUM	O
45699	years	NOUN	O
45699	.	PUNCT	O
45700	There	ADV	O
45700	was	VERB	O
45700	only	ADV	O
45700	18	NUM	O
45700	%	NOUN	O
45700	survival	NOUN	O
45700	after	ADP	O
45700	4	NUM	O
45700	years	NOUN	O
45700	in	ADP	O
45700	patients	NOUN	O
45700	with	ADP	O
45700	abnormal	ADJ	O
45700	ECG	PROPN	O
45700	and	CCONJ	O
45700	pronounced	VERB	O
45700	dilatation	NOUN	O
45700	of	ADP	O
45700	the	DET	O
45700	pulmonary	ADJ	O
45700	artery	NOUN	O
45700	and/or	CCONJ	O
45700	with	ADP	O
45700	enlarged	ADJ	O
45700	heart	NOUN	O
45700	,	PUNCT	O
45700	and	CCONJ	O
45700	only	ADV	O
45700	6	NUM	O
45700	%	NOUN	O
45700	in	ADP	O
45700	patients	NOUN	O
45700	from	ADP	O
45700	age	NOUN	O
45700	group	NOUN	O
45700	60	NUM	O
45700	-	SYM	O
45700	69	NUM	O
45700	.	PUNCT	O
45701	In	ADP	O
45701	patients	NOUN	O
45701	with	ADP	O
45701	abnormal	ADJ	O
45701	ECG	PROPN	O
45701	without	ADP	O
45701	enlarged	ADJ	O
45701	heart	NOUN	O
45701	and	CCONJ	O
45701	without	ADP	O
45701	pronounced	VERB	O
45701	dilatation	NOUN	O
45701	of	ADP	O
45701	the	DET	O
45701	pulmonary	ADJ	O
45701	artery	NOUN	O
45701	50	NUM	O
45701	-	SYM	O
45701	63	NUM	O
45701	%	NOUN	O
45701	had	VERB	O
45701	survived	VERB	O
45701	after	ADP	O
45701	4	NUM	O
45701	years	NOUN	O
45701	.	PUNCT	O
45702	Pulmonary	ADJ	O
45702	hyperinflation	NOUN	O
45702	was	VERB	O
45702	not	ADV	O
45702	important	ADJ	O
45702	for	ADP	O
45702	survival	NOUN	O
45702	during	ADP	O
45702	the	DET	O
45702	first	ADJ	O
45702	4	NUM	O
45702	years	NOUN	O
45702	.	PUNCT	O
45703	Pig	PROPN	O
45703	lymphocytes	VERB	O
45703	typed	VERB	O
45703	for	ADP	O
45703	products	NOUN	O
45703	of	ADP	O
45703	the	DET	O
45703	MHC	PROPN	O
45703	were	VERB	O
45703	primed	VERB	O
45703	in	ADP	O
45703	vitro	X	O
45703	against	ADP	O
45703	allogeneic	ADJ	O
45703	lymphocytes	NOUN	O
45703	.	PUNCT	O
45704	When	ADV	O
45704	rechallenged	VERB	O
45704	with	ADP	O
45704	a	DET	O
45704	panel	NOUN	O
45704	of	ADP	O
45704	different	ADJ	O
45704	cells	NOUN	O
45704	,	PUNCT	O
45704	specific	ADJ	O
45704	'	PUNCT	O
45704	typing	NOUN	O
45704	'	PUNCT	O
45704	responses	NOUN	O
45704	were	VERB	O
45704	distinguishable	ADJ	O
45704	which	ADJ	O
45704	were	VERB	O
45704	not	ADV	O
45704	obscured	VERB	O
45704	by	ADP	O
45704	high	ADJ	O
45704	non	ADJ	O
45704	-	PUNCT	O
45704	specific	ADJ	O
45704	responses	NOUN	O
45704	or	CCONJ	O
45704	by	ADP	O
45704	a	DET	O
45704	restimulator	NOUN	O
45704	gene	NOUN	O
45704	dose	NOUN	O
45704	effect	NOUN	O
45704	.	PUNCT	O
45705	A	DET	O
45705	gene	NOUN	O
45705	additive	ADJ	O
45705	effect	NOUN	O
45705	was	VERB	O
45705	observed	VERB	O
45705	in	ADP	O
45705	both	DET	O
45705	primary	ADJ	O
45705	MLR	PROPN	O
45705	and	CCONJ	O
45705	in	ADP	O
45705	the	DET	O
45705	primed	VERB	O
45705	lymphocyte	NOUN	O
45705	test	NOUN	O
45705	(	PUNCT	O
45705	PLT	PROPN	O
45705	)	PUNCT	O
45705	.	PUNCT	O
45706	The	DET	O
45706	age	NOUN	O
45706	dependence	NOUN	O
45706	of	ADP	O
45706	elicitation	NOUN	O
45706	of	ADP	O
45706	adjuvant	ADJ	O
45706	arthritis	NOUN	DISEASE
45706	in	ADP	O
45706	three	NUM	O
45706	different	ADJ	O
45706	strains	NOUN	O
45706	of	ADP	O
45706	rats	NOUN	O
45706	is	VERB	O
45706	recorded	VERB	O
45706	.	PUNCT	O
45707	In	ADP	O
45707	contrast	NOUN	O
45707	to	ADP	O
45707	the	DET	O
45707	existing	VERB	O
45707	literature	NOUN	O
45707	an	DET	O
45707	adjuvant	ADJ	O
45707	disease	NOUN	O
45707	can	VERB	O
45707	be	VERB	O
45707	elicited	VERB	O
45707	already	ADV	O
45707	in	ADP	O
45707	animals	NOUN	O
45707	of	ADP	O
45707	13	NUM	O
45707	to	PART	O
45707	15	NUM	O
45707	days	NOUN	O
45707	of	ADP	O
45707	age	NOUN	O
45707	,	PUNCT	O
45707	where	ADV	O
45707	significant	ADJ	O
45707	,	PUNCT	O
45707	obvious	ADJ	O
45707	genetical	ADJ	O
45707	differences	NOUN	O
45707	exist	VERB	O
45707	between	ADP	O
45707	the	DET	O
45707	used	VERB	O
45707	strains	NOUN	O
45707	with	ADP	O
45707	regard	NOUN	O
45707	to	ADP	O
45707	age	NOUN	O
45707	dependence	NOUN	O
45707	of	ADP	O
45707	the	DET	O
45707	occurence	NOUN	O
45707	of	ADP	O
45707	arthritis	NOUN	DISEASE
45707	.	PUNCT	O
45708	From	ADP	O
45708	the	DET	O
45708	results	NOUN	O
45708	is	VERB	O
45708	to	PART	O
45708	conclude	VERB	O
45708	,	PUNCT	O
45708	that	ADP	O
45708	in	ADP	O
45708	all	DET	O
45708	investigations	NOUN	O
45708	on	ADP	O
45708	adjuvant	ADJ	O
45708	arthritis	NOUN	DISEASE
45708	merely	ADV	O
45708	genetically	ADV	O
45708	identic	ADJ	O
45708	animals	NOUN	O
45708	are	VERB	O
45708	to	PART	O
45708	be	VERB	O
45708	used	VERB	O
45708	,	PUNCT	O
45708	and	CCONJ	O
45708	the	DET	O
45708	possibility	NOUN	O
45708	of	ADP	O
45708	strain	NOUN	O
45708	dependent	ADJ	O
45708	differences	NOUN	O
45708	in	ADP	O
45708	the	DET	O
45708	assessment	NOUN	O
45708	of	ADP	O
45708	the	DET	O
45708	results	NOUN	O
45708	are	VERB	O
45708	to	PART	O
45708	be	VERB	O
45708	considered	VERB	O
45708	.	PUNCT	O
45709	The	DET	O
45709	combination	NOUN	O
45709	of	ADP	O
45709	MN(Hp	NOUN	O
45709	2	NUM	O
45709	-	SYM	O
45709	2	NUM	O
45709	)	PUNCT	O
45709	blood	NOUN	O
45709	group	NOUN	O
45709	is	VERB	O
45709	more	ADV	O
45709	frequent	ADJ	O
45709	in	ADP	O
45709	bronchial	ADJ	O
45709	asthma	NOUN	O
45709	patients	NOUN	O
45709	than	ADP	O
45709	in	ADP	O
45709	the	DET	O
45709	normal	ADJ	O
45709	population	NOUN	O
45709	.	PUNCT	O
45710	The	DET	O
45710	highest	ADJ	O
45710	changes	NOUN	O
45710	of	ADP	O
45710	blood	NOUN	O
45710	serum	NOUN	O
45710	proteinogramm	NOUN	O
45710	were	VERB	O
45710	observed	VERB	O
45710	within	ADP	O
45710	the	DET	O
45710	first	ADJ	O
45710	week	NOUN	O
45710	after	ADP	O
45710	anti	ADV	O
45710	-	PUNCT	O
45710	typhus	ADV	DISEASE
45710	-	PUNCT	O
45710	paratyphus	ADJ	O
45710	-	PUNCT	O
45710	tetanus	NOUN	O
45710	vaccination	NOUN	O
45710	in	ADP	O
45710	persons	NOUN	O
45710	with	ADP	O
45710	haptoglobulin	NOUN	O
45710	of	ADP	O
45710	2	NUM	O
45710	-	SYM	O
45710	2	NUM	O
45710	type	NOUN	O
45710	,	PUNCT	O
45710	especially	ADV	O
45710	in	ADP	O
45710	combination	NOUN	O
45710	with	ADP	O
45710	NN	PROPN	O
45710	and	CCONJ	O
45710	MN	PROPN	O
45710	blood	NOUN	O
45710	groups	NOUN	O
45710	of	ADP	O
45710	MN	PROPN	O
45710	system	NOUN	O
45710	.	PUNCT	O
45710	The	DET	O
45710	highest	ADJ	O
45710	changes	NOUN	O
45710	of	ADP	O
45710	blood	NOUN	O
45710	serum	NOUN	O
45710	proteinogramm	NOUN	O
45710	were	VERB	O
45710	observed	VERB	O
45710	within	ADP	O
45710	the	DET	O
45710	first	ADJ	O
45710	week	NOUN	O
45710	after	ADP	O
45710	anti	ADV	O
45710	-	PUNCT	O
45710	typhus	ADV	O
45710	-	PUNCT	O
45710	paratyphus	ADJ	O
45710	-	PUNCT	O
45710	tetanus	NOUN	DISEASE
45710	vaccination	NOUN	O
45710	in	ADP	O
45710	persons	NOUN	O
45710	with	ADP	O
45710	haptoglobulin	NOUN	O
45710	of	ADP	O
45710	2	NUM	O
45710	-	SYM	O
45710	2	NUM	O
45710	type	NOUN	O
45710	,	PUNCT	O
45710	especially	ADV	O
45710	in	ADP	O
45710	combination	NOUN	O
45710	with	ADP	O
45710	NN	PROPN	O
45710	and	CCONJ	O
45710	MN	PROPN	O
45710	blood	NOUN	O
45710	groups	NOUN	O
45710	of	ADP	O
45710	MN	PROPN	O
45710	system	NOUN	O
45710	.	PUNCT	O
45711	The	DET	O
45711	most	ADV	O
45711	intense	ADJ	O
45711	increase	NOUN	O
45711	of	ADP	O
45711	antibody	ADJ	O
45711	titer	NOUN	O
45711	to	ADP	O
45711	typhoid	NOUN	DISEASE
45711	bacillus	NOUN	O
45711	was	VERB	O
45711	observed	VERB	O
45711	in	ADP	O
45711	a	DET	O
45711	month	NOUN	O
45711	after	ADP	O
45711	the	DET	O
45711	vaccination	NOUN	O
45711	in	ADP	O
45711	persons	NOUN	O
45711	with	ADP	O
45711	2	NUM	O
45711	-	SYM	O
45711	2	NUM	O
45711	type	NOUN	O
45711	of	ADP	O
45711	haptoglobin	NOUN	O
45711	.	PUNCT	O
45712	A	DET	O
45712	personal	ADJ	O
45712	monitoring	NOUN	O
45712	badge	NOUN	O
45712	has	VERB	O
45712	been	VERB	O
45712	developed	VERB	O
45712	for	ADP	O
45712	the	DET	O
45712	detection	NOUN	O
45712	of	ADP	O
45712	the	DET	O
45712	direct	ADJ	O
45712	-	PUNCT	O
45712	acting	NOUN	O
45712	,	PUNCT	O
45712	alkylating	VERB	O
45712	carcinogen	ADJ	O
45712	beta	NOUN	O
45712	-	PUNCT	O
45712	propiolactone	NOUN	O
45712	at	ADP	O
45712	atmospheric	ADJ	O
45712	concentrations	NOUN	O
45712	as	ADV	O
45712	low	ADJ	O
45712	as	ADP	O
45712	6	NUM	O
45712	ppb	NUM	O
45712	for	ADP	O
45712	24-hour	NUM	O
45712	and	CCONJ	O
45712	0.6	NUM	O
45712	ppm	NOUN	O
45712	for	ADP	O
45712	0.25-hour	NUM	O
45712	exposure	NOUN	O
45712	.	PUNCT	O
45713	The	DET	O
45713	method	NOUN	O
45713	employs	VERB	O
45713	the	DET	O
45713	trapping	VERB	O
45713	reagent	ADJ	O
45713	p	NOUN	O
45713	-	PUNCT	O
45713	nitrobenzyl	NOUN	O
45713	pyridine	NOUN	O
45713	(	PUNCT	O
45713	p	PROPN	O
45713	-	PUNCT	O
45713	NBP	PROPN	O
45713	)	PUNCT	O
45713	absorbed	VERB	O
45713	on	ADP	O
45713	a	DET	O
45713	cellulose	ADJ	O
45713	thin	ADJ	O
45713	-	PUNCT	O
45713	layer	NOUN	O
45713	chromatography	NOUN	O
45713	(	PUNCT	O
45713	TLC	PROPN	O
45713	)	PUNCT	O
45713	strip	NOUN	O
45713	.	PUNCT	O
45714	Deoxyguanosine	NOUN	O
45714	can	VERB	O
45714	be	VERB	O
45714	used	VERB	O
45714	in	ADP	O
45714	place	NOUN	O
45714	of	ADP	O
45714	p	NOUN	O
45714	-	PUNCT	O
45714	NBP	PROPN	O
45714	,	PUNCT	O
45714	but	CCONJ	O
45714	its	ADJ	O
45714	lower	ADJ	O
45714	limit	NOUN	O
45714	of	ADP	O
45714	detection	NOUN	O
45714	is	VERB	O
45714	60	NUM	O
45714	ppb	NUM	O
45714	for	ADP	O
45714	24-hour	NUM	O
45714	exposure	NOUN	O
45714	.	PUNCT	O
45715	The	DET	O
45715	authors	NOUN	O
45715	also	ADV	O
45715	obtained	VERB	O
45715	positive	ADJ	O
45715	results	NOUN	O
45715	with	ADP	O
45715	the	DET	O
45715	carcinogens	NOUN	O
45715	bis	NOUN	O
45715	(	PUNCT	O
45715	chloromethyl	NOUN	O
45715	)	PUNCT	O
45715	ether	NOUN	O
45715	,	PUNCT	O
45715	chloromethyl	NOUN	O
45715	methyl	NOUN	O
45715	ether	NOUN	O
45715	,	PUNCT	O
45715	diepoxybutane	NOUN	O
45715	,	PUNCT	O
45715	dimethylcarbamoyl	VERB	O
45715	chloride	ADJ	O
45715	,	PUNCT	O
45715	ethyleneimine	ADJ	O
45715	,	PUNCT	O
45715	and	CCONJ	O
45715	glycidaldehyde	NOUN	O
45715	.	PUNCT	O
45716	In	ADP	O
45716	practice	NOUN	O
45716	,	PUNCT	O
45716	the	DET	O
45716	TLC	PROPN	O
45716	strip	NOUN	O
45716	is	VERB	O
45716	positioned	VERB	O
45716	in	ADP	O
45716	a	DET	O
45716	filmbadge	NOUN	O
45716	holder	NOUN	O
45716	.	PUNCT	O
45717	The	DET	O
45717	TLC	PROPN	O
45717	strip	NOUN	O
45717	monitoring	NOUN	O
45717	badges	NOUN	O
45717	are	VERB	O
45717	easy	ADJ	O
45717	to	PART	O
45717	prepare	VERB	O
45717	;	PUNCT	O
45717	they	PRON	O
45717	should	VERB	O
45717	encounter	VERB	O
45717	no	DET	O
45717	resistance	NOUN	O
45717	of	ADP	O
45717	personnel	NOUN	O
45717	to	ADP	O
45717	their	ADJ	O
45717	use	NOUN	O
45717	since	ADP	O
45717	they	PRON	O
45717	are	VERB	O
45717	not	ADV	O
45717	cumbersome	ADJ	O
45717	.	PUNCT	O
45718	Monitoring	VERB	O
45718	at	ADP	O
45718	the	DET	O
45718	end	NOUN	O
45718	of	ADP	O
45718	an	DET	O
45718	exposure	NOUN	O
45718	is	VERB	O
45718	simple	ADJ	O
45718	and	CCONJ	O
45718	requires	VERB	O
45718	no	DET	O
45718	expensive	ADJ	O
45718	equipment	NOUN	O
45718	or	CCONJ	O
45718	specialized	ADJ	O
45718	personnel	NOUN	O
45718	.	PUNCT	O
45719	Kinetic	ADJ	O
45719	parameters	NOUN	O
45719	are	VERB	O
45719	reported	VERB	O
45719	for	ADP	O
45719	Mg2	NOUN	O
45719	+	NOUN	O
45719	,	PUNCT	O
45719	Na+	ADJ	O
45719	and	CCONJ	O
45719	K+	VERB	O
45719	as	ADP	O
45719	activators	NOUN	O
45719	of	ADP	O
45719	the	DET	O
45719	p	NOUN	O
45719	-	PUNCT	O
45719	nitrophenylphosphatase	NOUN	O
45719	activity	NOUN	O
45719	associated	VERB	O
45719	with	ADP	O
45719	(	PUNCT	O
45719	Na+	ADJ	O
45719	+	SYM	O
45719	K+)-ATPase	PROPN	O
45719	(	PUNCT	O
45719	ATP	PROPN	O
45719	-	PUNCT	O
45719	phosphohydrolase	NOUN	O
45719	,	PUNCT	O
45719	EC	PROPN	O
45719	3.6.1.3	NUM	O
45719	)	PUNCT	O
45719	of	ADP	O
45719	beef	NOUN	O
45719	brain	NOUN	O
45719	.	PUNCT	O
45720	In	ADP	O
45720	each	DET	O
45720	case	NOUN	O
45720	the	DET	O
45720	phosphatase	NOUN	O
45720	reaction	NOUN	O
45720	is	VERB	O
45720	activated	VERB	O
45720	at	ADP	O
45720	low	ADJ	O
45720	concentrations	NOUN	O
45720	of	ADP	O
45720	the	DET	O
45720	cation	NOUN	O
45720	and	CCONJ	O
45720	inhibited	VERB	O
45720	by	ADP	O
45720	higher	ADJ	O
45720	concentrations	NOUN	O
45720	.	PUNCT	O
45721	The	DET	O
45721	concentrations	NOUN	O
45721	of	ADP	O
45721	cation	NOUN	O
45721	that	ADJ	O
45721	produced	VERB	O
45721	half	ADJ	O
45721	-	PUNCT	O
45721	maximal	ADJ	O
45721	activation	NOUN	O
45721	and	CCONJ	O
45721	half	ADJ	O
45721	-	PUNCT	O
45721	maximal	ADJ	O
45721	inhibition	NOUN	O
45721	are	VERB	O
45721	increased	VERB	O
45721	as	ADP	O
45721	the	DET	O
45721	concentration	NOUN	O
45721	of	ADP	O
45721	either	DET	O
45721	of	ADP	O
45721	the	DET	O
45721	other	ADJ	O
45721	two	NUM	O
45721	cations	NOUN	O
45721	is	VERB	O
45721	increased	VERB	O
45721	.	PUNCT	O
45722	These	DET	O
45722	second	ADJ	O
45722	ligand	NOUN	O
45722	effects	NOUN	O
45722	are	VERB	O
45722	all	DET	O
45722	saturable	ADJ	O
45722	functions	NOUN	O
45722	.	PUNCT	O
45723	The	DET	O
45723	apparent	ADJ	O
45723	binding	ADJ	O
45723	constant	ADJ	O
45723	that	ADJ	O
45723	characterizes	VERB	O
45723	the	DET	O
45723	effect	NOUN	O
45723	on	ADP	O
45723	activation	NOUN	O
45723	is	VERB	O
45723	closely	ADV	O
45723	similar	ADJ	O
45723	to	ADP	O
45723	that	DET	O
45723	acting	VERB	O
45723	upon	ADP	O
45723	the	DET	O
45723	inhibitory	ADJ	O
45723	phase	NOUN	O
45723	in	ADP	O
45723	each	DET	O
45723	case	NOUN	O
45723	.	PUNCT	O
45724	A	DET	O
45724	case	NOUN	O
45724	of	ADP	O
45724	an	DET	O
45724	osteoid	NOUN	O
45724	osteoma	NOUN	O
45724	occurring	VERB	O
45724	in	ADP	O
45724	the	DET	O
45724	cervical	ADJ	O
45724	spine	NOUN	O
45724	and	CCONJ	O
45724	presenting	VERB	O
45724	as	ADP	O
45724	scapular	NOUN	O
45724	and	CCONJ	O
45724	arm	NOUN	O
45724	pain	NOUN	O
45724	has	VERB	O
45724	been	VERB	O
45724	described	VERB	O
45724	.	PUNCT	O
45725	Correct	ADJ	O
45725	diagnosis	NOUN	O
45725	was	VERB	O
45725	delayed	VERB	O
45725	for	ADP	O
45725	2	NUM	O
45725	years	NOUN	O
45725	.	PUNCT	O
45726	Plain	ADJ	O
45726	radiographs	NOUN	O
45726	may	VERB	O
45726	fail	VERB	O
45726	to	PART	O
45726	demonstrate	VERB	O
45726	a	DET	O
45726	lesion	NOUN	O
45726	in	ADP	O
45726	the	DET	O
45726	spine	NOUN	O
45726	.	PUNCT	O
45727	Radiographic	ADJ	O
45727	evaluation	NOUN	O
45727	,	PUNCT	O
45727	when	ADV	O
45727	osteoid	NOUN	O
45727	osteoma	NOUN	O
45727	is	VERB	O
45727	a	DET	O
45727	possibility	NOUN	O
45727	,	PUNCT	O
45727	should	VERB	O
45727	include	VERB	O
45727	bone	NOUN	O
45727	scanning	NOUN	O
45727	.	PUNCT	O
45728	If	ADP	O
45728	the	DET	O
45728	bone	NOUN	O
45728	scan	NOUN	O
45728	is	VERB	O
45728	abnormal	ADJ	O
45728	,	PUNCT	O
45728	tomography	NOUN	O
45728	of	ADP	O
45728	the	DET	O
45728	area	NOUN	O
45728	is	VERB	O
45728	indicated	VERB	O
45728	.	PUNCT	O
45729	If	ADP	O
45729	the	DET	O
45729	diagnosis	NOUN	O
45729	is	VERB	O
45729	still	ADV	O
45729	unclear	ADJ	O
45729	,	PUNCT	O
45729	selective	ADJ	O
45729	angiography	NOUN	O
45729	may	VERB	O
45729	reveal	VERB	O
45729	the	DET	O
45729	tumor	NOUN	O
45729	blush	NOUN	O
45729	typical	ADJ	O
45729	of	ADP	O
45729	osteoid	NOUN	O
45729	osteoma	NOUN	O
45729	.	PUNCT	O
45730	In	ADP	O
45730	certain	ADJ	O
45730	instances	NOUN	O
45730	,	PUNCT	O
45730	a	DET	O
45730	myelogram	NOUN	O
45730	may	VERB	O
45730	be	VERB	O
45730	helpful	ADJ	O
45730	to	PART	O
45730	establish	VERB	O
45730	whether	ADP	O
45730	there	ADV	O
45730	is	VERB	O
45730	encroachment	NOUN	O
45730	on	ADP	O
45730	the	DET	O
45730	spinal	ADJ	O
45730	canal	NOUN	O
45730	or	CCONJ	O
45730	nerve	NOUN	O
45730	root	NOUN	O
45730	.	PUNCT	O
45731	Pain	NOUN	O
45731	syndromes	NOUN	O
45731	in	ADP	O
45731	elderly	ADJ	O
45731	patients	NOUN	O
45731	are	VERB	O
45731	seldom	ADV	O
45731	psychogenic	ADJ	O
45731	or	CCONJ	O
45731	due	ADJ	O
45731	merely	ADV	O
45731	to	ADP	O
45731	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
These 	 O 	O
data 	 O 	O
suggested 	 O 	O
that 	 O 	O
the 	 O 	O
increased 	 O 	O
activities 	 O 	O
might 	 O 	O
be 	 O 	O
reflected 	 O 	O
on 	 O 	O
the 	 O 	O
active 	 O 	O
stage 	 O 	O
in 	 O 	O
chronic 	 DISEASE 	O
hepatitis 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Breast 	 DISEASE 	O
disease 	 DISEASE 	DISEASE
is 	 O 	O
a 	 O 	O
common 	 O 	O
problem 	 O 	O
found 	 O 	O
in 	 O 	O
approximately 	 O 	O
one 	 O 	O
of 	 O 	O
four 	 O 	O
women 	 O 	O
from 	 O 	O
puberty 	 O 	O
to 	 O 	O
old 	 O 	O
age 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Finally 	 O 	O
, 	 O 	O
the 	 O 	O
implications 	 O 	DISEASE
for 	 O 	O
a 	 O 	O
minimal 	 O 	O
design 	 O 	O
for 	 O 	O
artificial 	 O 	O
electrical 	 O 	O
multi 	 O 	O
- 	 O 	O
electrode 	 O 	O
array 	 O 	O
stimulation 	 O 	O
of 	 O 	O
the 	 O 	O
cochlea 	 O 	O
in 	 O 	O
order 	 O 	O
to 	 O 	O
impart 	 O 	O
speech 	 O 	O
information 	 O 	O
to 	 O 	O
the 	 O 	O
profoundly 	 O 	O
deaf 	 O 	O
, 	 O 	O
are 	 O 	O
explored 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
37 	 O 	O
primary 	 O 	O
teeth 	 O 	O
with 	 O 	O
no 	 O 	O
clinical 	 O 	O
or 	 O 	O
radiographic 	 O 	O
symptoms 	 O 	O
of 	 O 	O
total 	 O 	O
chronic 	 O 	DISEASE
pulpitis 	 DISEASE 	DISEASE
were 	 O 	O
extracted 	 O 	O
and 	 O 	O
the 	 O 	O
pulp 	 O 	O
was 	 O 	O
studied 	 O 	O
histologically 	 O 	O
by 	 O 	O
light 	 O 	O
microscopy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Of 	 O 	O
17 	 O 	O
patients 	 O 	O
with 	 O 	O
germ 	 O 	O
cell 	 O 	O
testicular 	 O 	O
tumors 	 O 	O
found 	 O 	O
to 	 O 	O
have 	 O 	O
elevated 	 O 	O
serum 	 O 	O
markers 	 O 	O
3 	 O 	O
had 	 O 	O
seminoma 	 DISEASE 	O
of 	 O 	O
the 	 O 	O
testis 	 O 	O
and 	 O 	O
all 	 O 	O
3 	 O 	O
had 	 O 	O
elevated 	 O 	O
beta 	 O 	O
- 	 O 	O
human 	 O 	O
chorionic 	 O 	O
gonadotropin 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Maxillary 	 O 	O
crowding 	 O 	O
may 	 O 	O
cause 	 O 	O
failure 	 O 	DISEASE
of 	 O 	O
eruption 	 O 	O
of 	 O 	O
the 	 O 	O
canine 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
a 	 O 	O
normal 	 O 	O
group 	 O 	O
( 	 O 	O
n 	 O 	O
= 	 O 	O
140 	 O 	O
, 	 O 	O
AFP 	 O 	O
levels 	 O 	O
below 	 O 	O
15 	 O 	O
ng 	 O 	O
/ 	 O 	O
ml 	 O 	O
) 	 O 	O
, 	 O 	O
most 	 O 	O
elevated 	 O 	O
AFP 	 O 	O
concentrations 	 O 	O
were 	 O 	O
found 	 O 	O
in 	 O 	O
18 	 O 	O
patients 	 O 	O
with 	 O 	O
primary 	 DISEASE 	O
liver 	 DISEASE 	DISEASE
cancer 	 DISEASE 	DISEASE
( 	 O 	O
PLC 	 O 	O
) 	 O 	O
, 	 O 	O
7 	 O 	O
of 	 O 	O
whom 	 O 	O
showed 	 O 	O
Ouchterlony 	 O 	O
- 	 O 	O
positive 	 O 	O
levels 	 O 	O
( 	 O 	O
above 	 O 	O
10,000 	 O 	O
ng 	 O 	O
/ 	 O 	O
ml 	 O 	O
) 	 O 	O
. 	 O 	O
cancerostatics 	 O 	O
it 	 O 	O
is 	 O 	O
pointed 	 O 	O
out 	 O 	O
that 	 O 	O
, 	 O 	O
thanks 	 O 	O
to 	 O 	O
recent 	 O 	O
advances 	 O 	O
in 	 O 	O
cell 	 O 	O
kinetics 	 O 	O
( 	 O 	O
cycle 	 O 	O
- 	 O 	O
adequate 	 O 	O
selection 	 O 	O
of 	 O 	O
cancerostatics 	 O 	O
) 	 O 	O
combined 	 O 	O
with 	 O 	O
microtopography 	 O 	O
of 	 O 	O
substrate 	 O 	O
supply 	 O 	O
in 	 O 	O
the 	 O 	O
intercapillary 	 O 	O
region 	 O 	O
of 	 O 	O
cancer 	 O 	O
tissue 	 O 	O
, 	 O 	O
chemotherapeutic 	 O 	O
treatment 	 O 	O
of 	 O 	DISEASE
cancer 	 DISEASE 	DISEASE
is 	 O 	O
developing 	 O 	O
into 	 O 	O
a 	 O 	O
theoretically 	 O 	O
founded 	 O 	O
and 	 O 	O
modifiable 	 O 	O
therapy 	 O 	O
. 	 O 	O
The 	 O 	O
technique 	 O 	O
has 	 O 	O
been 	 O 	O
combined 	 O 	O
with 	 O 	O
anodic 	 O 	O
control 	 O 	O
of 	 O 	O
local 	 O 	O
bacterial 	 O 	DISEASE
infection 	 O 	DISEASE
with 	 O 	O
promising 	 O 	O
results 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
an 	 O 	O
open 	 O 	O
pilot 	 O 	O
study 	 O 	O
of 	 O 	O
the 	 O 	O
effects 	 O 	O
of 	 O 	O
clonidine 	 O 	O
on 	 O 	O
longer 	 O 	O
- 	 O 	O
term 	 O 	O
opiate 	 O 	DISEASE
abstinence 	 O 	O
and 	 O 	O
symptoms 	 O 	O
, 	 O 	O
the 	 O 	O
same 	 O 	O
patients 	 O 	O
did 	 O 	O
well 	 O 	O
while 	 O 	O
taking 	 O 	O
clonidine 	 O 	O
for 	 O 	O
one 	 O 	O
week 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
These 	 O 	O
observations 	 O 	O
suggest 	 O 	O
that 	 O 	O
increased 	 O 	O
percentage 	 O 	O
of 	 O 	O
siderocytes 	 O 	O
in 	 O 	O
otherwise 	 O 	O
typical 	 O 	O
iron 	 DISEASE 	O
deficiency 	 DISEASE 	O
anemia 	 DISEASE 	DISEASE
may 	 O 	O
signify 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
a 	 O 	O
sideroblastic 	 O 	O
process 	 O 	O
masked 	 O 	O
by 	 O 	O
iron 	 O 	O
deficiency 	 O 	O
due 	 O 	O
to 	 O 	O
bleeding 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Replenishment 	 O 	O
of 	 O 	O
iron 	 O 	O
stores 	 O 	O
led 	 O 	O
to 	 O 	O
development 	 O 	O
of 	 O 	O
typical 	 O 	O
sideroblastic 	 DISEASE 	O
anemia 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Secretion 	 O 	O
can 	 O 	O
be 	 O 	O
elicited 	 O 	O
in 	 O 	O
vitro 	 O 	O
by 	 O 	O
adding 	 O 	O
cyclic 	 O 	O
AMP 	 O 	O
or 	 O 	O
a 	 O 	O
stimulator 	 O 	O
of 	 O 	O
intestinal 	 O 	O
mucosal 	 O 	O
adenylate 	 O 	O
cyclase 	 O 	O
( 	 O 	O
cholera 	 DISEASE 	O
and 	 O 	O
Escherichia 	 O 	O
coli 	 O 	O
enterotoxins 	 O 	O
, 	 O 	O
prostaglandins 	 O 	O
, 	 O 	O
vasoactive 	 O 	O
intestinal 	 O 	O
peptide 	 O 	O
) 	 O 	O
or 	 O 	O
an 	 O 	O
inhibitor 	 O 	O
of 	 O 	O
cyclic 	 O 	O
AMP 	 O 	O
phosphodiesterase 	 O 	O
( 	 O 	O
theophylline 	 O 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
effects 	 O 	O
of 	 O 	O
morphine 	 O 	O
may 	 O 	O
differ 	 O 	O
in 	 O 	O
the 	 O 	O
normal 	 O 	O
dog 	 O 	O
and 	 O 	O
man 	 O 	O
and 	 O 	O
may 	 O 	O
vary 	 O 	O
depending 	 O 	O
upon 	 O 	O
the 	 O 	O
presence 	 O 	O
or 	 O 	O
absence 	 O 	O
of 	 O 	O
coronary 	 DISEASE 	DISEASE
artery 	 DISEASE 	O
disease 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
California 	 O 	O
and 	 O 	O
bobwhite 	 O 	O
quail 	 O 	O
lysozymes 	 O 	O
were 	 O 	O
antigenically 	 O 	O
distinct 	 O 	O
from 	 O 	O
each 	 O 	O
other 	 O 	O
in 	 O 	O
quantitative 	 O 	O
microcomplement 	 O 	DISEASE
fixation 	 O 	O
tests 	 O 	O
, 	 O 	O
indicating 	 O 	O
that 	 O 	O
substitutions 	 O 	O
at 	 O 	O
one 	 O 	O
or 	 O 	O
both 	 O 	O
of 	 O 	O
these 	 O 	O
positions 	 O 	O
can 	 O 	O
alter 	 O 	O
the 	 O 	O
antigenic 	 O 	O
structure 	 O 	O
of 	 O 	O
lysozyme 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
It 	 O 	O
also 	 O 	O
requires 	 O 	O
an 	 O 	O
awareness 	 O 	O
of 	 O 	O
the 	 O 	O
disease 	 O 	O
entity 	 O 	O
by 	 O 	O
the 	 O 	O
physician 	 O 	O
and 	 O 	O
a 	 O 	O
realization 	 O 	O
that 	 O 	O
everything 	 O 	O
that 	 O 	O
bleeds 	 O 	O
around 	 O 	O
the 	 O 	O
anus 	 O 	O
is 	 O 	O
not 	 O 	O
due 	 O 	O
to 	 O 	O
hemorrhoidal 	 DISEASE 	O
disease 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
During 	 O 	O
the 	 O 	O
followup 	 O 	O
period 	 O 	O
, 	 O 	O
10 	 O 	O
grafts 	 O 	O
have 	 O 	O
occluded 	 O 	O
, 	 O 	O
one 	 O 	O
day 	 O 	O
to 	 O 	O
6 	 O 	O
1/2 	 O 	O
months 	 O 	O
postoperatively 	 O 	O
, 	 O 	O
two 	 O 	O
due 	 O 	O
to 	 O 	O
inflow 	 O 	DISEASE
deficiency 	 O 	O
, 	 O 	O
5 	 O 	O
due 	 O 	O
to 	 O 	O
poor 	 O 	O
outflow 	 O 	O
, 	 O 	O
one 	 O 	O
to 	 O 	O
an 	 O 	O
error 	 O 	O
in 	 O 	O
technique 	 O 	O
, 	 O 	O
and 	 O 	O
two 	 O 	O
occluded 	 O 	O
without 	 O 	O
known 	 O 	O
cause 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
authors 	 O 	O
report 	 O 	O
the 	 O 	O
case 	 O 	O
of 	 O 	O
a 	 O 	O
72 	 O 	O
year 	 O 	O
old 	 O 	O
man 	 O 	O
admitted 	 O 	O
to 	 O 	O
hospital 	 O 	O
for 	 O 	O
thoracic 	 O 	O
pain 	 O 	O
, 	 O 	O
who 	 O 	O
was 	 O 	O
found 	 O 	O
to 	 O 	O
have 	 O 	O
an 	 O 	O
Igd 	 O 	O
myeloma 	 DISEASE 	DISEASE
of 	 O 	O
lambda 	 O 	DISEASE
type 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
inoculation 	 O 	O
of 	 O 	O
E4 	 O 	O
tumor 	 O 	DISEASE
homogenate 	 O 	O
did 	 O 	O
not 	 O 	O
alter 	 O 	O
the 	 O 	O
cellular 	 O 	O
immune 	 O 	O
response 	 O 	O
of 	 O 	O
tuberculin 	 O 	O
- 	 O 	O
sensitized 	 O 	O
mice 	 O 	O
to 	 O 	O
tuberculin 	 O 	O
; 	 O 	O
and 	 O 	O
( 	 O 	O
c 	 O 	O
) 	 O 	O
the 	 O 	O
i.p 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
If 	 O 	O
groupings 	 O 	O
do 	 O 	O
exist 	 O 	O
, 	 O 	O
will 	 O 	O
facilities 	 O 	O
reimbursed 	 O 	O
for 	 O 	O
high 	 O 	O
- 	 O 	O
cost 	 O 	O
patients 	 O 	O
be 	 O 	O
encouraged 	 O 	O
to 	 O 	O
maintain 	 O 	O
them 	 O 	O
in 	 O 	O
a 	 O 	O
state 	 O 	O
of 	 O 	O
dependence 	 O 	DISEASE
? 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
from 	 O 	O
isolated 	 O 	O
tricuspid 	 O 	O
endocarditis 	 O 	O
was 	 O 	O
5 	 O 	O
% 	 O 	O
, 	 O 	O
from 	 O 	O
isolated 	 O 	O
mitral 	 O 	O
endocarditis 	 DISEASE 	O
33 	 O 	O
% 	 O 	O
, 	 O 	O
and 	 O 	O
from 	 O 	O
isolated 	 O 	O
aortic 	 O 	O
valve 	 O 	O
endocarditis 	 O 	O
100 	 O 	O
% 	 O 	O
. 	 O 	O
The 	 O 	O
mortality 	 O 	O
from 	 O 	O
isolated 	 O 	O
tricuspid 	 O 	O
endocarditis 	 O 	O
was 	 O 	O
5 	 O 	O
% 	 O 	O
, 	 O 	O
from 	 O 	O
isolated 	 O 	O
mitral 	 O 	O
endocarditis 	 O 	DISEASE
33 	 O 	O
% 	 O 	O
, 	 O 	O
and 	 O 	O
from 	 O 	O
isolated 	 O 	O
aortic 	 O 	O
valve 	 O 	O
endocarditis 	 DISEASE 	DISEASE
100 	 O 	O
% 	 O 	O
. 	 O 	O
A 	 O 	O
series 	 O 	O
is 	 O 	O
presented 	 O 	O
of 	 O 	O
10 	 O 	O
patients 	 O 	O
with 	 O 	O
intractable 	 O 	O
pain 	 O 	O
secondary 	 O 	O
to 	 O 	O
diffuse 	 O 	O
metastatic 	 O 	O
prostatic 	 O 	DISEASE
carcinoma 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
pathogenesis 	 O 	O
is 	 O 	O
yet 	 O 	O
unclear 	 O 	O
but 	 O 	O
the 	 O 	O
altered 	 O 	O
host 	 O 	O
factors 	 O 	O
appear 	 O 	O
to 	 O 	O
be 	 O 	O
the 	 O 	O
principal 	 O 	O
determinant 	 O 	O
: 	 O 	O
primary 	 O 	O
or 	 O 	O
secondary 	 O 	O
specific 	 O 	O
immunologic 	 O 	O
deficit 	 O 	O
and 	 O 	O
inability 	 O 	O
to 	 O 	O
eliminate 	 O 	O
the 	 O 	O
mites 	 O 	O
because 	 O 	O
of 	 O 	O
the 	 O 	O
absence 	 O 	O
of 	 O 	O
scratching 	 O 	O
, 	 O 	O
hereditary 	 O 	O
predisposition 	 O 	O
to 	 O 	O
keratotic 	 O 	O
reaction 	 O 	O
of 	 O 	O
the 	 O 	O
skin 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
of 	 O 	O
marasmus 	 O 	O
which 	 O 	O
gave 	 O 	O
every 	 O 	O
indication 	 O 	O
of 	 O 	O
an 	 O 	O
impending 	 O 	O
fatal 	 O 	O
termination 	 O 	O
. 	 O 	O
A 	 O 	O
5-month 	 O 	O
- 	 O 	O
old 	 O 	O
white 	 O 	O
infant 	 O 	O
with 	 O 	O
Hirschsprung 	 O 	DISEASE
's 	 O 	O
disease 	 O 	O
, 	 O 	O
complicated 	 O 	O
by 	 O 	O
a 	 O 	O
digestive 	 O 	O
upset 	 O 	O
and 	 O 	O
upper 	 O 	O
respiratory 	 O 	O
infection 	 O 	O
, 	 O 	O
developed 	 O 	O
a 	 O 	O
most 	 O 	O
extreme 	 O 	O
picture 	 O 	O
of 	 O 	O
marasmus 	 DISEASE 	O
which 	 O 	O
gave 	 O 	O
every 	 O 	O
indication 	 O 	O
of 	 O 	O
an 	 O 	O
impending 	 O 	O
fatal 	 O 	O
termination 	 O 	O
. 	 O 	O
Intrauterine 	 O 	O
infection 	 O 	DISEASE
results 	 O 	O
from 	 O 	O
primary 	 O 	O
or 	 O 	O
recurrent 	 O 	O
maternal 	 O 	O
involvement 	 O 	O
, 	 O 	O
the 	 O 	O
latter 	 O 	O
being 	 O 	O
more 	 O 	O
common 	 O 	O
in 	 O 	O
populations 	 O 	O
where 	 O 	O
infection 	 O 	O
is 	 O 	O
initially 	 O 	O
acquired 	 O 	O
during 	 O 	O
childhood 	 O 	O
or 	 O 	O
adolescence 	 O 	O
, 	 O 	O
such 	 O 	O
as 	 O 	O
in 	 O 	O
low 	 O 	O
socioeconomic 	 O 	O
settings 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
question 	 O 	O
of 	 O 	O
inheritance 	 O 	O
is 	 O 	O
being 	 O 	O
discussed 	 O 	O
in 	 O 	O
comparison 	 O 	O
with 	 O 	O
the 	 O 	O
existing 	 O 	O
literature 	 O 	O
, 	 O 	O
also 	 O 	O
taking 	 O 	O
into 	 O 	O
account 	 O 	O
the 	 O 	O
coexistence 	 O 	O
of 	 O 	O
cleft 	 O 	DISEASE
foot 	 O 	O
and 	 O 	O
syndaktylism 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Experiments 	 O 	O
were 	 O 	O
carried 	 O 	O
out 	 O 	O
to 	 O 	O
determine 	 O 	O
TCD50 	 O 	O
( 	 O 	O
50 	 O 	O
% 	 O 	O
tumor 	 O 	O
control 	 O 	O
dose 	 O 	O
) 	 O 	O
of 	 O 	O
3rd 	 O 	O
generation 	 O 	O
isotransplants 	 O 	O
of 	 O 	O
a 	 O 	O
C3H 	 O 	O
mouse 	 O 	O
mammary 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
treated 	 O 	O
or 	 O 	O
not 	 O 	O
treated 	 O 	O
with 	 O 	O
Bleomycin 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Ulceration 	 O 	O
recurred 	 O 	O
in 	 O 	O
24 	 O 	O
, 	 O 	O
always 	 O 	O
at 	 O 	O
the 	 O 	O
site 	 O 	O
of 	 O 	O
the 	 O 	O
original 	 O 	O
ulcer 	 O 	DISEASE
, 	 O 	O
the 	 O 	O
majority 	 O 	O
( 	 O 	O
14 	 O 	O
) 	 O 	O
of 	 O 	O
relapses 	 O 	O
occurring 	 O 	O
within 	 O 	O
12 	 O 	O
months 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
substance 	 O 	O
of 	 O 	O
low 	 O 	O
mass 	 O 	O
numer 	 O 	O
that 	 O 	O
causes 	 O 	O
a 	 O 	O
pronounced 	 O 	O
long 	 O 	O
- 	 O 	O
term 	 O 	O
stimulation 	 O 	O
of 	 O 	O
body 	 O 	O
own 	 O 	O
defence 	 O 	O
( 	 O 	O
e.g. 	 O 	O
our 	 O 	O
BA 	 O 	O
1 	 O 	O
, 	 O 	O
and 	 O 	O
N-(2-cyanoethylene)-urea 	 O 	O
) 	 O 	O
with 	 O 	O
a 	 O 	O
cancerostatic 	 O 	O
like 	 O 	O
CMT 	 O 	O
- 	 O 	O
selectine 	 O 	O
that 	 O 	O
-- 	 O 	O
in 	 O 	O
optimally 	 O 	O
hyperacidified 	 O 	DISEASE
cancer 	 DISEASE 	DISEASE
tissues 	 O 	O
-- 	 O 	O
reaches 	 O 	O
its 	 O 	O
active 	 O 	O
form 	 O 	O
only 	 O 	O
at 	 O 	O
a 	 O 	O
reduced 	 O 	O
pH 	 O 	O
Produced 	 O 	O
by 	 O 	O
the 	 O 	O
larval 	 O 	O
form 	 O 	O
of 	 O 	O
Taenia 	 O 	O
solium 	 O 	O
, 	 O 	O
human 	 O 	O
cysticercosis 	 DISEASE 	O
is 	 O 	O
especially 	 O 	O
redoutable 	 O 	O
because 	 O 	O
of 	 O 	O
its 	 O 	O
great 	 O 	O
affinity 	 O 	O
for 	 O 	O
the 	 O 	O
nervous 	 O 	O
system 	 O 	O
and 	 O 	O
the 	 O 	O
eyes 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
interposition 	 O 	O
mesocaval 	 O 	O
shunt 	 O 	O
is 	 O 	O
judged 	 O 	O
to 	 O 	O
be 	 O 	O
a 	 O 	O
safe 	 O 	O
, 	 O 	O
technically 	 O 	O
easy 	 O 	O
procedure 	 O 	O
that 	 O 	O
is 	 O 	O
currently 	 O 	O
a 	 O 	O
satisfactory 	 O 	O
solution 	 O 	O
to 	 O 	O
the 	 O 	O
problem 	 O 	O
of 	 O 	O
hemorrhage 	 O 	O
from 	 O 	O
esophageal 	 DISEASE 	O
varices 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
myxoid 	 O 	O
variant 	 O 	O
must 	 O 	O
also 	 O 	O
be 	 O 	O
clearly 	 O 	O
distinguished 	 O 	O
from 	 O 	O
benign 	 O 	O
myxoid 	 O 	O
lesions 	 O 	O
such 	 O 	O
as 	 O 	O
myxoma 	 O 	O
or 	 O 	O
nodular 	 DISEASE 	O
fasciitis 	 DISEASE 	O
, 	 O 	O
with 	 O 	O
which 	 O 	O
it 	 O 	O
is 	 O 	O
often 	 O 	O
confused 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
PCP 	 O 	DISEASE
is 	 O 	O
perhaps 	 O 	O
the 	 O 	O
most 	 O 	O
potent 	 O 	O
psychotomimetic 	 O 	O
compound 	 O 	O
known 	 O 	O
at 	 O 	O
the 	 O 	O
present 	 O 	O
time 	 O 	O
and 	 O 	O
is 	 O 	O
capable 	 O 	O
of 	 O 	O
inducing 	 O 	O
a 	 O 	O
psychosis 	 O 	O
which 	 O 	O
is 	 O 	O
clinically 	 O 	O
indistinguishable 	 O 	O
from 	 O 	O
schizophrenia 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
case 	 O 	O
of 	 O 	O
squamous 	 DISEASE 	DISEASE
cell 	 DISEASE 	DISEASE
carcinoma 	 DISEASE 	DISEASE
of 	 O 	DISEASE
the 	 O 	O
urinary 	 O 	DISEASE
bladder 	 O 	O
in 	 O 	O
which 	 O 	O
herpesvirus 	 O 	O
virions 	 O 	O
could 	 O 	O
be 	 O 	O
identified 	 O 	O
by 	 O 	O
electron 	 O 	O
microscopy 	 O 	O
is 	 O 	O
presented 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Successful 	 O 	O
resuscitation 	 O 	O
from 	 O 	O
cardiac 	 DISEASE 	O
arrest 	 DISEASE 	DISEASE
in 	 O 	O
the 	 O 	O
asphyxiated 	 O 	O
dog 	 O 	O
model 	 O 	O
has 	 O 	O
been 	 O 	O
ascribed 	 O 	O
to 	 O 	O
the 	 O 	O
use 	 O 	O
of 	 O 	O
artificial 	 O 	O
ventilation 	 O 	O
, 	 O 	O
closed 	 O 	O
chest 	 O 	O
cardiac 	 O 	O
massage 	 O 	O
, 	 O 	O
and 	 O 	O
administration 	 O 	O
of 	 O 	O
a 	 O 	O
vasopressor 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Concurrently 	 O 	O
, 	 O 	O
evidence 	 O 	O
of 	 O 	O
abnormal 	 O 	O
delayed 	 O 	O
hypersensitivity 	 DISEASE 	O
was 	 O 	O
manifested 	 O 	O
by 	 O 	O
the 	 O 	O
loss 	 O 	O
of 	 O 	O
reactivity 	 O 	O
to 	 O 	O
mumps 	 O 	O
skin 	 O 	O
test 	 O 	O
antigen 	 O 	O
. 	 O 	O
Concurrently 	 O 	O
, 	 O 	O
evidence 	 O 	O
of 	 O 	O
abnormal 	 O 	O
delayed 	 O 	O
hypersensitivity 	 O 	O
was 	 O 	O
manifested 	 O 	O
by 	 O 	O
the 	 O 	O
loss 	 O 	O
of 	 O 	O
reactivity 	 O 	O
to 	 O 	O
mumps 	 DISEASE 	DISEASE
skin 	 O 	O
test 	 O 	O
antigen 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Both 	 O 	O
these 	 O 	O
gases 	 O 	O
are 	 O 	O
present 	 O 	O
in 	 O 	O
sufficient 	 O 	O
proportion 	 O 	O
in 	 O 	O
intestinal 	 O 	O
gas 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
with 	 O 	O
the 	 O 	O
latter 	 O 	O
in 	 O 	O
one 	 O 	O
patient 	 O 	O
with 	 O 	O
a 	 O 	O
carcinoma 	 O 	DISEASE
of 	 O 	O
the 	 O 	O
lung 	 O 	O
. 	 O 	O
Homologous 	 O 	O
serum 	 O 	O
from 	 O 	O
both 	 O 	O
a 	 O 	O
carcinoma 	 O 	O
of 	 O 	O
the 	 O 	O
lung 	 O 	O
and 	 O 	O
breast 	 O 	O
without 	 O 	O
autologous 	 O 	O
blocking 	 O 	O
activity 	 O 	O
did 	 O 	O
not 	 O 	O
abolish 	 O 	O
migration 	 O 	O
inhibition 	 O 	O
with 	 O 	O
EF 	 O 	O
, 	 O 	O
except 	 O 	O
with 	 O 	O
the 	 O 	O
latter 	 O 	O
in 	 O 	O
one 	 O 	O
patient 	 O 	O
with 	 O 	O
a 	 O 	O
carcinoma 	 DISEASE 	DISEASE
of 	 O 	O
the 	 O 	O
lung 	 O 	DISEASE
. 	 O 	O
occurred 	 O 	O
respectively 	 O 	O
in 	 O 	O
2 	 O 	O
ALL 	 O 	O
mothers 	 O 	O
during 	 O 	O
their 	 O 	O
pregnancies 	 O 	O
involving 	 O 	O
the 	 O 	O
patients 	 O 	O
and 	 O 	O
in 	 O 	O
none 	 O 	O
of 	 O 	O
the 	 O 	O
other 	 O 	O
388 	 O 	O
pregnancies 	 O 	O
here 	 O 	O
reported 	 O 	O
. 	 O 	O
Varicella 	 O 	O
and 	 O 	O
herpes 	 DISEASE 	O
zoster 	 DISEASE 	O
occurred 	 O 	O
respectively 	 O 	O
in 	 O 	O
2 	 O 	O
ALL 	 O 	O
mothers 	 O 	O
during 	 O 	O
their 	 O 	O
pregnancies 	 O 	O
involving 	 O 	O
the 	 O 	O
patients 	 O 	O
and 	 O 	O
in 	 O 	O
none 	 O 	O
of 	 O 	O
the 	 O 	O
other 	 O 	O
388 	 O 	O
pregnancies 	 O 	O
here 	 O 	O
reported 	 O 	O
. 	 O 	O
Because 	 O 	O
of 	 O 	O
the 	 O 	O
many 	 O 	O
variables 	 O 	O
and 	 O 	O
complexity 	 O 	O
of 	 O 	O
mathematically 	 O 	O
computing 	 O 	O
the 	 O 	O
force 	 O 	O
effects 	 O 	O
of 	 O 	O
unilateral 	 O 	O
or 	 O 	O
asymmetric 	 O 	O
extraoral 	 O 	O
assemblies 	 O 	O
on 	 O 	O
molar 	 O 	O
teeth 	 O 	O
, 	 O 	O
a 	 O 	O
mechanical 	 O 	O
testing 	 O 	O
apparatus 	 O 	O
was 	 O 	O
designed 	 O 	O
to 	 O 	O
accommodate 	 O 	O
the 	 O 	O
various 	 O 	O
face 	 DISEASE 	O
- 	 O 	O
bows 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Hyperinsulinemia 	 DISEASE 	O
and 	 O 	O
ocular 	 O 	DISEASE
hypotony 	 O 	O
are 	 O 	O
associated 	 O 	O
with 	 O 	O
neovascular 	 O 	O
tufts 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Only 	 O 	O
HPV 	 O 	O
4 	 O 	O
particles 	 O 	O
, 	 O 	O
however 	 O 	O
, 	 O 	O
reacted 	 O 	O
with 	 O 	O
serum 	 O 	O
from 	 O 	O
a 	 O 	O
patient 	 O 	O
with 	 O 	O
epidermodysplasia 	 DISEASE 	O
verruciformis 	 DISEASE 	O
when 	 O 	O
tested 	 O 	O
by 	 O 	O
immuno 	 O 	O
- 	 O 	O
electron 	 O 	O
microscopy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
15 	 O 	O
, 	 O 	O
30 	 O 	O
, 	 O 	O
60 	 O 	O
, 	 O 	O
90 	 O 	O
and 	 O 	O
120 	 O 	O
minutes 	 O 	O
. 	 O 	O
Cyclic 	 O 	O
AMP 	 O 	O
and 	 O 	O
cyclic 	 O 	O
GMP 	 O 	O
were 	 O 	O
measured 	 O 	O
in 	 O 	O
glandular 	 O 	O
stomach 	 O 	O
of 	 O 	O
rats 	 O 	O
subjected 	 O 	O
to 	 O 	O
saline 	 O 	O
administration 	 O 	O
, 	 O 	O
cold 	 O 	DISEASE
( 	 O 	O
4 	 O 	O
degrees 	 O 	O
C 	 O 	O
) 	 O 	O
, 	 O 	O
restraint 	 O 	O
and 	 O 	O
restraint+cold 	 O 	O
after 	 O 	O
15 	 O 	O
, 	 O 	O
30 	 O 	O
, 	 O 	O
60 	 O 	O
, 	 O 	O
90 	 O 	O
and 	 O 	O
120 	 O 	O
minutes 	 O 	O
. 	 O 	O
The 	 O 	O
high 	 O 	O
frequency 	 O 	O
of 	 O 	O
hepatitis 	 O 	DISEASE
B 	 O 	O
antigen 	 O 	O
( 	 O 	O
HBsAg 	 O 	O
) 	 O 	O
in 	 O 	O
hepatocellular 	 O 	O
carcinoma 	 O 	O
( 	 O 	O
HCC 	 O 	O
) 	 O 	O
patients 	 O 	O
has 	 O 	O
led 	 O 	O
to 	 O 	O
the 	 O 	O
hypothesis 	 O 	O
that 	 O 	O
immunoresponsiveness 	 O 	O
to 	 O 	O
hepatitis 	 DISEASE 	O
B 	 O 	O
virus 	 O 	O
( 	 O 	O
HBV 	 O 	O
) 	 O 	O
may 	 O 	O
be 	 O 	O
deficient 	 O 	O
in 	 O 	O
some 	 O 	O
patients 	 O 	O
, 	 O 	O
and 	 O 	O
that 	 O 	O
the 	 O 	O
immune 	 O 	O
response 	 O 	O
deficiency 	 O 	O
may 	 O 	O
have 	 O 	O
a 	 O 	O
genetic 	 O 	O
basis 	 O 	O
. 	 O 	O
Fifty 	 O 	O
- 	 O 	O
seven 	 O 	O
herpes 	 DISEASE 	O
simplex 	 DISEASE 	O
virus 	 O 	O
strains 	 O 	O
, 	 O 	O
isolated 	 O 	O
from 	 O 	O
ocular 	 O 	O
herpes 	 O 	DISEASE
, 	 O 	O
were 	 O 	O
screened 	 O 	O
by 	 O 	O
complement 	 O 	O
fixation 	 O 	O
, 	 O 	O
seroneutralization 	 O 	O
and 	 O 	O
thermosensitivity 	 O 	O
tests 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
, 	 O 	O
in 	 O 	O
1975 	 O 	O
and 	 O 	O
1976 	 O 	O
from 	 O 	O
65 	 O 	O
cases 	 O 	O
of 	 O 	O
poliomyelitis 	 DISEASE 	O
- 	 O 	O
like 	 O 	O
disease 	 O 	O
( 	 O 	O
PLD 	 O 	O
) 	 O 	O
92 	 O 	O
strains 	 O 	O
of 	 O 	O
EV71 	 O 	O
were 	 O 	O
isolated 	 O 	O
, 	 O 	O
including 	 O 	O
37 	 O 	O
strains 	 O 	O
from 	 O 	O
the 	 O 	O
brain 	 O 	O
and 	 O 	O
medulla 	 O 	O
, 	 O 	O
1 	 O 	O
from 	 O 	O
the 	 O 	O
cerebrospinal 	 O 	O
fluid 	 O 	O
, 	 O 	O
10 	 O 	O
from 	 O 	O
mesenterial 	 O 	O
lymph 	 O 	O
nodes 	 O 	O
and 	 O 	O
tonsils 	 O 	O
and 	 O 	O
44 	 O 	O
from 	 O 	O
faeces 	 O 	O
. 	 O 	O
multiple 	 O 	O
adenoma 	 DISEASE 	O
formation 	 O 	O
was 	 O 	O
present 	 O 	O
in 	 O 	O
133 	 O 	O
patients 	 O 	O
, 	 O 	O
whereas 	 O 	O
diffuse 	 O 	O
hyperplasia 	 O 	O
was 	 O 	O
found 	 O 	O
in 	 O 	O
17 	 O 	O
and 	 O 	O
carcinoma 	 O 	O
in 	 O 	O
2 	 O 	O
other 	 O 	O
patients 	 O 	O
. 	 O 	O
At 	 O 	O
operation 	 O 	O
single 	 O 	O
or 	 O 	O
multiple 	 O 	O
adenoma 	 O 	O
formation 	 O 	O
was 	 O 	O
present 	 O 	O
in 	 O 	O
133 	 O 	O
patients 	 O 	O
, 	 O 	O
whereas 	 O 	O
diffuse 	 O 	O
hyperplasia 	 O 	O
was 	 O 	O
found 	 O 	O
in 	 O 	O
17 	 O 	O
and 	 O 	O
carcinoma 	 DISEASE 	DISEASE
in 	 O 	O
2 	 O 	O
other 	 O 	O
patients 	 O 	O
. 	 O 	O
It 	 O 	O
appears 	 O 	O
that 	 O 	O
miconazole 	 O 	O
is 	 O 	O
highly 	 O 	O
effective 	 O 	O
in 	 O 	O
reducing 	 O 	O
the 	 O 	O
incidence 	 O 	O
of 	 O 	O
systemic 	 DISEASE 	O
mycosis 	 DISEASE 	DISEASE
in 	 O 	O
patients 	 O 	O
suffering 	 O 	O
from 	 O 	O
malignant 	 O 	DISEASE
haemopathy 	 O 	O
and 	 O 	O
bone 	 O 	O
marrow 	 O 	O
failure 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Risk 	 O 	O
and 	 O 	O
limitations 	 O 	O
of 	 O 	O
immunosuppression 	 O 	O
have 	 O 	O
been 	 O 	O
better 	 O 	O
appreciated 	 O 	O
, 	 O 	O
ultrasound 	 O 	O
is 	 O 	O
used 	 O 	O
more 	 O 	O
often 	 O 	O
in 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
partial 	 O 	DISEASE
obstruction 	 O 	DISEASE
or 	 O 	O
perinephric 	 O 	O
fluid 	 O 	O
collections 	 O 	O
, 	 O 	O
and 	 O 	O
needle 	 O 	O
biopsy 	 O 	O
of 	 O 	O
the 	 O 	O
transplanted 	 O 	O
kidney 	 O 	O
has 	 O 	O
reduced 	 O 	O
the 	 O 	O
morbidity 	 O 	O
inherent 	 O 	O
in 	 O 	O
open 	 O 	O
biopsy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
detailed 	 O 	O
base 	 O 	O
line 	 O 	O
data 	 O 	O
on 	 O 	O
visna 	 O 	O
infection 	 O 	O
, 	 O 	O
suggest 	 O 	O
some 	 O 	O
of 	 O 	O
the 	 O 	O
mechanisms 	 O 	O
responsible 	 O 	O
for 	 O 	O
the 	 O 	O
persistence 	 O 	O
of 	 O 	O
infection 	 O 	O
and 	 O 	O
for 	 O 	O
the 	 O 	O
slowness 	 O 	O
and 	 O 	O
irregularity 	 O 	O
of 	 O 	O
disease 	 O 	O
occurrence 	 O 	O
, 	 O 	O
and 	 O 	O
form 	 O 	O
the 	 O 	O
basis 	 O 	O
for 	 O 	O
further 	 O 	O
experiments 	 O 	O
on 	 O 	O
the 	 O 	O
role 	 O 	O
of 	 O 	O
immunologic 	 O 	O
mechanisms 	 O 	O
in 	 O 	O
the 	 O 	O
pathogenesis 	 O 	O
of 	 O 	O
this 	 O 	O
slow 	 O 	O
infection 	 O 	DISEASE
. 	 O 	O
Normal 	 O 	O
and 	 O 	O
simian 	 O 	O
virus 	 O 	O
40-transformed 	 O 	O
WI-38 	 O 	O
cells 	 O 	O
exhibited 	 O 	O
a 	 O 	O
differential 	 O 	O
sensitivity 	 O 	O
to 	 O 	O
infection 	 O 	DISEASE
with 	 O 	O
type 	 O 	O
3 	 O 	O
reovirus 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Histologic 	 O 	O
examination 	 O 	O
of 	 O 	O
skin 	 O 	O
test 	 O 	O
sites 	 O 	O
showed 	 O 	O
that 	 O 	O
an 	 O 	O
apparently 	 O 	O
negative 	 O 	O
reaction 	 O 	O
did 	 O 	O
not 	 O 	O
necessarily 	 O 	O
imply 	 O 	O
total 	 O 	O
absence 	 O 	O
of 	 O 	O
a 	 O 	O
cellular 	 O 	O
inflammatory 	 O 	DISEASE
response 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
these 	 O 	O
, 	 O 	O
one 	 O 	O
of 	 O 	O
the 	 O 	O
infections 	 O 	O
was 	 O 	O
latent 	 O 	O
or 	 O 	O
was 	 O 	O
due 	 O 	O
to 	 O 	O
a 	 O 	O
previously 	 O 	O
experienced 	 O 	DISEASE
disease 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
No 	 O 	O
survivors 	 O 	O
had 	 O 	O
persistent 	 O 	O
chronic 	 O 	O
lung 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Fasting 	 O 	O
urinary 	 O 	DISEASE
ammonia 	 O 	O
excretion 	 O 	O
was 	 O 	O
unchanged 	 O 	O
whereas 	 O 	O
urea 	 O 	O
nitrogen 	 O 	O
excretion 	 O 	O
decreased 	 O 	O
significantly 	 O 	O
with 	 O 	O
therapy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
back 	 O 	O
to 	 O 	O
21 	 O 	O
patients 	 O 	O
with 	 O 	O
adenoma 	 DISEASE 	O
of 	 O 	O
the 	 O 	O
prostate 	 O 	O
and 	 O 	O
9 	 O 	O
patients 	 O 	O
with 	 O 	O
carcinoma 	 O 	O
of 	 O 	O
the 	 O 	O
prostate 	 O 	O
compared 	 O 	O
with 	 O 	O
healthy 	 O 	O
persons 	 O 	O
. 	 O 	O
The 	 O 	O
results 	 O 	O
hitherto 	 O 	O
got 	 O 	O
are 	 O 	O
traced 	 O 	O
back 	 O 	O
to 	 O 	O
21 	 O 	O
patients 	 O 	O
with 	 O 	O
adenoma 	 O 	O
of 	 O 	O
the 	 O 	O
prostate 	 O 	O
and 	 O 	O
9 	 O 	O
patients 	 O 	O
with 	 O 	O
carcinoma 	 DISEASE 	DISEASE
of 	 O 	O
the 	 O 	O
prostate 	 O 	DISEASE
compared 	 O 	O
with 	 O 	O
healthy 	 O 	O
persons 	 O 	O
. 	 O 	O
Data 	 O 	O
are 	 O 	O
presented 	 O 	O
indicating 	 O 	O
modifications 	 O 	O
of 	 O 	O
electrophoretic 	 O 	O
mobility 	 O 	O
due 	 O 	O
to 	 O 	O
herpes 	 DISEASE 	O
simplex 	 DISEASE 	O
virus 	 O 	O
type 	 O 	O
1 	 O 	O
infection 	 O 	O
and 	 O 	O
Rous 	 O 	O
sarcoma 	 O 	O
virus 	 O 	O
transformation 	 O 	O
of 	 O 	O
culture 	 O 	O
cells 	 O 	O
. 	 O 	O
Data 	 O 	O
are 	 O 	O
presented 	 O 	O
indicating 	 O 	O
modifications 	 O 	O
of 	 O 	O
electrophoretic 	 O 	O
mobility 	 O 	O
due 	 O 	O
to 	 O 	O
herpes 	 O 	O
simplex 	 O 	O
virus 	 O 	O
type 	 O 	O
1 	 O 	O
infection 	 O 	O
and 	 O 	O
Rous 	 O 	O
sarcoma 	 DISEASE 	DISEASE
virus 	 O 	O
transformation 	 O 	O
of 	 O 	O
culture 	 O 	O
cells 	 O 	O
. 	 O 	O
watery 	 O 	O
diarrhea 	 O 	DISEASE
, 	 O 	O
hypokalemia 	 O 	DISEASE
, 	 O 	O
and 	 O 	O
hypochlorhydria 	 O 	O
) 	 O 	O
, 	 O 	O
five 	 O 	O
ganglioneuroblastomas 	 O 	O
, 	 O 	O
five 	 O 	O
ganglioneuromas 	 O 	O
( 	 O 	O
two 	 O 	O
of 	 O 	O
which 	 O 	O
were 	 O 	O
associated 	 O 	O
with 	 O 	O
diarrheal 	 O 	O
syndromes 	 O 	O
) 	 O 	O
, 	 O 	O
an 	 O 	O
unusual 	 O 	O
mixed 	 O 	O
neuroblastoma 	 O 	O
- 	 O 	O
ganglioneuroma 	 DISEASE 	O
, 	 O 	O
and 	 O 	O
four 	 O 	O
normal 	 O 	O
sympathetic 	 O 	O
ganglia 	 O 	O
, 	 O 	O
vasoactive 	 O 	O
intestinal 	 O 	O
peptide 	 O 	O
was 	 O 	O
present 	 O 	O
in 	 O 	O
differentiating 	 O 	O
and 	 O 	O
mature 	 O 	O
ganglion 	 O 	O
cells 	 O 	O
. 	 O 	O
or 	 O 	O
plasma 	 O 	O
was 	 O 	O
closely 	 O 	O
associated 	 O 	O
with 	 O 	O
chronic 	 O 	O
mild 	 O 	O
intrahepatic 	 DISEASE 	O
cholestasis 	 DISEASE 	O
, 	 O 	O
particularly 	 O 	O
as 	 O 	O
in 	 O 	O
primary 	 O 	O
biliary 	 O 	O
cirrhosis 	 O 	O
and 	 O 	O
related 	 O 	O
conditions 	 O 	O
. 	 O 	O
The 	 O 	O
appearance 	 O 	O
of 	 O 	O
HDL 	 O 	O
- 	 O 	O
S 	 O 	O
in 	 O 	O
serum 	 O 	O
or 	 O 	O
plasma 	 O 	O
was 	 O 	O
closely 	 O 	O
associated 	 O 	O
with 	 O 	O
chronic 	 O 	O
mild 	 O 	O
intrahepatic 	 O 	O
cholestasis 	 O 	O
, 	 O 	O
particularly 	 O 	O
as 	 O 	O
in 	 O 	O
primary 	 DISEASE 	O
biliary 	 DISEASE 	DISEASE
cirrhosis 	 DISEASE 	DISEASE
and 	 O 	O
related 	 O 	O
conditions 	 O 	O
. 	 O 	O
Unilateral 	 O 	O
adrenalectomy 	 O 	DISEASE
with 	 O 	O
and 	 O 	O
without 	 O 	O
hydrocortisone 	 O 	O
replacement 	 O 	O
therapy 	 O 	O
were 	 O 	O
investigated 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Chickens 	 O 	O
treated 	 O 	O
with 	 O 	O
cyclophosphamide 	 O 	O
and 	 O 	O
then 	 O 	O
challenged 	 O 	O
with 	 O 	O
AMV 	 O 	O
developed 	 O 	O
acute 	 DISEASE 	O
myeloblastic 	 DISEASE 	O
leukemia 	 DISEASE 	DISEASE
in 	 O 	O
70 	 O 	O
percent 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
We 	 O 	O
have 	 O 	O
identified 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
suppressor 	 O 	O
cell 	 O 	O
activity 	 O 	O
in 	 O 	O
the 	 O 	O
peripheral 	 O 	O
blood 	 O 	O
of 	 O 	O
immunosuppressed 	 O 	O
stage 	 O 	O
IV 	 O 	DISEASE
cancer 	 DISEASE 	DISEASE
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
free 	 O 	O
to 	 O 	O
esterified 	 O 	O
cholesterol 	 O 	O
ratio 	 O 	O
in 	 O 	O
HDL 	 O 	O
was 	 O 	O
lower 	 O 	O
in 	 O 	O
Friedreich 	 DISEASE 	DISEASE
's 	 DISEASE 	O
ataxia 	 DISEASE 	DISEASE
because 	 O 	O
of 	 O 	O
a 	 O 	O
reduction 	 O 	O
in 	 O 	O
the 	 O 	O
amount 	 O 	O
of 	 O 	O
free 	 O 	O
cholesterol 	 O 	O
in 	 O 	O
this 	 O 	O
lipoprotein 	 O 	O
class 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
We 	 O 	O
present 	 O 	O
an 	 O 	O
experience 	 O 	O
with 	 O 	O
20 	 O 	O
patients 	 O 	O
undergoing 	 O 	O
interposition 	 O 	O
mesocaval 	 O 	O
shunts 	 O 	O
for 	 O 	O
decompression 	 O 	O
of 	 O 	O
esophageal 	 DISEASE 	O
varices 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
at 	 O 	O
one 	 O 	O
of 	 O 	O
four 	 O 	O
intervals 	 O 	O
of 	 O 	O
time 	 O 	O
after 	 O 	O
primary 	 O 	DISEASE
infection 	 O 	O
and 	 O 	O
killed 	 O 	O
ten 	 O 	O
weeks 	 O 	O
later 	 O 	O
, 	 O 	O
together 	 O 	O
with 	 O 	O
unchallenged 	 O 	O
appropriate 	 O 	O
primary 	 O 	O
infection 	 O 	O
controls 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Boundary 	 O 	O
layer 	 O 	O
separation 	 O 	O
may 	 O 	O
play 	 O 	O
a 	 O 	O
role 	 O 	O
in 	 O 	O
the 	 O 	O
development 	 O 	O
of 	 O 	O
anastomotic 	 O 	DISEASE
hyperplasia 	 O 	DISEASE
and 	 O 	O
atherosclerotic 	 O 	O
deposits 	 O 	O
in 	 O 	O
the 	 O 	O
vicinity 	 O 	O
of 	 O 	O
surgical 	 O 	O
anastomoses 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Typical 	 O 	O
causes 	 O 	O
were 	 O 	O
accidents 	 O 	O
, 	 O 	O
suicide 	 O 	O
, 	 O 	O
cirrhosis 	 DISEASE 	O
of 	 O 	O
the 	 O 	O
liver 	 O 	O
, 	 O 	O
cancers 	 O 	O
of 	 O 	O
the 	 O 	O
upper 	 O 	O
digestive 	 O 	O
and 	 O 	O
respiratory 	 O 	O
tracts 	 O 	O
and 	 O 	O
ischemic 	 O 	O
heart 	 O 	O
disease 	 O 	O
. 	 O 	O
Typical 	 O 	O
causes 	 O 	O
were 	 O 	O
accidents 	 O 	O
, 	 O 	O
suicide 	 O 	O
, 	 O 	O
cirrhosis 	 O 	O
of 	 O 	O
the 	 O 	O
liver 	 O 	O
, 	 O 	O
cancers 	 O 	O
of 	 O 	O
the 	 O 	O
upper 	 O 	O
digestive 	 O 	O
and 	 O 	O
respiratory 	 O 	O
tracts 	 O 	O
and 	 O 	O
ischemic 	 O 	O
heart 	 DISEASE 	DISEASE
disease 	 DISEASE 	DISEASE
. 	 O 	O
This 	 O 	O
study 	 O 	O
demonstrates 	 O 	O
the 	 O 	O
affection 	 O 	O
of 	 O 	O
both 	 O 	O
muscle 	 O 	O
fiber 	 O 	O
and 	 O 	O
motor 	 O 	O
end 	 O 	O
plate 	 O 	O
in 	 O 	O
mouse 	 O 	O
myotonic 	 O 	O
dystrophy 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
This 	 O 	O
case 	 O 	O
also 	 O 	O
indicates 	 O 	O
that 	 O 	O
not 	 O 	O
all 	 O 	O
sarcomas 	 O 	O
with 	 O 	O
storiform 	 O 	O
features 	 O 	O
are 	 O 	O
necessarily 	 O 	O
histiocytic 	 O 	DISEASE
in 	 O 	O
origin 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
conclusion 	 O 	O
, 	 O 	O
H.T.C.T. 	 O 	O
may 	 O 	O
be 	 O 	O
assumed 	 O 	O
to 	 O 	O
be 	 O 	O
a 	 O 	O
valid 	 O 	O
test 	 O 	O
for 	 O 	O
indicating 	 O 	O
the 	 O 	O
existence 	 O 	O
of 	 O 	O
a 	 O 	O
possible 	 O 	O
hypercoagulability 	 DISEASE 	O
state 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Additionally 	 O 	O
, 	 O 	O
alcoholism 	 DISEASE 	DISEASE
has 	 O 	O
been 	 O 	O
found 	 O 	O
to 	 O 	O
be 	 O 	O
highly 	 O 	O
correlated 	 O 	O
with 	 O 	O
specific 	 O 	O
gyncological 	 O 	O
disorders 	 O 	O
such 	 O 	O
as 	 O 	O
repeated 	 O 	O
spontaneous 	 O 	O
abortion 	 O 	O
and 	 O 	O
infertility 	 O 	O
. 	 O 	O
Additionally 	 O 	O
, 	 O 	O
alcoholism 	 O 	DISEASE
has 	 O 	O
been 	 O 	O
found 	 O 	O
to 	 O 	O
be 	 O 	O
highly 	 O 	O
correlated 	 O 	O
with 	 O 	O
specific 	 O 	O
gyncological 	 O 	O
disorders 	 O 	O
such 	 O 	O
as 	 O 	O
repeated 	 O 	O
spontaneous 	 O 	O
abortion 	 O 	O
and 	 O 	O
infertility 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Like 	 O 	O
the 	 O 	O
axolemma 	 O 	O
of 	 O 	O
the 	 O 	O
giant 	 O 	DISEASE
nerve 	 O 	O
fibre 	 O 	O
of 	 O 	O
the 	 O 	O
squid 	 O 	O
, 	 O 	O
the 	 O 	O
nodal 	 O 	O
membrane 	 O 	O
of 	 O 	O
frog 	 O 	O
myelinated 	 O 	O
nerve 	 O 	O
fibres 	 O 	O
after 	 O 	O
blocking 	 O 	O
transmembrane 	 O 	O
ionic 	 O 	O
currents 	 O 	O
exhibits 	 O 	O
asymmetrical 	 O 	O
displacement 	 O 	O
currents 	 O 	O
during 	 O 	O
and 	 O 	O
after 	 O 	O
hyperpolarizing 	 O 	O
and 	 O 	O
depolarizing 	 O 	O
voltage 	 O 	O
clamp 	 O 	O
pulses 	 O 	O
of 	 O 	O
equal 	 O 	O
size 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
immunoglobulin 	 O 	O
fractions 	 O 	O
or 	 O 	O
after 	 O 	O
elimination 	 O 	O
of 	 O 	O
IgG 	 O 	O
by 	 O 	O
absorption 	 O 	O
the 	 O 	O
immunofluorescence 	 O 	O
test 	 O 	O
for 	 O 	O
rubella 	 DISEASE 	O
IgM 	 O 	O
antibodies 	 O 	O
is 	 O 	O
more 	 O 	O
sensitive 	 O 	O
than 	 O 	O
in 	 O 	O
whole 	 O 	O
serum 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
- 	 O 	O
bound 	 O 	O
( 	 O 	O
Co(II 	 O 	O
) 	 O 	O
to 	 O 	O
the 	 O 	O
methyl 	 O 	O
protons 	 O 	O
and 	 O 	O
2 	 O 	O
carbon 	 O 	O
atoms 	 O 	O
of 	 O 	O
bound 	 O 	O
pyruvate 	 O 	O
and 	 O 	O
to 	 O 	O
12 	 O 	O
protons 	 O 	O
and 	 O 	O
3 	 O 	O
phosphorus 	 O 	O
atoms 	 O 	O
of 	 O 	O
bound 	 O 	O
propionyl 	 O 	O
- 	 O 	O
CoA 	 O 	O
, 	 O 	O
the 	 O 	O
present 	 O 	O
distances 	 O 	O
are 	 O 	O
used 	 O 	O
to 	 O 	O
derive 	 O 	O
a 	 O 	O
composite 	 O 	O
model 	 O 	O
of 	 O 	O
the 	 O 	O
bound 	 O 	O
substrates 	 O 	O
in 	 O 	O
the 	 O 	O
overall 	 O 	DISEASE
transcarboxylation 	 O 	O
reaction 	 O 	DISEASE
. 	 O 	O
The 	 O 	O
pulps 	 O 	O
were 	 O 	O
eliminated 	 O 	O
from 	 O 	O
164 	 O 	O
extracted 	 O 	O
human 	 O 	O
teeth 	 O 	O
by 	 O 	O
enzyme 	 O 	O
action 	 O 	O
; 	 O 	O
the 	 O 	O
pulp 	 O 	O
chambers 	 O 	O
and 	 O 	O
root 	 O 	O
canal 	 O 	O
systems 	 O 	O
were 	 O 	O
filled 	 O 	O
under 	 O 	O
vacuum 	 O 	O
with 	 O 	O
a 	 O 	O
water 	 O 	O
- 	 O 	O
soluble 	 O 	O
, 	 O 	O
radiopaque 	 O 	O
contrast 	 O 	O
medium 	 O 	O
; 	 O 	O
and 	 O 	O
each 	 O 	O
tooth 	 O 	O
was 	 O 	O
radiographed 	 O 	O
from 	 O 	O
three 	 O 	O
angles 	 O 	O
with 	 O 	O
the 	 O 	O
contrast 	 O 	O
medium 	 O 	O
in 	 O 	O
situ 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
The 	 O 	O
authors 	 O 	O
believe 	 O 	O
that 	 O 	O
in 	 O 	O
subjects 	 O 	O
with 	 O 	O
a 	 O 	O
persistent 	 O 	O
mllerian 	 O 	O
duct 	 O 	DISEASE
syndrome 	 O 	DISEASE
, 	 O 	O
surgical 	 O 	O
placement 	 O 	O
of 	 O 	O
the 	 O 	O
testes 	 O 	O
into 	 O 	O
the 	 O 	O
scrotum 	 O 	O
should 	 O 	O
be 	 O 	O
performed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
PAD 	 O 	O
was 	 O 	O
employed 	 O 	O
in 	 O 	O
100 	 O 	O
adult 	 O 	O
patients 	 O 	O
undergoing 	 O 	O
open 	 O 	O
heart 	 O 	O
surgery 	 O 	O
for 	 O 	O
coronary 	 O 	O
artery 	 O 	O
and/or 	 O 	O
valvular 	 DISEASE 	O
heart 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
have 	 O 	O
acute 	 DISEASE 	O
hepatitis 	 DISEASE 	O
and 	 O 	O
are 	 O 	O
persistent 	 O 	O
in 	 O 	O
virtually 	 O 	O
all 	 O 	O
with 	 O 	O
untreated 	 O 	O
chronic 	 O 	O
active 	 O 	O
hepatitis 	 O 	O
. 	 O 	O
Cell 	 O 	O
- 	 O 	O
mediated 	 O 	O
responses 	 O 	O
to 	 O 	O
liver 	 O 	O
- 	 O 	O
specific 	 O 	O
lipoprotein 	 O 	O
, 	 O 	O
a 	 O 	O
membrane 	 O 	O
antigen 	 O 	O
, 	 O 	O
occur 	 O 	O
transiently 	 O 	O
in 	 O 	O
many 	 O 	O
patients 	 O 	O
who 	 O 	O
have 	 O 	O
acute 	 O 	O
hepatitis 	 O 	O
and 	 O 	O
are 	 O 	O
persistent 	 O 	O
in 	 O 	O
virtually 	 O 	O
all 	 O 	O
with 	 O 	O
untreated 	 O 	O
chronic 	 O 	O
active 	 O 	O
hepatitis 	 DISEASE 	DISEASE
. 	 O 	O
Due 	 O 	O
to 	 O 	O
poor 	 O 	O
results 	 O 	O
with 	 O 	O
conventional 	 O 	O
operative 	 O 	O
therapy 	 O 	O
for 	 O 	O
diffuse 	 O 	O
hemorrhagic 	 O 	O
gastritis 	 DISEASE 	DISEASE
( 	 O 	O
DHG 	 O 	O
) 	 O 	O
, 	 O 	O
a 	 O 	O
prospective 	 O 	O
evaluation 	 O 	O
of 	 O 	O
gastric 	 O 	DISEASE
devascularization 	 O 	O
was 	 O 	O
performed 	 O 	O
on 	 O 	O
21 	 O 	O
patients 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
19 	 O 	O
of 	 O 	O
26 	 O 	O
patients 	 O 	O
with 	 O 	O
unstable 	 DISEASE 	O
angina 	 DISEASE 	O
pectoris 	 O 	O
also 	 O 	O
exhibited 	 O 	O
an 	 O 	O
uptake 	 O 	O
in 	 O 	O
the 	 O 	O
myocardium 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Possible 	 O 	O
implications 	 O 	DISEASE
for 	 O 	O
the 	 O 	O
evolution 	 O 	O
of 	 O 	O
H-2 	 O 	O
polymorphism 	 O 	O
and 	 O 	O
mechanisms 	 O 	O
of 	 O 	O
Ir 	 O 	O
gene 	 O 	O
function 	 O 	O
are 	 O 	O
discussed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
We 	 O 	O
conclude 	 O 	O
that 	 O 	O
hereditary 	 O 	O
hypophosphatemia 	 DISEASE 	DISEASE
in 	 O 	O
the 	 O 	O
mouse 	 O 	O
is 	 O 	O
associated 	 O 	O
with 	 O 	O
a 	 O 	O
renal 	 O 	O
tubular 	 O 	O
defect 	 O 	DISEASE
in 	 O 	O
phosphate 	 O 	O
reabsorption 	 O 	O
, 	 O 	O
which 	 O 	O
is 	 O 	O
independent 	 O 	O
of 	 O 	O
PTH 	 O 	O
and 	 O 	O
therefore 	 O 	O
represents 	 O 	O
a 	 O 	O
specific 	 O 	O
intrinsic 	 O 	O
abnormality 	 O 	O
of 	 O 	O
phosphate 	 O 	O
transport 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
scatter 	 O 	O
of 	 O 	O
the 	 O 	O
individual 	 O 	O
values 	 O 	O
for 	 O 	O
DHT 	 O 	O
indicated 	 O 	O
that 	 O 	O
this 	 O 	O
measurement 	 O 	O
has 	 O 	O
little 	 O 	O
practical 	 O 	O
clinical 	 O 	O
application 	 O 	O
in 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
prostatic 	 DISEASE 	O
hypertrophy 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Analysis 	 O 	O
of 	 O 	O
chromosomal 	 O 	O
banding 	 O 	O
patterns 	 O 	O
in 	 O 	O
acute 	 O 	O
nonlymphocytic 	 O 	DISEASE
leukemia 	 DISEASE 	DISEASE
( 	 O 	O
ANLL 	 O 	O
) 	 O 	O
reveals 	 O 	O
that 	 O 	O
approximately 	 O 	O
50 	 O 	O
% 	 O 	O
of 	 O 	O
patients 	 O 	O
have 	 O 	O
an 	 O 	O
abnormal 	 O 	O
karyotype 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
( 	 O 	O
Unin 	 O 	O
the 	 O 	O
( 	 O 	O
3H 	 O 	O
) 	 O 	O
Isoproterenol 	 O 	O
a 	 O 	O
fracciones 	 O 	O
subcelulares 	 O 	O
de 	 O 	O
partida 	 O 	O
de 	 O 	DISEASE
ratn 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
isolated 	 O 	O
sphenoid 	 O 	O
sinus 	 O 	O
opacification 	 O 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
sphenoid 	 DISEASE 	O
sinusitis 	 DISEASE 	O
with 	 O 	O
cavernous 	 O 	O
sinus 	 O 	O
thrombosis 	 O 	O
. 	 O 	O
The 	 O 	O
authors 	 O 	O
have 	 O 	O
used 	 O 	O
this 	 O 	O
approach 	 O 	O
to 	 O 	O
repair 	 O 	O
nasopharyngeal 	 O 	O
atresia 	 O 	O
, 	 O 	O
remove 	 O 	O
nasopharyngeal 	 O 	O
angiofibromas 	 O 	O
, 	 O 	O
approach 	 O 	O
the 	 O 	O
pituitary 	 O 	O
, 	 O 	O
craniopharyngioma 	 O 	O
and 	 O 	O
isolated 	 O 	O
sphenoid 	 O 	O
sinus 	 O 	O
opacification 	 O 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
sphenoid 	 O 	O
sinusitis 	 O 	O
with 	 O 	O
cavernous 	 DISEASE 	O
sinus 	 DISEASE 	O
thrombosis 	 DISEASE 	DISEASE
. 	 O 	O
The 	 O 	O
results 	 O 	O
suggest 	 O 	O
that 	 O 	O
cyclic 	 O 	O
AMP 	 O 	O
receptor 	 O 	O
is 	 O 	O
involved 	 O 	O
in 	 O 	O
the 	 O 	O
nuclear 	 O 	O
events 	 O 	O
of 	 O 	O
a 	 O 	O
hormone 	 O 	O
- 	 O 	O
dependent 	 O 	O
mammary 	 DISEASE 	DISEASE
tumor 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Turnip 	 O 	O
yellow 	 O 	DISEASE
mosaic 	 O 	O
virus 	 O 	O
( 	 O 	O
TYMV 	 O 	O
) 	 O 	O
and 	 O 	O
alphalpha 	 O 	O
mosaic 	 O 	O
virus 	 O 	O
( 	 O 	O
AMV 	 O 	O
) 	 O 	O
were 	 O 	O
used 	 O 	O
as 	 O 	O
immuno 	 O 	O
- 	 O 	O
electron 	 O 	O
microscopical 	 O 	O
markers 	 O 	O
to 	 O 	O
detect 	 O 	O
cell 	 O 	O
surface 	 O 	O
receptors 	 O 	O
on 	 O 	O
mononuclear 	 O 	O
cells 	 O 	O
in 	 O 	O
freeze 	 O 	O
- 	 O 	O
etch 	 O 	O
replicas 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
acute 	 O 	O
exudative 	 O 	O
interstitial 	 O 	O
pneumonia 	 DISEASE 	DISEASE
found 	 O 	O
at 	 O 	O
post 	 O 	O
mortem 	 O 	O
was 	 O 	O
typical 	 O 	O
of 	 O 	O
pneumonic 	 O 	O
pasteurellosis 	 O 	O
. 	 O 	O
The 	 O 	O
acute 	 O 	O
exudative 	 O 	O
interstitial 	 O 	O
pneumonia 	 O 	DISEASE
found 	 O 	O
at 	 O 	O
post 	 O 	O
mortem 	 O 	O
was 	 O 	O
typical 	 O 	O
of 	 O 	O
pneumonic 	 DISEASE 	O
pasteurellosis 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
histochemical 	 O 	O
and 	 O 	O
ultrastructural 	 O 	O
study 	 O 	O
of 	 O 	O
five 	 O 	O
cases 	 O 	O
of 	 O 	O
neuronal 	 DISEASE 	O
ceroid 	 DISEASE 	O
lipofuscinosis 	 DISEASE 	O
( 	 O 	O
NCL 	 O 	O
) 	 O 	O
revealed 	 O 	O
the 	 O 	O
existence 	 O 	O
of 	 O 	O
two 	 O 	O
related 	 O 	O
lipopigments 	 O 	O
differing 	 O 	O
in 	 O 	O
some 	 O 	O
tinctorial 	 O 	O
properties 	 O 	O
and 	 O 	O
ultrastructure 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
However 	 O 	O
, 	 O 	O
not 	 O 	O
all 	 O 	O
psoriasis 	 DISEASE 	O
patients 	 O 	O
have 	 O 	O
these 	 O 	O
antigens 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Motility 	 O 	DISEASE
required 	 O 	O
millimolar 	 O 	O
Mg2nlevels 	 O 	O
, 	 O 	O
free 	 O 	O
Ca2nat 	 O 	O
10 	 O 	O
minus 	 O 	O
7 	 O 	O
M 	 O 	O
or 	 O 	O
less 	 O 	O
and 	 O 	O
was 	 O 	O
inhibited 	 O 	O
by 	 O 	O
high 	 O 	O
levels 	 O 	O
of 	 O 	O
Clminus 	 O 	O
and 	 O 	O
by 	 O 	O
pH 	 O 	O
's 	 O 	O
on 	 O 	O
either 	 O 	O
side 	 O 	O
of 	 O 	O
7.0 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
factor 	 O 	O
provoking 	 O 	O
the 	 O 	O
symptom 	 O 	O
heartburn 	 O 	O
, 	 O 	O
low 	 O 	O
oesophageal 	 O 	O
pH 	 O 	O
need 	 O 	O
not 	 O 	O
necessarily 	 O 	O
give 	 O 	O
rise 	 O 	O
to 	 O 	O
symptoms 	 O 	O
, 	 O 	O
i.e. 	 O 	O
the 	 O 	O
sensibility 	 O 	O
to 	 O 	O
low 	 O 	O
pH 	 O 	O
is 	 O 	O
either 	 O 	O
individual 	 O 	O
, 	 O 	O
or 	 O 	O
patients 	 O 	O
with 	 O 	O
symptoms 	 O 	O
have 	 O 	O
considerably 	 O 	O
more 	 O 	O
frequent 	 O 	O
and 	 O 	O
longer 	 O 	O
lasting 	 O 	O
episodes 	 O 	O
of 	 O 	O
reflux 	 O 	O
with 	 O 	O
low 	 O 	O
oesophageal 	 O 	DISEASE
pH 	 O 	O
than 	 O 	O
have 	 O 	O
normal 	 O 	O
subjects 	 O 	O
. 	 O 	O
3.86 	 O 	O
mg 	 O 	O
/ 	 O 	O
g 	 O 	O
in 	 O 	O
the 	 O 	O
uremic 	 O 	DISEASE
group 	 O 	O
as 	 O 	O
compared 	 O 	O
to 	 O 	O
0.92 	 O 	O
+ 	 O 	O
/- 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
diagnosis 	 O 	O
was 	 O 	O
proven 	 O 	O
microscopically 	 O 	O
and 	 O 	O
on 	 O 	O
culture 	 O 	O
except 	 O 	O
in 	 O 	O
cases 	 O 	O
of 	 O 	O
pityriasis 	 DISEASE 	O
versicolor 	 DISEASE 	O
where 	 O 	O
it 	 O 	O
was 	 O 	O
proven 	 O 	O
microscopically 	 O 	O
only 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Although 	 O 	O
Yellow 	 DISEASE 	O
Fever 	 DISEASE 	O
virus 	 O 	O
is 	 O 	O
not 	 O 	O
transovarially 	 O 	O
transmitted 	 O 	O
by 	 O 	O
its 	 O 	O
vector 	 O 	O
Aedes 	 O 	O
aegypti 	 O 	O
, 	 O 	O
the 	 O 	O
mosquito 	 O 	O
only 	 O 	O
becomes 	 O 	O
infective 	 O 	O
some 	 O 	O
time 	 O 	O
after 	 O 	O
ingesting 	 O 	O
an 	 O 	O
infected 	 O 	O
blood 	 O 	O
meal 	 O 	O
( 	 O 	O
Chandler 	 O 	O
, 	 O 	O
1955 	 O 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
They 	 O 	O
appear 	 O 	O
to 	 O 	O
be 	 O 	O
a 	 O 	O
morphologic 	 O 	O
variant 	 O 	O
of 	 O 	O
rubeosis 	 DISEASE 	O
iridis 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Under 	 O 	O
both 	 O 	O
sets 	 O 	O
of 	 O 	O
conditions 	 O 	O
, 	 O 	O
cells 	 O 	O
from 	 O 	O
the 	 O 	O
familial 	 DISEASE 	O
hypercholesterolemia 	 DISEASE 	O
heterozygotes 	 O 	O
expressed 	 O 	O
an 	 O 	O
average 	 O 	O
of 	 O 	O
about 	 O 	O
one 	 O 	O
- 	 O 	O
half 	 O 	O
the 	 O 	O
normal 	 O 	O
number 	 O 	O
of 	 O 	O
LDL 	 O 	O
receptors 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
From 	 O 	O
E.E.G. 	 O 	O
point 	 O 	O
of 	 O 	O
view 	 O 	O
they 	 O 	DISEASE
had 	 O 	O
focal 	 O 	O
( 	 O 	O
mainly 	 O 	O
frontal 	 O 	O
) 	 O 	O
and 	 O 	O
diffuse 	 O 	O
abnormalities 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
However 	 O 	O
, 	 O 	O
in 	 O 	O
the 	 O 	O
acute 	 DISEASE 	O
myeloblastic 	 DISEASE 	O
leukemia 	 DISEASE 	DISEASE
, 	 O 	O
a 	 O 	O
significantly 	 O 	O
higher 	 O 	O
frequency 	 O 	O
of 	 O 	O
infection 	 O 	O
during 	 O 	O
or 	 O 	O
after 	 O 	O
the 	 O 	O
induction 	 O 	O
treatment 	 O 	O
was 	 O 	O
observed 	 O 	O
in 	 O 	O
the 	 O 	O
cases 	 O 	O
presenting 	 O 	O
initially 	 O 	O
without 	 O 	O
a 	 O 	O
raised 	 O 	O
serum 	 O 	O
lysozyme 	 O 	O
level 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Members 	 O 	O
of 	 O 	O
this 	 O 	O
family 	 O 	O
have 	 O 	O
a 	 O 	O
myeloproliferative 	 O 	O
disorder 	 O 	O
that 	 O 	O
has 	 O 	O
the 	 O 	O
potential 	 O 	O
for 	 O 	O
terminating 	 O 	O
in 	 O 	O
nonlymphocytic 	 O 	DISEASE
leukemia 	 DISEASE 	DISEASE
, 	 O 	O
a 	 O 	O
combination 	 O 	O
of 	 O 	O
events 	 O 	O
which 	 O 	O
appears 	 O 	O
not 	 O 	O
to 	 O 	O
have 	 O 	O
been 	 O 	O
reported 	 O 	O
previously 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
It 	 O 	O
consists 	 O 	O
of 	 O 	O
chronic 	 O 	O
infections 	 O 	O
in 	 O 	O
the 	 O 	O
respiratory 	 O 	O
system 	 O 	O
, 	 O 	O
male 	 DISEASE 	O
infertility 	 DISEASE 	O
, 	 O 	O
and 	 O 	O
in 	 O 	O
about 	 O 	O
1/2 	 O 	O
of 	 O 	O
the 	 O 	O
cases 	 O 	O
, 	 O 	O
situs 	 O 	O
inversus 	 O 	O
. 	 O 	O
It 	 O 	O
consists 	 O 	O
of 	 O 	O
chronic 	 O 	O
infections 	 O 	O
in 	 O 	O
the 	 O 	O
respiratory 	 O 	O
system 	 O 	O
, 	 O 	O
male 	 O 	O
infertility 	 O 	O
, 	 O 	O
and 	 O 	O
in 	 O 	O
about 	 O 	O
1/2 	 O 	O
of 	 O 	O
the 	 O 	O
cases 	 O 	O
, 	 O 	O
situs 	 DISEASE 	O
inversus 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
1968 	 O 	O
, 	 O 	O
studies 	 O 	O
of 	 O 	O
infectious 	 O 	DISEASE
hepatitis 	 DISEASE 	DISEASE
in 	 O 	O
volunteers 	 O 	O
were 	 O 	O
reported 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
biopsy 	 O 	O
specimen 	 O 	O
and 	 O 	O
results 	 O 	O
of 	 O 	O
a 	 O 	O
thorough 	 O 	O
medical 	 O 	O
work 	 O 	O
- 	 O 	O
up 	 O 	O
showed 	 O 	O
the 	 O 	O
lesion 	 O 	O
to 	 O 	O
be 	 O 	O
multiple 	 DISEASE 	O
myeloma 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Cobalt-57 	 O 	O
bleomycin 	 O 	O
imaging 	 O 	O
appears 	 O 	O
to 	 O 	O
be 	 O 	O
a 	 O 	O
promising 	 O 	O
technique 	 O 	O
for 	 O 	O
evaluating 	 O 	O
patients 	 O 	O
with 	 O 	DISEASE
head 	 O 	DISEASE
and 	 O 	DISEASE
neck 	 O 	DISEASE
tumors 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Clinical 	 O 	O
and 	 O 	O
pathological 	 O 	O
studies 	 O 	O
have 	 O 	O
revealed 	 O 	O
that 	 O 	O
in 	 O 	O
multiple 	 DISEASE 	O
sclerosis 	 DISEASE 	O
( 	 O 	O
MS 	 O 	O
) 	 O 	O
the 	 O 	O
involvement 	 O 	O
of 	 O 	O
the 	 O 	O
optic 	 O 	O
tracts 	 O 	O
is 	 O 	O
much 	 O 	O
more 	 O 	O
frequent 	 O 	O
than 	 O 	O
that 	 O 	O
of 	 O 	O
the 	 O 	O
olfactory 	 O 	O
tracts 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Certain 	 O 	O
epidemiological 	 O 	O
characteristics 	 O 	O
of 	 O 	O
human 	 O 	O
tumours 	 O 	O
favour 	 O 	O
a 	 O 	O
viral 	 O 	O
etiology 	 O 	O
, 	 O 	O
e.g. 	 O 	O
space 	 O 	O
and 	 O 	O
time 	 O 	O
clustering 	 O 	O
, 	 O 	O
vertical 	 O 	O
and 	 O 	O
horizontal 	 O 	O
transmission 	 O 	O
of 	 O 	O
a 	 O 	O
tumour 	 O 	O
risk 	 O 	O
, 	 O 	O
succession 	 O 	O
in 	 O 	O
space 	 O 	O
or 	 O 	O
in 	 O 	O
time 	 O 	O
of 	 O 	O
viral 	 O 	DISEASE
induced 	 O 	O
benign 	 O 	O
lesions 	 O 	O
and 	 O 	O
of 	 O 	O
malignant 	 O 	O
tumours 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
monomyeloblastic 	 O 	O
leukemia 	 DISEASE 	O
[ 	 O 	O
AMML 	 O 	O
] 	 O 	O
, 	 O 	O
or 	 O 	O
acute 	 O 	O
promyelocytic 	 O 	O
leukemia 	 O 	O
Previously 	 O 	O
untreated 	 O 	O
patients 	 O 	O
with 	 O 	O
acute 	 O 	DISEASE
leukemia 	 O 	O
exhibited 	 O 	O
an 	 O 	O
average 	 O 	O
PPI 	 O 	O
value 	 O 	O
three 	 O 	O
times 	 O 	O
that 	 O 	O
of 	 O 	O
normal 	 O 	O
bone 	 O 	O
marrow 	 O 	O
( 	 O 	O
37.5 	 O 	O
% 	 O 	O
for 	 O 	O
acute 	 O 	O
myeloblastic 	 O 	O
leukemia 	 O 	O
[ 	 O 	O
AML 	 O 	O
] 	 O 	O
, 	 O 	O
acute 	 O 	O
monomyeloblastic 	 O 	O
leukemia 	 O 	O
[ 	 O 	O
AMML 	 O 	O
] 	 O 	O
, 	 O 	O
or 	 O 	O
acute 	 DISEASE 	DISEASE
promyelocytic 	 DISEASE 	DISEASE
leukemia 	 DISEASE 	DISEASE
The 	 O 	O
findings 	 O 	O
support 	 O 	O
the 	 O 	O
hypothesis 	 O 	O
that 	 O 	O
an 	 O 	O
extra 	 O 	O
- 	 O 	O
adrenal 	 O 	O
stimulus 	 O 	O
may 	 O 	O
contribute 	 O 	O
to 	 O 	O
the 	 O 	O
pathogenesis 	 O 	O
of 	 O 	O
bilateral 	 O 	O
adrenal 	 O 	O
hyperplasia 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Enzymological 	 O 	O
studies 	 O 	O
of 	 O 	O
succinic 	 O 	O
dehydrogenase 	 O 	O
and 	 O 	O
cytochrome 	 O 	O
oxidase 	 O 	O
were 	 O 	O
made 	 O 	O
on 	 O 	O
human 	 O 	O
squamous 	 DISEASE 	DISEASE
cell 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
of 	 DISEASE 	O
the 	 DISEASE 	O
cervix 	 DISEASE 	O
uteri 	 DISEASE 	O
before 	 O 	O
, 	 O 	O
during 	 O 	O
and 	 O 	O
after 	 O 	O
radiation 	 O 	O
therapy 	 O 	O
by 	 O 	O
radium 	 O 	O
and 	 O 	O
60CO 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
of 	 O 	O
146 	 O 	O
seropositive 	 O 	O
and 	 O 	O
74 	 O 	O
seronegative 	 O 	O
patients 	 O 	O
with 	 O 	O
a 	 O 	O
variety 	 O 	O
of 	 O 	O
liver 	 O 	O
disorders 	 O 	O
, 	 O 	O
hepatocytes 	 O 	O
positive 	 O 	O
for 	 O 	O
HBSAg 	 O 	O
were 	 O 	O
found 	 O 	O
in 	 O 	O
only 	 O 	O
one 	 O 	O
of 	 O 	O
55 	 O 	O
patients 	 O 	O
with 	 O 	O
acute 	 DISEASE 	DISEASE
hepatitis 	 DISEASE 	O
type 	 O 	DISEASE
B 	 O 	O
, 	 O 	O
whereas 	 O 	O
large 	 O 	O
numbers 	 O 	O
of 	 O 	O
positive 	 O 	O
cells 	 O 	O
were 	 O 	O
seen 	 O 	O
in 	 O 	O
all 	 O 	O
22 	 O 	O
healthy 	 O 	O
carriers 	 O 	O
of 	 O 	O
the 	 O 	O
surface 	 O 	O
antigen 	 O 	O
. 	 O 	O
The 	 O 	O
case 	 O 	O
history 	 O 	O
of 	 O 	O
a 	 O 	O
male 	 O 	O
patient 	 O 	O
, 	 O 	O
62 	 O 	O
years 	 O 	O
old 	 O 	O
, 	 O 	O
in 	 O 	O
preterminal 	 O 	O
uremia 	 DISEASE 	O
at 	 O 	O
transplantation 	 O 	O
with 	 O 	O
a 	 O 	O
cadaveric 	 O 	O
kidney 	 O 	O
is 	 O 	O
described 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
No 	 O 	O
response 	 O 	O
following 	 O 	O
hyperbaric 	 O 	O
oxygen 	 O 	O
therapy 	 O 	O
indicated 	 O 	O
widespread 	 O 	O
mixed 	 O 	O
clostridial 	 O 	O
and 	 O 	O
non 	 O 	O
- 	 O 	O
clostridial 	 DISEASE 	O
infection 	 DISEASE 	DISEASE
, 	 O 	O
or 	 O 	O
infection 	 O 	O
due 	 O 	O
to 	 O 	O
organisms 	 O 	O
other 	 O 	O
than 	 O 	O
clostridia 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Systemic 	 O 	O
air 	 O 	O
embolism 	 O 	DISEASE
has 	 O 	O
been 	 O 	O
described 	 O 	O
as 	 O 	O
a 	 O 	O
complication 	 O 	O
of 	 O 	O
respiratory 	 O 	O
therapy 	 O 	O
using 	 O 	O
positive 	 O 	O
pressure 	 O 	O
ventilation 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
case 	 O 	O
of 	 O 	O
acid 	 O 	O
aspiration 	 DISEASE 	O
pneumonitis 	 DISEASE 	O
which 	 O 	O
occurred 	 O 	O
in 	 O 	O
the 	 O 	O
puerperium 	 O 	O
is 	 O 	O
described 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
An 	 O 	O
excellent 	 O 	O
correlation 	 O 	O
was 	 O 	O
observed 	 O 	O
between 	 O 	O
delayed 	 O 	O
cutaneous 	 O 	DISEASE
hypersensitivity 	 DISEASE 	DISEASE
to 	 O 	O
DNCB 	 O 	O
and 	 O 	O
the 	 O 	O
clinical 	 O 	O
extent 	 O 	O
of 	 O 	O
malignancy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Clinical 	 O 	O
and 	 O 	O
laboratory 	 O 	O
observations 	 O 	O
have 	 O 	O
strongly 	 O 	O
suggested 	 O 	O
that 	 O 	O
leukocytoclastic 	 O 	O
angitis 	 O 	O
is 	 O 	O
an 	 O 	O
immune 	 DISEASE 	O
complex 	 DISEASE 	O
disease 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Two 	 O 	O
patient 	 O 	O
with 	 O 	O
primary 	 DISEASE 	O
aldosteronism 	 DISEASE 	DISEASE
, 	 O 	O
one 	 O 	O
with 	 O 	O
a 	 O 	O
solitary 	 O 	O
adrenal 	 O 	O
adenoma 	 O 	O
and 	 O 	O
the 	 O 	O
other 	 O 	O
with 	 O 	O
bilateral 	 O 	O
nodular 	 O 	O
hyperplasia 	 O 	O
, 	 O 	O
are 	 O 	O
described 	 O 	O
. 	 O 	O
Two 	 O 	O
patient 	 O 	O
with 	 O 	O
primary 	 O 	O
aldosteronism 	 O 	O
, 	 O 	O
one 	 O 	O
with 	 O 	O
a 	 O 	O
solitary 	 O 	O
adrenal 	 DISEASE 	O
adenoma 	 DISEASE 	O
and 	 O 	O
the 	 O 	O
other 	 O 	O
with 	 O 	O
bilateral 	 O 	O
nodular 	 O 	O
hyperplasia 	 O 	DISEASE
, 	 O 	O
are 	 O 	O
described 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
These 	 O 	O
two 	 O 	O
compounds 	 O 	O
bind 	 O 	DISEASE
simultaneously 	 O 	O
but 	 O 	O
also 	 O 	O
cooperatively 	 O 	O
, 	 O 	O
the 	 O 	O
binding 	 O 	O
of 	 O 	O
one 	 O 	O
' 	 O 	O
fragment 	 O 	O
' 	 O 	O
leading 	 O 	O
to 	 O 	O
a 	 O 	O
50-fold 	 O 	O
increase 	 O 	O
in 	 O 	O
the 	 O 	O
affinity 	 O 	O
for 	 O 	O
the 	 O 	O
other 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
was 	 O 	O
markedly 	 O 	O
higher 	 O 	O
( 	 O 	O
8-fold 	 O 	O
) 	 O 	O
in 	 O 	O
the 	 O 	O
chloroma 	 O 	O
tissue 	 O 	O
. 	 O 	O
Although 	 O 	O
the 	 O 	O
overall 	 O 	O
biosynthesis 	 O 	O
of 	 O 	O
prostaglandin 	 O 	O
E2 	 O 	O
( 	 O 	O
PGE2 	 O 	O
) 	 O 	O
was 	 O 	O
higher 	 O 	O
in 	 O 	O
the 	 O 	O
hyperplastic 	 O 	O
bone 	 O 	O
marrow 	 O 	O
than 	 O 	O
in 	 O 	O
the 	 O 	O
chloroma 	 O 	DISEASE
tumor 	 O 	O
, 	 O 	O
the 	 O 	O
PGF2alpha 	 O 	O
: 	 O 	O
PGE2 	 O 	O
ratio 	 O 	O
was 	 O 	O
markedly 	 O 	O
higher 	 O 	O
( 	 O 	O
8-fold 	 O 	O
) 	 O 	O
in 	 O 	O
the 	 O 	O
chloroma 	 DISEASE 	O
tissue 	 O 	O
. 	 O 	O
Our 	 O 	O
results 	 O 	O
show 	 O 	O
that 	 O 	O
incomplete 	 O 	O
T 	 O 	O
cell 	 O 	O
depletion 	 O 	O
causes 	 O 	O
premature 	 O 	O
onset 	 O 	O
of 	 O 	O
non 	 O 	O
- 	 O 	O
T 	 O 	O
cell 	 O 	O
cytotoxicity 	 O 	O
, 	 O 	O
an 	 O 	O
augmentation 	 O 	O
of 	 O 	O
T 	 O 	O
cell 	 O 	O
cytotoxicity 	 O 	O
, 	 O 	O
and 	 O 	O
an 	 O 	O
alteration 	 O 	O
in 	 O 	O
a 	 O 	O
serum 	 O 	O
- 	 O 	O
blocking 	 O 	O
activity 	 O 	O
to 	 O 	O
mammary 	 DISEASE 	DISEASE
tumor 	 DISEASE 	O
target 	 O 	O
cells 	 O 	O
as 	 O 	O
tested 	 O 	O
in 	 O 	O
microcytotoxicity 	 O 	O
assay 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Tissue 	 O 	O
extracts 	 O 	O
of 	 O 	O
molar 	 O 	O
tissue 	 O 	O
or 	 O 	O
choriocarcinoma 	 DISEASE 	DISEASE
, 	 O 	O
blood 	 O 	O
, 	 O 	O
or 	 O 	O
urine 	 O 	O
of 	 O 	O
21 	 O 	O
women 	 O 	O
with 	 O 	O
gestational 	 O 	O
trophoblastic 	 O 	O
disease 	 O 	DISEASE
were 	 O 	O
analyzed 	 O 	O
for 	 O 	O
hCG 	 O 	O
and 	 O 	O
its 	 O 	O
subunits 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Operation 	 O 	O
report 	 O 	O
: 	 O 	O
Metastasis 	 O 	O
of 	 O 	O
a 	 O 	O
malignant 	 O 	DISEASE
insulinoma 	 DISEASE 	DISEASE
of 	 O 	O
the 	 O 	O
size 	 O 	O
of 	 O 	O
a 	 O 	O
hazel 	 O 	O
nut 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
multiple 	 O 	O
- 	 O 	O
type 	 O 	O
( 	 O 	O
combined 	 O 	O
) 	 O 	O
familial 	 O 	DISEASE
hyperlipidaemia 	 DISEASE 	DISEASE
could 	 O 	O
be 	 O 	O
demonstrated 	 O 	O
in 	 O 	O
30 	 O 	O
families 	 O 	O
and 	 O 	O
a 	 O 	O
single 	 O 	O
- 	 O 	O
type 	 O 	O
IIB 	 O 	O
or 	 O 	O
IV 	 O 	O
familial 	 O 	DISEASE
disease 	 O 	O
was 	 O 	O
found 	 O 	O
in 	 O 	O
6 	 O 	O
instances 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
simple 	 O 	O
technic 	 O 	O
may 	 O 	O
help 	 O 	O
in 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
lung 	 O 	DISEASE
infarction 	 O 	DISEASE
when 	 O 	O
the 	 O 	O
clinical 	 O 	O
features 	 O 	O
are 	 O 	O
not 	 O 	O
enough 	 O 	O
convincing 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
C 	 O 	O
serum 	 O 	O
but 	 O 	O
not 	 O 	O
with 	 O 	O
anti 	 O 	O
- 	 O 	O
group 	 DISEASE 	O
B 	 O 	O
serum 	 O 	O
would 	 O 	O
seem 	 O 	O
to 	 O 	O
exclude 	 O 	O
a. 	 O 	O
Further 	 O 	O
, 	 O 	O
chemical 	 O 	O
studies 	 O 	O
( 	 O 	O
periodate 	 O 	O
oxidation 	 O 	O
followed 	 O 	O
by 	 O 	O
tritiated 	 O 	O
NaBH4 	 O 	O
reduction 	 O 	O
) 	 O 	O
gave 	 O 	O
saccharides 	 O 	O
with 	 O 	O
a 	 O 	O
radioactive 	 O 	O
- 	 O 	O
labeling 	 O 	O
pattern 	 O 	O
expected 	 O 	O
for 	 O 	O
alternating 	 O 	O
2 	 O 	O
leads 	 O 	O
to 	 O 	O
8-alpha/2 	 O 	O
leads 	 O 	O
to 	 O 	O
9-alpha 	 O 	O
sialic 	 O 	O
acid 	 O 	O
linkages 	 O 	O
. 	 O 	O
The 	 O 	O
GGH 	 O 	O
with 	 O 	O
fatty 	 O 	O
changes 	 O 	O
were 	 O 	O
designated 	 O 	O
as 	 O 	O
type 	 O 	O
V. 	 O 	O
In 	 O 	O
all 	 O 	O
carriers 	 O 	O
and 	 O 	O
patients 	 O 	O
with 	 O 	O
minimal 	 O 	O
hepatitis 	 DISEASE 	O
GGH 	 O 	O
, 	 O 	O
mostly 	 O 	O
type 	 O 	O
I 	 O 	O
and 	 O 	O
II 	 O 	O
, 	 O 	O
appeared 	 O 	O
in 	 O 	O
extensive 	 O 	O
clusters 	 O 	O
within 	 O 	O
the 	 O 	O
lobules 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Recurrent 	 O 	O
infection 	 O 	DISEASE
by 	 O 	O
infectious 	 O 	O
bovine 	 O 	O
rhinotracheitis 	 O 	O
( 	 O 	O
IBR 	 O 	O
) 	 O 	O
virus 	 O 	O
was 	 O 	O
induced 	 O 	O
in 	 O 	O
calves 	 O 	O
by 	 O 	O
dexamethasone 	 O 	O
( 	 O 	O
DM 	 O 	O
) 	 O 	O
treatment 	 O 	O
( 	 O 	O
given 	 O 	O
5 	 O 	O
days 	 O 	O
) 	 O 	O
at 	 O 	O
5 	 O 	O
months 	 O 	O
after 	 O 	O
primary 	 O 	O
infection 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
balanoposthitis 	 DISEASE 	O
in 	 O 	O
bulls 	 O 	O
harbouring 	 O 	O
the 	 O 	O
virus 	 O 	O
infection 	 O 	O
. 	 O 	O
The 	 O 	O
problem 	 O 	O
is 	 O 	O
discussed 	 O 	O
of 	 O 	O
the 	 O 	O
correlation 	 O 	O
between 	 O 	O
sterility 	 O 	O
in 	 O 	O
cows 	 O 	O
showing 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
the 	 O 	O
IBR 	 O 	O
/ 	 O 	O
IPV 	 O 	O
virus 	 O 	O
and 	 O 	O
the 	 O 	O
symptoms 	 O 	O
of 	 O 	O
vulvovaginits 	 O 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
hypospermia 	 O 	O
and 	 O 	O
balanoposthitis 	 O 	O
in 	 O 	O
bulls 	 O 	O
harbouring 	 O 	O
the 	 O 	O
virus 	 DISEASE 	DISEASE
infection 	 DISEASE 	DISEASE
. 	 O 	O
A 	 O 	O
multiple 	 O 	O
stimulus 	 O 	O
( 	 O 	O
secondary 	 O 	O
or 	 O 	O
repetitive 	 O 	O
stimulus 	 O 	O
) 	 O 	O
to 	 O 	O
the 	 O 	O
sensory 	 O 	O
nerve 	 O 	O
endings 	 O 	O
in 	 O 	O
the 	 O 	O
skin 	 O 	O
and 	 O 	O
in 	 O 	O
the 	 O 	O
connective 	 O 	DISEASE
subcutaneous 	 O 	O
tissue 	 O 	O
is 	 O 	O
exerted 	 O 	O
by 	 O 	O
acupuncture 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bronchodilating 	 O 	O
effects 	 O 	O
of 	 O 	O
a 	 O 	O
Salbutamol 	 O 	O
+ 	 O 	O
Ipratropium 	 O 	O
Bromide 	 O 	O
combination 	 O 	O
administered 	 O 	O
by 	 O 	O
aerosol 	 O 	O
. 	 O 	O
27 	 O 	O
hospitalized 	 O 	O
patients 	 O 	O
( 	 O 	O
15 	 O 	O
suffering 	 O 	O
from 	 O 	O
chronic 	 O 	O
bronchitis 	 O 	DISEASE
with 	 O 	O
evident 	 O 	O
bronchospasm 	 DISEASE 	O
and 	 O 	O
12 	 O 	O
with 	 O 	O
extrinsic 	 O 	O
asthma 	 O 	O
) 	 O 	O
were 	 O 	O
evaluated 	 O 	O
with 	 O 	O
regard 	 O 	O
to 	 O 	O
the 	 O 	O
bronchodilating 	 O 	O
effects 	 O 	O
of 	 O 	O
a 	 O 	O
Salbutamol 	 O 	O
+ 	 O 	O
Ipratropium 	 O 	O
Bromide 	 O 	O
combination 	 O 	O
administered 	 O 	O
by 	 O 	O
aerosol 	 O 	O
. 	 O 	O
We 	 O 	O
therefore 	 O 	O
conclude 	 O 	O
that 	 O 	O
aortopulmonic 	 O 	O
window 	 O 	O
, 	 O 	O
anterior 	 O 	O
mediastinal 	 O 	O
, 	 O 	O
or 	 O 	O
subcarinal 	 O 	O
lymph 	 O 	O
node 	 O 	O
enlargement 	 O 	O
often 	 O 	O
accompany 	 O 	O
the 	 O 	O
characteristic 	 O 	O
lymphadenopathy 	 O 	O
of 	 O 	O
sarcoidosis 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
No 	 O 	O
cytopathic 	 O 	O
effect 	 O 	O
was 	 O 	O
observed 	 O 	O
in 	 O 	O
the 	 O 	O
latter 	 O 	O
cell 	 O 	O
system 	 O 	O
after 	 O 	O
infection 	 O 	DISEASE
with 	 O 	O
GPCMV 	 O 	O
, 	 O 	O
nor 	 O 	O
was 	 O 	O
there 	 O 	O
an 	 O 	O
increase 	 O 	O
in 	 O 	O
virus 	 O 	O
titer 	 O 	O
, 	 O 	O
although 	 O 	O
the 	 O 	O
cirus 	 O 	O
persisted 	 O 	O
in 	 O 	O
the 	 O 	O
kidney 	 O 	O
cells 	 O 	O
for 	 O 	O
2 	 O 	O
to 	 O 	O
3 	 O 	O
weeks 	 O 	O
postinfection 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
Zollinger 	 DISEASE 	O
- 	 DISEASE 	O
Ellison 	 DISEASE 	O
syndrome.3 	 DISEASE 	O
) 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Three 	 O 	O
illustrative 	 O 	O
cases 	 O 	O
are 	 O 	O
described 	 O 	O
in 	 O 	O
which 	 O 	O
there 	 O 	O
was 	 O 	O
complete 	 O 	O
, 	 O 	O
incomplete 	 O 	O
, 	 O 	O
and 	 O 	O
no 	 O 	O
aortic 	 O 	DISEASE
obstruction 	 O 	DISEASE
respectively 	 O 	O
at 	 O 	O
the 	 O 	O
time 	 O 	O
of 	 O 	O
reoperation 	 O 	O
, 	 O 	O
two 	 O 	O
of 	 O 	O
the 	 O 	O
cases 	 O 	O
presenting 	 O 	O
the 	 O 	O
additional 	 O 	O
complication 	 O 	O
of 	 O 	O
local 	 O 	O
aneurysm 	 O 	DISEASE
formation 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Of 	 O 	O
48 	 O 	O
bulls 	 O 	O
included 	 O 	O
in 	 O 	O
the 	 O 	O
investigation 	 O 	O
, 	 O 	O
23 	 O 	O
were 	 O 	O
on 	 O 	O
intensive 	 O 	O
feeding 	 O 	O
and 	 O 	O
they 	 O 	O
all 	 O 	O
were 	 O 	O
found 	 O 	O
to 	 O 	O
have 	 O 	O
osteochondrosis 	 DISEASE 	O
at 	 O 	O
several 	 O 	O
locations 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
ventral 	 O 	O
ACTH 	 O 	O
facilitatory 	 O 	O
area 	 O 	O
appears 	 O 	O
to 	 O 	O
be 	 O 	O
coincident 	 O 	O
with 	 O 	O
the 	 O 	O
medial 	 O 	O
forebrain 	 O 	O
bundle 	 O 	O
and 	 O 	O
to 	 O 	O
extend 	 O 	O
anteroventrally 	 O 	O
and 	 O 	O
medially 	 O 	O
through 	 O 	O
the 	 O 	O
supraoptic 	 O 	O
decussation 	 O 	O
to 	 O 	O
the 	 O 	O
suprachiasmatic 	 O 	O
, 	 O 	O
ventromedial 	 O 	O
, 	 O 	O
dorsomedial 	 O 	O
, 	 O 	O
periventricular 	 O 	DISEASE
, 	 O 	O
infundibular 	 O 	O
, 	 O 	O
and 	 O 	O
premammillary 	 O 	O
nuclei 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Visna 	 O 	O
virus 	 O 	O
particles 	 O 	O
inhibit 	 O 	DISEASE
influenza 	 DISEASE 	DISEASE
virus 	 O 	O
hemagglutination 	 O 	O
in 	 O 	O
an 	 O 	O
assay 	 O 	O
for 	 O 	O
neuraminic 	 O 	O
acid 	 O 	O
- 	 O 	O
containing 	 O 	O
viruses 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
After 	 O 	O
14 	 O 	O
days 	 O 	O
in 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
sheep 	 O 	O
erythropoetin 	 O 	O
( 	 O 	O
3U 	 O 	O
/ 	 O 	O
ml 	 O 	O
) 	 O 	O
erythropoetic 	 O 	O
bursts 	 O 	O
containing 	 O 	O
between 	 O 	O
3 	 O 	O
and 	 O 	O
10 	 O 	O
subcolonies 	 O 	O
were 	 O 	O
observed 	 O 	O
in 	 O 	O
normal 	 O 	O
and 	 O 	O
polycythemia 	 DISEASE 	O
vera 	 DISEASE 	DISEASE
cultures 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Blood 	 O 	O
lymphocytes 	 O 	O
from 	 O 	O
nineteen 	 O 	O
patients 	 O 	O
with 	 O 	O
Hodgkin 	 O 	O
's 	 O 	DISEASE
disease 	 O 	O
were 	 O 	O
tested 	 O 	O
in 	 O 	O
vitro 	 O 	O
before 	 O 	O
and 	 O 	O
after 	 O 	O
treatment 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
stress 	 O 	O
development 	 O 	O
( 	 O 	O
dsigma 	 O 	O
/ 	 O 	O
dt 	 O 	O
) 	 O 	O
was 	 O 	O
nearly 	 O 	O
identical 	 O 	O
in 	 O 	O
patients 	 O 	O
with 	 O 	O
aortic 	 O 	O
stenosis 	 O 	O
and 	 O 	O
in 	 O 	O
normal 	 O 	O
subjects 	 O 	O
over 	 O 	O
a 	 O 	O
wide 	 O 	O
range 	 O 	O
of 	 O 	O
values 	 O 	O
of 	 O 	O
sigmaD 	 O 	O
but 	 O 	O
was 	 O 	O
significantly 	 O 	O
lower 	 O 	O
in 	 O 	O
patients 	 O 	O
with 	 O 	O
cardiomyopathy 	 O 	O
( 	 O 	O
P 	 O 	O
less 	 O 	O
than 	 O 	O
0.01 	 O 	O
versus 	 O 	O
control 	 O 	O
subjects 	 O 	O
and 	 O 	O
patients 	 O 	O
with 	 O 	O
aortic 	 DISEASE 	DISEASE
stenosis 	 DISEASE 	O
) 	 O 	O
. 	 O 	O
Since 	 O 	O
this 	 O 	O
procedure 	 O 	O
causes 	 O 	O
severe 	 O 	O
gastric 	 O 	O
mucosal 	 O 	O
ischemia 	 DISEASE 	O
, 	 O 	O
it 	 O 	O
casts 	 O 	O
doubt 	 O 	O
only 	 O 	O
on 	 O 	O
the 	 O 	O
importance 	 O 	O
of 	 O 	O
this 	 O 	O
mechanism 	 O 	O
alone 	 O 	O
as 	 O 	O
the 	 O 	O
cause 	 O 	O
of 	 O 	O
	PUNCT	O
24134	stress	NOUN	O
24134	ulceration	NOUN	O
24134	.	PUNCT	O
24134	 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
ethylmaleimide 	 O 	O
to 	 O 	O
prevent 	 O 	DISEASE
interfering 	 O 	O
H+ 	 O 	O
reuptake 	 O 	O
via 	 O 	O
the 	 O 	O
phosphate 	 O 	O
carrier 	 O 	O
, 	 O 	O
close 	 O 	O
to 	 O 	O
8 	 O 	O
H+ 	 O 	O
were 	 O 	O
ejected 	 O 	O
per 	 O 	O
oxygen 	 O 	O
atom 	 O 	O
reduced 	 O 	O
( 	 O 	O
H+/O 	 O 	O
ejection 	 O 	O
ratio 	 O 	O
= 	 O 	O
8.0 	 O 	O
) 	 O 	O
; 	 O 	O
with 	 O 	O
the 	 O 	O
NAD 	 O 	O
- 	 O 	O
linked 	 O 	O
substrates 	 O 	O
pyruvate 	 O 	O
or 	 O 	O
pyruvate 	 O 	O
+ 	 O 	O
malate 	 O 	O
, 	 O 	O
the 	 O 	O
H+/O 	 O 	O
ejection 	 O 	O
ratio 	 O 	O
was 	 O 	O
close 	 O 	O
to 	 O 	O
12 	 O 	O
. 	 O 	O
An 	 O 	O
earlier 	 O 	O
study 	 O 	O
( 	 O 	O
Matsson 	 O 	O
& 	 O 	O
Attstrm 	 O 	O
1979 	 O 	O
) 	 O 	O
revealed 	 O 	O
an 	 O 	O
unexplained 	 O 	O
difference 	 O 	O
between 	 O 	O
juvenile 	 O 	O
and 	 O 	O
adult 	 O 	O
dogs 	 O 	O
in 	 O 	O
the 	 O 	O
propensity 	 O 	O
to 	 O 	O
develop 	 O 	O
clinical 	 O 	O
signs 	 O 	O
of 	 O 	DISEASE
gingivitis 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
After 	 O 	O
incubation 	 O 	O
of 	 O 	O
bone 	 O 	O
marrow 	 O 	O
cells 	 O 	O
obtained 	 O 	O
from 	 O 	O
normal 	 O 	O
subjects 	 O 	O
and 	 O 	O
patients 	 O 	O
with 	 O 	O
pancytopenia 	 DISEASE 	O
in 	 O 	O
the 	 O 	O
double 	 O 	O
layer 	 O 	O
agar 	 O 	O
culture 	 O 	O
( 	 O 	O
Robinson 	 O 	O
- 	 O 	O
Pike 	 O 	O
) 	 O 	O
, 	 O 	O
the 	 O 	O
clusters 	 O 	O
of 	 O 	O
different 	 O 	O
size 	 O 	O
and 	 O 	O
the 	 O 	O
colonies 	 O 	O
were 	 O 	O
counted 	 O 	O
on 	 O 	O
days 	 O 	O
2 	 O 	O
, 	 O 	O
3 	 O 	O
, 	 O 	O
5 	 O 	O
, 	 O 	O
7 	 O 	O
and 	 O 	O
10 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Mitteilungen 	 O 	O
aus 	 O 	O
dem 	 O 	O
Bundesgesundheitsamt 	 O 	DISEASE
	PUNCT	O
43203	which	ADJ	O
43203	permits	VERB	O
43203	the	DET	O
43203	incorporation	NOUN	O
43203	of	ADP	O
43203	IPPD	NOUN	O
43203	in	ADP	O
43203	these	DET	O
43203	kind	NOUN	O
43203	of	ADP	O
43203	rubber	NOUN	O
43203	parts	NOUN	O
43203	to	ADP	O
43203	a	DET	O
43203	percentage	NOUN	O
43203	of	ADP	O
43203	1,5	NUM	O
43203	%	NOUN	O
43203	.	PUNCT	O
43204	The	DET	O
43204	mixed	ADJ	O
43204	leukocyte	NOUN	O
43204	reaction	NOUN	O
43204	(	PUNCT	O
43204	MLR	PROPN	O
43204	)	PUNCT	O
43204	responses	NOUN	O
43204	of	ADP	O
43204	29	NUM	O
43204	patients	NOUN	O
43204	with	ADP	O
43204	classic	ADJ	O
43204	rheumatoid	NOUN	DISEASE
43204	arthritis	NOUN	DISEASE
43204	(	PUNCT	O
43204	RA	PROPN	O
43204	)	PUNCT	O
43204	were	VERB	O
43204	compared	VERB	O
43204	with	ADP	O
43204	those	DET	O
43204	of	ADP	O
43204	24	NUM	O
43204	age-	NOUN	O
43204	and	CCONJ	O
43204	sex	NOUN	O
43204	-	PUNCT	O
43204	matched	VERB	O
43204	healthy	ADJ	O
43204	controls	NOUN	O
43204	.	PUNCT	O
43205	Pools	NOUN	O
43205	of	ADP	O
43205	stimulating	VERB	O
43205	cells	NOUN	O
43205	were	VERB	O
43205	selected	VERB	O
43205	to	PART	O
43205	include	VERB	O
43205	the	DET	O
43205	major	ADJ	O
43205	cross	NOUN	O
43205	-	PUNCT	O
43205	reacting	VERB	O
43205	HL	NOUN	O
43205	-	PUNCT	O
43205	A	NOUN	O
43205	specificities	NOUN	O
43205	.	PUNCT	O
43206	In	ADP	O
43206	pooled	VERB	O
43206	human	ADJ	O
43206	serum	NOUN	O
43206	the	DET	O
43206	MLR	PROPN	O
43206	response	NOUN	O
43206	of	ADP	O
43206	the	DET	O
43206	RA	PROPN	O
43206	lymphocytes	NOUN	O
43206	was	VERB	O
43206	significantly	ADV	O
43206	enhanced	VERB	O
43206	relative	ADJ	O
43206	to	ADP	O
43206	the	DET	O
43206	response	NOUN	O
43206	controls	NOUN	O
43206	(	PUNCT	O
43206	P	NOUN	O
43206	less	ADJ	O
43206	than	ADP	O
43206	0.05	NUM	O
43206	)	PUNCT	O
43206	.	PUNCT	O
43207	In	ADP	O
43207	autologous	ADJ	O
43207	serum	NOUN	O
43207	there	ADV	O
43207	was	VERB	O
43207	suppression	NOUN	O
43207	of	ADP	O
43207	the	DET	O
43207	MLR	PROPN	O
43207	response	NOUN	O
43207	in	ADP	O
43207	patients	NOUN	O
43207	with	ADP	O
43207	RA	PROPN	O
43207	which	ADJ	O
43207	correlated	VERB	O
43207	with	ADP	O
43207	disease	NOUN	O
43207	activity	NOUN	O
43207	.	PUNCT	O
43208	The	DET	O
43208	data	NOUN	O
43208	suggest	VERB	O
43208	the	DET	O
43208	presence	NOUN	O
43208	of	ADP	O
43208	an	DET	O
43208	intrinsically	ADV	O
43208	enhanced	ADJ	O
43208	cellular	ADJ	O
43208	reactivity	NOUN	O
43208	of	ADP	O
43208	RA	PROPN	O
43208	lymphocytes	VERB	O
43208	suppressed	VERB	O
43208	by	ADP	O
43208	serologic	ADJ	O
43208	factor(s	PROPN	O
43208	)	PUNCT	O
43208	.	PUNCT	O
43209	The	DET	O
43209	mechanisms	NOUN	O
43209	of	ADP	O
43209	this	DET	O
43209	enhancement	NOUN	O
43209	of	ADP	O
43209	suppression	NOUN	O
43209	are	VERB	O
43209	discussed	VERB	O
43209	.	PUNCT	O
43210	A	DET	O
43210	study	NOUN	O
43210	was	VERB	O
43210	made	VERB	O
43210	of	ADP	O
43210	the	DET	O
43210	cytotoxic	ADJ	O
43210	effect	NOUN	O
43210	of	ADP	O
43210	antibacterial	ADJ	O
43210	antibody	NOUN	O
43210	and	CCONJ	O
43210	complement	NOUN	O
43210	reacting	VERB	O
43210	with	ADP	O
43210	bacterial	ADJ	O
43210	antigens	NOUN	O
43210	firmly	ADV	O
43210	adsorbed	ADJ	O
43210	to	ADP	O
43210	epidermal	ADJ	O
43210	cells	NOUN	O
43210	.	PUNCT	O
43211	It	PRON	O
43211	is	VERB	O
43211	believed	VERB	O
43211	that	ADP	O
43211	this	DET	O
43211	phenomenon	NOUN	O
43211	enhances	VERB	O
43211	the	DET	O
43211	severity	NOUN	O
43211	of	ADP	O
43211	the	DET	O
43211	lesions	NOUN	O
43211	and	CCONJ	O
43211	their	ADJ	O
43211	spread	NOUN	O
43211	in	ADP	O
43211	some	DET	O
43211	cases	NOUN	O
43211	of	ADP	O
43211	disseminated	ADJ	O
43211	eczema	NOUN	DISEASE
43211	.	PUNCT	O
43212	In	ADP	O
43212	this	DET	O
43212	first	ADJ	O
43212	part	NOUN	O
43212	of	ADP	O
43212	the	DET	O
43212	study	NOUN	O
43212	it	PRON	O
43212	is	VERB	O
43212	confirmed	VERB	O
43212	that	ADP	O
43212	Staphylococcus	PROPN	O
43212	aureus	PROPN	O
43212	and	CCONJ	O
43212	micrococci	NOUN	O
43212	are	VERB	O
43212	frequently	ADV	O
43212	present	ADJ	O
43212	on	ADP	O
43212	lesions	NOUN	O
43212	and	CCONJ	O
43212	'	PUNCT	O
43212	unaffected	ADJ	O
43212	'	PUNCT	O
43212	skin	NOUN	O
43212	of	ADP	O
43212	patients	NOUN	O
43212	with	ADP	O
43212	disseminated	ADJ	O
43212	eczema	NOUN	DISEASE
43212	.	PUNCT	O
43213	Intradermal	ADJ	O
43213	skin	NOUN	O
43213	tests	VERB	O
43213	with	ADP	O
43213	antigens	NOUN	O
43213	of	ADP	O
43213	staphylococci	NOUN	O
43213	and	CCONJ	O
43213	micrococci	VERB	O
43213	on	ADP	O
43213	122	NUM	O
43213	eczematous	ADJ	O
43213	patients	NOUN	O
43213	elicited	VERB	O
43213	immediate	ADJ	O
43213	,	PUNCT	O
43213	or	CCONJ	O
43213	combined	VERB	O
43213	immediate	ADJ	O
43213	and	CCONJ	O
43213	4	NUM	O
43213	h	NOUN	O
43213	(	PUNCT	O
43213	Arthus	ADV	O
43213	-	PUNCT	O
43213	like	ADJ	O
43213	)	PUNCT	O
43213	responses	NOUN	O
43213	,	PUNCT	O
43213	in	ADP	O
43213	a	DET	O
43213	large	ADJ	O
43213	proportion	NOUN	O
43213	,	PUNCT	O
43213	but	CCONJ	O
43213	few	ADJ	O
43213	showed	VERB	O
43213	uncombined	ADJ	O
43213	4	NUM	O
43213	h	NOUN	O
43213	responses	NOUN	O
43213	or	CCONJ	O
43213	delayed	VERB	O
43213	hypersensitivity	NOUN	DISEASE
43213	,	PUNCT	O
43213	in	ADP	O
43213	contrast	NOUN	O
43213	to	ADP	O
43213	findings	NOUN	O
43213	reported	VERB	O
43213	by	ADP	O
43213	others	NOUN	O
43213	.	PUNCT	O
43214	Immunofluorescence	NOUN	O
43214	tests	VERB	O
43214	on	ADP	O
43214	skin	NOUN	O
43214	of	ADP	O
43214	thirty	NUM	O
43214	patients	NOUN	O
43214	showed	VERB	O
43214	that	ADP	O
43214	IgG	NOUN	O
43214	and	CCONJ	O
43214	IgM	PROPN	O
43214	diffused	VERB	O
43214	into	ADP	O
43214	the	DET	O
43214	epidermis	NOUN	O
43214	,	PUNCT	O
43214	sometimes	ADV	O
43214	to	ADP	O
43214	the	DET	O
43214	skin	NOUN	O
43214	surface	NOUN	O
43214	,	PUNCT	O
43214	of	ADP	O
43214	lesional	ADJ	O
43214	skin	NOUN	O
43214	,	PUNCT	O
43214	and	CCONJ	O
43214	more	ADJ	O
43214	immunoglobulin	NOUN	O
43214	was	VERB	O
43214	found	VERB	O
43214	in	ADP	O
43214	skin	NOUN	O
43214	of	ADP	O
43214	'	PUNCT	O
43214	unaffected	ADJ	O
43214	'	PUNCT	O
43214	areas	NOUN	O
43214	than	ADP	O
43214	in	ADP	O
43214	skin	NOUN	O
43214	of	ADP	O
43214	normal	ADJ	O
43214	healthy	ADJ	O
43214	persons	NOUN	O
43214	,	PUNCT	O
43214	indicating	VERB	O
43214	that	ADP	O
43214	clinically	ADV	O
43214	unaffected	ADJ	O
43214	skin	NOUN	O
43214	in	ADP	O
43214	patients	NOUN	O
43214	with	ADP	O
43214	disseminated	ADJ	O
43214	eczema	NOUN	DISEASE
43214	is	VERB	O
43214	abnormal	ADJ	O
43214	.	PUNCT	O
43215	IgD	PROPN	O
43215	was	VERB	O
43215	present	ADJ	O
43215	in	ADP	O
43215	three	NUM	O
43215	of	ADP	O
43215	eight	NUM	O
43215	samples	NOUN	O
43215	of	ADP	O
43215	unfixed	ADJ	O
43215	,	PUNCT	O
43215	and	CCONJ	O
43215	six	NUM	O
43215	of	ADP	O
43215	eight	NUM	O
43215	samples	NOUN	O
43215	of	ADP	O
43215	fixed	VERB	O
43215	eczematous	ADJ	O
43215	skin	NOUN	O
43215	.	PUNCT	O
43216	Staphylococcal	ADJ	O
43216	and	CCONJ	O
43216	micrococcal	ADJ	O
43216	antigen	NOUN	O
43216	was	VERB	O
43216	shown	VERB	O
43216	on	ADP	O
43216	the	DET	O
43216	skin	NOUN	O
43216	surface	NOUN	O
43216	and	CCONJ	O
43216	also	ADV	O
43216	diffusely	ADV	O
43216	in	ADP	O
43216	the	DET	O
43216	cytoplasm	NOUN	O
43216	of	ADP	O
43216	cells	NOUN	O
43216	in	ADP	O
43216	the	DET	O
43216	dermis	NOUN	O
43216	beneath	ADP	O
43216	the	DET	O
43216	surface	NOUN	O
43216	deposits	NOUN	O
43216	,	PUNCT	O
43216	indicating	VERB	O
43216	percutaneous	ADJ	O
43216	absorption	NOUN	O
43216	.	PUNCT	O
43217	Further	ADJ	O
43217	small	ADJ	O
43217	amounts	NOUN	O
43217	of	ADP	O
43217	antigen	NOUN	O
43217	were	VERB	O
43217	adsorbed	VERB	O
43217	to	ADP	O
43217	some	DET	O
43217	epidermal	ADJ	O
43217	cells	NOUN	O
43217	.	PUNCT	O
43218	These	DET	O
43218	results	NOUN	O
43218	show	VERB	O
43218	that	ADP	O
43218	the	DET	O
43218	predisposing	VERB	O
43218	conditions	NOUN	O
43218	for	ADP	O
43218	a	DET	O
43218	cytotoxic	ADJ	O
43218	reaction	NOUN	O
43218	mediated	VERB	O
43218	by	ADP	O
43218	hypersensitivity	NOUN	DISEASE
43218	to	ADP	O
43218	bacteria	NOUN	O
43218	do	VERB	O
43218	occur	VERB	O
43218	.	PUNCT	O
43219	Increased	ADJ	O
43219	growth	NOUN	O
43219	of	ADP	O
43219	staphylococci	NOUN	O
43219	and	CCONJ	O
43219	micrococci	VERB	O
43219	on	ADP	O
43219	eczematous	ADJ	O
43219	skin	NOUN	O
43219	would	VERB	O
43219	result	VERB	O
43219	in	ADP	O
43219	increased	VERB	O
43219	deposits	NOUN	O
43219	of	ADP	O
43219	antigen	NOUN	O
43219	.	PUNCT	O
43220	Bacterial	PROPN	O
43220	antigens	NOUN	O
43220	are	VERB	O
43220	absorbed	VERB	O
43220	into	ADP	O
43220	the	DET	O
43220	skin	NOUN	O
43220	and	CCONJ	O
43220	bind	VERB	O
43220	with	ADP	O
43220	epidermal	ADJ	O
43220	cells	NOUN	O
43220	,	PUNCT	O
43220	and	CCONJ	O
43220	immunoglobulins	VERB	O
43220	diffuse	NOUN	O
43220	into	ADP	O
43220	the	DET	O
43220	epidermis	NOUN	O
43220	.	PUNCT	O
43221	Furthermore	ADV	O
43221	,	PUNCT	O
43221	skin	NOUN	O
43221	tests	NOUN	O
43221	showed	VERB	O
43221	that	ADP	O
43221	many	ADJ	O
43221	eczematous	ADJ	O
43221	patients	NOUN	O
43221	were	VERB	O
43221	hypersensitive	ADJ	O
43221	to	ADP	O
43221	bacteria	NOUN	O
43221	.	PUNCT	O
43222	Studies	NOUN	O
43222	on	ADP	O
43222	the	DET	O
43222	nature	NOUN	O
43222	of	ADP	O
43222	the	DET	O
43222	antibacterial	ADJ	O
43222	antibody	NOUN	O
43222	will	VERB	O
43222	be	VERB	O
43222	published	VERB	O
43222	in	ADP	O
43222	the	DET	O
43222	succeeding	VERB	O
43222	reports	NOUN	O
43222	.	PUNCT	O
43223	ATPase	VERB	O
43223	(	PUNCT	O
43224	ATP	PROPN	O
43224	phosphohydrolase	NOUN	O
43224	,	PUNCT	O
43224	EC	PROPN	O
43224	3.6.1.3	NUM	O
43224	)	PUNCT	O
43224	was	VERB	O
43224	detected	VERB	O
43224	in	ADP	O
43224	the	DET	O
43224	membrane	ADJ	O
43224	fraction	NOUN	O
43224	of	ADP	O
43224	the	DET	O
43224	strict	ADJ	O
43224	anaerobic	ADJ	O
43224	bacterium	NOUN	O
43224	,	PUNCT	O
43224	Clostridium	PROPN	O
43224	pasteurianum	NOUN	O
43224	.	PUNCT	O
43225	About	ADV	O
43225	70	NUM	O
43225	%	NOUN	O
43225	of	ADP	O
43225	the	DET	O
43225	total	ADJ	O
43225	activity	NOUN	O
43225	was	VERB	O
43225	found	VERB	O
43225	in	ADP	O
43225	the	DET	O
43225	particulate	NOUN	O
43225	fraction	NOUN	O
43225	.	PUNCT	O
43226	The	DET	O
43226	enzyme	NOUN	O
43226	was	VERB	O
43226	Mg2	ADJ	O
43226	+	CCONJ	O
43226	dependent	ADJ	O
43226	;	PUNCT	O
43226	Co2	NOUN	O
43226	+	NOUN	O
43226	and	CCONJ	O
43226	Mn2	NOUN	O
43226	+	X	O
43226	but	CCONJ	O
43226	not	ADV	O
43226	Ca2	NOUN	O
43226	+	SYM	O
43226	could	VERB	O
43226	replace	VERB	O
43226	Mg2	ADJ	O
43226	+	CCONJ	O
43226	to	ADP	O
43226	some	DET	O
43226	extent	NOUN	O
43226	;	PUNCT	O
43226	the	DET	O
43226	activation	NOUN	O
43226	by	ADP	O
43226	Mg2	NOUN	O
43226	+	CCONJ	O
43226	was	VERB	O
43226	slightly	ADV	O
43226	antagonized	VERB	O
43226	by	ADP	O
43226	Ca2	NOUN	O
43226	+	SYM	O
43226	.	PUNCT	O
43227	Even	ADV	O
43227	in	ADP	O
43227	the	DET	O
43227	presence	NOUN	O
43227	of	ADP	O
43227	Mg2	NOUN	O
43227	+	NOUN	O
43227	,	PUNCT	O
43227	Na+	PROPN	O
43227	or	CCONJ	O
43227	K+	VERB	O
43227	had	VERB	O
43227	no	DET	O
43227	stimulatory	ADJ	O
43227	effect	NOUN	O
43227	.	PUNCT	O
43228	The	DET	O
43228	ATPase	PROPN	O
43228	reaction	NOUN	O
43228	was	VERB	O
43228	effectively	ADV	O
43228	inhibited	VERB	O
43228	by	ADP	O
43228	one	NUM	O
43228	of	ADP	O
43228	its	ADJ	O
43228	products	NOUN	O
43228	,	PUNCT	O
43228	ADP	PROPN	O
43228	,	PUNCT	O
43228	and	CCONJ	O
43228	only	ADV	O
43228	slightly	ADV	O
43228	by	ADP	O
43228	the	DET	O
43228	other	ADJ	O
43228	product	NOUN	O
43228	,	PUNCT	O
43228	inorganic	ADJ	O
43228	phosphate	NOUN	O
43228	.	PUNCT	O
43229	Of	ADP	O
43229	the	DET	O
43229	nucleoside	NOUN	O
43229	triphosphates	NOUN	O
43229	tested	VERB	O
43229	ATP	PROPN	O
43229	was	VERB	O
43229	hydrolyzed	VERB	O
43229	with	ADP	O
43229	highest	ADJ	O
43229	affinity	NOUN	O
43229	(	PUNCT	O
43229	[	PUNCT	O
43229	S]0.5	NOUN	O
43229	v	ADP	O
43229	=	SYM	O
43229	1.3	NUM	O
43229	mM	NOUN	O
43229	)	PUNCT	O
43229	and	CCONJ	O
43229	maximal	ADJ	O
43229	activity	NOUN	O
43229	(	PUNCT	O
43229	120	NUM	O
43229	U	NOUN	O
43229	/	SYM	O
43229	g	PROPN	O
43229	)	PUNCT	O
43229	.	PUNCT	O
43230	The	DET	O
43230	ATPase	PROPN	O
43230	activity	NOUN	O
43230	could	VERB	O
43230	be	VERB	O
43230	nearly	ADV	O
43230	 	SPACE	O
43230	completely	ADV	O
43230	solubilized	VERB	O
43230	by	ADP	O
43230	treatment	NOUN	O
43230	of	ADP	O
43230	the	DET	O
43230	membranes	NOUN	O
43230	with	ADP	O
43230	2	NUM	O
43230	M	PROPN	O
43230	LiCl	PROPN	O
43230	in	ADP	O
43230	the	DET	O
43230	absence	NOUN	O
43230	of	ADP	O
43230	Mg2	NOUN	O
43230	+	NOUN	O
43230	.	PUNCT	O
43231	Solubilization	NOUN	O
43231	,	PUNCT	O
43231	however	ADV	O
43231	,	PUNCT	O
43231	led	VERB	O
43231	to	ADP	O
43231	instability	NOUN	O
43231	of	ADP	O
43231	the	DET	O
43231	enzyme	NOUN	O
43231	.	PUNCT	O
43232	The	DET	O
43232	clostridial	NOUN	O
43232	solubilized	VERB	O
43232	and	CCONJ	O
43232	membrane	NOUN	O
43232	-	PUNCT	O
43232	bound	VERB	O
43232	ATPase	PROPN	O
43232	showed	VERB	O
43232	different	ADJ	O
43232	properties	NOUN	O
43232	similar	ADJ	O
43232	to	ADP	O
43232	the	DET	O
43232	 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Binding 	 O 	O
constants 	 O 	O
of 	 O 	O
the 	 O 	O
dextran 	 O 	O
- 	 O 	O
reactive 	 O 	O
BALB 	 O 	O
/ 	 O 	O
c 	 O 	O
mouse 	 O 	O
IgA 	 O 	DISEASE
myeloma 	 DISEASE 	DISEASE
proteins 	 O 	O
W3129 	 O 	O
and 	 O 	O
QUPC 	 O 	O
52 	 O 	O
have 	 O 	O
been 	 O 	O
determined 	 O 	O
for 	 O 	O
each 	 O 	O
member 	 O 	O
of 	 O 	O
the 	 O 	O
isomaltose 	 O 	O
series 	 O 	O
of 	 O 	O
oligosaccharides 	 O 	O
and 	 O 	O
for 	 O 	O
methyl 	 O 	O
alphaDglucoside 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
studies 	 O 	O
indicate 	 O 	O
that 	 O 	O
phosphodiesterase 	 O 	O
I 	 O 	O
activity 	 O 	O
is 	 O 	O
greater 	 O 	O
than 	 O 	O
normal 	 O 	O
in 	 O 	O
serum 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
necrotic 	 O 	O
changes 	 O 	O
in 	 O 	O
the 	 O 	O
liver 	 O 	O
or 	 O 	O
kidney 	 O 	O
or 	 O 	O
in 	 O 	O
cases 	 O 	O
of 	 O 	O
breast 	 O 	DISEASE
cancer 	 O 	O
, 	 O 	O
but 	 O 	O
not 	 O 	O
in 	 O 	O
that 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
myocardial 	 O 	O
infarction 	 O 	O
, 	 O 	O
bone 	 O 	O
cancer 	 O 	DISEASE
, 	 O 	O
lung 	 O 	O
cancer 	 O 	O
, 	 O 	O
or 	 O 	O
chronic 	 O 	O
liver 	 DISEASE 	DISEASE
cirrhosis 	 DISEASE 	DISEASE
. 	 O 	O
Splenic 	 O 	O
bacterial 	 O 	DISEASE
uptake 	 O 	O
was 	 O 	O
measured 	 O 	O
by 	 O 	O
determining 	 O 	O
the 	 O 	O
isotopic 	 O 	O
activity 	 O 	O
of 	 O 	O
technetium-99m 	 O 	O
- 	 O 	O
labeled 	 O 	O
pneumococci 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Pedicle 	 O 	O
skin 	 O 	O
flaps 	 O 	O
or 	 O 	O
rotation 	 O 	O
flaps 	 O 	O
were 	 O 	O
used 	 O 	O
to 	 O 	O
cover 	 O 	O
the 	 O 	O
skin 	 O 	DISEASE
defect 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Combined 	 O 	O
modality 	 O 	O
approaches 	 O 	O
in 	 O 	O
advanced 	 O 	O
disease 	 O 	DISEASE
are 	 O 	O
encouraging 	 O 	O
but 	 O 	O
as 	 O 	O
yet 	 O 	O
long 	 O 	O
- 	 O 	O
term 	 O 	O
follow 	 O 	O
- 	 O 	O
up 	 O 	O
is 	 O 	O
not 	 O 	O
available 	 O 	O
to 	 O 	O
assess 	 O 	O
their 	 O 	O
worth 	 O 	O
vis 	 O 	O
- 	 O 	O
 	 O 	O
- 	 O 	O
vis 	 O 	O
existing 	 O 	O
therapies 	 O 	O
for 	 O 	O
advanced 	 O 	O
disease 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Pneumonia 	 DISEASE 	O
caused 	 O 	O
by 	 O 	O
Pseudomonas 	 O 	O
aeruginosa 	 O 	O
occurs 	 O 	O
frequently 	 O 	O
in 	 O 	O
critically 	 O 	O
ill 	 O 	O
patients 	 O 	O
and 	 O 	O
is 	 O 	O
associated 	 O 	O
with 	 O 	O
a 	 O 	O
mortality 	 O 	O
rate 	 O 	O
of 	 O 	O
70 	 O 	O
per 	 O 	O
cent 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
carbodiimide 	 O 	O
to 	 O 	O
give 	 O 	O
the 	 O 	O
corresponding 	 O 	O
amino 	 O 	O
derivatives 	 O 	O
, 	 O 	O
N6-([N-3-aminopropyl)carbamoylethyl]thiomethyl)-ADP 	 O 	O
( 	 O 	O
VIII 	 O 	O
) 	 O 	O
, 	 O 	O
N6-(N-(3-aminopropyl)carbamoylethyl]thiomethyl)-ATP 	 O 	O
( 	 O 	O
IX 	 O 	O
) 	 O 	O
, 	 O 	O
N6,N6-bis([N-(3-aminopropyl)carbamoylethyl]thiomethyl)-ADP 	 O 	O
( 	 O 	O
XIII 	 O 	DISEASE
) 	 O 	O
, 	 O 	O
and 	 O 	O
N6,N6-bis([N-(3-aminopropyl)carbamoylethyl]thiomethyl)-ATP 	 O 	O
( 	 O 	O
XIV 	 O 	O
) 	 O 	O
, 	 O 	O
which 	 O 	O
were 	 O 	O
further 	 O 	O
bound 	 O 	O
to 	 O 	O
CNBr 	 O 	O
- 	 O 	O
activated 	 O 	O
dextran 	 O 	O
to 	 O 	O
give 	 O 	O
new 	 O 	O
polymer 	 O 	O
- 	 O 	O
bound 	 O 	O
derivatives 	 O 	O
of 	 O 	O
ADP 	 O 	O
and 	 O 	O
ATP 	 O 	O
. 	 O 	O
At 	 O 	O
surgery 	 O 	O
one 	 O 	O
patient 	 O 	O
had 	 O 	O
a 	 O 	O
mature 	 DISEASE 	O
teratoma 	 DISEASE 	O
, 	 O 	O
the 	 O 	O
other 	 O 	O
a 	 O 	O
mature 	 O 	O
teratoma 	 O 	O
with 	 O 	O
a 	 O 	O
microscopic 	 O 	O
focus 	 O 	O
of 	 O 	O
an 	 O 	O
embryonal 	 O 	O
cell 	 O 	O
tumor 	 O 	O
. 	 O 	O
At 	 O 	O
surgery 	 O 	O
one 	 O 	O
patient 	 O 	O
had 	 O 	O
a 	 O 	O
mature 	 O 	O
teratoma 	 O 	O
, 	 O 	O
the 	 O 	O
other 	 O 	O
a 	 O 	O
mature 	 DISEASE 	O
teratoma 	 DISEASE 	O
with 	 O 	O
a 	 O 	O
microscopic 	 O 	O
focus 	 O 	O
of 	 O 	O
an 	 O 	O
embryonal 	 O 	DISEASE
cell 	 O 	DISEASE
tumor 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
rational 	 O 	O
, 	 O 	O
multidisciplinary 	 O 	O
approach 	 O 	O
to 	 O 	O
Hodgkin 	 O 	O
's 	 O 	DISEASE
disease 	 O 	O
and 	 O 	O
the 	 O 	O
non 	 O 	O
- 	 O 	O
Hodgkin 	 O 	O
's 	 O 	O
lymphomas 	 O 	O
has 	 O 	O
been 	 O 	O
responsible 	 O 	O
for 	 O 	O
major 	 O 	O
advances 	 O 	O
in 	 O 	O
therapy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
rheology 	 O 	O
of 	 O 	O
the 	 O 	O
blood 	 O 	O
was 	 O 	O
studied 	 O 	O
in 	 O 	O
20 	 O 	O
patients 	 O 	O
with 	 O 	O
Raynaud 	 O 	DISEASE
syndrome 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Quantitative 	 O 	O
measurements 	 O 	O
of 	 O 	O
global 	 O 	O
and 	 O 	O
regional 	 O 	O
cerebral 	 O 	O
blood 	 O 	O
flow 	 O 	O
were 	 O 	O
performed 	 O 	O
in 	 O 	O
18 	 O 	O
patients 	 O 	O
1 	 O 	O
to 	 O 	O
3 	 O 	O
days 	 O 	O
after 	 O 	O
the 	 O 	O
onset 	 O 	O
of 	 O 	O
symptoms 	 O 	O
of 	 O 	O
acute 	 O 	O
cerebral 	 DISEASE 	DISEASE
ischemia 	 DISEASE 	DISEASE
due 	 O 	O
to 	 O 	O
partial 	 O 	O
occlusion 	 O 	O
of 	 O 	O
the 	 O 	O
middle 	 O 	O
cerebral 	 O 	DISEASE
artery 	 O 	O
and 	 O 	O
were 	 O 	O
repeated 	 O 	O
21 	 O 	O
days 	 O 	O
thereafter 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Subsequent 	 O 	O
progress 	 O 	O
revealed 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
to 	 O 	O
be 	 O 	O
chronic 	 DISEASE 	O
lymphatic 	 DISEASE 	DISEASE
leukemia 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
These 	 O 	O
features 	 O 	O
in 	 O 	O
patients 	 O 	O
with 	 O 	O
coarctation 	 O 	O
of 	 O 	O
the 	 O 	O
aorta 	 O 	O
should 	 O 	O
suggest 	 O 	O
associated 	 O 	O
mitral 	 DISEASE 	O
valve 	 DISEASE 	O
disease 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
As 	 O 	O
a 	 O 	O
revertant 	 O 	O
of 	 O 	O
this 	 O 	O
character 	 O 	O
, 	 O 	O
a 	 O 	O
flaky 	 O 	O
mutant 	 O 	O
was 	 O 	O
isolated 	 O 	O
, 	 O 	O
showing 	 O 	O
a 	 O 	O
heavy 	 O 	O
flocculation 	 O 	O
during 	 O 	O
growth 	 O 	O
on 	 O 	O
liquid 	 O 	O
medium 	 O 	O
and 	 O 	O
resistance 	 O 	O
to 	 O 	O
catabolite 	 O 	O
repression 	 O 	O
for 	 O 	O
maltase 	 O 	DISEASE
, 	 O 	O
alpha 	 O 	O
- 	 O 	O
methyl 	 O 	O
- 	 O 	O
glucosidase 	 O 	O
, 	 O 	O
invertase 	 O 	O
, 	 O 	O
and 	 O 	O
succinate 	 O 	O
dehydrogenase 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Four 	 O 	O
months 	 O 	O
after 	 O 	O
the 	 O 	O
onset 	 O 	O
of 	 O 	O
the 	 O 	O
disease 	 O 	O
, 	 O 	O
the 	 O 	O
patient 	 O 	O
developed 	 O 	O
hemiplegia 	 DISEASE 	O
, 	 O 	O
became 	 O 	O
comatose 	 O 	O
, 	 O 	O
and 	 O 	O
died 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
the 	 O 	O
factor 	 O 	O
of 	 O 	O
autolytic 	 O 	DISEASE
environment 	 O 	O
, 	 O 	O
and 	 O 	O
the 	 O 	O
disentanglement 	 O 	O
of 	 O 	O
the 	 O 	O
changes 	 O 	O
occurring 	 O 	O
soon 	 O 	O
after 	 O 	O
death 	 O 	O
and 	 O 	O
the 	 O 	O
long 	 O 	O
- 	 O 	O
term 	 O 	O
gradual 	 O 	O
changes 	 O 	O
, 	 O 	O
have 	 O 	O
been 	 O 	O
discussed 	 O 	O
in 	 O 	O
an 	 O 	O
attempt 	 O 	O
to 	 O 	O
understand 	 O 	O
how 	 O 	O
the 	 O 	O
corpse 	 O 	O
changed 	 O 	O
in 	 O 	O
the 	 O 	O
course 	 O 	O
of 	 O 	O
time 	 O 	O
and 	 O 	O
why 	 O 	O
it 	 O 	O
was 	 O 	O
so 	 O 	O
well 	 O 	O
- 	 O 	O
preserved 	 O 	O
. 	 O 	O
to 	 O 	O
a 	 O 	O
normal 	 O 	O
test 	 O 	O
or 	 O 	O
relief 	 O 	O
of 	 O 	O
TET 	 O 	O
- 	 O 	O
induced 	 O 	O
angina 	 O 	DISEASE
following 	 O 	O
surgery 	 O 	O
is 	 O 	O
closely 	 O 	O
correlated 	 O 	O
with 	 O 	O
bypass 	 O 	O
graft 	 O 	O
patency 	 O 	O
, 	 O 	O
the 	 O 	O
high 	 O 	O
incidence 	 O 	O
of 	 O 	O
normal 	 O 	O
exercise 	 O 	O
tests 	 O 	O
in 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
residual 	 O 	O
coronary 	 DISEASE 	O
disease 	 DISEASE 	O
limits 	 O 	O
their 	 O 	O
usefulness 	 O 	O
in 	 O 	O
the 	 O 	O
individual 	 O 	O
postoperative 	 O 	O
patient 	 O 	O
in 	 O 	O
estimating 	 O 	O
the 	 O 	O
completeness 	 O 	O
of 	 O 	O
revascularization 	 O 	O
. 	 O 	O
with 	 O 	O
systemic 	 DISEASE 	DISEASE
lupus 	 DISEASE 	DISEASE
erythematosus 	 DISEASE 	DISEASE
, 	 O 	O
rheumatoid 	 O 	O
arthritis 	 O 	O
and 	 O 	O
scleroderma 	 O 	O
was 	 O 	O
studied 	 O 	O
. 	 O 	O
The 	 O 	O
mitogenic 	 O 	O
reactivity 	 O 	O
of 	 O 	O
lymphocytes 	 O 	O
from 	 O 	O
subjects 	 O 	O
with 	 O 	O
systemic 	 O 	O
lupus 	 O 	O
erythematosus 	 O 	DISEASE
, 	 O 	O
rheumatoid 	 DISEASE 	O
arthritis 	 DISEASE 	O
and 	 O 	O
scleroderma 	 O 	O
was 	 O 	O
studied 	 O 	O
. 	 O 	O
The 	 O 	O
mitogenic 	 O 	O
reactivity 	 O 	O
of 	 O 	O
lymphocytes 	 O 	O
from 	 O 	O
subjects 	 O 	O
with 	 O 	O
systemic 	 O 	O
lupus 	 O 	O
erythematosus 	 O 	O
, 	 O 	O
rheumatoid 	 O 	O
arthritis 	 O 	DISEASE
and 	 O 	O
scleroderma 	 DISEASE 	DISEASE
was 	 O 	O
studied 	 O 	O
. 	 O 	O
A 	 O 	O
single 	 O 	O
administration 	 O 	O
of 	 O 	O
SRBC 	 O 	O
- 	 O 	O
Pertussis 	 DISEASE 	O
evoked 	 O 	O
a 	 O 	O
considerable 	 O 	O
adjuvant 	 O 	O
effect 	 O 	O
as 	 O 	O
measured 	 O 	O
by 	 O 	O
hemagglutinating 	 O 	O
and 	 O 	O
opsonic 	 O 	O
adherent 	 O 	O
tests 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
most 	 O 	O
common 	 O 	O
location 	 O 	O
is 	 O 	O
in 	 O 	O
the 	 O 	O
palate 	 O 	O
; 	 O 	O
a 	 O 	O
plea 	 O 	O
is 	 O 	O
made 	 O 	O
for 	 O 	O
incisional 	 O 	O
biopsy 	 O 	O
of 	 O 	O
all 	 O 	O
oral 	 O 	O
lesions 	 O 	O
suspected 	 O 	O
of 	 O 	O
salivary 	 O 	DISEASE
gland 	 O 	O
origin 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
D.N.A. 	 O 	O
from 	 O 	O
amniotic 	 O 	O
- 	 O 	O
fluid 	 O 	O
cells 	 O 	O
produced 	 O 	O
both 	 O 	O
the 	 O 	O
7.6 	 O 	O
and 	 O 	O
the 	 O 	O
13.0 	 O 	O
bk 	 O 	O
beta 	 O 	O
- 	 O 	O
globin 	 O 	O
gene 	 O 	O
fragments 	 O 	O
, 	 O 	O
indicating 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
of 	 O 	O
sickle 	 DISEASE 	O
- 	 DISEASE 	O
cell 	 DISEASE 	O
trait 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
urethritis 	 O 	O
, 	 O 	O
53 	 O 	O
had 	 O 	O
possible 	 O 	O
nongonococcal 	 DISEASE 	DISEASE
urethritis 	 DISEASE 	O
, 	 O 	O
and 	 O 	O
123 	 O 	O
had 	 O 	O
no 	 O 	O
urethritis 	 O 	O
. 	 O 	O
Of 	 O 	O
377 	 O 	O
men 	 O 	O
attending 	 O 	O
clinics 	 O 	O
for 	 O 	O
the 	 O 	O
treatment 	 O 	O
of 	 O 	O
sexually 	 O 	O
transmitted 	 O 	O
disease 	 O 	O
, 	 O 	O
104 	 O 	O
had 	 O 	O
gonococcal 	 O 	O
urethritis 	 O 	O
, 	 O 	O
72 	 O 	O
had 	 O 	O
definite 	 O 	O
nongonococcal 	 O 	O
urethritis 	 O 	O
, 	 O 	O
53 	 O 	O
had 	 O 	O
possible 	 O 	O
nongonococcal 	 O 	O
urethritis 	 O 	O
, 	 O 	O
and 	 O 	O
123 	 O 	O
had 	 O 	O
no 	 O 	O
urethritis 	 DISEASE 	DISEASE
. 	 O 	O
Eruptive 	 O 	O
herpes 	 DISEASE 	DISEASE
zoster 	 DISEASE 	DISEASE
infection 	 O 	DISEASE
( 	 O 	O
VZV 	 O 	O
) 	 O 	O
and 	 O 	O
its 	 O 	O
primary 	 O 	O
and 	 O 	O
secondary 	 O 	O
diseases 	 O 	O
are 	 O 	O
reported 	 O 	O
in 	 O 	O
28 	 O 	O
patients 	 O 	O
aged 	 O 	O
between 	 O 	O
25 	 O 	O
and 	 O 	O
85 	 O 	O
years 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
T 	 O 	O
- 	 O 	O
types 	 O 	O
found 	 O 	O
corresponded 	 O 	O
to 	 O 	O
those 	 O 	O
previously 	 O 	O
reported 	 O 	O
as 	 O 	O
being 	 O 	O
pyoderma 	 DISEASE 	O
- 	 O 	O
associated 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
in 	 O 	O
one 	 O 	O
case 	 O 	O
each 	 O 	O
of 	 O 	O
adenocarcinoma 	 O 	DISEASE
and 	 O 	O
SCAC 	 O 	O
of 	 O 	O
the 	 O 	O
lung 	 O 	O
with 	 O 	O
proven 	 O 	O
CNS 	 O 	O
metastases 	 O 	O
. 	 O 	O
Significant 	 O 	O
increases 	 O 	O
were 	 O 	O
also 	 O 	O
observed 	 O 	O
in 	 O 	O
three 	 O 	O
cases 	 O 	O
of 	 O 	O
prostatic 	 O 	O
carcinoma 	 O 	O
with 	 O 	O
no 	 O 	O
apparent 	 O 	O
CNS 	 O 	O
involvement 	 O 	O
, 	 O 	O
and 	 O 	O
in 	 O 	O
one 	 O 	O
case 	 O 	O
each 	 O 	O
of 	 O 	O
adenocarcinoma 	 DISEASE 	DISEASE
and 	 O 	O
SCAC 	 O 	O
of 	 O 	O
the 	 O 	O
lung 	 O 	O
with 	 O 	O
proven 	 O 	O
CNS 	 O 	O
metastases 	 O 	O
. 	 O 	O
During 	 O 	O
the 	 O 	O
early 	 O 	O
phase 	 O 	O
of 	 O 	O
LCM 	 O 	O
virus 	 DISEASE 	O
infection 	 DISEASE 	O
there 	 O 	O
was 	 O 	O
a 	 O 	O
transient 	 O 	O
phase 	 O 	O
during 	 O 	O
which 	 O 	O
non 	 O 	O
- 	 O 	O
infected 	 O 	O
H-2 	 O 	O
histocompatible 	 O 	O
targets 	 O 	O
were 	 O 	O
lysed 	 O 	O
as 	 O 	O
efficiently 	 O 	O
as 	 O 	O
virus 	 O 	O
- 	 O 	O
infected 	 O 	O
target 	 O 	O
cells 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Sinus 	 O 	O
rhythm 	 O 	O
with 	 O 	O
atrial 	 O 	DISEASE
extrasystoles 	 O 	O
may 	 O 	O
show 	 O 	O
a 	 O 	O
combination 	 O 	O
of 	 O 	O
these 	 O 	O
features 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
patient 	 O 	O
with 	 O 	O
nitrazepam 	 O 	O
overdose 	 O 	O
and 	 O 	O
two 	 O 	O
of 	 O 	O
those 	 O 	O
with 	 O 	O
chlormethiazole 	 O 	O
intoxication 	 O 	O
conformed 	 O 	O
to 	 O 	O
the 	 O 	O
criteria 	 O 	O
of 	 O 	O
' 	 O 	O
alpha 	 O 	DISEASE
coma 	 O 	DISEASE
' 	 O 	O
, 	 O 	O
showing 	 O 	O
non 	 O 	O
- 	 O 	O
reactive 	 O 	O
generalized 	 O 	O
or 	 O 	O
frontally 	 O 	O
predominant 	 O 	O
alpha 	 O 	O
activity 	 O 	O
in 	 O 	O
the 	 O 	O
EEG 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
82 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
male 	 O 	O
patients 	 O 	O
with 	 O 	O
healthy 	 O 	O
urogenital 	 O 	DISEASE
tract 	 O 	O
showed 	 O 	O
an 	 O 	O
isoelectric 	 O 	O
line 	 O 	O
in 	 O 	O
the 	 O 	O
simultaneous 	 O 	O
EMG 	 O 	O
- 	 O 	O
derivation 	 O 	O
of 	 O 	O
the 	 O 	O
sphincter 	 O 	O
of 	 O 	O
the 	 O 	O
bladder 	 O 	O
under 	 O 	O
conditions 	 O 	O
of 	 O 	O
rest 	 O 	O
; 	 O 	O
in 	 O 	O
18 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
males 	 O 	O
a 	 O 	O
moderate 	 O 	O
activity 	 O 	O
was 	 O 	O
present 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Guanosine 	 O 	DISEASE
showed 	 O 	O
no 	 O 	O
significant 	 O 	O
effects 	 O 	O
at 	 O 	O
either 	 O 	O
10(-3 	 O 	O
) 	 O 	O
M 	 O 	O
or 	 O 	O
10(-5 	 O 	O
) 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
Arthus 	 DISEASE 	DISEASE
reaction 	 DISEASE 	O
belonging 	 O 	O
to 	 O 	O
type 	 O 	O
III 	 O 	O
reaction 	 O 	O
, 	 O 	O
however 	 O 	O
, 	 O 	O
was 	 O 	O
hardly 	 O 	O
affected 	 O 	O
with 	 O 	O
either 	 O 	O
BPS 	 O 	O
or 	 O 	O
BSS 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
78-year 	 O 	O
- 	 O 	O
old 	 O 	O
man 	 O 	O
suffered 	 O 	O
an 	 O 	O
unusual 	 O 	O
variant 	 O 	O
of 	 O 	O
sweat 	 DISEASE 	O
gland 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
of 	 O 	O
the 	 O 	O
eyelid 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
14 	 O 	O
% 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
gonococcal 	 DISEASE 	O
urethritis 	 DISEASE 	DISEASE
and 	 O 	O
definite 	 O 	O
nongonococcal 	 O 	O
urethritis 	 O 	O
, 	 O 	O
respectively 	 O 	O
( 	 O 	O
P 	 O 	O
less 	 O 	O
than 	 O 	O
0.001 	 O 	O
) 	 O 	O
. 	 O 	O
A 	 O 	O
purulent 	 O 	O
urethral 	 O 	O
discharge 	 O 	O
was 	 O 	O
noted 	 O 	O
in 	 O 	O
78 	 O 	O
% 	 O 	O
and 	 O 	O
14 	 O 	O
% 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
gonococcal 	 O 	O
urethritis 	 O 	O
and 	 O 	O
definite 	 O 	O
nongonococcal 	 DISEASE 	DISEASE
urethritis 	 DISEASE 	DISEASE
, 	 O 	O
respectively 	 O 	O
( 	 O 	O
P 	 O 	O
less 	 O 	O
than 	 O 	O
0.001 	 O 	O
) 	 O 	O
. 	 O 	O
of 	 O 	O
the 	 O 	O
consequences 	 O 	O
of 	 O 	O
Parainfluenza 	 O 	O
type 	 O 	O
1 	 O 	O
( 	 O 	O
Sendai 	 O 	O
) 	 O 	O
virus 	 DISEASE 	DISEASE
infection 	 DISEASE 	O
in 	 O 	O
inbred 	 O 	O
( 	 O 	O
C57B1/6J 	 O 	O
, 	 O 	O
C57Br 	 O 	O
, 	 O 	O
CBA 	 O 	O
, 	 O 	O
DBA 	 O 	O
) 	 O 	O
strains 	 O 	O
and 	 O 	O
a 	 O 	O
randomly 	 O 	O
bred 	 O 	O
( 	 O 	O
Swiss 	 O 	O
white 	 O 	O
) 	 O 	O
strain 	 O 	O
of 	 O 	O
mice 	 O 	O
showed 	 O 	O
significant 	 O 	O
mortality 	 O 	O
in 	 O 	O
the 	 O 	O
inbred 	 O 	O
strains 	 O 	O
but 	 O 	O
not 	 O 	O
in 	 O 	O
the 	 O 	O
randomly 	 O 	O
bred 	 O 	O
ones 	 O 	O
. 	 O 	O
The 	 O 	O
effects 	 O 	O
of 	 O 	O
chronic 	 O 	O
alcohol 	 O 	O
ingestion 	 O 	O
on 	 O 	O
drugs 	 O 	O
with 	 O 	O
low 	 O 	O
and 	 O 	O
high 	 O 	DISEASE
hepatic 	 O 	O
extraction 	 O 	O
, 	 O 	O
high 	 O 	O
and 	 O 	O
low 	 O 	O
binding 	 O 	O
, 	 O 	O
important 	 O 	O
tissue 	 O 	O
localisation 	 O 	O
and 	 O 	O
microsomal 	 O 	O
and 	 O 	O
non 	 O 	O
- 	 O 	O
microsomal 	 O 	O
metabolism 	 O 	O
will 	 O 	O
be 	 O 	O
quite 	 O 	O
different 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
prognosis 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
cerebral 	 O 	DISEASE
abscess 	 O 	O
depends 	 O 	O
on 	 O 	O
an 	 O 	O
early 	 O 	O
and 	 O 	O
accurate 	 O 	O
diagnosis 	 O 	O
and 	 O 	O
its 	 O 	O
delay 	 O 	O
carries 	 O 	O
a 	 O 	O
high 	 O 	O
mortality 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Consequently 	 O 	O
, 	 O 	O
at 	 O 	O
a 	 O 	O
given 	 O 	O
time 	 O 	O
during 	 O 	O
diastole 	 O 	O
, 	 O 	O
the 	 O 	O
relative 	 O 	O
velocity 	 O 	O
of 	 O 	O
transmitral 	 O 	O
flow 	 O 	O
and 	 O 	O
the 	 O 	O
percent 	 O 	O
of 	 O 	O
the 	 O 	O
stroke 	 DISEASE 	DISEASE
volume 	 O 	O
which 	 O 	O
has 	 O 	O
entered 	 O 	O
the 	 O 	O
left 	 O 	O
ventricle 	 O 	O
may 	 O 	O
be 	 O 	O
approximated 	 O 	O
noninvasively 	 O 	O
from 	 O 	O
the 	 O 	O
anterior 	 O 	O
mitral 	 O 	DISEASE
leaflet 	 O 	O
echogram 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Sixty 	 O 	O
ts 	 O 	O
mutants 	 O 	O
were 	 O 	O
isolated 	 O 	O
from 	 O 	O
the 	 O 	O
Pacheco 	 O 	O
strain 	 O 	O
of 	 O 	O
type 	 O 	O
O 	 O 	O
foot 	 O 	O
- 	 O 	O
and 	 O 	O
- 	 O 	O
mouth 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
virus 	 O 	O
after 	 O 	O
treatment 	 O 	O
with 	 O 	O
either 	 O 	O
5-fluorouracil 	 O 	O
or 	 O 	O
hydroxylamine 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Host 	 O 	O
parasite 	 O 	O
relationships 	 O 	O
in 	 O 	O
the 	 O 	O
female 	 O 	O
genital 	 O 	O
tract 	 O 	O
were 	 O 	O
studied 	 O 	O
in 	 O 	O
bovine 	 O 	O
venereal 	 O 	O
vibriosis 	 DISEASE 	O
by 	 O 	O
investigating 	 O 	O
agglutinin 	 O 	O
production 	 O 	O
and 	 O 	O
alterations 	 O 	O
in 	 O 	O
superficial 	 O 	O
antigens 	 O 	O
of 	 O 	O
the 	 O 	O
bacterium 	 O 	O
during 	 O 	O
the 	 O 	O
course 	 O 	O
of 	 O 	O
infection 	 O 	O
in 	 O 	O
two 	 O 	O
heifers 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
It 	 O 	O
has 	 O 	O
been 	 O 	O
reported 	 O 	O
that 	 O 	O
there 	 O 	O
is 	 O 	O
an 	 O 	O
increased 	 O 	O
incidence 	 O 	O
of 	 O 	O
Down 	 DISEASE 	DISEASE
's 	 DISEASE 	O
syndrome 	 DISEASE 	DISEASE
among 	 O 	O
the 	 O 	O
children 	 O 	O
of 	 O 	O
parents 	 O 	O
who 	 O 	O
have 	 O 	O
been 	 O 	O
exposed 	 O 	O
to 	 O 	O
ionizing 	 O 	O
radiations 	 O 	O
for 	 O 	O
radiodiagnostic 	 O 	O
or 	 O 	O
radiotherapeutic 	 O 	O
reasons 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Nephrosis 	 DISEASE 	O
was 	 O 	O
studied 	 O 	O
on 	 O 	O
the 	 O 	O
7th 	 O 	O
d 	 O 	O
after 	 O 	O
the 	 O 	O
injection 	 O 	O
of 	 O 	O
puromycin 	 O 	O
animonucleoside 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Kallikrein 	 O 	O
activation 	 O 	O
and 	 O 	O
extravasal 	 O 	O
formation 	 O 	O
of 	 O 	O
bradikinin 	 O 	O
were 	 O 	O
apparently 	 O 	O
the 	 O 	O
long 	 O 	O
- 	 O 	O
term 	 O 	O
affecting 	 O 	O
factors 	 O 	O
, 	 O 	O
supporting 	 O 	O
the 	 O 	O
state 	 O 	O
of 	 O 	O
increased 	 O 	O
vascular 	 O 	O
permeability 	 O 	O
in 	 O 	O
nephrotic 	 DISEASE 	O
syndrome 	 DISEASE 	O
; 	 O 	O
they 	 O 	O
had 	 O 	O
an 	 O 	O
aggravating 	 O 	O
role 	 O 	O
in 	 O 	O
pathogenesis 	 O 	O
of 	 O 	O
refractory 	 O 	O
nephrotic 	 O 	DISEASE
edema 	 O 	DISEASE
, 	 O 	O
nephrotic 	 O 	DISEASE
crises 	 O 	O
and 	 O 	O
cutaneous 	 O 	O
erythema 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Studies 	 O 	O
of 	 O 	O
the 	 O 	O
collagen 	 O 	O
indicate 	 O 	O
a 	 O 	O
disturbance 	 O 	O
, 	 O 	O
but 	 O 	O
present 	 O 	O
studies 	 O 	O
indicate 	 O 	O
the 	 O 	O
defect 	 O 	O
to 	 O 	O
be 	 O 	O
more 	 O 	O
a 	 O 	O
cellular 	 O 	O
defect 	 O 	DISEASE
in 	 O 	O
the 	 O 	O
fibroblast 	 O 	O
yet 	 O 	O
undetermined 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
During 	 O 	O
the 	 O 	O
period 	 O 	O
between 	 O 	O
1968 	 O 	O
- 	 O 	O
1974 	 O 	O
90 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
patients 	 O 	O
with 	 O 	O
superficial 	 O 	O
bladder 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
were 	 O 	O
still 	 O 	O
alive 	 O 	O
after 	 O 	O
3 	 O 	O
years 	 O 	O
, 	 O 	O
in 	 O 	O
comparison 	 O 	O
with 	 O 	O
only 	 O 	O
52 	 O 	O
% 	 O 	O
between 	 O 	O
1953 	 O 	O
- 	 O 	O
1967 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
central 	 O 	O
nervous 	 O 	O
system 	 O 	O
( 	 O 	O
CNS 	 O 	O
) 	 O 	O
. 	 O 	O
Virus 	 O 	O
antibody 	 O 	O
levels 	 O 	O
were 	 O 	O
studied 	 O 	O
in 	 O 	O
the 	 O 	O
cerebrospinal 	 O 	O
fluid 	 O 	O
( 	 O 	O
CSF 	 O 	O
) 	 O 	O
of 	 O 	O
58 	 O 	O
patients 	 O 	O
with 	 O 	O
optic 	 O 	O
neuritis 	 O 	O
and 	 O 	O
58 	 O 	O
control 	 O 	O
patients 	 O 	O
with 	 O 	O
no 	 O 	O
indication 	 O 	O
of 	 O 	O
multiple 	 DISEASE 	O
sclerosis 	 DISEASE 	DISEASE
( 	 O 	O
MS 	 O 	O
) 	 O 	O
or 	 O 	O
infectious 	 O 	O
disorders 	 O 	O
of 	 O 	O
the 	 O 	O
central 	 O 	O
nervous 	 O 	O
system 	 O 	O
( 	 O 	O
CNS 	 O 	O
) 	 O 	O
. 	 O 	O
Two 	 O 	O
children 	 O 	O
with 	 O 	O
  	 O 	O
multiple 	 O 	O
infiltrating 	 O 	O
glomus 	 O 	O
tumors 	 O 	O
of 	 O 	O
the 	 O 	O
lower 	 O 	O
extremities 	 O 	O
presented 	 O 	O
in 	 O 	O
infancy 	 O 	O
with 	 O 	O
clinical 	 O 	O
and 	 O 	O
, 	 O 	O
in 	 O 	O
one 	 O 	O
, 	 O 	O
radiological 	 O 	O
, 	 O 	O
signs 	 O 	O
of 	 O 	O
varicose 	 DISEASE 	O
veins 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
With 	 O 	O
a 	 O 	O
follow 	 O 	O
- 	 O 	O
up 	 O 	O
time 	 O 	O
of 	 O 	O
1.3 	 O 	O
to 	 O 	O
17.2 	 O 	O
years 	 O 	O
( 	 O 	O
mean 	 O 	O
of 	 O 	O
7.7 	 O 	O
years 	 O 	O
) 	 O 	O
, 	 O 	O
11/14 	 O 	DISEASE
remain 	 O 	O
clinically 	 O 	O
disease 	 O 	O
- 	 O 	O
free 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
encephalitis 	 DISEASE 	O
in 	 O 	O
ferrets 	 O 	O
may 	 O 	O
serve 	 O 	O
as 	 O 	O
a 	 O 	O
model 	 O 	O
for 	 O 	O
human 	 O 	O
subacute 	 O 	O
sclerosing 	 O 	DISEASE
panencephalitis 	 O 	O
. 	 O 	O
Excluding 	 O 	O
the 	 O 	O
electrophoresis 	 O 	O
data 	 O 	O
, 	 O 	O
other 	 O 	O
results 	 O 	O
are 	 O 	O
identical 	 O 	O
to 	 O 	O
those 	 O 	O
seen 	 O 	O
in 	 O 	O
human 	 O 	O
subacute 	 O 	O
sclerosing 	 O 	O
panencephalitis 	 O 	O
, 	 O 	O
indicating 	 O 	O
that 	 O 	O
the 	 O 	O
subacute 	 O 	O
encephalitis 	 O 	O
in 	 O 	O
ferrets 	 O 	O
may 	 O 	O
serve 	 O 	O
as 	 O 	O
a 	 O 	O
model 	 O 	O
for 	 O 	O
human 	 O 	O
subacute 	 DISEASE 	DISEASE
sclerosing 	 DISEASE 	DISEASE
panencephalitis 	 DISEASE 	DISEASE
. 	 O 	O
The 	 O 	O
importance 	 O 	O
of 	 O 	O
nonencapsulated 	 O 	O
strains 	 O 	O
of 	 O 	O
Haemophilus 	 O 	O
influenzae 	 O 	O
and 	 O 	O
H. 	 O 	O
parainfluenzae 	 O 	O
in 	 O 	O
the 	 O 	O
pathogenesis 	 O 	O
of 	 O 	O
chronic 	 DISEASE 	O
obstructive 	 DISEASE 	DISEASE
pulmonary 	 DISEASE 	DISEASE
disease 	 DISEASE 	DISEASE
( 	 O 	O
C.O.P.D. 	 O 	O
) 	 O 	O
has 	 O 	O
been 	 O 	O
investigated 	 O 	O
in 	 O 	O
150 	 O 	O
patients 	 O 	O
observed 	 O 	O
at 	 O 	O
two 	 O 	O
- 	 O 	O
month 	 O 	O
intervals 	 O 	O
from 	 O 	O
1968 	 O 	O
to 	 O 	O
1975 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
such 	 O 	O
cases 	 O 	O
, 	 O 	O
the 	 O 	O
physician 	 O 	O
should 	 O 	O
look 	 O 	O
for 	 O 	O
the 	 O 	O
scalenus 	 O 	O
syndrome 	 O 	DISEASE
, 	 O 	O
the 	 O 	O
costoclavicular 	 O 	O
syndrome 	 O 	O
, 	 O 	O
and 	 O 	O
the 	 O 	O
hyperabduction 	 O 	O
syndrome 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
For 	 O 	O
the 	 O 	O
practicing 	 O 	O
physician 	 O 	O
the 	 O 	O
medicamentous 	 O 	O
treatment 	 O 	O
of 	 O 	O
the 	 O 	O
patients 	 O 	O
with 	 O 	O
infarction 	 O 	DISEASE
is 	 O 	O
the 	 O 	O
main 	 O 	O
problem 	 O 	O
of 	 O 	O
the 	 O 	O
secondary 	 O 	O
prevention 	 O 	O
in 	 O 	O
the 	 O 	O
prehospital 	 O 	O
phase 	 O 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
in 	 O 	O
the 	 O 	O
after 	 O 	O
- 	 O 	O
treatment 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Because 	 O 	O
of 	 O 	O
the 	 O 	O
absence 	 O 	O
of 	 O 	O
industrial 	 O 	O
pollution 	 O 	O
and 	 O 	O
occupational 	 O 	O
exposure 	 O 	O
in 	 O 	O
Ivory 	 O 	O
Coast 	 O 	O
, 	 O 	O
the 	 O 	O
very 	 O 	O
important 	 O 	O
relation 	 O 	O
between 	 O 	O
bronchus 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
and 	 O 	O
smoking 	 O 	O
cigarettes 	 O 	O
is 	 O 	O
suggested 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Elastic 	 O 	O
membranous 	 O 	DISEASE
retraction 	 O 	O
fibers 	 O 	O
break 	 O 	O
upon 	 O 	O
culture 	 O 	O
agitation 	 O 	O
, 	 O 	O
leaving 	 O 	O
adhesion 	 O 	O
sites 	 O 	O
as 	 O 	O
substrate 	 O 	O
- 	 O 	O
attached 	 O 	O
material 	 O 	O
( 	 O 	O
SAM 	 O 	O
) 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
cases 	 O 	O
of 	 O 	O
the 	 O 	O
carcinoma 	 DISEASE 	DISEASE
of 	 DISEASE 	O
the 	 DISEASE 	O
rectum 	 DISEASE 	O
located 	 O 	O
in 	 O 	O
the 	 O 	O
middle 	 O 	O
and 	 O 	O
lower 	 O 	O
part 	 O 	O
causing 	 O 	O
a 	 O 	O
severe 	 O 	O
stenosis 	 O 	O
coagulation 	 O 	O
is 	 O 	O
an 	 O 	O
effective 	 O 	O
treatment 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Autosomal 	 O 	O
dominant 	 O 	O
inheritance 	 O 	O
with 	 O 	O
variable 	 O 	O
expressivity 	 O 	O
or 	 O 	O
multifactorial 	 O 	O
inheritance 	 O 	O
may 	 O 	O
explain 	 O 	O
the 	 O 	O
occurrence 	 O 	O
of 	 O 	O
gastroschisis 	 DISEASE 	O
in 	 O 	O
the 	 O 	O
two 	 O 	O
families 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
no 	 O 	O
neurogenic 	 O 	O
changes 	 O 	O
, 	 O 	O
but 	 O 	O
only 	 O 	O
myogenic 	 O 	O
changes 	 O 	O
manifested 	 O 	O
in 	 O 	O
the 	 O 	O
electromyogram 	 O 	O
. 	 O 	O
In 	 O 	O
such 	 O 	O
cases 	 O 	O
, 	 O 	O
a 	 O 	O
clear 	 O 	O
distinction 	 O 	O
must 	 O 	O
be 	 O 	O
made 	 O 	O
against 	 O 	O
bursitis 	 O 	O
of 	 O 	O
the 	 O 	O
shoulder 	 O 	O
( 	 O 	O
periarthritis 	 DISEASE 	O
humeroscapularis 	 O 	O
) 	 O 	O
, 	 O 	O
in 	 O 	O
which 	 O 	O
there 	 O 	O
are 	 O 	O
no 	 O 	O
neurogenic 	 O 	O
changes 	 O 	O
, 	 O 	O
but 	 O 	O
only 	 O 	O
myogenic 	 O 	O
changes 	 O 	O
manifested 	 O 	O
in 	 O 	O
the 	 O 	O
electromyogram 	 O 	O
. 	 O 	O
Serum 	 O 	O
dihydrotestosterone 	 O 	O
( 	 O 	O
DHT 	 O 	O
) 	 O 	O
and 	 O 	O
testosterone 	 O 	O
were 	 O 	O
measured 	 O 	O
by 	 O 	O
radioimmunoassay 	 O 	O
in 	 O 	O
24 	 O 	O
normal 	 O 	O
men 	 O 	O
aged 	 O 	O
60 	 O 	O
to 	 O 	O
80 	 O 	O
years 	 O 	O
and 	 O 	O
in 	 O 	O
25 	 O 	O
patients 	 O 	O
with 	 O 	O
benign 	 O 	O
prostatic 	 DISEASE 	DISEASE
hypertrophy 	 DISEASE 	O
in 	 O 	O
the 	 O 	O
same 	 O 	O
age 	 O 	O
range 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
in 	 O 	O
various 	 O 	O
ways 	 O 	O
, 	 O 	O
including 	 O 	O
analyses 	 O 	O
of 	 O 	O
the 	 O 	O
correlation 	 O 	O
between 	 O 	O
the 	 O 	O
immunoelectron 	 O 	O
microscopy 	 O 	O
results 	 O 	O
and 	 O 	O
determinations 	 O 	O
of 	 O 	O
ganglioside 	 O 	O
G(M1 	 O 	O
) 	 O 	O
in 	 O 	O
tissues 	 O 	O
with 	 O 	O
different 	 O 	O
ganglioside 	 O 	O
concentrations 	 O 	O
, 	 O 	O
tissues 	 O 	O
hydrolyzed 	 O 	O
with 	 O 	O
Vibrio 	 DISEASE 	O
cholerae 	 DISEASE 	O
sialidase 	 O 	O
, 	 O 	O
tissues 	 O 	O
in 	 O 	O
which 	 O 	O
exogenous 	 O 	O
G(M1 	 O 	O
) 	 O 	O
has 	 O 	O
been 	 O 	O
incorporated 	 O 	O
, 	 O 	O
and 	 O 	O
lipid 	 O 	O
- 	 O 	O
extracted 	 O 	O
tissues 	 O 	O
. 	 O 	O
The 	 O 	O
HPRS 	 O 	O
line 	 O 	O
1 	 O 	O
lymphoblastoid 	 O 	O
cells 	 O 	O
derived 	 O 	O
from 	 O 	O
an 	 O 	O
ovarian 	 DISEASE 	O
lymphoma 	 DISEASE 	DISEASE
induced 	 O 	O
by 	 O 	O
Marek 	 O 	O
's 	 O 	O
disease 	 O 	O
virus 	 O 	O
in 	 O 	O
chickens 	 O 	O
displayed 	 O 	O
increased 	 O 	O
agglutinability 	 O 	O
and 	 O 	O
haemadsorption 	 O 	O
when 	 O 	O
incubated 	 O 	O
with 	 O 	O
Con 	 O 	DISEASE
A. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
white 	 O 	O
pulp 	 O 	O
is 	 O 	O
an 	 O 	O
area 	 O 	O
enclosed 	 O 	O
by 	 O 	O
fibrous 	 O 	DISEASE
septae 	 O 	O
, 	 O 	O
containing 	 O 	O
lymphocytes 	 O 	O
, 	 O 	O
reticular 	 O 	O
cells 	 O 	O
and 	 O 	O
arterioles 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
98 	 O 	O
had 	 O 	O
gastric 	 O 	O
carcinoma 	 O 	O
. 	 O 	O
Seventy 	 O 	O
- 	 O 	O
seven 	 O 	O
patients 	 O 	O
had 	 O 	O
esophageal 	 O 	O
carcinoma 	 O 	O
, 	 O 	O
25 	 O 	O
had 	 O 	O
pulmonary 	 O 	O
carcinoma 	 DISEASE 	O
obstructing 	 O 	O
the 	 O 	O
esophagus 	 O 	O
, 	 O 	O
and 	 O 	O
98 	 O 	O
had 	 O 	O
gastric 	 O 	O
carcinoma 	 O 	O
. 	 O 	O
Seventy 	 O 	O
- 	 O 	O
seven 	 O 	O
patients 	 O 	O
had 	 O 	O
esophageal 	 O 	O
carcinoma 	 O 	O
, 	 O 	O
25 	 O 	O
had 	 O 	O
pulmonary 	 O 	O
carcinoma 	 O 	O
obstructing 	 O 	O
the 	 O 	O
esophagus 	 O 	O
, 	 O 	O
and 	 O 	O
98 	 O 	O
had 	 O 	O
gastric 	 DISEASE 	DISEASE
carcinoma 	 DISEASE 	DISEASE
. 	 O 	O
- 	 O 	O
old 	 O 	O
cotton 	 O 	O
rats 	 O 	O
. 	 O 	O
Bulgarian 	 O 	O
strains 	 O 	O
of 	 O 	O
enterovirus 	 O 	O
71 	 O 	O
regularly 	 O 	O
caused 	 O 	O
paralysis 	 O 	O
in 	 O 	O
monkeys 	 O 	O
and 	 O 	O
morphological 	 O 	O
poliomyelitis 	 O 	O
- 	 O 	O
like 	 O 	O
lesions 	 O 	O
in 	 O 	O
their 	 O 	O
CNS 	 O 	O
, 	 O 	O
and 	 O 	O
paralysis 	 O 	O
and 	 O 	O
myositis 	 DISEASE 	O
with 	 O 	O
Zenker 	 O 	O
necrosis 	 O 	O
in 	 O 	O
newborn 	 O 	O
white 	 O 	O
mice 	 O 	O
, 	 O 	O
cotton 	 O 	O
rats 	 O 	O
, 	 O 	O
Syrian 	 O 	O
hamsters 	 O 	O
, 	 O 	O
and 	 O 	O
3-week 	 O 	O
- 	 O 	O
old 	 O 	O
cotton 	 O 	O
rats 	 O 	O
. 	 O 	O
The 	 O 	O
platelet 	 O 	O
count 	 O 	O
, 	 O 	O
Owren 	 O 	O
's 	 O 	O
P&P 	 O 	O
( 	 O 	O
prothrombin 	 O 	O
plus 	 O 	O
factors 	 O 	O
VII 	 O 	O
and 	 O 	O
X 	 O 	O
) 	 O 	O
, 	 O 	O
plasminogen 	 O 	O
, 	 O 	O
factor 	 O 	O
XIII 	 O 	DISEASE
, 	 O 	O
and 	 O 	O
antithrombin 	 O 	O
III 	 O 	O
did 	 O 	O
not 	 O 	O
change 	 O 	O
during 	 O 	O
the 	 O 	O
treatment 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
combination 	 O 	O
was 	 O 	O
less 	 O 	O
effective 	 O 	O
than 	 O 	O
prednisone 	 O 	O
alone 	 O 	O
in 	 O 	O
treatment 	 O 	O
of 	 O 	O
active 	 O 	O
symptomatic 	 O 	DISEASE
disease 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Antigenic 	 O 	O
' 	 O 	DISEASE
drift 	 O 	DISEASE
' 	 O 	O
occurs 	 O 	O
more 	 O 	O
frequently 	 O 	O
than 	 O 	O
' 	 O 	O
shift 	 O 	O
' 	 O 	O
and 	 O 	O
involves 	 O 	O
subtle 	 O 	O
changes 	 O 	O
in 	 O 	O
the 	 O 	O
antigenic 	 O 	O
configuration 	 O 	O
of 	 O 	O
HA 	 O 	O
and 	 O 	O
and 	 O 	O
within 	 O 	O
a 	 O 	O
subtype 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Following 	 O 	O
the 	 O 	O
injection 	 O 	O
of 	 O 	O
ACTH 	 O 	O
in 	 O 	O
sodium 	 O 	O
chloride 	 O 	O
solution 	 O 	O
, 	 O 	O
neutrophilia 	 O 	O
, 	 O 	O
monocytosis 	 O 	O
, 	 O 	O
eosinopenia 	 O 	O
, 	 O 	O
and 	 O 	O
lymphopenia 	 DISEASE 	O
occurred 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
H6 	 O 	DISEASE
hepatoma 	 DISEASE 	DISEASE
cells 	 O 	O
contained 	 O 	O
Cu 	 O 	O
- 	 O 	O
Zn 	 O 	O
SD 	 O 	O
activity 	 O 	O
, 	 O 	O
but 	 O 	O
no 	 O 	O
Mn 	 O 	O
SD 	 O 	O
activity 	 O 	O
was 	 O 	O
detectable 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
writers 	 O 	O
present 	 O 	O
the 	 O 	O
case 	 O 	O
of 	 O 	O
a 	 O 	O
small 	 O 	O
girl 	 O 	O
affected 	 O 	O
by 	 O 	O
Larsen 	 O 	DISEASE
's 	 O 	O
syndrome 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Rats 	 O 	O
that 	 O 	O
had 	 O 	O
completely 	 O 	O
recovered 	 O 	O
from 	 O 	O
paralysis 	 O 	DISEASE
did 	 O 	O
not 	 O 	O
have 	 O 	O
any 	 O 	O
increased 	 O 	O
permeability 	 O 	O
in 	 O 	O
the 	 O 	O
central 	 O 	O
nervous 	 O 	O
system 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
We 	 O 	O
present 	 O 	O
the 	 O 	O
ocular 	 O 	O
manifestations 	 O 	O
in 	 O 	O
a 	 O 	O
series 	 O 	O
of 	 O 	O
37 	 O 	O
hemizygous 	 O 	O
male 	 O 	O
and 	 O 	O
25 	 O 	O
heterozygous 	 O 	O
female 	 O 	O
patients 	 O 	O
with 	 O 	O
Fabry 	 DISEASE 	DISEASE
's 	 DISEASE 	O
disease 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
HBs 	 O 	O
indicates 	 O 	O
that 	 O 	O
the 	 O 	O
infection 	 O 	O
has 	 O 	O
been 	 O 	O
overcome 	 O 	O
. 	 O 	O
The 	 O 	O
demonstration 	 O 	O
of 	 O 	O
HBs 	 O 	O
- 	 O 	O
Ag 	 O 	O
and 	 O 	O
the 	 O 	O
specific 	 O 	O
DNA 	 O 	O
polymerase 	 O 	O
in 	 O 	O
the 	 O 	O
serum 	 O 	O
indicate 	 O 	O
a 	 O 	O
hepatitis 	 O 	O
b 	 O 	O
virus 	 DISEASE 	DISEASE
infection 	 DISEASE 	O
with 	 O 	O
persistent 	 O 	O
reproduction 	 O 	O
of 	 O 	O
the 	 O 	O
agent 	 O 	O
, 	 O 	O
while 	 O 	O
demonstration 	 O 	O
of 	 O 	O
anti 	 O 	O
- 	 O 	O
HBs 	 O 	O
indicates 	 O 	O
that 	 O 	O
the 	 O 	O
infection 	 O 	O
has 	 O 	O
been 	 O 	O
overcome 	 O 	O
. 	 O 	O
Chronic 	 O 	O
adenovirus 	 O 	O
infection 	 O 	O
lacking 	 O 	O
the 	 O 	O
usual 	 O 	O
clinical 	 O 	O
picture 	 O 	O
of 	 O 	O
an 	 O 	O
acute 	 O 	O
follicular 	 O 	DISEASE
reaction 	 O 	O
has 	 O 	O
not 	 O 	O
hitherto 	 O 	O
been 	 O 	O
described 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Such 	 O 	O
antibodies 	 O 	O
may 	 O 	O
cause 	 O 	O
unresponsiveness 	 O 	O
to 	 O 	O
TSH 	 O 	O
stimulation 	 O 	O
, 	 O 	O
hypothyroidism 	 DISEASE 	DISEASE
, 	 O 	O
and 	 O 	O
, 	 O 	O
if 	 O 	O
this 	 O 	O
state 	 O 	O
persists 	 O 	O
for 	 O 	O
a 	 O 	O
long 	 O 	O
time 	 O 	O
, 	 O 	O
eventually 	 O 	O
may 	 O 	O
result 	 O 	O
in 	 O 	O
atrophy 	 O 	DISEASE
of 	 O 	O
the 	 O 	O
thyroid 	 O 	O
tissue 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
This 	 O 	O
inbred 	 O 	O
rat 	 O 	O
myelogenous 	 O 	O
leukemia 	 DISEASE 	O
should 	 O 	O
provide 	 O 	O
a 	 O 	O
useful 	 O 	O
model 	 O 	O
for 	 O 	O
studies 	 O 	O
of 	 O 	O
chemotherapy 	 O 	O
and 	 O 	O
immunoltherapy 	 O 	O
of 	 O 	O
human 	 O 	O
acute 	 O 	O
myelogenous 	 O 	O
leukemia 	 O 	O
. 	 O 	O
This 	 O 	O
inbred 	 O 	O
rat 	 O 	O
myelogenous 	 O 	O
leukemia 	 O 	O
should 	 O 	O
provide 	 O 	O
a 	 O 	O
useful 	 O 	O
model 	 O 	O
for 	 O 	O
studies 	 O 	O
of 	 O 	O
chemotherapy 	 O 	O
and 	 O 	O
immunoltherapy 	 O 	O
of 	 O 	O
human 	 O 	O
acute 	 DISEASE 	DISEASE
myelogenous 	 DISEASE 	DISEASE
leukemia 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
hypertension 	 O 	O
developed 	 O 	O
during 	 O 	O
the 	 O 	O
fat 	 O 	O
infusion 	 O 	O
without 	 O 	O
pneumonia 	 DISEASE 	O
, 	 O 	O
congestive 	 O 	O
heart 	 O 	DISEASE
failure 	 O 	O
or 	 O 	O
pulmonary 	 O 	DISEASE
edema 	 O 	O
. 	 O 	O
Pulmonary 	 O 	O
hypertension 	 O 	O
developed 	 O 	O
during 	 O 	O
the 	 O 	O
fat 	 O 	O
infusion 	 O 	O
without 	 O 	O
pneumonia 	 O 	O
, 	 O 	O
congestive 	 DISEASE 	O
heart 	 DISEASE 	DISEASE
failure 	 DISEASE 	O
or 	 O 	O
pulmonary 	 O 	DISEASE
edema 	 O 	O
. 	 O 	O
Pulmonary 	 O 	O
hypertension 	 O 	O
developed 	 O 	O
during 	 O 	O
the 	 O 	O
fat 	 O 	O
infusion 	 O 	O
without 	 O 	O
pneumonia 	 O 	O
, 	 O 	O
congestive 	 O 	O
heart 	 O 	O
failure 	 O 	O
or 	 O 	O
pulmonary 	 DISEASE 	DISEASE
edema 	 DISEASE 	DISEASE
. 	 O 	O
clinical 	 O 	O
feature 	 O 	O
was 	 O 	O
present 	 O 	O
; 	 O 	O
these 	 O 	O
respectively 	 O 	O
were 	 O 	O
hypertension 	 DISEASE 	DISEASE
, 	 O 	O
osteoporosis 	 O 	O
and 	 O 	O
obesity 	 O 	O
. 	 O 	O
In 	 O 	O
each 	 O 	O
only 	 O 	O
one 	 O 	O
clinical 	 O 	O
feature 	 O 	O
was 	 O 	O
present 	 O 	O
; 	 O 	O
these 	 O 	O
respectively 	 O 	O
were 	 O 	O
hypertension 	 O 	O
, 	 O 	O
osteoporosis 	 DISEASE 	O
and 	 O 	O
obesity 	 O 	O
. 	 O 	O
In 	 O 	O
each 	 O 	O
only 	 O 	O
one 	 O 	O
clinical 	 O 	O
feature 	 O 	O
was 	 O 	O
present 	 O 	O
; 	 O 	O
these 	 O 	O
respectively 	 O 	O
were 	 O 	O
hypertension 	 O 	O
, 	 O 	O
osteoporosis 	 O 	DISEASE
and 	 O 	O
obesity 	 DISEASE 	DISEASE
. 	 O 	O
There 	 O 	O
are 	 O 	O
many 	 O 	O
questions 	 O 	O
that 	 O 	O
have 	 O 	O
to 	 O 	O
be 	 O 	O
answered 	 O 	O
concerning 	 O 	O
the 	 O 	O
role 	 O 	O
of 	 O 	O
radiotherapy 	 O 	O
in 	 O 	O
the 	 O 	O
management 	 O 	O
of 	 O 	O
primary 	 DISEASE 	O
breast 	 DISEASE 	DISEASE
cancer 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
We 	 O 	O
doubt 	 O 	DISEASE
if 	 O 	O
we 	 O 	O
could 	 O 	O
give 	 O 	O
the 	 O 	O
naturally 	 O 	O
nervous 	 O 	O
baby 	 O 	O
who 	 O 	O
is 	 O 	O
a 	 O 	O
difficult 	 O 	O
feeder 	 O 	O
30 	 O 	O
- 	 O 	O
60 	 O 	O
mg 	 O 	O
of 	 O 	O
chloral 	 O 	O
hydrate 	 O 	O
as 	 O 	O
he 	 O 	O
suggests 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Although 	 O 	O
its 	 O 	O
pathogenesis 	 O 	O
has 	 O 	O
been 	 O 	O
debated 	 O 	O
, 	 O 	O
it 	 O 	O
is 	 O 	O
probably 	 O 	O
a 	 O 	O
type 	 O 	O
of 	 O 	O
fibrous 	 DISEASE 	O
histiocytoma 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
effect 	 O 	O
of 	 O 	O
mengovirus 	 O 	DISEASE
infection 	 O 	DISEASE
on 	 O 	O
the 	 O 	O
extent 	 O 	O
of 	 O 	O
phosphorylation 	 O 	O
of 	 O 	O
histone 	 O 	O
H1 	 O 	O
was 	 O 	O
studied 	 O 	O
in 	 O 	O
Ehrlich 	 O 	O
ascites 	 O 	O
tumor 	 O 	O
cells 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
Workshop 	 O 	O
on 	 O 	O
Receptor 	 O 	O
Assay 	 O 	O
in 	 O 	O
Breast 	 DISEASE 	O
Cancer 	 DISEASE 	O
Tissue 	 O 	O
at 	 O 	O
the 	 O 	O
Fourth 	 O 	O
International 	 O 	O
Congress 	 O 	O
on 	 O 	O
Hormonal 	 O 	O
Steroids 	 O 	O
was 	 O 	O
held 	 O 	O
in 	 O 	O
Mexico 	 O 	O
City 	 O 	O
, 	 O 	O
September 	 O 	O
2 	 O 	O
- 	 O 	O
7 	 O 	O
, 	 O 	O
1974 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Clinical 	 O 	O
, 	 O 	O
ECG 	 O 	O
and 	 O 	O
X 	 O 	O
- 	 O 	O
ray 	 O 	O
data 	 O 	O
as 	 O 	O
well 	 O 	O
as 	 O 	O
catheterizational 	 O 	O
and 	 O 	O
angiographic 	 O 	O
data 	 O 	O
on 	 O 	O
20 	 O 	O
patients 	 O 	O
with 	 O 	O
idiopathic 	 O 	O
hypertrophic 	 O 	O
subaortic 	 O 	O
stenosis 	 O 	DISEASE
were 	 O 	O
analysed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Pain 	 O 	O
, 	 O 	O
weakness 	 O 	O
, 	 O 	O
or 	 O 	O
paralysis 	 O 	O
from 	 O 	O
involvement 	 O 	O
of 	 O 	O
the 	 O 	O
spinal 	 O 	O
cord 	 O 	O
and 	 O 	O
nerve 	 O 	O
roots 	 O 	O
secondary 	 O 	O
to 	 O 	O
invasion 	 O 	O
of 	 O 	O
the 	 O 	O
vertebrae 	 O 	O
by 	 O 	O
a 	 O 	O
malignant 	 DISEASE 	DISEASE
tumor 	 DISEASE 	O
often 	 O 	O
can 	 O 	O
be 	 O 	O
avoided 	 O 	O
or 	 O 	O
alleviated 	 O 	O
by 	 O 	O
stabilization 	 O 	O
of 	 O 	O
the 	 O 	O
spine 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
fibroblasts 	 O 	O
from 	 O 	O
patients 	 O 	O
with 	 O 	O
Niemann 	 O 	DISEASE
- 	 O 	O
Pick 	 O 	DISEASE
diseases 	 O 	O
types 	 O 	O
A 	 O 	O
, 	 O 	O
B 	 O 	O
and 	 O 	O
C 	 O 	O
, 	 O 	O
acid 	 O 	O
phosphodiesterase 	 O 	O
activity 	 O 	O
was 	 O 	O
deficient 	 O 	O
whereas 	 O 	O
neutral 	 O 	O
activity 	 O 	O
was 	 O 	O
normal 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
histogenesis 	 O 	O
of 	 O 	O
mixed 	 O 	O
mesodermal 	 O 	O
tumor 	 O 	O
was 	 O 	O
discussed 	 O 	O
and 	 O 	O
it 	 O 	O
was 	 O 	O
concluded 	 O 	O
that 	 O 	O
the 	 O 	O
tumor 	 O 	O
might 	 O 	O
be 	 O 	O
derived 	 O 	O
from 	 O 	O
endometrial 	 O 	DISEASE
stromal 	 O 	O
cell 	 O 	O
which 	 O 	O
possessed 	 O 	O
the 	 O 	O
pluripotency 	 O 	O
to 	 O 	O
differentiate 	 O 	O
toward 	 O 	O
various 	 O 	O
epithelial 	 O 	O
and 	 O 	O
mesenchymal 	 O 	O
tissues 	 O 	O
including 	 O 	O
the 	 O 	O
heterologous 	 O 	O
mesenchymal 	 O 	O
tissue 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Bullet 	 O 	O
velocities 	 O 	O
at 	 O 	O
impact 	 O 	O
and 	 O 	O
exit 	 O 	DISEASE
were 	 O 	O
measured 	 O 	O
and 	 O 	O
transfer 	 O 	O
of 	 O 	O
energy 	 O 	O
to 	 O 	O
liver 	 O 	O
tissue 	 O 	O
calculated 	 O 	O
when 	 O 	O
feasible 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
possible 	 O 	O
role 	 O 	O
of 	 O 	O
bacterial 	 O 	DISEASE
lipids 	 O 	O
and 	 O 	O
lyso 	 O 	O
compounds 	 O 	O
in 	 O 	O
the 	 O 	O
control 	 O 	O
of 	 O 	O
bacterial 	 O 	DISEASE
survival 	 O 	O
in 	 O 	O
inflammatory 	 O 	O
sites 	 O 	O
is 	 O 	O
briefly 	 O 	O
discussed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
incomplete 	 O 	O
	PUNCT	O
21599	tubal	ADJ	O
21599	operations	NOUN	O
21599	and	CCONJ	O
21599	who	NOUN	O
21599	,	PUNCT	O
21599	because	ADP	O
21599	of	ADP	O
21599	pelvic	ADJ	O
21599	abnormalities	NOUN	O
21599	,	PUNCT	O
21599	required	VERB	O
21599	a	DET	O
21599	subsequent	ADJ	O
21599	definitive	ADJ	O
21599	gynecologic	ADJ	O
21599	operation	NOUN	O
21599	.	PUNCT	O
21600	The	DET	O
21600	patients	NOUN	O
21600	had	VERB	O
21600	originally	ADV	O
21600	undergone	VERB	O
21600	:	PUNCT	O
21600	1	PUNCT	O
21600	)	PUNCT	O
21600	bilateral	ADJ	O
21600	salpingectomy	NOUN	O
21600	(	PUNCT	O
21600	i.e.	X	O
21600	,	PUNCT	O
21600	removal	NOUN	O
21600	of	ADP	O
21600	both	DET	O
21600	tubes	NOUN	O
21600	and	CCONJ	O
21600	,	PUNCT	O
21600	in	ADP	O
21600	some	DET	O
21600	case	NOUN	O
21600	of	ADP	O
21600	both	DET	O
21600	ovaries	NOUN	O
21600	,	PUNCT	O
21600	but	CCONJ	O
21600	not	ADV	O
21600	of	ADP	O
21600	the	DET	O
21600	uterus	NOUN	O
21600	)	PUNCT	O
21600	;	PUNCT	O
21600	 	SPACE	O
21600	2	NUM	O
21600	)	PUNCT	O
21600	bilateral	ADJ	O
21600	tubal	ADJ	O
21600	ligation	NOUN	O
21600	in	ADP	O
21600	conjunction	NOUN	O
21600	with	ADP	O
21600	uterine	ADJ	O
21600	suspension	NOUN	O
21600	to	ADP	O
21600	the	DET	O
21600	abdominal	ADJ	O
21600	wall	NOUN	O
21600	;	PUNCT	O
21600	 	SPACE	O
21600	and	CCONJ	O
21600	3	PUNCT	O
21600	)	PUNCT	O
21600	bilateral	ADJ	O
21600	tubal	ADJ	O
21600	ligation	NOUN	O
21600	as	ADP	O
21600	a	DET	O
21600	method	NOUN	O
21600	of	ADP	O
21600	sterilization	NOUN	O
21600	.	PUNCT	O
21601	Symptoms	NOUN	O
21601	(	PUNCT	O
21601	pain	NOUN	O
21601	,	PUNCT	O
21601	bleeding	NOUN	O
21601	,	PUNCT	O
21601	or	CCONJ	O
21601	dysfunction	NOUN	O
21601	)	PUNCT	O
21601	,	PUNCT	O
21601	abnormal	ADJ	O
21601	pelvic	ADJ	O
21601	findings	NOUN	O
21601	,	PUNCT	O
21601	and	CCONJ	O
21601	biopsy	NOUN	O
21601	and	CCONJ	O
21601	curettage	NOUN	O
21601	indicated	VERB	O
21601	the	DET	O
21601	necessity	NOUN	O
21601	for	ADP	O
21601	definitive	ADJ	O
21601	operations	NOUN	O
21601	.	PUNCT	O
21602	Symptoms	NOUN	O
21602	,	PUNCT	O
21602	physical	ADJ	O
21602	findings	NOUN	O
21602	at	ADP	O
21602	the	DET	O
21602	subsequent	ADJ	O
21602	operation	NOUN	O
21602	,	PUNCT	O
21602	and	CCONJ	O
21602	operative	ADJ	O
21602	procedures	NOUN	O
21602	for	ADP	O
21602	the	DET	O
21602	subsequent	ADJ	O
21602	operation	NOUN	O
21602	are	VERB	O
21602	tabulated	VERB	O
21602	for	ADP	O
21602	each	DET	O
21602	of	ADP	O
21602	the	DET	O
21602	3	NUM	O
21602	groups	NOUN	O
21602	of	ADP	O
21602	patients	NOUN	O
21602	.	PUNCT	O
21603	Statistics	NOUN	O
21603	from	ADP	O
21603	this	DET	O
21603	study	NOUN	O
21603	show	VERB	O
21603	that	ADP	O
21603	the	DET	O
21603	retained	VERB	O
21603	uterus	NOUN	O
21603	and	CCONJ	O
21603	cervix	NOUN	O
21603	are	VERB	O
21603	the	DET	O
21603	most	ADV	O
21603	common	ADJ	O
21603	sites	NOUN	O
21603	for	ADP	O
21603	future	ADJ	O
21603	abnormalities	NOUN	O
21603	.	PUNCT	O
21604	Report	NOUN	O
21604	on	ADP	O
21604	301	NUM	O
21604	radiographs	NOUN	O
21604	of	ADP	O
21604	the	DET	O
21604	paranasal	NOUN	O
21604	sinuses	NOUN	O
21604	of	ADP	O
21604	cleft	ADJ	O
21604	patients	NOUN	O
21604	and	CCONJ	O
21604	on	ADP	O
21604	120	NUM	O
21604	radiographs	NOUN	O
21604	of	ADP	O
21604	the	DET	O
21604	paranasal	NOUN	O
21604	sinuses	NOUN	O
21604	of	ADP	O
21604	subjects	NOUN	O
21604	from	ADP	O
21604	a	DET	O
21604	control	NOUN	O
21604	group	NOUN	O
21604	to	PART	O
21604	illustrate	VERB	O
21604	the	DET	O
21604	development	NOUN	O
21604	of	ADP	O
21604	the	DET	O
21604	maxillary	ADJ	O
21604	and	CCONJ	O
21604	frontal	ADJ	O
21604	sinuses	NOUN	O
21604	.	PUNCT	O
21605	In	ADP	O
21605	female	ADJ	O
21605	individuals	NOUN	O
21605	as	ADV	O
21605	well	ADV	O
21605	as	ADP	O
21605	in	ADP	O
21605	male	ADJ	O
21605	ones	NOUN	O
21605	,	PUNCT	O
21605	the	DET	O
21605	maxillary	ADJ	O
21605	sinuses	NOUN	O
21605	on	ADP	O
21605	the	DET	O
21605	left	ADJ	O
21605	side	NOUN	O
21605	are	VERB	O
21605	greater	ADJ	O
21605	than	ADP	O
21605	those	DET	O
21605	on	ADP	O
21605	the	DET	O
21605	right	ADJ	O
21605	side	NOUN	O
21605	.	PUNCT	O
21606	Aplasia	PROPN	O
21606	of	ADP	O
21606	the	DET	O
21606	frontal	ADJ	O
21606	sinuses	NOUN	O
21606	on	ADP	O
21606	the	DET	O
21606	right	ADJ	O
21606	side	NOUN	O
21606	was	VERB	O
21606	observed	VERB	O
21606	in	ADP	O
21606	11.7	NUM	O
21606	%	NOUN	O
21606	;	PUNCT	O
21606	aplasia	NOUN	O
21606	of	ADP	O
21606	those	DET	O
21606	on	ADP	O
21606	the	DET	O
21606	left	ADJ	O
21606	side	NOUN	O
21606	,	PUNCT	O
21606	in	ADP	O
21606	3.3	NUM	O
21606	%	NOUN	O
21606	.	PUNCT	O
21607	The	DET	O
21607	maxillary	ADJ	O
21607	sinuses	NOUN	O
21607	on	ADP	O
21607	the	DET	O
21607	side	NOUN	O
21607	of	ADP	O
21607	the	DET	O
21607	cleft	NOUN	O
21607	are	VERB	O
21607	greater	ADJ	O
21607	than	ADP	O
21607	those	DET	O
21607	on	ADP	O
21607	the	DET	O
21607	opposite	ADJ	O
21607	side	NOUN	O
21607	.	PUNCT	O
21608	In	ADP	O
21608	patients	NOUN	O
21608	with	ADP	O
21608	clefts	NOUN	O
21608	of	ADP	O
21608	the	DET	O
21608	secondary	ADJ	O
21608	palate	NOUN	O
21608	,	PUNCT	O
21608	the	DET	O
21608	maxillary	ADJ	O
21608	sinuses	NOUN	O
21608	are	VERB	O
21608	significantly	ADV	O
21608	greater	ADJ	O
21608	than	ADP	O
21608	in	ADP	O
21608	patients	NOUN	O
21608	with	ADP	O
21608	clefts	NOUN	O
21608	of	ADP	O
21608	the	DET	O
21608	primary	ADJ	O
21608	palate	NOUN	O
21608	or	CCONJ	O
21608	with	ADP	O
21608	subtotal	ADJ	O
21608	or	CCONJ	O
21608	total	ADJ	O
21608	clefts	NOUN	O
21608	of	ADP	O
21608	the	DET	O
21608	secondary	ADJ	O
21608	palate	NOUN	O
21608	.	PUNCT	O
21609	Aplasia	PROPN	O
21609	of	ADP	O
21609	the	DET	O
21609	frontal	ADJ	O
21609	sinuses	NOUN	O
21609	on	ADP	O
21609	the	DET	O
21609	right	ADJ	O
21609	side	NOUN	O
21609	was	VERB	O
21609	seen	VERB	O
21609	in	ADP	O
21609	11	NUM	O
21609	%	NOUN	O
21609	;	PUNCT	O
21609	aplasia	NOUN	O
21609	of	ADP	O
21609	those	DET	O
21609	on	ADP	O
21609	the	DET	O
21609	left	ADJ	O
21609	side	NOUN	O
21609	,	PUNCT	O
21609	in	ADP	O
21609	6	NUM	O
21609	%	NOUN	O
21609	.	PUNCT	O
21610	Clusters	NOUN	O
21610	of	ADP	O
21610	cells	NOUN	O
21610	in	ADP	O
21610	cytologic	ADJ	O
21610	preparations	NOUN	O
21610	from	ADP	O
21610	the	DET	O
21610	urinary	ADJ	O
21610	tract	NOUN	O
21610	have	VERB	O
21610	been	VERB	O
21610	commented	VERB	O
21610	on	ADP	O
21610	repeatedly	ADV	O
21610	.	PUNCT	O
21611	To	PART	O
21611	determine	VERB	O
21611	their	ADJ	O
21611	significance	NOUN	O
21611	we	PRON	O
21611	studied	VERB	O
21611	88	NUM	O
21611	patients	NOUN	O
21611	with	ADP	O
21611	documented	VERB	O
21611	papillary	ADJ	O
21611	carcinomas	NOUN	O
21611	,	PUNCT	O
21611	Grades	PROPN	O
21611	I	PROPN	O
21611	-	PUNCT	O
21611	IV	PROPN	O
21611	,	PUNCT	O
21611	who	NOUN	O
21611	had	VERB	O
21611	cytologic	ADJ	O
21611	examination	NOUN	O
21611	of	ADP	O
21611	their	ADJ	O
21611	urine	NOUN	O
21611	.	PUNCT	O
21612	We	PRON	O
21612	defined	VERB	O
21612	two	NUM	O
21612	distinct	ADJ	O
21612	cluster	NOUN	O
21612	types	NOUN	O
21612	,	PUNCT	O
21612	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Most 	 O 	O
pyoderma 	 DISEASE 	O
- 	 O 	O
associated 	 O 	O
C. 	 O 	O
diphtheriae 	 O 	O
isolates 	 O 	O
were 	 O 	O
non 	 O 	O
- 	 O 	O
toxigenic 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
observed 	 O 	O
in 	 O 	O
blood 	 O 	O
samples 	 O 	O
from 	 O 	O
patients 	 O 	O
who 	 O 	O
had 	 O 	O
congenital 	 O 	O
or 	 O 	O
acquired 	 O 	O
abnormalities 	 O 	O
of 	 O 	O
the 	 O 	O
thymus 	 O 	O
, 	 O 	O
severe 	 DISEASE 	O
combined 	 DISEASE 	O
immunodeficiency 	 DISEASE 	O
, 	 O 	O
or 	 O 	O
an 	 O 	O
unexplained 	 O 	O
primary 	 O 	DISEASE
deficiency 	 O 	O
in 	 O 	O
cell 	 O 	O
- 	 O 	O
mediated 	 O 	O
immunity 	 O 	O
; 	 O 	O
most 	 O 	O
had 	 O 	O
too 	 O 	O
few 	 O 	O
circulating 	 O 	O
T 	 O 	O
- 	 O 	O
M 	 O 	O
cells 	 O 	O
and 	 O 	O
often 	 O 	O
an 	 O 	O
overabundance 	 O 	O
of 	 O 	O
T 	 O 	O
- 	 O 	O
G 	 O 	O
cells 	 O 	O
. 	 O 	O
A 	 O 	O
study 	 O 	O
was 	 O 	O
made 	 O 	O
of 	 O 	O
the 	 O 	O
in 	 O 	O
vitro 	 O 	O
effects 	 O 	O
of 	 O 	O
the 	 O 	O
abnormal 	 O 	O
serum 	 O 	O
lipoproteins 	 O 	O
associated 	 O 	O
with 	 O 	O
liver 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
on 	 O 	O
the 	 O 	O
activity 	 O 	O
of 	 O 	O
the 	 O 	O
enzyme 	 O 	O
lecithin 	 O 	O
: 	 O 	O
cholesterol 	 O 	O
acyltransferase 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
lactate 	 O 	O
ion 	 O 	O
in 	 O 	O
excess 	 O 	O
( 	 O 	O
5 	 O 	O
- 	 O 	O
-40 	 O 	O
mM 	 O 	O
, 	 O 	O
pH 	 O 	O
7.4 	 O 	O
) 	 O 	O
, 	 O 	O
calcium 	 O 	O
( 	 O 	O
50 	 O 	O
- 	 O 	O
-270 	 O 	O
nmol 	 O 	O
/ 	 O 	O
mg 	 O 	O
protein 	 O 	O
) 	 O 	O
, 	 O 	O
to 	 O 	O
lactic 	 DISEASE 	O
acidosis 	 DISEASE 	O
( 	 O 	O
pH 	 O 	O
6.3 	 O 	O
) 	 O 	O
, 	 O 	O
and 	 O 	O
to 	 O 	O
mitochondrial 	 O 	O
protein 	 O 	O
dilution 	 O 	O
( 	 O 	O
in 	 O 	O
vitro 	 O 	O
volume 	 O 	O
expansion 	 O 	O
) 	 O 	O
for 	 O 	O
10 	 O 	O
min 	 O 	O
to 	 O 	O
8 	 O 	O
h. 	 O 	O
Chronic 	 O 	O
Glomerulo 	 O 	O
- 	 O 	O
Nephritis 	 DISEASE 	O
( 	 O 	O
GN 	 O 	O
) 	 O 	O
are 	 O 	O
among 	 O 	O
nephrologic 	 O 	O
diseases 	 O 	O
, 	 O 	O
frequent 	 O 	O
and 	 O 	O
severe 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
twenty 	 O 	O
with 	 O 	O
Crohn 	 O 	DISEASE
's 	 O 	O
disease 	 O 	O
required 	 O 	O
rectal 	 O 	O
excision 	 O 	O
for 	 O 	O
complications 	 O 	O
apparently 	 O 	O
dating 	 O 	O
from 	 O 	O
the 	 O 	O
treatment 	 O 	O
of 	 O 	O
haemorrhoids 	 O 	O
. 	 O 	O
One 	 O 	O
of 	 O 	O
the 	 O 	O
forty 	 O 	O
- 	 O 	O
two 	 O 	O
patients 	 O 	O
with 	 O 	O
ulcerative 	 O 	O
colitis 	 O 	O
and 	 O 	O
six 	 O 	O
of 	 O 	O
the 	 O 	O
twenty 	 O 	O
with 	 O 	O
Crohn 	 DISEASE 	DISEASE
's 	 DISEASE 	DISEASE
disease 	 DISEASE 	DISEASE
required 	 O 	O
rectal 	 O 	O
excision 	 O 	O
for 	 O 	O
complications 	 O 	O
apparently 	 O 	O
dating 	 O 	O
from 	 O 	O
the 	 O 	O
treatment 	 O 	O
of 	 O 	O
haemorrhoids 	 O 	O
. 	 O 	O
This 	 O 	O
finding 	 O 	O
indicates 	 O 	O
that 	 O 	O
urinary 	 O 	O
pemphigoid 	 O 	DISEASE
antigen 	 O 	O
may 	 O 	O
exist 	 O 	O
both 	 O 	O
as 	 O 	O
a 	 O 	O
single 	 O 	O
monomeric 	 O 	O
form 	 O 	O
and 	 O 	O
in 	 O 	O
polymeric 	 O 	O
aggregates 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
These 	 O 	O
data 	 O 	O
suggest 	 O 	O
that 	 O 	O
formation 	 O 	O
of 	 O 	O
an 	 O 	O
enamine 	 O 	O
of 	 O 	O
possibly 	 O 	O
1 	 O 	O
, 	 O 	O
and 	 O 	O
certainly 	 O 	DISEASE
no 	 O 	O
more 	 O 	O
than 	 O 	O
3 	 O 	O
, 	 O 	O
lysine 	 O 	O
residue(s 	 O 	O
) 	 O 	O
in 	 O 	O
the 	 O 	O
catalytic 	 O 	O
center 	 O 	O
of 	 O 	O
the 	 O 	O
enzyme 	 O 	O
is 	 O 	O
responsible 	 O 	O
for 	 O 	O
inactivation 	 O 	O
by 	 O 	O
2,4-pentanedione 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
another 	 O 	O
reported 	 O 	O
group 	 O 	O
of 	 O 	O
65 	 O 	O
patients 	 O 	O
with 	 O 	O
intraductal 	 O 	O
carcinoma 	 DISEASE 	O
only 	 O 	O
, 	 O 	O
there 	 O 	O
were 	 O 	O
no 	 O 	O
deaths 	 O 	O
due 	 O 	O
to 	 O 	O
breast 	 O 	O
cancer 	 O 	O
in 	 O 	O
10 	 O 	O
years 	 O 	O
. 	 O 	O
In 	 O 	O
another 	 O 	O
reported 	 O 	O
group 	 O 	O
of 	 O 	O
65 	 O 	O
patients 	 O 	O
with 	 O 	O
intraductal 	 O 	O
carcinoma 	 O 	O
only 	 O 	O
, 	 O 	O
there 	 O 	O
were 	 O 	O
no 	 O 	O
deaths 	 O 	O
due 	 O 	O
to 	 O 	O
breast 	 DISEASE 	DISEASE
cancer 	 DISEASE 	DISEASE
in 	 O 	O
10 	 O 	O
years 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
To 	 O 	O
evaluate 	 O 	O
the 	 O 	O
possibility 	 O 	O
that 	 O 	O
the 	 O 	O
phosphate 	 O 	O
wasting 	 O 	O
was 	 O 	O
caused 	 O 	O
by 	 O 	O
an 	 O 	O
intrinsic 	 O 	O
tubular 	 O 	O
defect 	 O 	DISEASE
that 	 O 	O
was 	 O 	O
masked 	 O 	O
by 	 O 	O
TPTX 	 O 	O
, 	 O 	O
glomerular 	 O 	O
fluid 	 O 	O
phosphate 	 O 	O
concentration 	 O 	O
was 	 O 	O
raised 	 O 	O
by 	 O 	O
phosphate 	 O 	O
infusion 	 O 	O
in 	 O 	O
TPTX 	 O 	O
mutants 	 O 	O
to 	 O 	O
levels 	 O 	O
approaching 	 O 	O
those 	 O 	O
of 	 O 	O
control 	 O 	O
mice 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Thus 	 O 	O
, 	 O 	O
these 	 O 	O
studies 	 O 	O
have 	 O 	O
identified 	 O 	O
both 	 O 	O
structural 	 O 	O
and 	 O 	O
functional 	 O 	O
abnormalities 	 O 	O
in 	 O 	O
the 	 O 	O
C1 	 O 	O
inactivator 	 O 	O
protein 	 O 	O
isolated 	 O 	O
from 	 O 	O
two 	 O 	O
related 	 O 	O
patients 	 O 	O
with 	 O 	O
hereditary 	 DISEASE 	O
angioneurotic 	 DISEASE 	DISEASE
edema 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
from 	 O 	O
ten 	 O 	O
patients 	 O 	O
with 	 O 	O
multiple 	 O 	O
sclerosis 	 O 	O
( 	 O 	O
MS 	 O 	O
) 	 O 	O
. 	 O 	O
An 	 O 	O
imprint 	 O 	O
electroimmunofixation 	 O 	O
( 	 O 	O
IEIF 	 O 	O
) 	 O 	O
technique 	 O 	O
was 	 O 	O
used 	 O 	O
to 	 O 	O
study 	 O 	O
measles 	 O 	O
, 	 O 	O
rubella 	 O 	O
, 	 O 	O
mumps 	 O 	O
and 	 O 	O
herpes 	 O 	O
simplex 	 O 	O
virus 	 O 	O
antibodies 	 O 	O
in 	 O 	O
serum 	 O 	O
and 	 O 	O
concentrated 	 O 	O
cerebrospinal 	 O 	O
fluid 	 O 	O
( 	 O 	O
CSF 	 O 	O
) 	 O 	O
from 	 O 	O
ten 	 O 	O
patients 	 O 	O
with 	 O 	O
multiple 	 DISEASE 	O
sclerosis 	 DISEASE 	DISEASE
( 	 O 	O
MS 	 O 	O
) 	 O 	O
. 	 O 	O
This 	 O 	O
report 	 O 	O
describes 	 O 	O
two 	 O 	O
Egyptian 	 O 	O
patients 	 O 	O
who 	 O 	O
presented 	 O 	O
with 	 O 	O
the 	 O 	O
nephrotic 	 DISEASE 	DISEASE
syndrome 	 DISEASE 	O
and 	 O 	O
concurrent 	 O 	O
infections 	 O 	O
with 	 O 	O
Schistosoma 	 O 	O
mansoni 	 O 	O
and 	 O 	O
Salmonella 	 O 	O
paratyphi 	 O 	O
A. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Eleven 	 O 	O
hybridomas 	 O 	O
derived 	 O 	O
from 	 O 	O
spleen 	 O 	O
cells 	 O 	O
of 	 O 	O
mice 	 O 	O
immunized 	 O 	O
with 	 O 	O
influenza 	 DISEASE 	DISEASE
type 	 O 	O
A 	 O 	O
virus 	 O 	O
were 	 O 	O
directed 	 O 	O
against 	 O 	O
the 	 O 	O
viral 	 O 	DISEASE
hemagglutinin 	 O 	O
, 	 O 	O
one 	 O 	O
reacted 	 O 	O
with 	 O 	O
a 	 O 	O
host 	 O 	O
component 	 O 	O
derived 	 O 	O
from 	 O 	O
chickens 	 O 	O
, 	 O 	O
and 	 O 	O
one 	 O 	O
expressed 	 O 	O
a 	 O 	O
specificity 	 O 	O
not 	 O 	O
further 	 O 	O
characterized 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Deformation 	 O 	O
in 	 O 	O
blood 	 O 	DISEASE
composition 	 O 	O
is 	 O 	O
a 	 O 	O
secondary 	 O 	O
sequel 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
all 	 O 	O
cases 	 O 	O
but 	 O 	O
1 	 O 	O
where 	 O 	O
blood 	 O 	O
- 	 O 	O
ethanol 	 O 	O
was 	 O 	O
found 	 O 	O
, 	 O 	O
a 	 O 	O
drinking 	 O 	O
history 	 O 	O
was 	 O 	O
admitted 	 O 	O
on 	 O 	O
first 	 O 	O
attendance 	 O 	O
, 	 O 	O
and 	 O 	O
alcoholic 	 O 	O
liver 	 DISEASE 	O
disease 	 DISEASE 	O
was 	 O 	O
nearly 	 O 	O
always 	 O 	O
found 	 O 	O
on 	 O 	O
subsequent 	 O 	O
biopsy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
Heidelberg 	 O 	O
, 	 O 	O
an 	 O 	O
interdisciplinary 	 O 	O
oncologic 	 O 	O
group 	 O 	O
has 	 O 	O
been 	 O 	O
in 	 O 	O
existence 	 O 	O
since 	 O 	O
1966 	 O 	O
; 	 O 	O
this 	 O 	O
group 	 O 	O
forms 	 O 	O
the 	 O 	O
basis 	 O 	O
of 	 O 	O
a 	 O 	O
tumor 	 O 	O
center 	 O 	O
, 	 O 	O
consisting 	 O 	O
of 	 O 	O
the 	 O 	O
two 	 O 	O
academic 	 O 	O
clinics 	 O 	O
and 	 O 	O
the 	 O 	O
German 	 O 	O
Cancer 	 DISEASE 	O
Research 	 O 	O
Center 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Forty 	 O 	O
- 	 O 	O
two 	 O 	O
patients 	 O 	O
with 	 O 	O
other 	 O 	O
malignant 	 O 	O
and 	 O 	O
25 	 O 	O
patients 	 O 	O
with 	 O 	O
benign 	 O 	O
tumors 	 O 	O
of 	 O 	O
the 	 O 	O
head 	 O 	DISEASE
and 	 O 	O
neck 	 O 	DISEASE
showed 	 O 	O
positive 	 O 	O
rates 	 O 	O
of 	 O 	O
9.5 	 O 	O
% 	 O 	O
and 	 O 	O
8.0 	 O 	O
% 	 O 	O
, 	 O 	O
respectively 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
diagnostic 	 O 	O
significance 	 O 	O
of 	 O 	O
radioisotopic 	 O 	O
angiography 	 O 	O
in 	 O 	O
the 	 O 	O
clinical 	 O 	O
management 	 O 	O
of 	 O 	O
trophoblastic 	 O 	O
neoplasia 	 O 	DISEASE
was 	 O 	O
studied 	 O 	O
by 	 O 	O
analyzing 	 O 	O
the 	 O 	O
patterns 	 O 	O
of 	 O 	O
radioisotope 	 O 	O
( 	 O 	O
RI)-dynamic 	 O 	O
curve 	 O 	O
obtained 	 O 	O
by 	 O 	O
processing 	 O 	O
sequential 	 O 	O
image 	 O 	O
with 	 O 	O
a 	 O 	O
computer 	 O 	O
, 	 O 	O
and 	 O 	O
an 	 O 	O
attempt 	 O 	O
was 	 O 	O
made 	 O 	O
to 	 O 	O
express 	 O 	O
numerically 	 O 	O
the 	 O 	O
size 	 O 	O
of 	 O 	O
tumors 	 O 	O
present 	 O 	O
in 	 O 	O
vivo 	 O 	O
. 	 O 	O
bleached 	 O 	O
Some 	 O 	O
of 	 O 	O
them 	 O 	O
may 	 O 	O
be 	 O 	O
giant 	 O 	DISEASE
lysosomes 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
virion 	 O 	O
- 	 O 	O
associated 	 O 	O
DNA 	 O 	O
polymerase 	 O 	O
of 	 O 	O
SMRV 	 O 	O
can 	 O 	O
be 	 O 	O
clearly 	 O 	O
distinguished 	 O 	O
from 	 O 	O
those 	 O 	O
of 	 O 	O
MPV 	 O 	O
and 	 O 	O
the 	 O 	O
mouse 	 O 	O
mammary 	 DISEASE 	DISEASE
tumor 	 DISEASE 	O
viruses 	 O 	O
, 	 O 	O
however 	 O 	O
, 	 O 	O
by 	 O 	O
its 	 O 	O
preference 	 O 	O
for 	 O 	O
manganese 	 O 	O
as 	 O 	O
a 	 O 	O
divalent 	 O 	O
cation 	 O 	O
in 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
high 	 O 	O
salt 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Nonproductive 	 O 	O
human 	 O 	O
CMV 	 O 	O
  	 O 	DISEASE
infection 	 O 	O
of 	 O 	O
G.P. 	 O 	O
embryo 	 O 	O
cells 	 O 	O
induced 	 O 	O
cellular 	 O 	O
RNA 	 O 	O
and 	 O 	O
DNA 	 O 	O
synthesis 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
An 	 O 	O
automatic 	 O 	O
dual 	 O 	O
- 	 O 	O
demand 	 O 	O
pacemaker 	 O 	O
has 	 O 	O
been 	 O 	O
used 	 O 	O
in 	 O 	O
six 	 O 	O
patients 	 O 	O
to 	 O 	O
treat 	 O 	O
refractory 	 O 	O
attacks 	 O 	O
of 	 O 	O
paroxysmal 	 O 	O
re 	 O 	O
- 	 O 	O
entry 	 O 	O
atrioventricular 	 O 	O
tachycardia 	 O 	O
that 	 O 	O
occurred 	 O 	O
in 	 O 	O
the 	 O 	O
Wolff 	 DISEASE 	O
- 	 DISEASE 	O
Parkinson 	 DISEASE 	O
- 	 DISEASE 	O
White 	 DISEASE 	O
syndrome 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Raw 	 O 	O
was 	 O 	O
almost 	 O 	O
always 	 O 	O
increased 	 O 	O
, 	 O 	O
RV 	 O 	O
sometimes 	 O 	O
, 	 O 	O
helium 	 O 	O
mixing 	 O 	O
time 	 O 	O
was 	 O 	O
prolonged 	 O 	O
only 	 O 	O
in 	 O 	O
presence 	 O 	O
of 	 O 	O
COPD 	 DISEASE 	O
or 	 O 	O
lobar 	 O 	O
stenosis 	 O 	O
; 	 O 	O
pharmacological 	 O 	O
tests 	 O 	O
were 	 O 	O
negative 	 O 	O
in 	 O 	O
3 	 O 	O
out 	 O 	O
of 	 O 	O
4 	 O 	O
cases 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
HC20 	 O 	O
- 	 O 	O
511 	 O 	O
had 	 O 	O
a 	 O 	O
better 	 O 	O
effect 	 O 	O
, 	 O 	O
especially 	 O 	O
in 	 O 	O
chronic 	 O 	DISEASE
urticaria 	 DISEASE 	DISEASE
, 	 O 	O
where 	 O 	O
pruritus 	 O 	O
, 	 O 	O
erythema 	 O 	O
and 	 O 	O
papules 	 O 	O
quickly 	 O 	O
disappeared 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
incidence 	 O 	O
of 	 O 	O
primary 	 O 	O
malignant 	 O 	DISEASE
lymphoma 	 DISEASE 	DISEASE
of 	 DISEASE 	O
the 	 DISEASE 	O
stomach 	 DISEASE 	O
( 	 O 	O
16.6 	 O 	O
% 	 O 	O
) 	 O 	O
is 	 O 	O
much 	 O 	O
higher 	 O 	O
than 	 O 	O
in 	 O 	O
Western 	 O 	O
countries 	 O 	O
but 	 O 	O
is 	 O 	O
in 	 O 	O
accord 	 O 	O
with 	 O 	O
reports 	 O 	O
from 	 O 	O
countries 	 O 	O
in 	 O 	O
the 	 O 	O
Mediterranean 	 O 	DISEASE
basin 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
principal 	 O 	DISEASE
governors 	 O 	O
on 	 O 	O
where 	 O 	O
the 	 O 	O
monooxygen 	 O 	O
phenylalkanes 	 O 	O
kill 	 O 	O
cells 	 O 	O
seems 	 O 	O
to 	 O 	O
be 	 O 	O
merely 	 O 	O
their 	 O 	O
concentration 	 O 	O
or 	 O 	O
chemical 	 O 	O
potential 	 O 	O
, 	 O 	O
the 	 O 	O
number 	 O 	O
of 	 O 	O
aliphatic 	 O 	O
carbons 	 O 	O
, 	 O 	O
and 	 O 	O
the 	 O 	O
binding 	 O 	O
mechanism 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Treacher 	 O 	O
Collins 	 O 	O
Syndrome)--MFD 	 O 	O
-- 	 O 	O
are 	 O 	O
described 	 O 	O
as 	 O 	O
observed 	 O 	O
in 	 O 	O
a 	 O 	O
human 	 O 	O
fetus 	 O 	O
of 	 O 	O
approximately 	 O 	O
15 	 O 	O
weeks 	 O 	O
gestation 	 O 	O
age 	 O 	O
. 	 O 	O
The 	 O 	O
clinical 	 O 	O
, 	 O 	O
radiographic 	 O 	O
, 	 O 	O
and 	 O 	O
histologic 	 O 	O
aspects 	 O 	O
of 	 O 	O
Mandibulofacial 	 O 	O
Dysostosis 	 O 	O
( 	 O 	O
Treacher 	 DISEASE 	O
Collins 	 DISEASE 	O
Syndrome)--MFD 	 DISEASE 	O
-- 	 O 	O
are 	 O 	O
described 	 O 	O
as 	 O 	O
observed 	 O 	O
in 	 O 	O
a 	 O 	O
human 	 O 	O
fetus 	 O 	O
of 	 O 	O
approximately 	 O 	O
15 	 O 	O
weeks 	 O 	O
gestation 	 O 	O
age 	 O 	O
. 	 O 	O
The 	 O 	O
culture 	 O 	O
medium 	 O 	O
from 	 O 	O
the 	 O 	O
AtT-20 	 O 	O
mouse 	 O 	O
pituitary 	 O 	DISEASE
tumor 	 O 	O
cells 	 O 	O
contained 	 O 	O
approximately 	 O 	O
equimolar 	 O 	O
amounts 	 O 	O
of 	 O 	O
ACTH 	 O 	O
- 	 O 	O
related 	 O 	O
peptides 	 O 	O
and 	 O 	O
endorphin 	 O 	O
- 	 O 	O
related 	 O 	O
peptides 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
It 	 O 	O
is 	 O 	O
proposed 	 O 	O
that 	 O 	O
the 	 O 	O
failure 	 O 	O
of 	 O 	O
termination 	 O 	O
of 	 O 	O
HBV 	 O 	O
infection 	 O 	O
revealed 	 O 	O
by 	 O 	O
these 	 O 	O
high 	 O 	O
rates 	 O 	O
reflects 	 O 	DISEASE
an 	 O 	O
immunodeficiency 	 O 	O
state 	 O 	O
characterized 	 O 	O
by 	 O 	O
an 	 O 	O
inability 	 O 	O
to 	 O 	O
produce 	 O 	O
high 	 O 	O
- 	 O 	O
avidity 	 O 	O
HBsAb 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
median 	 O 	O
eminence 	 O 	O
extract 	 O 	O
significantly 	 O 	O
stimulated 	 O 	O
ACTH 	 O 	O
secretion 	 O 	O
and 	 O 	O
increased 	 O 	O
levels 	 O 	O
of 	 O 	O
intracellular 	 O 	O
cAMP 	 O 	O
in 	 O 	O
both 	 O 	O
cell 	 O 	O
preparations 	 O 	O
, 	 O 	O
and 	 O 	O
a 	 O 	O
dose 	 O 	O
- 	 O 	O
response 	 O 	O
relationship 	 O 	O
appeared 	 O 	O
to 	 O 	O
exist 	 O 	O
between 	 O 	O
the 	 O 	O
dose 	 O 	O
of 	 O 	O
rat 	 O 	O
median 	 O 	O
eminence 	 O 	O
extract 	 O 	O
added 	 O 	O
and 	 O 	O
either 	 O 	O
ACTH 	 O 	O
secretion 	 O 	O
or 	 O 	O
intracellular 	 O 	O
cAMP 	 O 	O
formation 	 O 	O
in 	 O 	O
the 	 O 	O
thymic 	 DISEASE 	O
tumor 	 DISEASE 	O
cells 	 O 	O
. 	 O 	O
The 	 O 	O
recurrence 	 O 	O
of 	 O 	O
gastroschisis 	 DISEASE 	O
, 	 O 	O
generally 	 O 	O
considered 	 O 	O
a 	 O 	O
sporadic 	 O 	O
congenital 	 O 	O
effect 	 O 	O
, 	 O 	O
suggests 	 O 	O
that 	 O 	O
the 	 O 	O
condition 	 O 	O
may 	 O 	O
be 	 O 	O
genetic 	 O 	O
in 	 O 	O
nature 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
the 	 O 	O
left 	 O 	O
ventricle 	 O 	O
end 	 O 	O
diastolic 	 O 	O
pressure 	 O 	O
were 	 O 	O
decreased 	 O 	O
all 	 O 	O
with 	 O 	O
statistical 	 O 	O
significant 	 O 	O
values 	 O 	O
. 	 O 	O
The 	 O 	O
cardiac 	 O 	O
index 	 O 	O
, 	 O 	O
stroke 	 O 	O
volume 	 O 	O
, 	 O 	O
dP 	 O 	O
/ 	 O 	O
dt 	 O 	O
and 	 O 	O
stroke 	 DISEASE 	O
work 	 O 	O
index 	 O 	O
were 	 O 	O
increased 	 O 	O
; 	 O 	O
the 	 O 	O
pulmonary 	 O 	O
pressure 	 O 	O
and 	 O 	O
the 	 O 	O
left 	 O 	O
ventricle 	 O 	O
end 	 O 	O
diastolic 	 O 	O
pressure 	 O 	O
were 	 O 	O
decreased 	 O 	O
all 	 O 	O
with 	 O 	O
statistical 	 O 	O
significant 	 O 	O
values 	 O 	O
. 	 O 	O
Both 	 O 	O
the 	 O 	O
narcolepsy 	 DISEASE 	O
- 	 O 	O
hypersomnia 	 O 	O
and 	 O 	O
the 	 O 	O
sleep 	 O 	O
apnea 	 O 	O
- 	 O 	O
hypersomnia 	 O 	O
syndromes 	 O 	O
are 	 O 	O
reviewed 	 O 	O
in 	 O 	O
detail 	 O 	O
. 	 O 	O
Both 	 O 	O
the 	 O 	O
narcolepsy 	 O 	O
- 	 O 	O
hypersomnia 	 O 	O
and 	 O 	O
the 	 O 	O
sleep 	 DISEASE 	O
apnea 	 DISEASE 	O
- 	 O 	O
hypersomnia 	 O 	O
syndromes 	 O 	O
are 	 O 	O
reviewed 	 O 	O
in 	 O 	O
detail 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
and 	 O 	O
more 	 O 	O
than 	 O 	O
8(1/2 	 O 	O
) 	 O 	O
mo 	 O 	O
in 	 O 	O
blastic 	 O 	O
crisis 	 O 	O
of 	 O 	O
chronic 	 O 	O
myeloid 	 O 	O
leukemia 	 O 	O
. 	 O 	O
Median 	 O 	O
survival 	 O 	O
times 	 O 	O
of 	 O 	O
the 	 O 	O
former 	 O 	O
group 	 O 	O
of 	 O 	O
patients 	 O 	O
were 	 O 	O
more 	 O 	O
than 	 O 	O
18 	 O 	O
mo 	 O 	O
in 	 O 	O
acute 	 O 	O
myeloid 	 O 	O
leukemia 	 O 	O
and 	 O 	O
acute 	 O 	O
lymphatic 	 O 	O
leukemia 	 O 	O
and 	 O 	O
more 	 O 	O
than 	 O 	O
8(1/2 	 O 	O
) 	 O 	O
mo 	 O 	O
in 	 O 	O
blastic 	 O 	O
crisis 	 O 	O
of 	 O 	O
chronic 	 DISEASE 	DISEASE
myeloid 	 DISEASE 	O
leukemia 	 DISEASE 	DISEASE
. 	 O 	O
further 	 O 	O
classification 	 O 	O
as 	 O 	O
juvenile 	 O 	O
ankylosing 	 O 	O
spondylitis 	 O 	O
, 	 O 	O
as 	 O 	O
juvenile 	 DISEASE 	O
chronic 	 DISEASE 	DISEASE
polyarthritis 	 DISEASE 	O
with 	 O 	O
or 	 O 	O
without 	 O 	O
sacroiliitis 	 O 	O
or 	 O 	O
as 	 O 	O
juvenile 	 O 	O
rheumatoid 	 O 	O
arthritis 	 O 	O
. 	 O 	O
Follow 	 O 	O
- 	 O 	O
up 	 O 	O
of 	 O 	O
the 	 O 	O
cases 	 O 	O
permitted 	 O 	O
their 	 O 	O
further 	 O 	O
classification 	 O 	O
as 	 O 	O
juvenile 	 O 	O
ankylosing 	 O 	O
spondylitis 	 O 	O
, 	 O 	O
as 	 O 	O
juvenile 	 O 	O
chronic 	 O 	O
polyarthritis 	 O 	O
with 	 O 	O
or 	 O 	O
without 	 O 	O
sacroiliitis 	 O 	O
or 	 O 	O
as 	 O 	O
juvenile 	 DISEASE 	DISEASE
rheumatoid 	 DISEASE 	DISEASE
arthritis 	 DISEASE 	DISEASE
. 	 O 	O
previously 	 O 	O
thought 	 O 	O
responsible 	 O 	O
for 	 O 	O
travelers 	 O 	DISEASE
' 	 O 	O
diarrhea 	 DISEASE 	DISEASE
were 	 O 	O
not 	 O 	O
responsible 	 O 	O
for 	 O 	O
gastroenteritis 	 O 	O
among 	 O 	O
United 	 O 	O
States 	 O 	O
Marines 	 O 	O
arriving 	 O 	O
in 	 O 	O
a 	 O 	O
temperate 	 O 	O
climate 	 O 	O
. 	 O 	O
It 	 O 	O
is 	 O 	O
concluded 	 O 	O
that 	 O 	O
infectious 	 O 	O
agents 	 O 	O
previously 	 O 	O
thought 	 O 	O
responsible 	 O 	O
for 	 O 	O
travelers 	 O 	O
' 	 O 	O
diarrhea 	 O 	O
were 	 O 	O
not 	 O 	O
responsible 	 O 	O
for 	 O 	O
gastroenteritis 	 DISEASE 	DISEASE
among 	 O 	O
United 	 O 	O
States 	 O 	O
Marines 	 O 	O
arriving 	 O 	O
in 	 O 	O
a 	 O 	O
temperate 	 O 	O
climate 	 O 	O
. 	 O 	O
Twenty 	 O 	O
- 	 O 	O
seven 	 O 	O
patients 	 O 	O
with 	 O 	O
acute 	 O 	O
toxic 	 O 	O
dilatation 	 O 	O
of 	 O 	O
the 	 O 	O
colon 	 O 	O
( 	 O 	O
TM 	 O 	O
) 	 O 	O
as 	 O 	O
a 	 O 	O
complication 	 O 	O
of 	 O 	O
inflammatory 	 O 	DISEASE
disease 	 O 	DISEASE
of 	 O 	O
the 	 O 	O
colon 	 O 	O
are 	 O 	O
reported 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Biopsy 	 O 	O
specimens 	 O 	O
of 	 O 	O
the 	 O 	O
upper 	 O 	O
tarsal 	 O 	O
conjunctiva 	 O 	O
in 	 O 	O
soft 	 O 	O
contact 	 O 	O
lens 	 O 	O
- 	 O 	O
associated 	 O 	O
giant 	 DISEASE 	O
papillary 	 DISEASE 	O
conjunctivitis 	 DISEASE 	DISEASE
were 	 O 	O
taken 	 O 	O
during 	 O 	O
( 	 O 	O
1 	 O 	O
) 	 O 	O
chronic 	 O 	O
exacerbation 	 O 	O
, 	 O 	O
( 	 O 	O
2 	 O 	O
) 	 O 	O
brief 	 O 	O
remission 	 O 	O
, 	 O 	O
and 	 O 	O
( 	 O 	O
3 	 O 	O
) 	 O 	O
intentional 	 O 	O
exacerbation 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
We 	 O 	O
compare 	 O 	O
the 	 O 	O
clinical 	 O 	O
responses 	 O 	O
of 	 O 	O
myeloblasts 	 O 	O
to 	 O 	O
Ara 	 O 	O
- 	 O 	O
C 	 O 	O
in 	 O 	O
6 	 O 	O
patients 	 O 	O
, 	 O 	O
who 	 O 	O
had 	 O 	O
high 	 O 	O
peripheral 	 O 	DISEASE
blood 	 O 	DISEASE
myeloblast 	 O 	O
counts 	 O 	O
, 	 O 	O
with 	 O 	O
the 	 O 	O
sensitivities 	 O 	O
of 	 O 	O
their 	 O 	O
myeloblasts 	 O 	O
to 	 O 	O
Ara 	 O 	O
- 	 O 	O
C 	 O 	O
in 	 O 	O
mice 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
order 	 O 	O
to 	 O 	O
determine 	 O 	O
the 	 O 	O
mechanism 	 O 	O
underlying 	 O 	O
prolongation 	 O 	O
of 	 O 	O
the 	 O 	O
pre 	 O 	O
- 	 O 	O
ejection 	 O 	O
period 	 O 	O
in 	 O 	O
patients 	 O 	O
with 	 O 	O
left 	 O 	O
ventricular 	 O 	O
disease 	 O 	O
, 	 O 	O
11 	 O 	O
patients 	 O 	O
with 	 O 	O
congestive 	 O 	O
cardiomyopathy 	 O 	DISEASE
and 	 O 	O
29 	 O 	O
with 	 O 	O
coronary 	 DISEASE 	DISEASE
artery 	 DISEASE 	DISEASE
disease 	 DISEASE 	DISEASE
, 	 O 	O
10 	 O 	O
of 	 O 	O
whom 	 O 	O
were 	 O 	O
taking 	 O 	O
beta 	 O 	O
- 	 O 	O
adrenergic 	 O 	O
blocking 	 O 	O
drugs 	 O 	O
, 	 O 	O
were 	 O 	O
studied 	 O 	O
non 	 O 	O
- 	 O 	O
invasively 	 O 	O
. 	 O 	O
The 	 O 	O
heterogeneity 	 O 	O
of 	 O 	O
human 	 O 	O
circulating 	 O 	O
anticoagulants 	 O 	O
against 	 O 	O
antihemophilic 	 O 	O
factor 	 O 	O
( 	 O 	O
AHF 	 O 	O
, 	 O 	O
factor 	 O 	O
VIII 	 O 	O
) 	 O 	O
observed 	 O 	O
in 	 O 	O
seven 	 O 	O
patients 	 O 	O
, 	 O 	O
both 	 O 	O
with 	 O 	O
and 	 O 	O
without 	 O 	O
classic 	 O 	O
hemophilia 	 DISEASE 	O
, 	 O 	O
was 	 O 	O
investigated 	 O 	O
by 	 O 	O
neutralization 	 O 	O
of 	 O 	O
their 	 O 	O
activity 	 O 	O
with 	 O 	O
antiserums 	 O 	O
directed 	 O 	O
to 	 O 	O
whole 	 O 	O
IgG 	 O 	O
and 	 O 	O
to 	 O 	O
lambda 	 O 	O
and 	 O 	O
kappa 	 O 	O
light 	 O 	O
chains 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Intracranial 	 O 	O
pressure 	 O 	DISEASE
sensors 	 O 	O
and 	 O 	O
subdural 	 O 	O
and 	 O 	O
subgaleal 	 O 	O
sensing 	 O 	O
tambours 	 O 	O
were 	 O 	O
used 	 O 	O
to 	 O 	O
measure 	 O 	O
the 	 O 	O
pressure 	 O 	O
difference 	 O 	O
between 	 O 	O
the 	 O 	O
intracranial 	 O 	O
and 	 O 	O
subgaleal 	 O 	O
spaces 	 O 	O
in 	 O 	O
two 	 O 	O
monkeys 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
possible 	 O 	O
mechanisms 	 O 	O
that 	 O 	O
underlie 	 O 	O
symptom 	 O 	O
formation 	 O 	O
in 	 O 	O
childhood 	 DISEASE 	O
schizophrenia 	 DISEASE 	DISEASE
are 	 O 	O
discussed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
PCP 	 O 	DISEASE
induced 	 O 	O
stereotyped 	 O 	O
behavior 	 O 	O
in 	 O 	O
all 	 O 	O
treated 	 O 	O
monkeys 	 O 	O
at 	 O 	O
each 	 O 	O
of 	 O 	O
three 	 O 	O
test 	 O 	O
doses 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
trend 	 O 	O
towards 	 O 	O
improved 	 O 	O
fetal 	 O 	O
scalp 	 O 	O
blood 	 O 	DISEASE
gas 	 O 	DISEASE
status 	 O 	DISEASE
and 	 O 	O
maternal 	 O 	O
- 	 O 	O
to 	 O 	O
- 	 O 	O
fetal 	 O 	O
acid 	 O 	O
- 	 O 	O
base 	 O 	O
matching 	 O 	O
was 	 O 	O
observed 	 O 	O
with 	 O 	O
enflurane 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
Swan 	 O 	O
- 	 O 	O
Ganz 	 O 	O
catheter 	 O 	O
and 	 O 	O
pulmonary 	 O 	DISEASE
artery 	 O 	O
pressure 	 O 	O
monitoring 	 O 	O
are 	 O 	O
the 	 O 	O
tools 	 O 	O
employed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Treatment 	 O 	O
of 	 O 	O
Balantidium 	 O 	O
coli 	 O 	O
and 	 O 	O
nematode 	 O 	O
infections 	 O 	O
of 	 O 	O
baboons 	 O 	O
is 	 O 	O
discussed 	 O 	O
as 	 O 	O
is 	 O 	O
the 	 O 	O
implication 	 O 	O
of 	 O 	O
some 	 O 	O
of 	 O 	O
these 	 O 	O
intestinal 	 O 	O
parasite 	 O 	O
infections 	 O 	O
in 	 O 	O
terms 	 O 	O
of 	 O 	O
potential 	 O 	O
human 	 O 	O
infection 	 O 	DISEASE
under 	 O 	O
natural 	 O 	O
conditions 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
75 	 O 	O
patients 	 O 	O
aged 	 O 	O
under 	 O 	O
70 	 O 	O
years 	 O 	O
who 	 O 	O
had 	 O 	O
survived 	 O 	O
acute 	 DISEASE 	O
myocardial 	 DISEASE 	DISEASE
infarction 	 DISEASE 	DISEASE
complicated 	 O 	O
by 	 O 	O
both 	 O 	O
significant 	 O 	O
arrhythmias 	 O 	O
and 	 O 	O
cardiac 	 O 	O
failure 	 O 	O
were 	 O 	O
followed 	 O 	O
- 	 O 	O
up 	 O 	O
for 	 O 	O
1 	 O 	O
year 	 O 	O
in 	 O 	O
an 	 O 	O
attempt 	 O 	O
to 	 O 	O
identify 	 O 	O
features 	 O 	O
which 	 O 	O
suggest 	 O 	O
the 	 O 	O
likelihood 	 O 	O
of 	 O 	O
late 	 O 	O
death 	 O 	O
or 	 O 	O
reinfarction 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
idiopathic 	 O 	O
epididymitis 	 O 	O
	PUNCT	O
21039	in	ADP	O
21039	men	NOUN	O
21039	,	PUNCT	O
21039	and	CCONJ	O
21039	was	VERB	O
21039	often	ADV	O
21039	associated	VERB	O
21039	with	ADP	O
21039	oligozoospermia	NOUN	O
21039	.	PUNCT	O
21039	C.	PROPN	O
21039	trachomatis	NOUN	O
21039	epididymitis	NOUN	O
21039	accounted	VERB	O
21039	for	ADP	O
21039	two	NUM	O
21039	thirds	NOUN	O
21039	of	ADP	O
21039	 	 O 	O
idiopathic 	 O 	O
epididymitis 	 DISEASE 	O
	PUNCT	O
21039	in	ADP	O
21039	men	NOUN	O
21039	,	PUNCT	O
21039	and	CCONJ	O
21039	was	VERB	O
21039	often	ADV	O
21039	associated	VERB	O
21039	with	ADP	O
21039	oligozoospermia	NOUN	O
21039	.	PUNCT	O
21040	Of	ADP	O
21040	nine	NUM	O
21040	female	ADJ	O
21040	sexual	ADJ	O
21040	partners	NOUN	O
21040	of	ADP	O
21040	men	NOUN	O
21040	with	ADP	O
21040	C.	PROPN	O
21040	trachomatis	NOUN	O
21040	infection	NOUN	O
21040	,	PUNCT	O
21040	six	NUM	O
21040	had	VERB	O
21040	antibody	NOUN	O
21040	to	ADP	O
21040	C.	PROPN	O
21040	trachomatis	NOUN	O
21040	,	PUNCT	O
21040	of	ADP	O
21040	whom	NOUN	O
21040	two	NUM	O
21040	had	VERB	O
21040	positive	ADJ	O
21040	cervical	ADJ	O
21040	cultures	NOUN	O
21040	for	ADP	O
21040	this	DET	O
21040	organism	NOUN	O
21040	,	PUNCT	O
21040	and	CCONJ	O
21040	the	DET	O
21040	others	NOUN	O
21040	had	VERB	O
21040	nongonococcal	ADJ	O
21040	pelvic	ADJ	DISEASE
21040	inflammatory	ADJ	DISEASE
21040	disease	NOUN	DISEASE
21040	.	PUNCT	O
21041	Antibiotic	ADJ	O
21041	therapy	NOUN	O
21041	with	ADP	O
21041	tetracycline	NOUN	O
21041	was	VERB	O
21041	effective	ADJ	O
21041	for	ADP	O
21041	the	DET	O
21041	treatment	NOUN	O
21041	of	ADP	O
21041	men	NOUN	O
21041	with	ADP	O
21041	C.	PROPN	O
21041	trachomatis	NOUN	O
21041	epididymitis	NOUN	DISEASE
21041	,	PUNCT	O
21041	and	CCONJ	O
21041	should	VERB	O
21041	be	VERB	O
21041	offered	VERB	O
21041	to	ADP	O
21041	their	ADJ	O
21041	female	ADJ	O
21041	sex	NOUN	O
21041	partner	NOUN	O
21041	.	PUNCT	O
21042	The	DET	O
21042	choice	NOUN	O
21042	of	ADP	O
21042	the	DET	O
21042	surgical	ADJ	O
21042	technique	NOUN	O
21042	in	ADP	O
21042	renal	ADJ	O
21042	artery	NOUN	O
21042	surgery	NOUN	O
21042	poses	VERB	O
21042	several	ADJ	O
21042	problems	NOUN	O
21042	:	PUNCT	O
21042	1	PUNCT	O
21042	)	PUNCT	O
21042	A	DET	O
21042	retroperitoneal	ADJ	O
21042	approach	NOUN	O
21042	may	VERB	O
21042	be	VERB	O
21042	indicated	VERB	O
21042	except	ADP	O
21042	when	ADV	O
21042	aortic	ADJ	O
21042	surgery	NOUN	O
21042	is	VERB	O
21042	associated	VERB	O
21042	;	PUNCT	O
21042	2	PUNCT	O
21042	)	PUNCT	O
21042	The	DET	O
21042	usual	ADJ	O
21042	techniques	NOUN	O
21042	involve	VERB	O
21042	hypogastric	ADJ	O
21042	venous	ADJ	O
21042	or	CCONJ	O
21042	arterial	ADJ	O
21042	autografts	NOUN	O
21042	.	PUNCT	O
21043	Extra	ADJ	O
21043	corporeal	ADJ	O
21043	surgery	NOUN	O
21043	is	VERB	O
21043	reserved	VERB	O
21043	for	ADP	O
21043	distal	ADJ	O
21043	lesions	NOUN	O
21043	or	CCONJ	O
21043	when	ADV	O
21043	there	ADV	O
21043	are	VERB	O
21043	technical	ADJ	O
21043	difficulties	NOUN	O
21043	.	PUNCT	O
21044	Complex	ADJ	O
21044	bypass	NOUN	O
21044	surgery	NOUN	O
21044	is	VERB	O
21044	reserved	VERB	O
21044	for	ADP	O
21044	certain	ADJ	O
21044	Takayashu	PROPN	O
21044	type	NOUN	O
21044	diseases	NOUN	O
21044	.	PUNCT	O
21045	The	DET	O
21045	concept	NOUN	O
21045	of	ADP	O
21045	nephron	NOUN	O
21045	protection	NOUN	O
21045	must	VERB	O
21045	be	VERB	O
21045	emphasised	VERB	O
21045	given	VERB	O
21045	the	DET	O
21045	risk	NOUN	O
21045	of	ADP	O
21045	obliteration	NOUN	O
21045	of	ADP	O
21045	severe	ADJ	O
21045	stenosis	NOUN	O
21045	,	PUNCT	O
21045	despite	ADP	O
21045	advances	NOUN	O
21045	in	ADP	O
21045	medical	ADJ	O
21045	anti	ADV	O
21045	hypertensive	ADJ	O
21045	therapy	NOUN	O
21045	.	PUNCT	O
21046	Some	DET	O
21046	molecular	ADJ	O
21046	properties	NOUN	O
21046	of	ADP	O
21046	the	DET	O
21046	purified	ADJ	O
21046	neutral	ADJ	O
21046	alpha	NOUN	O
21046	-	PUNCT	O
21046	glucosidase	NOUN	O
21046	from	ADP	O
21046	human	ADJ	O
21046	kidney	NOUN	O
21046	were	VERB	O
21046	studied	VERB	O
21046	.	PUNCT	O
21047	The	DET	O
21047	enzyme	NOUN	O
21047	is	VERB	O
21047	a	DET	O
21047	glycoprotein	NOUN	O
21047	with	ADP	O
21047	high	ADJ	O
21047	molecular	ADJ	O
21047	weight	NOUN	O
21047	(	PUNCT	O
21047	315000	NUM	O
21047	-	SYM	O
21047	352000	NUM	O
21047	according	VERB	O
21047	to	ADP	O
21047	the	DET	O
21047	method	NOUN	O
21047	used	VERB	O
21047	)	PUNCT	O
21047	.	PUNCT	O
21048	Its	ADJ	O
21048	sedimentation	NOUN	O
21048	coefficient	ADJ	O
21048	is	VERB	O
21048	12.9S.	NUM	O
21049	It	PRON	O
21049	exhibits	VERB	O
21049	at	ADV	O
21049	least	ADV	O
21049	three	NUM	O
21049	peaks	NOUN	O
21049	of	ADP	O
21049	activity	NOUN	O
21049	in	ADP	O
21049	isoelectric	ADJ	O
21049	focusing	VERB	O
21049	experiments	NOUN	O
21049	.	PUNCT	O
21050	This	DET	O
21050	heterogeneity	NOUN	O
21050	appears	VERB	O
21050	to	PART	O
21050	be	VERB	O
21050	related	VERB	O
21050	to	ADP	O
21050	sialic	ADJ	O
21050	acid	NOUN	O
21050	residues	NOUN	O
21050	from	ADP	O
21050	the	DET	O
21050	carbohydrate	NOUN	O
21050	moiety	NOUN	O
21050	.	PUNCT	O
21051	An	DET	O
21051	anti	ADV	O
21051	-	PUNCT	O
21051	human	ADJ	O
21051	renal	ADJ	O
21051	alpha	NOUN	O
21051	-	PUNCT	O
21051	glucosidase	NOUN	O
21051	antiserum	NOUN	O
21051	was	VERB	O
21051	raised	VERB	O
21051	from	ADP	O
21051	rabbit	NOUN	O
21051	.	PUNCT	O
21052	The	DET	O
21052	antiserum	NOUN	O
21052	effect	NOUN	O
21052	on	ADP	O
21052	human	ADJ	O
21052	intestinal	ADJ	O
21052	maltases	NOUN	O
21052	was	VERB	O
21052	studied	VERB	O
21052	in	ADP	O
21052	immunodiffusion	NOUN	O
21052	experiments	NOUN	O
21052	.	PUNCT	O
21053	An	DET	O
21053	identity	NOUN	O
21053	pattern	NOUN	O
21053	was	VERB	O
21053	observed	VERB	O
21053	between	ADP	O
21053	renal	ADJ	O
21053	neutral	ADJ	O
21053	alpha	NOUN	O
21053	-	PUNCT	O
21053	glucosidase	NOUN	O
21053	and	CCONJ	O
21053	intestinal	ADJ	O
21053	glucoamylase	NOUN	O
21053	.	PUNCT	O
21054	No	DET	O
21054	precipitation	NOUN	O
21054	occurred	VERB	O
21054	with	ADP	O
21054	intestinal	ADJ	O
21054	sucrase	NOUN	O
21054	.	PUNCT	O
21055	Renal	ADJ	O
21055	neutral	ADJ	O
21055	alpha	NOUN	O
21055	-	PUNCT	O
21055	glucosidase	NOUN	O
21055	and	CCONJ	O
21055	intestinal	ADJ	O
21055	glucoamylase	NOUN	O
21055	were	VERB	O
21055	both	DET	O
21055	completely	ADV	O
21055	precipitated	VERB	O
21055	by	ADP	O
21055	the	DET	O
21055	antiserum	NOUN	O
21055	,	PUNCT	O
21055	their	ADJ	O
21055	maltase	NOUN	O
21055	activity	NOUN	O
21055	being	VERB	O
21055	only	ADV	O
21055	slightly	ADV	O
21055	inhibited	VERB	O
21055	in	ADP	O
21055	the	DET	O
21055	antigen	NOUN	O
21055	-	PUNCT	O
21055	antibody	NOUN	O
21055	complex	NOUN	O
21055	.	PUNCT	O
21056	From	ADP	O
21056	their	ADJ	O
21056	molecular	ADJ	O
21056	and	CCONJ	O
21056	immunological	ADJ	O
21056	properties	NOUN	O
21056	a	DET	O
21056	large	ADJ	O
21056	homology	NOUN	O
21056	appears	VERB	O
21056	between	ADP	O
21056	human	ADJ	O
21056	renal	ADJ	O
21056	alpha	NOUN	O
21056	-	PUNCT	O
21056	glucosidase	NOUN	O
21056	and	CCONJ	O
21056	intestinal	ADJ	O
21056	glycoamylase	NOUN	O
21056	.	PUNCT	O
21057	Primary	ADJ	O
21057	osteomyelitis	NOUN	DISEASE
21057	consequent	NOUN	O
21057	to	PART	O
21057	obligate	VERB	O
21057	anaerobic	ADJ	O
21057	microorganisms	NOUN	O
21057	represents	VERB	O
21057	an	DET	O
21057	infrequently	ADV	O
21057	encountered	VERB	O
21057	type	NOUN	O
21057	of	ADP	O
21057	infection	NOUN	O
21057	in	ADP	O
21057	pediatric	ADJ	O
21057	patients	NOUN	O
21057	.	PUNCT	O
21058	Unlike	ADP	O
21058	osteomyelitis	NOUN	DISEASE
21058	caused	VERB	O
21058	by	ADP	O
21058	more	ADV	O
21058	common	ADJ	O
21058	microorganisms	NOUN	O
21058	such	ADJ	O
21058	as	ADP	O
21058	Staphylococcus	PROPN	O
21058	,	PUNCT	O
21058	children	NOUN	O
21058	with	ADP	O
21058	osseous	ADJ	O
21058	lesions	NOUN	O
21058	due	ADJ	O
21058	to	ADP	O
21058	anaerobic	ADJ	O
21058	microorganisms	NOUN	O
21058	are	VERB	O
21058	frequently	ADV	O
21058	minimally	ADV	O
21058	symptomatic	ADJ	O
21058	and	CCONJ	O
21058	rarely	ADV	O
21058	present	VERB	O
21058	the	DET	O
21058	classic	ADJ	O
21058	signs	NOUN	O
21058	of	ADP	O
21058	fulminant	ADJ	O
21058	osteomyelitis	NOUN	O
21058	.	PUNCT	O
21058	Unlike	ADP	O
21058	osteomyelitis	NOUN	O
21058	caused	VERB	O
21058	by	ADP	O
21058	more	ADV	O
21058	common	ADJ	O
21058	microorganisms	NOUN	O
21058	such	ADJ	O
21058	as	ADP	O
21058	Staphylococcus	PROPN	O
21058	,	PUNCT	O
21058	children	NOUN	O
21058	with	ADP	O
21058	osseous	ADJ	O
21058	lesions	NOUN	O
21058	due	ADJ	O
21058	to	ADP	O
21058	anaerobic	ADJ	O
21058	microorganisms	NOUN	O
21058	are	VERB	O
21058	frequently	ADV	O
21058	minimally	ADV	O
21058	symptomatic	ADJ	O
21058	and	CCONJ	O
21058	rarely	ADV	O
21058	present	VERB	O
21058	the	DET	O
21058	classic	ADJ	O
21058	signs	NOUN	O
21058	of	ADP	O
21058	fulminant	ADJ	O
21058	osteomyelitis	NOUN	DISEASE
21058	.	PUNCT	O
21059	Radiographically	ADV	O
21059	,	PUNCT	O
21059	the	DET	O
21059	lesions	NOUN	O
21059	may	VERB	O
21059	mimic	VERB	O
21059	malignant	ADJ	O
21059	osseous	ADJ	O
21059	tumors	NOUN	O
21059	.	PUNCT	O
21060	Fastidious	ADJ	O
21060	microbiologic	ADJ	O
21060	analysis	NOUN	O
21060	of	ADP	O
21060	the	DET	O
21060	material	NOUN	O
21060	obtained	VERB	O
21060	at	ADP	O
21060	surgery	NOUN	O
21060	is	VERB	O
21060	necessary	ADJ	O
21060	to	PART	O
21060	isolate	VERB	O
21060	obligate	NOUN	O
21060	anaerobes	NOUN	O
21060	.	PUNCT	O
21061	Basic	ADJ	O
21061	treatment	NOUN	O
21061	,	PUNCT	O
21061	comprising	VERB	O
21061	surgical	ADJ	O
21061	drainage	NOUN	O
21061	and	CCONJ	O
21061	appropriate	ADJ	O
21061	antimicrobial	ADJ	O
21061	agents	NOUN	O
21061	,	PUNCT	O
21061	does	VERB	O
21061	not	ADV	O
21061	differ	VERB	O
21061	from	ADP	O
21061	that	DET	O
21061	for	ADP	O
21061	osteomyelitis	NOUN	DISEASE
21061	caused	VERB	O
21061	by	ADP	O
21061	aerobic	ADJ	O
21061	or	CCONJ	O
21061	by	ADP	O
21061	facultative	ADJ	O
21061	anaerobic	ADJ	O
21061	microorganisms	NOUN	O
21061	.	PUNCT	O
21062	A	DET	O
21062	longitudinal	ADJ	O
21062	study	NOUN	O
21062	in	ADP	O
21062	60	NUM	O
21062	women	NOUN	O
21062	was	VERB	O
21062	undertaken	VERB	O
21062	to	PART	O
21062	observe	VERB	O
21062	the	DET	O
21062	changes	NOUN	O
21062	,	PUNCT	O
21062	if	ADP	O
21062	any	DET	O
21062	,	PUNCT	O
21062	in	ADP	O
21062	serum	NOUN	O
21062	bile	ADJ	O
21062	acids	NOUN	O
21062	after	ADP	O
21062	taking	VERB	O
21062	oral	ADJ	O
21062	combination	NOUN	O
21062	pills	NOUN	O
21062	containing	VERB	O
21062	either	CCONJ	O
21062	50	NUM	O
21062	or	CCONJ	O
21062	30	NUM	O
21062	microgram	NOUN	O
21062	of	ADP	O
21062	ethinyl	NOUN	O
21062	estradiol	NOUN	O
21062	.	PUNCT	O
21063	The	DET	O
21063	women	NOUN	O
21063	were	VERB	O
21063	followed	VERB	O
21063	up	PART	O
21063	to	PART	O
21063	12	NUM	O
21063	months	NOUN	O
21063	.	PUNCT	O
21064	Serum	VERB	O
21064	bile	ADJ	O
21064	acids	NOUN	O
21064	(	PUNCT	O
21064	cholyglycine	NOUN	O
21064	conjugates	NOUN	O
21064	)	PUNCT	O
21064	were	VERB	O
21064	estimated	VERB	O
21064	by	ADP	O
21064	radioimmunoassay	NOUN	O
21064	.	PUNCT	O
21065	The	DET	O
21065	combination	NOUN	O
21065	contraceptives	NOUN	O
21065	had	VERB	O
21065	no	DET	O
21065	appreciable	ADJ	O
21065	effect	NOUN	O
21065	on	ADP	O
21065	serum	NOUN	O
21065	bile	ADJ	O
21065	acids	NOUN	O
21065	.	PUNCT	O
21066	Renin	ADJ	O
21066	activity	NOUN	O
21066	and	CCONJ	O
21066	the	DET	O
21066	concentrations	NOUN	O
21066	of	ADP	O
21066	angiotensin	NOUN	O
21066	I	PRON	O
21066	and	CCONJ	O
21066	angiotensin	NOUN	O
21066	II	PROPN	O
21066	in	ADP	O
21066	amniotic	ADJ	O
21066	fluid	NOUN	O
21066	of	ADP	O
21066	second-	ADJ	O
21066	and	CCONJ	O
21066	third	ADJ	O
21066	-	PUNCT	O
21066	trimester	NOUN	O
21066	pregnancies	NOUN	O
21066	were	VERB	O
21066	determined	VERB	O
21066	by	ADP	O
21066	radioimmunoassay	NOUN	O
21066	.	PUNCT	O
21067	Between	ADP	O
21067	the	DET	O
21067	28th	ADJ	O
21067	and	CCONJ	O
21067	38th	ADJ	O
21067	wk	NOUN	O
21067	of	ADP	O
21067	gestation	NOUN	O
21067	,	PUNCT	O
21067	the	DET	O
21067	mean	ADJ	O
21067	renin	NOUN	O
21067	activity	NOUN	O
21067	in	ADP	O
21067	the	DET	O
21067	amniotic	ADJ	O
21067	fluid	NOUN	O
21067	was	VERB	O
21067	higher	ADJ	O
21067	than	ADP	O
21067	during	ADP	O
21067	early	ADJ	O
21067	pregnancy	NOUN	O
21067	(	PUNCT	O
21067	before	ADP	O
21067	the	DET	O
21067	18th	ADJ	O
21067	wk	NOUN	O
21067	of	ADP	O
21067	gestation	NOUN	O
21067	)	PUNCT	O
21067	.	PUNCT	O
21068	Both	DET	O
21068	renin	NOUN	O
21068	activity	NOUN	O
21068	and	CCONJ	O
21068	the	DET	O
21068	concentrations	NOUN	O
21068	of	ADP	O
21068	angiotensin	NOUN	O
21069	I	PRON	O
21069	and	CCONJ	O
21069	II	PROPN	O
21069	were	VERB	O
21069	increased	VERB	O
21069	on	ADP	O
21069	some	DET	O
21069	cases	NOUN	O
21069	of	ADP	O
21069	Rh	PROPN	O
21069	-	PUNCT	O
21069	incompatibility	NOUN	O
21069	.	PUNCT	O
21070	One	NUM	O
21070	to	PART	O
21070	two	NUM	O
21070	weeks	NOUN	O
21070	after	ADP	O
21070	the	DET	O
21070	administration	NOUN	O
21070	of	ADP	O
21070	betamethasone	NOUN	O
21070	to	ADP	O
21070	the	DET	O
21070	mother	NOUN	O
21070	with	ADP	O
21070	threatened	VERB	O
21070	premature	ADJ	O
21070	delivery	NOUN	O
21070	,	PUNCT	O
21070	the	DET	O
21070	intra	ADJ	O
21070	-	PUNCT	O
21070	amniotic	ADJ	O
21070	renin	NOUN	O
21070	--	PUNCT	O
21070	angiotensin	NOUN	O
21070	system	NOUN	O
21070	was	VERB	O
21070	slightly	ADV	O
21070	suppressed	VERB	O
21070	.	PUNCT	O
21071	In	ADP	O
21071	urine	NOUN	O
21071	samples	NOUN	O
21071	of	ADP	O
21071	newborns	NOUN	O
21071	,	PUNCT	O
21071	angiotensin	NOUN	O
21071	concentrations	NOUN	O
21071	were	VERB	O
21071	in	ADP	O
21071	the	DET	O
21071	same	ADJ	O
21071	range	NOUN	O
21071	as	ADP	O
21071	those	DET	O
21071	found	VERB	O
21071	in	ADP	O
21071	the	DET	O
21071	amniotic	ADJ	O
21071	fluid	NOUN	O
21071	;	PUNCT	O
21071	renin	NOUN	O
21071	activity	NOUN	O
21071	was	VERB	O
21071	very	ADV	O
21071	low	ADJ	O
21071	or	CCONJ	O
21071	undetectable	ADJ	O
21071	in	ADP	O
21071	the	DET	O
21071	urine	NOUN	O
21071	of	ADP	O
21071	male	ADJ	O
21071	neonates	NOUN	O
21071	(	PUNCT	O
21071	1	NUM	O
21071	-	PUNCT	O
21071	-7	ADJ	O
21071	days	NOUN	O
21071	of	ADP	O
21071	age	NOUN	O
21071	)	PUNCT	O
21071	.	PUNCT	O
21072	Thus	ADV	O
21072	,	PUNCT	O
21072	angiotensin	NOUN	O
21072	II	PROPN	O
21072	in	ADP	O
21072	the	DET	O
21072	amniotic	ADJ	O
21072	fluid	NOUN	O
21072	may	VERB	O
21072	be	VERB	O
21072	derived	VERB	O
21072	both	DET	O
21072	from	ADP	O
21072	fetal	ADJ	O
21072	urine	NOUN	O
21072	and/or	CCONJ	O
21072	as	ADP	O
21072	the	DET	O
21072	product	NOUN	O
21072	of	ADP	O
21072	enzymatic	ADJ	O
21072	reactions	NOUN	O
21072	in	ADP	O
21072	the	DET	O
21072	amniotic	ADJ	O
21072	sac	NOUN	O
21072	;	PUNCT	O
21072	the	DET	O
21072	latter	ADJ	O
21072	is	VERB	O
21072	dependent	ADJ	O
21072	not	ADV	O
21072	only	ADV	O
21072	on	ADP	O
21072	the	DET	O
21072	presence	NOUN	O
21072	of	ADP	O
21072	renin	NOUN	O
21072	and	CCONJ	O
21072	converting	VERB	O
21072	enzyme	NOUN	O
21072	but	CCONJ	O
21072	also	ADV	O
21072	on	ADP	O
21072	the	DET	O
21072	local	ADJ	O
21072	renin	NOUN	O
21072	substrate	NOUN	O
21072	(	PUNCT	O
21072	angiotensinogen	NOUN	O
21072	)	PUNCT	O
21072	concentration	NOUN	O
21072	.	PUNCT	O
21073	Plasma	NOUN	O
21073	renin	NOUN	O
21073	activity	NOUN	O
21073	(	PUNCT	O
21073	PRA	PROPN	O
21073	)	PUNCT	O
21073	in	ADP	O
21073	40	NUM	O
21073	diabetic	ADJ	O
21073	patients	NOUN	O
21073	and	CCONJ	O
21073	42	NUM	O
21073	healthy	ADJ	O
21073	controls	NOUN	O
21073	was	VERB	O
21073	investigated	VERB	O
21073	using	VERB	O
21073	the	DET	O
21073	method	NOUN	O
21073	of	ADP	O
21073	Pickens	PROPN	O
21073	in	ADP	O
21073	modification	NOUN	O
21073	of	ADP	O
21073	Serebrovskaja	PROPN	O
21073	et	PROPN	O
21073	al	PROPN	O
21073	.	PUNCT	O
21074	(	PUNCT	O
21074	1967	NUM	O
21074	)	PUNCT	O
21074	.	PUNCT	O
21075	PRA	PROPN	O
21075	was	VERB	O
21075	slightly	ADV	O
21075	lower	ADJ	O
21075	in	ADP	O
21075	the	DET	O
21075	whole	ADJ	O
21075	group	NOUN	O
21075	of	ADP	O
21075	diabetes	NOUN	O
21075	but	CCONJ	O
21075	the	DET	O
21075	difference	NOUN	O
21075	was	VERB	O
21075	not	ADV	O
21075	significant	ADJ	O
21075	.	PUNCT	O
21076	The	DET	O
21076	subgroup	NOUN	O
21076	of	ADP	O
21076	20	NUM	O
21076	maturity	NOUN	O
21076	-	PUNCT	O
21076	onset	NOUN	O
21076	diabetics	NOUN	O
21076	had	VERB	O
21076	significantly	ADV	O
21076	lower	ADJ	O
21076	PRA	PROPN	O
21076	in	ADP	O
21076	comparison	NOUN	O
21076	with	ADP	O
21076	22	NUM	O
21076	controls	NOUN	O
21076	of	ADP	O
21076	similar	ADJ	O
21076	age	NOUN	O
21076	,	PUNCT	O
21076	while	ADP	O
21076	PRA	PROPN	O
21076	in	ADP	O
21076	juvenile	ADJ	O
21076	diabetics	NOUN	O
21076	did	VERB	O
21076	not	ADV	O
21076	differ	VERB	O
21076	significantly	ADV	O
21076	from	ADP	O
21076	matched	VERB	O
21076	controls	NOUN	O
21076	.	PUNCT	O
21077	In	ADP	O
21077	patients	NOUN	O
21077	without	ADP	O
21077	clinical	ADJ	O
21077	signs	NOUN	O
21077	and	CCONJ	O
21077	symptoms	NOUN	O
21077	of	ADP	O
21077	microangiopathy	ADJ	O
21077	PRA	PROPN	O
21077	was	VERB	O
21077	as	ADV	O
21077	high	ADJ	O
21077	as	ADP	O
21077	in	ADP	O
21077	the	DET	O
21077	controls	NOUN	O
21077	.	PUNCT	O
21078	In	ADP	O
21078	diabetics	NOUN	O
21078	with	ADP	O
21078	microangiopathy	ADJ	O
21078	PRA	PROPN	O
21078	was	VERB	O
21078	significantly	ADV	O
21078	lower	ADJ	O
21078	.	PUNCT	O
21079	PRA	PROPN	O
21079	was	VERB	O
21079	also	ADV	O
21079	lower	ADJ	O
21079	in	ADP	O
21079	patients	NOUN	O
21079	with	ADP	O
21079	longer	ADJ	O
21079	duration	NOUN	O
21079	of	ADP	O
21079	the	DET	O
21079	disease	NOUN	O
21079	.	PUNCT	O
21080	The	DET	O
21080	stimulation	NOUN	O
21080	of	ADP	O
21080	juxtaglomerular	ADJ	O
21080	apparatus	NOUN	O
21080	with	ADP	O
21080	sodium	NOUN	O
21080	free	ADJ	O
21080	diet	NOUN	O
21080	and	CCONJ	O
21080	diuretic	ADJ	O
21080	drugs	NOUN	O
21080	resulted	VERB	O
21080	in	ADP	O
21080	an	DET	O
21080	increase	NOUN	O
21080	of	ADP	O
21080	PRA	PROPN	O
21080	both	CCONJ	O
21080	in	ADP	O
21080	controls	NOUN	O
21080	and	CCONJ	O
21080	diabetics	NOUN	O
21080	.	PUNCT	O
21081	This	DET	O
21081	suggests	VERB	O
21081	a	DET	O
21081	functional	ADJ	O
21081	depression	NOUN	O
21081	of	ADP	O
21081	PRA	PROPN	O
21081	in	ADP	O
21081	diabetic	ADJ	O
21081	patients	NOUN	O
21081	.	PUNCT	O
21082	In	ADP	O
21082	diabetics	NOUN	O
21082	with	ADP	O
21082	ketoacidosis	NOUN	O
21082	PRA	PROPN	O
21082	was	VERB	O
21082	higher	ADJ	O
21082	than	ADP	O
21082	in	ADP	O
21082	control	NOUN	O
21082	subjects	NOUN	O
21082	and	CCONJ	O
21082	decreased	VERB	O
21082	after	ADP	O
21082	disappearance	NOUN	O
21082	of	ADP	O
21082	ketoacidosis	NOUN	O
21082	.	PUNCT	O
21083	A	DET	O
21083	high	ADJ	O
21083	level	NOUN	O
21083	was	VERB	O
21083	recorded	VERB	O
21083	in	ADP	O
21083	a	DET	O
21083	patient	NOUN	O
21083	with	ADP	O
21083	hyperosmolar	NOUN	O
21083	coma	NOUN	O
21083	and	CCONJ	O
21083	a	DET	O
21083	very	ADV	O
21083	low	ADJ	O
21083	level	NOUN	O
21083	in	ADP	O
21083	a	DET	O
21083	patient	NOUN	O
21083	with	ADP	O
21083	polyneuropathy	ADJ	DISEASE
21083	and	CCONJ	O
21083	severe	ADJ	O
21083	orthostatic	ADJ	O
21083	hypotension	NOUN	O
21083	.	PUNCT	O
21084	The	DET	O
21084	possible	ADJ	O
21084	mechanisms	NOUN	O
21084	involved	VERB	O
21084	in	ADP	O
21084	the	DET	O
21084	changes	NOUN	O
21084	of	ADP	O
21084	PRA	PROPN	O
21084	in	ADP	O
21084	diabetic	ADJ	O
21084	patients	NOUN	O
21084	are	VERB	O
21084	discussed	VERB	O
21084	.	PUNCT	O
21085	The	DET	O
21085	enhancing	VERB	O
21085	effect	NOUN	O
21085	of	ADP	O
21085	TRH	PROPN	O
21085	on	ADP	O
21085	dopamine(DA	PROPN	O
21085	)	PUNCT	O
21085	release	NOUN	O
21085	from	ADP	O
21085	rat	ADJ	O
21085	striatal	ADJ	O
21085	slices	NOUN	O
21085	was	VERB	O
21085	investigated	VERB	O
21085	in	ADP	O
21085	relation	NOUN	O
21085	to	ADP	O
21085	Ca2	NOUN	O
21085	+	SYM	O
21085	and	CCONJ	O
21085	cholinergic	NOUN	O
21085	mechanisms	NOUN	O
21085	.	PUNCT	O
21086	TRH(10(-5)--10(-3	PUNCT	O
21086	)	PUNCT	O
21086	M	PROPN	O
21086	)	PUNCT	O
21086	facilitated	VERB	O
21086	concentration	NOUN	O
21086	dependently	ADV	O
21086	the	DET	O
21086	uptake	NOUN	O
21086	of	ADP	O
21086	14C	NUM	O
21086	-	PUNCT	O
21086	DA	PROPN	O
21086	by	ADP	O
21086	rat	ADJ	O
21086	striatal	ADJ	O
21086	slices	NOUN	O
21086	,	PUNCT	O
21086	while	ADP	O
21086	methamphetamine	NOUN	O
21086	(	PUNCT	O
21086	10(-6)--10(-4)M	NOUN	O
21086	)	PUNCT	O
21086	exhibited	VERB	O
21086	a	DET	O
21086	considerable	ADJ	O
21086	inhibitory	ADJ	O
21086	effect	NOUN	O
21086	.	PUNCT	O
21087	TRH	PROPN	O
21087	(	PUNCT	O
21087	10(-7)--10(--3)M	PROPN	O
21087	)	PUNCT	O
21087	alone	ADV	O
21087	did	VERB	O
21087	not	ADV	O
21087	increase	VERB	O
21087	the	DET	O
21087	DA	PROPN	O
21087	release	NOUN	O
21087	into	ADP	O
21087	the	DET	O
21087	incubation	NOUN	O
21087	medium	NOUN	O
21087	,	PUNCT	O
21087	but	CCONJ	O
21087	it	PRON	O
21087	clearly	ADV	O
21087	enhanced	VERB	O
21087	the	DET	O
21087	DA	PROPN	O
21087	release	NOUN	O
21087	in	ADP	O
21087	the	DET	O
21087	concomitant	ADJ	O
21087	presence	NOUN	O
21087	of	ADP	O
21087	desipramine	NOUN	O
21087	(	PUNCT	O
21087	5	NUM	O
21087	x	SYM	O
21087	10(-5)M	NUM	O
21087	)	PUNCT	O
21087	.	PUNCT	O
21088	In	ADP	O
21088	the	DET	O
21088	superfusion	NOUN	O
21088	study	NOUN	O
21088	,	PUNCT	O
21088	TRH	PROPN	O
21088	(	PUNCT	O
21088	10(-5)--10(-3)M	PROPN	O
21088	)	PUNCT	O
21088	,	PUNCT	O
21088	methamphetamine	NOUN	O
21088	(	PUNCT	O
21088	10(-6)--10(-4)M	NOUN	O
21088	)	PUNCT	O
21088	and	CCONJ	O
21088	KCl	NOUN	O
21088	(	PUNCT	O
21088	2.5	NUM	O
21088	-	PUNCT	O
21088	-5.0	NOUN	O
21088	x	SYM	O
21088	10(-2)M	NUM	O
21088	)	PUNCT	O
21088	enhanced	VERB	O
21088	the	DET	O
21088	DA	PROPN	O
21088	release	NOUN	O
21088	into	ADP	O
21088	the	DET	O
21088	perfusion	NOUN	O
21088	fluid	NOUN	O
21088	.	PUNCT	O
21089	The	DET	O
21089	DA	PROPN	O
21089	releasing	VERB	O
21089	effect	NOUN	O
21089	of	ADP	O
21089	TRH	PROPN	O
21089	was	VERB	O
21089	completely	ADV	O
21089	blocked	VERB	O
21089	by	ADP	O
21089	cholinergic	NOUN	O
21089	blockers	NOUN	O
21089	(	PUNCT	O
21089	scopolamine	NOUN	O
21089	,	PUNCT	O
21089	hexamethonium	NOUN	O
21089	and	CCONJ	O
21089	hemicholinium	NOUN	O
21089	)	PUNCT	O
21089	,	PUNCT	O
21089	Ca2	NOUN	O
21089	+	SYM	O
21089	chelator(EGTA	NOUN	O
21089	)	PUNCT	O
21089	,	PUNCT	O
21089	Ca2	NOUN	O
21089	+	SYM	O
21089	antagonist(CoCl2	PROPN	O
21089	)	PUNCT	O
21089	and	CCONJ	O
21089	Ca2	NOUN	O
21089	+	SYM	O
21089	influx	NOUN	O
21089	blocker(D-600	PROPN	O
21089	)	PUNCT	O
21089	or	CCONJ	O
21089	by	ADP	O
21089	the	DET	O
21089	removal	NOUN	O
21089	of	ADP	O
21089	Ca2	NOUN	O
21089	+	CCONJ	O
21089	from	ADP	O
21089	the	DET	O
21089	medium	NOUN	O
21089	.	PUNCT	O
21090	The	DET	O
21090	methamphetamine	NOUN	O
21090	-	PUNCT	O
21090	enhanced	VERB	O
21090	DA	PROPN	O
21090	release	NOUN	O
21090	,	PUNCT	O
21090	however	ADV	O
21090	,	PUNCT	O
21090	was	VERB	O
21090	not	ADV	O
21090	modified	VERB	O
21090	by	ADP	O
21090	the	DET	O
21090	above	ADJ	O
21090	treatments	NOUN	O
21090	except	ADP	O
21090	for	ADP	O
21090	a	DET	O
21090	partial	ADJ	O
21090	decline	NOUN	O
21090	produced	VERB	O
21090	by	ADP	O
21090	EGTA	PROPN	O
21090	coupled	VERB	O
21090	with	ADP	O
21090	the	DET	O
21090	removal	NOUN	O
21090	of	ADP	O
21090	Ca2	NOUN	O
21090	+	SYM	O
21090	.	PUNCT	O
21091	TRH(10(-4)M	PROPN	O
21091	)	PUNCT	O
21091	also	ADV	O
21091	facilitated	VERB	O
21091	the	DET	O
21091	uptake	NOUN	O
21091	of	ADP	O
21091	norepinephrine	NOUN	O
21091	(	PUNCT	O
21091	NE	PROPN	O
21091	)	PUNCT	O
21091	by	ADP	O
21091	rat	ADJ	O
21091	cerebral	ADJ	O
21091	cortex	NOUN	O
21091	slices	NOUN	O
21091	,	PUNCT	O
21091	but	CCONJ	O
21091	methamphetamine	NOUN	O
21091	(	PUNCT	O
21091	10-(6)--10(-4)M	NUM	O
21091	)	PUNCT	O
21091	exhibited	VERB	O
21091	a	DET	O
21091	considerable	ADJ	O
21091	inhibitory	ADJ	O
21091	effect	NOUN	O
21091	.	PUNCT	O
21092	In	ADP	O
21092	the	DET	O
21092	superfusion	NOUN	O
21092	study	NOUN	O
21092	,	PUNCT	O
21092	TRH	PROPN	O
21092	(	PUNCT	O
21092	10(-5)--10(-4)M	NUM	O
21092	)	PUNCT	O
21092	and	CCONJ	O
21092	methamphetamine	NOUN	O
21092	(	PUNCT	O
21092	10(-7)--10(-4)M	NUM	O
21092	)	PUNCT	O
21092	enhanced	VERB	O
21092	the	DET	O
21092	NE	PROPN	O
21092	release	NOUN	O
21092	into	ADP	O
21092	the	DET	O
21092	perfusion	NOUN	O
21092	fluid	NOUN	O
21092	.	PUNCT	O
21093	Therefore	ADV	O
21093	,	PUNCT	O
21093	it	PRON	O
21093	can	VERB	O
21093	be	VERB	O
21093	concluded	VERB	O
21093	that	ADP	O
21093	TRH	PROPN	O
21093	facilitated	VERB	O
21093	the	DET	O
21093	DA	PROPN	O
21093	release	NOUN	O
21093	from	ADP	O
21093	rat	ADJ	O
21093	striatal	ADJ	O
21093	slices	NOUN	O
21093	by	ADP	O
21093	mediating	VERB	O
21093	through	ADP	O
21093	a	DET	O
21093	cholinergic	NOUN	O
21093	mechanism	NOUN	O
21093	and	CCONJ	O
21093	enhancing	VERB	O
21093	the	DET	O
21093	influx	NOUN	O
21093	of	ADP	O
21093	Ca2	NOUN	O
21093	+	SYM	O
21093	.	PUNCT	O
21094	The	DET	O
21094	recessive	ADJ	O
21094	mutation	NOUN	O
21094	apterous	ADJ	O
21094	-	PUNCT	O
21094	blot	NOUN	O
21094	in	ADP	O
21094	Drosophila	PROPN	O
21094	melanogaster	NOUN	O
21094	causes	VERB	O
21094	replacement	NOUN	O
21094	of	ADP	O
21094	posterior	ADJ	O
21094	wing	NOUN	O
21094	structures	NOUN	O
21094	by	ADP	O
21094	anterior	NOUN	O
21094	ones	NOUN	O
21094	,	PUNCT	O
21094	with	ADP	O
21094	variable	ADJ	O
21094	penetrance	NOUN	O
21094	and	CCONJ	O
21094	expressivity	NOUN	O
21094	.	PUNCT	O
21095	Extreme	NOUN	O
21095	transformations	NOUN	O
21095	resemble	VERB	O
21095	mirror	NOUN	O
21095	-	PUNCT	O
21095	image	NOUN	O
21095	duplicate	NOUN	O
21095	anterior	NOUN	O
21095	wings	NOUN	O
21095	as	ADP	O
21095	in	ADP	O
21095	the	DET	O
21095	mutant	ADJ	O
21095	engrailed	VERB	O
21095	.	PUNCT	O
21096	Anterior	ADJ	O
21096	structures	NOUN	O
21096	in	ADP	O
21096	the	DET	O
21096	posterior	NOUN	O
21096	wing	NOUN	O
21096	only	ADV	O
21096	appear	VERB	O
21096	on	ADP	O
21096	the	DET	O
21096	dorsal	NOUN	O
21096	surface	NOUN	O
21096	.	PUNCT	O
21097	Duplications	NOUN	O
21097	solely	ADV	O
21097	of	ADP	O
21097	posterior	NOUN	O
21097	structures	NOUN	O
21097	are	VERB	O
21097	also	ADV	O
21097	seen	VERB	O
21097	.	PUNCT	O
21098	Clonal	ADJ	O
21098	analysis	NOUN	O
21098	shows	VERB	O
21098	that	ADP	O
21098	extra	ADJ	O
21098	cell	NOUN	O
21098	proliferation	NOUN	O
21098	occurs	VERB	O
21098	in	ADP	O
21098	the	DET	O
21098	posterior	NOUN	O
21098	area	NOUN	O
21098	but	CCONJ	O
21098	is	VERB	O
21098	complete	ADJ	O
21098	by	ADP	O
21098	108	NUM	O
21098	h	NOUN	O
21098	after	ADP	O
21098	egg	NOUN	O
21098	deposition	NOUN	O
21098	.	PUNCT	O
21099	Lineage	NOUN	O
21099	analysis	NOUN	O
21099	is	VERB	O
21099	consistent	ADJ	O
21099	with	ADP	O
21099	a	DET	O
21099	clonal	ADJ	O
21099	perpetuation	NOUN	O
21099	of	ADP	O
21099	the	DET	O
21099	transformation	NOUN	O
21099	.	PUNCT	O
21100	Genetic	ADJ	O
21100	mosaics	NOUN	O
21100	to	PART	O
21100	test	VERB	O
21100	the	DET	O
21100	cell	NOUN	O
21100	-	PUNCT	O
21100	autonomy	NOUN	O
21100	of	ADP	O
21100	apterous	ADJ	O
21100	-	PUNCT	O
21100	blot	NOUN	O
21100	show	NOUN	O
21100	that	ADP	O
21100	it	PRON	O
21100	is	VERB	O
21100	not	ADV	O
21100	autonomously	ADV	O
21100	expressed	VERB	O
21100	in	ADP	O
21100	clones	NOUN	O
21100	.	PUNCT	O
21101	The	DET	O
21101	results	NOUN	O
21101	of	ADP	O
21101	lineage	NOUN	O
21101	analysis	NOUN	O
21101	,	PUNCT	O
21101	the	DET	O
21101	phenotypes	NOUN	O
21101	of	ADP	O
21101	combinations	NOUN	O
21101	of	ADP	O
21101	apterous	ADJ	O
21101	-	PUNCT	O
21101	blot	NOUN	O
21101	with	ADP	O
21101	other	ADJ	O
21101	apterous	ADJ	O
21101	alleles	NOUN	O
21101	including	VERB	O
21101	a	DET	O
21101	deletion	NOUN	O
21101	for	ADP	O
21101	the	DET	O
21101	locus	NOUN	O
21101	and	CCONJ	O
21101	with	ADP	O
21101	various	ADJ	O
21101	other	ADJ	O
21101	homoeotic	ADJ	O
21101	mutations	NOUN	O
21101	,	PUNCT	O
21101	are	VERB	O
21101	together	ADV	O
21101	used	VERB	O
21101	to	PART	O
21101	distinguish	VERB	O
21101	three	NUM	O
21101	alternative	ADJ	O
21101	modes	NOUN	O
21101	of	ADP	O
21101	action	NOUN	O
21101	of	ADP	O
21101	this	DET	O
21101	mutation	NOUN	O
21101	.	PUNCT	O
21102	It	PRON	O
21102	is	VERB	O
21102	concluded	VERB	O
21102	that	ADP	O
21102	apterous	ADJ	O
21102	-	PUNCT	O
21102	blot	NOUN	O
21102	is	VERB	O
21102	unlikely	ADJ	O
21102	to	PART	O
21102	be	VERB	O
21102	a	DET	O
21102	selector	NOUN	O
21102	gene	NOUN	O
21102	mutation	NOUN	O
21102	but	CCONJ	O
21102	instead	ADV	O
21102	may	VERB	O
21102	cause	VERB	O
21102	the	DET	O
21102	transformation	NOUN	O
21102	by	ADP	O
21102	an	DET	O
21102	event	NOUN	O
21102	like	ADP	O
21102	transdetermination	NOUN	O
21102	following	VERB	O
21102	a	DET	O
21102	local	ADJ	O
21102	failure	NOUN	O
21102	in	ADP	O
21102	cell	NOUN	O
21102	function	NOUN	O
21102	in	ADP	O
21102	the	DET	O
21102	wing	NOUN	O
21102	disc	NOUN	O
21102	.	PUNCT	O
21103	The	DET	O
21103	mineral	NOUN	O
21103	composition	NOUN	O
21103	of	ADP	O
21103	38	NUM	O
21103	human	ADJ	O
21103	salivary	ADJ	O
21103	gland	NOUN	O
21103	stones	NOUN	O
21103	was	VERB	O
21103	described	VERB	O
21103	qualitatively	ADV	O
21103	on	ADP	O
21103	the	DET	O
21103	basis	NOUN	O
21103	of	ADP	O
21103	X	NOUN	O
21103	-	PUNCT	O
21103	ray	NOUN	O
21103	diffraction	NOUN	O
21103	and	CCONJ	O
21103	chemical	NOUN	O
21103	analysis	NOUN	O
21103	.	PUNCT	O
21104	In	ADP	O
21104	32	NUM	O
21104	submandibular	ADJ	O
21104	stones	NOUN	O
21104	,	PUNCT	O
21104	hydroxyapatite	NOUN	O
21104	was	VERB	O
21104	the	DET	O
21104	most	ADV	O
21104	frequently	ADV	O
21104	observed	VERB	O
21104	phase	NOUN	O
21104	with	ADP	O
21104	a	DET	O
21104	magnesium	NOUN	O
21104	-	PUNCT	O
21104	substituted	VERB	O
21104	whitlockite	ADJ	O
21104	co	NOUN	O
21104	-	PUNCT	O
21104	phase	NOUN	O
21104	(	PUNCT	O
21104	octacalcium	NOUN	O
21104	phosphate	NOUN	O
21104	was	VERB	O
21104	rarely	ADV	O
21104	present	ADJ	O
21104	)	PUNCT	O
21104	.	PUNCT	O
21105	In	ADP	O
21105	six	NUM	O
21105	parotid	ADJ	O
21105	gland	NOUN	O
21105	stones	NOUN	O
21105	,	PUNCT	O
21105	apatite	NOUN	O
21105	,	PUNCT	O
21105	magnesium	NOUN	O
21105	substituted	VERB	O
21105	whitlockite	NOUN	O
21105	and	CCONJ	O
21105	octacalcium	NOUN	O
21105	phosphate	NOUN	O
21105	were	VERB	O
21105	noted	VERB	O
21105	to	PART	O
21105	be	VERB	O
21105	the	DET	O
21105	major	ADJ	O
21105	crystalline	NOUN	O
21105	phases	NOUN	O
21105	.	PUNCT	O
21106	Brushite	PROPN	O
21106	was	VERB	O
21106	rarely	ADV	O
21106	found	VERB	O
21106	in	ADP	O
21106	either	CCONJ	O
21106	submandibular	ADJ	O
21106	or	CCONJ	O
21106	parotid	ADJ	O
21106	stones	NOUN	O
21106	.	PUNCT	O
21107	This	DET	O
21107	is	VERB	O
21107	the	DET	O
21107	first	ADJ	O
21107	report	NOUN	O
21107	of	ADP	O
21107	octacalcium	NOUN	O
21107	phosphate	NOUN	O
21107	in	ADP	O
21107	salivary	ADJ	O
21107	gland	NOUN	O
21107	stones	NOUN	O
21107	.	PUNCT	O
21108	All	DET	O
21108	stones	NOUN	O
21108	had	VERB	O
21108	ash	NOUN	O
21108	weights	NOUN	O
21108	ranging	VERB	O
21108	from	ADP	O
21108	75	NUM	O
21108	-	PUNCT	O
21108	-80	NOUN	O
21108	%	NOUN	O
21108	,	PUNCT	O
21108	but	CCONJ	O
21108	their	ADJ	O
21108	Ca	NOUN	O
21108	/	SYM	O
21108	P	NOUN	O
21108	ratios	NOUN	O
21108	could	VERB	O
21108	not	ADV	O
21108	be	VERB	O
21108	used	VERB	O
21108	to	PART	O
21108	predict	VERB	O
21108	the	DET	O
21108	crystalline	ADJ	O
21108	phases	NOUN	O
21108	present	ADJ	O
21108	.	PUNCT	O
21109	Whitlockite	PROPN	O
21109	was	VERB	O
21109	observed	VERB	O
21109	more	ADV	O
21109	frequently	ADV	O
21109	in	ADP	O
21109	the	DET	O
21109	central	ADJ	O
21109	regions	NOUN	O
21109	of	ADP	O
21109	the	DET	O
21109	submandibular	ADJ	O
21109	stones	NOUN	O
21109	than	ADP	O
21109	in	ADP	O
21109	the	DET	O
21109	outer	ADJ	O
21109	crusts	NOUN	O
21109	.	PUNCT	O
21110	Possible	ADJ	O
21110	explanations	NOUN	O
21110	for	ADP	O
21110	the	DET	O
21110	presence	NOUN	O
21110	of	ADP	O
21110	each	DET	O
21110	of	ADP	O
21110	these	DET	O
21110	phases	NOUN	O
21110	are	VERB	O
21110	discussed	VERB	O
21110	.	PUNCT	O
21111	Aggressive	ADJ	O
21111	pharmacotherapeutic	ADJ	O
21111	and	CCONJ	O
21111	surgical	ADJ	O
21111	measures	NOUN	O
21111	are	VERB	O
21111	often	ADV	O
21111	contra	ADJ	O
21111	-	PUNCT	O
21111	indicated	VERB	O
21111	in	ADP	O
21111	the	DET	O
21111	treatment	NOUN	O
21111	of	ADP	O
21111	colitis	NOUN	DISEASE
21111	ulcerosa	NOUN	O
21111	in	ADP	O
21111	pregnancy	NOUN	O
21111	.	PUNCT	O
21112	Especially	ADV	O
21112	in	ADP	O
21112	the	DET	O
21112	sensitive	ADJ	O
21112	embryonal	ADJ	O
21112	development	NOUN	O
21112	phase	NOUN	O
21112	,	PUNCT	O
21112	the	DET	O
21112	use	NOUN	O
21112	of	ADP	O
21112	antibiotics	NOUN	O
21112	,	PUNCT	O
21112	anti	ADV	O
21112	-	PUNCT	O
21112	inflammatory	ADJ	O
21112	drugs	NOUN	O
21112	,	PUNCT	O
21112	chemotherapeutics	NOUN	O
21112	and	CCONJ	O
21112	ACTH	PROPN	O
21112	is	VERB	O
21112	considered	VERB	O
21112	questionable	ADJ	O
21112	.	PUNCT	O
21113	The	DET	O
21113	subtotal	ADJ	O
21113	colectomies	NOUN	O
21113	and	CCONJ	O
21113	ileostomies	NOUN	O
21113	often	ADV	O
21113	demanded	VERB	O
21113	in	ADP	O
21113	toxically	ADV	O
21113	dramatic	ADJ	O
21113	colitides	NOUN	O
21113	place	VERB	O
21113	a	DET	O
21113	considerable	ADJ	O
21113	burden	NOUN	O
21113	on	ADP	O
21113	mother	NOUN	O
21113	and	CCONJ	O
21113	foetus	NOUN	O
21113	.	PUNCT	O
21114	A	DET	O
21114	conservative	ADJ	O
21114	therapeutic	ADJ	O
21114	regimen	NOUN	O
21114	,	PUNCT	O
21114	which	ADJ	O
21114	has	VERB	O
21114	been	VERB	O
21114	successfully	ADV	O
21114	used	VERB	O
21114	in	ADP	O
21114	more	ADJ	O
21114	than	ADP	O
21114	80	NUM	O
21114	patients	NOUN	O
21114	with	ADP	O
21114	inflammatory	ADJ	O
21114	intestinal	ADJ	O
21114	diseases	NOUN	O
21114	,	PUNCT	O
21114	was	VERB	O
21114	modified	VERB	O
21114	to	PART	O
21114	suit	VERB	O
21114	the	DET	O
21114	requirements	NOUN	O
21114	of	ADP	O
21114	pregnancy	NOUN	O
21114	.	PUNCT	O
21115	This	DET	O
21115	is	VERB	O
21115	a	DET	O
21115	combination	NOUN	O
21115	therapy	NOUN	O
21115	involving	VERB	O
21115	parenteral	ADJ	O
21115	feeding	NOUN	O
21115	,	PUNCT	O
21115	food	NOUN	O
21115	which	ADJ	O
21115	can	VERB	O
21115	be	VERB	O
21115	absorbed	VERB	O
21115	by	ADP	O
21115	the	DET	O
21115	intestinal	ADJ	O
21115	walls	NOUN	O
21115	,	PUNCT	O
21115	and	CCONJ	O
21115	a	DET	O
21115	suitably	ADV	O
21115	adapted	VERB	O
21115	pharmacotherapy	NOUN	O
21115	.	PUNCT	O
21116	In	ADP	O
21116	one	NUM	O
21116	case	NOUN	O
21116	of	ADP	O
21116	a	DET	O
21116	severe	ADJ	O
21116	toxic	ADJ	O
21116	relapse	NOUN	O
21116	of	ADP	O
21116	colitis	NOUN	DISEASE
21116	ulcerosa	NOUN	O
21116	during	ADP	O
21116	early	ADJ	O
21116	pregnancy	NOUN	O
21116	,	PUNCT	O
21116	remission	NOUN	O
21116	was	VERB	O
21116	achieved	VERB	O
21116	in	ADP	O
21116	a	DET	O
21116	patient	NOUN	O
21116	while	ADP	O
21116	fully	ADV	O
21116	maintaining	VERB	O
21116	the	DET	O
21116	pregnancy	NOUN	O
21116	.	PUNCT	O
21117	The	DET	O
21117	24	NUM	O
21117	strains	NOUN	O
21117	of	ADP	O
21117	Mycobacterium	PROPN	O
21117	simiae	NOUN	O
21117	described	VERB	O
21117	in	ADP	O
21117	this	DET	O
21117	report	NOUN	O
21117	were	VERB	O
21117	isolated	VERB	O
21117	from	ADP	O
21117	12	NUM	O
21117	black	ADJ	O
21117	Africans	PROPN	O
21117	,	PUNCT	O
21117	6	NUM	O
21117	from	ADP	O
21117	white	ADJ	O
21117	Europeans	PROPN	O
21117	,	PUNCT	O
21117	5	NUM	O
21117	from	ADP	O
21117	primates	NOUN	O
21117	and	CCONJ	O
21117	1	NUM	O
21117	from	ADP	O
21117	a	DET	O
21117	leprosy	NOUN	DISEASE
21117	infected	VERB	O
21117	Armadillo	PROPN	O
21117	.	PUNCT	O
21118	These	DET	O
21118	strains	NOUN	O
21118	form	VERB	O
21118	3	NUM	O
21118	groups	NOUN	O
21118	having	VERB	O
21118	the	DET	O
21118	similar	ADJ	O
21118	morphologic	NOUN	O
21118	and	CCONJ	O
21118	cultural	ADJ	O
21118	properties	NOUN	O
21118	as	ADP	O
21118	M.	PROPN	O
21118	intracellulare	VERB	O
21118	.	PUNCT	O
21119	Two	NUM	O
21119	groups	NOUN	O
21119	were	VERB	O
21119	similar	ADJ	O
21119	with	ADP	O
21119	respect	NOUN	O
21119	to	ADP	O
21119	pigmentation	NOUN	O
21119	,	PUNCT	O
21119	urease	NUM	O
21119	activity	NOUN	O
21119	and	CCONJ	O
21119	niacin	ADJ	O
21119	production	NOUN	O
21119	but	CCONJ	O
21119	differed	VERB	O
21119	serologically	ADV	O
21119	,	PUNCT	O
21119	the	DET	O
21119	second	ADJ	O
21119	group	NOUN	O
21119	being	VERB	O
21119	of	ADP	O
21119	M.	PROPN	O
21119	intracellulare	NOUN	O
21119	serotype	NOUN	O
21119	18	NUM	O
21119	.	PUNCT	O
21120	The	DET	O
21120	third	ADJ	O
21120	group	NOUN	O
21120	was	VERB	O
21120	less	ADV	O
21120	homogenous	ADJ	O
21120	and	CCONJ	O
21120	was	VERB	O
21120	intermediate	ADJ	O
21120	to	ADP	O
21120	M.	PROPN	O
21120	simiae	NOUN	O
21120	and	CCONJ	O
21120	M.	PROPN	O
21120	intracellulare	NOUN	O
21120	.	PUNCT	O
21121	Thus	ADV	O
21121	M.	PROPN	O
21121	simiae	NOUN	O
21121	belong	VERB	O
21121	to	ADP	O
21121	the	DET	O
21121	M.	PROPN	O
21121	avium	NOUN	O
21121	-	PUNCT	O
21121	intracellulare	ADJ	O
21121	-	PUNCT	O
21121	simiae	ADJ	O
21121	-	PUNCT	O
21121	scrofulaceum	NOUN	O
21121	(	PUNCT	O
21121	MAISS	PROPN	O
21121	)	PUNCT	O
21121	complex	NOUN	O
21121	.	PUNCT	O
21122	Two	NUM	O
21122	cases	NOUN	O
21122	of	ADP	O
21122	well	ADV	O
21122	characterized	VERB	O
21122	pulmonary	ADJ	O
21122	disease	NOUN	O
21122	progressed	VERB	O
21122	like	ADP	O
21122	M.	PROPN	O
21122	avium	NOUN	O
21122	mycobacteriosis	NOUN	O
21122	.	PUNCT	O
21123	Male	PROPN	O
21123	Sprague	PROPN	O
21123	-	PUNCT	O
21123	Dawley	PROPN	O
21123	rats	NOUN	O
21123	consumed	VERB	O
21123	a	DET	O
21123	diet	NOUN	O
21123	to	ADP	O
21123	which	ADJ	O
21123	100	NUM	O
21123	ppm	NOUN	O
21123	of	ADP	O
21123	various	ADJ	O
21123	polychlorinated	VERB	O
21123	biphenyl	NOUN	O
21123	(	PUNCT	O
21123	PCB	PROPN	O
21123	)	PUNCT	O
21123	mixtures	NOUN	O
21123	(	PUNCT	O
21123	Aroclors	NOUN	O
21123	1248	NUM	O
21123	,	PUNCT	O
21123	1254	NUM	O
21123	,	PUNCT	O
21123	and	CCONJ	O
21123	1262	NUM	O
21123	)	PUNCT	O
21123	were	VERB	O
21123	added	VERB	O
21123	for	ADP	O
21123	one	NUM	O
21123	year	NOUN	O
21123	.	PUNCT	O
21124	Rats	NOUN	O
21124	were	VERB	O
21124	hepatectomized	VERB	O
21124	at	ADP	O
21124	13	NUM	O
21124	,	PUNCT	O
21124	26	NUM	O
21124	,	PUNCT	O
21124	and	CCONJ	O
21124	52	NUM	O
21124	weeks	NOUN	O
21124	during	ADP	O
21124	feeding	NOUN	O
21124	and	CCONJ	O
21124	at	ADP	O
21124	13	NUM	O
21124	weeks	NOUN	O
21124	following	VERB	O
21124	the	DET	O
21124	discontinuation	NOUN	O
21124	of	ADP	O
21124	the	DET	O
21124	PCB	PROPN	O
21124	diets	NOUN	O
21124	.	PUNCT	O
21125	The	DET	O
21125	liver	NOUN	O
21125	homogenates	NOUN	O
21125	of	ADP	O
21125	these	DET	O
21125	rats	NOUN	O
21125	had	VERB	O
21125	an	DET	O
21125	increase	NOUN	O
21125	in	ADP	O
21125	protein	NOUN	O
21125	and	CCONJ	O
21125	RNA	PROPN	O
21125	on	ADP	O
21125	a	DET	O
21125	DNA	NOUN	O
21125	basis	NOUN	O
21125	and	CCONJ	O
21125	an	DET	O
21125	increase	NOUN	O
21125	in	ADP	O
21125	lipid	NOUN	O
21125	and	CCONJ	O
21125	a	DET	O
21125	decrease	NOUN	O
21125	in	ADP	O
21125	DNA	NOUN	O
21125	on	ADP	O
21125	the	DET	O
21125	liver	NOUN	O
21125	weight	NOUN	O
21125	basis	NOUN	O
21125	.	PUNCT	O
21126	The	DET	O
21126	hepatic	ADJ	O
21126	microsomes	NOUN	O
21126	from	ADP	O
21126	these	DET	O
21126	livers	NOUN	O
21126	also	ADV	O
21126	had	VERB	O
21126	an	DET	O
21126	increase	NOUN	O
21126	in	ADP	O
21126	protein	NOUN	O
21126	and	CCONJ	O
21126	cytochrome	NOUN	O
21126	P-450	ADP	O
21126	.	PUNCT	O
21127	The	DET	O
21127	RNA	PROPN	O
21127	/	SYM	O
21127	microsomal	ADJ	O
21127	protein	NOUN	O
21127	levels	NOUN	O
21127	were	VERB	O
21127	decreased	VERB	O
21127	,	PUNCT	O
21127	and	CCONJ	O
21127	no	DET	O
21127	marked	ADJ	O
21127	alterations	NOUN	O
21127	were	VERB	O
21127	recorded	VERB	O
21127	for	ADP	O
21127	the	DET	O
21127	phospholipids	NOUN	O
21127	and	CCONJ	O
21127	cholesterol	NOUN	O
21127	on	ADP	O
21127	a	DET	O
21127	microsomal	ADJ	O
21127	protein	NOUN	O
21127	basis	NOUN	O
21127	.	PUNCT	O
21128	Increased	VERB	O
21128	enzymatic	ADJ	O
21128	activity	NOUN	O
21128	was	VERB	O
21128	recorded	VERB	O
21128	for	ADP	O
21128	N	NOUN	O
21128	-	PUNCT	O
21128	demethylase	NOUN	O
21128	and	CCONJ	O
21128	nitroreductase	NOUN	O
21128	.	PUNCT	O
21129	However	ADV	O
21129	,	PUNCT	O
21129	the	DET	O
21129	specific	ADJ	O
21129	activity	NOUN	O
21129	of	ADP	O
21129	glucose-6-phosphatase	NOUN	O
21129	was	VERB	O
21129	decreased	VERB	O
21129	throughout	ADP	O
21129	the	DET	O
21129	treatment	NOUN	O
21129	period	NOUN	O
21129	.	PUNCT	O
21130	In	ADP	O
21130	previous	ADJ	O
21130	communications	NOUN	O
21130	we	PRON	O
21130	have	VERB	O
21130	demonstrated	VERB	O
21130	that	ADP	O
21130	the	DET	O
21130	subunits	NOUN	O
21130	of	ADP	O
21130	normal	ADJ	O
21130	human	ADJ	O
21130	erythrocyte	NOUN	O
21130	purine	NOUN	O
21130	nucleoside	NOUN	O
21130	phosphorylase	NOUN	O
21130	can	VERB	O
21130	be	VERB	O
21130	resolved	VERB	O
21130	into	ADP	O
21130	four	NUM	O
21130	major	ADJ	O
21130	(	PUNCT	O
21130	1	NUM	O
21130	-	SYM	O
21130	4	NUM	O
21130	)	PUNCT	O
21130	and	CCONJ	O
21130	two	NUM	O
21130	minor	ADJ	O
21130	(	PUNCT	O
21130	1p	NOUN	O
21130	and	CCONJ	O
21130	2p	NUM	O
21130	)	PUNCT	O
21130	components	NOUN	O
21130	with	ADP	O
21130	the	DET	O
21130	same	ADJ	O
21130	molecular	ADJ	O
21130	weight	NOUN	O
21130	but	CCONJ	O
21130	different	ADJ	O
21130	apparent	ADJ	O
21130	isoelectric	ADJ	O
21130	points	NOUN	O
21130	(	PUNCT	O
21130	and	CCONJ	O
21130	net	ADJ	O
21130	ionic	ADJ	O
21130	charge	NOUN	O
21130	)	PUNCT	O
21130	.	PUNCT	O
21131	The	DET	O
21131	existence	NOUN	O
21131	of	ADP	O
21131	subunits	NOUN	O
21131	with	ADP	O
21131	different	ADJ	O
21131	charge	NOUN	O
21131	results	NOUN	O
21131	in	ADP	O
21131	a	DET	O
21131	complex	ADJ	O
21131	isoelectric	ADJ	O
21131	focusing	NOUN	O
21131	pattern	NOUN	O
21131	of	ADP	O
21131	the	DET	O
21131	native	ADJ	O
21131	erythrocytic	ADJ	O
21131	enzyme	NOUN	O
21131	.	PUNCT	O
21132	In	ADP	O
21132	contrast	NOUN	O
21132	,	PUNCT	O
21132	the	DET	O
21132	isoelectric	ADJ	O
21132	focusing	NOUN	O
21132	pattern	NOUN	O
21132	of	ADP	O
21132	the	DET	O
21132	native	ADJ	O
21132	enzyme	NOUN	O
21132	obtained	VERB	O
21132	from	ADP	O
21132	cultured	ADJ	O
21132	human	ADJ	O
21132	fibroblasts	NOUN	O
21132	is	VERB	O
21132	simpler	ADJ	O
21132	.	PUNCT	O
21133	The	DET	O
21133	multiple	ADJ	O
21133	native	ADJ	O
21133	isoenzymes	NOUN	O
21133	obtained	VERB	O
21133	from	ADP	O
21133	human	ADJ	O
21133	erythrocytes	NOUN	O
21133	and	CCONJ	O
21133	human	ADJ	O
21133	brain	NOUN	O
21133	have	VERB	O
21133	isoelectric	ADJ	O
21133	points	NOUN	O
21133	ranging	VERB	O
21133	from	ADP	O
21133	5.0	NUM	O
21133	to	ADP	O
21133	6.4	NUM	O
21133	and	CCONJ	O
21133	from	ADP	O
21133	5.2	NUM	O
21133	to	ADP	O
21133	5.8	NUM	O
21133	respectively	ADV	O
21133	,	PUNCT	O
21133	whereas	ADP	O
21133	cultured	ADJ	O
21133	human	ADJ	O
21133	fibroblasts	NOUN	O
21133	have	VERB	O
21133	two	NUM	O
21133	major	ADJ	O
21133	native	ADJ	O
21133	isoenzymes	NOUN	O
21133	with	ADP	O
21133	apparent	ADJ	O
21133	isoelectric	ADJ	O
21133	points	NOUN	O
21133	of	ADP	O
21133	5.1	NUM	O
21133	and	CCONJ	O
21133	5.6	NUM	O
21133	.	PUNCT	O
21134	Purine	PROPN	O
21134	nucleoside	NOUN	O
21134	phosphorylase	NOUN	O
21134	has	VERB	O
21134	been	VERB	O
21134	purified	VERB	O
21134	at	ADP	O
21134	least	ADJ	O
21134	a	DET	O
21134	hundredfold	NOUN	O
21134	from	ADP	O
21134	35S	NUM	O
21134	-	PUNCT	O
21134	labeled	VERB	O
21134	cultured	ADJ	O
21134	human	ADJ	O
21134	fibroblasts	NOUN	O
21134	.	PUNCT	O
21135	A	DET	O
21135	two	NUM	O
21135	-	PUNCT	O
21135	dimensional	ADJ	O
21135	electrophoretic	ADJ	O
21135	analysis	NOUN	O
21135	of	ADP	O
21135	the	DET	O
21135	denatured	VERB	O
21135	purified	VERB	O
21135	normal	ADJ	O
21135	fibroblast	NOUN	O
21135	enzyme	NOUN	O
21135	revealed	VERB	O
21135	that	ADP	O
21135	it	PRON	O
21135	consists	VERB	O
21135	mainly	ADV	O
21135	of	ADP	O
21135	subunit	NOUN	O
21135	1	NUM	O
21135	(	PUNCT	O
21135	90	NUM	O
21135	%	NOUN	O
21135	)	PUNCT	O
21135	with	ADP	O
21135	small	ADJ	O
21135	amounts	NOUN	O
21135	of	ADP	O
21135	subunits	NOUN	O
21135	2	NUM	O
21135	(	PUNCT	O
21135	10	NUM	O
21135	%	NOUN	O
21135	)	PUNCT	O
21135	and	CCONJ	O
21135	3	NUM	O
21135	(	PUNCT	O
21135	1	NUM	O
21135	%	NOUN	O
21135	)	PUNCT	O
21135	.	PUNCT	O
21136	This	DET	O
21136	accounts	VERB	O
21136	for	ADP	O
21136	the	DET	O
21136	observed	ADJ	O
21136	differences	NOUN	O
21136	between	ADP	O
21136	the	DET	O
21136	native	ADJ	O
21136	isoelectric	ADJ	O
21136	focusing	NOUN	O
21136	and	CCONJ	O
21136	the	DET	O
21136	electrophoretic	ADJ	O
21136	patterns	NOUN	O
21136	of	ADP	O
21136	the	DET	O
21136	erythrocyte	NOUN	O
21136	and	CCONJ	O
21136	fibroblast	ADJ	O
21136	enzymes	NOUN	O
21136	.	PUNCT	O
21137	The	DET	O
21137	purine	NOUN	O
21137	nucleoside	ADJ	O
21137	phosphorylase	NOUN	O
21137	subunit	NOUN	O
21137	1	NUM	O
21137	is	VERB	O
21137	detectable	ADJ	O
21137	in	ADP	O
21137	the	DET	O
21137	autoradiogram	NOUN	O
21137	from	ADP	O
21137	a	DET	O
21137	two	NUM	O
21137	-	PUNCT	O
21137	dimensional	ADJ	O
21137	electrophoretic	ADJ	O
21137	analysis	NOUN	O
21137	of	ADP	O
21137	a	DET	O
21137	crude	NOUN	O
21137	,	PUNCT	O
21137	unpurified	ADJ	O
21137	extract	NOUN	O
21137	of	ADP	O
21137	35S	NUM	O
21137	-	PUNCT	O
21137	labeled	VERB	O
21137	cultured	ADJ	O
21137	normal	ADJ	O
21137	human	ADJ	O
21137	fibroblasts	NOUN	O
21137	.	PUNCT	O
21138	The	DET	O
21138	fibroblast	NOUN	O
21138	phosphorylase	NOUN	O
21138	coincides	VERB	O
21138	with	ADP	O
21138	the	DET	O
21138	erythrocytic	NOUN	O
21138	subunit	NOUN	O
21138	1	NUM	O
21138	of	ADP	O
21138	the	DET	O
21138	same	ADJ	O
21138	enzyme	NOUN	O
21138	,	PUNCT	O
21138	and	CCONJ	O
21138	the	DET	O
21138	cultured	ADJ	O
21138	fibroblasts	NOUN	O
21138	of	ADP	O
21138	a	DET	O
21138	purine	NOUN	O
21138	nucleoside	NOUN	O
21138	phosphorylase	NOUN	O
21138	deficient	ADJ	O
21138	patient	NOUN	O
21138	(	PUNCT	O
21138	patient	ADJ	O
21138	I	PRON	O
21138	)	PUNCT	O
21138	lack	VERB	O
21138	this	DET	O
21138	protein	NOUN	O
21138	component	NOUN	O
21138	,	PUNCT	O
21138	genetically	ADV	O
21138	confirming	VERB	O
21138	the	DET	O
21138	identity	NOUN	O
21138	of	ADP	O
21138	the	DET	O
21138	purine	NOUN	O
21138	nucleoside	ADJ	O
21138	phosphorylase	NOUN	O
21138	subunit	NOUN	O
21138	in	ADP	O
21138	cultured	ADJ	O
21138	fibroblasts	NOUN	O
21138	.	PUNCT	O
21139	The	DET	O
21139	procedures	NOUN	O
21139	for	ADP	O
21139	lymphocyte	ADJ	O
21139	activation	NOUN	O
21139	and	CCONJ	O
21139	for	ADP	O
21139	removing	VERB	O
21139	the	DET	O
21139	cells	NOUN	O
21139	from	ADP	O
21139	the	DET	O
21139	radioactive	ADJ	O
21139	loading	NOUN	O
21139	solution	NOUN	O
21139	in	ADP	O
21139	incubation	NOUN	O
21139	medium	NOUN	O
21139	were	VERB	O
21139	modified	VERB	O
21139	to	PART	O
21139	routinely	ADV	O
21139	obtain	VERB	O
21139	significant	ADJ	O
21139	and	CCONJ	O
21139	reproducible	ADJ	O
21139	45Ca2	NUM	O
21139	+	SYM	O
21139	uptakes	NOUN	O
21139	in	ADP	O
21139	mitogen	NOUN	O
21139	-	PUNCT	O
21139	induced	VERB	O
21139	mouse	NOUN	O
21139	T	PROPN	O
21139	and	CCONJ	O
21139	B	PROPN	O
21139	lymphocytes	NOUN	O
21139	.	PUNCT	O
21140	Factors	NOUN	O
21140	such	ADJ	O
21140	as	ADP	O
21140	mouse	NOUN	O
21140	strain	NOUN	O
21140	,	PUNCT	O
21140	lymphocyte	ADJ	O
21140	origin	NOUN	O
21140	,	PUNCT	O
21140	and	CCONJ	O
21140	media	NOUN	O
21140	pH	NOUN	O
21140	were	VERB	O
21140	not	ADV	O
21140	critical	ADJ	O
21140	to	ADP	O
21140	the	DET	O
21140	45Ca2	NUM	O
21140	+	SYM	O
21140	uptake	ADJ	O
21140	measurements	NOUN	O
21140	.	PUNCT	O
21141	In	ADP	O
21141	contrast	NOUN	O
21141	,	PUNCT	O
21141	factors	NOUN	O
21141	such	ADJ	O
21141	as	ADP	O
21141	lymphocyte	ADJ	O
21141	cell	NOUN	O
21141	concentration	NOUN	O
21141	during	ADP	O
21141	mitogenic	ADJ	O
21141	activation	NOUN	O
21141	,	PUNCT	O
21141	filtering	VERB	O
21141	the	DET	O
21141	45Ca2+:3H2O	NUM	O
21141	mixtures	NOUN	O
21141	,	PUNCT	O
21141	and	CCONJ	O
21141	the	DET	O
21141	nature	NOUN	O
21141	and	CCONJ	O
21141	purity	NOUN	O
21141	of	ADP	O
21141	the	DET	O
21141	B	PROPN	O
21141	-	PUNCT	O
21141	cell	NOUN	O
21141	mitogens	NOUN	O
21141	were	VERB	O
21141	critical	ADJ	O
21141	for	ADP	O
21141	obtaining	VERB	O
21141	maximal	ADJ	O
21141	and	CCONJ	O
21141	reproducible	ADJ	O
21141	45Ca2	NUM	O
21141	+	SYM	O
21141	uptakes	NOUN	O
21141	.	PUNCT	O
21142	Centrifugation	NOUN	O
21142	through	ADP	O
21142	silicone	NOUN	O
21142	oil	NOUN	O
21142	into	ADP	O
21142	sucrose	NOUN	O
21142	was	VERB	O
21142	an	DET	O
21142	efficient	ADJ	O
21142	and	CCONJ	O
21142	rapid	ADJ	O
21142	procedure	NOUN	O
21142	for	ADP	O
21142	separating	VERB	O
21142	the	DET	O
21142	cells	NOUN	O
21142	from	ADP	O
21142	the	DET	O
21142	radioactive	ADJ	O
21142	loading	NOUN	O
21142	solution	NOUN	O
21142	in	ADP	O
21142	the	DET	O
21142	incubation	NOUN	O
21142	medium	NOUN	O
21142	.	PUNCT	O
21143	Using	VERB	O
21143	optimal	ADJ	O
21143	conditions	NOUN	O
21143	,	PUNCT	O
21143	an	DET	O
21143	approximate	ADJ	O
21143	twofold	NOUN	O
21143	increase	NOUN	O
21143	in	ADP	O
21143	45Ca2	NUM	O
21143	+	SYM	O
21143	uptake	NOUN	O
21143	(	PUNCT	O
21143	representing	VERB	O
21143	an	DET	O
21143	influx	NOUN	O
21143	of	ADP	O
21143	approximately	ADV	O
21143	97	NUM	O
21143	amol	NOUN	O
21143	per	ADP	O
21143	lymphocyte	NOUN	O
21143	and	CCONJ	O
21143	an	DET	O
21143	increase	NOUN	O
21143	in	ADP	O
21143	average	ADJ	O
21143	cellular	ADJ	O
21143	Ca2	NOUN	O
21143	+	CCONJ	O
21143	of	ADP	O
21143	approximately	ADV	O
21143	0.72	NUM	O
21143	mM	PROPN	O
21143	)	PUNCT	O
21143	was	VERB	O
21143	routinely	ADV	O
21143	obtained	VERB	O
21143	with	ADP	O
21143	purified	ADJ	O
21143	mouse	NOUN	O
21143	lymphocytes	VERB	O
21143	activated	VERB	O
21143	with	ADP	O
21143	a	DET	O
21143	variety	NOUN	O
21143	of	ADP	O
21143	T-	PROPN	O
21143	and	CCONJ	O
21143	B	NOUN	O
21143	-	PUNCT	O
21143	cell	NOUN	O
21143	mitogens	NOUN	O
21143	(	PUNCT	O
21143	using	VERB	O
21143	concentrations	NOUN	O
21143	resulting	VERB	O
21143	in	ADP	O
21143	maximal	ADJ	O
21143	[	PUNCT	O
21143	3H]thymidine	NUM	O
21143	incorporation	NOUN	O
21143	)	PUNCT	O
21143	.	PUNCT	O
21144	A	DET	O
21144	larger	ADJ	O
21144	45Ca2	NUM	O
21144	+	CCONJ	O
21144	uptake	NOUN	O
21144	was	VERB	O
21144	routinely	ADV	O
21144	obtained	VERB	O
21144	with	ADP	O
21144	mitogenic	ADJ	O
21144	concentrations	NOUN	O
21144	of	ADP	O
21144	A23187	PROPN	O
21144	,	PUNCT	O
21144	a	DET	O
21144	divalent	ADJ	O
21144	cation	NOUN	O
21144	ionophore	NOUN	O
21144	stimulating	VERB	O
21144	T	PROPN	O
21144	cells	NOUN	O
21144	.	PUNCT	O
21145	Experiments	NOUN	O
21145	employing	VERB	O
21145	[	PUNCT	O
21145	14C]sucrose	NUM	O
21145	and	CCONJ	O
21145	[	PUNCT	O
21145	14C]inulin	NUM	O
21145	with	ADP	O
21145	control	NOUN	O
21145	and	CCONJ	O
21145	mitogen	NOUN	O
21145	-	PUNCT	O
21145	induced	VERB	O
21145	lymphocytes	NOUN	O
21145	showed	VERB	O
21145	that	ADP	O
21145	the	DET	O
21145	trapped	VERB	O
21145	extracellular	ADJ	O
21145	fluid	ADJ	O
21145	measurements	NOUN	O
21145	in	ADP	O
21145	the	DET	O
21145	cell	NOUN	O
21145	pellets	NOUN	O
21145	should	VERB	O
21145	be	VERB	O
21145	used	VERB	O
21145	to	PART	O
21145	correct	VERB	O
21145	the	DET	O
21145	magnitude	NOUN	O
21145	of	ADP	O
21145	the	DET	O
21145	45Ca2	NUM	O
21145	+	SYM	O
21145	uptake	ADJ	O
21145	measurements	NOUN	O
21145	.	PUNCT	O
21146	A	DET	O
21146	high	ADJ	O
21146	-	PUNCT	O
21146	affinity	NOUN	O
21146	(	PUNCT	O
21146	Km	PROPN	O
21146	=	SYM	O
21146	2.7	NUM	O
21146	x	SYM	O
21146	10(-7	NUM	O
21146	)	PUNCT	O
21146	M	NOUN	O
21146	)	PUNCT	O
21146	energy	NOUN	O
21146	-	PUNCT	O
21146	requiring	VERB	O
21146	methionine	NOUN	O
21146	-	PUNCT	O
21146	transport	NOUN	O
21146	system	NOUN	O
21146	has	VERB	O
21146	been	VERB	O
21146	characterized	VERB	O
21146	in	ADP	O
21146	RM	PROPN	O
21146	46	NUM	O
21146	and	CCONJ	O
21146	RM	PROPN	O
21146	48	NUM	O
21146	,	PUNCT	O
21146	two	NUM	O
21146	different	ADJ	O
21146	PAO	PROPN	O
21146	methionine	NOUN	O
21146	auxotrophs	NOUN	O
21146	of	ADP	O
21146	Pseudomonas	PROPN	O
21146	aeruginosa	NOUN	O
21146	.	PUNCT	O
21147	After	ADP	O
21147	8	NUM	O
21147	s	NOUN	O
21147	of	ADP	O
21147	transport	NOUN	O
21147	40	NUM	O
21147	-	PUNCT	O
21147	-60	PUNCT	O
21147	%	NOUN	O
21147	of	ADP	O
21147	the	DET	O
21147	methionine	NOUN	O
21147	label	NOUN	O
21147	in	ADP	O
21147	the	DET	O
21147	alcohol	NOUN	O
21147	extract	NOUN	O
21147	appears	VERB	O
21147	in	ADP	O
21147	S	PROPN	O
21147	-	PUNCT	O
21147	adenosyl	NOUN	O
21147	-	PUNCT	O
21147	L	NOUN	O
21147	-	PUNCT	O
21147	methionine	PROPN	O
21147	(	PUNCT	O
21147	SAM	PROPN	O
21147	)	PUNCT	O
21147	with	ADP	O
21147	the	DET	O
21147	remaining	VERB	O
21147	activity	NOUN	O
21147	in	ADP	O
21147	free	ADJ	O
21147	methionine	NOUN	O
21147	.	PUNCT	O
21148	Methionine	PROPN	O
21148	transport	NOUN	O
21148	required	VERB	O
21148	a	DET	O
21148	high	ADJ	O
21148	degree	NOUN	O
21148	of	ADP	O
21148	structural	ADJ	O
21148	specificity	NOUN	O
21148	for	ADP	O
21148	transport	NOUN	O
21148	.	PUNCT	O
21149	Stimulation	NOUN	O
21149	of	ADP	O
21149	transport	NOUN	O
21149	occurred	VERB	O
21149	by	ADP	O
21149	addition	NOUN	O
21149	of	ADP	O
21149	glucose	NOUN	O
21149	or	CCONJ	O
21149	organic	ADJ	O
21149	acids	NOUN	O
21149	.	PUNCT	O
21150	The	DET	O
21150	ability	NOUN	O
21150	of	ADP	O
21150	a	DET	O
21150	given	VERB	O
21150	substrate	NOUN	O
21150	to	PART	O
21150	stimulate	VERB	O
21150	transport	NOUN	O
21150	was	VERB	O
21150	related	VERB	O
21150	to	ADP	O
21150	the	DET	O
21150	type	NOUN	O
21150	of	ADP	O
21150	carbon	NOUN	O
21150	source	NOUN	O
21150	used	VERB	O
21150	for	ADP	O
21150	growth	NOUN	O
21150	.	PUNCT	O
21151	Transport	PROPN	O
21151	was	VERB	O
21151	sensitive	ADJ	O
21151	to	ADP	O
21151	sulfhydryl	NOUN	O
21151	reagents	NOUN	O
21151	and	CCONJ	O
21151	required	VERB	O
21151	oxidative	ADJ	O
21151	phosphorylation	NOUN	O
21151	,	PUNCT	O
21151	as	ADP	O
21151	indicated	VERB	O
21151	by	ADP	O
21151	the	DET	O
21151	inhibitory	ADJ	O
21151	effects	NOUN	O
21151	of	ADP	O
21151	anaerobiosis	NOUN	O
21151	,	PUNCT	O
21151	cyanide	NOUN	O
21151	,	PUNCT	O
21151	and	CCONJ	O
21151	arsenate	VERB	O
21151	.	PUNCT	O
21152	The	DET	O
21152	degree	NOUN	O
21152	of	ADP	O
21152	inhibition	NOUN	O
21152	by	ADP	O
21152	arsenate	NOUN	O
21152	correlated	VERB	O
21152	with	ADP	O
21152	the	DET	O
21152	level	NOUN	O
21152	of	ADP	O
21152	ATP	PROPN	O
21152	in	ADP	O
21152	the	DET	O
21152	cell	NOUN	O
21152	.	PUNCT	O
21153	Rapid	ADJ	O
21153	transport	NOUN	O
21153	in	ADP	O
21153	a	DET	O
21153	SAM	PROPN	O
21153	-	PUNCT	O
21153	deficient	ADJ	O
21153	mutant	NOUN	O
21153	(	PUNCT	O
21153	TM	NOUN	O
21153	1	NUM	O
21153	)	PUNCT	O
21153	and	CCONJ	O
21153	inhibition	NOUN	O
21153	by	ADP	O
21153	arsenate	NOUN	O
21153	of	ADP	O
21153	transport	NOUN	O
21153	in	ADP	O
21153	this	DET	O
21153	mutant	NOUN	O
21153	suggested	VERB	O
21153	that	ADP	O
21153	SAM	PROPN	O
21153	formation	NOUN	O
21153	was	VERB	O
21153	not	ADV	O
21153	directly	ADV	O
21153	linked	VERB	O
21153	to	ADP	O
21153	transport	VERB	O
21153	and	CCONJ	O
21153	that	ADP	O
21153	ATP	PROPN	O
21153	supplied	VERB	O
21153	energy	NOUN	O
21153	for	ADP	O
21153	transport	NOUN	O
21153	.	PUNCT	O
21154	Inhibition	NOUN	O
21154	by	ADP	O
21154	arsenate	NOUN	O
21154	was	VERB	O
21154	more	ADV	O
21154	severe	ADJ	O
21154	in	ADP	O
21154	glucose-	NOUN	O
21154	compared	VERB	O
21154	to	ADP	O
21154	citrate	NOUN	O
21154	-	PUNCT	O
21154	stimulated	VERB	O
21154	cells	NOUN	O
21154	.	PUNCT	O
21155	This	DET	O
21155	result	NOUN	O
21155	was	VERB	O
21155	also	ADV	O
21155	observed	VERB	O
21155	with	ADP	O
21155	proline	ADJ	O
21155	transport	NOUN	O
21155	indicating	VERB	O
21155	that	ADP	O
21155	this	DET	O
21155	was	VERB	O
21155	not	ADV	O
21155	a	DET	O
21155	peculiarity	NOUN	O
21155	of	ADP	O
21155	the	DET	O
21155	methionine	ADJ	O
21155	-	PUNCT	O
21155	transport	NOUN	O
21155	system	NOUN	O
21155	.	PUNCT	O
21156	These	DET	O
21156	data	NOUN	O
21156	emphasize	VERB	O
21156	the	DET	O
21156	close	ADJ	O
21156	link	NOUN	O
21156	between	ADP	O
21156	glucose	NOUN	O
21156	metabolism	NOUN	O
21156	,	PUNCT	O
21156	ATP	PROPN	O
21156	levels	NOUN	O
21156	,	PUNCT	O
21156	and	CCONJ	O
21156	transport	NOUN	O
21156	.	PUNCT	O
21157	This	DET	O
21157	ATP	PROPN	O
21157	level	NOUN	O
21157	is	VERB	O
21157	not	ADV	O
21157	so	ADV	O
21157	critical	ADJ	O
21157	for	ADP	O
21157	transport	NOUN	O
21157	in	ADP	O
21157	cells	NOUN	O
21157	metabolizing	VERB	O
21157	citrate	ADJ	O
21157	.	PUNCT	O
21158	The	DET	O
21158	development	NOUN	O
21158	of	ADP	O
21158	bile	ADJ	O
21158	acid	NOUN	O
21158	synthesis	NOUN	O
21158	,	PUNCT	O
21158	secretion	NOUN	O
21158	and	CCONJ	O
21158	absorption	NOUN	O
21158	was	VERB	O
21158	studied	VERB	O
21158	in	ADP	O
21158	laboratory	NOUN	O
21158	animals	NOUN	O
21158	and	CCONJ	O
21158	humans	NOUN	O
21158	.	PUNCT	O
21159	Although	ADP	O
21159	there	ADV	O
21159	is	VERB	O
21159	species	NOUN	O
21159	variation	NOUN	O
21159	,	PUNCT	O
21159	a	DET	O
21159	developmental	ADJ	O
21159	pattern	NOUN	O
21159	emerges	VERB	O
21159	.	PUNCT	O
21160	Bile	ADJ	O
21160	acid	NOUN	O
21160	pool	NOUN	O
21160	size	NOUN	O
21160	and	CCONJ	O
21160	synthesis	NOUN	O
21160	rates	NOUN	O
21160	increase	VERB	O
21160	during	ADP	O
21160	the	DET	O
21160	final	ADJ	O
21160	third	NOUN	O
21160	of	ADP	O
21160	gestation	NOUN	O
21160	and	CCONJ	O
21160	the	DET	O
21160	perinatal	ADJ	O
21160	period	NOUN	O
21160	.	PUNCT	O
21161	Similarly	ADV	O
21161	,	PUNCT	O
21161	bile	ADJ	O
21161	acid	NOUN	O
21161	secretion	NOUN	O
21161	is	VERB	O
21161	a	DET	O
21161	developing	VERB	O
21161	function	NOUN	O
21161	during	ADP	O
21161	the	DET	O
21161	final	ADJ	O
21161	third	NOUN	O
21161	of	ADP	O
21161	gestation	NOUN	O
21161	and	CCONJ	O
21161	is	VERB	O
21161	incompletely	ADV	O
21161	developed	VERB	O
21161	at	ADP	O
21161	birth	NOUN	O
21161	.	PUNCT	O
21162	The	DET	O
21162	ileal	ADJ	O
21162	mechanism	NOUN	O
21162	for	ADP	O
21162	active	ADJ	O
21162	bile	ADJ	O
21162	acid	NOUN	O
21162	transport	NOUN	O
21162	is	VERB	O
21162	absent	ADJ	O
21162	at	ADP	O
21162	birth	NOUN	O
21162	and	CCONJ	O
21162	only	ADV	O
21162	develops	VERB	O
21162	during	ADP	O
21162	the	DET	O
21162	first	ADJ	O
21162	2	NUM	O
21162	-	PUNCT	O
21162	-5	NOUN	O
21162	weeks	NOUN	O
21162	or	CCONJ	O
21162	more	ADJ	O
21162	of	ADP	O
21162	life	NOUN	O
21162	.	PUNCT	O
21163	It	PRON	O
21163	is	VERB	O
21163	therefore	ADV	O
21163	possible	ADJ	O
21163	that	ADP	O
21163	the	DET	O
21163	intestinal	ADJ	O
21163	conservation	NOUN	O
21163	of	ADP	O
21163	bile	ADJ	O
21163	acid	NOUN	O
21163	is	VERB	O
21163	ineffective	ADJ	O
21163	in	ADP	O
21163	the	DET	O
21163	newborn	NOUN	O
21163	.	PUNCT	O
21164	The	DET	O
21164	combination	NOUN	O
21164	of	ADP	O
21164	immaturity	NOUN	O
21164	of	ADP	O
21164	bile	ADJ	O
21164	acid	NOUN	O
21164	synthesis	NOUN	O
21164	,	PUNCT	O
21164	secretion	NOUN	O
21164	and	CCONJ	O
21164	absorption	NOUN	O
21164	probably	ADV	O
21164	contributes	VERB	O
21164	to	ADP	O
21164	the	DET	O
21164	fat	ADJ	O
21164	malabsorption	NOUN	O
21164	especially	ADV	O
21164	evident	ADJ	O
21164	in	ADP	O
21164	low	ADJ	O
21164	birth	NOUN	O
21164	weight	NOUN	O
21164	infants	NOUN	O
21164	.	PUNCT	O
21165	Finally	ADV	O
21165	,	PUNCT	O
21165	synthesis	NOUN	O
21165	,	PUNCT	O
21165	secretion	NOUN	O
21165	and	CCONJ	O
21165	absorption	NOUN	O
21165	can	VERB	O
21165	be	VERB	O
21165	induced	VERB	O
21165	to	PART	O
21165	develop	VERB	O
21165	early	ADV	O
21165	by	ADP	O
21165	the	DET	O
21165	administration	NOUN	O
21165	of	ADP	O
21165	adrenocortical	ADJ	O
21165	steroid	NOUN	O
21165	.	PUNCT	O
21166	The	DET	O
21166	induction	NOUN	O
21166	of	ADP	O
21166	mechanisms	NOUN	O
21166	for	ADP	O
21166	bile	ADJ	O
21166	acid	ADJ	O
21166	metabolism	NOUN	O
21166	raises	VERB	O
21166	the	DET	O
21166	possibility	NOUN	O
21166	of	ADP	O
21166	therapeutic	ADJ	O
21166	intervention	NOUN	O
21166	in	ADP	O
21166	severe	ADJ	O
21166	cases	NOUN	O
21166	of	ADP	O
21166	neonatal	ADJ	O
21166	malabsorption	NOUN	O
21166	of	ADP	O
21166	lipid	NOUN	O
21166	.	PUNCT	O
21167	Drug	NOUN	O
21167	-	PUNCT	O
21167	metabolizing	VERB	O
21167	enzymes	NOUN	O
21167	,	PUNCT	O
21167	especially	ADV	O
21167	monooxygenases	VERB	O
21167	,	PUNCT	O
21167	play	VERB	O
21167	a	DET	O
21167	major	ADJ	O
21167	role	NOUN	O
21167	in	ADP	O
21167	biotransformation	NOUN	O
21167	and	CCONJ	O
21167	detoxification	NOUN	O
21167	of	ADP	O
21167	many	ADJ	O
21167	foreign	ADJ	O
21167	compounds	NOUN	O
21167	including	VERB	O
21167	environmental	ADJ	O
21167	carcinogens	NOUN	O
21167	.	PUNCT	O
21168	Although	ADP	O
21168	largely	ADV	O
21168	localized	VERB	O
21168	in	ADP	O
21168	the	DET	O
21168	liver	NOUN	O
21168	they	PRON	O
21168	are	VERB	O
21168	also	ADV	O
21168	found	VERB	O
21168	in	ADP	O
21168	the	DET	O
21168	small	ADJ	O
21168	intestine	NOUN	O
21168	,	PUNCT	O
21168	which	ADJ	O
21168	is	VERB	O
21168	the	DET	O
21168	portal	NOUN	O
21168	of	ADP	O
21168	entry	NOUN	O
21168	of	ADP	O
21168	dietary	ADJ	O
21168	toxins	NOUN	O
21168	.	PUNCT	O
21169	Therefore	ADV	O
21169	cytochrome	NOUN	O
21169	P-450	ADP	O
21169	content	NOUN	O
21169	as	ADV	O
21169	well	ADV	O
21169	as	ADP	O
21169	monooxygenase	NOUN	O
21169	(	PUNCT	O
21169	7-ethoxycoumarin	ADJ	O
21169	O	NOUN	O
21169	-	PUNCT	O
21169	deethylase	NOUN	O
21169	)	PUNCT	O
21169	and	CCONJ	O
21169	NADPH	PROPN	O
21169	-	PUNCT	O
21169	cytochrome	NOUN	O
21169	c	NOUN	O
21169	reductase	NOUN	O
21169	activities	NOUN	O
21169	were	VERB	O
21169	determined	VERB	O
21169	in	ADP	O
21169	surgical	ADJ	O
21169	specimens	NOUN	O
21169	of	ADP	O
21169	the	DET	O
21169	human	ADJ	O
21169	small	ADJ	O
21169	intestine	NOUN	O
21169	and	CCONJ	O
21169	in	ADP	O
21169	jejunal	ADJ	O
21169	biopsy	ADJ	O
21169	material	NOUN	O
21169	obtained	VERB	O
21169	from	ADP	O
21169	patients	NOUN	O
21169	by	ADP	O
21169	use	NOUN	O
21169	of	ADP	O
21169	a	DET	O
21169	hydraulic	ADJ	O
21169	biopsy	NOUN	O
21169	instrument	NOUN	O
21169	.	PUNCT	O
21170	Microsomes	NOUN	O
21170	were	VERB	O
21170	prepared	VERB	O
21170	from	ADP	O
21170	surgical	ADJ	O
21170	material	NOUN	O
21170	;	PUNCT	O
21170	these	DET	O
21170	ranged	VERB	O
21170	in	ADP	O
21170	P-450	ADJ	O
21170	content	NOUN	O
21170	from	ADP	O
21170	30	NUM	O
21170	to	PART	O
21170	120	NUM	O
21170	pmole	NOUN	O
21170	/	SYM	O
21170	mg	PROPN	O
21170	protein	NOUN	O
21170	and	CCONJ	O
21170	in	ADP	O
21170	monooxygenase	NOUN	O
21170	activity	NOUN	O
21170	from	ADP	O
21170	60	NUM	O
21170	to	PART	O
21170	110	NUM	O
21170	pmole	NOUN	O
21170	/	SYM	O
21170	min	NOUN	O
21170	-	PUNCT	O
21170	mg	PROPN	O
21170	protein	NOUN	O
21170	.	PUNCT	O
21171	In	ADP	O
21171	the	DET	O
21171	20,000	NUM	O
21171	g	DET	O
21171	supernatant	NOUN	O
21171	of	ADP	O
21171	the	DET	O
21171	homogenized	ADJ	O
21171	biopsy	NOUN	O
21171	material	NOUN	O
21171	,	PUNCT	O
21171	monooxygenase	NOUN	O
21171	activity	NOUN	O
21171	was	VERB	O
21171	undetectable	ADJ	O
21171	in	ADP	O
21171	patients	NOUN	O
21171	who	NOUN	O
21171	had	VERB	O
21171	total	ADJ	O
21171	villous	ADJ	O
21171	atrophy	NOUN	O
21171	,	PUNCT	O
21171	and	CCONJ	O
21171	low	ADJ	O
21171	enzyme	NOUN	O
21171	rates	NOUN	O
21171	were	VERB	O
21171	found	VERB	O
21171	when	ADV	O
21171	the	DET	O
21171	mucosa	NOUN	O
21171	showed	VERB	O
21171	a	DET	O
21171	partial	ADJ	O
21171	villous	ADJ	O
21171	atrophy	NOUN	O
21171	.	PUNCT	O
21172	The	DET	O
21172	mucosal	NOUN	O
21172	monooxygenase	NOUN	O
21172	activity	NOUN	O
21172	of	ADP	O
21172	patients	NOUN	O
21172	with	ADP	O
21172	normal	ADJ	O
21172	jejunal	ADJ	O
21172	histology	NOUN	O
21172	and	CCONJ	O
21172	steatorrhea	NOUN	DISEASE
21172	was	VERB	O
21172	significantly	ADV	O
21172	higher	ADJ	O
21172	than	ADP	O
21172	in	ADP	O
21172	mucosa	NOUN	O
21172	with	ADP	O
21172	villous	ADJ	O
21172	atrophy	NOUN	O
21172	but	CCONJ	O
21172	was	VERB	O
21172	only	ADV	O
21172	half	NOUN	O
21172	of	ADP	O
21172	that	DET	O
21172	observed	VERB	O
21172	in	ADP	O
21172	normal	ADJ	O
21172	controls	NOUN	O
21172	.	PUNCT	O
21173	These	DET	O
21173	eight	NUM	O
21173	control	NOUN	O
21173	patients	NOUN	O
21173	had	VERB	O
21173	normal	ADJ	O
21173	histology	NOUN	O
21173	and	CCONJ	O
21173	no	DET	O
21173	malassimilation	NOUN	O
21173	.	PUNCT	O
21174	Our	ADJ	O
21174	results	NOUN	O
21174	suggest	VERB	O
21174	that	ADP	O
21174	monooxygenase	NOUN	O
21174	activity	NOUN	O
21174	in	ADP	O
21174	the	DET	O
21174	human	ADJ	O
21174	small	ADJ	O
21174	intestine	NOUN	O
21174	is	VERB	O
21174	dependent	ADJ	O
21174	on	ADP	O
21174	the	DET	O
21174	morphological	ADJ	O
21174	integrity	NOUN	O
21174	of	ADP	O
21174	the	DET	O
21174	mucosa	NOUN	O
21174	and	CCONJ	O
21174	that	ADP	O
21174	in	ADP	O
21174	normal	ADJ	O
21174	mucosa	NOUN	O
21174	the	DET	O
21174	enzyme	NOUN	O
21174	rates	NOUN	O
21174	are	VERB	O
21174	reduced	VERB	O
21174	when	ADV	O
21174	malassimilation	NOUN	O
21174	is	VERB	O
21174	present	ADJ	O
21174	.	PUNCT	O
21175	In	ADP	O
21175	chemical	ADJ	O
21175	terms	NOUN	O
21175	the	DET	O
21175	mediators	NOUN	O
21175	of	ADP	O
21175	inflammation	NOUN	O
21175	can	VERB	O
21175	be	VERB	O
21175	divided	VERB	O
21175	in	ADP	O
21175	amines	NOUN	O
21175	(	PUNCT	O
21175	histamine	NOUN	O
21175	,	PUNCT	O
21175	serotonine	NOUN	O
21175	)	PUNCT	O
21175	,	PUNCT	O
21175	peptides	NOUN	O
21175	(	PUNCT	O
21175	ECF	PROPN	O
21175	-	PUNCT	O
21175	A	PROPN	O
21175	,	PUNCT	O
21175	bradykinin	NOUN	O
21175	)	PUNCT	O
21175	,	PUNCT	O
21175	proteins	NOUN	O
21175	(	PUNCT	O
21175	lysosomal	ADJ	O
21175	enzymes	NOUN	O
21175	)	PUNCT	O
21175	,	PUNCT	O
21175	and	CCONJ	O
21175	lipids	NOUN	O
21175	.	PUNCT	O
21176	They	PRON	O
21176	mainly	ADV	O
21176	act	VERB	O
21176	at	ADP	O
21176	three	NUM	O
21176	levels	NOUN	O
21176	:	PUNCT	O
21176	1	PUNCT	O
21176	.	PUNCT	O
21176	)	PUNCT	O
21177	They	PRON	O
21177	induce	VERB	O
21177	vascular	ADJ	O
21177	reactions	NOUN	O
21177	and	CCONJ	O
21177	are	VERB	O
21177	responsible	ADJ	O
21177	for	ADP	O
21177	the	DET	O
21177	classical	ADJ	O
21177	symptoms	NOUN	O
21177	of	ADP	O
21177	inflammation	NOUN	O
21177	,	PUNCT	O
21177	2	NUM	O
21177	.	PUNCT	O
21177	)	PUNCT	O
21178	they	PRON	O
21178	define	VERB	O
21178	and	CCONJ	O
21178	modulate	VERB	O
21178	the	DET	O
21178	cellular	ADJ	O
21178	response	NOUN	O
21178	towards	ADP	O
21178	the	DET	O
21178	inflammatory	ADJ	O
21178	stimulus	NOUN	O
21178	such	ADJ	O
21178	as	ADP	O
21178	the	DET	O
21178	morphology	NOUN	O
21178	of	ADP	O
21178	the	DET	O
21178	tissue	NOUN	O
21178	infiltrate	NOUN	O
21178	,	PUNCT	O
21178	3	NUM	O
21178	.	PUNCT	O
21178	)	PUNCT	O
21179	they	PRON	O
21179	act	VERB	O
21179	on	ADP	O
21179	haemostasis	NOUN	O
21179	by	ADP	O
21179	interaction	NOUN	O
21179	with	ADP	O
21179	platelets	NOUN	O
21179	.	PUNCT	O
21180	While	ADP	O
21180	in	ADP	O
21180	the	DET	O
21180	past	ADJ	O
21180	investigations	NOUN	O
21180	on	ADP	O
21180	classical	ADJ	O
21180	mediators	NOUN	O
21180	have	VERB	O
21180	dominated	VERB	O
21180	research	NOUN	O
21180	,	PUNCT	O
21180	recently	ADV	O
21180	the	DET	O
21180	biological	ADJ	O
21180	role	NOUN	O
21180	of	ADP	O
21180	lipid	NOUN	O
21180	mediators	NOUN	O
21180	has	VERB	O
21180	been	VERB	O
21180	appreciated	VERB	O
21180	.	PUNCT	O
21181	They	PRON	O
21181	can	VERB	O
21181	be	VERB	O
21181	detected	VERB	O
21181	only	ADV	O
21181	in	ADP	O
21181	minute	NOUN	O
21181	quantities	NOUN	O
21181	;	PUNCT	O
21181	they	PRON	O
21181	often	ADV	O
21181	have	VERB	O
21181	a	DET	O
21181	short	ADJ	O
21181	half	ADJ	O
21181	-	PUNCT	O
21181	life	NOUN	O
21181	and	CCONJ	O
21181	are	VERB	O
21181	not	ADV	O
21181	preformed	VERB	O
21181	within	ADP	O
21181	the	DET	O
21181	cells	NOUN	O
21181	.	PUNCT	O
21182	The	DET	O
21182	most	ADV	O
21182	common	ADJ	O
21182	precursor	NOUN	O
21182	of	ADP	O
21182	the	DET	O
21182	lipid	NOUN	O
21182	mediators	NOUN	O
21182	is	VERB	O
21182	arachidonic	ADJ	O
21182	acid	NOUN	O
21182	.	PUNCT	O
21183	This	DET	O
21183	unsaturated	ADJ	O
21183	fatty	ADJ	O
21183	acid	NOUN	O
21183	is	VERB	O
21183	generated	VERB	O
21183	from	ADP	O
21183	phospholipids	NOUN	O
21183	after	ADP	O
21183	phospholipase	NOUN	O
21183	activation	NOUN	O
21183	of	ADP	O
21183	cells	NOUN	O
21183	and	CCONJ	O
21183	is	VERB	O
21183	transformed	VERB	O
21183	by	ADP	O
21183	the	DET	O
21183	enzyme	NOUN	O
21183	cycloxygenase	NOUN	O
21183	to	ADP	O
21183	a	DET	O
21183	series	NOUN	O
21183	of	ADP	O
21183	compounds	NOUN	O
21183	such	ADJ	O
21183	as	ADP	O
21183	the	DET	O
21183	prostaglandins	NOUN	O
21183	.	PUNCT	O
21184	They	PRON	O
21184	induce	VERB	O
21184	the	DET	O
21184	classical	ADJ	O
21184	signs	NOUN	O
21184	of	ADP	O
21184	inflammation	NOUN	O
21184	such	ADJ	O
21184	asvescular	ADJ	O
21184	dilatation	NOUN	O
21184	,	PUNCT	O
21184	increase	NOUN	O
21184	in	ADP	O
21184	permeability	NOUN	O
21184	,	PUNCT	O
21184	pain	NOUN	O
21184	,	PUNCT	O
21184	hyperalgesia	NOUN	O
21184	etc	X	O
21184	.	PUNCT	O
21185	By	ADP	O
21185	the	DET	O
21185	same	ADJ	O
21185	process	NOUN	O
21185	,	PUNCT	O
21185	the	DET	O
21185	thromboxanes	NOUN	O
21185	and	CCONJ	O
21185	prostacycline	NOUN	O
21185	are	VERB	O
21185	generated	VERB	O
21185	which	ADJ	O
21185	mainly	ADV	O
21185	act	VERB	O
21185	on	ADP	O
21185	the	DET	O
21185	coagulation	NOUN	O
21185	system	NOUN	O
21185	.	PUNCT	O
21186	Various	ADJ	O
21186	products	NOUN	O
21186	are	VERB	O
21186	obtained	VERB	O
21186	from	ADP	O
21186	arachidonic	ADJ	O
21186	acid	NOUN	O
21186	via	ADP	O
21186	lipoxygenase	NOUN	O
21186	activation	NOUN	O
21186	.	PUNCT	O
21187	To	ADP	O
21187	these	DET	O
21187	belong	VERB	O
21187	a	DET	O
21187	factor	NOUN	O
21187	chemically	ADV	O
21187	not	ADV	O
21187	completely	ADV	O
21187	defined	VERB	O
21187	with	ADP	O
21187	classical	ADJ	O
21187	SRS	PROPN	O
21187	-	PUNCT	O
21187	A	NOUN	O
21187	activity	NOUN	O
21187	;	PUNCT	O
21187	there	ADV	O
21187	is	VERB	O
21187	strong	ADJ	O
21187	evidence	NOUN	O
21187	that	ADP	O
21187	PAF	PROPN	O
21187	and	CCONJ	O
21187	ECF	PROPN	O
21187	are	VERB	O
21187	formed	VERB	O
21187	on	ADP	O
21187	the	DET	O
21187	same	ADJ	O
21187	line	NOUN	O
21187	.	PUNCT	O
21188	Experiments	NOUN	O
21188	in	ADP	O
21188	recent	ADJ	O
21188	years	NOUN	O
21188	have	VERB	O
21188	supported	VERB	O
21188	the	DET	O
21188	idea	NOUN	O
21188	that	ADP	O
21188	neutrophils	NOUN	O
21188	and	CCONJ	O
21188	mononuclear	NOUN	O
21188	cells	NOUN	O
21188	are	VERB	O
21188	by	ADP	O
21188	far	ADV	O
21188	the	DET	O
21188	main	ADJ	O
21188	producers	NOUN	O
21188	of	ADP	O
21188	lipid	NOUN	O
21188	mediators	NOUN	O
21188	,	PUNCT	O
21188	thus	ADV	O
21188	indicating	VERB	O
21188	the	DET	O
21188	cellular	ADJ	O
21188	interdependence	NOUN	O
21188	during	ADP	O
21188	the	DET	O
21188	inflammatory	ADJ	O
21188	process	NOUN	O
21188	.	PUNCT	O
21189	Adult	ADJ	O
21189	rat	NOUN	O
21189	heart	NOUN	O
21189	was	VERB	O
21189	dissociated	VERB	O
21189	into	ADP	O
21189	a	DET	O
21189	single	ADJ	O
21189	cell	NOUN	O
21189	suspension	NOUN	O
21189	by	ADP	O
21189	a	DET	O
21189	perfusion	NOUN	O
21189	technique	NOUN	O
21189	which	ADJ	O
21189	used	VERB	O
21189	0.05	NUM	O
21189	%	NOUN	O
21189	collagenase	NOUN	O
21189	and	CCONJ	O
21189	0.1	NUM	O
21189	%	NOUN	O
21189	hyaluronidase	NOUN	O
21189	in	ADP	O
21189	Krebs	PROPN	O
21189	-	PUNCT	O
21189	Ringer	PROPN	O
21189	phosphate	NOUN	O
21189	buffer	NOUN	O
21189	(	PUNCT	O
21189	KRP	PROPN	O
21189	)	PUNCT	O
21189	.	PUNCT	O
21190	The	DET	O
21190	non	ADJ	O
21190	-	PUNCT	O
21190	muscle	NOUN	O
21190	cells	NOUN	O
21190	of	ADP	O
21190	the	DET	O
21190	suspension	NOUN	O
21190	were	VERB	O
21190	separated	VERB	O
21190	from	ADP	O
21190	the	DET	O
21190	myocytes	NOUN	O
21190	by	ADP	O
21190	centrifugation	NOUN	O
21190	through	ADP	O
21190	3	NUM	O
21190	%	NOUN	O
21190	Ficoll	PROPN	O
21190	solution	NOUN	O
21190	in	ADP	O
21190	KRP	PROPN	O
21190	with	ADP	O
21190	0.01	NUM	O
21190	mM	PROPN	O
21190	Ca2	NOUN	O
21190	+	SYM	O
21190	.	PUNCT	O
21191	An	DET	O
21191	approximately	ADV	O
21191	90	NUM	O
21191	%	NOUN	O
21191	pure	ADJ	O
21191	suspension	NOUN	O
21191	of	ADP	O
21191	isolated	ADJ	O
21191	single	ADJ	O
21191	muscle	NOUN	O
21191	cells	NOUN	O
21191	was	VERB	O
21191	obtained	VERB	O
21191	with	ADP	O
21191	this	DET	O
21191	method	NOUN	O
21191	.	PUNCT	O
21192	The	DET	O
21192	effects	NOUN	O
21192	of	ADP	O
21192	the	DET	O
21192	successive	ADJ	O
21192	steps	NOUN	O
21192	in	ADP	O
21192	the	DET	O
21192	dissociation	NOUN	O
21192	procedure	NOUN	O
21192	on	ADP	O
21192	the	DET	O
21192	ultrastructure	NOUN	O
21192	of	ADP	O
21192	the	DET	O
21192	heart	NOUN	O
21192	were	VERB	O
21192	studied	VERB	O
21192	by	ADP	O
21192	scanning	NOUN	O
21192	and	CCONJ	O
21192	transmission	NOUN	O
21192	electron	NOUN	O
21192	microscopy	NOUN	O
21192	.	PUNCT	O
21193	After	ADP	O
21193	30	NUM	O
21193	minutes	NOUN	O
21193	of	ADP	O
21193	enzyme	NOUN	O
21193	digestion	NOUN	O
21193	,	PUNCT	O
21193	dissociation	NOUN	O
21193	of	ADP	O
21193	the	DET	O
21193	inner	ADJ	O
21193	endothelial	ADJ	O
21193	lining	NOUN	O
21193	of	ADP	O
21193	the	DET	O
21193	ventricle	NOUN	O
21193	into	ADP	O
21193	single	ADJ	O
21193	cells	NOUN	O
21193	or	CCONJ	O
21193	small	ADJ	O
21193	groups	NOUN	O
21193	of	ADP	O
21193	cells	NOUN	O
21193	became	VERB	O
21193	apparent	ADJ	O
21193	.	PUNCT	O
21194	In	ADP	O
21194	addition	NOUN	O
21194	,	PUNCT	O
21194	the	DET	O
21194	underlying	VERB	O
21194	cardiac	ADJ	O
21194	skeleton	NOUN	O
21194	began	VERB	O
21194	to	PART	O
21194	disintegrate	VERB	O
21194	and	CCONJ	O
21194	linear	ADJ	O
21194	arrays	NOUN	O
21194	of	ADP	O
21194	cardiac	ADJ	O
21194	muscle	NOUN	O
21194	cells	NOUN	O
21194	were	VERB	O
21194	observed	VERB	O
21194	.	PUNCT	O
21195	After	ADP	O
21195	45	NUM	O
21195	minutes	NOUN	O
21195	of	ADP	O
21195	enzyme	NOUN	O
21195	digestion	NOUN	O
21195	the	DET	O
21195	number	NOUN	O
21195	of	ADP	O
21195	released	VERB	O
21195	single	ADJ	O
21195	cells	NOUN	O
21195	was	VERB	O
21195	higher	ADJ	O
21195	because	ADP	O
21195	of	ADP	O
21195	the	DET	O
21195	separation	NOUN	O
21195	of	ADP	O
21195	intercalated	ADJ	O
21195	discs	NOUN	O
21195	.	PUNCT	O
21196	The	DET	O
21196	majority	NOUN	O
21196	of	ADP	O
21196	non	ADJ	O
21196	-	PUNCT	O
21196	muscle	NOUN	O
21196	cells	NOUN	O
21196	were	VERB	O
21196	by	ADP	O
21196	now	ADV	O
21196	dissociated	VERB	O
21196	from	ADP	O
21196	the	DET	O
21196	surfaces	NOUN	O
21196	of	ADP	O
21196	muscle	NOUN	O
21196	cells	NOUN	O
21196	.	PUNCT	O
21197	Widening	VERB	O
21197	of	ADP	O
21197	the	DET	O
21197	lateral	ADJ	O
21197	intercellular	ADJ	O
21197	spaces	NOUN	O
21197	between	ADP	O
21197	the	DET	O
21197	myocardial	ADJ	O
21197	cells	NOUN	O
21197	was	VERB	O
21197	associated	VERB	O
21197	with	ADP	O
21197	separation	NOUN	O
21197	of	ADP	O
21197	desmosomes	NOUN	O
21197	.	PUNCT	O
21198	In	ADP	O
21198	some	DET	O
21198	regions	NOUN	O
21198	of	ADP	O
21198	the	DET	O
21198	heart	NOUN	O
21198	,	PUNCT	O
21198	intact	ADJ	O
21198	desmosomes	NOUN	O
21198	,	PUNCT	O
21198	fasciae	ADJ	O
21198	adherentes	NOUN	O
21198	and	CCONJ	O
21198	gap	NOUN	O
21198	junctions	NOUN	O
21198	were	VERB	O
21198	observed	VERB	O
21198	even	ADV	O
21198	though	ADP	O
21198	lateral	ADJ	O
21198	intercellular	ADJ	O
21198	spaces	NOUN	O
21198	had	VERB	O
21198	widened	VERB	O
21198	greatly	ADV	O
21198	.	PUNCT	O
21199	The	DET	O
21199	majority	NOUN	O
21199	of	ADP	O
21199	myocardial	ADJ	O
21199	cells	NOUN	O
21199	had	VERB	O
21199	become	VERB	O
21199	separated	VERB	O
21199	from	ADP	O
21199	one	NUM	O
21199	another	DET	O
21199	after	ADP	O
21199	60	NUM	O
21199	minutes	NOUN	O
21199	of	ADP	O
21199	enzyme	NOUN	O
21199	digestion	NOUN	O
21199	.	PUNCT	O
21200	Separation	NOUN	O
21200	of	ADP	O
21200	gap	NOUN	O
21200	junctional	ADJ	O
21200	sites	NOUN	O
21200	took	VERB	O
21200	place	NOUN	O
21200	in	ADP	O
21200	two	NUM	O
21200	ways	NOUN	O
21200	:	PUNCT	O
21200	(	PUNCT	O
21200	1	PUNCT	O
21200	)	PUNCT	O
21200	by	ADP	O
21200	'	PUNCT	O
21200	unzipping	VERB	O
21200	'	PUNCT	O
21200	them	PRON	O
21200	through	ADP	O
21200	enzyme	NOUN	O
21200	action	NOUN	O
21200	;	PUNCT	O
21200	(	PUNCT	O
21200	2	PUNCT	O
21200	)	PUNCT	O
21200	by	ADP	O
21200	tearing	VERB	O
21200	them	PRON	O
21200	mechanically	ADV	O
21200	.	PUNCT	O
21201	Gap	NOUN	O
21201	junction	NOUN	O
21201	remnants	NOUN	O
21201	were	VERB	O
21201	sometimes	ADV	O
21201	observed	VERB	O
21201	in	ADP	O
21201	a	DET	O
21201	vesiculated	ADJ	O
21201	state	NOUN	O
21201	within	ADP	O
21201	the	DET	O
21201	cell	NOUN	O
21201	.	PUNCT	O
21202	The	DET	O
21202	dissociation	NOUN	O
21202	of	ADP	O
21202	the	DET	O
21202	heart	NOUN	O
21202	was	VERB	O
21202	ineffective	ADJ	O
21202	when	ADV	O
21202	perfused	VERB	O
21202	with	ADP	O
21202	media	NOUN	O
21202	containing	VERB	O
21202	1.0	NUM	O
21202	or	CCONJ	O
21202	2	NUM	O
21202	mM	NOUN	O
21202	Ca2	NOUN	O
21202	+	SYM	O
21202	.	PUNCT	O
21203	Alcian	ADJ	O
21203	blue	ADJ	O
21203	treatment	NOUN	O
21203	after	ADP	O
21203	60	NUM	O
21203	minutes	NOUN	O
21203	of	ADP	O
21203	enzyme	NOUN	O
21203	digestion	NOUN	O
21203	revealed	VERB	O
21203	that	ADP	O
21203	the	DET	O
21203	basement	NOUN	O
21203	membrane	NOUN	O
21203	,	PUNCT	O
21203	and	CCONJ	O
21203	its	ADJ	O
21203	accompanying	VERB	O
21203	collagen	NOUN	O
21203	fibrils	NOUN	O
21203	,	PUNCT	O
21203	was	VERB	O
21203	still	ADV	O
21203	present	ADJ	O
21203	on	ADP	O
21203	the	DET	O
21203	plasma	NOUN	O
21203	membrane	NOUN	O
21203	of	ADP	O
21203	dissociated	ADJ	O
21203	single	ADJ	O
21203	cells	NOUN	O
21203	.	PUNCT	O
21204	The	DET	O
21204	isolated	ADJ	O
21204	myocardial	ADJ	O
21204	cells	NOUN	O
21204	retained	VERB	O
21204	their	ADJ	O
21204	normal	ADJ	O
21204	morphological	ADJ	O
21204	characteristics	NOUN	O
21204	.	PUNCT	O
21205	This	DET	O
21205	study	NOUN	O
21205	has	VERB	O
21205	enabled	VERB	O
21205	us	PRON	O
21205	to	PART	O
21205	understand	VERB	O
21205	in	ADP	O
21205	detail	NOUN	O
21205	how	ADV	O
21205	dismantlement	ADJ	O
21205	of	ADP	O
21205	highly	ADV	O
21205	ordered	VERB	O
21205	adult	NOUN	O
21205	cardiac	ADJ	O
21205	tissue	NOUN	O
21205	into	ADP	O
21205	a	DET	O
21205	single	ADJ	O
21205	cell	NOUN	O
21205	suspension	NOUN	O
21205	takes	VERB	O
21205	place	NOUN	O
21205	.	PUNCT	O
21206	Cell	NOUN	O
21206	suspensions	NOUN	O
21206	of	ADP	O
21206	this	DET	O
21206	type	NOUN	O
21206	should	VERB	O
21206	be	VERB	O
21206	invaluable	ADJ	O
21206	in	ADP	O
21206	the	DET	O
21206	study	NOUN	O
21206	of	ADP	O
21206	metabolic	ADJ	O
21206	and	CCONJ	O
21206	synthetic	ADJ	O
21206	activities	NOUN	O
21206	in	ADP	O
21206	adult	NOUN	O
21206	myocardial	ADJ	O
21206	cells	NOUN	O
21206	.	PUNCT	O
21207	An	DET	O
21207	armed	ADJ	O
21207	robbery	NOUN	O
21207	alarm	NOUN	O
21207	system	NOUN	O
21207	was	VERB	O
21207	implemented	VERB	O
21207	in	ADP	O
21207	48	NUM	O
21207	different	ADJ	O
21207	stores	NOUN	O
21207	in	ADP	O
21207	two	NUM	O
21207	separate	ADJ	O
21207	geographical	ADJ	O
21207	areas	NOUN	O
21207	for	ADP	O
21207	6	NUM	O
21207	months	NOUN	O
21207	and	CCONJ	O
21207	12	NUM	O
21207	months	NOUN	O
21207	,	PUNCT	O
21207	respectively	ADV	O
21207	.	PUNCT	O
21208	The	DET	O
21208	alarms	NOUN	O
21208	were	VERB	O
21208	placed	VERB	O
21208	in	ADP	O
21208	the	DET	O
21208	two	NUM	O
21208	separate	ADJ	O
21208	areas	NOUN	O
21208	at	ADP	O
21208	different	ADJ	O
21208	times	NOUN	O
21208	and	CCONJ	O
21208	all	DET	O
21208	alarms	NOUN	O
21208	were	VERB	O
21208	eventually	ADV	O
21208	removed	VERB	O
21208	.	PUNCT	O
21209	Thus	ADV	O
21209	,	PUNCT	O
21209	multiple	ADJ	O
21209	baseline	NOUN	O
21209	and	CCONJ	O
21209	reversal	NOUN	O
21209	strategies	NOUN	O
21209	were	VERB	O
21209	used	VERB	O
21209	to	PART	O
21209	evaluate	VERB	O
21209	program	NOUN	O
21209	impact	NOUN	O
21209	.	PUNCT	O
21210	A	DET	O
21210	device	NOUN	O
21210	planted	VERB	O
21210	in	ADP	O
21210	a	DET	O
21210	cash	NOUN	O
21210	drawer	NOUN	O
21210	was	VERB	O
21210	triggered	VERB	O
21210	whenever	ADV	O
21210	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
hyperplastic 	 O 	O
transformation 	 O 	O
	PUNCT	O
43902	.	PUNCT	O
43903	Mouse	NOUN	O
43903	tail	NOUN	O
43903	epidermis	NOUN	O
43903	shows	VERB	O
43903	a	DET	O
43903	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Maternal 	 O 	O
and 	 O 	O
fetal 	 O 	DISEASE
lungs 	 O 	O
differed 	 O 	O
greatly 	 O 	O
in 	 O 	O
their 	 O 	O
handling 	 O 	O
of 	 O 	O
PGF2 	 O 	O
alpha 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
As 	 O 	O
ODOD 	 O 	O
is 	 O 	O
usually 	 O 	O
transmitted 	 O 	O
as 	 O 	O
an 	 O 	O
autosomal 	 O 	O
dominant 	 O 	O
, 	 O 	O
and 	 O 	O
in 	 O 	O
view 	 O 	O
of 	 O 	O
the 	 O 	O
unusual 	 O 	O
severity 	 O 	O
of 	 O 	O
the 	 O 	O
manifestations 	 O 	O
in 	 O 	O
our 	 O 	O
patients 	 O 	O
, 	 O 	O
it 	 O 	O
is 	 O 	O
possible 	 O 	O
that 	 O 	O
the 	 O 	O
condition 	 O 	O
is 	 O 	O
heterogeneous 	 O 	O
and 	 O 	O
that 	 O 	O
they 	 O 	O
had 	 O 	O
a 	 O 	O
distinct 	 O 	O
autosomal 	 O 	O
recessive 	 O 	O
form 	 O 	O
of 	 O 	O
the 	 O 	O
disorder 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
to 	 O 	O
5 	 O 	O
normal 	 O 	O
males 	 O 	O
, 	 O 	O
6 	 O 	O
patients 	 O 	O
with 	 O 	O
hemochromatosis 	 DISEASE 	O
prior 	 O 	O
to 	 O 	O
therapeutic 	 O 	O
removal 	 O 	O
of 	 O 	O
iron 	 O 	O
, 	 O 	O
and 	 O 	O
5 	 O 	O
patients 	 O 	O
with 	 O 	O
varying 	 O 	O
levels 	 O 	O
of 	 O 	O
iron 	 O 	O
loading 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Transfusion 	 O 	O
- 	 O 	O
associated 	 O 	O
cytomegalovirus 	 O 	DISEASE
mononucleosis 	 DISEASE 	DISEASE
is 	 O 	O
generally 	 O 	O
considered 	 O 	O
only 	 O 	O
as 	 O 	O
a 	 O 	O
complication 	 O 	O
of 	 O 	O
extracorporeal 	 O 	O
circulation 	 O 	O
following 	 O 	O
cardiac 	 O 	O
surgery 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
incorporation 	 O 	O
13-fold 	 O 	O
in 	 O 	O
host 	 O 	O
liver 	 O 	O
and 	 O 	O
hepatoma 	 O 	O
16 	 O 	O
nuclei 	 O 	O
, 	 O 	O
8-fold 	 O 	O
in 	 O 	O
hepatoma 	 DISEASE 	O
7800 	 O 	O
nuclei 	 O 	O
, 	 O 	O
and 	 O 	O
3-fold 	 O 	O
in 	 O 	O
hepatoma 	 O 	O
7777 	 O 	O
nuclei 	 O 	O
. 	 O 	O
Bleomycin 	 O 	O
stimulates 	 O 	O
[ 	 O 	O
3H]TTP 	 O 	O
incorporation 	 O 	O
13-fold 	 O 	O
in 	 O 	O
host 	 O 	O
liver 	 O 	O
and 	 O 	O
hepatoma 	 O 	O
16 	 O 	O
nuclei 	 O 	O
, 	 O 	O
8-fold 	 O 	O
in 	 O 	O
hepatoma 	 O 	O
7800 	 O 	O
nuclei 	 O 	O
, 	 O 	O
and 	 O 	O
3-fold 	 O 	O
in 	 O 	O
hepatoma 	 DISEASE 	DISEASE
7777 	 O 	O
nuclei 	 O 	O
. 	 O 	O
Dibutyryl 	 O 	O
cycle 	 O 	O
AMP 	 O 	O
and 	 O 	O
theophylline 	 O 	O
have 	 O 	O
two 	 O 	O
effects 	 O 	O
: 	 O 	O
one 	 O 	O
is 	 O 	O
a 	 O 	O
specific 	 O 	O
inhibitory 	 O 	O
action 	 O 	O
on 	 O 	O
cells 	 O 	O
in 	 O 	O
the 	 O 	O
G2 	 O 	O
phase 	 O 	O
and 	 O 	O
the 	 O 	O
second 	 O 	O
is 	 O 	O
a 	 O 	O
short 	 O 	O
- 	 O 	O
term 	 O 	O
action 	 O 	O
limiting 	 O 	O
thymidine 	 O 	O
uptake 	 O 	O
by 	 O 	O
cells 	 O 	O
in 	 O 	O
S 	 O 	O
phase 	 O 	O
without 	 O 	O
affecting 	 O 	O
the 	 O 	O
transition 	 O 	O
of 	 O 	O
cells 	 O 	O
from 	 O 	O
G1 	 O 	O
to 	 O 	O
S. 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
On 	 O 	O
the 	 O 	O
other 	 O 	O
hand 	 O 	O
, 	 O 	O
complete 	 O 	O
neonatal 	 O 	O
thymectomy 	 O 	O
effectively 	 O 	O
and 	 O 	O
completely 	 O 	O
abrogates 	 O 	O
immune 	 O 	O
response 	 O 	O
to 	 O 	O
mammary 	 DISEASE 	DISEASE
tumor 	 DISEASE 	O
target 	 O 	O
cells 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
pulmonary 	 DISEASE 	DISEASE
tuberculosis 	 DISEASE 	DISEASE
and 	 O 	O
10.1 	 O 	O
per 	 O 	O
cent 	 O 	O
had 	 O 	O
extra 	 O 	O
- 	 O 	O
pulmonary 	 O 	O
tuberculosis 	 O 	O
only 	 O 	O
. 	 O 	O
Of 	 O 	O
1884 	 O 	O
patients 	 O 	O
in 	 O 	O
the 	 O 	O
random 	 O 	O
sample 	 O 	O
, 	 O 	O
87.4 	 O 	O
per 	 O 	O
cent 	 O 	O
had 	 O 	O
pulmonary 	 O 	DISEASE
tuberculosis 	 O 	O
only 	 O 	O
, 	 O 	O
2.5 	 O 	O
per 	 O 	O
cent 	 O 	O
had 	 O 	O
pulmonary 	 O 	O
and 	 O 	O
extra 	 O 	O
- 	 O 	O
pulmonary 	 O 	O
tuberculosis 	 O 	O
and 	 O 	O
10.1 	 O 	O
per 	 O 	O
cent 	 O 	O
had 	 O 	O
extra 	 O 	O
- 	 O 	O
pulmonary 	 DISEASE 	DISEASE
tuberculosis 	 DISEASE 	DISEASE
only 	 O 	O
. 	 O 	O
membranous 	 O 	O
nephropathy 	 O 	DISEASE
) 	 O 	O
in 	 O 	O
man 	 O 	O
. 	 O 	O
This 	 O 	O
failure 	 O 	O
to 	 O 	O
modify 	 O 	O
the 	 O 	O
course 	 O 	O
of 	 O 	O
established 	 O 	O
renal 	 O 	O
disease 	 O 	O
( 	 O 	O
AIC 	 O 	O
) 	 O 	O
in 	 O 	O
an 	 O 	O
experimental 	 O 	O
animal 	 O 	O
with 	 O 	O
generally 	 O 	O
available 	 O 	O
pharmacologic 	 O 	O
agents 	 O 	O
, 	 O 	O
is 	 O 	O
similar 	 O 	O
to 	 O 	O
the 	 O 	O
usual 	 O 	O
results 	 O 	O
of 	 O 	O
such 	 O 	O
treatment 	 O 	O
in 	 O 	O
chronic 	 O 	O
renal 	 O 	O
disease 	 O 	O
( 	 O 	O
idiopathic 	 O 	O
membranous 	 DISEASE 	DISEASE
nephropathy 	 DISEASE 	DISEASE
) 	 O 	O
in 	 O 	O
man 	 O 	O
. 	 O 	O
In 	 O 	O
contrast 	 O 	O
to 	 O 	O
the 	 O 	O
other 	 O 	O
system 	 O 	O
( 	 O 	O
Walker 	 O 	O
256 	 O 	O
carcinosarcoma 	 DISEASE 	O
) 	 O 	O
which 	 O 	O
we 	 O 	O
studied 	 O 	O
by 	 O 	O
a 	 O 	O
similar 	 O 	O
method 	 O 	O
, 	 O 	O
in 	 O 	O
the 	 O 	O
DMBA 	 O 	O
- 	 O 	O
induced 	 O 	O
tumours 	 O 	O
we 	 O 	O
found 	 O 	O
a 	 O 	O
close 	 O 	O
parallel 	 O 	O
between 	 O 	O
the 	 O 	O
ESR 	 O 	O
spectra 	 O 	O
before 	 O 	O
and 	 O 	O
after 	 O 	O
lyophilization 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
isoresponse 	 O 	O
surface 	 O 	O
	PUNCT	O
19516	upon	ADP	O
19516	which	ADJ	O
19516	the	DET	O
19516	subject	NOUN	O
19516	reclines	VERB	O
19516	.	PUNCT	O
19517	This	DET	O
19517	surface	NOUN	O
19517	is	VERB	O
19517	curved	VERB	O
19517	from	ADP	O
19517	head	NOUN	O
19517	to	ADP	O
19517	knee	NOUN	O
19517	and	CCONJ	O
19517	from	ADP	O
19517	left	VERB	O
19517	to	ADP	O
19517	right	NOUN	O
19517	,	PUNCT	O
19517	so	ADP	O
19517	that	ADP	O
19517	a	DET	O
19517	gamma	NOUN	O
19517	-	PUNCT	O
19517	ray	NOUN	O
19517	emitting	NOUN	O
19517	object	NOUN	O
19517	is	VERB	O
19517	detected	VERB	O
19517	with	ADP	O
19517	equal	ADJ	O
19517	efficiency	NOUN	O
19517	when	ADV	O
19517	placed	VERB	O
19517	anywhere	ADV	O
19517	upon	ADP	O
19517	it	PRON	O
19517	.	PUNCT	O
19518	The	DET	O
19518	positioner	NOUN	O
19518	and	CCONJ	O
19518	detectors	NOUN	O
19518	are	VERB	O
19518	housed	VERB	O
19518	in	ADP	O
19518	a	DET	O
19518	low	ADJ	O
19518	background	NOUN	O
19518	enclosure	NOUN	O
19518	constructed	VERB	O
19518	of	ADP	O
19518	steel	NOUN	O
19518	31	NUM	O
19518	cm	NOUN	O
19518	thick	ADJ	O
19518	with	ADP	O
19518	a	DET	O
19518	graded	VERB	O
19518	inner	ADJ	O
19518	lining	NOUN	O
19518	of	ADP	O
19518	lead	NOUN	O
19518	+	SYM	O
19518	cadmium	NOUN	O
19518	+	SYM	O
19518	copper	NOUN	O
19518	.	PUNCT	O
19519	Calibration	NOUN	O
19519	of	ADP	O
19519	the	DET	O
19519	system	NOUN	O
19519	was	VERB	O
19519	accomplished	VERB	O
19519	by	ADP	O
19519	administering	VERB	O
19519	trace	NOUN	O
19519	amounts	NOUN	O
19519	of	ADP	O
19519	various	ADJ	O
19519	radionuclides	NOUN	O
19519	to	ADP	O
19519	48	NUM	O
19519	human	ADJ	O
19519	subjects	NOUN	O
19519	of	ADP	O
19519	various	ADJ	O
19519	sizes	NOUN	O
19519	,	PUNCT	O
19519	ranging	VERB	O
19519	in	ADP	O
19519	age	NOUN	O
19519	from	ADP	O
19519	4	NUM	O
19519	-	PUNCT	O
19519	-80	NOUN	O
19519	years	NOUN	O
19519	.	PUNCT	O
19520	Counting	VERB	O
19520	rates	NOUN	O
19520	per	ADP	O
19520	retained	VERB	O
19520	muCi	NOUN	O
19520	at	ADP	O
19520	0.53	NUM	O
19520	,	PUNCT	O
19520	0.66	NUM	O
19520	,	PUNCT	O
19520	1.53	NUM	O
19520	,	PUNCT	O
19520	and	CCONJ	O
19520	2.75	NUM	O
19520	MeV	PROPN	O
19520	(	PUNCT	O
19520	83Rb	PROPN	O
19520	,	PUNCT	O
19520	137Cs	NUM	O
19520	,	PUNCT	O
19520	42	NUM	O
19520	K	NOUN	O
19520	,	PUNCT	O
19520	and	CCONJ	O
19520	24Na	NUM	O
19520	)	PUNCT	O
19520	were	VERB	O
19520	determined	VERB	O
19520	as	ADP	O
19520	a	DET	O
19520	function	NOUN	O
19520	of	ADP	O
19520	body	NOUN	O
19520	size	NOUN	O
19520	and	CCONJ	O
19520	were	VERB	O
19520	compared	VERB	O
19520	with	ADP	O
19520	counting	VERB	O
19520	rates	NOUN	O
19520	per	ADP	O
19520	muCi	NOUN	O
19520	of	ADP	O
19520	corresponding	VERB	O
19520	emitters	NOUN	O
19520	centered	VERB	O
19520	in	ADP	O
19520	a	DET	O
19520	polyethylene	NOUN	O
19520	cylinder	NOUN	O
19520	of	ADP	O
19520	radius	NOUN	O
19520	10.3	NUM	O
19520	cm	NOUN	O
19520	.	PUNCT	O
19521	Limits	NOUN	O
19521	of	ADP	O
19521	detection	NOUN	O
19521	,	PUNCT	O
19521	corresponding	VERB	O
19521	to	ADP	O
19521	three	NUM	O
19521	times	NOUN	O
19521	the	DET	O
19521	standard	ADJ	O
19521	deviation	NOUN	O
19521	of	ADP	O
19521	a	DET	O
19521	50	NUM	O
19521	min	NOUN	O
19521	background	NOUN	O
19521	,	PUNCT	O
19521	were	VERB	O
19521	170	NUM	O
19521	nCi	NOUN	O
19521	90Sr	NUM	O
19521	(	PUNCT	O
19521	via	ADP	O
19521	Bremsstrahlung	PROPN	O
19521	X	NOUN	O
19521	-	PUNCT	O
19521	rays	NOUN	O
19521	)	PUNCT	O
19521	,	PUNCT	O
19521	0.78	NUM	O
19521	nCi	NOUN	O
19521	131I	NUM	O
19521	,	PUNCT	O
19521	0.48	NUM	O
19521	nCi	NOUN	O
19521	83Rb	NUM	O
19521	,	PUNCT	O
19521	0.52	NUM	O
19521	nCi	NOUN	O
19521	137	NUM	O
19521	Cs	PROPN	O
19521	,	PUNCT	O
19521	4.9	NUM	O
19521	nCi	NOUN	O
19521	40	NUM	O
19521	K	PROPN	O
19521	(	PUNCT	O
19521	or	CCONJ	O
19521	5.8	NUM	O
19521	g	NOUN	O
19521	of	ADP	O
19521	natural	ADJ	O
19521	potassium	NOUN	O
19521	)	PUNCT	O
19521	and	CCONJ	O
19521	1.7	NUM	O
19521	nCi	NOUN	O
19521	222Rn	NUM	O
19521	.	PUNCT	O
19522	Oral	ADJ	O
19522	challenge	NOUN	O
19522	tests	VERB	O
19522	with	ADP	O
19522	acetylsalicylic	ADJ	O
19522	acid	NOUN	O
19522	,	PUNCT	O
19522	tartrazine	NOUN	O
19522	or	CCONJ	O
19522	benzoic	NOUN	O
19522	acid	NOUN	O
19522	were	VERB	O
19522	performed	VERB	O
19522	in	ADP	O
19522	7	NUM	O
19522	intolerant	ADJ	O
19522	asthmatic	ADJ	O
19522	patients	NOUN	O
19522	after	ADP	O
19522	a	DET	O
19522	3-day	NUM	O
19522	treatment	NOUN	O
19522	with	ADP	O
19522	either	DET	O
19522	orally	ADV	O
19522	taken	VERB	O
19522	ketotifen	NOUN	O
19522	(	PUNCT	O
19522	1	NUM	O
19522	mg	NOUN	O
19522	twice	ADV	O
19522	daily	ADV	O
19522	)	PUNCT	O
19522	or	CCONJ	O
19522	inhaled	VERB	O
19522	disodium	NOUN	O
19522	cromoglycate	NOUN	O
19522	(	PUNCT	O
19522	20	NUM	O
19522	mg	ADP	O
19522	four	NUM	O
19522	times	NOUN	O
19522	daily	ADV	O
19522	)	PUNCT	O
19522	at	ADP	O
19522	random	ADJ	O
19522	.	PUNCT	O
19523	Protection	NOUN	O
19523	was	VERB	O
19523	noted	VERB	O
19523	with	ADP	O
19523	ketotifen	NOUN	O
19523	in	ADP	O
19523	5	NUM	O
19523	,	PUNCT	O
19523	with	ADP	O
19523	DSCG	PROPN	O
19523	in	ADP	O
19523	3	NUM	O
19523	patients	NOUN	O
19523	.	PUNCT	O
19524	On	ADP	O
19524	the	DET	O
19524	evaluation	NOUN	O
19524	of	ADP	O
19524	the	DET	O
19524	mean	ADJ	O
19524	percentage	NOUN	O
19524	of	ADP	O
19524	the	DET	O
19524	maximum	ADJ	O
19524	decline	NOUN	O
19524	in	ADP	O
19524	the	DET	O
19524	forced	ADJ	O
19524	expiratory	NOUN	O
19524	volume	NOUN	O
19524	in	ADP	O
19524	1	NUM	O
19524	sec	NOUN	O
19524	(	PUNCT	O
19524	FEV1	PROPN	O
19524	)	PUNCT	O
19524	only	ADV	O
19524	ketotifen	NOUN	O
19524	afforded	VERB	O
19524	significant	ADJ	O
19524	protection	NOUN	O
19524	statistically	ADV	O
19524	(	PUNCT	O
19524	p	ADV	O
19524	less	ADJ	O
19524	than	ADP	O
19524	0.05	NUM	O
19524	)	PUNCT	O
19524	.	PUNCT	O
19525	All	ADJ	O
19525	the	DET	O
19525	intolerant	ADJ	O
19525	asthmatics	NOUN	O
19525	studies	NOUN	O
19525	showed	VERB	O
19525	,	PUNCT	O
19525	as	ADP	O
19525	an	DET	O
19525	immunological	ADJ	O
19525	abnormity	NOUN	O
19525	,	PUNCT	O
19525	a	DET	O
19525	slight	ADJ	O
19525	,	PUNCT	O
19525	but	CCONJ	O
19525	significant	ADJ	O
19525	decrease	NOUN	O
19525	of	ADP	O
19525	the	DET	O
19525	C1-inhibitor	NOUN	O
19525	levels	NOUN	O
19525	.	PUNCT	O
19526	Moreover	ADV	O
19526	,	PUNCT	O
19526	in	ADP	O
19526	three	NUM	O
19526	out	ADP	O
19526	of	ADP	O
19526	these	DET	O
19526	the	DET	O
19526	alpha	NOUN	O
19526	1-antitrypsin	NOUN	O
19526	serum	NOUN	O
19526	values	NOUN	O
19526	were	VERB	O
19526	under	ADP	O
19526	the	DET	O
19526	lower	ADV	O
19526	normal	ADJ	O
19526	range	NOUN	O
19526	.	PUNCT	O
19527	Protein	NOUN	O
19527	differing	VERB	O
19527	from	ADP	O
19527	the	DET	O
19527	normal	ADJ	O
19527	one	NOUN	O
19527	by	ADP	O
19527	the	DET	O
19527	content	NOUN	O
19527	of	ADP	O
19527	S	PROPN	O
19527	-	PUNCT	O
19527	S	PROPN	O
19527	-	PUNCT	O
19527	bonds	NOUN	O
19527	and	CCONJ	O
19527	by	ADP	O
19527	the	DET	O
19527	amount	NOUN	O
19527	of	ADP	O
19527	the	DET	O
19527	carbohydrate	NOUN	O
19527	component	NOUN	O
19527	was	VERB	O
19527	found	VERB	O
19527	in	ADP	O
19527	the	DET	O
19527	acid	NOUN	O
19527	-	PUNCT	O
19527	soluble	ADJ	O
19527	fraction	NOUN	O
19527	of	ADP	O
19527	skin	NOUN	O
19527	collagen	NOUN	O
19527	in	ADP	O
19527	rats	NOUN	O
19527	which	ADJ	O
19527	were	VERB	O
19527	fed	VERB	O
19527	the	DET	O
19527	protein	NOUN	O
19527	-	PUNCT	O
19527	free	ADJ	O
19527	diet	NOUN	O
19527	and	CCONJ	O
19527	the	DET	O
19527	protein	NOUN	O
19527	-	PUNCT	O
19527	free	ADJ	O
19527	diet	NOUN	O
19527	with	ADP	O
19527	the	DET	O
19527	glycine	NOUN	O
19527	loading	NOUN	O
19527	for	ADP	O
19527	3	NUM	O
19527	and	CCONJ	O
19527	14	NUM	O
19527	days	NOUN	O
19527	and	CCONJ	O
19527	tryptophan	NOUN	O
19527	for	ADP	O
19527	1	NUM	O
19527	,	PUNCT	O
19527	2	NUM	O
19527	and	CCONJ	O
19527	3	NUM	O
19527	days	NOUN	O
19527	.	PUNCT	O
19528	The	DET	O
19528	result	NOUN	O
19528	testifies	VERB	O
19528	to	ADP	O
19528	the	DET	O
19528	fact	NOUN	O
19528	that	ADP	O
19528	under	ADP	O
19528	extremal	ADJ	O
19528	states	NOUN	O
19528	in	ADP	O
19528	the	DET	O
19528	animal	NOUN	O
19528	skin	NOUN	O
19528	there	ADV	O
19528	occurs	VERB	O
19528	the	DET	O
19528	synthesis	NOUN	O
19528	of	ADP	O
19528	collagen	NOUN	O
19528	the	DET	O
19528	structure	NOUN	O
19528	of	ADP	O
19528	which	ADJ	O
19528	differs	VERB	O
19528	from	ADP	O
19528	that	DET	O
19528	in	ADP	O
19528	the	DET	O
19528	normal	ADJ	O
19528	animal	NOUN	O
19528	skin	NOUN	O
19528	.	PUNCT	O
19529	Unit	NOUN	O
19529	activity	NOUN	O
19529	of	ADP	O
19529	the	DET	O
19529	dorsal	ADJ	O
19529	hippocampus	NOUN	O
19529	in	ADP	O
19529	response	NOUN	O
19529	to	ADP	O
19529	electrical	ADJ	O
19529	stimulation	NOUN	O
19529	of	ADP	O
19529	the	DET	O
19529	posterior	NOUN	O
19529	hypothalamus	NOUN	O
19529	was	VERB	O
19529	recorded	VERB	O
19529	in	ADP	O
19529	3	NUM	O
19529	-	PUNCT	O
19529	-3.5	PUNCT	O
19529	months	NOUN	O
19529	old	ADJ	O
19529	alert	ADJ	O
19529	rabbits	NOUN	O
19529	in	ADP	O
19529	chronic	ADJ	O
19529	and	CCONJ	O
19529	acute	ADJ	O
19529	experiments	NOUN	O
19529	.	PUNCT	O
19530	Electrical	ADJ	O
19530	stimulation	NOUN	O
19530	of	ADP	O
19530	the	DET	O
19530	sties	NOUN	O
19530	of	ADP	O
19530	the	DET	O
19530	posterior	NOUN	O
19530	hypothalamus	NOUN	O
19530	which	ADJ	O
19530	had	VERB	O
19530	produced	VERB	O
19530	orienting	ADJ	O
19530	behavior	NOUN	O
19530	in	ADP	O
19530	preliminary	ADJ	O
19530	tests	NOUN	O
19530	,	PUNCT	O
19530	led	VERB	O
19530	to	ADP	O
19530	the	DET	O
19530	appearance	NOUN	O
19530	in	ADP	O
19530	the	DET	O
19530	majority	NOUN	O
19530	of	ADP	O
19530	cells	NOUN	O
19530	at	ADP	O
19530	all	DET	O
19530	hippocampal	ADJ	O
19530	levels	NOUN	O
19530	of	ADP	O
19530	tonic	NOUN	O
19530	inhibitory	ADJ	O
19530	and	CCONJ	O
19530	activational	ADJ	O
19530	reactions	NOUN	O
19530	with	ADP	O
19530	a	DET	O
19530	long	ADJ	O
19530	-	PUNCT	O
19530	term	NOUN	O
19530	after	ADP	O
19530	-	PUNCT	O
19530	effect	NOUN	O
19530	.	PUNCT	O
19531	With	ADP	O
19531	increased	VERB	O
19531	frequency	NOUN	O
19531	of	ADP	O
19531	the	DET	O
19531	stimulating	ADJ	O
19531	current	NOUN	O
19531	there	ADV	O
19531	was	VERB	O
19531	an	DET	O
19531	increase	NOUN	O
19531	in	ADP	O
19531	the	DET	O
19531	number	NOUN	O
19531	of	ADP	O
19531	responding	VERB	O
19531	elements	NOUN	O
19531	and	CCONJ	O
19531	in	ADP	O
19531	the	DET	O
19531	reactivity	NOUN	O
19531	of	ADP	O
19531	neurones	NOUN	O
19531	.	PUNCT	O
19532	The	DET	O
19532	conditioning	NOUN	O
19532	stimulation	NOUN	O
19532	of	ADP	O
19532	the	DET	O
19532	posterior	NOUN	O
19532	hypothalamus	NOUN	O
19532	increased	VERB	O
19532	the	DET	O
19532	pronouncement	NOUN	O
19532	and	CCONJ	O
19532	duration	NOUN	O
19532	of	ADP	O
19532	hippocampal	ADJ	O
19532	unit	NOUN	O
19532	responses	VERB	O
19532	to	PART	O
19532	sound	VERB	O
19532	stimuli	NOUN	O
19532	.	PUNCT	O
19533	It	PRON	O
19533	is	VERB	O
19533	concluded	VERB	O
19533	that	ADP	O
19533	functional	ADJ	O
19533	manifestations	NOUN	O
19533	of	ADP	O
19533	the	DET	O
19533	afferentation	NOUN	O
19533	,	PUNCT	O
19533	ascending	VERB	O
19533	from	ADP	O
19533	the	DET	O
19533	posterior	NOUN	O
19533	hypothalamus	NOUN	O
19533	to	ADP	O
19533	the	DET	O
19533	hippocampus	NOUN	O
19533	during	ADP	O
19533	the	DET	O
19533	development	NOUN	O
19533	of	ADP	O
19533	orienting	ADJ	O
19533	reaction	NOUN	O
19533	,	PUNCT	O
19533	are	VERB	O
19533	determined	VERB	O
19533	by	ADP	O
19533	a	DET	O
19533	nonspecific	ADJ	O
19533	character	NOUN	O
19533	of	ADP	O
19533	its	ADJ	O
19533	influences	NOUN	O
19533	on	ADP	O
19533	the	DET	O
19533	neurones	NOUN	O
19533	of	ADP	O
19533	the	DET	O
19533	dorsal	ADJ	O
19533	hippocampus	NOUN	O
19533	.	PUNCT	O
19534	The	DET	O
19534	specific	ADJ	O
19534	granules	NOUN	O
19534	found	VERB	O
19534	in	ADP	O
19534	the	DET	O
19534	atrial	ADJ	O
19534	cardiac	ADJ	O
19534	muscle	NOUN	O
19534	cells	NOUN	O
19534	of	ADP	O
19534	the	DET	O
19534	normal	ADJ	O
19534	rat	NOUN	O
19534	were	VERB	O
19534	studied	VERB	O
19534	.	PUNCT	O
19535	The	DET	O
19535	ultrastructural	ADJ	O
19535	appearance	NOUN	O
19535	of	ADP	O
19535	these	DET	O
19535	granules	NOUN	O
19535	demonstrated	VERB	O
19535	a	DET	O
19535	fixative	ADJ	O
19535	-	PUNCT	O
19535	dependent	ADJ	O
19535	lability	NOUN	O
19535	.	PUNCT	O
19536	Fixation	NOUN	O
19536	with	ADP	O
19536	cacodylate	NOUN	O
19536	buffered	VERB	O
19536	aldehydes	NOUN	O
19536	yields	VERB	O
19536	three	NUM	O
19536	types	NOUN	O
19536	of	ADP	O
19536	granules	NOUN	O
19536	.	PUNCT	O
19537	However	ADV	O
19537	,	PUNCT	O
19537	fixation	NOUN	O
19537	with	ADP	O
19537	phosphate	ADJ	O
19537	buffered	VERB	O
19537	aldehydes	NOUN	O
19537	or	CCONJ	O
19537	primary	ADJ	O
19537	fixation	NOUN	O
19537	with	ADP	O
19537	OsO4	NOUN	O
19537	yields	NOUN	O
19537	granules	NOUN	O
19537	of	ADP	O
19537	uniform	ADJ	O
19537	appearance	NOUN	O
19537	.	PUNCT	O
19538	The	DET	O
19538	granules	NOUN	O
19538	are	VERB	O
19538	found	VERB	O
19538	predominantly	ADV	O
19538	in	ADP	O
19538	the	DET	O
19538	perinuclear	NOUN	O
19538	zone	NOUN	O
19538	;	PUNCT	O
19538	78	NUM	O
19538	%	NOUN	O
19538	of	ADP	O
19538	the	DET	O
19538	granules	NOUN	O
19538	are	VERB	O
19538	within	ADP	O
19538	ten	NUM	O
19538	linear	ADJ	O
19538	micrometers	NOUN	O
19538	of	ADP	O
19538	the	DET	O
19538	center	NOUN	O
19538	of	ADP	O
19538	the	DET	O
19538	nucleus	NOUN	O
19538	.	PUNCT	O
19539	Two	NUM	O
19539	independent	ADJ	O
19539	methods	NOUN	O
19539	of	ADP	O
19539	measurement	NOUN	O
19539	demonstrate	VERB	O
19539	spherical	ADJ	O
19539	diameters	NOUN	O
19539	of	ADP	O
19539	these	DET	O
19539	granules	NOUN	O
19539	of	ADP	O
19539	0.30	NUM	O
19539	micron	NOUN	O
19539	and	CCONJ	O
19539	0.37	NUM	O
19539	micron	NOUN	O
19539	respectively	ADV	O
19539	.	PUNCT	O
19540	The	DET	O
19540	granules	NOUN	O
19540	are	VERB	O
19540	found	VERB	O
19540	in	ADP	O
19540	greater	ADJ	O
19540	concentration	NOUN	O
19540	at	ADP	O
19540	one	NUM	O
19540	pole	NOUN	O
19540	of	ADP	O
19540	the	DET	O
19540	nucleus	NOUN	O
19540	than	ADP	O
19540	at	ADP	O
19540	the	DET	O
19540	other	ADJ	O
19540	.	PUNCT	O
19541	On	ADP	O
19541	the	DET	O
19541	high	ADJ	O
19541	density	NOUN	O
19541	side	NOUN	O
19541	there	ADV	O
19541	are	VERB	O
19541	4.07	NUM	O
19541	granules	NOUN	O
19541	/	SYM	O
19541	micrometers3	NOUN	O
19541	which	ADJ	O
19541	occupy	VERB	O
19541	5.8	NUM	O
19541	%	NOUN	O
19541	of	ADP	O
19541	the	DET	O
19541	cytoplasmic	ADJ	O
19541	volume	NOUN	O
19541	.	PUNCT	O
19542	On	ADP	O
19542	the	DET	O
19542	low	ADJ	O
19542	density	NOUN	O
19542	side	NOUN	O
19542	there	ADV	O
19542	are	VERB	O
19542	2.15	NUM	O
19542	granules	NOUN	O
19542	/	SYM	O
19542	micrometers3	NOUN	O
19542	which	ADJ	O
19542	occupy	VERB	O
19542	3.0	NUM	O
19542	%	NOUN	O
19542	of	ADP	O
19542	the	DET	O
19542	cytoplasmic	ADJ	O
19542	volume	NOUN	O
19542	.	PUNCT	O
19543	The	DET	O
19543	granules	NOUN	O
19543	at	ADP	O
19543	both	DET	O
19543	poles	NOUN	O
19543	are	VERB	O
19543	the	DET	O
19543	same	ADJ	O
19543	size	NOUN	O
19543	.	PUNCT	O
19544	Atrial	ADJ	O
19544	walls	NOUN	O
19544	were	VERB	O
19544	incubated	VERB	O
19544	in	ADP	O
19544	a	DET	O
19544	modified	VERB	O
19544	Tyrode	PROPN	O
19544	's	PART	O
19544	solution	NOUN	O
19544	.	PUNCT	O
19545	One	NUM	O
19545	hour	NOUN	O
19545	of	ADP	O
19545	incubation	NOUN	O
19545	caused	VERB	O
19545	no	DET	O
19545	change	NOUN	O
19545	in	ADP	O
19545	the	DET	O
19545	atrial	ADJ	O
19545	granules	NOUN	O
19545	.	PUNCT	O
19546	Addition	NOUN	O
19546	of	ADP	O
19546	norepinephrine	NOUN	O
19546	or	CCONJ	O
19546	L	PROPN	O
19546	-	PUNCT	O
19546	Dopa	PROPN	O
19546	resulted	VERB	O
19546	in	ADP	O
19546	the	DET	O
19546	appearance	NOUN	O
19546	of	ADP	O
19546	more	ADJ	O
19546	granules	NOUN	O
19546	but	CCONJ	O
19546	the	DET	O
19546	size	NOUN	O
19546	of	ADP	O
19546	the	DET	O
19546	granules	NOUN	O
19546	remained	VERB	O
19546	the	DET	O
19546	same	ADJ	O
19546	.	PUNCT	O
19547	Incubation	NOUN	O
19547	with	ADP	O
19547	reserpine	NOUN	O
19547	had	VERB	O
19547	no	DET	O
19547	effect	NOUN	O
19547	upon	ADP	O
19547	the	DET	O
19547	atrial	ADJ	O
19547	granules	NOUN	O
19547	.	PUNCT	O
19548	Apparently	ADV	O
19548	the	DET	O
19548	atrial	ADJ	O
19548	myocardial	ADJ	O
19548	cell	NOUN	O
19548	is	VERB	O
19548	stimulated	VERB	O
19548	by	ADP	O
19548	exogenous	ADJ	O
19548	catecholamine	NOUN	O
19548	to	PART	O
19548	synthesize	VERB	O
19548	more	ADJ	O
19548	atrial	ADJ	O
19548	granules	NOUN	O
19548	which	ADJ	O
19548	themselves	PRON	O
19548	do	VERB	O
19548	not	ADV	O
19548	appear	VERB	O
19548	to	PART	O
19548	contain	VERB	O
19548	catecholamines	NOUN	O
19548	.	PUNCT	O
19549	Mutations	NOUN	O
19549	affecting	VERB	O
19549	quantitatively	ADV	O
19549	the	DET	O
19549	production	NOUN	O
19549	of	ADP	O
19549	the	DET	O
19549	sporulation	NOUN	O
19549	-	PUNCT	O
19549	associated	VERB	O
19549	extracellular	ADJ	O
19549	alkaline	NOUN	O
19549	protease	NOUN	O
19549	were	VERB	O
19549	isolated	VERB	O
19549	and	CCONJ	O
19549	characterized	VERB	O
19549	.	PUNCT	O
19550	They	PRON	O
19550	fall	VERB	O
19550	into	ADP	O
19550	at	ADV	O
19550	least	ADV	O
19550	five	NUM	O
19550	genes	NOUN	O
19550	,	PUNCT	O
19550	three	NUM	O
19550	of	ADP	O
19550	which	ADJ	O
19550	,	PUNCT	O
19550	ScoA	VERB	O
19550	,	PUNCT	O
19550	B	NOUN	O
19550	and	CCONJ	O
19550	C	PROPN	O
19550	,	PUNCT	O
19550	were	VERB	O
19550	mapped	VERB	O
19550	in	ADP	O
19550	the	DET	O
19550	argC	NOUN	O
19550	-	PUNCT	O
19550	metC	NOUN	O
19550	region	NOUN	O
19550	.	PUNCT	O
19551	The	DET	O
19551	pleiotropic	ADJ	O
19551	effects	NOUN	O
19551	of	ADP	O
19551	these	DET	O
19551	mutations	NOUN	O
19551	concern	NOUN	O
19551	several	ADJ	O
19551	or	CCONJ	O
19551	all	DET	O
19551	of	ADP	O
19551	the	DET	O
19551	following	ADJ	O
19551	:	PUNCT	O
19551	rate	NOUN	O
19551	and	CCONJ	O
19551	timing	NOUN	O
19551	of	ADP	O
19551	protease	NOUN	O
19551	production	NOUN	O
19551	,	PUNCT	O
19551	synthesis	NOUN	O
19551	of	ADP	O
19551	alkaline	NOUN	O
19551	phosphatase	NOUN	O
19551	,	PUNCT	O
19551	time	NOUN	O
19551	-	PUNCT	O
19551	course	NOUN	O
19551	of	ADP	O
19551	spore	NOUN	O
19551	formation	NOUN	O
19551	.	PUNCT	O
19552	Electron	NOUN	O
19552	microscopic	ADJ	O
19552	evidence	NOUN	O
19552	indicates	VERB	O
19552	delayed	VERB	O
19552	switch	NOUN	O
19552	from	ADP	O
19552	one	NUM	O
19552	morphological	ADJ	O
19552	stage	NOUN	O
19552	to	ADP	O
19552	another	DET	O
19552	.	PUNCT	O
19553	The	DET	O
19553	nature	NOUN	O
19553	of	ADP	O
19553	the	DET	O
19553	Sco	PROPN	O
19553	mutations	NOUN	O
19553	and	CCONJ	O
19553	the	DET	O
19553	genetic	ADJ	O
19553	regulation	NOUN	O
19553	of	ADP	O
19553	sporulation	NOUN	O
19553	are	VERB	O
19553	discussed	VERB	O
19553	.	PUNCT	O
19554	The	DET	O
19554	in	X	O
19554	vitro	X	O
19554	activity	NOUN	O
19554	of	ADP	O
19554	rosamicin	NOUN	O
19554	and	CCONJ	O
19554	erythromycin	NOUN	O
19554	was	VERB	O
19554	compared	VERB	O
19554	at	ADP	O
19554	various	ADJ	O
19554	pH	PROPN	O
19554	values	NOUN	O
19554	against	ADP	O
19554	311	NUM	O
19554	strains	NOUN	O
19554	of	ADP	O
19554	bacteria	NOUN	O
19554	representing	VERB	O
19554	common	ADJ	O
19554	urinary	ADJ	O
19554	tract	NOUN	O
19554	pathogens	NOUN	O
19554	.	PUNCT	O
19555	Alkalinization	NOUN	O
19555	of	ADP	O
19555	the	DET	O
19555	media	NOUN	O
19555	consistently	ADV	O
19555	and	CCONJ	O
19555	significantly	ADV	O
19555	increased	VERB	O
19555	the	DET	O
19555	antibacterial	ADJ	O
19555	activity	NOUN	O
19555	of	ADP	O
19555	rosamicin	NOUN	O
19555	against	ADP	O
19555	all	DET	O
19555	of	ADP	O
19555	the	DET	O
19555	organisms	NOUN	O
19555	tested	VERB	O
19555	.	PUNCT	O
19556	This	DET	O
19556	was	VERB	O
19556	also	ADV	O
19556	true	ADJ	O
19556	for	ADP	O
19556	erythromycin	NOUN	O
19556	except	ADP	O
19556	when	ADV	O
19556	tested	VERB	O
19556	against	ADP	O
19556	strains	NOUN	O
19556	of	ADP	O
19556	Proteus	PROPN	O
19556	.	PUNCT	O
19557	At	ADP	O
19557	pH	PROPN	O
19557	8	NUM	O
19557	,	PUNCT	O
19557	rosamicin	NOUN	O
19557	was	VERB	O
19557	two-	ADJ	O
19557	to	PART	O
19557	sixfold	VERB	O
19557	more	ADV	O
19557	active	ADJ	O
19557	than	ADP	O
19557	erythromycin	NOUN	O
19557	against	ADP	O
19557	Enterobacteriaceae	PROPN	O
19557	.	PUNCT	O
19558	The	DET	O
19558	activity	NOUN	O
19558	of	ADP	O
19558	both	DET	O
19558	antibiotics	NOUN	O
19558	against	ADP	O
19558	Pseudomonas	PROPN	O
19558	aeruginosa	NOUN	O
19558	was	VERB	O
19558	very	ADV	O
19558	similar	ADJ	O
19558	when	ADV	O
19558	tested	VERB	O
19558	at	ADP	O
19558	pH	PROPN	O
19558	8	NUM	O
19558	.	PUNCT	O
19559	Erythromycin	PROPN	O
19559	was	VERB	O
19559	twice	ADV	O
19559	as	ADV	O
19559	active	ADJ	O
19559	as	ADP	O
19559	rosamicin	NOUN	O
19559	at	ADP	O
19559	pH	PROPN	O
19559	8	NUM	O
19559	against	ADP	O
19559	group	NOUN	O
19559	D	NOUN	O
19559	streptococci	NOUN	O
19559	.	PUNCT	O
19560	The	DET	O
19560	activity	NOUN	O
19560	of	ADP	O
19560	both	DET	O
19560	antibiotics	NOUN	O
19560	was	VERB	O
19560	bacteriostatic	ADJ	O
19560	and	CCONJ	O
19560	inoculum	ADJ	O
19560	size	NOUN	O
19560	dependent	ADJ	O
19560	,	PUNCT	O
19560	regardless	ADV	O
19560	of	ADP	O
19560	the	DET	O
19560	organism	NOUN	O
19560	tested	VERB	O
19560	or	CCONJ	O
19560	the	DET	O
19560	pH	NOUN	O
19560	of	ADP	O
19560	the	DET	O
19560	test	NOUN	O
19560	media	NOUN	O
19560	.	PUNCT	O
19561	The	DET	O
19561	greater	ADJ	O
19561	activity	NOUN	O
19561	of	ADP	O
19561	rosamicin	NOUN	O
19561	against	ADP	O
19561	Enterobacteriaceae	PROPN	O
19561	warrants	NOUN	O
19561	clinical	ADJ	O
19561	investigation	NOUN	O
19561	.	PUNCT	O
19562	Serial	ADJ	O
19562	prospective	ADJ	O
19562	studies	NOUN	O
19562	of	ADP	O
19562	coagulation	NOUN	O
19562	status	NOUN	O
19562	have	VERB	O
19562	been	VERB	O
19562	undertaken	VERB	O
19562	on	ADP	O
19562	73	NUM	O
19562	babies	NOUN	O
19562	with	ADP	O
19562	a	DET	O
19562	positive	ADJ	O
19562	Coombs	PROPN	O
19562	test	NOUN	O
19562	.	PUNCT	O
19563	No	DET	O
19563	abnormalities	NOUN	O
19563	were	VERB	O
19563	detected	VERB	O
19563	in	ADP	O
19563	the	DET	O
19563	babies	NOUN	O
19563	with	ADP	O
19563	mild	ADJ	O
19563	haemolytic	ADJ	O
19563	disease	NOUN	O
19563	,	PUNCT	O
19563	but	CCONJ	O
19563	seven	NUM	O
19563	of	ADP	O
19563	the	DET	O
19563	36	NUM	O
19563	babies	NOUN	O
19563	with	ADP	O
19563	severe	ADJ	O
19563	haemolytic	ADJ	O
19563	disease	NOUN	O
19563	(	PUNCT	O
19563	cord	NOUN	O
19563	Hb	PROPN	O
19563	less	ADJ	O
19563	than	ADP	O
19563	11	NUM	O
19563	g	PUNCT	O
19563	/	SYM	O
19563	dl	NOUN	O
19563	or	CCONJ	O
19563	cord	NOUN	O
19563	bilirubin	NOUN	O
19563	greater	ADJ	O
19563	than	ADP	O
19563	85	NUM	O
19563	mumol/1	NOUN	O
19563	)	PUNCT	O
19563	showed	VERB	O
19563	evidence	NOUN	O
19563	of	ADP	O
19563	transient	ADJ	O
19563	defibrination	NOUN	O
19563	1	NUM	O
19563	d	X	O
19563	after	ADP	O
19563	birth	NOUN	O
19563	and	CCONJ	O
19563	another	DET	O
19563	six	NUM	O
19563	had	VERB	O
19563	evidence	NOUN	O
19563	of	ADP	O
19563	coagulation	NOUN	O
19563	failure	NOUN	O
19563	at	ADP	O
19563	birth	NOUN	O
19563	with	ADP	O
19563	a	DET	O
19563	platelet	NOUN	O
19563	count	NOUN	O
19563	of	ADP	O
19563	less	ADJ	O
19563	than	ADP	O
19563	150	NUM	O
19564	x	PUNCT	O
19564	10(9)/1	NUM	O
19564	and	CCONJ	O
19564	a	DET	O
19564	severe	ADJ	O
19564	deficiency	NOUN	O
19564	of	ADP	O
19564	multiple	ADJ	O
19564	coagulation	NOUN	O
19564	factors	NOUN	O
19564	.	PUNCT	O
19565	The	DET	O
19565	level	NOUN	O
19565	of	ADP	O
19565	factor	NOUN	O
19565	II	PROPN	O
19565	and	CCONJ	O
19565	factor	NOUN	O
19565	X	NOUN	O
19565	was	VERB	O
19565	less	ADJ	O
19565	than	ADP	O
19565	a	DET	O
19565	fifth	NOUN	O
19565	of	ADP	O
19565	the	DET	O
19565	normal	ADJ	O
19565	cord	NOUN	O
19565	blood	NOUN	O
19565	level	NOUN	O
19565	in	ADP	O
19565	these	DET	O
19565	six	NUM	O
19565	babies	NOUN	O
19565	and	CCONJ	O
19565	the	DET	O
19565	level	NOUN	O
19565	of	ADP	O
19565	I	PRON	O
19565	,	PUNCT	O
19565	VII	PROPN	O
19565	and	CCONJ	O
19565	IX	PROPN	O
19565	was	VERB	O
19565	severely	ADV	O
19565	reduced	VERB	O
19565	;	PUNCT	O
19565	the	DET	O
19565	factor	NOUN	O
19565	VIII	PROPN	O
19565	level	NOUN	O
19565	was	VERB	O
19565	normal	ADJ	O
19565	or	CCONJ	O
19565	high	ADJ	O
19565	.	PUNCT	O
19566	Exchange	NOUN	O
19566	transfusion	NOUN	O
19566	started	VERB	O
19566	within	ADP	O
19566	1	NUM	O
19566	h	NOUN	O
19566	of	ADP	O
19566	birth	NOUN	O
19566	corrected	VERB	O
19566	the	DET	O
19566	immediate	ADJ	O
19566	factor	NOUN	O
19566	deficiency	NOUN	O
19566	in	ADP	O
19566	these	DET	O
19566	six	NUM	O
19566	babies	NOUN	O
19566	,	PUNCT	O
19566	but	CCONJ	O
19566	evidence	NOUN	O
19566	of	ADP	O
19566	defibrination	NOUN	O
19566	then	ADV	O
19566	became	VERB	O
19566	apparent	ADJ	O
19566	with	ADP	O
19566	afibrinogenaemia	ADJ	O
19566	,	PUNCT	O
19566	a	DET	O
19566	marked	ADJ	O
19566	fall	NOUN	O
19566	in	ADP	O
19566	factors	NOUN	O
19566	II	PROPN	O
19566	and	CCONJ	O
19566	V	NOUN	O
19566	,	PUNCT	O
19566	less	ADV	O
19566	constant	ADJ	O
19566	falls	NOUN	O
19566	in	ADP	O
19566	factors	NOUN	O
19566	VII	PROPN	O
19566	,	PUNCT	O
19566	IX	PROPN	O
19566	and	CCONJ	O
19566	X	NOUN	O
19566	,	PUNCT	O
19566	and	CCONJ	O
19566	a	DET	O
19566	raised	VERB	O
19566	fibrin	NOUN	O
19566	:	PUNCT	O
19566	fibrinogen	NOUN	O
19566	degradation	NOUN	O
19566	product	NOUN	O
19566	level	NOUN	O
19566	.	PUNCT	O
19567	One	NUM	O
19567	of	ADP	O
19567	these	DET	O
19567	six	NUM	O
19567	babies	NOUN	O
19567	died	VERB	O
19567	with	ADP	O
19567	severe	ADJ	O
19567	pulmonary	ADJ	O
19567	hypoplasia	NOUN	O
19567	within	ADP	O
19567	an	DET	O
19567	hour	NOUN	O
19567	of	ADP	O
19567	birth	NOUN	O
19567	;	PUNCT	O
19567	the	DET	O
19567	other	ADJ	O
19567	five	NUM	O
19567	died	VERB	O
19567	from	ADP	O
19567	haemorrhage	NOUN	O
19567	into	ADP	O
19567	the	DET	O
19567	lung	NOUN	O
19567	or	CCONJ	O
19567	brain	NOUN	O
19567	1	NUM	O
19567	1/2	NUM	O
19567	-	PUNCT	O
19567	-6	PUNCT	O
19567	d	NOUN	O
19567	after	ADP	O
19567	birth	NOUN	O
19567	.	PUNCT	O
19568	The	DET	O
19568	very	ADV	O
19568	low	ADJ	O
19568	vitamin	NOUN	O
19568	-	PUNCT	O
19568	K	NOUN	O
19568	dependent	ADJ	O
19568	factor	NOUN	O
19568	levels	NOUN	O
19568	in	ADP	O
19568	the	DET	O
19568	cord	NOUN	O
19568	blood	NOUN	O
19568	of	ADP	O
19568	the	DET	O
19568	babies	NOUN	O
19568	who	NOUN	O
19568	died	VERB	O
19568	are	VERB	O
19568	presumably	ADV	O
19568	the	DET	O
19568	result	NOUN	O
19568	of	ADP	O
19568	liver	NOUN	O
19568	damage	NOUN	O
19568	in	ADP	O
19568	utero	NOUN	O
19568	,	PUNCT	O
19568	but	CCONJ	O
19568	the	DET	O
19568	subsequent	ADJ	O
19568	changes	NOUN	O
19568	are	VERB	O
19568	those	DET	O
19568	of	ADP	O
19568	a	DET	O
19568	comsumption	NOUN	O
19568	coagulopathy	NOUN	O
19568	.	PUNCT	O
19569	Simple	ADJ	O
19569	screening	NOUN	O
19569	tests	NOUN	O
19569	at	ADP	O
19569	birth	NOUN	O
19569	served	VERB	O
19569	to	PART	O
19569	indicate	VERB	O
19569	which	ADJ	O
19569	babies	NOUN	O
19569	were	VERB	O
19569	at	ADP	O
19569	risk	NOUN	O
19569	and	CCONJ	O
19569	it	PRON	O
19569	is	VERB	O
19569	concluded	VERB	O
19569	that	ADP	O
19569	death	NOUN	O
19569	due	ADP	O
19569	to	ADP	O
19569	haemorrhage	NOUN	O
19569	might	VERB	O
19569	be	VERB	O
19569	reduced	VERB	O
19569	by	ADP	O
19569	more	ADV	O
19569	intensive	ADJ	O
19569	factor	NOUN	O
19569	replacement	NOUN	O
19569	before	ADP	O
19569	there	ADV	O
19569	is	VERB	O
19569	overt	ADJ	O
19569	evidence	NOUN	O
19569	of	ADP	O
19569	haemorrhage	NOUN	O
19569	in	ADP	O
19569	these	DET	O
19569	babies	NOUN	O
19569	.	PUNCT	O
19570	A	DET	O
19570	method	NOUN	O
19570	is	VERB	O
19570	presented	VERB	O
19570	for	ADP	O
19570	determination	NOUN	O
19570	of	ADP	O
19570	the	DET	O
19570	enantiomeric	NOUN	O
19570	composition	NOUN	O
19570	of	ADP	O
19570	hydroxyperoxides	NOUN	O
19570	formed	VERB	O
19570	by	ADP	O
19570	enzymic	ADJ	O
19570	oxygenation	NOUN	O
19570	of	ADP	O
19570	unsaturated	ADJ	O
19570	fatty	ADJ	O
19570	acids	NOUN	O
19570	.	PUNCT	O
19571	After	ADP	O
19571	reduction	NOUN	O
19571	of	ADP	O
19571	the	DET	O
19571	hydroperoxy	ADJ	O
19571	group	NOUN	O
19571	with	ADP	O
19571	NaBH4	NOUN	O
19571	,	PUNCT	O
19571	and	CCONJ	O
19571	esterification	NOUN	O
19571	,	PUNCT	O
19571	the	DET	O
19571	positional	ADJ	O
19571	isomers	NOUN	O
19571	of	ADP	O
19571	the	DET	O
19571	resulting	VERB	O
19571	hydroxy	ADJ	O
19571	compounds	NOUN	O
19571	are	VERB	O
19571	separated	VERB	O
19571	by	ADP	O
19571	high	ADJ	O
19571	performance	NOUN	O
19571	liquid	NOUN	O
19571	chromatography	NOUN	O
19571	.	PUNCT	O
19572	The	DET	O
19572	latter	ADJ	O
19572	are	VERB	O
19572	subsequently	ADV	O
19572	subjected	VERB	O
19572	to	ADP	O
19572	a	DET	O
19572	chiral	NOUN	O
19572	derivatization	NOUN	O
19572	to	PART	O
19572	form	VERB	O
19572	diastereomeric	ADJ	O
19572	alpha	NOUN	O
19572	-	PUNCT	O
19572	methoxy	ADJ	O
19572	-	PUNCT	O
19572	alpha	NOUN	O
19572	-	PUNCT	O
19572	trifluoromethylphenylacetate	ADJ	O
19572	esters	NOUN	O
19572	.	PUNCT	O
19573	Determination	NOUN	O
19573	of	ADP	O
19573	the	DET	O
19573	diastereomeric	NOUN	O
19573	composition	NOUN	O
19573	by	ADP	O
19573	a	DET	O
19573	NMR	PROPN	O
19573	shift	NOUN	O
19573	experiment	NOUN	O
19573	furnishes	VERB	O
19573	the	DET	O
19573	enantiomeric	NOUN	O
19573	composition	NOUN	O
19573	of	ADP	O
19573	the	DET	O
19573	parent	NOUN	O
19573	hydroperoxides	NOUN	O
19573	.	PUNCT	O
19574	The	DET	O
19574	method	NOUN	O
19574	has	VERB	O
19574	been	VERB	O
19574	applied	VERB	O
19574	to	ADP	O
19574	the	DET	O
19574	hydroperoxides	NOUN	O
19574	formed	VERB	O
19574	by	ADP	O
19574	incubation	NOUN	O
19574	of	ADP	O
19574	linoleic	ADJ	O
19574	acid	NOUN	O
19574	by	ADP	O
19574	corn	NOUN	O
19574	germ	NOUN	O
19574	or	CCONJ	O
19574	soybean	NOUN	O
19574	lipoxygenase	NOUN	O
19574	.	PUNCT	O
19575	Our	ADJ	O
19575	results	NOUN	O
19575	indicate	VERB	O
19575	that	ADP	O
19575	under	ADP	O
19575	the	DET	O
19575	conditions	NOUN	O
19575	used	VERB	O
19575	the	DET	O
19575	hydroperoxides	NOUN	O
19575	are	VERB	O
19575	mainly	ADV	O
19575	enantiospecifically	ADV	O
19575	formed	VERB	O
19575	.	PUNCT	O
19576	A	DET	O
19576	Vero	PROPN	O
19576	cell	NOUN	O
19576	adapted	VERB	O
19576	Green	PROPN	O
19576	strain	NOUN	O
19576	of	ADP	O
19576	canine	NOUN	O
19576	distemper	ADJ	O
19576	virus	NOUN	O
19576	(	PUNCT	O
19576	CDV	PROPN	O
19576	)	PUNCT	O
19576	was	VERB	O
19576	tested	VERB	O
19576	for	ADP	O
19576	its	ADJ	O
19576	plaque	NOUN	O
19576	-	PUNCT	O
19576	forming	VERB	O
19576	capacity	NOUN	O
19576	in	ADP	O
19576	different	ADJ	O
19576	cell	NOUN	O
19576	lines	NOUN	O
19576	.	PUNCT	O
19577	Plaque	NOUN	O
19577	formation	NOUN	O
19577	was	VERB	O
19577	observed	VERB	O
19577	in	ADP	O
19577	HEp-2	PROPN	O
19577	,	PUNCT	O
19577	BS	PROPN	O
19577	-	PUNCT	O
19577	C-1	PROPN	O
19577	,	PUNCT	O
19577	and	CCONJ	O
19577	HeLa	NOUN	O
19577	cells	NOUN	O
19577	but	CCONJ	O
19577	not	ADV	O
19577	in	ADP	O
19577	Vero	PROPN	O
19577	or	CCONJ	O
19577	dog	NOUN	O
19577	kidney	NOUN	O
19577	cells	NOUN	O
19577	even	ADV	O
19577	though	ADP	O
19577	replication	NOUN	O
19577	and	CCONJ	O
19577	cytopathology	NOUN	O
19577	were	VERB	O
19577	observed	VERB	O
19577	in	ADP	O
19577	the	DET	O
19577	latter	ADJ	O
19577	cell	NOUN	O
19577	types	NOUN	O
19577	.	PUNCT	O
19578	In	ADP	O
19578	the	DET	O
19578	cells	NOUN	O
19578	in	ADP	O
19578	which	ADJ	O
19578	the	DET	O
19578	virus	NOUN	O
19578	was	VERB	O
19578	capable	ADJ	O
19578	of	ADP	O
19578	producing	VERB	O
19578	plaques	NOUN	O
19578	,	PUNCT	O
19578	the	DET	O
19578	plaques	NOUN	O
19578	were	VERB	O
19578	observed	VERB	O
19578	within	ADP	O
19578	24	NUM	O
19578	h	NOUN	O
19578	post	NOUN	O
19578	infection	NOUN	O
19578	and	CCONJ	O
19578	continued	VERB	O
19578	to	PART	O
19578	increase	VERB	O
19578	in	ADP	O
19578	size	NOUN	O
19578	with	ADP	O
19578	subsequent	ADJ	O
19578	cellular	ADJ	O
19578	destruction	NOUN	O
19578	such	ADJ	O
19578	that	ADP	O
19578	by	ADP	O
19578	72	NUM	O
19578	h	NOUN	O
19578	postinfection	NOUN	O
19578	the	DET	O
19578	size	NOUN	O
19578	of	ADP	O
19578	the	DET	O
19578	plaques	NOUN	O
19578	approached	VERB	O
19578	0.5	NUM	O
19578	mm	NOUN	O
19578	.	PUNCT	O
19579	With	ADP	O
19579	the	DET	O
19579	use	NOUN	O
19579	of	ADP	O
19579	the	DET	O
19579	plaquing	NOUN	O
19579	technique	NOUN	O
19579	,	PUNCT	O
19579	it	PRON	O
19579	was	VERB	O
19579	possible	ADJ	O
19579	to	PART	O
19579	demonstrate	VERB	O
19579	the	DET	O
19579	thermal	ADJ	O
19579	lability	NOUN	O
19579	of	ADP	O
19579	the	DET	O
19579	virus	NOUN	O
19579	as	ADV	O
19579	well	ADV	O
19579	as	ADP	O
19579	the	DET	O
19579	kinetics	NOUN	O
19579	of	ADP	O
19579	adsorption	NOUN	O
19579	.	PUNCT	O
19580	Thus	ADV	O
19580	,	PUNCT	O
19580	it	PRON	O
19580	was	VERB	O
19580	shown	VERB	O
19580	that	ADP	O
19580	the	DET	O
19580	half	ADJ	O
19580	-	PUNCT	O
19580	life	NOUN	O
19580	of	ADP	O
19580	the	DET	O
19580	virus	NOUN	O
19580	was	VERB	O
19580	125	NUM	O
19580	min	NOUN	O
19580	at	ADP	O
19580	25	NUM	O
19580	degrees	NOUN	O
19580	C	NOUN	O
19580	,	PUNCT	O
19580	75	NUM	O
19580	min	NOUN	O
19580	at	ADP	O
19580	35	NUM	O
19580	degrees	NOUN	O
19580	C	NOUN	O
19580	,	PUNCT	O
19580	and	CCONJ	O
19580	65	NUM	O
19580	min	NOUN	O
19580	at	ADP	O
19580	37	NUM	O
19580	degrees	NOUN	O
19580	C.	PROPN	O
19581	The	DET	O
19581	rate	NOUN	O
19581	of	ADP	O
19581	adsorption	NOUN	O
19581	of	ADP	O
19581	CDV	PROPN	O
19581	to	ADP	O
19581	HEp-2	PROPN	O
19581	cells	NOUN	O
19581	was	VERB	O
19581	17.2	NUM	O
19581	%	NOUN	O
19581	in	ADP	O
19581	30	NUM	O
19581	min	NOUN	O
19581	at	ADP	O
19581	37	NUM	O
19581	degrees	NOUN	O
19581	C	PROPN	O
19581	and	CCONJ	O
19581	continued	VERB	O
19581	slowly	ADV	O
19581	for	ADP	O
19581	4	NUM	O
19581	h	NOUN	O
19581	before	ADP	O
19581	completion	NOUN	O
19581	.	PUNCT	O
19582	Application	NOUN	O
19582	of	ADP	O
19582	this	DET	O
19582	rapid	ADJ	O
19582	plaque	NOUN	O
19582	-	PUNCT	O
19582	forming	VERB	O
19582	assay	ADJ	O
19582	to	ADP	O
19582	plaque	NOUN	O
19582	-	PUNCT	O
19582	reduction	NOUN	O
19582	tests	NOUN	O
19582	for	ADP	O
19582	CDV	PROPN	O
19582	antibody	NOUN	O
19582	and	CCONJ	O
19582	for	ADP	O
19582	CDV	PROPN	O
19582	-	PUNCT	O
19582	infected	VERB	O
19582	cells	NOUN	O
19582	by	ADP	O
19582	the	DET	O
19582	infectious	ADJ	O
19582	center	NOUN	O
19582	assay	NOUN	O
19582	are	VERB	O
19582	described	VERB	O
19582	.	PUNCT	O
19583	Reactive	PROPN	O
19583	LRH	PROPN	O
19583	neurons	NOUN	O
19583	of	ADP	O
19583	the	DET	O
19583	preoptico	ADJ	O
19583	-	PUNCT	O
19583	terminal	NOUN	O
19583	trace	NOUN	O
19583	were	VERB	O
19583	studied	VERB	O
19583	with	ADP	O
19583	rabbit	NOUN	O
19583	antisera	NOUN	O
19583	to	ADP	O
19583	unconjugated	VERB	O
19583	or	CCONJ	O
19583	conjugated	VERB	O
19583	synthetic	ADJ	O
19583	LRH	PROPN	O
19583	in	ADP	O
19583	normally	ADV	O
19583	cyclic	ADJ	O
19583	female	ADJ	O
19583	squirrel	ADJ	O
19583	monkeys	NOUN	O
19583	.	PUNCT	O
19584	The	DET	O
19584	specific	ADJ	O
19584	immunoreactive	ADJ	O
19584	material	NOUN	O
19584	present	NOUN	O
19584	along	ADP	O
19584	the	DET	O
19584	preoptic	ADJ	O
19584	-	PUNCT	O
19584	terminal	NOUN	O
19584	LRH	PROPN	O
19584	tract	NOUN	O
19584	showed	VERB	O
19584	significant	ADJ	O
19584	modifications	NOUN	O
19584	that	ADJ	O
19584	were	VERB	O
19584	particularly	ADV	O
19584	distinct	ADJ	O
19584	(	PUNCT	O
19584	1	PUNCT	O
19584	)	PUNCT	O
19584	at	ADP	O
19584	the	DET	O
19584	level	NOUN	O
19584	of	ADP	O
19584	the	DET	O
19584	perikarya	NOUN	O
19584	,	PUNCT	O
19584	and	CCONJ	O
19584	(	PUNCT	O
19584	2	PUNCT	O
19584	)	PUNCT	O
19584	in	ADP	O
19584	the	DET	O
19584	axons	NOUN	O
19584	and	CCONJ	O
19584	axonal	ADJ	O
19584	endings	NOUN	O
19584	situated	VERB	O
19584	around	ADP	O
19584	the	DET	O
19584	short	ADJ	O
19584	and	CCONJ	O
19584	long	ADJ	O
19584	capillary	ADJ	O
19584	loops	NOUN	O
19584	of	ADP	O
19584	the	DET	O
19584	lamina	ADJ	O
19584	terminalis	NOUN	O
19584	.	PUNCT	O
19585	Conspicuous	ADJ	O
19585	variations	NOUN	O
19585	were	VERB	O
19585	observed	VERB	O
19585	during	ADP	O
19585	the	DET	O
19585	luteal	NOUN	O
19585	phase	NOUN	O
19585	(	PUNCT	O
19585	with	ADP	O
19585	distinct	ADJ	O
19585	and	CCONJ	O
19585	fast	ADJ	O
19585	refilling	NOUN	O
19585	)	PUNCT	O
19585	,	PUNCT	O
19585	and	CCONJ	O
19585	the	DET	O
19585	early	ADJ	O
19585	and	CCONJ	O
19585	mid	ADJ	O
19585	-	PUNCT	O
19585	follicular	ADJ	O
19585	phases	NOUN	O
19585	(	PUNCT	O
19585	suggesting	VERB	O
19585	a	DET	O
19585	pulsatile	NOUN	O
19585	mode	NOUN	O
19585	of	ADP	O
19585	release	NOUN	O
19585	)	PUNCT	O
19585	;	PUNCT	O
19585	minimum	ADJ	O
19585	concentrations	NOUN	O
19585	were	VERB	O
19585	attained	VERB	O
19585	during	ADP	O
19585	the	DET	O
19585	late	ADJ	O
19585	and	CCONJ	O
19585	peri	ADJ	O
19585	-	PUNCT	O
19585	ovulatory	ADJ	O
19585	phases	NOUN	O
19585	.	PUNCT	O
19586	A	DET	O
19586	comparison	NOUN	O
19586	is	VERB	O
19586	made	VERB	O
19586	between	ADP	O
19586	these	DET	O
19586	modifications	NOUN	O
19586	and	CCONJ	O
19586	those	DET	O
19586	observed	VERB	O
19586	along	ADP	O
19586	the	DET	O
19586	hypothalamo	NOUN	O
19586	-	PUNCT	O
19586	infundibular	ADJ	O
19586	LRH	PROPN	O
19586	tract	NOUN	O
19586	in	ADP	O
19586	the	DET	O
19586	same	ADJ	O
19586	animals	NOUN	O
19586	.	PUNCT	O
19587	The	DET	O
19587	preoptico	NOUN	O
19587	-	PUNCT	O
19587	terminal	NOUN	O
19587	LRH	PROPN	O
19587	tract	NOUN	O
19587	is	VERB	O
19587	thought	VERB	O
19587	to	PART	O
19587	be	VERB	O
19587	one	NUM	O
19587	of	ADP	O
19587	the	DET	O
19587	possible	ADJ	O
19587	mechanisms	NOUN	O
19587	controlling	VERB	O
19587	the	DET	O
19587	sensitivity	NOUN	O
19587	of	ADP	O
19587	gonadotropic	ADJ	O
19587	cells	NOUN	O
19587	to	ADP	O
19587	LRH	PROPN	O
19587	,	PUNCT	O
19587	and	CCONJ	O
19587	the	DET	O
19587	synthesis	NOUN	O
19587	and	CCONJ	O
19587	storage	NOUN	O
19587	of	ADP	O
19587	gonadotropins	NOUN	O
19587	before	ADP	O
19587	their	ADJ	O
19587	mid	ADJ	O
19587	-	PUNCT	O
19587	cycle	NOUN	O
19587	discharge	NOUN	O
19587	.	PUNCT	O
19588	The	DET	O
19588	effect	NOUN	O
19588	of	ADP	O
19588	thyroid	NOUN	O
19588	hormone	NOUN	O
19588	on	ADP	O
19588	the	DET	O
19588	development	NOUN	O
19588	of	ADP	O
19588	diencephalic	ADJ	O
19588	monoaminergic	NOUN	O
19588	neurons	NOUN	O
19588	was	VERB	O
19588	studied	VERB	O
19588	in	ADP	O
19588	tadpoles	NOUN	O
19588	of	ADP	O
19588	Bufo	PROPN	O
19588	bufo	DET	O
19588	japonicus	NOUN	O
19588	.	PUNCT	O
19589	Monoamine	NOUN	O
19589	-	PUNCT	O
19589	containing	VERB	O
19589	neurons	NOUN	O
19589	in	ADP	O
19589	the	DET	O
19589	preoptic	ADJ	O
19589	recess	NOUN	O
19589	organ	NOUN	O
19589	(	PUNCT	O
19589	PRO	PROPN	O
19589	)	PUNCT	O
19589	appeared	VERB	O
19589	later	ADV	O
19589	than	ADP	O
19589	those	DET	O
19589	in	ADP	O
19589	the	DET	O
19589	paraventricular	ADJ	O
19589	organ	NOUN	O
19589	(	PUNCT	O
19589	PVO	PROPN	O
19589	)	PUNCT	O
19589	and	CCONJ	O
19589	nucleus	NOUN	O
19589	infundibularis	NOUN	O
19589	dorsalis	NOUN	O
19589	(	PUNCT	O
19589	NID	PROPN	O
19589	)	PUNCT	O
19589	.	PUNCT	O
19590	After	ADP	O
19590	deprivation	NOUN	O
19590	of	ADP	O
19590	thyroidal	ADJ	O
19590	primordium	NOUN	O
19590	no	DET	O
19590	fluorescent	ADJ	O
19590	neurons	NOUN	O
19590	developed	VERB	O
19590	in	ADP	O
19590	the	DET	O
19590	PRO	NOUN	O
19590	.	PUNCT	O
19591	Development	NOUN	O
19591	of	ADP	O
19591	monoaminergic	ADJ	O
19591	neurons	NOUN	O
19591	in	ADP	O
19591	the	DET	O
19591	PVO	PROPN	O
19591	and	CCONJ	O
19591	NID	PROPN	O
19591	was	VERB	O
19591	not	ADV	O
19591	affected	VERB	O
19591	by	ADP	O
19591	thyroidectomy	NOUN	O
19591	.	PUNCT	O
19592	Thyroxine	ADJ	O
19592	treatment	NOUN	O
19592	brought	VERB	O
19592	about	ADP	O
19592	the	DET	O
19592	fluorescent	ADJ	O
19592	neurons	NOUN	O
19592	in	ADP	O
19592	the	DET	O
19592	PRO	NOUN	O
19592	of	ADP	O
19592	the	DET	O
19592	thyroidectomized	VERB	O
19592	tadpoles	NOUN	O
19592	.	PUNCT	O
19593	Fluorescent	NOUN	O
19593	terminals	NOUN	O
19593	in	ADP	O
19593	the	DET	O
19593	median	ADJ	O
19593	eminence	NOUN	O
19593	became	VERB	O
19593	conspicuous	ADJ	O
19593	around	ADP	O
19593	the	DET	O
19593	capillaries	NOUN	O
19593	which	ADJ	O
19593	penetrated	VERB	O
19593	to	ADP	O
19593	the	DET	O
19593	median	ADJ	O
19593	emience	NOUN	O
19593	,	PUNCT	O
19593	when	ADV	O
19593	the	DET	O
19593	tadpoles	NOUN	O
19593	reached	VERB	O
19593	late	ADJ	O
19593	prometamorphic	ADJ	O
19593	stage	NOUN	O
19593	.	PUNCT	O
19594	In	ADP	O
19594	the	DET	O
19594	median	ADJ	O
19594	eminence	NOUN	O
19594	of	ADP	O
19594	thyroidectomized	ADJ	O
19594	tadpoles	NOUN	O
19594	,	PUNCT	O
19594	the	DET	O
19594	monoaminergic	NOUN	O
19594	axon	NOUN	O
19594	terminals	NOUN	O
19594	did	VERB	O
19594	not	ADV	O
19594	develop	VERB	O
19594	.	PUNCT	O
19595	Thyroxine	NOUN	O
19595	induced	VERB	O
19595	both	DET	O
19595	the	DET	O
19595	fluorescent	ADJ	O
19595	terminals	NOUN	O
19595	and	CCONJ	O
19595	the	DET	O
19595	capillary	ADJ	O
19595	penetration	NOUN	O
19595	in	ADP	O
19595	the	DET	O
19595	median	ADJ	O
19595	eminence	NOUN	O
19595	of	ADP	O
19595	the	DET	O
19595	thyroidectomized	VERB	O
19595	tadpoles	NOUN	O
19595	.	PUNCT	O
19596	In	ADP	O
19596	the	DET	O
19596	tadpoles	NOUN	O
19596	hypophysectomized	VERB	O
19596	at	ADP	O
19596	tail	NOUN	O
19596	-	PUNCT	O
19596	bud	NOUN	O
19596	stage	NOUN	O
19596	,	PUNCT	O
19596	thyroxine	VERB	O
19596	induced	VERB	O
19596	neither	CCONJ	O
19596	the	DET	O
19596	fluorescent	ADJ	O
19596	terminals	NOUN	O
19596	nor	CCONJ	O
19596	the	DET	O
19596	capillaries	NOUN	O
19596	in	ADP	O
19596	the	DET	O
19596	median	ADJ	O
19596	eminence	NOUN	O
19596	.	PUNCT	O
19597	Plane	NOUN	O
19597	-	PUNCT	O
19597	tree	NOUN	O
19597	pollen	NOUN	O
19597	grains	NOUN	O
19597	were	VERB	O
19597	incubated	VERB	O
19597	in	ADP	O
19597	vitro	X	O
19597	with	ADP	O
19597	alveolar	ADJ	O
19597	macrophages	NOUN	O
19597	from	ADP	O
19597	inbred	ADJ	O
19597	Rats	PROPN	O
19597	,	PUNCT	O
19597	and	CCONJ	O
19597	the	DET	O
19597	possibility	NOUN	O
19597	of	ADP	O
19597	phagocytosis	NOUN	O
19597	was	VERB	O
19597	investigated	VERB	O
19597	.	PUNCT	O
19598	No	DET	O
19598	phagocytosis	NOUN	O
19598	was	VERB	O
19598	observed	VERB	O
19598	even	ADV	O
19598	after	ADP	O
19598	48	NUM	O
19598	hrs	NUM	O
19598	incubation	NOUN	O
19598	.	PUNCT	O
19599	But	CCONJ	O
19599	alveolar	NOUN	O
19599	cells	NOUN	O
19599	were	VERB	O
19599	bound	VERB	O
19599	to	PART	O
19599	pollen	VERB	O
19599	grains	NOUN	O
19599	generally	ADV	O
19599	at	ADP	O
19599	the	DET	O
19599	apertures	NOUN	O
19599	.	PUNCT	O
19600	This	DET	O
19600	binding	VERB	O
19600	did	VERB	O
19600	not	ADV	O
19600	require	VERB	O
19600	the	DET	O
19600	Fc	PROPN	O
19600	receptor	NOUN	O
19600	on	ADP	O
19600	the	DET	O
19600	macrophage	NOUN	O
19600	membrane	NOUN	O
19600	.	PUNCT	O
19601	The	DET	O
19601	availability	NOUN	O
19601	of	ADP	O
19601	inhaled	VERB	O
19601	beclomethasone	NOUN	O
19601	diproprionate	NOUN	O
19601	permitted	VERB	O
19601	the	DET	O
19601	discontinuation	NOUN	O
19601	of	ADP	O
19601	continuous	ADJ	O
19601	,	PUNCT	O
19601	long	ADJ	O
19601	-	PUNCT	O
19601	term	NOUN	O
19601	systemic	ADJ	O
19601	corticosteroid	NOUN	O
19601	therapy	NOUN	O
19601	(	PUNCT	O
19601	SCT	PROPN	O
19601	)	PUNCT	O
19601	in	ADP	O
19601	a	DET	O
19601	group	NOUN	O
19601	of	ADP	O
19601	asthmatics	NOUN	O
19601	who	NOUN	O
19601	had	VERB	O
19601	previously	ADV	O
19601	required	VERB	O
19601	SCT	PROPN	O
19601	to	PART	O
19601	control	VERB	O
19601	their	ADJ	O
19601	asthma	NOUN	O
19601	.	PUNCT	O
19602	Twelve	NUM	O
19602	patients	NOUN	O
19602	had	VERB	O
19602	been	VERB	O
19602	on	ADP	O
19602	SCT	PROPN	O
19602	for	ADP	O
19602	a	DET	O
19602	period	NOUN	O
19602	of	ADP	O
19602	2	NUM	O
19602	-	SYM	O
19602	22	NUM	O
19602	years	NOUN	O
19602	with	ADP	O
19602	an	DET	O
19602	average	ADJ	O
19602	duration	NOUN	O
19602	of	ADP	O
19602	7	NUM	O
19602	years	NOUN	O
19602	.	PUNCT	O
19603	To	PART	O
19603	determine	VERB	O
19603	whether	ADP	O
19603	this	DET	O
19603	previous	ADJ	O
19603	long	ADJ	O
19603	-	PUNCT	O
19603	term	NOUN	O
19603	SCT	PROPN	O
19603	and	CCONJ	O
19603	the	DET	O
19603	current	ADJ	O
19603	use	NOUN	O
19603	of	ADP	O
19603	inhaled	VERB	O
19603	beclomethasone	NOUN	O
19603	diproprionate	NOUN	O
19603	had	VERB	O
19603	an	DET	O
19603	effect	NOUN	O
19603	on	ADP	O
19603	leucocyte	NOUN	O
19603	functions	NOUN	O
19603	,	PUNCT	O
19603	a	DET	O
19603	variety	NOUN	O
19603	of	ADP	O
19603	studies	NOUN	O
19603	reflecting	VERB	O
19603	T	PROPN	O
19603	lymphocyte	NOUN	O
19603	,	PUNCT	O
19603	B	NOUN	O
19603	lymphocyte	NOUN	O
19603	and	CCONJ	O
19603	granulocyte	NOUN	O
19603	function	NOUN	O
19603	was	VERB	O
19603	done	VERB	O
19603	.	PUNCT	O
19604	The	DET	O
19604	results	NOUN	O
19604	were	VERB	O
19604	compared	VERB	O
19604	with	ADP	O
19604	those	DET	O
19604	of	ADP	O
19604	twelve	NUM	O
19604	asthmatic	ADJ	O
19604	patients	NOUN	O
19604	of	ADP	O
19604	similar	ADJ	O
19604	age	NOUN	O
19604	ranges	VERB	O
19604	who	NOUN	O
19604	had	VERB	O
19604	never	ADV	O
19604	received	VERB	O
19604	steroids	NOUN	O
19604	.	PUNCT	O
19605	Results	NOUN	O
19605	showed	VERB	O
19605	that	ADP	O
19605	the	DET	O
19605	two	NUM	O
19605	patient	ADJ	O
19605	populations	NOUN	O
19605	could	VERB	O
19605	not	ADV	O
19605	be	VERB	O
19605	differentiated	VERB	O
19605	on	ADP	O
19605	the	DET	O
19605	basis	NOUN	O
19605	of	ADP	O
19605	phytohaemagglutinin	ADJ	O
19605	stimulation	NOUN	O
19605	of	ADP	O
19605	lymphocytes	NOUN	O
19605	,	PUNCT	O
19605	sheep	NOUN	O
19605	erythrocyte	NOUN	O
19605	rosette	NOUN	O
19605	formation	NOUN	O
19605	,	PUNCT	O
19605	IgG	PROPN	O
19605	,	PUNCT	O
19605	IgA	PROPN	O
19605	,	PUNCT	O
19605	IgM	PROPN	O
19605	and	CCONJ	O
19605	IgE	PROPN	O
19605	concentrations	NOUN	O
19605	or	CCONJ	O
19605	granulocyte	NOUN	O
19605	bactericidal	NOUN	O
19605	activity	NOUN	O
19605	.	PUNCT	O
19606	Delayed	ADJ	O
19606	skin	NOUN	O
19606	reactivity	NOUN	O
19606	was	VERB	O
19606	present	ADJ	O
19606	in	ADP	O
19606	both	DET	O
19606	groups	NOUN	O
19606	,	PUNCT	O
19606	with	ADP	O
19606	more	ADV	O
19606	positive	ADJ	O
19606	reactions	NOUN	O
19606	in	ADP	O
19606	the	DET	O
19606	non	ADJ	O
19606	-	PUNCT	O
19606	SCT	PROPN	O
19606	group	NOUN	O
19606	.	PUNCT	O
19607	Polymorphonuclear	NOUN	O
19607	adherence	NOUN	O
19607	values	NOUN	O
19607	were	VERB	O
19607	slightly	ADV	O
19607	lower	ADJ	O
19607	in	ADP	O
19607	the	DET	O
19607	SCT	PROPN	O
19607	female	ADJ	O
19607	population	NOUN	O
19607	using	VERB	O
19607	beclomethasone	NOUN	O
19607	diproprionate	ADJ	O
19607	.	PUNCT	O
19608	The	DET	O
19608	latter	ADJ	O
19608	two	NUM	O
19608	minor	ADJ	O
19608	differences	NOUN	O
19608	may	VERB	O
19608	be	VERB	O
19608	due	ADJ	O
19608	to	ADP	O
19608	the	DET	O
19608	previous	ADJ	O
19608	SCT	PROPN	O
19608	,	PUNCT	O
19608	the	DET	O
19608	use	NOUN	O
19608	of	ADP	O
19608	beclomethasone	NOUN	O
19608	diproprionate	ADJ	O
19608	or	CCONJ	O
19608	the	DET	O
19608	limited	ADJ	O
19608	population	NOUN	O
19608	of	ADP	O
19608	patients	NOUN	O
19608	studied	VERB	O
19608	.	PUNCT	O
19609	We	PRON	O
19609	conclude	VERB	O
19609	from	ADP	O
19609	these	DET	O
19609	studies	NOUN	O
19609	that	ADP	O
19609	the	DET	O
19609	long	ADJ	O
19609	-	PUNCT	O
19609	term	NOUN	O
19609	use	NOUN	O
19609	of	ADP	O
19609	SCT	PROPN	O
19609	at	ADP	O
19609	the	DET	O
19609	low	ADJ	O
19609	doses	NOUN	O
19609	required	VERB	O
19609	for	ADP	O
19609	control	NOUN	O
19609	of	ADP	O
19609	asthma	NOUN	O
19609	resulted	VERB	O
19609	in	ADP	O
19609	little	ADJ	O
19609	permanent	ADJ	O
19609	effect	NOUN	O
19609	on	ADP	O
19609	the	DET	O
19609	variety	NOUN	O
19609	of	ADP	O
19609	lymphocyte	NOUN	O
19609	and	CCONJ	O
19609	granulocyte	NOUN	O
19609	functions	NOUN	O
19609	tested	VERB	O
19609	.	PUNCT	O
19610	Four	NUM	O
19610	hydrolases	NOUN	O
19610	,	PUNCT	O
19610	beta	NOUN	O
19610	-	PUNCT	O
19610	galactosidase	NOUN	O
19610	,	PUNCT	O
19610	beta	NOUN	O
19610	-	PUNCT	O
19610	glucuronidase	NOUN	O
19610	,	PUNCT	O
19610	beta	NOUN	O
19610	-	PUNCT	O
19610	N	NOUN	O
19610	-	PUNCT	O
19610	acetylglucosaminidase	NOUN	O
19610	and	CCONJ	O
19610	acid	NOUN	O
19610	phosphatase	NOUN	O
19610	were	VERB	O
19610	examined	VERB	O
19610	in	ADP	O
19610	red	ADJ	O
19610	blood	NOUN	O
19610	cells	NOUN	O
19610	(	PUNCT	O
19610	RBC	PROPN	O
19610	)	PUNCT	O
19610	of	ADP	O
19610	normal	ADJ	O
19610	donors	NOUN	O
19610	and	CCONJ	O
19610	patients	NOUN	O
19610	with	ADP	O
19610	homozygous	ADJ	O
19610	beta	NOUN	O
19610	-	PUNCT	O
19610	thalassaemia	NOUN	O
19610	.	PUNCT	O
19611	Highly	ADV	O
19611	sensitive	ADJ	O
19611	fluorimetric	ADJ	O
19611	substrates	NOUN	O
19611	were	VERB	O
19611	used	VERB	O
19611	to	PART	O
19611	determine	VERB	O
19611	the	DET	O
19611	specific	ADJ	O
19611	activities	NOUN	O
19611	of	ADP	O
19611	these	DET	O
19611	enzymes	NOUN	O
19611	.	PUNCT	O
19612	In	ADP	O
19612	order	NOUN	O
19612	to	PART	O
19612	avoid	VERB	O
19612	contamination	NOUN	O
19612	by	ADP	O
19612	lysosomal	ADJ	O
19612	activities	NOUN	O
19612	derived	VERB	O
19612	from	ADP	O
19612	white	ADJ	O
19612	blood	NOUN	O
19612	cells	NOUN	O
19612	(	PUNCT	O
19612	WBC	PROPN	O
19612	)	PUNCT	O
19612	,	PUNCT	O
19612	the	DET	O
19612	mature	ADJ	O
19612	RBV	PROPN	O
19612	were	VERB	O
19612	separated	VERB	O
19612	from	ADP	O
19612	other	ADJ	O
19612	blood	NOUN	O
19612	elements	NOUN	O
19612	by	ADP	O
19612	cellulose	ADJ	O
19612	chromatography	NOUN	O
19612	.	PUNCT	O
19613	The	DET	O
19613	hydrolase	NOUN	O
19613	activities	NOUN	O
19613	in	ADP	O
19613	normal	ADJ	O
19613	RBC	PROPN	O
19613	were	VERB	O
19613	detected	VERB	O
19613	only	ADV	O
19613	in	ADP	O
19613	their	ADJ	O
19613	plasma	NOUN	O
19613	membranes	NOUN	O
19613	and	CCONJ	O
19613	were	VERB	O
19613	found	VERB	O
19613	to	PART	O
19613	be	VERB	O
19613	considerably	ADV	O
19613	lower	ADJ	O
19613	than	ADP	O
19613	in	ADP	O
19613	WBC	PROPN	O
19613	or	CCONJ	O
19613	platelets	NOUN	O
19613	.	PUNCT	O
19614	In	ADP	O
19614	thalassaemic	ADJ	O
19614	RBC	PROPN	O
19614	,	PUNCT	O
19614	hydrolase	NOUN	O
19614	activities	NOUN	O
19614	were	VERB	O
19614	present	ADJ	O
19614	in	ADP	O
19614	both	DET	O
19614	plasma	NOUN	O
19614	membranes	NOUN	O
19614	and	CCONJ	O
19614	in	ADP	O
19614	the	DET	O
19614	soluble	ADJ	O
19614	fraction	NOUN	O
19614	.	PUNCT	O
19615	The	DET	O
19615	normoblast	ADJ	O
19615	fraction	NOUN	O
19615	contributed	VERB	O
19615	most	ADJ	O
19615	of	ADP	O
19615	the	DET	O
19615	hydrolase	NOUN	O
19615	activity	NOUN	O
19615	found	VERB	O
19615	in	ADP	O
19615	these	DET	O
19615	preparations	NOUN	O
19615	,	PUNCT	O
19615	suggesting	VERB	O
19615	the	DET	O
19615	presence	NOUN	O
19615	of	ADP	O
19615	lysosomal	ADJ	O
19615	particles	NOUN	O
19615	in	ADP	O
19615	thalassaemic	ADJ	O
19615	RBC	PROPN	O
19615	.	PUNCT	O
19616	No	DET	O
19616	differences	NOUN	O
19616	in	ADP	O
19616	the	DET	O
19616	enzymatic	ADJ	O
19616	activities	NOUN	O
19616	were	VERB	O
19616	found	VERB	O
19616	when	ADV	O
19616	purified	VERB	O
19616	membranes	NOUN	O
19616	of	ADP	O
19616	mature	ADJ	O
19616	RBC	PROPN	O
19616	from	ADP	O
19616	thalassemic	ADJ	O
19616	and	CCONJ	O
19616	normal	ADJ	O
19616	preparations	NOUN	O
19616	were	VERB	O
19616	compared	VERB	O
19616	.	PUNCT	O
19617	The	DET	O
19617	origin	NOUN	O
19617	and	CCONJ	O
19617	roles	NOUN	O
19617	of	ADP	O
19617	these	DET	O
19617	hydrolytic	ADJ	O
19617	enzymes	NOUN	O
19617	in	ADP	O
19617	normal	ADJ	O
19617	and	CCONJ	O
19617	thalassaemic	ADJ	O
19617	RBC	PROPN	O
19617	membranes	NOUN	O
19617	are	VERB	O
19617	not	ADV	O
19617	known	VERB	O
19617	.	PUNCT	O
19618	Forty	NUM	O
19618	-	PUNCT	O
19618	one	NUM	O
19618	women	NOUN	O
19618	with	ADP	O
19618	oligo	NOUN	O
19618	-	PUNCT	O
19618	menorrhoea	NOUN	O
19618	and/or	CCONJ	O
19618	galactorrhoea	NOUN	DISEASE
19618	were	VERB	O
19618	subjected	VERB	O
19618	to	ADP	O
19618	hypothalamic	ADJ	O
19618	pituitary	ADJ	O
19618	-	PUNCT	O
19618	thyroid	NOUN	O
19618	testing	NOUN	O
19618	in	ADP	O
19618	an	DET	O
19618	attempt	NOUN	O
19618	to	PART	O
19618	establish	VERB	O
19618	the	DET	O
19618	presence	NOUN	O
19618	or	CCONJ	O
19618	absence	NOUN	O
19618	of	ADP	O
19618	an	DET	O
19618	underlying	ADJ	O
19618	pituitary	ADJ	O
19618	microadenoma	NOUN	O
19618	.	PUNCT	O
19619	They	PRON	O
19619	were	VERB	O
19619	divided	VERB	O
19619	into	ADP	O
19619	two	NUM	O
19619	groups	NOUN	O
19619	in	ADP	O
19619	accordance	NOUN	O
19619	with	ADP	O
19619	the	DET	O
19619	serum	NOUN	O
19619	level	NOUN	O
19619	of	ADP	O
19619	prolactin	NOUN	O
19619	(	PUNCT	O
19619	PRL	PROPN	O
19619	)	PUNCT	O
19619	:	PUNCT	O
19619	Group	PROPN	O
19619	I	PRON	O
19619	(	PUNCT	O
19619	N	NOUN	O
19619	=	SYM	O
19619	25	NUM	O
19619	,	PUNCT	O
19619	mean	VERB	O
19619	+	X	O
19619	/-	PUNCT	O
19620	SE	PROPN	O
19620	17.6	NUM	O
19620	+	X	O
19620	/-	PUNCT	O
19621	1.5	NUM	O
19621	ng	NOUN	O
19621	/	SYM	O
19621	ml	PROPN	O
19621	)	PUNCT	O
19621	and	CCONJ	O
19621	Group	PROPN	O
19621	II	PROPN	O
19621	(	PUNCT	O
19621	N	PROPN	O
19621	=	SYM	O
19621	16	NUM	O
19621	,	PUNCT	O
19621	102.8	NUM	O
19621	+	X	O
19621	/-	PUNCT	O
19622	29.7	NUM	O
19622	ng	NOUN	O
19622	/	SYM	O
19622	ml	PROPN	O
19622	)	PUNCT	O
19622	.	PUNCT	O
19623	The	DET	O
19623	dynamic	ADJ	O
19623	tests	NOUN	O
19623	performed	VERB	O
19623	were	VERB	O
19623	a	DET	O
19623	TRH	PROPN	O
19623	test	NOUN	O
19623	,	PUNCT	O
19623	a	DET	O
19623	stimulation	NOUN	O
19623	test	NOUN	O
19623	with	ADP	O
19623	metoclopramide	ADJ	O
19623	(	PUNCT	O
19623	MCP	PROPN	O
19623	)	PUNCT	O
19623	and	CCONJ	O
19623	a	DET	O
19623	suppression	NOUN	O
19623	test	NOUN	O
19623	with	ADP	O
19623	bromocriptine	NOUN	O
19623	.	PUNCT	O
19624	The	DET	O
19624	results	NOUN	O
19624	of	ADP	O
19624	these	DET	O
19624	tests	NOUN	O
19624	were	VERB	O
19624	compared	VERB	O
19624	with	ADP	O
19624	those	DET	O
19624	obtained	VERB	O
19624	in	ADP	O
19624	nine	NUM	O
19624	normal	ADJ	O
19624	women	NOUN	O
19624	and	CCONJ	O
19624	eleven	NUM	O
19624	patients	NOUN	O
19624	with	ADP	O
19624	surgically	ADV	O
19624	proved	VERB	O
19624	pituitary	ADJ	O
19624	microadenoma	NOUN	O
19624	.	PUNCT	O
19625	Radiologically	ADV	O
19625	abnormal	ADJ	O
19625	pituitary	ADJ	O
19625	fossas	NOUN	O
19625	were	VERB	O
19625	found	VERB	O
19625	in	ADP	O
19625	ten	NUM	O
19625	subjects	NOUN	O
19625	from	ADP	O
19625	Group	PROPN	O
19625	I	PROPN	O
19625	and	CCONJ	O
19625	in	ADP	O
19625	fourteen	NUM	O
19625	from	ADP	O
19625	Group	PROPN	O
19625	II	PROPN	O
19625	.	PUNCT	O
19626	All	DET	O
19626	patients	NOUN	O
19626	were	VERB	O
19626	euthyroid	ADJ	O
19626	.	PUNCT	O
19627	A	DET	O
19627	persistently	ADV	O
19627	elevated	ADJ	O
19627	serum	NOUN	O
19627	TSH	NOUN	O
19627	in	ADP	O
19627	response	NOUN	O
19627	to	ADP	O
19627	TRH	PROPN	O
19627	was	VERB	O
19627	observed	VERB	O
19627	in	ADP	O
19627	patients	NOUN	O
19627	of	ADP	O
19627	Group	PROPN	O
19627	II	PROPN	O
19627	suggesting	VERB	O
19627	an	DET	O
19627	hypothalamic	ADJ	O
19627	abnormality	NOUN	O
19627	and	CCONJ	O
19627	a	DET	O
19627	progressive	ADJ	O
19627	decrease	NOUN	O
19627	in	ADP	O
19627	the	DET	O
19627	120-min	NUM	O
19627	use	NOUN	O
19627	of	ADP	O
19627	serum	NOUN	O
19627	T3	PROPN	O
19627	was	VERB	O
19627	noted	VERB	O
19627	with	ADP	O
19627	increasing	VERB	O
19627	evidence	NOUN	O
19627	of	ADP	O
19627	the	DET	O
19627	existence	NOUN	O
19627	of	ADP	O
19627	a	DET	O
19627	pituitary	ADJ	O
19627	tumour	NOUN	O
19627	.	PUNCT	O
19628	A	DET	O
19628	negative	ADJ	O
19628	correlation	NOUN	O
19628	was	VERB	O
19628	found	VERB	O
19628	between	ADP	O
19628	the	DET	O
19628	basal	NOUN	O
19628	serum	NOUN	O
19628	PRL	PROPN	O
19628	and	CCONJ	O
19628	the	DET	O
19628	rise	NOUN	O
19628	of	ADP	O
19628	serum	NOUN	O
19628	PRL	PROPN	O
19628	with	ADP	O
19628	TRH	PROPN	O
19628	.	PUNCT	O
19629	Patients	NOUN	O
19629	from	ADP	O
19629	Group	PROPN	O
19629	II	PROPN	O
19629	showed	VERB	O
19629	a	DET	O
19629	lower	ADJ	O
19629	PRL	NOUN	O
19629	response	NOUN	O
19629	to	ADP	O
19629	MCP	NOUN	O
19629	when	ADV	O
19629	compared	VERB	O
19629	to	ADP	O
19629	Group	PROPN	O
19629	I	PROPN	O
19629	and	CCONJ	O
19629	again	ADV	O
19629	a	DET	O
19629	negative	ADJ	O
19629	correlation	NOUN	O
19629	between	ADP	O
19629	basal	NOUN	O
19629	level	NOUN	O
19629	of	ADP	O
19629	serum	NOUN	O
19629	PRL	PROPN	O
19629	and	CCONJ	O
19629	the	DET	O
19629	change	NOUN	O
19629	after	ADP	O
19629	MCP	PROPN	O
19629	was	VERB	O
19629	observed	VERB	O
19629	.	PUNCT	O
19630	No	DET	O
19630	clear	ADJ	O
19630	difference	NOUN	O
19630	in	ADP	O
19630	the	DET	O
19630	4-h	NUM	O
19630	response	NOUN	O
19630	to	ADP	O
19630	bromocriptine	NOUN	O
19630	was	VERB	O
19630	found	VERB	O
19630	between	ADP	O
19630	the	DET	O
19630	different	ADJ	O
19630	groups	NOUN	O
19630	of	ADP	O
19630	subjects	NOUN	O
19630	.	PUNCT	O
19631	In	ADP	O
19631	conclusion	NOUN	O
19631	,	PUNCT	O
19631	none	NOUN	O
19631	of	ADP	O
19631	the	DET	O
19631	three	NUM	O
19631	tests	NOUN	O
19631	analysed	VERB	O
19631	permitted	VERB	O
19631	us	PRON	O
19631	to	PART	O
19631	establish	VERB	O
19631	which	ADJ	O
19631	of	ADP	O
19631	the	DET	O
19631	patients	NOUN	O
19631	had	VERB	O
19631	an	DET	O
19631	underlying	ADJ	O
19631	pituitary	ADJ	O
19631	microadenoma	NOUN	O
19631	.	PUNCT	O
19632	Since	ADP	O
19632	the	DET	O
19632	early	ADJ	O
19632	diagnosis	NOUN	O
19632	of	ADP	O
19632	alpha	NOUN	DISEASE
19632	chain	NOUN	DISEASE
19632	disease	NOUN	DISEASE
19632	(	PUNCT	O
19632	alphaCD	NOUN	O
19632	)	PUNCT	O
19632	)	PUNCT	O
19632	is	VERB	O
19632	essential	ADJ	O
19632	to	ADP	O
19632	successful	ADJ	O
19632	treatment	NOUN	O
19632	and	CCONJ	O
19632	to	ADP	O
19632	epidemiological	ADJ	O
19632	studies	NOUN	O
19632	,	PUNCT	O
19632	the	DET	O
19632	available	ADJ	O
19632	immunodiagnostic	ADJ	O
19632	techniques	NOUN	O
19632	were	VERB	O
19632	compared	VERB	O
19632	for	ADP	O
19632	their	ADJ	O
19632	sensitivity	NOUN	O
19632	,	PUNCT	O
19632	specificity	NOUN	O
19632	and	CCONJ	O
19632	ease	NOUN	O
19632	of	ADP	O
19632	performance	NOUN	O
19632	on	ADP	O
19632	a	DET	O
19632	panel	NOUN	O
19632	of	ADP	O
19632	sixteen	NUM	O
19632	sera	NOUN	O
19632	,	PUNCT	O
19632	comprising	VERB	O
19632	ten	NUM	O
19632	alphaCD	PROPN	O
19632	sera	NOUN	O
19632	and	CCONJ	O
19632	six	NUM	O
19632	control	NOUN	O
19632	sera	NOUN	O
19632	containing	VERB	O
19632	either	CCONJ	O
19632	IgA	PROPN	O
19632	myeloma	NOUN	O
19632	protein	NOUN	O
19632	or	CCONJ	O
19632	high	ADJ	O
19632	levels	NOUN	O
19632	of	ADP	O
19632	polyclonal	ADJ	O
19632	IgA.	PROPN	O
19632	Immunoselection	PROPN	O
19632	by	ADP	O
19632	immunoelectrophoresis	NOUN	O
19632	into	ADP	O
19632	gel	NOUN	O
19632	containing	VERB	O
19632	a	DET	O
19632	specially	ADV	O
19632	developed	VERB	O
19632	anti	ADV	O
19632	-	PUNCT	O
19632	Fabalpha	PROPN	O
19632	antiserum	NOUN	O
19632	provided	VERB	O
19632	the	DET	O
19632	most	ADV	O
19632	sensitive	ADJ	O
19632	and	CCONJ	O
19632	specific	ADJ	O
19632	detection	NOUN	O
19632	system	NOUN	O
19632	for	ADP	O
19632	alphaCD	PROPN	O
19632	protein	NOUN	O
19632	.	PUNCT	O
19632	Since	ADP	O
19632	the	DET	O
19632	early	ADJ	O
19632	diagnosis	NOUN	O
19632	of	ADP	O
19632	alpha	NOUN	O
19632	chain	NOUN	O
19632	disease	NOUN	O
19632	(	PUNCT	O
19632	alphaCD	NOUN	O
19632	)	PUNCT	O
19632	)	PUNCT	O
19632	is	VERB	O
19632	essential	ADJ	O
19632	to	ADP	O
19632	successful	ADJ	O
19632	treatment	NOUN	O
19632	and	CCONJ	O
19632	to	ADP	O
19632	epidemiological	ADJ	O
19632	studies	NOUN	O
19632	,	PUNCT	O
19632	the	DET	O
19632	available	ADJ	O
19632	immunodiagnostic	ADJ	O
19632	techniques	NOUN	O
19632	were	VERB	O
19632	compared	VERB	O
19632	for	ADP	O
19632	their	ADJ	O
19632	sensitivity	NOUN	O
19632	,	PUNCT	O
19632	specificity	NOUN	O
19632	and	CCONJ	O
19632	ease	NOUN	O
19632	of	ADP	O
19632	performance	NOUN	O
19632	on	ADP	O
19632	a	DET	O
19632	panel	NOUN	O
19632	of	ADP	O
19632	sixteen	NUM	O
19632	sera	NOUN	O
19632	,	PUNCT	O
19632	comprising	VERB	O
19632	ten	NUM	O
19632	alphaCD	PROPN	O
19632	sera	NOUN	O
19632	and	CCONJ	O
19632	six	NUM	O
19632	control	NOUN	O
19632	sera	NOUN	O
19632	containing	VERB	O
19632	either	CCONJ	O
19632	IgA	PROPN	O
19632	myeloma	NOUN	DISEASE
19632	protein	NOUN	O
19632	or	CCONJ	O
19632	high	ADJ	O
19632	levels	NOUN	O
19632	of	ADP	O
19632	polyclonal	ADJ	O
19632	IgA.	PROPN	O
19632	Immunoselection	PROPN	O
19632	by	ADP	O
19632	immunoelectrophoresis	NOUN	O
19632	into	ADP	O
19632	gel	NOUN	O
19632	containing	VERB	O
19632	a	DET	O
19632	specially	ADV	O
19632	developed	VERB	O
19632	anti	ADV	O
19632	-	PUNCT	O
19632	Fabalpha	PROPN	O
19632	antiserum	NOUN	O
19632	provided	VERB	O
19632	the	DET	O
19632	most	ADV	O
19632	sensitive	ADJ	O
19632	and	CCONJ	O
19632	specific	ADJ	O
19632	detection	NOUN	O
19632	system	NOUN	O
19632	for	ADP	O
19632	alphaCD	PROPN	O
19632	protein	NOUN	O
19632	.	PUNCT	O
19633	The	DET	O
19633	same	ADJ	O
19633	technique	NOUN	O
19633	using	VERB	O
19633	anti	ADV	O
19633	-	PUNCT	O
19633	light	NOUN	O
19633	chain	NOUN	O
19633	antiserum	NOUN	O
19633	for	ADP	O
19633	immunoselection	NOUN	O
19633	was	VERB	O
19633	also	ADV	O
19633	highly	ADV	O
19633	sensitive	ADJ	O
19633	,	PUNCT	O
19633	but	CCONJ	O
19633	proved	VERB	O
19633	less	ADV	O
19633	specific	ADJ	O
19633	,	PUNCT	O
19633	being	VERB	O
19633	prone	ADJ	O
19633	to	ADP	O
19633	false	ADJ	O
19633	positives	NOUN	O
19633	with	ADP	O
19633	difficult	ADJ	O
19633	IgA	PROPN	O
19633	myeloma	NOUN	DISEASE
19633	proteins	NOUN	O
19633	.	PUNCT	O
19634	Somewhat	ADV	O
19634	less	ADV	O
19634	sensitive	ADJ	O
19634	,	PUNCT	O
19634	but	CCONJ	O
19634	specific	ADJ	O
19634	and	CCONJ	O
19634	simple	ADJ	O
19634	to	PART	O
19634	perform	VERB	O
19634	,	PUNCT	O
19634	was	VERB	O
19634	immunoelectrophoresis	NOUN	O
19634	using	VERB	O
19634	an	DET	O
19634	antiserum	NOUN	O
19634	recognizing	VERB	O
19634	the	DET	O
19634	conformational	ADJ	O
19634	specificities	NOUN	O
19634	of	ADP	O
19634	Fabalpha	PROPN	O
19634	as	ADV	O
19634	well	ADV	O
19634	as	ADP	O
19634	those	DET	O
19634	of	ADP	O
19634	the	DET	O
19634	constant	ADJ	O
19634	region	NOUN	O
19634	of	ADP	O
19634	alpha	NOUN	O
19634	chains	NOUN	O
19634	.	PUNCT	O
19635	Immunoselection	NOUN	O
19635	using	VERB	O
19635	the	DET	O
19635	Ouchterlony	PROPN	O
19635	or	CCONJ	O
19635	rocket	NOUN	O
19635	techniques	NOUN	O
19635	proved	VERB	O
19635	to	PART	O
19635	be	VERB	O
19635	less	ADV	O
19635	sensitive	ADJ	O
19635	and	CCONJ	O
19635	prone	ADJ	O
19635	to	ADP	O
19635	false	ADJ	O
19635	positives	NOUN	O
19635	when	ADV	O
19635	some	DET	O
19635	IgA	PROPN	O
19635	myeloma	NOUN	DISEASE
19635	sera	NOUN	O
19635	were	VERB	O
19635	tested	VERB	O
19635	.	PUNCT	O
19636	The	DET	O
19636	conformation	NOUN	O
19636	of	ADP	O
19636	the	DET	O
19636	dinucleotide	NOUN	O
19636	adenylyl(3'-5')adenosine	NOUN	O
19636	2'-phosphate	NUM	O
19636	(	PUNCT	O
19636	ApA2'p	NOUN	O
19636	)	PUNCT	O
19636	in	ADP	O
19636	aqueous	ADJ	O
19636	solution	NOUN	O
19636	at	ADP	O
19636	different	ADJ	O
19636	pH	VERB	O
19636	values	NOUN	O
19636	and	CCONJ	O
19636	temperatures	NOUN	O
19636	has	VERB	O
19636	been	VERB	O
19636	studied	VERB	O
19636	using	VERB	O
19636	the	DET	O
19636	lanthanide(III	NOUN	O
19636	)	PUNCT	O
19636	ethylenodiaminetetraacetate(EDTA	NOUN	O
19636	)	PUNCT	O
19636	1:1	NUM	O
19636	complexes	NOUN	O
19636	as	ADP	O
19636	shift	NOUN	O
19636	and	CCONJ	O
19636	relaxation	NOUN	O
19636	probes	NOUN	O
19636	.	PUNCT	O
19637	The	DET	O
19637	conformational	ADJ	O
19637	analysis	NOUN	O
19637	,	PUNCT	O
19637	based	VERB	O
19637	on	ADP	O
19637	mixing	VERB	O
19637	different	ADJ	O
19637	conformations	NOUN	O
19637	in	ADP	O
19637	fast	ADJ	O
19637	exchange	NOUN	O
19637	within	ADP	O
19637	the	DET	O
19637	nuclear	ADJ	O
19637	magnetic	ADJ	O
19637	resonance	NOUN	O
19637	time	NOUN	O
19637	scale	NOUN	O
19637	,	PUNCT	O
19637	agrees	VERB	O
19637	well	ADV	O
19637	with	ADP	O
19637	the	DET	O
19637	results	NOUN	O
19637	from	ADP	O
19637	vicinal	ADJ	O
19637	coupling	NOUN	O
19637	constants	NOUN	O
19637	and	CCONJ	O
19637	dimerization	NOUN	O
19637	shifts	NOUN	O
19637	obtained	VERB	O
19637	for	ADP	O
19637	the	DET	O
19637	metal	NOUN	O
19637	-	PUNCT	O
19637	free	ADJ	O
19637	system	NOUN	O
19637	.	PUNCT	O
19638	The	DET	O
19638	dinucleotide	NOUN	O
19638	exists	VERB	O
19638	in	ADP	O
19638	a	DET	O
19638	temperature	NOUN	O
19638	-	PUNCT	O
19638	dependent	ADJ	O
19638	and	CCONJ	O
19638	pH	VERB	O
19638	-	PUNCT	O
19638	dependent	ADJ	O
19638	conformational	ADJ	O
19638	equilibrium	NOUN	O
19638	between	ADP	O
19638	unstacked	ADJ	O
19638	and	CCONJ	O
19638	base	NOUN	O
19638	-	PUNCT	O
19638	stacked	VERB	O
19638	forms	NOUN	O
19638	.	PUNCT	O
19639	At	ADP	O
19639	neutral	ADJ	O
19639	pH	PROPN	O
19639	and	CCONJ	O
19639	low	ADJ	O
19639	temperature	NOUN	O
19639	,	PUNCT	O
19639	the	DET	O
19639	stacked	VERB	O
19639	form	NOUN	O
19639	predominates	VERB	O
19639	,	PUNCT	O
19639	and	CCONJ	O
19639	it	PRON	O
19639	is	VERB	O
19639	a	DET	O
19639	predominantly	ADV	O
19639	right	ADJ	O
19639	helical	ADJ	O
19639	structure	NOUN	O
19639	,	PUNCT	O
19639	characterized	VERB	O
19639	as	ADP	O
19639	an	DET	O
19639	anti	ADV	O
19639	,	PUNCT	O
19639	3E	NOUN	O
19639	,	PUNCT	O
19639	g-	NOUN	O
19639	,	PUNCT	O
19639	g-	X	O
19640	g-	X	O
19640	,	PUNCT	O
19640	g'g	NOUN	O
19640	'	PUNCT	O
19640	,	PUNCT	O
19640	gg	ADP	O
19640	,	PUNCT	O
19640	3E	NOUN	O
19640	,	PUNCT	O
19641	anti	ADV	O
19641	conformation	NOUN	O
19641	.	PUNCT	O
19642	This	DET	O
19642	situation	NOUN	O
19642	contrasts	VERB	O
19642	with	ADP	O
19642	adenylyl(3'-5')adenosine	NOUN	O
19642	(	PUNCT	O
19642	ApA	NOUN	O
19642	)	PUNCT	O
19642	,	PUNCT	O
19642	where	ADV	O
19642	both	CCONJ	O
19642	right	ADJ	O
19642	and	CCONJ	O
19642	left	VERB	O
19642	helices	NOUN	O
19642	contribute	VERB	O
19642	to	ADP	O
19642	the	DET	O
19642	stacked	VERB	O
19642	form	NOUN	O
19642	.	PUNCT	O
19643	The	DET	O
19643	nucleotidyl	ADJ	O
19643	units	NOUN	O
19643	of	ADP	O
19643	the	DET	O
19643	unstacked	ADJ	O
19643	form	NOUN	O
19643	of	ADP	O
19643	ApA2'p	PROPN	O
19643	have	VERB	O
19643	average	ADJ	O
19643	conformations	NOUN	O
19643	which	ADJ	O
19643	are	VERB	O
19643	very	ADV	O
19643	similar	ADJ	O
19643	to	ADP	O
19643	those	DET	O
19643	of	ADP	O
19643	the	DET	O
19643	corresponding	VERB	O
19643	mononucleotides	NOUN	O
19643	in	ADP	O
19643	similar	ADJ	O
19643	conditions	NOUN	O
19643	.	PUNCT	O
19644	Several	ADJ	O
19644	inbred	ADJ	O
19644	mouse	NOUN	O
19644	strains	NOUN	O
19644	,	PUNCT	O
19644	all	DET	O
19644	of	ADP	O
19644	them	PRON	O
19644	derived	VERB	O
19644	from	ADP	O
19644	the	DET	O
19644	C57BL	ADJ	O
19644	background	NOUN	O
19644	,	PUNCT	O
19644	have	VERB	O
19644	genetically	ADV	O
19644	determined	VERB	O
19644	increased	VERB	O
19644	resistance	NOUN	O
19644	to	ADP	O
19644	infection	NOUN	O
19644	with	ADP	O
19644	Listeria	PROPN	O
19644	monocytogenes	NOUN	O
19644	,	PUNCT	O
19644	whereas	ADP	O
19644	a	DET	O
19644	variety	NOUN	O
19644	of	ADP	O
19644	other	ADJ	O
19644	strains	NOUN	O
19644	are	VERB	O
19644	relatively	ADV	O
19644	sensitive	ADJ	O
19644	to	ADP	O
19644	this	DET	O
19644	infection	NOUN	O
19644	.	PUNCT	O
19645	Comparison	PROPN	O
19645	of	ADP	O
19645	the	DET	O
19645	host	NOUN	O
19645	response	NOUN	O
19645	to	ADP	O
19645	L.	PROPN	O
19645	monocytogenes	NOUN	O
19645	in	ADP	O
19645	the	DET	O
19645	sensitive	ADJ	O
19645	A	DET	O
19645	strain	NOUN	O
19645	and	CCONJ	O
19645	the	DET	O
19645	resistant	ADJ	O
19645	C57BL/6	PROPN	O
19645	(	PUNCT	O
19645	B6	PROPN	O
19645	)	PUNCT	O
19645	strain	NOUN	O
19645	revealed	VERB	O
19645	that	ADP	O
19645	the	DET	O
19645	B6	NOUN	O
19645	mice	NOUN	O
19645	were	VERB	O
19645	superior	ADJ	O
19645	to	ADP	O
19645	A	DET	O
19645	mice	NOUN	O
19645	both	CCONJ	O
19645	in	ADP	O
19645	the	DET	O
19645	T	PROPN	O
19645	-	PUNCT	O
19645	cell	NOUN	O
19645	-	PUNCT	O
19645	independent	ADJ	O
19645	and	CCONJ	O
19645	in	ADP	O
19645	the	DET	O
19645	T	PROPN	O
19645	-	PUNCT	O
19645	cell	NOUN	O
19645	-	PUNCT	O
19645	dependent	ADJ	O
19645	phase	NOUN	O
19645	of	ADP	O
19645	the	DET	O
19645	response	NOUN	O
19645	.	PUNCT	O
19646	Although	ADP	O
19646	animals	NOUN	O
19646	of	ADP	O
19646	both	DET	O
19646	strains	NOUN	O
19646	had	VERB	O
19646	equal	ADJ	O
19646	ability	NOUN	O
19646	to	PART	O
19646	clear	VERB	O
19646	their	ADJ	O
19646	circulation	NOUN	O
19646	of	ADP	O
19646	intravenously	ADV	O
19646	administered	VERB	O
19646	Listeria	PROPN	O
19646	and	CCONJ	O
19646	to	PART	O
19646	take	VERB	O
19646	up	PART	O
19646	comparable	ADJ	O
19646	amounts	NOUN	O
19646	of	ADP	O
19646	bacteria	NOUN	O
19646	in	ADP	O
19646	their	ADJ	O
19646	livers	NOUN	O
19646	and	CCONJ	O
19646	spleens	NOUN	O
19646	,	PUNCT	O
19646	already	ADV	O
19646	24	NUM	O
19646	to	PART	O
19646	48	NUM	O
19646	h	NOUN	O
19646	after	ADP	O
19646	infection	NOUN	O
19646	the	DET	O
19646	genetic	ADJ	O
19646	advantage	NOUN	O
19646	of	ADP	O
19646	B6	NOUN	O
19646	strain	NOUN	O
19646	mice	NOUN	O
19646	to	PART	O
19646	suppress	VERB	O
19646	bacterial	ADJ	O
19646	proliferation	NOUN	O
19646	was	VERB	O
19646	apparent	ADJ	O
19646	.	PUNCT	O
19647	Both	CCONJ	O
19647	the	DET	O
19647	primary	ADJ	O
19647	(	PUNCT	O
19647	early	ADJ	O
19647	and	CCONJ	O
19647	late	ADJ	O
19647	)	PUNCT	O
19647	and	CCONJ	O
19647	the	DET	O
19647	secondary	ADJ	O
19647	responses	NOUN	O
19647	as	ADV	O
19647	well	ADV	O
19647	as	ADP	O
19647	the	DET	O
19647	ability	NOUN	O
19647	to	PART	O
19647	inactivate	VERB	O
19647	the	DET	O
19647	bacterial	ADJ	O
19647	load	NOUN	O
19647	after	ADP	O
19647	adoptive	ADJ	O
19647	protection	NOUN	O
19647	by	ADP	O
19647	syngeneic	NOUN	O
19647	immune	ADJ	O
19647	lymphocytes	NOUN	O
19647	were	VERB	O
19647	more	ADV	O
19647	efficient	ADJ	O
19647	in	ADP	O
19647	the	DET	O
19647	B6	NOUN	O
19647	animals	NOUN	O
19647	,	PUNCT	O
19647	suggesting	VERB	O
19647	that	ADP	O
19647	the	DET	O
19647	common	ADJ	O
19647	effector	NOUN	O
19647	macrophage	NOUN	O
19647	arm	NOUN	O
19647	of	ADP	O
19647	the	DET	O
19647	antilisterial	ADJ	O
19647	resistance	NOUN	O
19647	rather	ADV	O
19647	than	ADP	O
19647	the	DET	O
19647	lymphocyte	ADJ	O
19647	arm	NOUN	O
19647	(	PUNCT	O
19647	mediating	VERB	O
19647	the	DET	O
19647	T	PROPN	O
19647	-	PUNCT	O
19647	cell	NOUN	O
19647	-	PUNCT	O
19647	dependent	ADJ	O
19647	phase	NOUN	O
19647	of	ADP	O
19647	response	NOUN	O
19647	)	PUNCT	O
19647	is	VERB	O
19647	genetically	ADV	O
19647	controlled	VERB	O
19647	.	PUNCT	O
19648	An	DET	O
19648	anti	ADV	O
19648	-	PUNCT	O
19648	hemoglobin	NOUN	O
19648	antiserum	NOUN	O
19648	obtained	VERB	O
19648	from	ADP	O
19648	a	DET	O
19648	sheep	NOUN	O
19648	immunized	VERB	O
19648	with	ADP	O
19648	human	ADJ	O
19648	carboxyhemoglobin	NOUN	O
19648	A0	PROPN	O
19648	demonstrated	VERB	O
19648	little	ADJ	O
19648	difference	NOUN	O
19648	in	ADP	O
19648	its	ADJ	O
19648	reactivity	NOUN	O
19648	with	ADP	O
19648	deoxy-	NOUN	O
19648	or	CCONJ	O
19648	carboxyhemoglobin	NOUN	O
19648	A0	PROPN	O
19648	.	PUNCT	O
19649	However	ADV	O
19649	,	PUNCT	O
19649	a	DET	O
19649	subpopulation	NOUN	O
19649	of	ADP	O
19649	this	DET	O
19649	antiserum	NOUN	O
19649	isolated	VERB	O
19649	by	ADP	O
19649	synthetic	ADJ	O
19649	peptide	NOUN	O
19649	affinity	NOUN	O
19649	chromatography	VERB	O
19649	clearly	ADV	O
19649	distinguished	VERB	O
19649	between	ADP	O
19649	these	DET	O
19649	two	NUM	O
19649	hemoglobin	NOUN	O
19649	species	NOUN	O
19649	.	PUNCT	O
19650	This	DET	O
19650	subpopulation	NOUN	O
19650	,	PUNCT	O
19650	designated	VERB	O
19650	alpha(129	NUM	O
19650	-	PUNCT	O
19650	141	NUM	O
19650	)	PUNCT	O
19650	anti	ADV	O
19650	-	PUNCT	O
19650	hemoglobin	NOUN	O
19650	antibodies	NOUN	O
19650	,	PUNCT	O
19650	represents	VERB	O
19650	less	ADJ	O
19650	than	ADP	O
19650	1	NUM	O
19650	%	NOUN	O
19650	of	ADP	O
19650	the	DET	O
19650	total	ADJ	O
19650	anti	ADV	O
19650	-	PUNCT	O
19650	hemoglobin	NOUN	O
19650	antibodies	NOUN	O
19650	.	PUNCT	O
19651	They	PRON	O
19651	are	VERB	O
19651	nonprecipitating	VERB	O
19651	by	ADP	O
19651	Ouchterlony	PROPN	O
19651	analysis	NOUN	O
19651	,	PUNCT	O
19651	and	CCONJ	O
19651	fluorescence	NOUN	O
19651	-	PUNCT	O
19651	quenching	VERB	O
19651	studies	NOUN	O
19651	demonstrate	VERB	O
19651	the	DET	O
19651	interaction	NOUN	O
19651	of	ADP	O
19651	a	DET	O
19651	single	ADJ	O
19651	antibody	NOUN	O
19651	binding	ADJ	O
19651	site	NOUN	O
19651	per	ADP	O
19651	hemoglobin	NOUN	O
19651	dimer	NOUN	O
19651	.	PUNCT	O
19652	These	DET	O
19652	antibodies	NOUN	O
19652	bind	VERB	O
19652	preferentially	ADV	O
19652	to	ADP	O
19652	carboxyhemoglobin	NOUN	O
19652	with	ADP	O
19652	a	DET	O
19652	median	ADJ	O
19652	affinity	NOUN	O
19652	constant	ADJ	O
19652	of	ADP	O
19652	5	NUM	O
19652	X	NOUN	O
19652	10(8	NUM	O
19652	)	PUNCT	O
19652	M-1	PROPN	O
19652	compared	VERB	O
19652	to	ADP	O
19652	binding	VERB	O
19652	to	PART	O
19652	deoxyhemoglobin	VERB	O
19652	with	ADP	O
19652	a	DET	O
19652	binding	VERB	O
19652	affinity	NOUN	O
19652	of	ADP	O
19652	less	ADJ	O
19652	than	ADP	O
19652	1	NUM	O
19652	X	NOUN	O
19652	10(8	NUM	O
19652	)	PUNCT	O
19652	M-1	PROPN	O
19652	.	PUNCT	O
19653	Furthermore	ADV	O
19653	,	PUNCT	O
19653	the	DET	O
19653	presence	NOUN	O
19653	of	ADP	O
19653	these	DET	O
19653	antibodies	NOUN	O
19653	in	ADP	O
19653	stoichiometric	ADJ	O
19653	amounts	NOUN	O
19653	increases	VERB	O
19653	the	DET	O
19653	oxygen	NOUN	O
19653	affinity	NOUN	O
19653	of	ADP	O
19653	hemoglobin	NOUN	O
19653	,	PUNCT	O
19653	and	CCONJ	O
19653	thus	ADV	O
19653	antibody	NOUN	O
19653	and	CCONJ	O
19653	oxygen	NOUN	O
19653	binding	ADJ	O
19653	to	ADP	O
19653	hemoglobin	NOUN	O
19653	can	VERB	O
19653	be	VERB	O
19653	considered	VERB	O
19653	as	ADP	O
19653	a	DET	O
19653	linked	VERB	O
19653	function	NOUN	O
19653	.	PUNCT	O
19654	Peritoneal	ADJ	O
19654	macrophages	NOUN	O
19654	from	ADP	O
19654	non	ADJ	O
19654	-	PUNCT	O
19654	immunised	VERB	O
19654	C57/bl	PROPN	O
19654	,	PUNCT	O
19654	C3H	PROPN	O
19654	,	PUNCT	O
19654	and	CCONJ	O
19654	DBA/2	PROPN	O
19654	mice	NOUN	O
19654	were	VERB	O
19654	examined	VERB	O
19654	for	ADP	O
19654	their	ADJ	O
19654	capability	NOUN	O
19654	of	ADP	O
19654	inhibiting	VERB	O
19654	the	DET	O
19654	growth	NOUN	O
19654	of	ADP	O
19654	mastocytoma	ADJ	DISEASE
19654	P-815	PROPN	O
19654	cells	NOUN	O
19654	in	ADP	O
19654	vitro	X	O
19654	.	PUNCT	O
19655	The	DET	O
19655	rate	NOUN	O
19655	of	ADP	O
19655	tumour	NOUN	O
19655	cell	NOUN	O
19655	growth	NOUN	O
19655	was	VERB	O
19655	measured	VERB	O
19655	by	ADP	O
19655	the	DET	O
19655	uptake	NOUN	O
19655	of	ADP	O
19655	125IUDR	NUM	O
19655	into	ADP	O
19655	the	DET	O
19655	DNA	NOUN	O
19655	of	ADP	O
19655	the	DET	O
19655	tumor	NOUN	O
19655	cells	NOUN	O
19655	.	PUNCT	O
19656	Sodium	NOUN	O
19656	thioglycollate	NOUN	O
19656	-	PUNCT	O
19656	induced	VERB	O
19656	macrophages	NOUN	O
19656	as	ADV	O
19656	well	ADV	O
19656	as	ADP	O
19656	resident	ADJ	O
19656	macrophages	NOUN	O
19656	inhibited	VERB	O
19656	the	DET	O
19656	growth	NOUN	O
19656	of	ADP	O
19656	allogeneic	ADJ	O
19656	tumor	NOUN	O
19656	cells	NOUN	O
19656	distinctly	ADV	O
19656	,	PUNCT	O
19656	when	ADV	O
19656	incubated	VERB	O
19656	for	ADP	O
19656	48	NUM	O
19656	h.	NOUN	O
19657	The	DET	O
19657	effect	NOUN	O
19657	depended	VERB	O
19657	on	ADP	O
19657	the	DET	O
19657	effector	NOUN	O
19657	to	PART	O
19657	target	VERB	O
19657	cell	NOUN	O
19657	ratio	NOUN	O
19657	.	PUNCT	O
19658	Tumor	NOUN	O
19658	cell	NOUN	O
19658	growth	NOUN	O
19658	was	VERB	O
19658	still	ADV	O
19658	reduced	VERB	O
19658	at	ADP	O
19658	a	DET	O
19658	ratio	NOUN	O
19658	of	ADP	O
19658	one	NUM	O
19658	macrophage	NOUN	O
19658	to	ADP	O
19658	one	NUM	O
19658	tumor	NOUN	O
19658	cell	NOUN	O
19658	.	PUNCT	O
19659	A	DET	O
19659	decrease	NOUN	O
19659	in	ADP	O
19659	the	DET	O
19659	proliferative	ADJ	O
19659	activity	NOUN	O
19659	of	ADP	O
19659	mastocytoma	NOUN	DISEASE
19659	cells	NOUN	O
19659	was	VERB	O
19659	observed	VERB	O
19659	in	ADP	O
19659	the	DET	O
19659	presence	NOUN	O
19659	of	ADP	O
19659	non	ADJ	O
19659	-	PUNCT	O
19659	stimulated	VERB	O
19659	and	CCONJ	O
19659	non	ADJ	O
19659	-	PUNCT	O
19659	immune	ADJ	O
19659	macrophages	NOUN	O
19659	from	ADP	O
19659	DBA/2	PROPN	O
19659	mice	NOUN	O
19659	.	PUNCT	O
19660	This	DET	O
19660	decrease	NOUN	O
19660	in	ADP	O
19660	target	NOUN	O
19660	cell	NOUN	O
19660	proliferation	NOUN	O
19660	,	PUNCT	O
19660	however	ADV	O
19660	,	PUNCT	O
19660	occurred	VERB	O
19660	more	ADV	O
19660	slowly	ADV	O
19660	.	PUNCT	O
19661	We	PRON	O
19661	exposed	VERB	O
19661	division	NOUN	O
19661	-	PUNCT	O
19661	synchronized	VERB	O
19661	Tetrahymena	PROPN	O
19661	pyriformis	NOUN	O
19661	to	ADP	O
19661	pulse	VERB	O
19661	treatments	NOUN	O
19661	with	ADP	O
19661	the	DET	O
19661	structural	ADJ	O
19661	amino	NOUN	O
19661	acid	NOUN	O
19661	analogue	NOUN	O
19661	p	NOUN	O
19661	-	PUNCT	O
19661	fluorophenylalanine	NOUN	O
19661	.	PUNCT	O
19662	We	PRON	O
19662	related	VERB	O
19662	the	DET	O
19662	timing	NOUN	O
19662	of	ADP	O
19662	the	DET	O
19662	treatments	NOUN	O
19662	to	ADP	O
19662	the	DET	O
19662	delays	NOUN	O
19662	in	ADP	O
19662	onset	NOUN	O
19662	or	CCONJ	O
19662	completion	NOUN	O
19662	of	ADP	O
19662	division	NOUN	O
19662	,	PUNCT	O
19662	or	CCONJ	O
19662	both	DET	O
19662	.	PUNCT	O
19663	The	DET	O
19663	results	NOUN	O
19663	enable	VERB	O
19663	us	PRON	O
19663	to	PART	O
19663	distinguish	VERB	O
19663	between	ADP	O
19663	early	ADJ	O
19663	and	CCONJ	O
19663	late	ADJ	O
19663	phases	NOUN	O
19663	in	ADP	O
19663	cell	NOUN	O
19663	division	NOUN	O
19663	in	ADP	O
19663	which	ADJ	O
19663	the	DET	O
19663	cells	NOUN	O
19663	bring	VERB	O
19663	into	ADP	O
19663	action	NOUN	O
19663	proteins	NOUN	O
19663	which	ADJ	O
19663	contribute	VERB	O
19663	to	PART	O
19663	initiate	VERB	O
19663	and	CCONJ	O
19663	complete	ADJ	O
19663	division	NOUN	O
19663	,	PUNCT	O
19663	respectively	ADV	O
19663	.	PUNCT	O
19664	Normally	ADV	O
19664	,	PUNCT	O
19664	these	DET	O
19664	events	NOUN	O
19664	are	VERB	O
19664	separated	VERB	O
19664	by	ADP	O
19664	25	NUM	O
19664	-	SYM	O
19664	30	NUM	O
19664	min	NOUN	O
19664	.	PUNCT	O
19665	An	DET	O
19665	individual	NOUN	O
19665	is	VERB	O
19665	described	VERB	O
19665	who	NOUN	O
19665	appeared	VERB	O
19665	to	PART	O
19665	be	VERB	O
19665	sensitive	ADJ	O
19665	to	ADP	O
19665	nonvenom	ADJ	O
19665	contaminants	NOUN	O
19665	in	ADP	O
19665	a	DET	O
19665	venom	NOUN	O
19665	preparation	NOUN	O
19665	.	PUNCT	O
19666	His	ADJ	O
19666	IgE	NOUN	O
19666	antibodies	NOUN	O
19666	,	PUNCT	O
19666	measured	VERB	O
19666	by	ADP	O
19666	the	DET	O
19666	immediate	ADJ	O
19666	direct	ADJ	O
19666	skin	NOUN	O
19666	test	NOUN	O
19666	and	CCONJ	O
19666	the	DET	O
19666	radioallergosorbent	ADJ	O
19666	test	NOUN	O
19666	(	PUNCT	O
19666	RAST	PROPN	O
19666	)	PUNCT	O
19666	,	PUNCT	O
19666	reacted	VERB	O
19666	with	ADP	O
19666	a	DET	O
19666	yellow	ADJ	O
19666	jacket	NOUN	O
19666	venom	NOUN	O
19666	preparation	NOUN	O
19666	obtained	VERB	O
19666	by	ADP	O
19666	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Poliovirus 	 O 	O
, 	 O 	O
Newcastle 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
virus 	 O 	O
, 	 O 	O
and 	 O 	O
lymphocytic 	 O 	O
choriomeningitis 	 O 	O
virus 	 O 	O
were 	 O 	O
centrifuged 	 O 	O
to 	 O 	O
equilibrium 	 O 	O
in 	 O 	O
gradients 	 O 	O
made 	 O 	O
of 	 O 	O
these 	 O 	O
substances 	 O 	O
. 	 O 	O
Poliovirus 	 O 	O
, 	 O 	O
Newcastle 	 O 	O
disease 	 O 	O
virus 	 O 	O
, 	 O 	O
and 	 O 	O
lymphocytic 	 DISEASE 	DISEASE
choriomeningitis 	 DISEASE 	DISEASE
virus 	 O 	O
were 	 O 	O
centrifuged 	 O 	O
to 	 O 	O
equilibrium 	 O 	O
in 	 O 	O
gradients 	 O 	O
made 	 O 	O
of 	 O 	O
these 	 O 	O
substances 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
virus 	 O 	O
( 	 O 	O
EBV 	 O 	O
) 	 O 	O
developed 	 O 	O
diffuse 	 O 	O
malignant 	 O 	DISEASE
lymphoma 	 DISEASE 	O
resembling 	 O 	O
reticulum 	 O 	O
cell 	 O 	O
or 	 O 	O
immunoblastic 	 O 	O
sarcoma 	 O 	O
of 	 O 	O
man 	 O 	O
. 	 O 	O
6 	 O 	O
of 	 O 	O
20 	 O 	O
cotton 	 O 	O
- 	 O 	O
top 	 O 	O
tamarins 	 O 	O
( 	 O 	O
Saguinus 	 O 	O
oedipus 	 O 	O
) 	 O 	O
inoculated 	 O 	O
with 	 O 	O
Epstein 	 O 	O
- 	 O 	O
Barr 	 O 	O
virus 	 O 	O
( 	 O 	O
EBV 	 O 	O
) 	 O 	O
developed 	 O 	O
diffuse 	 O 	O
malignant 	 O 	O
lymphoma 	 O 	O
resembling 	 O 	O
reticulum 	 O 	O
cell 	 O 	O
or 	 O 	O
immunoblastic 	 O 	O
sarcoma 	 DISEASE 	DISEASE
of 	 O 	O
man 	 O 	O
. 	 O 	O
Two 	 O 	O
brothers 	 O 	O
showed 	 O 	O
a 	 O 	O
similar 	 O 	O
in 	 O 	O
vitro 	 O 	O
defect 	 O 	DISEASE
but 	 O 	O
were 	 O 	O
clinically 	 O 	O
not 	 O 	O
affected 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
, 	 O 	O
as 	 O 	O
in 	 O 	O
heart 	 O 	O
or 	 O 	O
marrow 	 O 	O
transplantation 	 O 	O
, 	 O 	O
or 	 O 	O
when 	 O 	O
dysfunction 	 O 	O
of 	 O 	O
all 	 O 	O
cellular 	 O 	O
activity 	 O 	O
is 	 O 	O
extreme 	 O 	O
, 	 O 	O
as 	 O 	O
in 	 O 	O
the 	 O 	O
case 	 O 	O
of 	 O 	O
severe 	 O 	O
combined 	 O 	O
immune 	 O 	O
deficiency 	 O 	O
and 	 O 	O
far 	 O 	O
- 	 O 	O
advanced 	 O 	O
neoplasia 	 O 	O
, 	 O 	O
dissemination 	 O 	O
of 	 O 	DISEASE
infection 	 O 	DISEASE
with 	 O 	O
multiple 	 O 	O
- 	 O 	O
organ 	 O 	O
involvement 	 O 	O
ensues 	 O 	O
( 	 O 	O
17 	 O 	O
, 	 O 	O
20 	 O 	O
- 	 O 	O
22 	 O 	O
) 	 O 	O
. 	 O 	O
With 	 O 	O
submassive 	 O 	O
embolism 	 O 	DISEASE
, 	 O 	O
23 	 O 	O
per 	 O 	O
cent 	 O 	O
of 	 O 	O
patients 	 O 	O
( 	 O 	O
9 	 O 	O
of 	 O 	O
40 	 O 	O
) 	 O 	O
had 	 O 	O
a 	 O 	O
normal 	 O 	O
electrocardiogram 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Although 	 O 	O
ECG 	 O 	O
monitoring 	 O 	O
has 	 O 	O
been 	 O 	O
claimed 	 O 	O
to 	 O 	O
be 	 O 	O
a 	 O 	O
useful 	 O 	O
aid 	 O 	O
in 	 O 	O
the 	 O 	O
management 	 O 	O
of 	 O 	O
diabetic 	 DISEASE 	DISEASE
ketoacidosis 	 DISEASE 	O
, 	 O 	O
this 	 O 	O
study 	 O 	O
clearly 	 O 	O
demonstrates 	 O 	O
that 	 O 	O
significant 	 O 	O
ECG 	 O 	O
changes 	 O 	O
are 	 O 	O
rare 	 O 	O
and 	 O 	O
ECG 	 O 	O
monitoring 	 O 	O
thereafter 	 O 	O
adds 	 O 	O
little 	 O 	O
to 	 O 	O
careful 	 O 	O
clinical 	 O 	O
observation 	 O 	O
and 	 O 	O
regular 	 O 	O
biochemical 	 O 	O
assessment 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Thus 	 O 	O
, 	 O 	O
a 	 O 	O
family 	 O 	O
history 	 O 	O
of 	 O 	O
abdominal 	 O 	O
wall 	 O 	O
defects 	 O 	O
may 	 O 	O
increase 	 O 	O
the 	 O 	O
risk 	 O 	O
for 	 O 	O
gastroschisis 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
progress 	 O 	O
of 	 O 	O
new 	 O 	O
- 	 O 	O
born 	 O 	O
medicine 	 O 	O
and 	 O 	O
the 	 O 	O
prevention 	 O 	O
from 	 O 	O
the 	 O 	O
occurrence 	 O 	O
of 	 O 	O
mental 	 O 	O
and 	 O 	O
physical 	 DISEASE 	O
disorder 	 DISEASE 	O
in 	 O 	O
children 	 O 	O
	PUNCT	O
52744	.	PUNCT	O
52745	The	DET	O
52745	second	ADJ	O
52745	day	NOUN	O
52745	's	PART	O
52745	discussion	NOUN	O
52745	was	VERB	O
52745	held	VERB	O
52745	byT.	NUM	O
52745	Kobayashi	PROPN	O
52745	,	PUNCT	O
52745	with	ADP	O
52745	a	DET	O
52745	theme	NOUN	O
52745	of	ADP	O
52745	 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Cholangiocarcinoma 	 DISEASE 	O
is 	 O 	O
a 	 O 	O
rare 	 O 	O
complication 	 O 	O
of 	 O 	O
comgenital 	 O 	DISEASE
hepatic 	 O 	O
fibrosis 	 O 	DISEASE
, 	 O 	O
with 	 O 	O
only 	 O 	O
two 	 O 	O
previously 	 O 	O
documented 	 O 	O
cases 	 O 	O
reported 	 O 	O
, 	 O 	O
to 	 O 	O
our 	 O 	O
knowledge 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
reduction 	 O 	O
in 	 O 	O
red 	 O 	O
- 	 O 	O
cell 	 O 	O
deformability 	 O 	O
by 	 O 	O
retarding 	 O 	O
blood 	 O 	O
- 	 O 	O
flow 	 O 	O
through 	 O 	O
the 	 O 	O
microcirculation 	 O 	O
may 	 O 	O
be 	 O 	O
an 	 O 	O
important 	 O 	O
factor 	 O 	O
in 	 O 	O
states 	 O 	O
of 	 O 	O
peripheral 	 O 	O
vascular 	 O 	O
insufficiency 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Antibodies 	 O 	O
to 	 O 	O
IgA 	 O 	DISEASE
may 	 O 	O
cause 	 O 	O
severe 	 O 	O
anaphylactic 	 O 	O
reactions 	 O 	O
during 	 O 	O
blood 	 O 	O
transfusions 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Periventricular 	 O 	DISEASE
tumor 	 O 	DISEASE
spread 	 O 	O
can 	 O 	O
, 	 O 	O
however 	 O 	O
, 	 O 	O
be 	 O 	O
readily 	 O 	O
dmonstrated 	 O 	O
by 	 O 	O
contrast 	 O 	O
- 	 O 	O
enhanced 	 O 	O
CT 	 O 	O
scanning 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
acute 	 DISEASE 	DISEASE
myeloid 	 DISEASE 	O
leukemia 	 DISEASE 	DISEASE
, 	 O 	O
in 	 O 	O
which 	 O 	O
myeloid 	 O 	O
cells 	 O 	O
early 	 O 	O
in 	 O 	O
differentiation 	 O 	O
predominate 	 O 	O
, 	 O 	O
the 	 O 	O
vast 	 O 	O
majority 	 O 	O
of 	 O 	O
cells 	 O 	O
were 	 O 	O
strongly 	 O 	O
positive 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
accumulation 	 O 	O
of 	 O 	O
glycogen 	 O 	O
observed 	 O 	O
when 	 O 	O
E. 	 O 	O
coli 	 O 	O
B 	 O 	O
or 	 O 	O
SG14 	 O 	O
shifts 	 O 	O
from 	 O 	O
exponential 	 O 	O
phase 	 O 	O
to 	 O 	O
stationary 	 O 	O
phase 	 O 	O
of 	 O 	O
growth 	 O 	O
in 	 O 	O
nitrogen 	 O 	O
- 	 O 	O
limiting 	 O 	O
media 	 O 	DISEASE
can 	 O 	O
be 	 O 	O
accounted 	 O 	O
for 	 O 	O
by 	 O 	O
the 	 O 	O
2.4-fold 	 O 	O
increase 	 O 	O
of 	 O 	O
the 	 O 	O
levels 	 O 	O
of 	 O 	O
the 	 O 	O
glycogen 	 O 	O
biosynthetic 	 O 	O
enzymes 	 O 	O
, 	 O 	O
glycogen 	 O 	O
synthase 	 O 	O
, 	 O 	O
and 	 O 	O
ADP 	 O 	O
- 	 O 	O
glucose 	 O 	O
pyrophosphorylase 	 O 	O
. 	 O 	O
The 	 O 	O
study 	 O 	O
demonstrated 	 O 	O
that 	 O 	O
periodontal 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
was 	 O 	O
a 	 O 	O
major 	 O 	O
dental 	 O 	O
health 	 O 	O
problem 	 O 	O
despite 	 O 	O
the 	 O 	O
fact 	 O 	O
that 	 O 	O
88.9 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
subjects 	 O 	O
visited 	 O 	O
a 	 O 	O
dentist 	 O 	O
regularly 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
polycomplexes 	 O 	O
	PUNCT	O
53810	as	ADP	O
53810	had	VERB	O
53810	been	VERB	O
53810	already	ADV	O
53810	suggested	VERB	O
53810	.	PUNCT	O
53811	This	DET	O
53811	prevented	VERB	O
53811	a	DET	O
53811	thermodynamic	ADJ	O
53811	study	NOUN	O
53811	of	ADP	O
53811	the	DET	O
53811	system	NOUN	O
53811	.	PUNCT	O
53812	The	DET	O
53812	acid	ADJ	O
53812	-	PUNCT	O
53812	base	NOUN	O
53812	titration	NOUN	O
53812	was	VERB	O
53812	further	ADV	O
53812	investigated	VERB	O
53812	as	ADP	O
53812	a	DET	O
53812	function	NOUN	O
53812	of	ADP	O
53812	ionic	ADJ	O
53812	strength	NOUN	O
53812	and	CCONJ	O
53812	temperature	NOUN	O
53812	.	PUNCT	O
53813	The	DET	O
53813	pK	PROPN	O
53813	's	PART	O
53813	showed	VERB	O
53813	considerably	ADV	O
53813	lower	ADJ	O
53813	ionic	ADJ	O
53813	strength	NOUN	O
53813	dependence	NOUN	O
53813	than	ADP	O
53813	observed	VERB	O
53813	for	ADP	O
53813	polyribonucleotide	NOUN	O
53813	complexes	NOUN	O
53813	.	PUNCT	O
53814	The	DET	O
53814	thermal	ADJ	O
53814	transitions	NOUN	O
53814	permitted	VERB	O
53814	to	PART	O
53814	establish	VERB	O
53814	the	DET	O
53814	relative	ADJ	O
53814	stabilities	NOUN	O
53814	of	ADP	O
53814	the	DET	O
53814	various	ADJ	O
53814	complexes	NOUN	O
53814	between	ADP	O
53814	pH	VERB	O
53814	2.5	NUM	O
53814	and	CCONJ	O
53814	pH	VERB	O
53814	12.0	NUM	O
53814	.	PUNCT	O
53815	Duplex	ADJ	O
53815	DNA	NOUN	O
53815	containing	VERB	O
53815	oligo(dG.dC)-rich	NUM	O
53815	clusters	NOUN	O
53815	can	VERB	O
53815	be	VERB	O
53815	isolated	VERB	O
53815	by	ADP	O
53815	specific	ADJ	O
53815	binding	VERB	O
53815	to	ADP	O
53815	poly(rC)-Sephadex	NOUN	O
53815	.	PUNCT	O
53816	This	DET	O
53816	binding	VERB	O
53816	,	PUNCT	O
53816	probably	ADV	O
53816	mediated	VERB	O
53816	by	ADP	O
53816	the	DET	O
53816	formation	NOUN	O
53816	of	ADP	O
53816	an	DET	O
53816	oligo(dG.dC)rC+	ADJ	O
53816	triple	ADJ	O
53816	helix	NOUN	O
53816	,	PUNCT	O
53816	is	VERB	O
53816	optimal	ADJ	O
53816	at	ADP	O
53816	pH	PROPN	O
53816	5	NUM	O
53816	in	ADP	O
53816	50	NUM	O
53816	%	NOUN	O
53816	formamide	NOUN	O
53816	,	PUNCT	O
53816	2	NUM	O
53816	M	PROPN	O
53816	LiCl	PROPN	O
53816	;	PUNCT	O
53816	the	DET	O
53816	bound	VERB	O
53816	DNA	NOUN	O
53816	is	VERB	O
53816	recovered	VERB	O
53816	by	ADP	O
53816	elution	NOUN	O
53816	at	ADP	O
53816	pH	PROPN	O
53816	7.5	NUM	O
53816	.	PUNCT	O
53817	Using	VERB	O
53817	this	DET	O
53817	method	NOUN	O
53817	we	PRON	O
53817	find	VERB	O
53817	that	ADP	O
53817	the	DET	O
53817	viral	ADJ	O
53817	DNAs	PROPN	O
53817	PM2	PROPN	O
53817	,	PUNCT	O
53817	lambda	VERB	O
53817	and	CCONJ	O
53817	SV40	PROPN	O
53817	contain	VERB	O
53817	at	ADP	O
53817	least	ADJ	O
53817	1	NUM	O
53817	,	PUNCT	O
53817	1	NUM	O
53817	and	CCONJ	O
53817	2	NUM	O
53817	sites	NOUN	O
53817	for	ADP	O
53817	binding	VERB	O
53817	to	ADP	O
53817	poly(rC)-Sephadex	NOUN	O
53817	,	PUNCT	O
53817	respectively	ADV	O
53817	.	PUNCT	O
53818	These	DET	O
53818	binding	VERB	O
53818	sites	NOUN	O
53818	have	VERB	O
53818	been	VERB	O
53818	mapped	VERB	O
53818	in	ADP	O
53818	the	DET	O
53818	case	NOUN	O
53818	of	ADP	O
53818	SV40	PROPN	O
53818	;	PUNCT	O
53818	the	DET	O
53818	binding	VERB	O
53818	sites	NOUN	O
53818	can	VERB	O
53818	in	ADP	O
53818	turn	NOUN	O
53818	be	VERB	O
53818	used	VERB	O
53818	for	ADP	O
53818	physical	ADJ	O
53818	mapping	NOUN	O
53818	studies	NOUN	O
53818	of	ADP	O
53818	DNAs	NOUN	O
53818	containing	VERB	O
53818	(	PUNCT	O
53818	dG.dC	NOUN	O
53818	)	PUNCT	O
53818	clusters	NOUN	O
53818	.	PUNCT	O
53819	Inspection	NOUN	O
53819	of	ADP	O
53819	the	DET	O
53819	sequence	NOUN	O
53819	of	ADP	O
53819	the	DET	O
53819	bound	VERB	O
53819	fragments	NOUN	O
53819	of	ADP	O
53819	SV40	PROPN	O
53819	DNA	PROPN	O
53819	shows	VERB	O
53819	that	ADP	O
53819	a	DET	O
53819	(	PUNCT	O
53819	dG.dC)6	PROPN	O
53819	-	SYM	O
53819	7	NUM	O
53819	tract	NOUN	O
53819	is	VERB	O
53819	required	VERB	O
53819	for	ADP	O
53819	the	DET	O
53819	binding	NOUN	O
53819	of	ADP	O
53819	duplex	ADJ	O
53819	DNA	NOUN	O
53819	to	ADP	O
53819	poly(rC)-Sephadex	NOUN	O
53819	.	PUNCT	O
53820	Although	ADP	O
53820	about	ADV	O
53820	60	NUM	O
53820	%	NOUN	O
53820	of	ADP	O
53820	rabbit	NOUN	O
53820	DNA	NOUN	O
53820	cleaved	VERB	O
53820	with	ADP	O
53820	restriction	NOUN	O
53820	endonuclease	NOUN	O
53820	KpnI	PROPN	O
53820	binds	NOUN	O
53820	to	ADP	O
53820	poly(rC)-Sephadex	NOUN	O
53820	,	PUNCT	O
53820	no	DET	O
53820	binding	VERB	O
53820	is	VERB	O
53820	observed	VERB	O
53820	for	ADP	O
53820	the	DET	O
53820	5.1	NUM	O
53820	kb	ADP	O
53820	DNA	NOUN	O
53820	fragment	NOUN	O
53820	generated	VERB	O
53820	by	ADP	O
53820	KpnI	PROPN	O
53820	digestion	NOUN	O
53820	,	PUNCT	O
53820	which	ADJ	O
53820	contains	VERB	O
53820	the	DET	O
53820	rabbit	NOUN	O
53820	beta	NOUN	O
53820	-	PUNCT	O
53820	globin	NOUN	O
53820	gene	NOUN	O
53820	.	PUNCT	O
53821	This	DET	O
53821	indicates	VERB	O
53821	that	ADP	O
53821	oligo(dG.dC	NOUN	O
53821	)	PUNCT	O
53821	clusters	NOUN	O
53821	are	VERB	O
53821	not	ADV	O
53821	found	VERB	O
53821	close	ADJ	O
53821	to	ADP	O
53821	the	DET	O
53821	rabbit	NOUN	O
53821	beta	NOUN	O
53821	-	PUNCT	O
53821	globin	NOUN	O
53821	gene	NOUN	O
53821	.	PUNCT	O
53822	The	DET	O
53822	pattern	NOUN	O
53822	of	ADP	O
53822	action	NOUN	O
53822	of	ADP	O
53822	effectors	NOUN	O
53822	(	PUNCT	O
53822	AMP	PROPN	O
53822	,	PUNCT	O
53822	IMP	PROPN	O
53822	,	PUNCT	O
53822	CMP	PROPN	O
53822	,	PUNCT	O
53822	anthranilic	ADJ	O
53822	acid	NOUN	O
53822	,	PUNCT	O
53822	tryptophane	NOUN	O
53822	,	PUNCT	O
53822	alanine	NOUN	O
53822	,	PUNCT	O
53822	glutamine	ADJ	O
53822	,	PUNCT	O
53822	glycine	NOUN	O
53822	,	PUNCT	O
53822	histidine	NOUN	O
53822	)	PUNCT	O
53822	and	CCONJ	O
53822	glutamine	ADJ	O
53822	synthetase	NOUN	O
53822	(	PUNCT	O
53822	GS	PROPN	O
53822	)	PUNCT	O
53822	extracted	VERB	O
53822	from	ADP	O
53822	the	DET	O
53822	fodder	NOUN	O
53822	yeast	NOUN	O
53822	Candida	PROPN	O
53822	tropicalis	NOUN	O
53822	and	CCONJ	O
53822	stored	VERB	O
53822	at	ADP	O
53822	room	NOUN	O
53822	temperature	NOUN	O
53822	for	ADP	O
53822	1.5	NUM	O
53822	-	SYM	O
53822	2	NUM	O
53822	hrs	NOUN	O
53822	was	VERB	O
53822	examined	VERB	O
53822	.	PUNCT	O
53823	As	ADP	O
53823	regards	VERB	O
53823	the	DET	O
53823	action	NOUN	O
53823	of	ADP	O
53823	effectors	NOUN	O
53823	on	ADP	O
53823	GS	PROPN	O
53823	after	ADP	O
53823	its	ADJ	O
53823	exposure	NOUN	O
53823	at	ADP	O
53823	room	NOUN	O
53823	temperature	NOUN	O
53823	,	PUNCT	O
53823	they	PRON	O
53823	can	VERB	O
53823	be	VERB	O
53823	subdivided	VERB	O
53823	into	ADP	O
53823	four	NUM	O
53823	groups	NOUN	O
53823	:	PUNCT	O
53823	1	PUNCT	O
53823	)	PUNCT	O
53823	the	DET	O
53823	effector	NOUN	O
53823	loses	VERB	O
53823	completely	ADV	O
53823	its	ADJ	O
53823	inhibitory	ADJ	O
53823	effect	NOUN	O
53823	(	PUNCT	O
53823	glutamine	ADJ	O
53823	,	PUNCT	O
53823	CMP	PROPN	O
53823	,	PUNCT	O
53823	anthranilic	ADJ	O
53823	acid	NOUN	O
53823	in	ADP	O
53823	the	DET	O
53823	synthetase	NOUN	O
53823	reaction	NOUN	O
53823	)	PUNCT	O
53823	;	PUNCT	O
53823	2	PUNCT	O
53823	)	PUNCT	O
53823	the	DET	O
53823	inhibitory	ADJ	O
53823	effect	NOUN	O
53823	on	ADP	O
53823	the	DET	O
53823	enzyme	NOUN	O
53823	increases	NOUN	O
53823	(	PUNCT	O
53823	AMP	PROPN	O
53823	,	PUNCT	O
53823	IMP	PROPN	O
53823	,	PUNCT	O
53823	anthranilic	ADJ	O
53823	acid	NOUN	O
53823	in	ADP	O
53823	the	DET	O
53823	transferase	ADJ	O
53823	reaction	NOUN	O
53823	)	PUNCT	O
53823	;	PUNCT	O
53823	3	PUNCT	O
53823	)	PUNCT	O
53823	at	ADP	O
53823	low	ADJ	O
53823	concentrations	NOUN	O
53823	of	ADP	O
53823	the	DET	O
53823	effector	NOUN	O
53823	the	DET	O
53823	peak	NOUN	O
53823	of	ADP	O
53823	activation	NOUN	O
53823	appears	VERB	O
53823	(	PUNCT	O
53823	tryptophane	NOUN	O
53823	,	PUNCT	O
53823	GMP	PROPN	O
53823	,	PUNCT	O
53823	alanine	NOUN	O
53823	,	PUNCT	O
53823	glycine	NOUN	O
53823	)	PUNCT	O
53823	;	PUNCT	O
53823	4	PUNCT	O
53823	)	PUNCT	O
53823	at	ADP	O
53823	low	ADJ	O
53823	concentrations	NOUN	O
53823	of	ADP	O
53823	the	DET	O
53823	enzyme	NOUN	O
53823	two	NUM	O
53823	peaks	NOUN	O
53823	of	ADP	O
53823	activation	NOUN	O
53823	appear	VERB	O
53823	(	PUNCT	O
53823	histidine	NOUN	O
53823	)	PUNCT	O
53823	.	PUNCT	O
53824	Similar	ADJ	O
53824	results	NOUN	O
53824	were	VERB	O
53824	obtained	VERB	O
53824	with	ADP	O
53824	the	DET	O
53824	purified	ADJ	O
53824	preparation	NOUN	O
53824	of	ADP	O
53824	GS	PROPN	O
53824	.	PUNCT	O
53825	Highly	ADV	O
53825	purified	ADJ	O
53825	poly(A	NOUN	O
53825	)	PUNCT	O
53825	polymerase	NOUN	O
53825	(	PUNCT	O
53825	polynucleotide	NOUN	O
53825	adenylyltransferase	NOUN	O
53825	,	PUNCT	O
53825	EC	PROPN	O
53825	2.7.7.19	NUM	O
53825	)	PUNCT	O
53825	,	PUNCT	O
53825	which	ADJ	O
53825	synthesizes	VERB	O
53825	poly(A	NOUN	O
53825	)	PUNCT	O
53825	from	ADP	O
53825	ATP	PROPN	O
53825	substrate	NOUN	O
53825	,	PUNCT	O
53825	can	VERB	O
53825	also	ADV	O
53825	catalyze	VERB	O
53825	hydrolysis	NOUN	O
53825	of	ADP	O
53825	poly(A	NOUN	O
53825	)	PUNCT	O
53825	.	PUNCT	O
53826	The	DET	O
53826	enzyme	NOUN	O
53826	,	PUNCT	O
53826	designated	VERB	O
53826	as	ADP	O
53826	poly(A	NOUN	O
53826	)	PUNCT	O
53826	hydrolase	NOUN	O
53826	,	PUNCT	O
53826	requires	VERB	O
53826	either	CCONJ	O
53826	Mn2	NOUN	O
53826	+	SYM	O
53826	or	CCONJ	O
53826	Mg2	NOUN	O
53826	+	NOUN	O
53826	for	ADP	O
53826	activity	NOUN	O
53826	.	PUNCT	O
53827	Although	ADP	O
53827	AMP	PROPN	O
53827	is	VERB	O
53827	the	DET	O
53827	predominant	ADJ	O
53827	product	NOUN	O
53827	of	ADP	O
53827	the	DET	O
53827	reaction	NOUN	O
53827	,	PUNCT	O
53827	ADP	PROPN	O
53827	and	CCONJ	O
53827	ATP	PROPN	O
53827	are	VERB	O
53827	also	ADV	O
53827	formed	VERB	O
53827	.	PUNCT	O
53828	The	DET	O
53828	enzyme	NOUN	O
53828	is	VERB	O
53828	a	DET	O
53828	3'-exonuclease	NUM	O
53828	that	ADJ	O
53828	does	VERB	O
53828	not	ADV	O
53828	degrade	VERB	O
53828	poly(A	NOUN	O
53828	)	PUNCT	O
53828	associated	VERB	O
53828	with	ADP	O
53828	poly(A	NOUN	O
53828	)	PUNCT	O
53828	poly(U	PUNCT	O
53828	)	PUNCT	O
53828	helical	ADJ	O
53828	structure	NOUN	O
53828	.	PUNCT	O
53829	AMP	PROPN	O
53829	,	PUNCT	O
53829	ADP	PROPN	O
53829	,	PUNCT	O
53829	and	CCONJ	O
53829	ATP	PROPN	O
53829	inhibit	VERB	O
53829	the	DET	O
53829	hydrolytic	ADJ	O
53829	reaction	NOUN	O
53829	.	PUNCT	O
53830	These	DET	O
53830	data	NOUN	O
53830	suggest	VERB	O
53830	that	ADP	O
53830	(	PUNCT	O
53830	i	PUNCT	O
53830	)	PUNCT	O
53830	the	DET	O
53830	levels	NOUN	O
53830	of	ADP	O
53830	adenine	ADJ	O
53830	nucleotides	NOUN	O
53830	regulate	VERB	O
53830	synthesis	NOUN	O
53830	and	CCONJ	O
53830	degradation	NOUN	O
53830	of	ADP	O
53830	poly(A	NOUN	O
53830	)	PUNCT	O
53830	,	PUNCT	O
53830	(	PUNCT	O
53830	ii	PUNCT	O
53830	)	PUNCT	O
53830	poly(A	NOUN	O
53830	)	PUNCT	O
53830	itself	PRON	O
53830	is	VERB	O
53830	a	DET	O
53830	storage	NOUN	O
53830	form	NOUN	O
53830	of	ADP	O
53830	adenine	ADJ	O
53830	nucleotides	NOUN	O
53830	,	PUNCT	O
53830	(	PUNCT	O
53830	iii	PUNCT	O
53830	)	PUNCT	O
53830	the	DET	O
53830	hydrolytic	ADJ	O
53830	reaction	NOUN	O
53830	is	VERB	O
53830	responsible	ADJ	O
53830	for	ADP	O
53830	poly(A	NOUN	O
53830	)	PUNCT	O
53830	shortening	NOUN	O
53830	or	CCONJ	O
53830	turnover	NOUN	O
53830	observed	VERB	O
53830	in	ADP	O
53830	vivo	NOUN	O
53830	,	PUNCT	O
53830	and	CCONJ	O
53830	(	PUNCT	O
53830	iv	PUNCT	O
53830	)	PUNCT	O
53830	the	DET	O
53830	synthetic	ADJ	O
53830	and	CCONJ	O
53830	hydrolytic	ADJ	O
53830	activities	NOUN	O
53830	are	VERB	O
53830	functions	NOUN	O
53830	of	ADP	O
53830	the	DET	O
53830	same	ADJ	O
53830	protein	NOUN	O
53830	molecule	NOUN	O
53830	.	PUNCT	O
53831	In	ADP	O
53831	18	NUM	O
53831	unconscious	ADJ	O
53831	patients	NOUN	O
53831	with	ADP	O
53831	traumatic	ADJ	O
53831	brain	NOUN	O
53831	injury	NOUN	O
53831	,	PUNCT	O
53831	the	DET	O
53831	cerebral	ADJ	O
53831	autoregulation	NOUN	O
53831	was	VERB	O
53831	tested	VERB	O
53831	during	ADP	O
53831	the	DET	O
53831	first	ADJ	O
53831	2	NUM	O
53831	-	SYM	O
53831	3	NUM	O
53831	weeks	NOUN	O
53831	after	ADP	O
53831	the	DET	O
53831	acute	ADJ	O
53831	trauma	NOUN	O
53831	.	PUNCT	O
53832	Regional	ADJ	O
53832	cerebral	ADJ	O
53832	blood	NOUN	O
53832	flow	NOUN	O
53832	(	PUNCT	O
53832	rCBF	PROPN	O
53832	)	PUNCT	O
53832	was	VERB	O
53832	measured	VERB	O
53832	by	ADP	O
53832	the	DET	O
53832	intra	ADJ	O
53832	-	PUNCT	O
53832	arterial	ADJ	O
53832	133xenon	NUM	O
53832	washout	NOUN	O
53832	method	NOUN	O
53832	before	ADP	O
53832	and	CCONJ	O
53832	after	ADP	O
53832	an	DET	O
53832	increase	NOUN	O
53832	of	ADP	O
53832	about	ADV	O
53832	20	NUM	O
53832	%	NOUN	O
53832	in	ADP	O
53832	the	DET	O
53832	mean	ADJ	O
53832	arterial	ADJ	O
53832	blood	NOUN	O
53832	pressure	NOUN	O
53832	(	PUNCT	O
53832	MABP	PROPN	O
53832	)	PUNCT	O
53832	by	ADP	O
53832	angiotensin	NOUN	O
53832	.	PUNCT	O
53833	The	DET	O
53833	difference	NOUN	O
53833	between	ADP	O
53833	MABP	PROPN	O
53833	and	CCONJ	O
53833	intraventricular	ADJ	O
53833	pressure	NOUN	O
53833	(	PUNCT	O
53833	IVP	PROPN	O
53833	)	PUNCT	O
53833	was	VERB	O
53833	used	VERB	O
53833	as	ADP	O
53833	cerebral	ADJ	O
53833	perfusion	NOUN	O
53833	pressure	NOUN	O
53833	(	PUNCT	O
53833	PP	PROPN	O
53833	)	PUNCT	O
53833	.	PUNCT	O
53834	Simultaneously	ADV	O
53834	,	PUNCT	O
53834	ventricular	ADJ	O
53834	fluid	NOUN	O
53834	pH	NOUN	O
53834	,	PUNCT	O
53834	lactate	NOUN	O
53834	and	CCONJ	O
53834	pyruvate	NOUN	O
53834	were	VERB	O
53834	measured	VERB	O
53834	.	PUNCT	O
53835	Regional	ADJ	O
53835	loss	NOUN	O
53835	of	ADP	O
53835	autoregulation	NOUN	O
53835	indicated	VERB	O
53835	by	ADP	O
53835	a	DET	O
53835	20	NUM	O
53835	%	NOUN	O
53835	flow	NOUN	O
53835	increase	NOUN	O
53835	was	VERB	O
53835	observed	VERB	O
53835	in	ADP	O
53835	29	NUM	O
53835	out	ADP	O
53835	of	ADP	O
53835	35	NUM	O
53835	studies	NOUN	O
53835	(	PUNCT	O
53835	83	NUM	O
53835	%	NOUN	O
53835	)	PUNCT	O
53835	,	PUNCT	O
53835	while	ADP	O
53835	hemispheric	ADJ	O
53835	loss	NOUN	O
53835	of	ADP	O
53835	autoregulation	NOUN	O
53835	was	VERB	O
53835	observed	VERB	O
53835	in	ADP	O
53835	only	ADV	O
53835	one	NUM	O
53835	study	NOUN	O
53835	.	PUNCT	O
53836	The	DET	O
53836	results	NOUN	O
53836	of	ADP	O
53836	the	DET	O
53836	autoregulation	NOUN	O
53836	tests	NOUN	O
53836	were	VERB	O
53836	unrelated	ADJ	O
53836	to	ADP	O
53836	the	DET	O
53836	clinical	ADJ	O
53836	outcome	NOUN	O
53836	,	PUNCT	O
53836	the	DET	O
53836	presence	NOUN	O
53836	of	ADP	O
53836	brain	NOUN	O
53836	-	PUNCT	O
53836	stem	NOUN	O
53836	lesion	NOUN	O
53836	,	PUNCT	O
53836	and	CCONJ	O
53836	the	DET	O
53836	ventricular	ADJ	O
53836	fluid	NOUN	O
53836	pH	NOUN	O
53836	,	PUNCT	O
53836	lactate	VERB	O
53836	and	CCONJ	O
53836	lactate	NOUN	O
53836	/	SYM	O
53836	pyruvate	NOUN	O
53836	ratio	NOUN	O
53836	.	PUNCT	O
53837	In	ADP	O
53837	repeated	VERB	O
53837	studies	NOUN	O
53837	,	PUNCT	O
53837	a	DET	O
53837	gradual	ADJ	O
53837	normalization	NOUN	O
53837	of	ADP	O
53837	the	DET	O
53837	autoregulation	NOUN	O
53837	was	VERB	O
53837	observed	VERB	O
53837	about	ADP	O
53837	5	NUM	O
53837	days	NOUN	O
53837	after	ADP	O
53837	the	DET	O
53837	acute	ADJ	O
53837	trauma	NOUN	O
53837	.	PUNCT	O
53838	The	DET	O
53838	electroimmunoassay	NOUN	O
53838	(	PUNCT	O
53838	quantitative	ADJ	O
53838	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Byssinosis 	 DISEASE 	O
and 	 O 	O
farmer 	 O 	DISEASE
's 	 O 	O
lung 	 O 	O
have 	 O 	O
now 	 O 	O
been 	 O 	O
acknowledged 	 O 	O
as 	 O 	O
occupational 	 O 	O
diseases 	 O 	O
. 	 O 	O
Byssinosis 	 O 	O
and 	 O 	O
farmer 	 DISEASE 	O
's 	 DISEASE 	O
lung 	 DISEASE 	O
have 	 O 	O
now 	 O 	O
been 	 O 	O
acknowledged 	 O 	O
as 	 O 	O
occupational 	 O 	O
diseases 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
1958 	 O 	O
- 	 O 	O
72 	 O 	O
, 	 O 	O
985 	 O 	O
cases 	 O 	O
of 	 O 	O
tetanus 	 DISEASE 	DISEASE
( 	 O 	O
excluding 	 O 	O
tetanus 	 O 	O
of 	 O 	O
the 	 O 	O
newborn 	 O 	O
) 	 O 	O
were 	 O 	O
admitted 	 O 	O
to 	 O 	O
a 	 O 	O
hospital 	 O 	O
in 	 O 	O
Haiti 	 O 	O
. 	 O 	O
In 	 O 	O
1958 	 O 	O
- 	 O 	O
72 	 O 	O
, 	 O 	O
985 	 O 	O
cases 	 O 	O
of 	 O 	O
tetanus 	 O 	O
( 	 O 	O
excluding 	 O 	DISEASE
tetanus 	 DISEASE 	DISEASE
of 	 O 	O
the 	 O 	O
newborn 	 O 	O
) 	 O 	O
were 	 O 	O
admitted 	 O 	O
to 	 O 	O
a 	 O 	O
hospital 	 O 	O
in 	 O 	O
Haiti 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
remarkably 	 O 	O
painless 	 O 	O
deformation 	 O 	O
of 	 O 	O
the 	 O 	O
shoulder 	 O 	O
joint 	 O 	O
should 	 O 	O
also 	 O 	O
suggest 	 O 	O
neurogenic 	 DISEASE 	O
arthropathy 	 DISEASE 	O
in 	 O 	O
syringomyelia 	 O 	O
. 	 O 	O
A 	 O 	O
remarkably 	 O 	O
painless 	 O 	O
deformation 	 O 	O
of 	 O 	O
the 	 O 	O
shoulder 	 O 	O
joint 	 O 	O
should 	 O 	O
also 	 O 	O
suggest 	 O 	O
neurogenic 	 O 	O
arthropathy 	 O 	O
in 	 O 	O
syringomyelia 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
There 	 O 	O
were 	 O 	O
62 	 O 	O
women 	 O 	O
with 	 O 	O
primary 	 O 	O
disease 	 O 	O
and 	 O 	O
95 	 O 	O
with 	 O 	O
recurrent 	 O 	O
infection 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
a 	 O 	O
nonrandomized 	 O 	O
comparison 	 O 	O
of 	 O 	O
treatment 	 O 	O
results 	 O 	O
of 	 O 	O
244 	 O 	O
patients 	 O 	O
with 	 O 	O
stage 	 O 	O
IB 	 O 	DISEASE
carcinoma 	 DISEASE 	DISEASE
of 	 O 	O
the 	 O 	O
uterine 	 O 	O
cervix 	 O 	O
treated 	 O 	O
by 	 O 	O
radiation 	 O 	O
alone 	 O 	O
and 	 O 	O
92 	 O 	O
treated 	 O 	O
with 	 O 	O
preoperative 	 O 	O
radiation 	 O 	O
and 	 O 	O
surgery 	 O 	O
and 	 O 	O
77 	 O 	O
patients 	 O 	O
with 	 O 	O
stage 	 O 	O
IIA 	 O 	O
treated 	 O 	O
by 	 O 	O
radiation 	 O 	O
alone 	 O 	O
and 	 O 	O
24 	 O 	O
treated 	 O 	O
with 	 O 	O
a 	 O 	O
combination 	 O 	O
of 	 O 	O
radiation 	 O 	O
and 	 O 	O
surgery 	 O 	O
. 	 O 	O
All 	 O 	O
showed 	 O 	O
the 	 O 	O
adult 	 DISEASE 	O
respiratory 	 DISEASE 	O
distress 	 DISEASE 	DISEASE
syndrome 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
One 	 O 	O
automatic 	 O 	O
blood 	 O 	O
- 	 O 	O
gas 	 O 	DISEASE
analyser 	 O 	O
gave 	 O 	O
aberrant 	 O 	O
values 	 O 	O
for 	 O 	O
oxygen 	 O 	O
pressure 	 O 	O
( 	 O 	O
PO2 	 O 	O
) 	 O 	O
due 	 O 	O
to 	 O 	O
electrode 	 O 	O
dysfunction 	 O 	O
that 	 O 	O
was 	 O 	O
not 	 O 	O
indicated 	 O 	O
by 	 O 	O
the 	 O 	O
fault 	 O 	O
- 	 O 	O
finding 	 O 	O
system 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
organic 	 O 	O
amblyopia 	 DISEASE 	O
the 	 O 	O
diminution 	 O 	O
of 	 O 	O
central 	 O 	O
visual 	 O 	O
acuity 	 O 	O
is 	 O 	O
not 	 O 	O
sufficient 	 O 	O
to 	 O 	O
impair 	 O 	O
the 	 O 	O
oculomotor 	 O 	O
reflexes 	 O 	O
which 	 O 	O
usually 	 O 	O
remain 	 O 	O
unchanged 	 O 	O
until 	 O 	O
the 	 O 	O
vision 	 O 	O
becomes 	 O 	O
very 	 O 	O
poor 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
relacn 	 O 	O
con 	 O 	O
la 	 O 	DISEASE
formacn 	 O 	O
de 	 O 	O
nucletidos 	 O 	O
cclicos 	 O 	O
y 	 O 	O
la 	 O 	O
estimulacin 	 O 	DISEASE
de 	 O 	DISEASE
la 	 O 	DISEASE
sntesis 	 O 	O
de 	 O 	DISEASE
DNA 	 O 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Such 	 O 	O
derivatized 	 O 	O
microspheres 	 O 	O
were 	 O 	O
capable 	 O 	O
of 	 O 	O
inhibiting 	 O 	O
approximately 	 O 	O
one 	 O 	O
mole 	 O 	O
of 	 O 	O
elastase 	 O 	O
per 	 O 	O
mole 	 O 	DISEASE
of 	 O 	O
albumin 	 O 	O
, 	 O 	O
which 	 O 	O
is 	 O 	O
comparable 	 O 	O
to 	 O 	O
the 	 O 	O
inhibitory 	 O 	O
activity 	 O 	O
of 	 O 	O
alpha 	 O 	O
1-antitrypsin 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Transmissible 	 O 	O
gastro 	 O 	O
- 	 O 	O
enteritis 	 O 	O
is 	 O 	O
a 	 O 	O
virus 	 O 	O
- 	 O 	O
caused 	 O 	O
diarrhoeal 	 O 	O
disease 	 O 	DISEASE
of 	 O 	O
swine 	 O 	DISEASE
which 	 O 	O
may 	 O 	O
result 	 O 	O
in 	 O 	O
up 	 O 	O
to 	 O 	O
a 	 O 	O
total 	 O 	O
loss 	 O 	O
among 	 O 	O
newborn 	 O 	O
animals 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
article 	 O 	O
presents 	 O 	O
data 	 O 	O
on 	 O 	O
7 	 O 	O
sectional 	 O 	O
observations 	 O 	O
on 	 O 	O
congenital 	 DISEASE 	O
heart 	 DISEASE 	O
defects 	 DISEASE 	O
in 	 O 	O
elderly 	 O 	O
and 	 O 	O
old 	 O 	O
persons 	 O 	O
( 	 O 	O
57 	 O 	O
to 	 O 	O
75 	 O 	O
years 	 O 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
1 	 O 	O
. 	 O 	O
Suspicion 	 O 	O
of 	 O 	O
a 	 O 	O
submucous 	 O 	O
myoma 	 DISEASE 	O
, 	 O 	O
particularly 	 O 	O
if 	 O 	O
there 	 O 	O
may 	 O 	O
have 	 O 	O
been 	 O 	O
bleeding 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
( 	 O 	O
right 	 DISEASE 	O
bundle 	 DISEASE 	O
branch 	 DISEASE 	O
block 	 DISEASE 	O
with 	 O 	O
left 	 O 	O
anterior 	 O 	O
or 	 O 	O
posterior 	 O 	O
hemiblock 	 O 	O
, 	 O 	O
or 	 O 	O
left 	 O 	O
bundle 	 O 	O
branch 	 O 	O
block 	 O 	O
) 	 O 	O
. 	 O 	O
( 	 O 	O
right 	 O 	O
bundle 	 O 	O
branch 	 O 	O
block 	 O 	O
with 	 O 	O
left 	 O 	O
anterior 	 O 	O
or 	 O 	O
posterior 	 O 	O
hemiblock 	 O 	O
, 	 O 	O
or 	 O 	O
left 	 DISEASE 	O
bundle 	 DISEASE 	O
branch 	 DISEASE 	O
block 	 DISEASE 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
We 	 O 	O
conclude 	 O 	O
that 	 O 	O
despite 	 O 	O
immunosuppressant 	 O 	O
therapy 	 O 	O
( 	 O 	O
with 	 O 	O
azathioprine 	 O 	O
and 	 O 	O
corticosteroids 	 O 	O
) 	 O 	O
, 	 O 	O
humoral 	 O 	O
immunity 	 O 	O
to 	 O 	O
CMV 	 O 	O
is 	 O 	O
not 	 O 	O
impaired 	 O 	O
in 	 O 	O
transplant 	 O 	O
patients 	 O 	O
with 	 O 	O
either 	 O 	O
a 	 O 	O
primary 	 O 	O
or 	 O 	O
secondary 	 O 	DISEASE
infection 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
This 	 O 	O
means 	 O 	O
9.2 	 O 	O
% 	 O 	O
of 	 O 	O
all 	 O 	O
operations 	 O 	O
caused 	 O 	O
by 	 O 	O
cholelithiasis 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
cells 	 O 	O
still 	 O 	O
retain 	 O 	O
unique 	 O 	O
morphological 	 O 	O
and 	 O 	O
structural 	 O 	O
characteristics 	 O 	O
of 	 O 	O
oat 	 DISEASE 	O
cell 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
and 	 O 	O
showed 	 O 	O
	PUNCT	O
34736	tumor	NOUN	O
34736	takes	VERB	O
34736	 	 O 	O
when 	 O 	O
transplanted 	 O 	O
into 	 O 	O
nude 	 O 	O
mice 	 O 	O
and 	 O 	O
conditioned 	 O 	O
young 	 O 	O
Syrian 	 O 	O
Golden 	 O 	O
hamsters 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
activities 	 O 	O
of 	 O 	O
various 	 O 	O
nucleoside 	 O 	O
triphosphates 	 O 	O
as 	 O 	O
phosphate 	 O 	O
donors 	 O 	O
for 	 O 	O
Herpes 	 DISEASE 	DISEASE
simplex 	 DISEASE 	O
virus 	 O 	O
Type 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
statistically 	 O 	O
significant 	 O 	O
rise 	 O 	O
in 	 O 	O
serum 	 O 	O
transferrin 	 O 	O
concentration 	 O 	O
was 	 O 	O
demonstrated 	 O 	O
only 	 O 	O
in 	 O 	O
patients 	 O 	O
with 	 O 	O
sideropenic 	 O 	DISEASE
anaemia 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
tumor 	 DISEASE 	O
virus 	 O 	O
( 	 O 	O
MTV 	 O 	O
) 	 O 	O
are 	 O 	O
cytotoxic 	 O 	O
to 	 O 	O
MTV 	 O 	O
- 	 O 	O
induced 	 O 	O
mammary 	 O 	O
tumor 	 O 	O
cells 	 O 	O
in 	 O 	O
microcytotoxocity 	 O 	O
assay 	 O 	O
. 	 O 	O
Spleen 	 O 	O
cells 	 O 	O
from 	 O 	O
BALB 	 O 	O
/ 	 O 	O
c 	 O 	O
females 	 O 	O
exposed 	 O 	O
to 	 O 	O
or 	 O 	O
neonatally 	 O 	O
infected 	 O 	O
with 	 O 	O
mammary 	 O 	O
tumor 	 O 	O
virus 	 O 	O
( 	 O 	O
MTV 	 O 	O
) 	 O 	O
are 	 O 	O
cytotoxic 	 O 	O
to 	 O 	O
MTV 	 O 	O
- 	 O 	O
induced 	 O 	O
mammary 	 DISEASE 	DISEASE
tumor 	 DISEASE 	O
cells 	 O 	O
in 	 O 	O
microcytotoxocity 	 O 	O
assay 	 O 	O
. 	 O 	O
Previous 	 O 	O
workers 	 O 	O
have 	 O 	O
suggested 	 O 	O
that 	 O 	O
the 	 O 	O
development 	 O 	O
of 	 O 	O
thrombocytopenia 	 DISEASE 	O
with 	 O 	O
a 	 O 	O
hypoplastic 	 O 	O
marrow 	 O 	O
following 	 O 	O
total 	 O 	O
lymphoid 	 O 	O
irradiation 	 O 	O
indicated 	 O 	O
recurrent 	 O 	O
Hodgkin 	 O 	DISEASE
's 	 O 	O
disease 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
5 	 O 	O
normal 	 O 	O
persons 	 O 	O
, 	 O 	O
1 	 O 	O
patient 	 O 	O
with 	 O 	O
pernicious 	 DISEASE 	DISEASE
anemia 	 DISEASE 	DISEASE
, 	 O 	O
5 	 O 	O
patients 	 O 	O
with 	 O 	O
renal 	 O 	O
insufficiency 	 O 	O
in 	 O 	O
the 	 O 	O
state 	 O 	O
of 	 O 	O
compensation 	 O 	O
, 	 O 	O
and 	 O 	O
in 	 O 	O
one 	 O 	O
patient 	 O 	O
with 	 O 	O
chronic 	 O 	DISEASE
hemodialysis 	 O 	O
Schilling 	 O 	O
tests 	 O 	O
, 	 O 	O
activity 	 O 	O
of 	 O 	O
57Co 	 O 	O
and 	 O 	O
vitamin 	 O 	O
B12 	 O 	O
serum 	 O 	O
levels 	 O 	O
were 	 O 	O
measured 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
effect 	 O 	O
of 	 O 	O
field 	 O 	O
feline 	 DISEASE 	O
viral 	 DISEASE 	O
rhinotracheitis 	 DISEASE 	O
( 	 O 	O
FVR 	 O 	O
) 	 O 	O
virus 	 O 	O
challenge 	 O 	O
on 	 O 	O
cats 	 O 	O
previously 	 O 	O
vaccinated 	 O 	O
with 	 O 	O
a 	 O 	O
combined 	 O 	O
FVR 	 O 	O
/ 	 O 	O
feline 	 O 	O
calicivirus 	 O 	O
intramuscular 	 O 	O
vaccine 	 O 	O
was 	 O 	O
studied 	 O 	O
in 	 O 	O
relation 	 O 	O
to 	 O 	O
the 	 O 	O
development 	 O 	O
of 	 O 	O
an 	 O 	O
FVR 	 O 	O
carrier 	 O 	O
state 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
, 	 O 	O
and 	 O 	O
, 	 O 	O
therefore 	 O 	O
, 	 O 	O
might 	 O 	O
be 	 O 	O
predisposed 	 O 	O
to 	 O 	O
hepatic 	 O 	O
cirrhosis 	 O 	O
. 	 O 	O
It 	 O 	O
had 	 O 	O
been 	 O 	O
observed 	 O 	O
by 	 O 	O
others 	 O 	O
that 	 O 	O
subjects 	 O 	O
with 	 O 	O
endogenous 	 O 	O
familial 	 O 	O
hypertriglyceridemia 	 O 	O
( 	 O 	O
type 	 O 	O
IV 	 O 	O
hyperlipoproteinemia 	 O 	O
) 	 O 	O
showed 	 O 	O
an 	 O 	O
exaggerated 	 O 	O
lipidemic 	 O 	O
response 	 O 	O
to 	 O 	O
ingestion 	 O 	O
of 	 O 	O
alcohol 	 O 	O
, 	 O 	O
and 	 O 	O
, 	 O 	O
therefore 	 O 	O
, 	 O 	O
might 	 O 	O
be 	 O 	O
predisposed 	 O 	O
to 	 O 	O
hepatic 	 O 	DISEASE
cirrhosis 	 DISEASE 	DISEASE
. 	 O 	O
Four 	 O 	O
- 	 O 	O
year 	 O 	O
observations 	 O 	O
( 	 O 	O
1970 	 O 	O
- 	 O 	O
1973 	 O 	O
) 	 O 	O
indicated 	 O 	O
that 	 O 	O
such 	 O 	O
functional 	 O 	O
divisions 	 O 	O
designed 	 O 	O
in 	 O 	O
a 	 O 	O
multipurpose 	 O 	O
hospital 	 O 	O
for 	 O 	O
treatment 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
suppurative 	 O 	DISEASE
- 	 O 	O
inflammatory 	 O 	O
processes 	 O 	O
along 	 O 	O
with 	 O 	O
the 	 O 	O
routine 	 O 	O
prophylactic 	 O 	O
measures 	 O 	O
allowed 	 O 	O
a 	 O 	O
considerable 	 O 	O
reduction 	 O 	O
in 	 O 	O
the 	 O 	O
incidence 	 O 	O
of 	 O 	O
postoperative 	 O 	O
suppurative 	 O 	O
complications 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
pulmonary 	 O 	O
fibrosis 	 O 	DISEASE
, 	 O 	O
as 	 O 	O
compared 	 O 	O
with 	 O 	O
production 	 O 	O
workers 	 O 	O
and 	 O 	O
with 	 O 	O
maintenance 	 O 	O
personnel 	 O 	O
assigned 	 O 	O
to 	 O 	O
specific 	 O 	O
departments 	 O 	O
. 	 O 	O
Men 	 O 	O
working 	 O 	O
in 	 O 	O
general 	 O 	O
plant 	 O 	O
maintenance 	 O 	O
displayed 	 O 	O
a 	 O 	O
striking 	 O 	O
lack 	 O 	O
of 	 O 	O
deaths 	 O 	O
due 	 O 	O
to 	 O 	O
pneumoconiosis 	 O 	O
- 	 O 	O
pulmonary 	 DISEASE 	DISEASE
fibrosis 	 DISEASE 	O
, 	 O 	O
as 	 O 	O
compared 	 O 	O
with 	 O 	O
production 	 O 	O
workers 	 O 	O
and 	 O 	O
with 	 O 	O
maintenance 	 O 	O
personnel 	 O 	O
assigned 	 O 	O
to 	 O 	O
specific 	 O 	O
departments 	 O 	O
. 	 O 	O
More 	 O 	O
frequent 	 O 	O
in 	 O 	O
men 	 O 	O
, 	 O 	O
the 	 O 	O
course 	 O 	O
of 	 O 	O
illness 	 O 	O
is 	 O 	O
acute 	 O 	O
our 	 O 	O
subacute 	 O 	DISEASE
but 	 O 	O
pleural 	 O 	O
sequelae 	 O 	O
are 	 O 	O
seldom 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
are 	 O 	O
required 	 O 	O
for 	 O 	O
the 	 O 	O
formation 	 O 	O
of 	 O 	O
microfilaments 	 O 	O
. 	 O 	O
In 	 O 	O
contrast 	 O 	O
to 	 O 	O
the 	 O 	O
ultrastructure 	 O 	O
of 	 O 	O
pituitary 	 O 	O
adenomas 	 O 	O
associated 	 O 	O
with 	 O 	O
Cushing 	 DISEASE 	O
's 	 DISEASE 	DISEASE
syndrome 	 DISEASE 	O
, 	 O 	O
no 	 O 	O
or 	 O 	O
only 	 O 	O
very 	 O 	O
few 	 O 	O
microfilaments 	 O 	O
were 	 O 	O
detected 	 O 	O
in 	 O 	O
the 	 O 	O
cytoplasm 	 O 	O
of 	 O 	O
the 	 O 	O
tumor 	 O 	O
cells 	 O 	O
, 	 O 	O
suggesting 	 O 	O
that 	 O 	O
adrenocortical 	 O 	O
steroids 	 O 	O
are 	 O 	O
required 	 O 	O
for 	 O 	O
the 	 O 	O
formation 	 O 	O
of 	 O 	O
microfilaments 	 O 	O
. 	 O 	O
While 	 O 	O
respiratory 	 O 	O
resistance 	 O 	O
at 	 O 	O
27.1 	 O 	O
mm 	 O 	O
H2O 	 O 	O
/ 	 O 	O
l 	 O 	O
and 	 O 	O
sec 	 O 	O
was 	 O 	O
only 	 O 	O
slightly 	 O 	O
increased 	 O 	O
in 	 O 	O
35 	 O 	O
patients 	 O 	O
with 	 O 	O
unilateral 	 O 	O
recurrent 	 O 	O
nerve 	 O 	O
paralysis 	 O 	O
and 	 O 	O
not 	 O 	O
even 	 O 	O
perceived 	 O 	O
by 	 O 	O
most 	 O 	O
of 	 O 	O
them 	 O 	O
, 	 O 	O
considerably 	 O 	O
increased 	 O 	O
resistance 	 O 	O
was 	 O 	O
found 	 O 	O
in 	 O 	O
65 	 O 	O
patients 	 O 	O
with 	 O 	O
bilateral 	 O 	O
paralysis 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Behcet 	 DISEASE 	O
's 	 DISEASE 	DISEASE
disease 	 DISEASE 	O
) 	 O 	O
and 	 O 	O
the 	 O 	O
absence 	 O 	O
of 	 O 	O
HLA 	 O 	O
W 	 O 	O
27 	 O 	O
( 	 O 	O
ankylosing 	 O 	O
spondylitis 	 O 	O
) 	 O 	O
. 	 O 	O
A 	 O 	O
study 	 O 	O
of 	 O 	O
the 	 O 	O
HLA 	 O 	O
system 	 O 	O
in 	 O 	O
this 	 O 	O
patient 	 O 	O
, 	 O 	O
showed 	 O 	O
the 	 O 	O
presence 	 O 	O
of 	 O 	O
an 	 O 	O
HLA 	 O 	O
5 	 O 	O
( 	 O 	O
Behcet 	 O 	O
's 	 O 	O
disease 	 O 	O
) 	 O 	O
and 	 O 	O
the 	 O 	O
absence 	 O 	O
of 	 O 	O
HLA 	 O 	O
W 	 O 	O
27 	 O 	O
( 	 O 	O
ankylosing 	 DISEASE 	O
spondylitis 	 DISEASE 	DISEASE
) 	 O 	O
. 	 O 	O
concluded 	 O 	O
that 	 O 	O
patients 	 O 	O
with 	 O 	O
chronic 	 O 	O
myelomonocytic 	 O 	O
leukemia 	 O 	DISEASE
who 	 O 	O
have 	 O 	O
thrombocytopenia 	 DISEASE 	O
or 	 O 	O
a 	 O 	O
bleeding 	 O 	O
tendency 	 O 	O
should 	 O 	O
be 	 O 	O
evaluated 	 O 	O
for 	 O 	O
evidence 	 O 	O
of 	 O 	O
disseminated 	 O 	O
intravascular 	 O 	O
coagulation 	 O 	O
. 	 O 	O
It 	 O 	O
is 	 O 	O
concluded 	 O 	O
that 	 O 	O
patients 	 O 	O
with 	 O 	O
chronic 	 O 	O
myelomonocytic 	 O 	O
leukemia 	 O 	O
who 	 O 	O
have 	 O 	O
thrombocytopenia 	 O 	DISEASE
or 	 O 	O
a 	 O 	O
bleeding 	 O 	O
tendency 	 O 	O
should 	 O 	O
be 	 O 	O
evaluated 	 O 	O
for 	 O 	O
evidence 	 O 	O
of 	 O 	O
disseminated 	 DISEASE 	O
intravascular 	 DISEASE 	O
coagulation 	 DISEASE 	O
. 	 O 	O
These 	 O 	O
clinical 	 O 	O
and 	 O 	O
autopsy 	 O 	O
data 	 O 	O
suggest 	 O 	O
the 	 O 	O
need 	 O 	O
for 	 O 	O
aggressive 	 O 	O
treatment 	 O 	O
of 	 O 	O
the 	 O 	O
local 	 O 	O
tumor 	 O 	O
in 	 O 	O
all 	 O 	O
cell 	 O 	O
types 	 O 	O
, 	 O 	O
and 	 O 	O
systemic 	 O 	O
therapy 	 O 	O
for 	 O 	O
small 	 DISEASE 	O
cell 	 DISEASE 	DISEASE
carcinoma 	 DISEASE 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Nine 	 O 	O
women 	 O 	O
were 	 O 	O
referred 	 O 	O
with 	 O 	O
a 	 O 	O
possible 	 O 	O
inherited 	 O 	O
metabolic 	 O 	O
defect 	 O 	DISEASE
: 	 O 	O
one 	 O 	O
fetus 	 O 	O
affected 	 O 	O
with 	 O 	O
congenital 	 DISEASE 	O
adrenal 	 DISEASE 	O
hyperplasia 	 DISEASE 	DISEASE
was 	 O 	O
detected 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
also 	 O 	O
in 	 O 	O
those 	 O 	O
with 	 O 	O
Hashimoto 	 O 	DISEASE
's 	 O 	O
thyroiditis 	 O 	O
by 	 O 	O
using 	 O 	O
the 	 O 	O
radioreceptor 	 O 	O
assay 	 O 	O
of 	 O 	O
TSH 	 O 	O
. 	 O 	O
TSH 	 O 	O
- 	 O 	O
binding 	 O 	O
inhibitor 	 O 	O
immunoglobulins 	 O 	O
( 	 O 	O
TBII 	 O 	O
) 	 O 	O
have 	 O 	O
been 	 O 	O
detected 	 O 	O
not 	 O 	O
only 	 O 	O
in 	 O 	O
patients 	 O 	O
with 	 O 	O
Graves 	 O 	O
' 	 O 	O
disease 	 O 	O
but 	 O 	O
also 	 O 	O
in 	 O 	O
those 	 O 	O
with 	 O 	O
Hashimoto 	 DISEASE 	DISEASE
's 	 DISEASE 	DISEASE
thyroiditis 	 DISEASE 	DISEASE
by 	 O 	O
using 	 O 	O
the 	 O 	O
radioreceptor 	 O 	O
assay 	 O 	O
of 	 O 	O
TSH 	 O 	O
. 	 O 	O
The 	 O 	O
possibility 	 O 	O
of 	 O 	O
using 	 O 	O
staining 	 O 	O
for 	 O 	O
acid 	 O 	O
phosphatase 	 O 	O
as 	 O 	O
a 	 O 	O
screening 	 O 	O
method 	 O 	O
for 	 O 	O
the 	 O 	O
detection 	 O 	O
of 	 O 	O
active 	 O 	O
, 	 O 	O
antigen 	 O 	O
- 	 O 	O
containing 	 O 	O
macrophages 	 O 	O
in 	 O 	O
human 	 O 	O
chronic 	 DISEASE 	O
pyelonephritis 	 DISEASE 	DISEASE
is 	 O 	O
discussed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
values 	 O 	O
; 	 O 	O
in 	 O 	O
two 	 O 	O
cases 	 O 	O
the 	 O 	O
abnormalities 	 O 	O
were 	 O 	O
consistent 	 O 	O
with 	 O 	O
disseminated 	 DISEASE 	O
intravascular 	 DISEASE 	O
coagulation 	 DISEASE 	O
and 	 O 	O
correlated 	 O 	O
with 	 O 	O
a 	 O 	O
hemorrhagic 	 O 	O
diathesis 	 O 	O
. 	 O 	O
Most 	 O 	O
importantly 	 O 	O
, 	 O 	O
seven 	 O 	O
of 	 O 	O
nine 	 O 	O
patients 	 O 	O
had 	 O 	O
abnormal 	 O 	O
coagulation 	 O 	O
values 	 O 	O
; 	 O 	O
in 	 O 	O
two 	 O 	O
cases 	 O 	O
the 	 O 	O
abnormalities 	 O 	O
were 	 O 	O
consistent 	 O 	O
with 	 O 	O
disseminated 	 O 	O
intravascular 	 O 	O
coagulation 	 O 	O
and 	 O 	O
correlated 	 O 	O
with 	 O 	O
a 	 O 	O
hemorrhagic 	 DISEASE 	DISEASE
diathesis 	 DISEASE 	O
. 	 O 	O
The 	 O 	O
authors 	 O 	O
report 	 O 	O
a 	 O 	O
case 	 O 	O
of 	 O 	O
multiple 	 O 	DISEASE
circumscribed 	 O 	O
colonic 	 O 	DISEASE
lipomas 	 O 	O
and 	 O 	O
undertake 	 O 	O
a 	 O 	O
review 	 O 	O
of 	 O 	O
the 	 O 	O
literature 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Twelve 	 O 	O
adult 	 O 	O
males 	 O 	O
with 	 O 	O
documented 	 O 	O
active 	 O 	O
Cushing 	 O 	DISEASE
's 	 O 	O
disease 	 O 	DISEASE
were 	 O 	O
studied 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
SLE 	 O 	O
patients 	 O 	O
with 	 O 	O
anti 	 O 	O
- 	 O 	O
RNP 	 O 	O
antibodies 	 O 	O
had 	 O 	O
a 	 O 	O
significantly 	 O 	O
lower 	 O 	O
anti 	 O 	O
- 	 O 	O
DNA 	 O 	O
antibody 	 O 	O
titer 	 O 	O
and 	 O 	O
a 	 O 	O
significantly 	 O 	O
lower 	 O 	O
incidence 	 O 	O
of 	 O 	O
nephritis 	 DISEASE 	O
and 	 O 	O
impaired 	 O 	O
renal 	 O 	O
function 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Epoxydent 	 O 	O
	PUNCT	O
20571	on	ADP	O
20571	a	DET	O
20571	macaca	ADJ	O
20571	speciosa	NOUN	O
20571	monkey	NOUN	O
20571	and	CCONJ	O
20571	examined	VERB	O
20571	with	ADP	O
20571	the	DET	O
20571	electron	NOUN	O
20571	microscope	NOUN	O
20571	after	ADP	O
20571	a	DET	O
20571	15	NUM	O
20571	months	NOUN	O
20571	functional	ADJ	O
20571	period	NOUN	O
20571	.	PUNCT	O
20572	Statistically	ADV	O
20572	significant	ADJ	O
20572	differences	NOUN	O
20572	in	ADP	O
20572	the	DET	O
20572	size	NOUN	O
20572	of	ADP	O
20572	the	DET	O
20572	marginal	ADJ	O
20572	space	NOUN	O
20572	were	VERB	O
20572	found	VERB	O
20572	to	PART	O
20572	be	VERB	O
20572	larger	ADJ	O
20572	than	ADP	O
20572	in	ADP	O
20572	comparable	ADJ	O
20572	composites	NOUN	O
20572	Adaptic	PROPN	O
20572	,	PUNCT	O
20572	Concise	PROPN	O
20572	,	PUNCT	O
20572	Compo	PROPN	O
20572	-	PUNCT	O
20572	Cap	PROPN	O
20572	and	CCONJ	O
20572	Cosmic	PROPN	O
20572	.	PUNCT	O
20573	The	DET	O
20573	spaces	NOUN	O
20573	were	VERB	O
20573	frequently	ADV	O
20573	not	ADV	O
20573	located	VERB	O
20573	on	ADP	O
20573	the	DET	O
20573	filling	VERB	O
20573	margin	NOUN	O
20573	but	CCONJ	O
20573	inside	ADV	O
20573	,	PUNCT	O
20573	within	ADP	O
20573	the	DET	O
20573	filling	NOUN	O
20573	material	NOUN	O
20573	.	PUNCT	O
20574	This	DET	O
20574	is	VERB	O
20574	attributed	VERB	O
20574	to	ADP	O
20574	the	DET	O
20574	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
National 	 O 	O
Wilms 	 DISEASE 	DISEASE
' 	 DISEASE 	O
Tumor 	 DISEASE 	O
Study 	 O 	O
, 	 O 	O
initiated 	 O 	O
in 	 O 	O
1969 	 O 	O
, 	 O 	O
tested 	 O 	O
competing 	 O 	O
treatment 	 O 	O
strategems 	 O 	O
for 	 O 	O
patients 	 O 	O
with 	 O 	O
tumors 	 O 	O
ranging 	 O 	O
from 	 O 	O
Group 	 O 	O
( 	 O 	O
Gp 	 O 	O
) 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
This 	 O 	O
treatment 	 O 	O
decreased 	 O 	O
prostatic 	 O 	DISEASE
and 	 O 	O
testicular 	 O 	O
weights 	 O 	O
of 	 O 	O
mature 	 O 	O
rats 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
islet 	 O 	DISEASE
cell 	 O 	O
is 	 O 	O
found 	 O 	O
in 	 O 	O
small 	 O 	O
clusters 	 O 	O
and 	 O 	O
its 	 O 	O
dendrites 	 O 	O
and 	 O 	O
axonal 	 O 	O
arbor 	 O 	O
are 	 O 	O
confined 	 O 	O
within 	 O 	O
the 	 O 	O
SG 	 O 	O
layer 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Dominant 	 O 	O
Amylase-2 	 O 	O
	PUNCT	O
46379	)	PUNCT	O
46379	up	ADP	O
46379	to	ADP	O
46379	the	DET	O
46379	same	ADJ	O
46379	levels	NOUN	O
46379	as	ADP	O
46379	major	ADJ	O
46379	isoenzymes	NOUN	O
46379	(	PUNCT	O
46379	Amylase-1	NOUN	O
46379	and	CCONJ	O
46379	3	NUM	O
46379	)	PUNCT	O
46379	,	PUNCT	O
46379	along	ADP	O
46379	with	ADP	O
46379	Amylase-1	PROPN	O
46379	.	PUNCT	O
46379	Pedigree	ADJ	O
46379	study	NOUN	O
46379	confirmed	VERB	O
46379	an	DET	O
46379	autosomal	NOUN	O
46379	dominant	ADJ	O
46379	mode	NOUN	O
46379	of	ADP	O
46379	inheritance	NOUN	O
46379	for	ADP	O
46379	Dominant	PROPN	O
46379	Amylase-2	PROPN	O
46379	.	PUNCT	O
46380	Knowledge	NOUN	O
46380	of	ADP	O
46380	the	DET	O
46380	genetic	ADJ	O
46380	polymorphism	NOUN	O
46380	is	VERB	O
46380	of	ADP	O
46380	importance	NOUN	O
46380	in	ADP	O
46380	clinical	ADJ	O
46380	assessment	NOUN	O
46380	of	ADP	O
46380	amylase	NOUN	O
46380	isoenzymes	NOUN	O
46380	in	ADP	O
46380	patients	NOUN	O
46380	having	VERB	O
46380	an	DET	O
46380	elevated	ADJ	O
46380	Amylase-2	PROPN	O
46380	suggestive	NOUN	O
46380	of	ADP	O
46380	pancreatitis	NOUN	DISEASE
46380	.	PUNCT	O
46381	Predominance	NOUN	O
46381	of	ADP	O
46381	the	DET	O
46381	pancreatic	ADJ	O
46381	components	NOUN	O
46381	in	ADP	O
46381	serum	NOUN	O
46381	and	CCONJ	O
46381	urine	NOUN	O
46381	has	VERB	O
46381	been	VERB	O
46381	revealed	VERB	O
46381	to	PART	O
46381	be	VERB	O
46381	a	DET	O
46381	specific	ADJ	O
46381	index	NOUN	O
46381	of	ADP	O
46381	pancreatic	ADJ	O
46381	involvement	NOUN	O
46381	.	PUNCT	O
46382	However	ADV	O
46382	,	PUNCT	O
46382	the	DET	O
46382	existecne	NOUN	O
46382	of	ADP	O
46382	an	DET	O
46382	inherited	VERB	O
46382	trait	NOUN	O
46382	of	ADP	O
46382	pancreatitis	NOUN	DISEASE
46382	-	PUNCT	O
46382	like	ADJ	O
46382	isoamylase	NOUN	O
46382	pattern	NOUN	O
46382	in	ADP	O
46382	healthy	ADJ	O
46382	individuals	NOUN	O
46382	must	VERB	O
46382	be	VERB	O
46382	borne	VERB	O
46382	in	ADP	O
46382	mind	NOUN	O
46382	.	PUNCT	O
46383	On	ADP	O
46383	the	DET	O
46383	basis	NOUN	O
46383	of	ADP	O
46383	the	DET	O
46383	present	ADJ	O
46383	study	NOUN	O
46383	,	PUNCT	O
46383	it	PRON	O
46383	may	VERB	O
46383	be	VERB	O
46383	concluded	VERB	O
46383	that	ADP	O
46383	a	DET	O
46383	rise	NOUN	O
46383	in	ADP	O
46383	the	DET	O
46383	pancreatic	ADJ	O
46383	type	NOUN	O
46383	isoenzymes	NOUN	O
46383	may	VERB	O
46383	not	ADV	O
46383	necessarily	ADV	O
46383	indicate	VERB	O
46383	underlying	VERB	O
46383	pancreatitis	NOUN	DISEASE
46383	,	PUNCT	O
46383	especially	ADV	O
46383	in	ADP	O
46383	the	DET	O
46383	absence	NOUN	O
46383	of	ADP	O
46383	elevated	ADJ	O
46383	amylase	NOUN	O
46383	and	CCONJ	O
46383	lipase	NOUN	O
46383	levels	NOUN	O
46383	.	PUNCT	O
46384	Varicosities	NOUN	O
46384	of	ADP	O
46384	the	DET	O
46384	renal	ADJ	O
46384	veins	NOUN	O
46384	and	CCONJ	O
46384	of	ADP	O
46384	the	DET	O
46384	veins	NOUN	O
46384	of	ADP	O
46384	the	DET	O
46384	upper	ADJ	O
46384	urinary	ADJ	O
46384	tract	NOUN	O
46384	may	VERB	O
46384	occur	VERB	O
46384	with	ADP	O
46384	or	CCONJ	O
46384	without	ADP	O
46384	haematuria	NOUN	O
46384	.	PUNCT	O
46385	The	DET	O
46385	urogram	NOUN	O
46385	may	VERB	O
46385	be	VERB	O
46385	negative	ADJ	O
46385	.	PUNCT	O
46386	Frequently	ADV	O
46386	,	PUNCT	O
46386	however	ADV	O
46386	,	PUNCT	O
46386	there	ADV	O
46386	are	VERB	O
46386	single	ADJ	O
46386	or	CCONJ	O
46386	multiple	ADJ	O
46386	impressions	NOUN	O
46386	on	ADP	O
46386	the	DET	O
46386	ureters	NOUN	O
46386	as	ADP	O
46386	a	DET	O
46386	result	NOUN	O
46386	of	ADP	O
46386	the	DET	O
46386	venous	ADJ	O
46386	varicosities	NOUN	O
46386	.	PUNCT	O
46387	Arteriography	PROPN	O
46387	,	PUNCT	O
46387	which	ADJ	O
46387	should	VERB	O
46387	always	ADV	O
46387	be	VERB	O
46387	carried	VERB	O
46387	out	PART	O
46387	in	ADP	O
46387	the	DET	O
46387	presence	NOUN	O
46387	of	ADP	O
46387	undiagnosed	ADJ	O
46387	haematuria	NOUN	O
46387	,	PUNCT	O
46387	is	VERB	O
46387	unable	ADJ	O
46387	to	PART	O
46387	demonstrate	VERB	O
46387	the	DET	O
46387	venous	ADJ	O
46387	abnormalities	NOUN	O
46387	.	PUNCT	O
46388	Since	ADP	O
46388	the	DET	O
46388	symptoms	NOUN	O
46388	are	VERB	O
46388	also	ADV	O
46388	not	ADV	O
46388	characteristic	ADJ	O
46388	,	PUNCT	O
46388	it	PRON	O
46388	is	VERB	O
46388	necessary	ADJ	O
46388	to	PART	O
46388	carry	VERB	O
46388	out	PART	O
46388	renal	ADJ	O
46388	vein	NOUN	O
46388	pharmaco	NOUN	O
46388	-	PUNCT	O
46388	phlebography	NOUN	O
46388	.	PUNCT	O
46389	The	DET	O
46389	clinical	ADJ	O
46389	features	NOUN	O
46389	,	PUNCT	O
46389	radiological	ADJ	O
46389	appearances	NOUN	O
46389	and	CCONJ	O
46389	aetiology	NOUN	O
46389	of	ADP	O
46389	this	DET	O
46389	rare	ADJ	O
46389	condition	NOUN	O
46389	are	VERB	O
46389	illustrated	VERB	O
46389	by	ADP	O
46389	three	NUM	O
46389	cases	NOUN	O
46389	.	PUNCT	O
46390	Intravascular	ADJ	O
46390	coagulation	NOUN	O
46390	,	PUNCT	O
46390	thrombosis	NOUN	DISEASE
46390	,	PUNCT	O
46390	and	CCONJ	O
46390	fibrin	VERB	O
46390	deposition	NOUN	O
46390	often	ADV	O
46390	produce	VERB	O
46390	tissue	NOUN	O
46390	damage	NOUN	O
46390	in	ADP	O
46390	allogeneic	ADJ	O
46390	inflammatory	ADJ	O
46390	reactions	NOUN	O
46390	such	ADJ	O
46390	as	ADP	O
46390	allograft	NOUN	O
46390	rejection	NOUN	O
46390	.	PUNCT	O
46391	The	DET	O
46391	mechanisms	NOUN	O
46391	which	ADJ	O
46391	initiate	VERB	O
46391	blood	NOUN	O
46391	clotting	NOUN	O
46391	in	ADP	O
46391	these	DET	O
46391	reactions	NOUN	O
46391	are	VERB	O
46391	poorly	ADV	O
46391	understood	VERB	O
46391	.	PUNCT	O
46392	We	PRON	O
46392	find	VERB	O
46392	that	ADP	O
46392	allogeneic	ADJ	O
46392	stimulation	NOUN	O
46392	of	ADP	O
46392	human	ADJ	O
46392	leukocytes	NOUN	O
46392	in	ADP	O
46392	vitro	X	O
46392	increases	NOUN	O
46392	production	NOUN	O
46392	and	CCONJ	O
46392	expression	NOUN	O
46392	of	ADP	O
46392	tissue	NOUN	O
46392	thromboplastin	NOUN	O
46392	-	PUNCT	O
46392	like	ADJ	O
46392	activity	NOUN	O
46392	.	PUNCT	O
46393	In	ADP	O
46393	our	ADJ	O
46393	experiments	NOUN	O
46393	mixed	ADJ	O
46393	leukocyte	NOUN	O
46393	cultures	NOUN	O
46393	(	PUNCT	O
46393	MLC	PROPN	O
46393	)	PUNCT	O
46393	of	ADP	O
46393	cells	NOUN	O
46393	from	ADP	O
46393	allogeneic	ADJ	O
46393	(	PUNCT	O
46393	unrelated	ADJ	O
46393	)	PUNCT	O
46393	donors	NOUN	O
46393	produced	VERB	O
46393	and	CCONJ	O
46393	expressed	VERB	O
46393	more	ADJ	O
46393	procoagulant	ADJ	O
46393	activity	NOUN	O
46393	than	ADP	O
46393	control	NOUN	O
46393	cultures	NOUN	O
46393	of	ADP	O
46393	cells	NOUN	O
46393	from	ADP	O
46393	each	DET	O
46393	donor	NOUN	O
46393	alone	ADV	O
46393	.	PUNCT	O
46394	After	ADP	O
46394	7	NUM	O
46394	days	NOUN	O
46394	,	PUNCT	O
46394	allogeneic	ADJ	O
46394	MLC	PROPN	O
46394	had	VERB	O
46394	5-	NUM	O
46394	to	ADP	O
46394	50-fold	NUM	O
46394	more	ADJ	O
46394	total	ADJ	O
46394	procoagulant	ADJ	O
46394	activity	NOUN	O
46394	than	ADP	O
46394	controls	NOUN	O
46394	,	PUNCT	O
46394	as	ADP	O
46394	shown	VERB	O
46394	by	ADP	O
46394	assaying	VERB	O
46394	lysed	VERB	O
46394	whole	ADJ	O
46394	cultures	NOUN	O
46394	.	PUNCT	O
46395	Additionally	ADV	O
46395	,	PUNCT	O
46395	allogeneic	ADJ	O
46395	MLC	PROPN	O
46395	had	VERB	O
46395	8-	NUM	O
46395	to	ADP	O
46395	240-fold	NUM	O
46395	more	ADJ	O
46395	procoagulant	ADJ	O
46395	activity	NOUN	O
46395	expressed	VERB	O
46395	on	ADP	O
46395	leukocyte	NOUN	O
46395	surfaces	NOUN	O
46395	and	CCONJ	O
46395	in	ADP	O
46395	culture	NOUN	O
46395	supernates	NOUN	O
46395	than	ADP	O
46395	controls	NOUN	O
46395	after	ADP	O
46395	7	NUM	O
46395	days	NOUN	O
46395	,	PUNCT	O
46395	as	ADP	O
46395	shown	VERB	O
46395	by	ADP	O
46395	assaying	VERB	O
46395	intact	ADJ	O
46395	whole	ADJ	O
46395	cultures	NOUN	O
46395	and	CCONJ	O
46395	cell	NOUN	O
46395	-	PUNCT	O
46395	free	ADJ	O
46395	supernates	NOUN	O
46395	.	PUNCT	O
46396	These	DET	O
46396	increases	NOUN	O
46396	were	VERB	O
46396	largely	ADV	O
46396	accounted	VERB	O
46396	for	ADP	O
46396	by	ADP	O
46396	gains	NOUN	O
46396	in	ADP	O
46396	the	DET	O
46396	amounts	NOUN	O
46396	of	ADP	O
46396	procoagulant	ADJ	O
46396	activity	NOUN	O
46396	produced	VERB	O
46396	and	CCONJ	O
46396	expressed	VERB	O
46396	per	ADP	O
46396	cell	NOUN	O
46396	in	ADP	O
46396	MLC	PROPN	O
46396	as	ADP	O
46396	compared	VERB	O
46396	to	ADP	O
46396	controls	NOUN	O
46396	.	PUNCT	O
46397	Controls	NOUN	O
46397	and	CCONJ	O
46397	MLC	PROPN	O
46397	produced	VERB	O
46397	and	CCONJ	O
46397	expressed	VERB	O
46397	considerable	ADJ	O
46397	amounts	NOUN	O
46397	of	ADP	O
46397	procoagulant	ADJ	O
46397	activity	NOUN	O
46397	during	ADP	O
46397	the	DET	O
46397	1st	ADJ	O
46397	day	NOUN	O
46397	of	ADP	O
46397	culture	NOUN	O
46397	,	PUNCT	O
46397	and	CCONJ	O
46397	there	ADV	O
46397	were	VERB	O
46397	no	DET	O
46397	differential	ADJ	O
46397	effects	NOUN	O
46397	of	ADP	O
46397	allogeneic	ADJ	O
46397	stimulation	NOUN	O
46397	on	ADP	O
46397	day	NOUN	O
46397	1	NUM	O
46397	.	PUNCT	O
46398	However	ADV	O
46398	,	PUNCT	O
46398	after	ADP	O
46398	day	NOUN	O
46398	1	NUM	O
46398	,	PUNCT	O
46398	the	DET	O
46398	total	ADJ	O
46398	amount	NOUN	O
46398	of	ADP	O
46398	procoagulant	ADJ	O
46398	activity	NOUN	O
46398	produced	VERB	O
46398	and	CCONJ	O
46398	the	DET	O
46398	amount	NOUN	O
46398	expressed	VERB	O
46398	declined	VERB	O
46398	steadily	ADV	O
46398	in	ADP	O
46398	controls	NOUN	O
46398	,	PUNCT	O
46398	nearly	ADV	O
46398	reaching	VERB	O
46398	preculture	NOUN	O
46398	levels	NOUN	O
46398	by	ADP	O
46398	day	NOUN	O
46398	7	NUM	O
46398	.	PUNCT	O
46399	In	ADP	O
46399	contrast	NOUN	O
46399	,	PUNCT	O
46399	the	DET	O
46399	total	ADJ	O
46399	amount	NOUN	O
46399	of	ADP	O
46399	procoagulant	ADJ	O
46399	activity	NOUN	O
46399	in	ADP	O
46399	allogeneic	ADJ	O
46399	MLC	PROPN	O
46399	remained	VERB	O
46399	high	ADJ	O
46399	,	PUNCT	O
46399	and	CCONJ	O
46399	the	DET	O
46399	amount	NOUN	O
46399	of	ADP	O
46399	activity	NOUN	O
46399	expressed	VERB	O
46399	on	ADP	O
46399	cell	NOUN	O
46399	surfaces	NOUN	O
46399	and	CCONJ	O
46399	in	ADP	O
46399	supernates	NOUN	O
46399	increased	VERB	O
46399	severalfold	VERB	O
46399	by	ADP	O
46399	day	NOUN	O
46399	7	NUM	O
46399	.	PUNCT	O
46400	MLC	PROPN	O
46400	of	ADP	O
46400	syngeneic	NOUN	O
46400	(	PUNCT	O
46400	identical	ADJ	O
46400	twin	NOUN	O
46400	)	PUNCT	O
46400	cells	NOUN	O
46400	produced	VERB	O
46400	and	CCONJ	O
46400	expressed	VERB	O
46400	the	DET	O
46400	same	ADJ	O
46400	amount	NOUN	O
46400	of	ADP	O
46400	activity	NOUN	O
46400	as	ADP	O
46400	controls	NOUN	O
46400	over	ADP	O
46400	a	DET	O
46400	7-day	NUM	O
46400	period	NOUN	O
46400	,	PUNCT	O
46400	whereas	ADP	O
46400	MLC	PROPN	O
46400	of	ADP	O
46400	cells	NOUN	O
46400	from	ADP	O
46400	each	DET	O
46400	twin	NOUN	O
46400	and	CCONJ	O
46400	an	DET	O
46400	allogeneic	ADJ	O
46400	donor	NOUN	O
46400	produced	VERB	O
46400	and	CCONJ	O
46400	expressed	VERB	O
46400	more	ADJ	O
46400	activity	NOUN	O
46400	than	ADP	O
46400	controls	NOUN	O
46400	(	PUNCT	O
46400	at	ADP	O
46400	least	ADJ	O
46400	9-	NUM	O
46400	and	CCONJ	O
46400	35-fold	NUM	O
46400	more	ADJ	O
46400	,	PUNCT	O
46400	respectively	ADV	O
46400	)	PUNCT	O
46400	.	PUNCT	O
46401	Thus	ADV	O
46401	,	PUNCT	O
46401	increases	NOUN	O
46401	of	ADP	O
46401	procoagulant	ADJ	O
46401	activity	NOUN	O
46401	production	NOUN	O
46401	and	CCONJ	O
46401	expression	NOUN	O
46401	were	VERB	O
46401	found	VERB	O
46401	only	ADV	O
46401	in	ADP	O
46401	MLC	PROPN	O
46401	of	ADP	O
46401	genetically	ADV	O
46401	dissimilar	ADJ	O
46401	cells	NOUN	O
46401	.	PUNCT	O
46402	Therefore	ADV	O
46402	,	PUNCT	O
46402	these	DET	O
46402	increases	NOUN	O
46402	must	VERB	O
46402	have	VERB	O
46402	resulted	VERB	O
46402	from	ADP	O
46402	allogeneic	ADJ	O
46402	stimulation	NOUN	O
46402	.	PUNCT	O
46403	A	DET	O
46403	group	NOUN	O
46403	of	ADP	O
46403	495	NUM	O
46403	patients	NOUN	O
46403	who	NOUN	O
46403	underwent	VERB	O
46403	laparoscopic	ADJ	O
46403	sterilization	NOUN	O
46403	by	ADP	O
46403	coagulation	NOUN	O
46403	and	CCONJ	O
46403	division	NOUN	O
46403	technique	NOUN	O
46403	was	VERB	O
46403	compared	VERB	O
46403	with	ADP	O
46403	another	DET	O
46403	group	NOUN	O
46403	who	NOUN	O
46403	underwent	VERB	O
46403	coagulation	NOUN	O
46403	and	CCONJ	O
46403	resection	NOUN	O
46403	sterilization	NOUN	O
46403	as	ADP	O
46403	to	ADP	O
46403	late	ADJ	O
46403	complications	NOUN	O
46403	.	PUNCT	O
46404	The	DET	O
46404	1st	ADJ	O
46404	technique	NOUN	O
46404	involved	VERB	O
46404	use	NOUN	O
46404	of	ADP	O
46404	3	NUM	O
46404	mm	NOUN	O
46404	forceps	NOUN	O
46404	and	CCONJ	O
46404	minimal	ADJ	O
46404	tissue	NOUN	O
46404	destruction	NOUN	O
46404	while	ADP	O
46404	the	DET	O
46404	2nd	ADJ	O
46404	technique	NOUN	O
46404	utilized	VERB	O
46404	a	DET	O
46404	5	NUM	O
46404	mm	NOUN	O
46404	Palmer	PROPN	O
46404	drill	NOUN	O
46404	forceps	NOUN	O
46404	and	CCONJ	O
46404	much	ADV	O
46404	more	ADJ	O
46404	tissue	NOUN	O
46404	destruction	NOUN	O
46404	.	PUNCT	O
46405	There	ADV	O
46405	was	VERB	O
46405	no	DET	O
46405	statistically	ADV	O
46405	significant	ADJ	O
46405	difference	NOUN	O
46405	between	ADP	O
46405	the	DET	O
46405	2	NUM	O
46405	groups	NOUN	O
46405	in	ADP	O
46405	the	DET	O
46405	incidence	NOUN	O
46405	of	ADP	O
46405	abnormal	ADJ	O
46405	uterine	ADJ	O
46405	bleeding	NOUN	O
46405	,	PUNCT	O
46405	pain	NOUN	O
46405	,	PUNCT	O
46405	dysmenorrhea	NOUN	O
46405	,	PUNCT	O
46405	or	CCONJ	O
46405	subsequent	ADJ	O
46405	hysterectomy	NOUN	O
46405	.	PUNCT	O
46406	The	DET	O
46406	percentage	NOUN	O
46406	of	ADP	O
46406	totally	ADV	O
46406	asymptomatic	ADJ	O
46406	patients	NOUN	O
46406	in	ADP	O
46406	the	DET	O
46406	2	NUM	O
46406	groups	NOUN	O
46406	was	VERB	O
46406	identical	ADJ	O
46406	.	PUNCT	O
46407	Patients	NOUN	O
46407	using	VERB	O
46407	oral	ADJ	O
46407	contraceptives	NOUN	O
46407	at	ADP	O
46407	the	DET	O
46407	time	NOUN	O
46407	of	ADP	O
46407	their	ADJ	O
46407	sterilization	NOUN	O
46407	procedure	NOUN	O
46407	had	VERB	O
46407	a	DET	O
46407	higher	ADJ	O
46407	incidence	NOUN	O
46407	of	ADP	O
46407	later	ADV	O
46407	menstrual	ADJ	O
46407	problems	NOUN	O
46407	and	CCONJ	O
46407	patients	NOUN	O
46407	with	ADP	O
46407	previous	ADJ	O
46407	menstrual	ADJ	O
46407	disorders	NOUN	O
46407	which	ADJ	O
46407	had	VERB	O
46407	required	VERB	O
46407	treatment	NOUN	O
46407	had	VERB	O
46407	the	DET	O
46407	highest	ADJ	O
46407	incidence	NOUN	O
46407	of	ADP	O
46407	postoperative	ADJ	O
46407	uterine	ADJ	O
46407	bleeding	NOUN	O
46407	.	PUNCT	O
46408	Results	NOUN	O
46408	of	ADP	O
46408	this	DET	O
46408	study	NOUN	O
46408	do	VERB	O
46408	not	ADV	O
46408	suggest	VERB	O
46408	that	ADP	O
46408	disruption	NOUN	O
46408	of	ADP	O
46408	the	DET	O
46408	blood	NOUN	O
46408	supply	NOUN	O
46408	through	ADP	O
46408	tissue	NOUN	O
46408	destruction	NOUN	O
46408	is	VERB	O
46408	responsible	ADJ	O
46408	for	ADP	O
46408	subsequent	ADJ	O
46408	poststerilization	NOUN	O
46408	complications	NOUN	O
46408	.	PUNCT	O
46409	Cases	NOUN	O
46409	were	VERB	O
46409	reviewed	VERB	O
46409	in	ADP	O
46409	which	ADJ	O
46409	both	DET	O
46409	laparoscopy	NOUN	O
46409	and	CCONJ	O
46409	ultrasound	NOUN	O
46409	were	VERB	O
46409	performed	VERB	O
46409	for	ADP	O
46409	diagnostic	ADJ	O
46409	purposes	NOUN	O
46409	at	ADP	O
46409	the	DET	O
46409	Ben	PROPN	O
46409	Taub	PROPN	O
46409	General	PROPN	O
46409	Hospital	PROPN	O
46409	,	PUNCT	O
46409	Houston	PROPN	O
46409	,	PUNCT	O
46409	Texas	PROPN	O
46409	,	PUNCT	O
46409	from	ADP	O
46409	January	PROPN	O
46409	1976	NUM	O
46409	through	ADP	O
46409	May	PROPN	O
46409	1977	NUM	O
46409	.	PUNCT	O
46410	Thirty	NUM	O
46410	patients	NOUN	O
46410	were	VERB	O
46410	found	VERB	O
46410	to	PART	O
46410	have	VERB	O
46410	undergone	VERB	O
46410	both	DET	O
46410	procedures	NOUN	O
46410	.	PUNCT	O
46411	The	DET	O
46411	most	ADV	O
46411	common	ADJ	O
46411	reason	NOUN	O
46411	(	PUNCT	O
46411	13	NUM	O
46411	cases	NOUN	O
46411	)	PUNCT	O
46411	was	VERB	O
46411	the	DET	O
46411	presence	NOUN	O
46411	of	ADP	O
46411	an	DET	O
46411	adnexal	NOUN	O
46411	mass	NOUN	O
46411	.	PUNCT	O
46412	The	DET	O
46412	findings	NOUN	O
46412	from	ADP	O
46412	both	DET	O
46412	techniques	NOUN	O
46412	agreed	VERB	O
46412	in	ADP	O
46412	20	NUM	O
46412	cases	NOUN	O
46412	,	PUNCT	O
46412	for	ADP	O
46412	a	DET	O
46412	positive	ADJ	O
46412	correlation	NOUN	O
46412	of	ADP	O
46412	66.7	NUM	O
46412	%	NOUN	O
46412	.	PUNCT	O
46413	Different	ADJ	O
46413	diagnoses	NOUN	O
46413	were	VERB	O
46413	found	VERB	O
46413	in	ADP	O
46413	10	NUM	O
46413	cases	NOUN	O
46413	,	PUNCT	O
46413	for	ADP	O
46413	a	DET	O
46413	negative	ADJ	O
46413	correlation	NOUN	O
46413	of	ADP	O
46413	33.3	NUM	O
46413	%	NOUN	O
46413	.	PUNCT	O
46414	The	DET	O
46414	major	ADJ	O
46414	cause	NOUN	O
46414	of	ADP	O
46414	the	DET	O
46414	discrepancy	NOUN	O
46414	was	VERB	O
46414	the	DET	O
46414	presence	NOUN	O
46414	of	ADP	O
46414	pelvic	ADJ	O
46414	adhesive	ADJ	O
46414	disease	NOUN	O
46414	,	PUNCT	O
46414	not	ADV	O
46414	diagnosed	VERB	O
46414	by	ADP	O
46414	ultrasound	NOUN	O
46414	but	CCONJ	O
46414	observed	ADJ	O
46414	via	ADP	O
46414	laparoscopy	NOUN	O
46414	.	PUNCT	O
46415	When	ADV	O
46415	the	DET	O
46415	ultrasound	NOUN	O
46415	findings	NOUN	O
46415	were	VERB	O
46415	reported	VERB	O
46415	as	ADP	O
46415	 	 O 	DISEASE
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Hypertensive 	 O 	O
lesions 	 O 	O
were 	 O 	O
found 	 O 	O
regularly 	 O 	O
in 	 O 	O
chronic 	 O 	O
interstitial 	 O 	O
pneumonia 	 O 	O
, 	 O 	O
frequently 	 O 	O
in 	 O 	O
scleroderma 	 O 	O
and 	 O 	O
rheumatoid 	 O 	O
arthritis 	 O 	O
and 	 O 	O
occasionally 	 O 	O
in 	 O 	O
dermatomyositis 	 DISEASE 	O
and 	 O 	O
disseminated 	 O 	O
lupus 	 O 	O
erythematosus 	 O 	O
. 	 O 	O
Hypertensive 	 O 	O
lesions 	 O 	O
were 	 O 	O
found 	 O 	O
regularly 	 O 	O
in 	 O 	O
chronic 	 O 	O
interstitial 	 O 	O
pneumonia 	 O 	O
, 	 O 	O
frequently 	 O 	O
in 	 O 	O
scleroderma 	 O 	O
and 	 O 	O
rheumatoid 	 O 	O
arthritis 	 O 	O
and 	 O 	O
occasionally 	 O 	O
in 	 O 	O
dermatomyositis 	 O 	O
and 	 O 	O
disseminated 	 DISEASE 	DISEASE
lupus 	 DISEASE 	DISEASE
erythematosus 	 DISEASE 	DISEASE
. 	 O 	O
Six 	 O 	O
long 	 O 	O
term 	 O 	O
survivors 	 O 	O
of 	 O 	O
bone 	 O 	O
marrow 	 O 	O
transplants 	 O 	O
developed 	 O 	O
a 	 O 	O
syndrome 	 O 	O
similar 	 O 	O
to 	 O 	O
progressive 	 DISEASE 	O
systemic 	 DISEASE 	DISEASE
sclerosis 	 DISEASE 	DISEASE
( 	 O 	O
PSS 	 O 	O
) 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
five 	 O 	O
patients 	 O 	O
, 	 O 	O
procainamide 	 O 	O
induced 	 O 	O
second 	 O 	O
or 	 O 	O
third 	 O 	O
degree 	 O 	O
AV 	 DISEASE 	O
block 	 DISEASE 	O
below 	 O 	O
the 	 O 	O
level 	 O 	O
of 	 O 	O
the 	 O 	O
bundle 	 O 	O
of 	 O 	O
His 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
However 	 O 	O
, 	 O 	O
for 	 O 	O
the 	 O 	O
partially 	 O 	O
sighted 	 O 	O
subjects 	 O 	O
in 	 O 	O
the 	 O 	O
study 	 O 	O
, 	 O 	O
there 	 O 	O
emerged 	 O 	O
no 	 O 	O
clear 	 O 	O
relationship 	 O 	O
between 	 O 	O
age 	 O 	O
of 	 O 	O
onset 	 O 	O
of 	 O 	O
visual 	 DISEASE 	O
impairment 	 DISEASE 	O
and 	 O 	O
amount 	 O 	O
of 	 O 	O
symbolism 	 O 	O
in 	 O 	O
dreams 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Urethral 	 DISEASE 	O
diverticulum 	 DISEASE 	O
, 	 O 	O
either 	 O 	O
congenital 	 O 	O
or 	 O 	O
acquired 	 O 	O
, 	 O 	O
is 	 O 	O
very 	 O 	O
rare 	 O 	O
and 	 O 	O
becomes 	 O 	O
symptomatic 	 O 	O
when 	 O 	O
complicated 	 O 	O
by 	 O 	O
infection 	 O 	O
and 	 O 	O
lithiasis 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
technique 	 O 	O
obviates 	 O 	O
the 	 O 	O
disadvantages 	 O 	O
of 	 O 	O
surgical 	 O 	O
reaction 	 O 	O
, 	 O 	O
intravascular 	 O 	O
thrombosis 	 DISEASE 	O
, 	 O 	O
and 	 O 	O
gross 	 O 	O
cerebral 	 O 	DISEASE
edema 	 O 	O
observed 	 O 	O
in 	 O 	O
prior 	 O 	O
animal 	 O 	O
stroke 	 O 	O
models 	 O 	O
. 	 O 	O
The 	 O 	O
technique 	 O 	O
obviates 	 O 	O
the 	 O 	O
disadvantages 	 O 	O
of 	 O 	O
surgical 	 O 	O
reaction 	 O 	O
, 	 O 	O
intravascular 	 O 	O
thrombosis 	 O 	O
, 	 O 	O
and 	 O 	O
gross 	 O 	O
cerebral 	 O 	O
edema 	 O 	O
observed 	 O 	O
in 	 O 	O
prior 	 O 	O
animal 	 O 	O
stroke 	 DISEASE 	DISEASE
models 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
central 	 O 	O
theme 	 O 	O
of 	 O 	O
this 	 O 	O
communication 	 O 	O
is 	 O 	O
the 	 O 	O
recognition 	 O 	O
of 	 O 	O
an 	 O 	O
immunodiagnostic 	 O 	O
potential 	 O 	O
in 	 O 	O
a 	 O 	O
herpes 	 O 	DISEASE
virus 	 O 	O
antigen 	 O 	O
, 	 O 	O
the 	 O 	O
molecular 	 O 	O
interrelationship 	 O 	O
of 	 O 	O
which 	 O 	O
with 	 O 	O
cervical 	 O 	O
tumor 	 O 	O
cells 	 O 	O
is 	 O 	O
described 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
rationale 	 O 	O
for 	 O 	O
these 	 O 	O
experiments 	 O 	O
is 	 O 	O
to 	 O 	O
try 	 O 	O
to 	 O 	O
find 	 O 	O
a 	 O 	O
	PUNCT	O
22884	myeloproliferative	ADJ	O
22884	factor	NOUN	O
22884	 	 O 	O
, 	 O 	O
which 	 O 	O
augments 	 O 	O
the 	 O 	O
number 	 O 	O
of 	 O 	O
stem 	 O 	O
cells 	 O 	O
as 	 O 	O
described 	 O 	O
in 	 O 	O
sera 	 O 	O
of 	 O 	O
patients 	 O 	O
with 	 O 	O
polycythaemia 	 O 	O
vera 	 O 	DISEASE
, 	 O 	O
osteomyelofibrosis 	 O 	O
, 	 O 	O
and 	 O 	O
lethally 	 O 	O
irradiated 	 O 	O
mice 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Deoxythymidine 	 O 	O
kinases 	 O 	O
( 	 O 	O
EC 	 O 	O
2.7.1.-- 	 O 	O
) 	 O 	O
induced 	 O 	O
in 	 O 	O
HeLa 	 O 	O
TK- 	 O 	O
cells 	 O 	O
by 	 O 	O
Herpes 	 DISEASE 	DISEASE
simplex 	 DISEASE 	O
Type 	 O 	O
I 	 O 	O
and 	 O 	O
Type 	 O 	O
II 	 O 	O
viruses 	 O 	O
both 	 O 	O
had 	 O 	O
a 	 O 	O
requirement 	 O 	O
for 	 O 	O
divalent 	 O 	O
cations 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
chronic 	 O 	O
sinusitis 	 O 	O
. 	 O 	O
We 	 O 	O
studied 	 O 	O
the 	 O 	O
fine 	 O 	O
structure 	 O 	O
of 	 O 	O
respiratory 	 O 	O
- 	 O 	O
tract 	 O 	O
cilia 	 O 	O
in 	 O 	O
three 	 O 	O
siblings 	 O 	O
with 	 O 	O
chronic 	 O 	O
respiratory 	 O 	O
disease 	 O 	O
, 	 O 	O
comparing 	 O 	O
them 	 O 	O
with 	 O 	O
those 	 O 	O
from 	 O 	O
a 	 O 	O
patient 	 O 	O
with 	 O 	O
Kartagener 	 O 	O
's 	 O 	O
syndrome 	 O 	O
who 	 O 	O
had 	 O 	O
dynein 	 O 	O
- 	 O 	O
deficient 	 O 	O
cilia 	 O 	O
and 	 O 	O
with 	 O 	O
control 	 O 	O
patients 	 O 	O
who 	 O 	O
had 	 O 	O
chronic 	 O 	O
bronchitis 	 O 	DISEASE
or 	 O 	O
chronic 	 O 	DISEASE
sinusitis 	 DISEASE 	O
. 	 O 	O
The 	 O 	O
pneumoconiotic 	 O 	O
process 	 O 	O
develops 	 O 	O
slowly 	 O 	O
and 	 O 	O
is 	 O 	O
characterized 	 O 	O
by 	 O 	O
changes 	 O 	O
typical 	 O 	O
of 	 O 	O
the 	 O 	O
interstitial 	 O 	O
form 	 O 	O
of 	 O 	O
pneumoconiotic 	 O 	O
fibrosis 	 O 	DISEASE
in 	 O 	O
the 	 O 	O
lungs 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
the 	 O 	O
pedigree 	 O 	O
of 	 O 	O
one 	 O 	O
of 	 O 	O
the 	 O 	O
families 	 O 	O
suggests 	 O 	O
that 	 O 	O
gastroschisis 	 DISEASE 	O
may 	 O 	O
be 	 O 	O
a 	 O 	O
severe 	 O 	O
expression 	 O 	O
of 	 O 	O
umbilical 	 O 	O
hernia 	 O 	O
or 	 O 	O
other 	 O 	O
abdominal 	 O 	O
wall 	 O 	O
defects 	 O 	O
. 	 O 	O
Furthermore 	 O 	O
, 	 O 	O
the 	 O 	O
pedigree 	 O 	O
of 	 O 	O
one 	 O 	O
of 	 O 	O
the 	 O 	O
families 	 O 	O
suggests 	 O 	O
that 	 O 	O
gastroschisis 	 O 	O
may 	 O 	O
be 	 O 	O
a 	 O 	O
severe 	 O 	O
expression 	 O 	O
of 	 O 	O
umbilical 	 DISEASE 	O
hernia 	 DISEASE 	O
or 	 O 	O
other 	 O 	O
abdominal 	 O 	O
wall 	 O 	O
defects 	 O 	O
. 	 O 	O
Prophylaxis 	 O 	O
with 	 O 	O
co 	 O 	O
- 	 O 	O
trimoxazole 	 O 	O
is 	 O 	O
important 	 O 	O
in 	 O 	O
preventing 	 O 	O
or 	 O 	O
delaying 	 O 	O
the 	 O 	O
development 	 O 	O
of 	 O 	O
infection 	 O 	DISEASE
in 	 O 	O
neutropenic 	 O 	O
patients 	 O 	O
receiving 	 O 	O
therapy 	 O 	O
for 	 O 	O
acute 	 O 	O
leukaemia 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
microcomplement 	 O 	DISEASE
fixation 	 O 	O
assay 	 O 	O
was 	 O 	O
used 	 O 	O
to 	 O 	O
study 	 O 	O
changes 	 O 	O
in 	 O 	O
the 	 O 	O
antigenicity 	 O 	O
of 	 O 	O
chick 	 O 	O
oviduct 	 O 	O
chromatin 	 O 	O
following 	 O 	O
estrogen 	 O 	O
withdrawal 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Clinical 	 O 	O
implications 	 O 	DISEASE
are 	 O 	O
that 	 O 	O
TPh 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
During 	 O 	O
the 	 O 	O
past 	 O 	O
10 	 O 	O
years 	 O 	O
80 	 O 	O
% 	 O 	O
of 	 O 	O
the 	 O 	O
bladder 	 DISEASE 	O
cancer 	 DISEASE 	DISEASE
patients 	 O 	O
were 	 O 	O
treated 	 O 	O
by 	 O 	O
TUR 	 O 	O
most 	 O 	O
ofter 	 O 	O
followed 	 O 	O
by 	 O 	O
external 	 O 	O
irradiation 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
This 	 O 	O
confirmed 	 O 	O
the 	 O 	O
diagnosis 	 O 	O
reached 	 O 	O
after 	 O 	O
investigation 	 O 	O
of 	 O 	O
a 	 O 	O
100 	 O 	O
% 	 O 	O
sample 	 O 	O
of 	 O 	O
fetal 	 O 	O
blood 	 O 	DISEASE
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
A 	 O 	O
localized 	 O 	O
Arthus 	 DISEASE 	O
reaction 	 DISEASE 	O
was 	 O 	O
produced 	 O 	O
in 	 O 	O
the 	 O 	O
lung 	 O 	O
of 	 O 	O
sensitized 	 O 	O
rabbits 	 O 	O
by 	 O 	O
delivery 	 O 	O
of 	 O 	O
antigen 	 O 	O
into 	 O 	O
a 	 O 	O
lower 	 O 	O
lobe 	 O 	O
bronchus 	 O 	O
using 	 O 	O
a 	 O 	O
method 	 O 	O
of 	 O 	O
selective 	 O 	O
bronchial 	 O 	O
catheterization 	 O 	O
under 	 O 	O
fluoroscopy 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
the 	 O 	O
kidney 	 O 	O
Me 	 O 	O
- 	 O 	O
Cbl 	 O 	O
and 	 O 	O
Ado 	 O 	O
- 	 O 	O
Cbl 	 O 	O
were 	 O 	O
disproportionally 	 O 	O
decreased 	 O 	O
whereas 	 O 	O
in 	 O 	O
the 	 O 	O
liver 	 O 	DISEASE
only 	 O 	O
Ado 	 O 	O
- 	 O 	O
Cbl 	 O 	O
was 	 O 	O
significantly 	 O 	O
reduced 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Saralasin 	 O 	O
is 	 O 	O
without 	 O 	O
effect 	 O 	O
on 	 O 	O
blood 	 O 	DISEASE
pressure 	 O 	O
and 	 O 	O
plasma 	 O 	O
renin 	 O 	O
in 	 O 	O
conscious 	 O 	O
normal 	 O 	O
rats 	 O 	O
and 	 O 	O
in 	 O 	O
spontaneously 	 O 	O
hypertensive 	 O 	O
rats 	 O 	O
, 	 O 	O
while 	 O 	O
it 	 O 	O
causes 	 O 	O
a 	 O 	O
transient 	 O 	O
3 	 O 	O
to 	 O 	O
27 	 O 	O
fold 	 O 	O
increase 	 O 	O
in 	 O 	O
plasma 	 O 	O
renin 	 O 	O
concentration 	 O 	O
in 	 O 	O
anaesthetized 	 O 	O
rats 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Firmly 	 O 	O
established 	 O 	O
transplantable 	 O 	O
C3H 	 O 	O
/ 	 O 	O
HeJ 	 O 	O
mammary 	 O 	O
carcinomas 	 O 	O
can 	 O 	O
be 	 O 	O
inhibited 	 O 	O
by 	 O 	O
host 	 O 	O
challenge 	 O 	O
with 	 O 	O
Vibrio 	 DISEASE 	O
cholerae 	 DISEASE 	O
neuraminidase 	 O 	O
( 	 O 	O
VCN)-treated 	 O 	O
tumor 	 O 	O
cells 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
In 	 O 	O
contrast 	 O 	O
, 	 O 	O
bilateral 	 O 	O
adrenalectomy 	 O 	DISEASE
did 	 O 	O
not 	 O 	O
affect 	 O 	O
the 	 O 	O
darkness 	 O 	O
- 	 O 	O
induced 	 O 	O
rise 	 O 	O
in 	 O 	O
pineal 	 O 	O
NAT 	 O 	O
activity 	 O 	O
, 	 O 	O
although 	 O 	O
pineal 	 O 	O
sympathetic 	 O 	O
denervation 	 O 	O
( 	 O 	O
by 	 O 	O
bilateral 	 O 	O
superior 	 O 	O
cervical 	 O 	O
ganglionectomy 	 O 	O
) 	 O 	O
did 	 O 	O
block 	 O 	O
this 	 O 	O
response 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Following 	 O 	O
pretreatment 	 O 	O
with 	 O 	O
methscopolamine 	 O 	DISEASE
, 	 O 	O
arecholine 	 O 	O
shortened 	 O 	O
the 	 O 	O
REM 	 O 	O
latency 	 O 	O
and 	 O 	O
increased 	 O 	O
the 	 O 	O
number 	 O 	O
of 	 O 	O
REM 	 O 	O
periods 	 O 	O
without 	 O 	O
altering 	 O 	O
the 	 O 	O
duration 	 O 	O
of 	 O 	O
individual 	 O 	O
REM 	 O 	O
periods 	 O 	O
or 	 O 	O
altering 	 O 	O
the 	 O 	O
REM 	 O 	O
-- 	 O 	O
REM 	 O 	O
intervals 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Both 	 O 	O
serologic 	 O 	O
evidence 	 O 	O
and 	 O 	O
viral 	 O 	O
isolations 	 O 	O
seem 	 O 	O
to 	 O 	O
indicate 	 O 	O
that 	 O 	O
polyomaviruses 	 O 	O
( 	 O 	O
BK 	 O 	O
type 	 O 	O
) 	 O 	O
might 	 O 	O
cause 	 O 	O
a 	 O 	O
chronic 	 O 	DISEASE
infection 	 O 	DISEASE
in 	 O 	O
humans 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
fine 	 O 	O
structure 	 O 	O
of 	 O 	O
an 	 O 	O
ovarian 	 DISEASE 	O
clear 	 DISEASE 	O
cell 	 DISEASE 	O
carcinoma 	 DISEASE 	DISEASE
in 	 O 	O
a 	 O 	O
65 	 O 	O
year 	 O 	O
old 	 O 	O
woman 	 O 	O
was 	 O 	O
analysed 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Fifty 	 O 	O
- 	 O 	O
one 	 O 	O
women 	 O 	O
in 	 O 	O
labor 	 O 	DISEASE
had 	 O 	O
continuous 	 O 	O
monitoring 	 O 	O
of 	 O 	O
fetal 	 O 	O
scalp 	 O 	O
tissue 	 O 	O
pH 	 O 	O
, 	 O 	O
fetal 	 O 	O
heart 	 O 	O
rate 	 O 	O
by 	 O 	O
ECG 	 O 	O
, 	 O 	O
and 	 O 	O
uterine 	 O 	O
contractions 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
On 	 O 	O
the 	 O 	O
other 	 O 	O
hand 	 O 	O
, 	 O 	O
when 	 O 	O
epidermis 	 O 	O
from 	 O 	O
the 	 O 	O
involved 	 O 	O
skin 	 O 	O
of 	 O 	O
psoriatic 	 O 	DISEASE
patients 	 O 	O
was 	 O 	O
incubated 	 O 	O
under 	 O 	O
the 	 O 	O
same 	 O 	O
experimental 	 O 	O
conditions 	 O 	O
, 	 O 	O
the 	 O 	O
cyclic 	 O 	O
AMP 	 O 	O
level 	 O 	O
increased 	 O 	O
only 	 O 	O
2 	 O 	O
- 	 O 	O
5 	 O 	O
times 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Mild 	 O 	DISEASE
cold 	 DISEASE 	DISEASE
stimuli 	 O 	O
favour 	 O 	O
the 	 O 	O
accumulation 	 O 	O
of 	 O 	O
proteins 	 O 	O
and 	 O 	O
of 	 O 	O
oxidative 	 O 	O
enzymes 	 O 	O
, 	 O 	O
in 	 O 	O
particular 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
The 	 O 	O
Km 	 O 	O
values 	 O 	O
of 	 O 	O
ATP 	 O 	O
and 	 O 	O
CTP 	 O 	O
for 	 O 	O
the 	 O 	O
Herpes 	 DISEASE 	DISEASE
simplex 	 DISEASE 	O
virus 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
Histogenesis 	 O 	O
of 	 O 	O
the 	 O 	DISEASE
sarcoma 	 DISEASE 	DISEASE
, 	 O 	O
one 	 O 	O
or 	 O 	O
more 	 O 	O
recurrences 	 O 	O
after 	 O 	O
previous 	 O 	O
operations 	 O 	O
, 	 O 	O
and 	 O 	O
treatment 	 O 	O
by 	 O 	O
an 	 O 	O
immediate 	 O 	O
definitive 	 O 	O
procedure 	 O 	O
at 	 O 	O
the 	 O 	O
time 	 O 	O
of 	 O 	O
biopsy 	 O 	O
and 	 O 	O
diagnosis 	 O 	O
by 	 O 	O
frozen 	 O 	O
section 	 O 	O
had 	 O 	O
no 	 O 	O
significant 	 O 	O
relationship 	 O 	O
to 	 O 	O
the 	 O 	O
rates 	 O 	O
of 	 O 	O
local 	 O 	O
recurrence 	 O 	O
or 	 O 	O
metastasis 	 O 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
This 	 O 	O
examination 	 O 	O
provided 	 O 	O
valuable 	 O 	O
diagnostic 	 O 	O
information 	 O 	O
on 	 O 	O
some 	 O 	O
neuronal 	 O 	O
storage 	 O 	O
diseases 	 O 	O
but 	 O 	O
not 	 O 	O
on 	 O 	O
Morquio 	 O 	O
disease 	 O 	O
or 	 O 	O
highly 	 O 	O
suspected 	 O 	O
adrenoleukodystrophy 	 DISEASE 	O
. 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
bleached 	 O 	O
